false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX,  <e1> NSAIDs </e1> , corticosteroids, TNF blocking agents, azathioprine, chloroquine,  <e2> gold </e2> , hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA:  <e1> MTX </e1> , NSAIDs, corticosteroids,  <e2> TNF blocking agents </e2> , azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids,  <e1> TNF blocking agents </e1> , azathioprine, chloroquine, gold,  <e2> hydroxychloroquine </e2> , leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold,  <e1> hydroxychloroquine </e1> ,  <e2> leflunomide </e2> , sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine,  <e1> leflunomide </e1> , sulfasalazine, and  <e2> anakinra </e2> .
false	Concurrent administration of a TNF antagonist with  <e1> ORENCIA </e1>  has been associated with an increased risk of serious infections and no significant additional efficacy over use of the  <e2> TNF antagonists </e2>  alone.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents,  <e1> azathioprine </e1> ,  <e2> chloroquine </e2> , gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine,  <e1> gold </e1> , hydroxychloroquine, leflunomide, sulfasalazine, and  <e2> anakinra </e2> .
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine,  <e1> leflunomide </e1> ,  <e2> sulfasalazine </e2> , and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine,  <e1> chloroquine </e1> , gold,  <e2> hydroxychloroquine </e2> , leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs,  <e1> corticosteroids </e1> , TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and  <e2> anakinra </e2> .
advise	Concurrent therapy with  <e1> ORENCIA </e1>  and  <e2> TNF antagonists </e2>  is not recommended.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids,  <e1> TNF blocking agents </e1> , azathioprine,  <e2> chloroquine </e2> , gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX,  <e1> NSAIDs </e1> , corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and  <e2> anakinra </e2> .
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA:  <e1> MTX </e1> , NSAIDs, corticosteroids, TNF blocking agents,  <e2> azathioprine </e2> , chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with  <e1> ORENCIA </e1> : MTX, NSAIDs,  <e2> corticosteroids </e2> , TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine,  <e1> leflunomide </e1> , sulfasalazine, and  <e2> anakinra </e2> .
false	These medications have included  <e1> heparin </e1> ,  <e2> warfarin </e2> , beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.
false	These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates,  <e1> ticlopidine </e1> , and  <e2> aspirin </e2> .
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs,  <e1> corticosteroids </e1> , TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and  <e2> anakinra </e2> .
false	Concurrent administration of a TNF antagonist with  <e1> ORENCIA </e1>  has been associated with an increased risk of serious infections and no significant additional efficacy over use of the  <e2> TNF antagonists </e2>  alone.
false	Heparin, other  <e1> anticoagulants </e1> , thrombolytics, and  <e2> anti platelet agents </e2>  are associated with an increase in bleeding.
false	These medications have included heparin, warfarin,  <e1> beta-adrenergic receptor blockers </e1> , calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates,  <e2> ticlopidine </e2> , and aspirin.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with  <e1> ORENCIA </e1> : MTX, NSAIDs,  <e2> corticosteroids </e2> , TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	These medications have included heparin, warfarin,  <e1> beta-adrenergic receptor blockers </e1> ,  <e2> calcium channel antagonists </e2> , angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.
false	Heparin, other  <e1> anticoagulants </e1> ,  <e2> thrombolytics </e2> , and anti platelet agents are associated with an increase in bleeding.
false	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with  <e1> anxiolytics </e1> ,  <e2> hypnotics </e2>  and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.
false	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics,  <e1> hypnotics </e1>  and sedatives (including benzodiazepines), or  <e2> non-opioid analgesics </e2>  was similar to that of subjects taking placebo with these concomitant medications.
false	The pharmacokinetics of  <e1> naltrexone </e1>  and its major metabolite  <e2> 6-beta-naltrexol </e2>  were unaffected following co-administration with Acamprosate.
false	Pharmacokinetic studies indicate that administration of disulfiram or  <e1> diazepam </e1>  does not affect the pharmacokinetics of  <e2> acamprosate </e2> .
false	The concomitant intake of alcohol and  <e1> Acamprosate </e1>  does not affect the pharmacokinetics of either  <e2> alcohol </e2>  or acamprosate.
false	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  <e1> Acamprosate </e1>  concomitantly with anxiolytics, hypnotics and sedatives (including  <e2> benzodiazepines </e2> ), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.
false	Co-administration of  <e1> naltrexone </e1>  with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of  <e2> acamprosate </e2> .
false	The pharmacokinetics of naltrexone and its major metabolite  <e1> 6-beta-naltrexol </e1>  were unaffected following co-administration with  <e2> Acamprosate </e2> .
false	Co-administration of  <e1> naltrexone </e1>  with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of  <e2> acamprosate </e2> .
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin,  <e2> nicotinic acid </e2> , sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	Intestinal adsorbents (e. g., charcoal) and  <e1> digestive enzyme preparations </e1>  containing carbohydrate-splitting enzymes (e. g., amylase,  <e2> pancreatin </e2> ) may reduce the effect of Acarbose and should not be taken concomitantly.
false	Intestinal adsorbents (e. g., charcoal) and  <e1> digestive enzyme preparations </e1>  containing carbohydrate-splitting enzymes (e. g.,  <e2> amylase </e2> , pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and  <e2> isoniazid </e2> .
mechanism	Intestinal adsorbents (e. g.,  <e1> charcoal </e1> ) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of  <e2> Acarbose </e2>  and should not be taken concomitantly.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines,  <e1> thyroid products </e1> , estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel-blocking drugs </e2> , and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids,  <e1> phenothiazines </e1> , thyroid products,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	The pharmacokinetics of  <e1> naltrexone </e1>  and its major metabolite  <e2> 6-beta-naltrexol </e2>  were unaffected following co-administration with Acamprosate.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel-blocking drugs </e2> , and isoniazid.
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid,  <e2> sympathomimetics </e2> , calcium channel-blocking drugs, and isoniazid.
false	 <e1> Intestinal adsorbents </e1>  (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase,  <e2> pancreatin </e2> ) may reduce the effect of Acarbose and should not be taken concomitantly.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral  <e2> contraceptives </e2> , phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e1> calcium channel-blocking drugs </e1> , and  <e2> isoniazid </e2> .
false	Studies in healthy volunteers have shown that  <e1> Acarbose </e1>  has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine,  <e2> propranolol </e2> , or ranitidine.
mechanism	 <e1> Acarbose </e1>  has been shown to change the bioavailabillty  <e2> digoxin </e2>  when they are co-administered, which may require digoxin dose adjustment.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel-blocking drugs </e2> , and isoniazid.
false	Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of  <e1> digoxin </e1> , nifedipine,  <e2> propranolol </e2> , or ranitidine.
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines,  <e2> thyroid products </e2> , estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines,  <e1> thyroid products </e1> ,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives,  <e2> phenytoin </e2> , nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products,  <e1> estrogens </e1> , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel-blocking drugs </e2> , and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin,  <e1> nicotinic acid </e1> , sympathomimetics, calcium channel-blocking drugs, and  <e2> isoniazid </e2> .
false	Studies in healthy volunteers have shown that  <e1> Acarbose </e1>  has no effect on either the pharmacokinetics or pharmacodynamics of digoxin,  <e2> nifedipine </e2> , propranolol, or ranitidine.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral  <e1> contraceptives </e1> , phenytoin, nicotinic acid,  <e2> sympathomimetics </e2> , calcium channel-blocking drugs, and isoniazid.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin,  <e2> nicotinic acid </e2> , sympathomimetics, calcium channel-blocking drugs, and isoniazid.
mechanism	 <e1> Acarbose </e1>  has been shown to change the bioavailabillty  <e2> digoxin </e2>  when they are co-administered, which may require digoxin dose adjustment.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines,  <e1> thyroid products </e1> , estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel-blocking drugs </e2> , and isoniazid.
effect	Blunting of the antihypertensive effect of  <e1> beta-adrenoceptor blocking agents </e1>  by  <e2> nonsteroidal anti-inflammatory drugs </e2>  has been reported.
false	 <e1> Intestinal adsorbents </e1>  (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase,  <e2> pancreatin </e2> ) may reduce the effect of Acarbose and should not be taken concomitantly.
false	 <e1> Catecholamine-depleting drugs </e1> , such as  <e2> reserpine </e2> , may have an additive effect when given with beta-blocking agents.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral  <e2> contraceptives </e2> , phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	No significant interactions with digoxin, hydrochlorothiazide, hydralazine,  <e1> sulfinpyrazone </e1> , oral  <e2> contraceptives </e2> , tolbutamide, or warfarin have been observed.
false	No significant interactions with  <e1> digoxin </e1> , hydrochlorothiazide,  <e2> hydralazine </e2> , sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.
false	Studies in healthy volunteers have shown that  <e1> Acarbose </e1>  has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine,  <e2> propranolol </e2> , or ranitidine.
false	No significant interactions with digoxin,  <e1> hydrochlorothiazide </e1> ,  <e2> hydralazine </e2> , sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral  <e2> contraceptives </e2> , phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
mechanism	By decreasing the gastrointestinal absorption of primidone,  <e1> DIAMOX </e1>  may decrease serum concentrations of  <e2> primidone </e2>  and its metabolites, with a consequent possible decrease in anticonvulsant effect.
false	No significant interactions with digoxin, hydrochlorothiazide, hydralazine,  <e1> sulfinpyrazone </e1> , oral  <e2> contraceptives </e2> , tolbutamide, or warfarin have been observed.
effect	 <e1> Acetazolamide </e1>  may increase the effects of other  <e2> folic acid antagonists </e2> .
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines,  <e1> thyroid products </e1> , estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel-blocking drugs </e2> , and isoniazid.
false	No significant interactions with digoxin, hydrochlorothiazide, hydralazine,  <e1> sulfinpyrazone </e1> , oral  <e2> contraceptives </e2> , tolbutamide, or warfarin have been observed.
false	Other: There appears to be no pharmacokinetic interaction between  <e1> acitretin </e1>  and  <e2> cimetidine </e2> , digoxin, or glyburide.
false	Vitamin A and oral  <e1> retinoids </e1> : Concomitant administration of  <e2> vitamin A </e2>  and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
false	It is not known whether other  <e1> progestational contraceptives </e1> , such as implants and injectables, are adequate methods of contraception during  <e2> acitretin </e2>  therapy.
false	Repeating the study with 6 healthy male volunteers in the absence of  <e1> glibenclamide </e1>  did not detect an effect of  <e2> acitretin </e2>  on glucose tolerance.
false	Investigations into the effect of acitretin on the protein binding of  <e1> anticoagulants of the coumarin type </e1>  ( <e2> warfarin </e2> ) revealed no interaction.
effect	Methotrexate: An increased risk of hepatitis has been reported to result from combined use of  <e1> methotrexate </e1>  and  <e2> etretinate </e2> .
advise	Microdosed minipill  <e1> progestin </e1>  preparations are not recommended for use with  <e2> Soriatane </e2> .
false	 <e1> Phenytoin </e1> : If  <e2> acitretin </e2>  is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.
mechanism	Phenytoin: If  <e1> acitretin </e1>  is given concurrently with  <e2> phenytoin </e2> , the protein binding of phenytoin may be reduced.
false	Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of  <e1> glibenclamide </e1>  (a sulfonylurea similar to  <e2> chlorpropamide </e2> ) in 3 of the 7 subjects.
false	Other: There appears to be no pharmacokinetic interaction between  <e1> acitretin </e1>  and cimetidine, digoxin, or  <e2> glyburide </e2> .
false	 <e1> Glibenclamide </e1> : In a study of 7 healthy male volunteers,  <e2> acitretin </e2>  treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
false	 <e1> Anakinra </e1> : Concurrent administration of anakinra (an interleukin-1 antagonist) and another  <e2> TNF-blocking agent </e2>  has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
false	 <e1> Anakinra </e1> : Concurrent administration of  <e2> anakinra </e2>  (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
false	 <e1> Glibenclamide </e1> : In a study of 7 healthy male volunteers,  <e2> acitretin </e2>  treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
effect	Therefore the, combination of  <e1> anakinra </e1>  with other TNF-blocking agents, including  <e2> HUMIRA </e2> , may also result i n similar toxicities.
false	Anakinra: Concurrent administration of  <e1> anakinra </e1>  (an  <e2> interleukin-1 antagonist </e2> ) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
false	 <e1> Anakinra </e1> : Concurrent administration of anakinra (an interleukin-1 antagonist) and another  <e2> TNF-blocking agent </e2>  has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
false	 <e1> Glibenclamide </e1> : In a study of 7 healthy male volunteers,  <e2> acitretin </e2>  treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
false	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin,  <e1> amikacin </e1> ), amphotericin B,  <e2> cyclosporine </e2> , non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.
false	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin),  <e1> amphotericin B </e1> ,  <e2> cyclosporine </e2> , non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.
false	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  <e1> aminoglycosides </e1>  (e.g., gentamicin,  <e2> amikacin </e2> ), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.
false	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin),  <e1> amphotericin B </e1> , cyclosporine, non-steroidal anti-inflammatory drugs (e.g.,  <e2> ibuprofen </e2> ), tacrolimus, vancomycin.
false	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g.,  <e1> gentamicin </e1> , amikacin),  <e2> amphotericin B </e2> , cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.
false	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g.,  <e1> gentamicin </e1> , amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus,  <e2> vancomycin </e2> .
false	 <e1> Glibenclamide </e1> : In a study of 7 healthy male volunteers,  <e2> acitretin </e2>  treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
advise	In the presence of these  <e1> methylxanthines </e1> , larger doses of  <e2> adenosine </e2>  may be required or adenosine may not be effective.
false	 <e1> Digoxin </e1>  and  <e2> verapamil </e2>  use may be rarely associated with ventricular fibrillation when combined with Adenocard.
false	Intravenous Adenocard ( <e1> adenosine </e1> ) has been effectively administered in the presence of other cardioactive drugs, such as  <e2> quinidine </e2> , beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.
false	The effects of adenosine are antagonized by  <e1> methylxanthines </e1>  such as  <e2> caffeine </e2>  and theophylline.
effect	 <e1> Adenosine </e1>  effects are potentiated by  <e2> dipyridamole </e2> .
false	Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine,  <e1> beta-adrenergic blocking agents </e1> , calcium channel blocking agents, and  <e2> angiotensin converting enzyme inhibitors </e2> , without any change in the adverse reaction profile.
false	Intravenous Adenocard ( <e1> adenosine </e1> ) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents,  <e2> calcium channel blocking agents </e2> , and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.
effect	Digoxin and  <e1> verapamil </e1>  use may be rarely associated with ventricular fibrillation when combined with  <e2> Adenocard </e2> .
false	 <e1> Glibenclamide </e1> : In a study of 7 healthy male volunteers,  <e2> acitretin </e2>  treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
false	 <e1> Digoxin </e1>  and  <e2> verapamil </e2>  use may be rarely associated with ventricular fibrillation when combined with Adenocard.
false	Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine,  <e1> beta-adrenergic blocking agents </e1> , calcium channel blocking agents, and  <e2> angiotensin converting enzyme inhibitors </e2> , without any change in the adverse reaction profile.
false	 <e1> Nafazodone </e1> ,  <e2> fluvoxamine </e2> , cimetidine (consider Xanax dose reduction).
false	Intravenous Adenocard ( <e1> adenosine </e1> ) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents,  <e2> calcium channel blocking agents </e2> , and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.
false	Co-administration with  <e1> antifungal agents </e1>  such as  <e2> ketoconazole </e2>  or itraconazole is not recommended.
advise	In the presence of these  <e1> methylxanthines </e1> , larger doses of  <e2> adenosine </e2>  may be required or adenosine may not be effective.
effect	 <e1> Adenosine </e1>  effects are potentiated by  <e2> dipyridamole </e2> .
false	 <e1> Digoxin </e1>  and  <e2> verapamil </e2>  use may be rarely associated with ventricular fibrillation when combined with Adenocard.
false	Dexamethasone: Steady-state trough concentrations of  <e1> albendazole sulfoxide </e1>  were about 56% higher when 8 mg dexamethasone was coadministered with each dose of  <e2> albendazole </e2>  (15 mg/kg/day) in eight neurocysticercosis patients.
false	 <e1> Cimetidine </e1> : Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with  <e2> albendazole </e2>  (20 mg/kg/day) alone (n=12).
false	 <e1> Praziquantel </e1> : In the fed state,  <e2> praziquantel </e2>  (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.
false	 <e1> Theophylline </e1> : The pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of  <e2> albendazole </e2>  (400 mg) in 6 healthy subjects.
false	 <e1> Praziquantel </e1> : In the fed state,  <e2> praziquantel </e2>  (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.
false	Although glucocorticoids have been shown to reduce  <e1> PROLEUKIN </e1> -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12  <e2> Beta-blockers </e2>  and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
false	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics,  <e1> antiemetics </e1> , sedatives,  <e2> tranquilizers </e2> ).
false	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12  <e1> Beta-blockers </e1>  and other  <e2> antihypertensives </e2>  may potentiate the hypotension seen with PROLEUKIN.
false	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g.,  <e1> cytotoxic </e1>  chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g.,  <e2> methotrexate </e2> , asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
effect	Although  <e1> glucocorticoids </e1>  have been shown to reduce  <e2> PROLEUKIN </e2> -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
false	Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with  <e1> PROLEUKIN </e1>  may reduce the antitumor effectiveness of  <e2> PROLEUKIN </e2>  and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
false	Delayed Adverse Reactions to  <e1> Iodinated Contrast Media </e1> : A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various  <e2> interleukin-2 </e2>  containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.
effect	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g.,  <e1> cytotoxic </e1>  chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with  <e2> PROLEUKIN </e2>  may increase toxicity in these organ systems.
false	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum,  <e1> tamoxifen </e1>  and  <e2> interferon-alfa </e2> .
false	Concurrent administration of drugs possessing nephrotoxic (e.g.,  <e1> aminoglycosides </e1> , indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g.,  <e2> methotrexate </e2> , asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
effect	Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various  <e1> interleukin-2 </e1>  containing regimens who were subsequently administered  <e2> radiographic iodinated contrast media </e2>  experienced acute, atypical adverse reactions.
false	Concurrent administration of drugs possessing nephrotoxic (e.g.,  <e1> aminoglycosides </e1> , indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g.,  <e2> doxorubicin </e2> ) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
effect	Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of  <e1> interferon-alfa </e1>  and  <e2> PROLEUKIN </e2> , including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.
false	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides,  <e1> indomethacin </e1> ), myelotoxic (e.g.,  <e2> cytotoxic </e2>  chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
false	The safety and efficacy of  <e1> PROLEUKIN </e1>  in combination with any  <e2> antineoplastic agents </e2>  have not been established.
false	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides,  <e1> indomethacin </e1> ), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate,  <e2> asparaginase </e2> ) effects with PROLEUKIN may increase toxicity in these organ systems.
false	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g.,  <e1> methotrexate </e1> ,  <e2> asparaginase </e2> ) effects with PROLEUKIN may increase toxicity in these organ systems.
effect	Although  <e1> glucocorticoids </e1>  have been shown to reduce  <e2> PROLEUKIN </e2> -induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
false	The duration of the period following treatment with  <e1> AMEVIVE </e1>   before one should consider starting other  <e2> immunosuppressive </e2>  therapy has not been evaluated.
false	Since the effect of AMEVIVE on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking  <e1> AMEVIVE </e1>  who become pregnant into the Biogen Pregnancy Registry by calling 1-866- <e2> AMEVIVE </e2>  (1-866-263-8483).
false	Delayed Adverse Reactions to  <e1> Iodinated Contrast Media </e1> : A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various  <e2> interleukin-2 </e2>  containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.
false	The safety and efficacy of  <e1> PROLEUKIN </e1>  in combination with any  <e2> antineoplastic agents </e2>  have not been established.
false	The duration of the period following treatment with  <e1> AMEVIVE </e1>   before one should consider starting other  <e2> immunosuppressive </e2>  therapy has not been evaluated.
false	Products containing  <e1> calcium </e1>  and other  <e2> multivalent cations </e2>  likely will interfere with absorption of alendronate.
effect	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when  <e1> ALFENTA </e1>  is administered in combination with other  <e2> CNS depressants </e2>  such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
false	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following  <e1> ALFENTA </e1>  induction The concomitant use of erythromycin with ALFENTA can significantly inhibit  <e2> ALFENTA </e2>  clearance and may increase the risk of prolonged or delayed respiratory depression.
false	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as  <e1> barbiturates </e1> ,  <e2> tranquilizers </e2> , opioids, or inhalation general anesthetics.
false	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following  <e1> ALFENTA </e1>  induction The concomitant use of  <e2> erythromycin </e2>  with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
false	Limited clinical experience indicates that requirements for  <e1> volatile inhalation anesthetics </e1>  are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of  <e2> erythromycin </e2>  with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
false	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as  <e1> barbiturates </e1> ,  <e2> tranquilizers </e2> , opioids, or inhalation general anesthetics.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan,  <e1> metformin </e1>  and  <e2> amlodipine </e2>  did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of  <e1> lovastatin </e1> , atenolol,  <e2> warfarin </e2> , furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of lovastatin,  <e1> atenolol </e1> , warfarin, furosemide, digoxin, celecoxib,  <e2> hydrochlorothiazide </e2> , ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of  <e1> lovastatin </e1> , digoxin, valsartan, amlodipine,  <e2> metformin </e2> , celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
false	Co-administration of  <e1> lovastatin </e1> , atenolol, warfarin, furosemide,  <e2> digoxin </e2> , celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of lovastatin,  <e1> atenolol </e1> , warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in  <e2> aliskiren </e2>  exposure.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide,  <e1> ramipril </e1> , valsartan, metformin and  <e2> amlodipine </e2>  did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide,  <e1> digoxin </e1> , celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and  <e2> amlodipine </e2>  did not result in clinically significant increases in aliskiren exposure.
false	Furosemide: When aliskiren was co-administered with  <e1> furosemide </e1> , the AUC and Cmax of  <e2> furosemide </e2>  were reduced by about 30% and 50%, respectively.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin,  <e1> celecoxib </e1> ,  <e2> hydrochlorothiazide </e2> , ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril,  <e1> valsartan </e1> ,  <e2> metformin </e2>  and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of  <e1> lovastatin </e1> , digoxin, valsartan,  <e2> amlodipine </e2> , metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide,  <e1> digoxin </e1> , celecoxib, hydrochlorothiazide,  <e2> ramipril </e2> , valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin,  <e1> digoxin </e1> , valsartan, amlodipine,  <e2> metformin </e2> , celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
mechanism	Ketoconazole: Co-administration of 200 mg twice-daily  <e1> ketoconazole </e1>  with  <e2> aliskiren </e2>  resulted in an approximate 80% increase in plasma levels of aliskiren.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril,  <e1> valsartan </e1> , metformin and amlodipine did not result in clinically significant increases in  <e2> aliskiren </e2>  exposure.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin,  <e1> celecoxib </e1> , hydrochlorothiazide,  <e2> ramipril </e2> , valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin,  <e1> celecoxib </e1> , hydrochlorothiazide, ramipril, valsartan,  <e2> metformin </e2>  and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine,  <e1> metformin </e1> , celecoxib, atenolol, atorvastatin, ramipril or  <e2> hydrochlorothiazide </e2> .
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide,  <e1> ramipril </e1> ,  <e2> valsartan </e2> , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of lovastatin, atenolol,  <e1> warfarin </e1> , furosemide,  <e2> digoxin </e2> , celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Ketoconazole: Co-administration of 200 mg twice-daily  <e1> ketoconazole </e1>  with aliskiren resulted in an approximate 80% increase in plasma levels of  <e2> aliskiren </e2> .
false	Co-administration of lovastatin,  <e1> atenolol </e1> , warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide,  <e2> ramipril </e2> , valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of  <e1> lovastatin </e1> , digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or  <e2> hydrochlorothiazide </e2> .
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin,  <e1> valsartan </e1> , amlodipine, metformin, celecoxib,  <e2> atenolol </e2> , atorvastatin, ramipril or hydrochlorothiazide.
false	Co-administration of  <e1> lovastatin </e1> , atenolol, warfarin,  <e2> furosemide </e2> , digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of lovastatin, atenolol, warfarin,  <e1> furosemide </e1> , digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and  <e2> amlodipine </e2>  did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of  <e1> aliskiren </e1>  did not significantly affect the pharmacokinetics of lovastatin,  <e2> digoxin </e2> , valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide,  <e1> ramipril </e1> , valsartan, metformin and  <e2> amlodipine </e2>  did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of lovastatin,  <e1> atenolol </e1> , warfarin, furosemide, digoxin, celecoxib,  <e2> hydrochlorothiazide </e2> , ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including  <e1> protease inhibitors </e1> , macrolide antibiotics, and azole antifungals, the effect of  <e2> Panretin </e2>  gel on the steady-state concentrations of these drugs is not known.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide,  <e1> digoxin </e1> , celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and  <e2> amlodipine </e2>  did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine,  <e1> metformin </e1> , celecoxib, atenolol, atorvastatin, ramipril or  <e2> hydrochlorothiazide </e2> .
advise	Patients who are applying  <e1> Panretin </e1>  gel should not concurrently use products that contain DEET (N,  <e2> N-diethyl-m-toluamide </e2> ), a common component of insect repellent products.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril,  <e1> valsartan </e1> , metformin and amlodipine did not result in clinically significant increases in  <e2> aliskiren </e2>  exposure.
false	Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including  <e1> protease inhibitors </e1> ,  <e2> macrolide antibiotics </e2> , and azole antifungals, the effect of Panretin gel on the steady-state concentrations of these drugs is not known.
false	Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic  <e1> antiretroviral agents </e1> , including  <e2> protease inhibitors </e2> , macrolide antibiotics, and azole antifungals, the effect of Panretin gel on the steady-state concentrations of these drugs is not known.
false	However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with  <e1> cyclophosphamide </e1> , doxorubicin, bleomycin, procarbazine and/or  <e2> mechlorethamine </e2> .
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide,  <e1> ramipril </e1> , valsartan, metformin and  <e2> amlodipine </e2>  did not result in clinically significant increases in aliskiren exposure.
false	However, in a well-controlled study of patients with lymphoma on combination therapy,  <e1> allopurinol </e1>  did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or  <e2> mechlorethamine </e2> .
mechanism	Mercaptopurine/Azathioprine:  <e1> Allopurinol </e1>  inhibits the enzymatic oxidation of mercaptopurine and  <e2> azathioprine </e2>  to 6-thiouric acid.
false	However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with  <e1> cyclophosphamide </e1> , doxorubicin,  <e2> bleomycin </e2> , procarbazine and/or mechlorethamine.
false	In patients receiving mercaptopurine ( <e1> Purinethol </e1> ) or azathioprine ( <e2> Imuran </e2> ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
false	In patients receiving  <e1> mercaptopurine </e1>  (Purinethol) or  <e2> azathioprine </e2>  (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
false	Dicumarol: It has been reported that allopurinol prolongs the half-life of the  <e1> anticoagulant </e1> ,  <e2> dicumarol </e2> .
false	 <e1> Thiazide Diuretics </e1> : The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of  <e2> allopurinol </e2>  toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
false	In patients receiving mercaptopurine ( <e1> Purinethol </e1> ) or azathioprine (Imuran), the concomitant administration of 300-600 mg of  <e2> allopurinol </e2>  per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
effect	Thiazide Diuretics: The reports that the concomitant use of  <e1> allopurinol </e1>  and  <e2> thiazide diuretics </e2>  may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
false	Uricosuric Agents: Since the excretion of  <e1> oxipurinol </e1>  is similar to that of urate,  <e2> uricosuric agents </e2> , which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.
false	In patients receiving mercaptopurine ( <e1> Purinethol </e1> ) or  <e2> azathioprine </e2>  (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
false	However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with  <e1> cyclophosphamide </e1> , doxorubicin, bleomycin,  <e2> procarbazine </e2>  and/or mechlorethamine.
false	Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving  <e1> ampicillin </e1>  or  <e2> amoxicillin </e2>  concurrently with allopurinol compared to patients who are not receiving both drugs.
false	 <e1> Ampicillin </e1> /Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with  <e2> allopurinol </e2>  compared to patients who are not receiving both drugs.
false	Mercaptopurine/Azathioprine:  <e1> Allopurinol </e1>  inhibits the enzymatic oxidation of mercaptopurine and azathioprine to  <e2> 6-thiouric acid </e2> .
false	However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide,  <e1> doxorubicin </e1> ,  <e2> bleomycin </e2> , procarbazine and/or mechlorethamine.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide,  <e1> digoxin </e1> , celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and  <e2> amlodipine </e2>  did not result in clinically significant increases in aliskiren exposure.
false	Thiazide Diuretics: The reports that the concomitant use of  <e1> allopurinol </e1>  and thiazide diuretics may contribute to the enhancement of  <e2> allopurinol </e2>  toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
false	 <e1> Ampicillin </e1> / <e2> Amoxicillin </e2> : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
advise	In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of  <e1> allopurinol </e1>  per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of  <e2> mercaptopurine </e2>  or azathioprine.
false	 <e1> Propanolol </e1> : The pharmacokinetics of almotriptan were not affected by coadministration of  <e2> propranolol </e2> .
false	Although the interaction between  <e1> almotriptan </e1>  and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when  <e2> almotriptan </e2>  is used concomitantly with these medications.
advise	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g.,  <e1> itraconazole </e1> , ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when  <e2> almotriptan </e2>  is used concomitantly with these medications.
mechanism	Monoamine Oxidase Inhibitors: Coadministration of  <e1> moclobemide </e1>  resulted in a 27% decrease in  <e2> almotriptan </e2>  clearance and an increase in Cmax of approximately 6%.
false	Verapamil: Coadministration of  <e1> almotriptan </e1>  and verapamil resulted in a 24% increase in plasma concentrations of  <e2> almotriptan </e2> .
false	Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine,  <e1> fluvoxamine </e1> , paroxetine,  <e2> sertraline </e2> ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
false	Although the interaction between  <e1> almotriptan </e1>  and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and  <e2> erythromycin </e2> ) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
false	Dicumarol: It has been reported that allopurinol prolongs the half-life of the  <e1> anticoagulant </e1> ,  <e2> dicumarol </e2> .
false	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g.,  <e1> itraconazole </e1> , ritonavir, and erythromycin) has not been studied, increased exposures to  <e2> almotriptan </e2>  may be expected when almotriptan is used concomitantly with these medications.
false	Because there is a theoretical basis that these effects may be additive, use of  <e1> ergotamine </e1> -containing or ergot-type medications (like dihydroergotamine or  <e2> methysergide </e2> ) and AXERT within 24 hours of each other should be avoided.
effect	Selective Serotonin Reuptake Inhibitors (SSRIs):  <e1> SSRIs </e1>  (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  <e2> 5-HT1 agonists </e2> .
false	Selective Serotonin Reuptake Inhibitors ( <e1> SSRIs </e1> ): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine,  <e2> sertraline </e2> ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
advise	If concomitant treatment with  <e1> AXERT </e1>  and an  <e2> SSRI </e2>  is clinically warranted, appropriate observation of the patient is advised.
false	Selective Serotonin Reuptake Inhibitors (SSRIs):  <e1> SSRIs </e1>  (e.g., fluoxetine, fluvoxamine,  <e2> paroxetine </e2> , sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
false	Although the interaction between  <e1> almotriptan </e1>  and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to  <e2> almotriptan </e2>  may be expected when almotriptan is used concomitantly with these medications.
false	Uricosuric Agents: Since the excretion of  <e1> oxipurinol </e1>  is similar to that of urate,  <e2> uricosuric agents </e2> , which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.
false	Selective Serotonin Reuptake Inhibitors ( <e1> SSRIs </e1> ): SSRIs (e.g., fluoxetine, fluvoxamine,  <e2> paroxetine </e2> , sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
false	Selective Serotonin Reuptake Inhibitors ( <e1> SSRIs </e1> ):  <e2> SSRIs </e2>  (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
false	 <e1> Verapamil </e1> : Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of  <e2> almotriptan </e2> .
effect	Selective Serotonin Reuptake Inhibitors (SSRIs):  <e1> SSRIs </e1>  (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  <e2> 5-HT1 agonists </e2> .
false	Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral  <e1> contraceptive agents </e1>  ethinyl estradiol and  <e2> levonorgestrel </e2>  (CYP3A4 substrates).
false	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g.,  <e1> itraconazole </e1> , ritonavir, and erythromycin) has not been studied, increased exposures to  <e2> almotriptan </e2>  may be expected when almotriptan is used concomitantly with these medications.
false	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin,  <e1> protease inhibitors </e1> ,  <e2> voriconazole </e2> , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
false	Uricosuric Agents: Since the excretion of  <e1> oxipurinol </e1>  is similar to that of urate,  <e2> uricosuric agents </e2> , which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.
false	 <e1> Verapamil </e1> : Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of  <e2> almotriptan </e2> .
advise	Caution should be used when  <e1> alosetron </e1>  and  <e2> ketoconazole </e2>  are administered concomitantly.
false	In a pharmacokinetic study, 40 healthy female subjects received  <e1> fluvoxamine </e1>  in escalating doses from 50 to 200 mg per day for 16 days, with coadministration of  <e2> alosetron </e2>  1 mg on the last day.
false	Dicumarol: It has been reported that allopurinol prolongs the half-life of the  <e1> anticoagulant </e1> ,  <e2> dicumarol </e2> .
false	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin,  <e1> telithromycin </e1> ,  <e2> protease inhibitors </e2> , voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
advise	Concomitant administration of  <e1> alosetron </e1>  and  <e2> fluvoxamine </e2>  is contraindicated.
false	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving  <e1> Alprazolam </e1>  (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with  <e2> alprazolam </e2>  increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to  <e1> alprazolam </e1>  or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as  <e2> erythromycin </e2>  and clarithromycin, and grapefruit juice.
int	Data from in vitro studies of benzodiazepines other than  <e1> alprazolam </e1>  suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone,  <e2> nicardipine </e2> , and nifedipine.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than  <e1> alprazolam </e1>  suggest a possible drug interaction with alprazolam for the following:  <e2> diltiazem </e2> , isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  <e1> benzodiazepines </e1>  metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with  <e2> alprazolam </e2>  for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to  <e1> alprazolam </e1>  or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of  <e2> benzodiazepines </e2>  other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with  <e1> alprazolam </e1> ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as  <e2> erythromycin </e2>  and clarithromycin, and grapefruit juice.
mechanism	Coadministration of oral  <e1> contraceptives </e1>  increased the maximum plasma concentration of  <e2> alprazolam </e2>  by 18%, decreased clearance by 22%, and increased half-life by 29%.
int	Data from in vitro studies of benzodiazepines other than  <e1> alprazolam </e1>  suggest a possible drug interaction for the following:  <e2> ergotamine </e2> , cyclosporine, amiodarone, nicardipine, and nifedipine.
false	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other  <e1> psychotropic medications </e1> ,  <e2> anticonvulsants </e2> , antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other  <e1> benzodiazepines </e1>  (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and  <e2> clarithromycin </e2> , and grapefruit juice.
int	Data from in vitro studies of  <e1> benzodiazepines </e1>  other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine,  <e2> amiodarone </e2> , nicardipine, and nifedipine.
effect	The  <e1> benzodiazepines </e1> , including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics,  <e2> ethanol </e2> , and other drugs which themselves produce CNS depression.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other  <e1> benzodiazepines </e1>  (caution is recommended during coadministration with  <e2> alprazolam </e2> ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to  <e1> alprazolam </e1>  or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid,  <e2> macrolide antibiotics </e2>  such as erythromycin and clarithromycin, and grapefruit juice.
advise	Caution should be used when  <e1> alosetron </e1>  and  <e2> ketoconazole </e2>  are administered concomitantly.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than  <e1> alprazolam </e1>  suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as  <e2> erythromycin </e2>  and clarithromycin, and grapefruit juice.
false	Drugs That Inhibit  <e1> Alprazolam </e1>  Metabolism Via Cytochrome P450 3A: The initial step in  <e2> alprazolam </e2>  metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with  <e1> alprazolam </e1>  or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid,  <e2> macrolide antibiotics </e2>  such as erythromycin and clarithromycin, and grapefruit juice.
effect	The  <e1> benzodiazepines </e1> , including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications,  <e2> anticonvulsants </e2> , antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than  <e1> alprazolam </e1>  suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and  <e2> clarithromycin </e2> , and grapefruit juice.
false	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants,  <e1> antihistaminics </e1> ,  <e2> ethanol </e2> , and other drugs which themselves produce CNS depression.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem,  <e1> isoniazid </e1> , macrolide antibiotics such as  <e2> erythromycin </e2>  and clarithromycin, and grapefruit juice.
int	Data from in vitro studies of  <e1> benzodiazepines </e1>  other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and  <e2> nifedipine </e2> .
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other  <e1> benzodiazepines </e1>  (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following:  <e2> diltiazem </e2> , isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of  <e1> benzodiazepines </e1>  other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and  <e2> clarithromycin </e2> , and grapefruit juice.
false	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following:  <e1> ergotamine </e1> , cyclosporine, amiodarone, nicardipine, and  <e2> nifedipine </e2> .
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of  <e1> benzodiazepines </e1>  other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem,  <e2> isoniazid </e2> , macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  <e1> benzodiazepines </e1>  metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with  <e2> alprazolam </e2> ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  <e1> benzodiazepines </e1>  metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as  <e2> erythromycin </e2>  and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than  <e1> alprazolam </e1>  suggest a possible drug interaction with alprazolam for the following: diltiazem,  <e2> isoniazid </e2> , macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
effect	The  <e1> benzodiazepines </e1> , including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics,  <e2> ethanol </e2> , and other drugs which themselves produce CNS depression.
false	 <e1> vasopressors </e1> , such as  <e2> dopamine </e2>  and isoproterenol;
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of  <e1> benzodiazepines </e1>  other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem,  <e2> isoniazid </e2> , macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	vasopressors, such as  <e1> dopamine </e1>  and  <e2> isoproterenol </e2> ;
false	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants,  <e1> antihistaminics </e1> ,  <e2> ethanol </e2> , and other drugs which themselves produce CNS depression.
false	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other  <e1> psychotropic medications </e1> ,  <e2> anticonvulsants </e2> , antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
int	Data from in vitro studies of benzodiazepines other than  <e1> alprazolam </e1>  suggest a possible drug interaction for the following:  <e2> ergotamine </e2> , cyclosporine, amiodarone, nicardipine, and nifedipine.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to  <e1> alprazolam </e1>  or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of  <e2> benzodiazepines </e2>  other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of  <e1> benzodiazepines </e1>  other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem,  <e2> isoniazid </e2> , macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	In addition to bleeding associated with heparin and  <e1> vitamin K antagonists </e1> , drugs that alter platelet function (such as acetylsalicylic acid,  <e2> dipyridamole </e2>  and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
effect	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid,  <e1> dipyridamole </e1>  and Abciximab) may increase the risk of bleeding if administered prior to, during, or after  <e2> Activase </e2>  therapy.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to  <e1> alprazolam </e1>  or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of  <e2> benzodiazepines </e2>  other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
int	Data from in vitro studies of benzodiazepines other than  <e1> alprazolam </e1>  suggest a possible drug interaction for the following:  <e2> ergotamine </e2> , cyclosporine, amiodarone, nicardipine, and nifedipine.
false	Use of  <e1> Antithrombotics </e1>  Aspirin and  <e2> heparin </e2>  have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.
false	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other  <e1> psychotropic medications </e1> ,  <e2> anticonvulsants </e2> , antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
advise	however, it adversely affected response duration suggesting that  <e1> pyridoxine </e1>  should not be administered with HEXALEN and/or  <e2> cisplatin </e2> .1
false	Use of  <e1> Antithrombotics </e1>  Aspirin and  <e2> heparin </e2>  have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.
false	Data from a randomized trial of HEXALEN and cisplatin plus or minus  <e1> pyridoxine </e1>  in ovarian cancer indicated that  <e2> pyridoxine </e2>  significantly reduced neurotoxicity;
false	Concurrent administration of  <e1> HEXALEN </e1>  and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased  <e2> altretamine </e2> s half-life and toxicity in a rat model.
advise	however, it adversely affected response duration suggesting that  <e1> pyridoxine </e1>  should not be administered with HEXALEN and/or  <e2> cisplatin </e2> .1
advise	Special consideration should be given to the administration of  <e1> ETHYOL </e1>  in patients receiving  <e2> antihypertensive medications </e2>  or other drugs that could cause or potentiate hypotension.
effect	In some patients, the administration of a  <e1> non-steroidal anti-inflammatory agent </e1>  can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and  <e2> thiazide diuretics </e2> .
false	Therefore, when MIDAMOR and  <e1> non-steroidal anti-inflammatory agents </e1>  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  <e2> diuretic </e2>  is obtained.
false	therefore, if  <e1> glucocorticoid </e1>  replacement is needed,  <e2> hydrocortisone </e2>  should be prescribed.
effect	 <e1> Aminoglutethimide </e1>  diminishes the effect of coumarin and  <e2> warfarin </e2> .
effect	Renal clearance measurements of  <e1> PAH </e1>  cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or  <e2> thiazolesulfone </e2> .
false	Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving  <e1> sulfonamides </e1> , procaine, or  <e2> thiazolesulfone </e2> .
false	It is, however, possible that concomitant use of other known photosensitizing agents such as  <e1> griseofulvin </e1> ,  <e2> thiazide diuretics </e2> , sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
false	It is, however, possible that concomitant use of other known  <e1> photosensitizing agents </e1>  such as griseofulvin, thiazide diuretics, sulfonylureas,  <e2> phenothiazines </e2> , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
effect	Renal clearance measurements of  <e1> PAH </e1>  cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or  <e2> thiazolesulfone </e2> .
false	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics,  <e1> sulfonylureas </e1> , phenothiazines,  <e2> sulfonamides </e2>  and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
false	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas,  <e1> phenothiazines </e1> , sulfonamides and  <e2> tetracyclines </e2>  might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
false	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics,  <e1> sulfonylureas </e1> ,  <e2> phenothiazines </e2> , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
false	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics,  <e1> sulfonylureas </e1> , phenothiazines,  <e2> sulfonamides </e2>  and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
false	Aminosalicylic acid may decrease the amount of digoxin ( <e1> Lanoxin </e1> ,  <e2> Lanoxicaps </e2> ) that gets absorbed into your body.
advise	Therefore you may need to take a  <e1> vitamin B12 </e1>  supplement while taking  <e2> aminosalicylic acid </e2> .
false	Administration of  <e1> rifampin </e1>  concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of  <e2> amiodarone </e2>  and desethylamiodarone.
false	There have been case reports of increased steady-state levels of  <e1> quinidine </e1> ,  <e2> procainamide </e2> , and phenytoin during concomitant therapy with amiodarone.
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  - <e1> receptor </e1>  blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a  <e2> CYP3A4 </e2>  substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	HMG-CoA Reductase Inhibitors:  <e1> Simvastatin </e1>  (CYP3A4 substrate) in combination with  <e2> amiodarone </e2>  has been associated with reports of myopathy/rhabdomyolysis.
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a  <e1> CYP3A4 </e1>  inhibitor) or calcium channel antagonists (e.g.,  <e2> verapamil </e2> , a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	Since  <e1> amiodarone </e1>  is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced  <e2> amiodarone </e2>  levels.
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g.,  <e1> verapamil </e1> , a CYP3A4 substrate, and  <e2> diltiazem </e2> , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a  <e1> CYP3A4 </e1>  substrate, and diltiazem, a  <e2> CYP3A4 </e2>  inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	The continued need for the other  <e1> antiarrhythmic </e1>  agent should be reviewed after the effects of  <e2> amiodarone </e2>  have been established, and discontinuation ordinarily should be attempted.
false	In addition to the interactions noted above, chronic (  2 weeks) oral  <e1> Cordarone </e1>  administration impairs metabolism of phenytoin,  <e2> dextromethorphan </e2> , and methotrexate.
false	Some  <e1> drugs </e1> /substances are known to accelerate the metabolism of  <e2> amiodarone </e2>  by stimulating the synthesis of CYP3A4 (enzyme induction).
false	Anticoagulants: Potentiation of  <e1> warfarin </e1> -type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving  <e2> amiodarone </e2>  and can result in serious or fatal bleeding.
false	There have been reports of QTc prolongation, with or without TdP, in patients taking  <e1> amiodarone </e1>  when fluoroquinolones,  <e2> macrolide antibiotics </e2> , or azoles were administered concomitantly.
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  - <e1> receptor </e1>  blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or  <e2> calcium channel </e2>  antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics,  <e1> sulfonylureas </e1> , phenothiazines,  <e2> sulfonamides </e2>  and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
false	Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine ( <e1> CYP3A4 </e1>  substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of  <e2> cyclosporine </e2> .
false	Amiodarone may suppress certain CYP450 enzymes, including  <e1> CYP1A2 </e1> ,  <e2> CYP2C9 </e2> , CYP2D6, and CYP3A4.
false	Antiarrhythmics: Other antiarrhythmic drugs, such as  <e1> quinidine </e1> , procainamide, disopyramide, and  <e2> phenytoin </e2> , have been used concurrently with amiodarone.
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  - <e1> receptor </e1>  blocking agents (e.g.,  <e2> propranolol </e2> , a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	 <e1> Antihypertensives </e1> : Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a  <e2> CYP3A4 </e2>  inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	Seizure, associated with increased  <e1> lidocaine </e1>  concentrations, has been reported with concomitant administration of intravenous  <e2> amiodarone </e2> .
false	 <e1> Amiodarone </e1>  may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9,  <e2> CYP2D6 </e2> , and CYP3A4.
false	Reported examples of this interaction include the following: Immunosuppressives:  <e1> Cyclosporine </e1>  (CYP3A4 substrate) administered in combination with oral  <e2> amiodarone </e2>  has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.
false	Combination of  <e1> amiodarone </e1>  with other  <e2> antiarrhythmic </e2>  therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.
false	Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with  <e1> propranolol </e1> , diltiazem, and  <e2> verapamil </e2> .
false	 <e1> Anticoagulants </e1> : Potentiation of warfarin-type ( <e2> CYP2C9 </e2>  and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
false	Antiarrhythmics: Other antiarrhythmic drugs, such as  <e1> quinidine </e1> , procainamide, disopyramide, and phenytoin, have been used concurrently with  <e2> amiodarone </e2> .
mechanism	A case report of one patient taking  <e1> amiodarone </e1>  200 mg and  <e2> indinavir </e2>  800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  - <e1> receptor </e1>  blocking agents (e.g., propranolol, a  <e2> CYP3A4 </e2>  inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	Amiodarone taken concomitantly with  <e1> procainamide </e1>  for less than seven days increases plasma concentrations of procainamide and n-acetyl  <e2> procainamide </e2>  by 55% and 33%, respectively.
false	There have been case reports of increased steady-state levels of quinidine,  <e1> procainamide </e1> , and phenytoin during concomitant therapy with  <e2> amiodarone </e2> .
false	 <e1> Dextromethorphan </e1>  is a substrate for both CYP2D6 and  <e2> CYP3A4 </e2> .
false	 <e1> Anticoagulants </e1> : Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving  <e2> amiodarone </e2>  and can result in serious or fatal bleeding.
false	because of this, the dosage of  <e1> flecainide </e1>  should be adjusted when these  <e2> drugs </e2>  are administered concomitantly.
false	 <e1> Dextromethorphan </e1>  is a substrate for both  <e2> CYP2D6 </e2>  and CYP3A4.
false	There have been case reports of increased steady-state levels of quinidine, procainamide, and  <e1> phenytoin </e1>  during concomitant therapy with  <e2> amiodarone </e2> .
false	Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine,  <e1> procainamide </e1> , disopyramide, and phenytoin, have been used concurrently with  <e2> amiodarone </e2> .
false	Cardiovasculars: Cardiac glycosides: In patients receiving  <e1> digoxin </e1>  therapy, administration of oral  <e2> amiodarone </e2>  regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.
false	Amiodarone may suppress certain CYP450 enzymes, including CYP1A2,  <e1> CYP2C9 </e1> , CYP2D6, and  <e2> CYP3A4 </e2> .
false	Reported examples of this interaction include the following: Immunosuppressives:  <e1> Cyclosporine </e1>  (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of  <e2> cyclosporine </e2>  resulting in elevated creatinine, despite reduction in dose of cyclosporine.
false	There have been case reports of increased steady-state levels of  <e1> quinidine </e1> , procainamide, and phenytoin during concomitant therapy with  <e2> amiodarone </e2> .
false	Antiarrhythmics: Other antiarrhythmic drugs, such as  <e1> quinidine </e1> , procainamide,  <e2> disopyramide </e2> , and phenytoin, have been used concurrently with amiodarone.
false	Administration of rifampin concomitantly with oral  <e1> amiodarone </e1>  has been shown to result in decreases in serum concentrations of amiodarone and  <e2> desethylamiodarone </e2> .
false	Cimetidine is reported to reduce hepatic metabolism of certain  <e1> tricyclic antidepressants </e1> , thereby delaying elimination and increasing steady-state concentrations of these  <e2> drugs </e2> .
false	Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine ( <e1> CYP3A4 </e1>  substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of  <e2> cyclosporine </e2> .
false	and disulfiram When amitriptyline HCl is given with  <e1> anticholinergic </e1>  agents or  <e2> sympathomimetic </e2>  drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.
false	cimetidine) and many that are substrates for P450 2D6 (many other  <e1> antidepressants </e1> ,  <e2> phenothiazines </e2> , and the Type 1C antiarrhythmics propafenone and flecainide).
false	 <e1> Anticoagulants </e1> : Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving  <e2> amiodarone </e2>  and can result in serious or fatal bleeding.
false	 <e1> cimetidine </e1> ) and many that are substrates for P450 2D6 (many other antidepressants,  <e2> phenothiazines </e2> , and the Type 1C antiarrhythmics propafenone and flecainide).
false	Discontinuation of  <e1> cimetidine </e1>  in well-controlled patients receiving tricyclic antidepressants and  <e2> cimetidine </e2>  may decrease the plasma levels and efficacy of the antidepressants.
false	Reported examples of this interaction include the following: Immunosuppressives:  <e1> Cyclosporine </e1>  (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of  <e2> cyclosporine </e2>  resulting in elevated creatinine, despite reduction in dose of cyclosporine.
false	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine,  <e1> sertraline </e1> , and  <e2> paroxetine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	and disulfiram When amitriptyline HCl is given with anticholinergic agents or  <e1> sympathomimetic </e1>  drugs, including  <e2> epinephrine </e2>  combined with local anesthetics, close supervision and careful adjustment of dosages are required.
false	Seizure, associated with increased  <e1> lidocaine </e1>  concentrations, has been reported with concomitant administration of intravenous  <e2> amiodarone </e2> .
mechanism	A case report of one patient taking  <e1> amiodarone </e1>  200 mg and  <e2> indinavir </e2>  800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.
false	Administration of rifampin concomitantly with oral  <e1> amiodarone </e1>  has been shown to result in decreases in serum concentrations of amiodarone and  <e2> desethylamiodarone </e2> .
effect	Hyperpyrexia has been reported when  <e1> amitriptyline HCl </e1>  is administered with  <e2> anticholinergic </e2>  agents or with neuroleptic drugs, particularly during hot weather.
false	Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when  <e1> cimetidine </e1>  was added to the  <e2> drug </e2>  regimen.
false	While all the selective serotonin reuptake inhibitors (SSRIs), e.g.,  <e1> fluoxetine </e1> ,  <e2> sertraline </e2> , and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
false	Cardiovasculars: Cardiac glycosides: In patients receiving  <e1> digoxin </e1>  therapy, administration of oral  <e2> amiodarone </e2>  regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.
false	Antiarrhythmics: Other antiarrhythmic drugs, such as  <e1> quinidine </e1> , procainamide, disopyramide, and  <e2> phenytoin </e2> , have been used concurrently with amiodarone.
false	Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly  <e1> anticholinergic </e1> , have been reported when  <e2> cimetidine </e2>  was added to the drug regimen.
false	Increases in plasma levels of  <e1> tricyclic antidepressants </e1> , and in the frequency and severity of side effects, particularly  <e2> anticholinergic </e2> , have been reported when cimetidine was added to the drug regimen.
false	Antiarrhythmics: Other antiarrhythmic drugs, such as  <e1> quinidine </e1> , procainamide, disopyramide, and phenytoin, have been used concurrently with  <e2> amiodarone </e2> .
false	While all the selective  <e1> serotonin reuptake inhibitors </e1>  (SSRIs), e.g., fluoxetine,  <e2> sertraline </e2> , and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
false	and  <e1> disulfiram </e1>  When amitriptyline HCl is given with  <e2> anticholinergic </e2>  agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.
effect	Skeletal muscle relaxants:  <e1> amphotericin B </e1> -induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g.,  <e2> tubocurarine </e2> ).
false	Imidazoles (e. g., ketoconazole,  <e1> miconazole </e1> ,  <e2> clotrimazole </e2> , fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
false	 <e1> Flucytosine </e1> : while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of  <e2> flucytosine </e2>  by possibly increasing its cellular uptake and/or impairing its renal excretion.
false	Imidazoles (e. g., ketoconazole, miconazole, clotrimazole,  <e1> fluconazole </e1> , etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to  <e2> amphotericin B </e2> .
false	 <e1> Skeletal muscle relaxants </e1> :  <e2> amphotericin B </e2> -induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
false	Imidazoles (e. g.,  <e1> ketoconazole </e1> , miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and  <e2> imidazoles </e2>  suggest that imidazoles may induce fungal resistance to amphotericin B.
false	Antiarrhythmics: Other antiarrhythmic drugs, such as  <e1> quinidine </e1> , procainamide, disopyramide, and  <e2> phenytoin </e2> , have been used concurrently with amiodarone.
false	Other nephrotoxic medications: agents such as  <e1> aminoglycosides </e1> ,  <e2> cyclosporine </e2> , and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.
false	and disulfiram When amitriptyline HCl is given with  <e1> anticholinergic </e1>  agents or  <e2> sympathomimetic </e2>  drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.
false	Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of  <e1> amphotericin B </e1>  and imidazoles suggest that imidazoles may induce fungal resistance to  <e2> amphotericin B </e2> .
false	 <e1> Skeletal muscle relaxants </e1> : amphotericin B-induced hypokalemia may enhance the curariform effect of  <e2> skeletal muscle relaxants </e2>  (e.g., tubocurarine).
false	Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when  <e1> cimetidine </e1>  was added to the  <e2> drug </e2>  regimen.
false	Reported examples of this interaction include the following: Immunosuppressives:  <e1> Cyclosporine </e1>  (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of  <e2> cyclosporine </e2>  resulting in elevated creatinine, despite reduction in dose of cyclosporine.
false	Discontinuation of  <e1> cimetidine </e1>  in well-controlled patients receiving tricyclic antidepressants and  <e2> cimetidine </e2>  may decrease the plasma levels and efficacy of the antidepressants.
false	Other nephrotoxic medications: agents such as  <e1> aminoglycosides </e1> , cyclosporine, and  <e2> pentamidine </e2>  may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.
effect	 <e1> Corticosteroids </e1>  and Corticotropin (ACTH): may potentiate  <e2> amphotericin B </e2> - induced hypokalemia which may predispose the patient to cardiac dysfunction.
false	Bacteriostatic Antibiotics:  <e1> Chloramphenicol </e1> ,  <e2> erythromycins </e2> , sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
false	 <e1> Bacteriostatic Antibiotics </e1> : Chloramphenicol, erythromycins, sulfonamides, or  <e2> tetracyclines </e2>  may interfere with the bactericidal effect of penicillins.
effect	Skeletal muscle relaxants:  <e1> amphotericin B </e1> -induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g.,  <e2> tubocurarine </e2> ).
false	Other nephrotoxic medications: agents such as  <e1> aminoglycosides </e1> , cyclosporine, and  <e2> pentamidine </e2>  may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.
false	Bacteriostatic Antibiotics: Chloramphenicol, erythromycins,  <e1> sulfonamides </e1> , or  <e2> tetracyclines </e2>  may interfere with the bactericidal effect of penicillins.
false	 <e1> Flucytosine </e1> : while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of  <e2> flucytosine </e2>  by possibly increasing its cellular uptake and/or impairing its renal excretion.
false	Methadone: Coadministration of amprenavir and  <e1> methadone </e1>  can decrease plasma levels of  <e2> methadone </e2> .
false	Other nephrotoxic medications: agents such as  <e1> aminoglycosides </e1> , cyclosporine, and  <e2> pentamidine </e2>  may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.
mechanism	Coadministration of  <e1> amprenavir </e1>  and  <e2> methadone </e2>  as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.
false	 <e1> Bacteriostatic Antibiotics </e1> : Chloramphenicol, erythromycins, sulfonamides, or  <e2> tetracyclines </e2>  may interfere with the bactericidal effect of penicillins.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were  <e1> aspirin </e1> , acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and  <e2> allopurinol </e2> .
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were  <e1> aspirin </e1> , acetaminophen,  <e2> furosemide </e2> , iron, ranitidine, hydroxyurea, and allopurinol.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  <e1> anagrelide </e1>  in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and  <e2> allopurinol </e2> .
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin,  <e1> acetaminophen </e1> , furosemide, iron,  <e2> ranitidine </e2> , hydroxyurea, and allopurinol.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  <e1> anagrelide </e1>  in clinical trials were aspirin,  <e2> acetaminophen </e2> , furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  <e1> anagrelide </e1>  in clinical trials were  <e2> aspirin </e2> , acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were  <e1> aspirin </e1> , acetaminophen, furosemide, iron, ranitidine,  <e2> hydroxyurea </e2> , and allopurinol.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  <e1> anagrelide </e1>  in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine,  <e2> hydroxyurea </e2> , and allopurinol.
false	In vivo interaction studies in humans have demonstrated that  <e1> digoxin </e1>  and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of  <e2> digoxin </e2>  or warfarin.
effect	The effects of medicinal products with similar properties such as inotropes milrinone, enoximone,  <e1> amrinone </e1> , olprinone and cilostazol may be exacerbated by  <e2> anagrelide </e2> .
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  <e1> anagrelide </e1>  in clinical trials were aspirin, acetaminophen, furosemide, iron,  <e2> ranitidine </e2> , hydroxyurea, and allopurinol.
false	The effects of medicinal products with similar properties such as inotropes milrinone,  <e1> enoximone </e1> , amrinone, olprinone and  <e2> cilostazol </e2>  may be exacerbated by anagrelide.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  <e1> anagrelide </e1>  in clinical trials were aspirin,  <e2> acetaminophen </e2> , furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  <e1> anagrelide </e1>  in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and  <e2> allopurinol </e2> .
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  <e1> anagrelide </e1>  in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine,  <e2> hydroxyurea </e2> , and allopurinol.
advise	Based on clinical and pharmacokinetic results from the ATAC trial,  <e1> tamoxifen </e1>  should not be administered with  <e2> anastrozole </e2>  (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).
false	Although there have been no formal interaction studies other than with  <e1> antipyrine </e1> , based on these in vivo and in vitro studies, it is unlikely that co-administration of a 1 mg dose of  <e2> ARIMIDEX </e2>  with other drugs will result in clinically significant drug inhibition of cytochrome P450-mediated metabolism of the other drugs.
false	At a median follow-up of 33 months, the combination of  <e1> ARIMIDEX </e1>  and tamoxifen did not demonstrate any efficacy benefit when compared with  <e2> tamoxifen </e2>  in all patients as well as in the hormone receptor-positive subpopulation.
false	Co-administration of anastrozole and tamoxifen resulted in a reduction of  <e1> anastrozole </e1>  plasma levels by 27% compared with those achieved with  <e2> anastrozole </e2>  alone.
false	Caution should be observed when anileridine is coadministered with other opioids, sedatives,  <e1> phenothiazines </e1> , or  <e2> anesthetics </e2> , as these agents may increase respiratory and circulatory depression.
advise	Caution should be observed when  <e1> anileridine </e1>  is coadministered with other opioids, sedatives,  <e2> phenothiazines </e2> , or anesthetics, as these agents may increase respiratory and circulatory depression.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin; <e1> haloperidol </e1> ;meprobamate;oral contraceptives;paraldehyde;primidone; <e2> ranitidine </e2> *;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e2> phenylbutazone </e2> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e1> naproxen </e1> ;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e2> phenylbutazone </e2> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e1> quinine </e1> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e2> glucagon </e2> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e1> metronidazole </e1> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e1> salicylates </e1> ;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e1> nalidixic acid </e1> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e1> prolonged narcotics </e1> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e2> dextrothyroxine </e2> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e1> pentoxifylline </e1> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e2> miconazole </e2> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids; <e1> alcohol </e1> *;antacids;antihistamines; <e2> barbiturates </e2> ;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K; <e1> diuretics </e1> *;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e2> meprobamate </e2> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone; <e1> ranitidine </e1> *;rifampin;unreliable prothrombin time determinations;vitamin C; <e2> warfarin sodium </e2>  under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e2> indomethacin </e2> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e2> miconazole </e2> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ;disulfiram;drugs affecting blood elements; <e2> ethacrynic acid </e2> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e1> naproxen </e1> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that have been reported to diminish oral  <e1> anticoagulant </e1>  response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives; <e2> paraldehyde </e2> ;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran; <e2> dextrothyroxine </e2> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*; <e2> chlorpropamide </e2> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e1> disulfiram </e1> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide; <e1> cholestyramine </e1> ;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*; <e2> rifampin </e2> ;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine; <e2> cinchophen </e2> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e2> cinchophen </e2> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e2> diflunisal </e2> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e2> mefenamic acid </e2> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e1> naproxen </e1> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*; <e1> antacids </e1> ;antihistamines;barbiturates; <e2> carbamazepine </e2> ;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e2> ibuprofen </e2> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e1> indomethacin </e1> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids; <e1> alcohol </e1> *; <e2> antacids </e2> ;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e1> indomethacin </e1> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e1> metronidazole </e1> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e2> clofibrate </e2> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e2> metronidazole </e2> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e2> fenoprofen </e2> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e2> diazoxide </e2> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e1> disulfiram </e1> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide; <e1> cholestyramine </e1> ;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e2> meprobamate </e2> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e1> prolonged narcotics </e1> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that have been reported to diminish oral  <e1> anticoagulant </e1>  response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*; <e2> rifampin </e2> ;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e2> glucagon </e2> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e2> mefenamic acid </e2> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e1> metronidazole </e1> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e2> phenylbutazone </e2> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e2> influenza virus vaccine </e2> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone; <e1> ranitidine </e1> *; <e2> rifampin </e2> ;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e1> disulfiram </e1> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e2> influenza virus vaccine </e2> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids; <e1> antihistamines </e1> ;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives; <e2> paraldehyde </e2> ;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e1> disulfiram </e1> ;drugs affecting blood elements; <e2> ethacrynic acid </e2> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e1> phenyramidol </e1> ;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that have been reported to diminish oral  <e1> anticoagulant </e1>  response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide; <e2> cholestyramine </e2> ;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e1> quinidine </e1> ;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e2> ethacrynic acid </e2> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs; <e2> ibuprofen </e2> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide; <e1> cholestyramine </e1> ;diet high in  <e2> vitamin K </e2> ;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal; <e2> disulfiram </e2> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e1> oxolinic acid </e1> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e2> phenylbutazone </e2> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e2> glucagon </e2> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e1> phenytoin </e1> ;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids; <e1> antihistamines </e1> ;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e2> meprobamate </e2> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e1> disulfiram </e1> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e1> sulfinpyrazone </e1> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines; <e1> barbiturates </e1> ;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives; <e2> paraldehyde </e2> ;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e1> tolbutamide </e1> ; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e1> indomethacin </e1> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e1> phenytoin </e1> ;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e1> phenylbutazone </e1> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e2> metronidazole </e2> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drug/Laboratory Test Interferences:  <e1> Dicumarol </e1>  and  <e2> indanedione anticoagulants </e2> , including anisindione, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*; <e1> antacids </e1> ;antihistamines;barbiturates;carbamazepine; <e2> chloral hydrate </e2> *;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e1> tolbutamide </e1> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e1> nalidixic acid </e1> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e2> miconazole </e2> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e1> nalidixic acid </e1> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*; <e1> chlordiazepoxide </e1> ;cholestyramine;diet high in vitamin K;diuretics*; <e2> ethchlorvynol </e2> ;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drug/Laboratory Test Interferences:  <e1> Dicumarol </e1>  and indanedione anticoagulants, including  <e2> anisindione </e2> , or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide; <e1> cholestyramine </e1> ;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations; <e2> vitamin C </e2> ;warfarin sodium under-dosage.
effect	Drugs that have been reported to diminish oral  <e1> anticoagulant </e1>  response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e2> meprobamate </e2> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e2> miconazole </e2> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e2> anesthetics </e2> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e2> miconazole </e2> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e2> dextran </e2> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e2> mefenamic acid </e2> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*; <e1> antacids </e1> ;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*; <e2> rifampin </e2> ;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
advise	Caution should be observed when  <e1> anileridine </e1>  is coadministered with other opioids, sedatives,  <e2> phenothiazines </e2> , or anesthetics, as these agents may increase respiratory and circulatory depression.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e1> oxolinic acid </e1> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e1> sulindac </e1> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Oral anticoagulants may potentiate the hypoglycemic action of  <e1> hypoglycemic agents </e1> , eg,  <e2> tolbutamide </e2>  and chlorpropamide, by inhibiting their metabolism in the liver.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e2> chlorpropamide </e2> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K; <e1> diuretics </e1> *;ethchlorvynol;glutethimide;griseofulvin; <e2> haloperidol </e2> ;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e1> disulfiram </e1> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e2> mefenamic acid </e2> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e1> phenyramidol </e1> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline; <e2> phenylbutazone </e2> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e1> pentoxifylline </e1> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids; <e1> alcohol </e1> *;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e2> griseofulvin </e2> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e1> thyroid drugs </e1> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e2> chymotrypsin </e2> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e1> metronidazole </e1> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e2> chlorpropamide </e2> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e1> quinidine </e1> ;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e1> naproxen </e1> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e2> ethacrynic acid </e2> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine; <e1> chloral hydrate </e1> *;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone; <e2> ranitidine </e2> *;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include:  <e1> adrenocortical steroids </e1> ;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*; <e2> rifampin </e2> ;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e2> chloral hydrate </e2> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e2> ethacrynic acid </e2> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in  <e1> vitamin K </e1> ;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral  <e2> contraceptives </e2> ;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e1> disulfiram </e1> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e2> indomethacin </e2> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone; <e2> anabolic steroids </e2> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids; <e1> alcohol </e1> *;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*; <e2> rifampin </e2> ;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e2> cimetidine </e2> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide; <e1> cholestyramine </e1> ;diet high in vitamin K;diuretics*;ethchlorvynol; <e2> glutethimide </e2> ;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e1> triclofos sodium </e1> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
effect	Drugs that have been reported to diminish oral  <e1> anticoagulant </e1>  response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C; <e2> warfarin sodium </e2>  under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate; <e2> metronidazole </e2> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include:  <e1> adrenocortical steroids </e1> ;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e2> griseofulvin </e2> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e2> anesthetics </e2> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e2> metronidazole </e2> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran; <e2> dextrothyroxine </e2> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e1> pentoxifylline </e1> ;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e1> indomethacin </e1> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e1> phenylbutazone </e1> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e2> disulfiram </e2> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that have been reported to diminish oral  <e1> anticoagulant </e1>  response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral  <e2> contraceptives </e2> ;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e2> fenoprofen </e2> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as  <e1> antineoplastic agents </e1> ) or drugs which inhibit platelet function (eg, aspirin and other  <e2> non-steroidal anti-inflammatory drugs </e2> , dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol; <e1> glutethimide </e1> ;griseofulvin;haloperidol;meprobamate;oral contraceptives; <e2> paraldehyde </e2> ;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e2> chloral hydrate </e2> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e1> pentoxifylline </e1> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide; <e1> cholestyramine </e1> ;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives; <e2> paraldehyde </e2> ;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e2> ethacrynic acid </e2> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drug/Laboratory Test Interferences: Dicumarol and  <e1> indanedione anticoagulants </e1> , including  <e2> anisindione </e2> , or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine; <e2> cinchophen </e2> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*; <e2> chlorpropamide </e2> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e2> miconazole </e2> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e1> phenylbutazone </e1> ;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e1> pyrazolones </e1> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e2> fenoprofen </e2> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e2> diflunisal </e2> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids; <e1> alcohol </e1> *;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin; <e2> haloperidol </e2> ;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e1> metronidazole </e1> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e1> naproxen </e1> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include:  <e1> adrenocortical steroids </e1> ;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol; <e2> glutethimide </e2> ;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*; <e1> antacids </e1> ;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e2> griseofulvin </e2> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K; <e1> diuretics </e1> *;ethchlorvynol;glutethimide; <e2> griseofulvin </e2> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin; <e1> haloperidol </e1> ;meprobamate;oral contraceptives;paraldehyde; <e2> primidone </e2> ;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e1> miconazole </e1> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e1> pentoxifylline </e1> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e2> glucagon </e2> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine; <e1> chloral hydrate </e1> *;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e2> griseofulvin </e2> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e2> fenoprofen </e2> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e2> diflunisal </e2> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e1> indomethacin </e1> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K; <e1> diuretics </e1> *;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C; <e2> warfarin sodium </e2>  under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e2> mefenamic acid </e2> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e1> indomethacin </e1> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e2> metronidazole </e2> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*; <e1> antacids </e1> ;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e2> meprobamate </e2> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e2> indomethacin </e2> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*; <e1> ethchlorvynol </e1> ;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives; <e2> paraldehyde </e2> ;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e1> nalidixic acid </e1> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e1> nalidixic acid </e1> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e2> phenylbutazone </e2> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e2> phenylbutazone </e2> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ; <e2> clofibrate </e2> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*; <e1> antacids </e1> ;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K; <e2> diuretics </e2> *;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e1> metronidazole </e1> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e2> cinchophen </e2> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e2> diazoxide </e2> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation  <e2> anesthetics </e2> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e1> miconazole </e1> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e1> quinidine </e1> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include:  <e1> adrenocortical steroids </e1> ;alcohol*;antacids;antihistamines;barbiturates;carbamazepine; <e2> chloral hydrate </e2> *;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e2> ethacrynic acid </e2> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg,  <e1> aspirin </e1>  and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine,  <e2> clofibrate </e2> , dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines; <e1> barbiturates </e1> ;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*; <e2> rifampin </e2> ;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e1> sulindac </e1> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e2> clofibrate </e2> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e1> phenylbutazone </e1> ;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as  <e1> antineoplastic agents </e1> ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine,  <e2> clofibrate </e2> , dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*; <e1> chlordiazepoxide </e1> ;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C; <e2> warfarin sodium </e2>  under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e1> sulfonamides </e1> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e2> indomethacin </e2> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates; <e1> carbamazepine </e1> ;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral  <e2> contraceptives </e2> ;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e1> phenylbutazone </e1> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines; <e1> barbiturates </e1> ;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral  <e2> contraceptives </e2> ;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide; <e1> cholestyramine </e1> ;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral  <e2> contraceptives </e2> ;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e2> phenylbutazone </e2> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e1> trimethoprim </e1> / <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e1> pentoxifylline </e1> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e1> phenylbutazone </e1> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
mechanism	Oral  <e1> anticoagulants </e1>  may potentiate the hypoglycemic action of hypoglycemic agents, eg,  <e2> tolbutamide </e2>  and chlorpropamide, by inhibiting their metabolism in the liver.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e2> anesthetics </e2> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e2> ibuprofen </e2> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine; <e1> chloral hydrate </e1> *;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e2> meprobamate </e2> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example,  <e1> ondansetron </e1> , granisetron, dolasetron,  <e2> palonosetron </e2> , and alosetron) is contraindicated .
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with  <e1> ondansetron </e1> , the concomitant use of apomorphine with drugs of the  <e2> 5HT3 antagonist class </e2>  (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
false	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as  <e1> antineoplastic agents </e1> ) or drugs which inhibit platelet function (eg, aspirin and other  <e2> non-steroidal anti-inflammatory drugs </e2> , dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*; <e1> chlordiazepoxide </e1> ;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C; <e2> warfarin sodium </e2>  under-dosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with  <e1> ondansetron </e1> , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron,  <e2> dolasetron </e2> , palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e1> quinidine </e1> ;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the  <e1> 5HT3 antagonist class </e1>  (including, for example, ondansetron, granisetron, dolasetron,  <e2> palonosetron </e2> , and alosetron) is contraindicated .
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include:  <e1> adrenocortical steroids </e1> ;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e2> griseofulvin </e2> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of  <e2> APOKYN </e2> .
false	Antihypertensive Medications and  <e1> Vasodilators </e1> : The following adverse events were experienced more commonly in patients receiving concomitant  <e2> antihypertensive medications </e2>  or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e2> ethacrynic acid </e2> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids; <e1> alcohol </e1> *;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e2> griseofulvin </e2> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when  <e1> apomorphine </e1>  was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example,  <e2> ondansetron </e2> , granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
effect	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when  <e1> apomorphine </e1>  was administered with  <e2> ondansetron </e2> , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e2> diflunisal </e2> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e1> pyrazolones </e1> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines,  <e1> butyrophenones </e1> , thioxanthenes) or metoclopramide, may diminish the effectiveness of  <e2> APOKYN </e2> .
advise	Caution should be observed when  <e1> anileridine </e1>  is coadministered with other opioids, sedatives,  <e2> phenothiazines </e2> , or anesthetics, as these agents may increase respiratory and circulatory depression.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e1> phenylbutazone </e1> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide; <e1> cholestyramine </e1> ;diet high in vitamin K;diuretics*;ethchlorvynol; <e2> glutethimide </e2> ;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	 <e1> 5HT3 Antagonists </e1> : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with  <e2> ondansetron </e2> , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone; <e1> ranitidine </e1> *;rifampin;unreliable prothrombin time determinations;vitamin C; <e2> warfarin sodium </e2>  under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with  <e1> ondansetron </e1> , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example,  <e2> ondansetron </e2> , granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example,  <e1> ondansetron </e1> ,  <e2> granisetron </e2> , dolasetron, palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	 <e1> 5HT3 Antagonists </e1> : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron,  <e2> dolasetron </e2> , palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Dopamine Antagonists: Since  <e1> apomorphine </e1>  is a  <e2> dopamine agonist </e2> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e1> naproxen </e1> ;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	 <e1> Dopamine Antagonists </e1> : Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones,  <e2> thioxanthenes </e2> ) or metoclopramide, may diminish the effectiveness of APOKYN.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e1> phenytoin </e1> ;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Dopamine Antagonists: Since apomorphine is a  <e1> dopamine agonist </e1> , it is possible that  <e2> dopamine antagonists </e2> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that have been reported to diminish oral  <e1> anticoagulant </e1>  response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e2> meprobamate </e2> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e2> fenoprofen </e2> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e1> sulindac </e1> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	 <e1> Dopamine Antagonists </e1> : Since apomorphine is a dopamine agonist, it is possible that  <e2> dopamine antagonists </e2> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e2> miconazole </e2> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Antihypertensive Medications and  <e1> Vasodilators </e1> : The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or  <e2> vasodilators </e2>  (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron,  <e1> granisetron </e1> ,  <e2> dolasetron </e2> , palonosetron, and alosetron) is contraindicated .
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide; <e1> cholestyramine </e1> ;diet high in  <e2> vitamin K </e2> ;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	 <e1> 5HT3 Antagonists </e1> : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example,  <e2> ondansetron </e2> , granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e2> diflunisal </e2> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the  <e1> neuroleptics </e1>  (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of  <e2> APOKYN </e2> .
false	 <e1> Dopamine Antagonists </e1> : Since apomorphine is a  <e2> dopamine agonist </e2> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids; <e1> alcohol </e1> *;antacids;antihistamines; <e2> barbiturates </e2> ;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the  <e1> 5HT3 antagonist class </e1>  (including, for example, ondansetron, granisetron,  <e2> dolasetron </e2> , palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone; <e1> ranitidine </e1> *; <e2> rifampin </e2> ;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the  <e1> neuroleptics </e1>  (phenothiazines, butyrophenones, thioxanthenes) or  <e2> metoclopramide </e2> , may diminish the effectiveness of APOKYN.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e1> prolonged narcotics </e1> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e1> disulfiram </e1> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	 <e1> 5HT3 Antagonists </e1> : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron,  <e2> granisetron </e2> , dolasetron, palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e2> ibuprofen </e2> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e1> nalidixic acid </e1> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	 <e1> Dopamine Antagonists </e1> : Since  <e2> apomorphine </e2>  is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e2> phenylbutazone </e2> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
advise	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of  <e1> IOPIDINE </e1>  0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates,  <e2> opiates </e2> , sedatives, anesthetics) should be considered.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the  <e1> 5HT3 antagonist class </e1>  (including, for example, ondansetron, granisetron,  <e2> dolasetron </e2> , palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with  <e1> ondansetron </e1> , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example,  <e2> ondansetron </e2> , granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of  <e2> APOKYN </e2> .
effect	An additive hypotensive effect has been reported with the combination of systemic  <e1> clonidine </e1>  and  <e2> neuroleptic </e2>  therapy.
false	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants ( <e1> alcohol </e1> , barbiturates, opiates, sedatives,  <e2> anesthetics </e2> ) should be considered.
false	Dopamine Antagonists: Since apomorphine is a  <e1> dopamine agonist </e1> , it is possible that  <e2> dopamine antagonists </e2> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
false	 <e1> 5HT3 Antagonists </e1> : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with  <e2> ondansetron </e2> , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with  <e1> CNS depressants </e1>  (alcohol, barbiturates, opiates, sedatives,  <e2> anesthetics </e2> ) should be considered.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids; <e1> alcohol </e1> *;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e2> griseofulvin </e2> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron,  <e1> granisetron </e1> ,  <e2> dolasetron </e2> , palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e2> fenoprofen </e2> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e1> sulindac </e1> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e1> prolonged narcotics </e1> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e2> ethacrynic acid </e2> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as  <e1> antineoplastic agents </e1> ) or drugs which inhibit platelet function (eg, aspirin and other  <e2> non-steroidal anti-inflammatory drugs </e2> , dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
advise	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of  <e1> IOPIDINE </e1>  0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol,  <e2> barbiturates </e2> , opiates, sedatives, anesthetics) should be considered.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Oral contraceptives:  <e1> Aprepitant </e1> , when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of  <e2> ethinyl estradiol </e2>  by 43%, and decreased the AUC of norethindrone by 8%;
mechanism	The daily dose of  <e1> dexamethasone </e1>  administered in clinical studies with  <e2> Aprepitant </e2>  reflects an approximate 50% reduction of the dose of dexamethasone.
false	The oral dexamethasone doses should be reduced by approximately 50% when coadministered with  <e1> Aprepitant </e1> , to achieve exposures of dexamethasone similar to those obtained when it is given without  <e2> Aprepitant </e2> .
false	The IV  <e1> methylprednisolone </e1>  dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without  <e2> Aprepitant </e2> .
false	 <e1> Ketoconazole </e1> : When a single 125-mg dose of  <e2> Aprepitant </e2>  was administered on Day5 of a
false	Oral  <e1> contraceptives </e1> :  <e2> Aprepitant </e2> , when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
false	Coadministration of  <e1> Aprepitant </e1>  with drugs that induce CYP3A4 activity may result in reduced plasma concentrations and decreased efficacy of  <e2> Aprepitant </e2> .
false	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole,  <e1> nefazodone </e1> ,  <e2> troleandomycin </e2> , clarithromycin, ritonavir, nelfinavir) should be approached with caution.
false	 <e1> 5-HT3 antagonists </e1> : In clinical drug interaction studies,  <e2> aprepitant </e2>  did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron.
advise	The IV methylprednisolone dose should be reduced by approximately 25%, and the oral  <e1> methylprednisolone </e1>  dose should be reduced by approximately 50% when coadministered with  <e2> Aprepitant </e2>  to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
false	 <e1> Corticosteroids </e1> : Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with  <e2> dexamethasone </e2>  coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
false	Aprepitant increased the AUC of  <e1> midazolam </e1>  by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of  <e2> Aprepitant </e2>  on Days 1 through 3.
false	Tolbutamide:  <e1> Aprepitant </e1> , when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of  <e2> tolbutamide </e2>  (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
false	 <e1> 5-HT3 antagonists </e1> : In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or  <e2> granisetron </e2> .
false	Midazolam:  <e1> Aprepitant </e1>  increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of  <e2> Aprepitant </e2>  125 mg on Day 1 and 80 mg/day on Days 2 through 5.
false	The potential effects of increased plasma concentrations of midazolam or other  <e1> benzodiazepines </e1>  metabolized via CYP3A4 ( <e2> alprazolam </e2> , triazolam) should be considered when coadministering these agents with Aprepitant.
false	Diltiazem: In patients with mild to moderate hypertension, administration of  <e1> aprepitant </e1>  once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of  <e2> diltiazem </e2>  AUC.
false	therefore, coadministration of  <e1> Aprepitant </e1>  with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of  <e2> aprepitant </e2> .
false	 <e1> Corticosteroids </e1> : Dexamethasone: Aprepitant, when given as a regimen of 125mg with  <e2> dexamethasone </e2>  coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
mechanism	 <e1> Aprepitant </e1>  increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of  <e2> midazolam </e2>  by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
false	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine,  <e1> phenytoin </e1> ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of  <e2> Aprepitant </e2> .
false	 <e1> Midazolam </e1> : Aprepitant increased the AUC of  <e2> midazolam </e2> , a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e1> sulindac </e1> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with  <e1> Aprepitant </e1>  to achieve exposures of methylprednisolone similar to those obtained when it is given without  <e2> Aprepitant </e2> .
advise	Although a 3-day regimen of  <e1> Aprepitant </e1>  given concomitantly with oral  <e2> contraceptives </e2>  has not been studied, alternative or back-up methods of contraception should be used.
false	 <e1> 5HT3 Antagonists </e1> : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with  <e2> ondansetron </e2> , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
false	therefore, coadministration of  <e1> Aprepitant </e1>  with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of  <e2> Aprepitant </e2> .
mechanism	 <e1> Aprepitant </e1>  has been shown to induce the metabolism of S(-) warfarin and  <e2> tolbutamide </e2> , which are metabolized through CYP2C9.
false	Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-)  <e1> warfarin </e1>  determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with  <e2> Aprepitant </e2> .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	 <e1> Tolbutamide </e1> :  <e2> Aprepitant </e2> , when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
false	Diltiazem: In patients with mild to moderate hypertension, administration of  <e1> aprepitant </e1>  once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of  <e2> aprepitant </e2>  AUC and a simultaneous 1.7-fold increase of diltiazem AUC.
advise	The potential effects of increased plasma concentrations of midazolam or other  <e1> benzodiazepines </e1>  metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with  <e2> Aprepitant </e2> .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin,  <e1> ritonavir </e1> ,  <e2> nelfinavir </e2> ) should be approached with caution.
false	Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with  <e1> dexamethasone </e1>  coadministered orally as 8 mg on Days 2 through 5, increased the AUC of  <e2> dexamethasone </e2> , a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
false	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g.,  <e1> ketoconazole </e1> , itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir,  <e2> nelfinavir </e2> ) should be approached with caution.
false	Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral  <e1> contraceptive </e1>  containing 35 mcg of ethinyl estradiol and 1 mg of  <e2> norethindrone </e2> , decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
false	Ketoconazole: When a single 125-mg dose of  <e1> Aprepitant </e1>  was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of  <e2> aprepitant </e2>  increased approximately 3-fold.
advise	Consequently, concomitant administration of  <e1> Aprepitant </e1>  with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin,  <e2> ritonavir </e2> , nelfinavir) should be approached with caution.
false	 <e1> Warfarin </e1> : A single 125-mg dose of  <e2> Aprepitant </e2>  was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy.
false	Corticosteroids: Dexamethasone:  <e1> Aprepitant </e1> , when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with  <e2> dexamethasone </e2>  coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
false	Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with  <e1> paroxetine </e1>  20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both  <e2> aprepitant </e2>  and paroxetine.
false	Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and  <e1> Aprepitant </e1>  when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of  <e2> dexamethasone </e2> , a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
false	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with  <e1> CNS depressants </e1>  (alcohol, barbiturates, opiates, sedatives,  <e2> anesthetics </e2> ) should be considered.
mechanism	Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and  <e1> Aprepitant </e1>  when given as 80 mg/day with  <e2> dexamethasone </e2>  coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
false	 <e1> Diltiazem </e1> : In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of  <e2> diltiazem </e2>  AUC.
false	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants ( <e1> alcohol </e1> , barbiturates, opiates, sedatives,  <e2> anesthetics </e2> ) should be considered.
false	 <e1> Tolbutamide </e1> :  <e2> Aprepitant </e2> , when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
advise	Although a 3-day regimen of  <e1> Aprepitant </e1>  given concomitantly with oral  <e2> contraceptives </e2>  has not been studied, alternative or back-up methods of contraception should be used.
false	Ketoconazole: When a single 125-mg dose of  <e1> Aprepitant </e1>  was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of  <e2> aprepitant </e2>  increased approximately 3-fold.
false	Antidepressants ( <e1> tricyclic </e1> ), atropine or other anticholinergic agents, or  <e2> digitalis glycosides </e2> : concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
false	Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-)  <e1> warfarin </e1>  determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with  <e2> Aprepitant </e2> .
false	Aprepitant increased the AUC of  <e1> midazolam </e1>  by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of  <e2> Aprepitant </e2>  on Days 1 through 3.
false	Antidepressants ( <e1> tricyclic </e1> ),  <e2> atropine </e2>  or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
false	Antiarrhythmic agents, class I (such as flecainide,  <e1> lidocaine </e1> , or quinidine): concurrent use with  <e2> arbutamine </e2>  may have a proarrhythmic effect.
false	 <e1> 5-HT3 antagonists </e1> : In clinical drug interaction studies,  <e2> aprepitant </e2>  did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron.
false	Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with  <e1> paroxetine </e1>  20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both  <e2> aprepitant </e2>  and paroxetine.
false	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine,  <e1> phenytoin </e1> ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of  <e2> Aprepitant </e2> .
false	Antidepressants ( <e1> tricyclic </e1> ), atropine or other  <e2> anticholinergic agents </e2> , or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
false	Antidepressants (tricyclic), atropine or other anticholinergic agents, or  <e1> digitalis glycosides </e1> : concurrent use with  <e2> arbutamine </e2>  may produce additive inotropic and/or chronotropic effects.
false	Oral contraceptives:  <e1> Aprepitant </e1> , when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of  <e2> ethinyl estradiol </e2>  by 43%, and decreased the AUC of norethindrone by 8%;
mechanism	 <e1> Aprepitant </e1>  has been shown to induce the metabolism of S(-) warfarin and  <e2> tolbutamide </e2> , which are metabolized through CYP2C9.
false	 <e1> Anticoagulants </e1>  including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as  <e2> nonsteroidal anti-inflammatory drugs </e2>  (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
effect	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and  <e1> aspirin </e1>  may increase the risk of bleeding when administered concomitantly with  <e2> ardeparin </e2> .
false	Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-)  <e1> warfarin </e1>  determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with  <e2> Aprepitant </e2> .
false	Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with  <e1> paroxetine </e1>  20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both  <e2> aprepitant </e2>  and paroxetine.
false	Antidepressants ( <e1> tricyclic </e1> ), atropine or other  <e2> anticholinergic agents </e2> , or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
effect	Concomitant treatment with methylxanthines ( <e1> aminophylline </e1> , theophylline), steroids, or diuretics may potentiate any hypokalemic effect of  <e2> adrenergic agonists </e2> .
false	Antidepressants ( <e1> tricyclic </e1> ), atropine or other  <e2> anticholinergic agents </e2> , or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
false	The concurrent use of intravenously or orally administered  <e1> methylxanthines </e1>  (e.g., aminophylline,  <e2> theophylline </e2> ) by patients receiving BROVANA has not been completely evaluated.
effect	BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with  <e1> monoamine oxidase inhibitors </e1> , tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of  <e2> adrenergic agonists </e2>  on the cardiovascular system may be potentiated by these agents.
effect	The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide  <e1> diuretics </e1> ) can be acutely worsened by  <e2> beta-agonists </e2> , especially when the recommended dose of the beta-agonist is exceeded.
false	Concomitant treatment with  <e1> methylxanthines </e1>  ( <e2> aminophylline </e2> , theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
false	The concurrent use of intravenously or orally administered methylxanthines (e.g.,  <e1> aminophylline </e1> , theophylline) by patients receiving  <e2> BROVANA </e2>  has not been completely evaluated.
false	The concurrent use of intravenously or orally administered methylxanthines (e.g.,  <e1> aminophylline </e1> ,  <e2> theophylline </e2> ) by patients receiving BROVANA has not been completely evaluated.
false	In a 12-month controlled trial that included a 50 mcg once daily  <e1> BROVANA </e1>  dose, 30 of the 528 BROVANA -treated subjects received concomitant  <e2> theophylline </e2>  at study entry.
false	In two combined 12-week placebo controlled trials that included  <e1> BROVANA </e1>  doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA -treated subjects received concomitant  <e2> theophylline </e2>  at study entry.
advise	BROVANA, as with other  <e1> beta2-agonists </e1> , should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors,  <e2> tricyclic antidepressants </e2> , or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
false	The ECG changes and/or hypokalemia that may result from the administration of  <e1> non-potassium sparing diuretics </e1>  (such as loop or  <e2> thiazide diuretics </e2> ) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
false	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered  <e1> aspirin </e1>  (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or  <e2> acetaminophen </e2>  (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
effect	The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide  <e1> diuretics </e1> ) can be acutely worsened by  <e2> beta-agonists </e2> , especially when the recommended dose of the beta-agonist is exceeded.
false	 <e1> Aspirin </e1> /Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of  <e2> Argatroban </e2>  1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
false	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between  <e1> Argatroban </e1>  and concomitantly administered  <e2> aspirin </e2>  (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
false	 <e1> Aspirin </e1> /Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between  <e2> Argatroban </e2>  and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
effect	Co-administration: Concomitant use of  <e1> Argatroban </e1>  with antiplatelet agents,  <e2> thrombolytics </e2> , and other anticoagulants may increase the risk of bleeding.
false	 <e1> Thrombolytic agents </e1> : The safety and effectiveness of Argatroban with  <e2> thrombolytic agents </e2>  have not been established.
false	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of  <e1> Argatroban </e1>  1  g/kg/min. over 4 hours) or  <e2> acetaminophen </e2>  (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
false	Oral  <e1> anticoagulant agents </e1> : Pharmacokinetic drug-drug interactions between  <e2> Argatroban </e2>  and warfarin (7.5 mg single oral dose) have not been demonstrated.
false	Heparin: Since  <e1> heparin </e1>  is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of  <e2> Argatroban </e2>  and heparin is unlikely for this indication.
false	In a 12-month controlled trial that included a 50 mcg once daily  <e1> BROVANA </e1>  dose, 30 of the 528 BROVANA -treated subjects received concomitant  <e2> theophylline </e2>  at study entry.
false	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between  <e1> Argatroban </e1>  and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of  <e2> Argatroban </e2>  1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
false	Heparin: Since heparin is contraindicated in patients with  <e1> heparin </e1> -induced thrombocytopenia, the co-administration of  <e2> Argatroban </e2>  and heparin is unlikely for this indication.
false	In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 ( <e1> warfarin </e1> ), CYP2C19 ( <e2> omeprazole </e2> , warfarin), and CYP3A4 (dextromethorphan) substrates.
false	 <e1> Alcohol </e1> : There was no significant difference between aripiprazole coadministered with  <e2> ethanol </e2>  and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.
false	In in vivo studies, 10- to 30-mg/day doses of  <e1> aripiprazole </e1>  had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 ( <e2> dextromethorphan </e2> ) substrates.
mechanism	Agents that induce CYP3A4 (eg,  <e1> carbamazepine </e1> ) could cause an increase in  <e2> aripiprazole </e2>  clearance and lower blood levels.
false	Other significant inhibitors of CYP2D6, such as  <e1> fluoxetine </e1>  or  <e2> paroxetine </e2> , would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions.
false	 <e1> Ketoconazole </e1> : Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of  <e2> aripiprazole </e2>  and its active metabolite by 63% and 77%, respectively.
false	Inhibitors of CYP3A4 (eg,  <e1> ketoconazole </e1> ) or CYP2D6 (eg, quinidine,  <e2> fluoxetine </e2> , or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
advise	When  <e1> carbamazepine </e1>  is withdrawn from the combination therapy,  <e2> aripiprazole </e2>  dose should then be reduced.
false	Potential for Other Drugs to Affect  <e1> ABILIFY </e1>   <e2> Aripiprazole </e2>  is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes.
false	In in vivo studies, 10- to 30-mg/day doses of  <e1> aripiprazole </e1>  had no significant effect on metabolism by CYP2D6 ( <e2> dextromethorphan </e2> ), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.
false	Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with  <e1> aripiprazole </e1>  (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both  <e2> aripiprazole </e2>  and its active metabolite, dehydro-aripiprazole.
false	In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 ( <e1> warfarin </e1> ), CYP2C19 (omeprazole, warfarin), and CYP3A4 ( <e2> dextromethorphan </e2> ) substrates.
advise	Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when  <e1> ABILIFY </e1>  is taken in combination with other  <e2> centrally acting drugs </e2>  and alcohol.
false	Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with  <e1> aripiprazole </e1>  (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite,  <e2> dehydro-aripiprazole </e2> .
false	Drug-Drug Interactions Given the primary CNS effects of  <e1> aripiprazole </e1> , caution should be used when ABILIFY is taken in combination with other  <e2> centrally acting drugs </e2>  and alcohol.
false	In a 12-month controlled trial that included a 50 mcg once daily  <e1> BROVANA </e1>  dose, 30 of the 528 BROVANA -treated subjects received concomitant  <e2> theophylline </e2>  at study entry.
false	In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 ( <e1> dextromethorphan </e1> ), CYP2C9 (warfarin), CYP2C19 ( <e2> omeprazole </e2> , warfarin), and CYP3A4 (dextromethorphan) substrates.
false	 <e1> Carbamazepine </e1> : Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both  <e2> aripiprazole </e2>  and its active metabolite, dehydro-aripiprazole.
false	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg,  <e1> quinidine </e1> ,  <e2> fluoxetine </e2> , or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
false	In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 ( <e1> warfarin </e1> ), CYP2C19 (omeprazole, warfarin), and CYP3A4 ( <e2> dextromethorphan </e2> ) substrates.
false	Inhibitors of CYP3A4 (eg,  <e1> ketoconazole </e1> ) or CYP2D6 (eg, quinidine,  <e2> fluoxetine </e2> , or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
false	Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or  <e1> thioridazine </e1> ) or lead to electrolyte abnormalities (such as diuretics or  <e2> amphotericin B </e2> ).
false	In a 12-month controlled trial that included a 50 mcg once daily  <e1> BROVANA </e1>  dose, 30 of the 528 BROVANA -treated subjects received concomitant  <e2> theophylline </e2>  at study entry.
advise	Caution is advised when  <e1> TRISENOX </e1>  is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or  <e2> thioridazine </e2> ) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
false	Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain  <e1> antiarrhythmics </e1>  or thioridazine) or lead to electrolyte abnormalities (such as diuretics or  <e2> amphotericin B </e2> ).
advise	These results would seem to dictate against the clinical use of  <e1> methotrexate </e1>  with  <e2> ELSPAR </e2> , or during the period following ELSPAR therapy when plasma asparagine levels are below normal.
false	Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or  <e1> thioridazine </e1> ) or lead to electrolyte abnormalities (such as diuretics or  <e2> amphotericin B </e2> ).
false	Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of  <e1> methotrexate </e1>  on malignant cells.14 This effect on  <e2> methotrexate </e2>  activity persists as long as plasma asparagine levels are suppressed.
false	 <e1> Antacids </e1> : Enteric Coated Aspirin should not be given concurrently with  <e2> antacids </e2> , since an increase in the pH of the stomach may effect the enteric coating of the tablets.
false	 <e1> Nonsteroidal Antiinflammatory </e1>  Agents:  <e2> Aspirin </e2>  is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.
false	 <e1> Phenytoin </e1> : Serum phenytoin levels may be increased by  <e2> aspirin </e2> .
effect	 <e1> Propranolol </e1> : May decrease  <e2> aspirins </e2>  anti-inflammatory action by competing for the same receptors.
false	Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or  <e1> thioridazine </e1> ) or lead to electrolyte abnormalities (such as diuretics or  <e2> amphotericin B </e2> ).
false	Pyrazolone Derivatives (phenylbutazone,  <e1> oxyphenbutazone </e1> , and possibly  <e2> dipyrone </e2> ): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
effect	Uricosuric Agents:  <e1> Aspirin </e1>  may decrease the effects of probenecid, sulfinpyrazone, and  <e2> phenylbutazone </e2> .
false	Pyrazolone Derivatives (phenylbutazone,  <e1> oxyphenbutazone </e1> , and possibly  <e2> dipyrone </e2> ): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
false	 <e1> Nonsteroidal Antiinflammatory </e1>  Agents:  <e2> Aspirin </e2>  is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.
effect	 <e1> Propranolol </e1> : May decrease  <e2> aspirins </e2>  anti-inflammatory action by competing for the same receptors.
false	If replacing  <e1> clonidine </e1>  by beta-blocker therapy, the introduction of  <e2> beta blockers </e2>  should be delayed for several days after clonidine administration has stopped.
advise	If the two drugs are coadministered, the  <e1> beta blocker </e1>  should be withdrawn several days before the gradual withdrawal of  <e2> clonidine </e2> .
effect	Concomitant use of prostaglandin synthase inhibiting drugs, eg,  <e1> indomethacin </e1> , may decrease the hypotensive effects of  <e2> beta blockers </e2> .
false	If replacing clonidine by  <e1> beta-blocker </e1>  therapy, the introduction of beta blockers should be delayed for several days after  <e2> clonidine </e2>  administration has stopped.
false	Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous)  <e1> albuterol </e1>  (or other beta2 agonists) because the action of  <e2> albuterol </e2>  on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
mechanism	In EM individuals treated with paroxetine or  <e1> fluoxetine </e1> , the AUC of  <e2> atomoxetine </e2>  is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
false	Drug-Drug Interactions Albuterol -  <e1> STRATTERA </e1>  should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other  <e2> beta2 agonists </e2> ) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
advise	Dosage adjustment of  <e1> STRATTERA </e1>  may be necessary when coadministered with CYP2D6 inhibitors, e.g.,  <e2> paroxetine </e2> , fluoxetine, and quinidine.
false	If replacing  <e1> clonidine </e1>  by beta-blocker therapy, the introduction of  <e2> beta blockers </e2>  should be delayed for several days after clonidine administration has stopped.
false	Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other  <e1> beta2 agonists </e1> ) because the action of  <e2> albuterol </e2>  on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
false	 <e1> Erythromycin </e1> : In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and  <e2> erythromycin </e2> , a known inhibitor of cytochrome P450 3A4.
false	 <e1> Antacid </e1> : When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of  <e2> atorvastatin </e2>  decreased approximately 35%.
advise	Caution should be exercised if an  <e1> HMG-CoA reductase inhibitor </e1>  is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole,  <e2> spironolactone </e2> , and cimetidine.
false	Oral  <e1> Contraceptives </e1> : Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and  <e2> ethinyl estradiol </e2>  by approximately 30% and 20%.
false	If replacing  <e1> clonidine </e1>  by beta-blocker therapy, the introduction of  <e2> beta blockers </e2>  should be delayed for several days after clonidine administration has stopped.
false	 <e1> Erythromycin </e1> : In healthy individuals, plasma concentrations of  <e2> atorvastatin </e2>  increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
false	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin ( <e1> nicotinic acid </e1> ), erythromycin,  <e2> azole antifungals </e2> .
false	Digoxin: When multiple doses of  <e1> atorvastatin </e1>  and digoxin were coadministered, steady-state plasma  <e2> digoxin </e2>  concentrations increased by approximately 20%.
mechanism	In EM individuals treated with paroxetine or  <e1> fluoxetine </e1> , the AUC of  <e2> atomoxetine </e2>  is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
false	 <e1> Antipyrine </e1> : Because  <e2> atorvastatin </e2>  does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.
false	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of  <e1> cyclosporine </e1> , fibric acid derivatives, niacin (nicotinic acid),  <e2> erythromycin </e2> , azole antifungals.
false	Antipyrine: Because atorvastatin does not affect the pharmacokinetics of  <e1> antipyrine </e1> , interactions with other  <e2> drugs </e2>  metabolized via the same cytochrome isozymes are not expected.
false	 <e1> Colestipol </e1> : Plasma concentrations of atorvastatin decreased approximately 25% when  <e2> colestipol </e2>  and atorvastatin were coadministered.
false	Erythromycin: In healthy individuals, plasma concentrations of  <e1> atorvastatin </e1>  increased approximately 40% with coadministration of  <e2> atorvastatin </e2>  and erythromycin, a known inhibitor of cytochrome P450 3A4.
false	 <e1> Rifampin </e1> : Coadministration of rifampin and  <e2> MEPRON </e2>  Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
false	 <e1> Rifampin </e1> : Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma  <e2> atovaquone </e2>  concentrations.
false	 <e1> Rifabutin </e1> , another rifamycin, is structurally similar to  <e2> rifampin </e2>  and may possibly have some of the same drug interactions as rifampin.
advise	Caution should be exercised if an  <e1> HMG-CoA reductase inhibitor </e1>  is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole,  <e2> spironolactone </e2> , and cimetidine.
mechanism	Rifampin: Coadministration of  <e1> rifampin </e1>  and  <e2> MEPRON </e2>  Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
false	 <e1> Erythromycin </e1> : In healthy individuals, plasma concentrations of  <e2> atorvastatin </e2>  increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
false	Erythromycin: In healthy individuals, plasma concentrations of  <e1> atorvastatin </e1>  increased approximately 40% with coadministration of  <e2> atorvastatin </e2>  and erythromycin, a known inhibitor of cytochrome P450 3A4.
false	The extent of plasma protein binding of  <e1> atovaquone </e1>  in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of  <e2> phenytoin </e2>  affected by the presence of atovaquone.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane; <e1> halothane </e1> ;certain antibiotics, especially the aminoglycosides and  <e2> polymyxins </e2> ;lithium;magnesium salts;procainamide;and quinidine.
effect	Drugs which may enhance the neuromuscular blocking action of  <e1> TRACRIUM </e1>  include: enflurane;isoflurane; <e2> halothane </e2> ;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
advise	 <e1> TRACRIUM </e1>  should not be administered until a patient has recovered from  <e2> succinylcholine </e2> -induced neuromuscular block.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane; <e1> halothane </e1> ;certain antibiotics, especially the aminoglycosides and polymyxins;lithium; <e2> magnesium </e2>  salts;procainamide;and quinidine.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium; <e1> magnesium </e1>  salts; <e2> procainamide </e2> ;and quinidine.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and  <e1> polymyxins </e1> ;lithium;magnesium salts;procainamide;and  <e2> quinidine </e2> .
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain  <e1> antibiotics </e1> , especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and  <e2> quinidine </e2> .
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane; <e1> isoflurane </e1> ;halothane;certain antibiotics, especially the aminoglycosides and  <e2> polymyxins </e2> ;lithium;magnesium salts;procainamide;and quinidine.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane; <e1> isoflurane </e1> ;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium; <e2> magnesium </e2>  salts;procainamide;and quinidine.
effect	Drugs which may enhance the neuromuscular blocking action of  <e1> TRACRIUM </e1>  include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and  <e2> polymyxins </e2> ;lithium;magnesium salts;procainamide;and quinidine.
false	 <e1> Rifabutin </e1> , another rifamycin, is structurally similar to  <e2> rifampin </e2>  and may possibly have some of the same drug interactions as rifampin.
effect	Drugs which may enhance the neuromuscular blocking action of  <e1> TRACRIUM </e1>  include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and  <e2> quinidine </e2> .
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane; <e1> isoflurane </e1> ;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts; <e2> procainamide </e2> ;and quinidine.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane; <e1> isoflurane </e1> ;halothane;certain antibiotics, especially the  <e2> aminoglycosides </e2>  and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
false	 <e1> Rifampin </e1> : Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma  <e2> atovaquone </e2>  concentrations.
false	 <e1> Rifabutin </e1> , another rifamycin, is structurally similar to  <e2> rifampin </e2>  and may possibly have some of the same drug interactions as rifampin.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane; <e1> halothane </e1> ;certain antibiotics, especially the aminoglycosides and  <e2> polymyxins </e2> ;lithium;magnesium salts;procainamide;and quinidine.
effect	Drugs which may enhance the neuromuscular blocking action of  <e1> TRACRIUM </e1>  include: enflurane;isoflurane; <e2> halothane </e2> ;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
false	When  <e1> atropine </e1>  and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of  <e2> atropine </e2> .
false	 <e1> Rifampin </e1> : Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma  <e2> atovaquone </e2>  concentrations.
false	Auranofin should not be used together with  <e1> penicillamine </e1>  ( <e2> Depen </e2> , Cuprimine), another arthritis medication.
advise	 <e1> Auranofin </e1>  should be avoided by patients with a history of serious reaction to any gold medication, including  <e2> Solganal </e2>  and Myochrysine.
false	Auranofin should be avoided by patients with a history of serious reaction to any  <e1> gold medication </e1> , including Solganal and  <e2> Myochrysine </e2> .
false	Auranofin should be avoided by patients with a history of serious reaction to any  <e1> gold medication </e1> , including Solganal and  <e2> Myochrysine </e2> .
effect	Concomitant use of  <e1> antihistamines </e1>  with  <e2> alcohol </e2> , tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
mechanism	 <e1> Antacids </e1>  increase the rate of absorption of  <e2> pseudoephedrine </e2> , while kaolin decreases it.
false	Concomitant use of antihistamines with alcohol, tricyclic antidepressants,  <e1> barbiturates </e1> , or other  <e2> central nervous system depressants </e2>  may have an additive effect.
false	Concomitant use of antihistamines with  <e1> alcohol </e1> ,  <e2> tricyclic antidepressants </e2> , barbiturates, or other central nervous system depressants may have an additive effect.
effect	The antihypertensive effects of methyldopa, mecamylamine, reserpine, and  <e1> veratrum alkaloids </e1>  may be reduced by  <e2> sympathomimetics </e2> .
false	Concomitant use of antihistamines with alcohol,  <e1> tricyclic antidepressants </e1> , barbiturates, or other  <e2> central nervous system depressants </e2>  may have an additive effect.
false	Use with  <e1> Angiotensln Converting Enzyme Inhibitors </e1> : The use of  <e2> angiotensin converting enzyme inhibitors </e2>  to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.
false	Patients receiving azathioprine and  <e1> allopurinol </e1>  concomitantly should have a dose reduction of  <e2> azathioprine </e2> , to approximately 1/3 to 1/4 the usual dose.
mechanism	 <e1> Antacids </e1>  increase the rate of absorption of  <e2> pseudoephedrine </e2> , while kaolin decreases it.
false	Use with  <e1> Angiotensln Converting Enzyme Inhibitors </e1> : The use of  <e2> angiotensin converting enzyme inhibitors </e2>  to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of  <e1> atorvastatin </e1> , carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam,  <e2> rifabutin </e2> , sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole,  <e1> indinavir </e1> ,  <e2> midazolam </e2> , rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	 <e1> Azithromycin </e1>  did not affect the prothrombin time response to a single dose of  <e2> warfarin </e2> .
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of  <e1> atorvastatin </e1> , carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil,  <e2> theophylline </e2>  (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	 <e1> Ergotamine </e1>  or  <e2> dihydroergotamine </e2>  acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
effect	Co-administration of  <e1> nelfinavir </e1>  at steady-state with a single dose of  <e2> azithromycin </e2>  (2 x 600 mg tablets) results in increased azithromycin serum concentrations.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of  <e1> atorvastatin </e1> , carbamazepine, cetirizine, didanosine, efavirenz, fluconazole,  <e2> indinavir </e2> , midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin,  <e1> carbamazepine </e1> , cetirizine, didanosine,  <e2> efavirenz </e2> , fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral),  <e1> triazolam </e1> ,  <e2> trimethoprim </e2> /sulfamethoxazole or zidovudine.
mechanism	When used in therapeutic doses,  <e1> azithromycin </e1>  had a modest effect on the pharmacokinetics of  <e2> atorvastatin </e2> , carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral),  <e1> triazolam </e1> , trimethoprim/sulfamethoxazole or  <e2> zidovudine </e2> .
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine,  <e1> efavirenz </e1> , fluconazole, indinavir,  <e2> midazolam </e2> , rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin,  <e1> carbamazepine </e1> , cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or  <e2> zidovudine </e2> .
mechanism	When used in therapeutic doses,  <e1> azithromycin </e1>  had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam,  <e2> trimethoprim </e2> /sulfamethoxazole or zidovudine.
mechanism	When used in therapeutic doses,  <e1> azithromycin </e1>  had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral),  <e2> triazolam </e2> , trimethoprim/sulfamethoxazole or zidovudine.
advise	Although a dose adjustment of  <e1> azithromycin </e1>  is not recommended when administered in combination with  <e2> nelfinavir </e2> , close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole,  <e1> indinavir </e1> , midazolam, rifabutin, sildenafil, theophylline (intravenous and oral),  <e2> triazolam </e2> , trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole,  <e1> indinavir </e1> , midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/ <e2> sulfamethoxazole </e2>  or zidovudine.
false	Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised:  <e1> Digoxin </e1>  elevated  <e2> digoxin </e2>  concentrations.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz,  <e1> fluconazole </e1> ,  <e2> indinavir </e2> , midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin,  <e1> sildenafil </e1> ,  <e2> theophylline </e2>  (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil,  <e1> theophylline </e1>  (intravenous and oral), triazolam, trimethoprim/ <e2> sulfamethoxazole </e2>  or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine,  <e1> cetirizine </e1> , didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or  <e2> zidovudine </e2> .
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole,  <e1> indinavir </e1> , midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or  <e2> zidovudine </e2> .
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin,  <e1> sildenafil </e1> , theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or  <e2> zidovudine </e2> .
false	Until further data are developed regarding drug interactions when  <e1> azithromycin </e1>  and these drugs are used concomitantly, careful monitoring of patients is advised:  <e2> Digoxin </e2>  elevated digoxin concentrations.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine,  <e1> cetirizine </e1> ,  <e2> didanosine </e2> , efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
mechanism	Co-administration with efavirenz or  <e1> fluconazole </e1>  had a modest effect on the pharmacokinetics of  <e2> azithromycin </e2> .
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine,  <e1> cetirizine </e1> , didanosine, efavirenz, fluconazole, indinavir, midazolam,  <e2> rifabutin </e2> , sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir,  <e1> midazolam </e1> , rifabutin, sildenafil, theophylline (intravenous and oral), triazolam,  <e2> trimethoprim </e2> /sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral),  <e1> triazolam </e1> ,  <e2> trimethoprim </e2> /sulfamethoxazole or zidovudine.
false	Azlocillin should not be administered concomitantly with amikacin,  <e1> ciprofloxacin </e1> ,  <e2> gentamicin </e2> , netilmicin, or tobramycin.
false	Until further data are developed regarding drug interactions when  <e1> azithromycin </e1>  and these drugs are used concomitantly, careful monitoring of patients is advised:  <e2> Digoxin </e2>  elevated digoxin concentrations.
advise	 <e1> Azlocillin </e1>  should not be administered concomitantly with  <e2> amikacin </e2> , ciprofloxacin, gentamicin, netilmicin, or tobramycin.
false	Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin,  <e1> gentamicin </e1> ,  <e2> netilmicin </e2> , or tobramycin.
false	Azlocillin should not be administered concomitantly with  <e1> amikacin </e1> ,  <e2> ciprofloxacin </e2> , gentamicin, netilmicin, or tobramycin.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole,  <e1> indinavir </e1> , midazolam, rifabutin, sildenafil, theophylline (intravenous and oral),  <e2> triazolam </e2> , trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of  <e1> atorvastatin </e1> , carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil,  <e2> theophylline </e2>  (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
mechanism	Co-administration with efavirenz or  <e1> fluconazole </e1>  had a modest effect on the pharmacokinetics of  <e2> azithromycin </e2> .
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole,  <e1> indinavir </e1> , midazolam, rifabutin, sildenafil, theophylline (intravenous and oral),  <e2> triazolam </e2> , trimethoprim/sulfamethoxazole or zidovudine.
false	The adverse experience profile seen with  <e1> KEMSTROTM </e1>  was similar to that seen with  <e2> baclofen </e2>  tablets.
false	The adverse experience profile seen with  <e1> KEMSTROTM </e1>  was similar to that seen with  <e2> baclofen </e2>  tablets.
false	Total body clearance of Simulect was reduced by an average 22% and 51% when  <e1> azathioprine </e1>  and  <e2> mycophenolate mofetil </e2> , respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.
false	Nonetheless, the range of individual  <e1> Simulect </e1>  clearance values in the presence of  <e2> azathioprine </e2>  (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).
false	No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including  <e1> cyclosporine </e1> , corticosteroids, and either azathioprine or  <e2> mycophenolate mofetil </e2> .
false	The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG,  <e1> azathioprine </e1> , corticosteroids, cyclosporine, mycophenolate mofetil, and  <e2> muromonab-CD3 </e2> .
false	No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either  <e1> azathioprine </e1>  or  <e2> mycophenolate mofetil </e2> .
false	Nonetheless, the range of individual  <e1> Simulect </e1>  clearance values in the presence of azathioprine (12-57 mL/h) or  <e2> mycophenolate mofetil </e2>  (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).
mechanism	Total body clearance of  <e1> Simulect </e1>  was reduced by an average 22% and 51% when  <e2> azathioprine </e2>  and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.
false	Total body clearance of Simulect was reduced by an average 22% and 51% when  <e1> azathioprine </e1>  and mycophenolate mofetil, respectively, were added to a regimen consisting of  <e2> cyclosporine </e2> , USP (MODIFIED) and corticosteroids.
false	The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids,  <e1> cyclosporine </e1> ,  <e2> mycophenolate mofetil </e2> , and muromonab-CD3.
false	Nonetheless, the range of individual  <e1> Simulect </e1>  clearance values in the presence of azathioprine (12-57 mL/h) or  <e2> mycophenolate mofetil </e2>  (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).
false	Albuterol, Antihistamines,  <e1> antidiabetic drugs </e1> ,  <e2> diuretics </e2> , digitalis.
false	 <e1> Albuterol </e1> ,  <e2> Antihistamines </e2> , antidiabetic drugs, diuretics, digitalis.
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone,  <e1> furosemide </e1> ,  <e2> digoxin </e2> , propranolol, atenolol, naproxen, or cimetidine.
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide,  <e1> chlorthalidone </e1> , furosemide, digoxin, propranolol, atenolol,  <e2> naproxen </e2> , or cimetidine.
false	 <e1> Lotensin </e1>  has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents,  <e2> diuretics </e2> , digoxin, and hydralazine, without evidence of clinically important adverse interactions.
false	Oral  <e1> Anticoagulants </e1>  Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these  <e2> anticoagulants </e2> .
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with  <e1> hydrochlorothiazide </e1> , chlorthalidone, furosemide, digoxin, propranolol, atenolol,  <e2> naproxen </e2> , or cimetidine.
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with  <e1> hydrochlorothiazide </e1> , chlorthalidone, furosemide, digoxin,  <e2> propranolol </e2> , atenolol, naproxen, or cimetidine.
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone, furosemide, digoxin,  <e1> propranolol </e1> , atenolol,  <e2> naproxen </e2> , or cimetidine.
false	Potassium-sparing diuretics (spironolactone, amiloride,  <e1> triamterene </e1> , and others) or  <e2> potassium </e2>  supplements can increase the risk of hyperkalemia.
false	 <e1> Lotensin </e1>  has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and  <e2> hydralazine </e2> , without evidence of clinically important adverse interactions.
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide,  <e1> chlorthalidone </e1> , furosemide, digoxin, propranolol, atenolol, naproxen, or  <e2> cimetidine </e2> .
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide,  <e1> chlorthalidone </e1> , furosemide, digoxin, propranolol,  <e2> atenolol </e2> , naproxen, or cimetidine.
effect	Potassium Supplements and  <e1> Potassium-Sparing Diuretics </e1>  Lotensin can attenuate potassium loss caused by  <e2> thiazide diuretics </e2> .
false	Oral Anticoagulants Interaction studies with  <e1> warfarin </e1>  and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these  <e2> anticoagulants </e2> .
false	Lotensin has been used concomitantly with beta-adrenergic-blocking agents,  <e1> calcium-channel-blocking agents </e1> , diuretics,  <e2> digoxin </e2> , and hydralazine, without evidence of clinically important adverse interactions.
false	Potassium-sparing diuretics ( <e1> spironolactone </e1> , amiloride, triamterene, and others) or  <e2> potassium </e2>  supplements can increase the risk of hyperkalemia.
false	Oral Anticoagulants Interaction studies with  <e1> warfarin </e1>  and  <e2> acenocoumarol </e2>  failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.
false	 <e1> Lithium </e1> : Increased serum  <e2> lithium </e2>  levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
false	Oral  <e1> Anticoagulants </e1>  Interaction studies with  <e2> warfarin </e2>  and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.
false	Potassium-sparing diuretics (spironolactone, amiloride,  <e1> triamterene </e1> , and others) or  <e2> potassium </e2>  supplements can increase the risk of hyperkalemia.
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide,  <e1> chlorthalidone </e1> , furosemide, digoxin, propranolol, atenolol, naproxen, or  <e2> cimetidine </e2> .
false	May interact with the following:  <e1> cholestyramine </e1> ,  <e2> colestipol </e2>  (use with thiazide diuretics may prevent the diuretic from working properly;
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with  <e1> hydrochlorothiazide </e1> , chlorthalidone, furosemide, digoxin,  <e2> propranolol </e2> , atenolol, naproxen, or cimetidine.
false	Bentiromide may interact with  <e1> acetaminophen </e1>  (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some  <e2> multivitamins </e2> ), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local  <e1> anesthetics </e1>  (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines),  <e2> thiazide diuretics </e2>  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	May interact with the following:  <e1> cholestyramine </e1> ,  <e2> colestipol </e2>  (use with thiazide diuretics may prevent the diuretic from working properly;
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g.,  <e1> Chloromycetin </e1> ), local  <e2> anesthetics </e2>  (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
int	 <e1> Bentiromide </e1>  may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines),  <e2> thiazide diuretics </e2>  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol),  <e1> chloramphenicol </e1>  (e.g., Chloromycetin), local  <e2> anesthetics </e2>  (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local  <e1> anesthetics </e1>  (e.g., benzocaine and lidocaine),  <e2> para-aminobenzoic acid </e2>  (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol),  <e1> chloramphenicol </e1>  (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl),  <e2> sulfonamides </e2>  (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and  <e1> lidocaine </e1> ), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g.,  <e2> Pronestyl </e2> ), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with  <e1> acetaminophen </e1>  (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl),  <e2> sulfonamides </e2>  (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g.,  <e1> Tylenol </e1> ),  <e2> chloramphenicol </e2>  (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g.,  <e1> Chloromycetin </e1> ), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins),  <e2> procainamide </e2>  (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
int	 <e1> Bentiromide </e1>  may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g.,  <e2> Pronestyl </e2> ), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
int	 <e1> Bentiromide </e1>  may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g.,  <e2> Chloromycetin </e2> ), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g.,  <e1> Chloromycetin </e1> ), local anesthetics (e.g.,  <e2> benzocaine </e2>  and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g.,  <e1> Tylenol </e1> ), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g.,  <e2> benzocaine </e2>  and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and  <e1> lidocaine </e1> ),  <e2> para-aminobenzoic acid </e2>  (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid ( <e1> PABA </e1> )-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g.,  <e2> Pronestyl </e2> ), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide,  <e1> chlorthalidone </e1> , furosemide, digoxin, propranolol, atenolol, naproxen, or  <e2> cimetidine </e2> .
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g.,  <e1> Chloromycetin </e1> ), local anesthetics (e.g., benzocaine and  <e2> lidocaine </e2> ), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g.,  <e1> Chloromycetin </e1> ), local anesthetics (e.g., benzocaine and lidocaine),  <e2> para-aminobenzoic acid </e2>  (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g.,  <e1> Chloromycetin </e1> ), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g.,  <e2> Pronestyl </e2> ), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and  <e1> lidocaine </e1> ), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g.,  <e2> Pronestyl </e2> ), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local  <e1> anesthetics </e1>  (e.g., benzocaine and lidocaine),  <e2> para-aminobenzoic acid </e2>  (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with  <e1> acetaminophen </e1>  (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some  <e2> multivitamins </e2> ), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g.,  <e1> Tylenol </e1> ),  <e2> chloramphenicol </e2>  (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and  <e1> lidocaine </e1> ), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g.,  <e2> Pronestyl </e2> ), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine,  <e1> NSAIDs </e1>  like Aleve or  <e2> Ibuprofen </e2> , and high blood pressure medications.
false	Benzthiazide may interact with alcohol,  <e1> blood thinner </e1> s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like  <e2> Aleve </e2>  or Ibuprofen, and high blood pressure medications.
false	Benzthiazide may interact with alcohol,  <e1> blood thinner </e1> s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine,  <e2> NSAIDs </e2>  like Aleve or Ibuprofen, and high blood pressure medications.
false	Benzthiazide may interact with alcohol, blood thinners,  <e1> decongestant drugs </e1>  (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like  <e2> Aleve </e2>  or Ibuprofen, and high blood pressure medications.
false	Benzthiazide may interact with alcohol, blood thinners,  <e1> decongestant drugs </e1>  (allergy, cold, and sinus medicines), diabetic drugs,  <e2> lithium </e2> , norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
int	 <e1> Benzthiazide </e1>  may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium,  <e2> norepinephrine </e2> , NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
false	 <e1> Antipsychotic drugs </e1>  such as  <e2> phenothiazines </e2>  or haloperidol;
false	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide,  <e1> cardiac glycosides </e1>  and  <e2> tricyclic anti-depressants </e2> .
false	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as  <e1> quinidine </e1>  and procainamide,  <e2> cardiac glycosides </e2>  and tricyclic anti-depressants.
false	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including  <e1> anti-arrhythmic agents </e1>  such as quinidine and procainamide, cardiac glycosides and  <e2> tricyclic anti-depressants </e2> .
false	In general, these are drugs that have one or more pharmacologic activities similar to  <e1> bepridil hydrochloride </e1> , including anti-arrhythmic agents such as  <e2> quinidine </e2>  and procainamide, cardiac glycosides and tricyclic anti-depressants.
false	Oral Hypoglycemics:  <e1> Bepridil </e1>  has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral  <e2> hypoglycemic agents </e2> .
false	 <e1> Antipsychotic drugs </e1>  such as  <e2> phenothiazines </e2>  or haloperidol;
false	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide,  <e1> cardiac glycosides </e1>  and  <e2> tricyclic anti-depressants </e2> .
false	The following drugs have been coadministered with  <e1> Kerlone </e1>  and have not altered its pharmacokinetics:  <e2> cimetidine </e2> , nifedipine, chlorthalidone, and hydrochlorothiazide.
false	Hypotension was more likely to occur if the calcium antagonist were a  <e1> dihydropyridine derivative </e1> , e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or  <e2> diltiazem </e2> .
false	Hypotension was more likely to occur if the  <e1> calcium antagonist </e1>  were a dihydropyridine derivative, e.g.,  <e2> nifedipine </e2> , while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.
false	The following drugs have been coadministered with Kerlone and have not altered its pharmacokinetics: cimetidine,  <e1> nifedipine </e1> , chlorthalidone, and  <e2> hydrochlorothiazide </e2> .
false	Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to  <e1> epinephrine </e1>  in the treatment of anaphylactic shock,  <e2> beta-blockers </e2>  can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
false	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide,  <e1> cardiac glycosides </e1>  and  <e2> tricyclic anti-depressants </e2> .
false	Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to  <e1> epinephrine </e1>  in the treatment of anaphylactic shock,  <e2> beta-blockers </e2>  can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
false	In Study 1, patients with colorectal cancer were given  <e1> irinotecan </e1> /5-FU/leucovorin (bolus-IFL) with or without  <e2> AVASTIN </e2> .
false	In Study 1, patients with colorectal cancer were given  <e1> irinotecan </e1> /5-FU/ <e2> leucovorin </e2>  (bolus-IFL) with or without AVASTIN.
false	Due to high inter-patient variability and limited sampling, the extent of the increase in  <e1> SN38 </e1>  levels in patients receiving concurrent irinotecan and  <e2> AVASTIN </e2>  is uncertain.
false	Concomitant administration of Targretin capsules and  <e1> gemfibrozil </e1>  resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by  <e2> gemfibrozil </e2> .
false	Under similar conditions,  <e1> bexarotene </e1>  concentrations were not affected by concomitant  <e2> atorvastatin </e2>  administration.
mechanism	On the basis of the metabolism of bexarotene by cytochrome P450 3A4,  <e1> ketoconazole </e1> , itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma  <e2> bexarotene </e2>  concentrations.
false	On the basis of the metabolism of bexarotene by cytochrome P450 3A4,  <e1> ketoconazole </e1> , itraconazole,  <e2> erythromycin </e2> , gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
false	Furthermore,  <e1> rifampin </e1> ,  <e2> phenytoin </e2> , phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
false	Concomitant administration of Targretin capsules and  <e1> gemfibrozil </e1>  resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by  <e2> gemfibrozil </e2> .
false	- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g.  <e1> cholestryramine </e1> ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or  <e2> Bezalip retard </e2>  is impaired
false	- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  <e1> Bezalip </e1>  or  <e2> Bezalip retard </e2>  is impaired
false	Under similar conditions,  <e1> bexarotene </e1>  concentrations were not affected by concomitant  <e2> atorvastatin </e2>  administration.
advise	- When Bezalip or  <e1> Bezalip retard </e1>  is used concurrently with  <e2> anion-exchange resins </e2>  (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
advise	For this reason, the dose of the  <e1> anticoagulant </e1>  should be reduced by 30 - 50% at the start of treatment with Bezalip or  <e2> Bezalip </e2>  retard and then titrated according to the blood clotting parameters
false	- When Bezalip or Bezalip retard is used concurrently with  <e1> anion-exchange resins </e1>  (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or  <e2> Bezalip retard </e2>  is impaired
effect	When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: -  <e1> Bezalip </e1>  and Bezalip retard may enhance the action of  <e2> anticoagulants of the coumarin type </e2> .
effect	- The action of sulphonylureas and  <e1> insulin </e1>  may be enhanced by  <e2> Bezalip </e2>  or Bezalip retard.
advise	It is recommended that if  <e1> CASODEX </e1>  is started in patients already receiving  <e2> coumarin anticoagulants </e2> , prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.
false	- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  <e1> Bezalip </e1>  or  <e2> Bezalip retard </e2>  is impaired
false	Concomitant administration of Targretin capsules and  <e1> gemfibrozil </e1>  resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by  <e2> gemfibrozil </e2> .
effect	- The action of sulphonylureas and  <e1> insulin </e1>  may be enhanced by  <e2> Bezalip </e2>  or Bezalip retard.
mechanism	In vitro studies have shown CASODEX can displace  <e1> coumarin anticoagulant </e1> s, such as  <e2> warfarin </e2> , from their protein-binding sites.
false	Concomitant administration of Targretin capsules and  <e1> gemfibrozil </e1>  resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by  <e2> gemfibrozil </e2> .
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics,  <e1> tricyclic antidepressants </e1> , certain  <e2> antiarrhythmics </e2>  such as the quinidine salts, and antihistamines.
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the  <e1> phenothiazines </e1>  and other antipsychotics, tricyclic antidepressants, certain  <e2> antiarrhythmics </e2>  such as the quinidine salts, and antihistamines.
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as  <e1> meperidine </e1> , the phenothiazines and other antipsychotics, tricyclic antidepressants, certain  <e2> antiarrhythmics </e2>  such as the quinidine salts, and antihistamines.
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain  <e1> narcotic analgesics </e1>  such as meperidine, the phenothiazines and other  <e2> antipsychotics </e2> , tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the  <e1> phenothiazines </e1>  and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and  <e2> antihistamines </e2> .
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as  <e1> AKINETON </e1>  are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the  <e2> phenothiazines </e2>  and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as  <e1> AKINETON </e1>  are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain  <e2> antiarrhythmics </e2>  such as the quinidine salts, and antihistamines.
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics,  <e1> tricyclic antidepressants </e1> , certain antiarrhythmics such as the quinidine salts, and  <e2> antihistamines </e2> .
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as  <e1> AKINETON </e1>  are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics,  <e2> tricyclic antidepressants </e2> , certain antiarrhythmics such as the quinidine salts, and antihistamines.
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as  <e1> AKINETON </e1>  are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics,  <e2> tricyclic antidepressants </e2> , certain antiarrhythmics such as the quinidine salts, and antihistamines.
false	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the  <e1> phenylalkylamine </e1>  [verapamil] and benzothiazepine [diltiazem] classes), or  <e2> antiarrhythmic agents </e2> , such as disopyramide, are used concurrently.
false	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [ <e1> verapamil </e1> ] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as  <e2> disopyramide </e2> , are used concurrently.
false	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain  <e1> calcium antagonists </e1>  (particularly of the phenylalkylamine [verapamil] and benzothiazepine [ <e2> diltiazem </e2> ] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
advise	 <e1> ZEBETA </e1>  should not be combined with other  <e2> beta-blocking agents </e2> .
false	Concurrent use of  <e1> rifampin </e1>  increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of  <e2> ZEBETA </e2> .
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the  <e1> phenothiazines </e1>  and other antipsychotics, tricyclic antidepressants, certain  <e2> antiarrhythmics </e2>  such as the quinidine salts, and antihistamines.
false	Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including  <e1> thiazide diuretics </e1> , digoxin, and  <e2> cimetidine </e2> .
false	ZEBETA should be used with care when  <e1> myocardial depressants </e1>  or inhibitors of AV conduction, such as certain  <e2> calcium antagonists </e2>  (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
advise	 <e1> ZEBETA </e1>  should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or  <e2> antiarrhythmic agents </e2> , such as disopyramide, are used concurrently.
false	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain  <e1> calcium antagonists </e1>  (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as  <e2> disopyramide </e2> , are used concurrently.
advise	If you are also using a  <e1> steroid </e1>  inhaler, take  <e2> bitolterol </e2>  first and then wait about 15 minutes before using the steroid inhaler.
false	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain  <e1> calcium antagonists </e1>  (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as  <e2> disopyramide </e2> , are used concurrently.
effect	This allows  <e1> bitolterol </e1>  to open air passages, increasing the effectiveness of the  <e2> steroid </e2> .
false	Concurrent use of  <e1> rifampin </e1>  increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of  <e2> ZEBETA </e2> .
false	Among 494 subjects who received  <e1> Angiomax </e1>  in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive  <e2> bivalirudin </e2>  antibody tests.
effect	In clinical trials in patients undergoing PTCA/PCI, co-administration of  <e1> Angiomax </e1>  with heparin, warfarin,  <e2> thrombolytics </e2>  or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
false	There is no experience with co-administration of  <e1> Angiomax </e1>  and plasma expanders such as  <e2> dextran </e2> .
false	Certain antibiotic, cisplatin,  <e1> cyclosporine </e1> ,  <e2> diuretic </e2> , foscarnet, and vaccines.
false	Certain  <e1> antibiotic </e1> , cisplatin, cyclosporine, diuretic,  <e2> foscarnet </e2> , and vaccines.
false	Certain antibiotic, cisplatin, cyclosporine, diuretic,  <e1> foscarnet </e1> , and  <e2> vaccines </e2> .
false	Certain antibiotic,  <e1> cisplatin </e1> ,  <e2> cyclosporine </e2> , diuretic, foscarnet, and vaccines.
false	Certain  <e1> antibiotic </e1> , cisplatin, cyclosporine, diuretic,  <e2> foscarnet </e2> , and vaccines.
false	 <e1> Tacrolimus </e1> : Co-administration of  <e2> tacrolimus </e2>  and bosentan has not been studied in man.
mechanism	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of  <e1> bosentan </e1>  and the oral hormonal contraceptive  <e2> Ortho-Novum </e2>  produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.
false	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of  <e1> bosentan </e1>  and the oral hormonal contraceptive Ortho-Novum produced average decreases of  <e2> norethindrone </e2>  and ethinyl estradiol levels of 14% and 31%, respectively.
false	Digoxin, Nimodipine and  <e1> Losartan </e1> : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of  <e2> bosentan </e2> .
false	 <e1> Digoxin </e1> ,  <e2> Nimodipine </e2>  and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.
false	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable  <e1> Contraceptives </e1> : An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of  <e2> norethindrone </e2>  and ethinyl estradiol levels of 14% and 31%, respectively.
advise	Patients using CYP3A4 metabolized  <e1> statins </e1>  should have cholesterol levels monitored after  <e2> TRACLEER </e2>  is initiated to see whether the statin dose needs adjustment.
false	 <e1> Hormonal Contraceptives </e1> , Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive  <e2> Ortho-Novum </e2>  produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.
false	 <e1> Digoxin </e1> , Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and  <e2> nimodipine </e2> , and losartan has no significant effect on plasma levels of bosentan.
false	Digoxin,  <e1> Nimodipine </e1>  and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and  <e2> nimodipine </e2> , and losartan has no significant effect on plasma levels of bosentan.
false	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral  <e1> hormonal contraceptive </e1>  Ortho-Novum produced average decreases of  <e2> norethindrone </e2>  and ethinyl estradiol levels of 14% and 31%, respectively.
false	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral  <e1> hormonal contraceptive </e1>   <e2> Ortho-Novum </e2>  produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.
false	 <e1> Ketoconazole </e1> : Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of  <e2> bosentan </e2>  by approximately 2-fold.
false	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable  <e1> Contraceptives </e1> : An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive  <e2> Ortho-Novum </e2>  produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.
mechanism	Steady-state  <e1> bosentan </e1>  plasma concentrations were 3- to 4-fold higher than in the absence of  <e2> cyclosporine A </e2> .
false	 <e1> Ketoconazole </e1> : Co-administration of bosentan 125 mg b.i.d. and  <e2> ketoconazole </e2> , a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.
false	 <e1> Tacrolimus </e1> : Co-administration of tacrolimus and  <e2> bosentan </e2>  has not been studied in man.
false	Digoxin, Nimodipine and  <e1> Losartan </e1> : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and  <e2> losartan </e2>  has no significant effect on plasma levels of bosentan.
false	Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with  <e1> digoxin </e1>  and nimodipine, and losartan has no significant effect on plasma levels of  <e2> bosentan </e2> .
false	Patients using CYP3A4 metabolized  <e1> statins </e1>  should have cholesterol levels monitored after TRACLEER is initiated to see whether the  <e2> statin </e2>  dose needs adjustment.
mechanism	Steady-state  <e1> bosentan </e1>  plasma concentrations were 3- to 4-fold higher than in the absence of  <e2> cyclosporine A </e2> .
false	 <e1> Tacrolimus </e1> : Co-administration of tacrolimus and  <e2> bosentan </e2>  has not been studied in man.
false	Co-administration of BOTOX and  <e1> aminoglycosides </e1>  or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the  <e2> toxin </e2>  may be potentiated.
false	 <e1> Tacrolimus </e1> : Co-administration of  <e2> tacrolimus </e2>  and bosentan has not been studied in man.
false	Co-administration of  <e1> BOTOX </e1>  and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the  <e2> toxin </e2>  may be potentiated.
false	Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g.,  <e1> curare-like compounds </e1> ) should only be performed with caution as the effect of the  <e2> toxin </e2>  may be potentiated.
advise	Co-administration of  <e1> MYOBLOC </e1>  and aminoglycosides or other agents interfering with neuromuscular transmission (e.g.,  <e2> curare-like compounds </e2> ) should only be performed with caution as the effect of the toxin may be potentiated.
false	The pressor effects of catecholamines such as  <e1> dopamine </e1>  or  <e2> norepinephrine </e2>  are enhanced by Bretylium Tosylate.
effect	 <e1> Digitalis </e1>  toxicity may be aggravated by the initial release of norepinephrine caused by  <e2> Bretylium Tosylate </e2>  Injection.
effect	 <e1> Tricyclic antidepressants </e1>  have been reported to blunt the hypotensive effect of systemic  <e2> clonidine </e2> .It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.
false	 <e1> Tricyclic antidepressants </e1>  have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with  <e2> ALPHAGAN P </e2>  in humans can lead to resulting interference with the IOP lowering effect.
false	Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic  <e1> clonidine </e1> .It is not known whether the concurrent use of these agents with  <e2> ALPHAGAN P </e2>  in humans can lead to resulting interference with the IOP lowering effect.
false	The pressor effects of catecholamines such as  <e1> dopamine </e1>  or  <e2> norepinephrine </e2>  are enhanced by Bretylium Tosylate.
false	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates,  <e1> opiates </e1> , sedatives, or  <e2> anesthetics </e2> ) should be considered.
advise	Although specific drug interaction studies have not been conducted with  <e1> ALPHAGAN P </e1> , the possibility of an additive or potentiating effect with  <e2> CNS depressants </e2>  (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
false	Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic  <e1> clonidine </e1> .It is not known whether the concurrent use of these agents with  <e2> ALPHAGAN P </e2>  in humans can lead to resulting interference with the IOP lowering effect.
false	The risk of using  <e1> bromocriptine mesylate </e1>  in combination with other drugs has not been systematically evaluated, but  <e2> alcohol </e2>  may potentiate the side effects of bromocriptine mesylate.
int	 <e1> Bromocriptine mesylate </e1>  may interact with dopamine antagonists,  <e2> butyrophenones </e2> , and certain other agents.
false	The risk of using  <e1> bromocriptine mesylate </e1>  in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of  <e2> bromocriptine mesylate </e2> .
effect	Compounds in these categories result in a decreased efficacy of  <e1> bromocriptine mesylate </e1> :  <e2> phenothiazines </e2> , haloperidol, metoclopramide, pimozide.
effect	 <e1> Dexbrompheniramine </e1>  can interact with alcohol or other  <e2> CNS depressants </e2>  (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e1> monoamine oxidase (MAO) inhibitors </e1>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of  <e2> antihistamines </e2> ).
false	Dexbrompheniramine can interact with alcohol or other  <e1> CNS depressants </e1>  (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e2> monoamine oxidase (MAO) inhibitors </e2>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	 <e1> Dexbrompheniramine </e1>  can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  <e2> antihistamines </e2> ), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e1> monoamine oxidase (MAO) inhibitors </e1>  (concurrent use with  <e2> antihistamines </e2>  may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e1> anticholinergics </e1>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e2> monoamine oxidase (MAO) inhibitors </e2>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other  <e1> CNS depressants </e1>  (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e2> anticholinergics </e2>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or  <e1> antihistamines </e1> ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with  <e2> antihistamines </e2>  may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e1> monoamine oxidase (MAO) inhibitors </e1>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of  <e2> antihistamines </e2> ).
false	This drug may interact with  <e1> alcohol </e1>  or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e2> monoamine oxidase (MAO) inhibitors </e2>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with  <e1> alcohol </e1>  or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e2> anticholinergics </e2>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with alcohol or other  <e1> CNS depressants </e1>  (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of  <e2> antihistamines </e2> ).
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  <e1> antihistamines </e1> ), and monoamine oxidase (MAO) inhibitors (concurrent use with  <e2> antihistamines </e2>  may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or  <e1> antihistamines </e1> ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  <e2> antihistamines </e2> ), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e1> anticholinergics </e1>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e2> monoamine oxidase (MAO) inhibitors </e2>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	If treatment with inhibitors of CYP3A4 activity (such as  <e1> ketoconazole </e1> , intraconazole,  <e2> ritonavir </e2> , indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e1> anticholinergics </e1>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e2> monoamine oxidase (MAO) inhibitors </e2>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole,  <e1> ritonavir </e1> ,  <e2> indinavir </e2> , saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
false	If treatment with inhibitors of CYP3A4 activity (such as  <e1> ketoconazole </e1> , intraconazole, ritonavir, indinavir, saquinavir,  <e2> erythromycin </e2> , etc.) is indicated, reduction of the budesonide dose should be considered.
false	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole,  <e1> intraconazole </e1> , ritonavir, indinavir,  <e2> saquinavir </e2> , erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
advise	If treatment with inhibitors of CYP3A4 activity (such as  <e1> ketoconazole </e1> , intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the  <e2> budesonide </e2>  dose should be considered.
advise	If treatment with inhibitors of CYP3A4 activity (such as  <e1> ketoconazole </e1> , intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the  <e2> budesonide </e2>  dose should be considered.
false	-  <e1> Antihypertensives </e1> :  <e2> Bumetanide </e2>  may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.
false	- Lithium:  <e1> Lithium </e1>  should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of  <e2> lithium </e2>  toxicity.
false	-  <e1> Lithium </e1> : Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of  <e2> lithium </e2>  toxicity.
false	-  <e1> Lithium </e1> : Lithium should generally not be given with diuretics (such as  <e2> bumetanide </e2> ) because they reduce its renal clearance and add a high risk of lithium toxicity.
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e1> anticholinergics </e1>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e2> monoamine oxidase (MAO) inhibitors </e2>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
mechanism	This antagonistic effect of  <e1> probenecid </e1>  on  <e2> bumetanide </e2>  natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.
false	-  <e1> Antihypertensives </e1> : Bumetanide may potentiate the effect of various  <e2> antihypertensive drugs </e2> , necessitating a reduction in the dosage of these drugs.
effect	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or norepinephrine to patients receiving monoamine oxidase inhibitors or  <e2> tricyclic antidepressants </e2>  may produce severe, prolonged hypertension.
false	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or  <e2> norepinephrine </e2>  to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
false	The administration of local  <e1> anesthetic solutions </e1>  containing epinephrine or norepinephrine to patients receiving  <e2> monoamine oxidase inhibitors </e2>  or tricyclic antidepressants may produce severe, prolonged hypertension.
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e1> anticholinergics </e1>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e2> monoamine oxidase (MAO) inhibitors </e2>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g.  <e1> ritonavir </e1> , indinavir and saquinavir) should have their dose of SUBUTEX or  <e2> SUBOXONE </e2>  adjusted.
false	Because CYP 3A4 inhibitors may increase plasma concentrations of  <e1> buprenorphine </e1> , patients already on CYP 3A4 inhibitors such as  <e2> azole antifungals </e2>  (e.g.
false	 <e1> ketoconazole </e1> ), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and  <e2> saquinavir </e2> ) should have their dose of SUBUTEX or SUBOXONE adjusted.
false	ketoconazole),  <e1> macrolide antibiotics </e1>  (e.g. erythromycin), and HIV protease inhibitors (e.g.  <e2> ritonavir </e2> , indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
advise	SUBUTEX and  <e1> SUBOXONE </e1>  should be prescribed with caution to patients on  <e2> benzodiazepines </e2>  or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.
false	ketoconazole), macrolide antibiotics (e.g. erythromycin), and  <e1> HIV protease inhibitors </e1>  (e.g. ritonavir,  <e2> indinavir </e2>  and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
false	ketoconazole),  <e1> macrolide antibiotics </e1>  (e.g.  <e2> erythromycin </e2> ), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
effect	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or norepinephrine to patients receiving monoamine oxidase inhibitors or  <e2> tricyclic antidepressants </e2>  may produce severe, prolonged hypertension.
false	ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g.  <e1> ritonavir </e1> ,  <e2> indinavir </e2>  and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
false	In many of these cases,  <e1> buprenorphine </e1>  was misused by self-injection of crushed  <e2> SUBUTEX </e2>  tablets.
false	 <e1> ketoconazole </e1> ), macrolide antibiotics (e.g. erythromycin), and  <e2> HIV protease inhibitors </e2>  (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
false	 <e1> Alcohol </e1> : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with  <e2> WELLBUTRIN </e2> .
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain  <e1> antidepressants </e1>  (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine),  <e2> beta-blockers </e2>  (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol,  <e1> risperidone </e1> , thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
advise	Therefore, co-administration of  <e1> bupropion </e1>  with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain  <e1> antidepressants </e1>  (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine,  <e2> sertraline </e2> ), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
int	Therefore, the potential exists for a drug interaction between  <e1> WELLBUTRIN </e1>  and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and  <e2> cyclophosphamide </e2> ).
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine,  <e1> paroxetine </e1> , fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g.,  <e2> metoprolol </e2> ), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g.,  <e1> haloperidol </e1> , risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone,  <e2> flecainide </e2> ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	 <e1> ketoconazole </e1> ), macrolide antibiotics (e.g. erythromycin), and  <e2> HIV protease inhibitors </e2>  (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
false	In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of  <e1> bupropion </e1>  given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of  <e2> desipramine </e2>  by an average of approximately 2-, 5- and 2-fold, respectively.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine,  <e1> desipramine </e1> , paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers,  <e1> antiarrhythmics </e1> , and  <e2> antipsychotics </e2>  are metabolized by the CYP2D6 isoenzyme.
advise	Therefore, co-administration of  <e1> bupropion </e1>  with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine,  <e2> paroxetine </e2> , fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline,  <e1> imipramine </e1> ,  <e2> desipramine </e2> , paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many  <e1> tricyclics </e1> ),  <e2> beta-blockers </e2> , antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.
false	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics),  <e1> beta-blockers </e1> ,  <e2> antiarrhythmics </e2> , and antipsychotics are metabolized by the CYP2D6 isoenzyme.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain  <e1> antidepressants </e1>  (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone,  <e2> thioridazine </e2> ), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone,  <e1> thioridazine </e1> ), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine,  <e1> sertraline </e1> ), antipsychotics (e.g., haloperidol,  <e2> risperidone </e2> , thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g.,  <e1> haloperidol </e1> , risperidone, thioridazine), beta-blockers (e.g., metoprolol), and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol,  <e1> risperidone </e1> , thioridazine), beta-blockers (e.g.,  <e2> metoprolol </e2> ), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain  <e1> antidepressants </e1>  (e.g.,  <e2> nortriptyline </e2> , imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
advise	Drugs that Lower Seizure Threshold: Concurrent administration of  <e1> WELLBUTRIN </e1>  and agents (e.g., antipsychotics, other  <e2> antidepressants </e2> , theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline,  <e1> imipramine </e1> , desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g.,  <e1> nortriptyline </e1> , imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol,  <e2> risperidone </e2> , thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Because CYP 3A4 inhibitors may increase plasma concentrations of  <e1> buprenorphine </e1> , patients already on CYP 3A4 inhibitors such as  <e2> azole antifungals </e2>  (e.g.
effect	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or norepinephrine to patients receiving monoamine oxidase inhibitors or  <e2> tricyclic antidepressants </e2>  may produce severe, prolonged hypertension.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g.,  <e1> nortriptyline </e1> , imipramine,  <e2> desipramine </e2> , paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of  <e1> bupropion </e1>  is enhanced by the  <e2> MAO inhibitor </e2>  phenelzine .
false	 <e1> Levodopa </e1>  and  <e2> Amantadine </e2> : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g.,  <e1> haloperidol </e1> , risperidone, thioridazine), beta-blockers (e.g.,  <e2> metoprolol </e2> ), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g.,  <e1> nortriptyline </e1> , imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine,  <e1> desipramine </e1> , paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone,  <e1> thioridazine </e1> ), beta-blockers (e.g.,  <e2> metoprolol </e2> ), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g.,  <e1> metoprolol </e1> ), and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
advise	Administration of  <e1> WELLBUTRIN </e1>  Tablets to patients receiving either levodopa or  <e2> amantadine </e2>  concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.
false	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many  <e1> tricyclics </e1> ), beta-blockers,  <e2> antiarrhythmics </e2> , and antipsychotics are metabolized by the CYP2D6 isoenzyme.
mechanism	While not systematically studied, certain drugs may induce the metabolism of  <e1> bupropion </e1>  (e.g., carbamazepine, phenobarbital,  <e2> phenytoin </e2> ).
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g.,  <e1> propafenone </e1> ,  <e2> flecainide </e2> ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
advise	Therefore, co-administration of  <e1> bupropion </e1>  with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol,  <e2> risperidone </e2> , thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine,  <e1> paroxetine </e1> , fluoxetine, sertraline),  <e2> antipsychotics </e2>  (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g.,  <e1> antipsychotics </e1> , other antidepressants,  <e2> theophylline </e2> , systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine,  <e1> paroxetine </e1> , fluoxetine,  <e2> sertraline </e2> ), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline),  <e1> antipsychotics </e1>  (e.g., haloperidol, risperidone,  <e2> thioridazine </e2> ), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
effect	There is one report suggesting that the concomitant use of trazodone hydrochloride ( <e1> Desyrel </e1> ) and  <e2> buspirone HCl </e2>  may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g.,  <e1> metoprolol </e1> ), and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many  <e1> tricyclics </e1> ), beta-blockers,  <e2> antiarrhythmics </e2> , and antipsychotics are metabolized by the CYP2D6 isoenzyme.
false	In a study in normal volunteers, concomitant administration of  <e1> buspirone HCl </e1>  and haloperidol resulted in increased serum  <e2> haloperidol </e2>  concentrations.
advise	Therefore, co-administration of  <e1> bupropion </e1>  with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol,  <e2> risperidone </e2> , thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine,  <e1> sertraline </e1> ), antipsychotics (e.g., haloperidol,  <e2> risperidone </e2> , thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol,  <e1> risperidone </e1> , thioridazine), beta-blockers (e.g.,  <e2> metoprolol </e2> ), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	 <e1> Alcohol </e1> : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with  <e2> WELLBUTRIN </e2> .
false	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers,  <e1> antiarrhythmics </e1> , and  <e2> antipsychotics </e2>  are metabolized by the CYP2D6 isoenzyme.
false	In vitro, buspirone does not displace tightly bound drugs like  <e1> phenytoin </e1> , propranolol, and  <e2> warfarin </e2>  from serum proteins.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g.,  <e1> nortriptyline </e1> , imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	In vitro,  <e1> buspirone </e1>  does not displace tightly bound drugs like phenytoin,  <e2> propranolol </e2> , and warfarin from serum proteins.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine,  <e1> paroxetine </e1> , fluoxetine,  <e2> sertraline </e2> ), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of  <e1> bupropion </e1>  given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of  <e2> desipramine </e2>  by an average of approximately 2-, 5- and 2-fold, respectively.
false	Because  <e1> busulfan </e1>  is eliminated from the body via conjugation with glutathione, use of  <e2> acetaminophen </e2>  prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g.,  <e1> nortriptyline </e1> , imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	In vitro,  <e1> buspirone </e1>  does not displace tightly bound drugs like phenytoin,  <e2> propranolol </e2> , and warfarin from serum proteins.
false	Since the pharmacokinetics of BUSULFEX were studied in patients treated with  <e1> phenytoin </e1> , the clearance of  <e2> BUSULFEX </e2>  at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.
false	Because busulfan is eliminated from the body via conjugation with glutathione, use of  <e1> acetaminophen </e1>  prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of  <e2> acetaminophen </e2>  to decrease glutathione levels in the blood and tissues.
false	Since the pharmacokinetics of BUSULFEX were studied in patients treated with  <e1> phenytoin </e1> , the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with  <e2> phenytoin </e2> .
mechanism	Because busulfan is eliminated from the body via conjugation with glutathione, use of  <e1> acetaminophen </e1>  prior to ( 72 hours) or concurrent with  <e2> BUSULFEX </e2>  may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.
false	Fluconazole, and the 5-HT3 antiemetics ondansetron ( <e1> Zofran </e1> ) and granisetron ( <e2> Kytril </e2> ) have all been used with BUSULFEX.
false	 <e1> Fluconazole </e1> , and the 5-HT3 antiemetics  <e2> ondansetron </e2>  (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.
false	In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of  <e1> bupropion </e1>  given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of  <e2> desipramine </e2>  by an average of approximately 2-, 5- and 2-fold, respectively.
false	Fluconazole, and the  <e1> 5-HT3 antiemetics </e1>  ondansetron (Zofran) and  <e2> granisetron </e2>  (Kytril) have all been used with BUSULFEX.
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( <e1> blood thinner </e1> s),  <e2> carbamazepine </e2> , corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( <e1> blood thinner </e1> s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral  <e2> contraceptives </e2>  containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with  <e1> barbiturates </e1>  may result in increased CNS depressant effects),  <e2> divalproex sodium </e2> , valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine),  <e1> anticoagulants </e1>  (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral  <e2> contraceptives </e2> , and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine),  <e1> anticoagulants </e1>  (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( <e2> barbiturates </e2>  may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium,  <e1> valproic acid </e1>  (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( <e2> barbiturates </e2>  may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Since the pharmacokinetics of BUSULFEX were studied in patients treated with  <e1> phenytoin </e1> , the clearance of  <e2> BUSULFEX </e2>  at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing  <e1> estrogens </e1>  ( <e2> barbiturates </e2>  may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with  <e1> barbiturates </e1>  may change the amount of either medicine that you need to take), and oral  <e2> contraceptives </e2>  containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	 <e1> Fluconazole </e1> , and the 5-HT3 antiemetics  <e2> ondansetron </e2>  (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects),  <e1> divalproex sodium </e1> , valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing  <e2> estrogens </e2>  (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral  <e1> contraceptives </e1>  containing estrogens (barbiturates may decrease the effectiveness of these oral  <e2> contraceptives </e2> , and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners),  <e1> carbamazepine </e1> , corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( <e2> barbiturates </e2>  may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with  <e1> barbiturates </e1>  may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( <e2> barbiturates </e2>  may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with  <e1> barbiturates </e1>  may result in increased CNS depressant effects), divalproex sodium,  <e2> valproic acid </e2>  (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine,  <e1> corticotropin </e1>  (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with  <e2> barbiturates </e2>  may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners),  <e1> carbamazepine </e1> , corticotropin (barbiturates may decrease the effects of these medicines),  <e2> central nervous system (CNS) depressants </e2>  (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with  <e1> barbiturates </e1>  may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral  <e2> contraceptives </e2> , and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine),  <e1> anticoagulants </e1>  (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing  <e2> estrogens </e2>  (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( <e1> blood thinner </e1> s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral  <e2> contraceptives </e2> , and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( <e1> blood thinner </e1> s),  <e2> carbamazepine </e2> , corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Since the pharmacokinetics of BUSULFEX were studied in patients treated with  <e1> phenytoin </e1> , the clearance of  <e2> BUSULFEX </e2>  at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.
false	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics,  <e1> alcohol </e1> , general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other  <e2> CNS depressants </e2> , causing increased CNS depression.
false	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide,  <e1> sedative-hypnotics </e1> , or other  <e2> CNS depressants </e2> , causing increased CNS depression.
effect	Butalbital,  <e1> acetaminophen </e1>  and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other  <e2> CNS depressants </e2> , causing increased CNS depression.
effect	Butalbital,  <e1> acetaminophen </e1>  and caffeine may enhance the effects of: other  <e2> narcotic analgesic </e2> s, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
false	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as  <e1> chlordiazepoxide </e1> ,  <e2> sedative-hypnotics </e2> , or other CNS depressants, causing increased CNS depression.
effect	 <e1> Butalbital </e1> , acetaminophen and caffeine may enhance the effects of: other narcotic analgesics,  <e2> alcohol </e2> , general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
false	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general  <e1> anesthetics </e1> , tranquilizers such as chlordiazepoxide,  <e2> sedative-hypnotics </e2> , or other CNS depressants, causing increased CNS depression.
effect	Butalbital, acetaminophen and  <e1> caffeine </e1>  may enhance the effects of: other narcotic analgesics, alcohol, general  <e2> anesthetics </e2> , tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
false	Butalbital, acetaminophen and caffeine may enhance the effects of: other  <e1> narcotic analgesic </e1> s, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other  <e2> CNS depressants </e2> , causing increased CNS depression.
false	 <e1> Butalbital </e1> ,  <e2> acetaminophen </e2>  and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with  <e1> barbiturates </e1>  may change the amount of either medicine that you need to take), and oral  <e2> contraceptives </e2>  containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
effect	Butalbital, acetaminophen and  <e1> caffeine </e1>  may enhance the effects of: other  <e2> narcotic analgesic </e2> s, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
effect	Butalbital,  <e1> acetaminophen </e1>  and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other  <e2> CNS depressants </e2> , causing increased CNS depression.
false	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as  <e1> chlordiazepoxide </e1> ,  <e2> sedative-hypnotics </e2> , or other CNS depressants, causing increased CNS depression.
false	Potential drug interactions between  <e1> Mentax </e1>  ( <e2> butenafine HCl </e2>  cream) Cream, 1%, and other drugs have not been systematically evaluated.
false	Concurrent use of butorphanol with  <e1> central nervous system depressants </e1>  (e.g., alcohol, barbiturates, tranquilizers, and  <e2> antihistamines </e2> ) may result in increased central nervous system depressant effects.
false	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol,  <e1> barbiturates </e1> ,  <e2> tranquilizers </e2> , and antihistamines) may result in increased central nervous system depressant effects.
effect	Butalbital,  <e1> acetaminophen </e1>  and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other  <e2> CNS depressants </e2> , causing increased CNS depression.
mechanism	However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of  <e1> STADOL NS </e1>  was administered 1 minute after a 20-mg dose of  <e2> sumatriptan </e2>  nasal spray.
false	When used concurrently with such drugs, the dose of  <e1> butorphanol </e1>  should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of  <e2> opioids </e2> .
false	The safety of using  <e1> STADOL NS </e1>  and IMITREX ( <e2> sumatriptan </e2> ) Nasal Spray during the same episode of migraine has not been established.
false	The fraction of  <e1> STADOL NS </e1>  absorbed is unaffected by the concomitant administration of a nasal vasoconstrictor ( <e2> oxymetazoline </e2> ), but the rate of absorption is decreased.
false	The safety of using STADOL NS and  <e1> IMITREX </e1>  ( <e2> sumatriptan </e2> ) Nasal Spray during the same episode of migraine has not been established.
false	However, in another study in healthy volunteers, the pharmacokinetics of  <e1> butorphanol </e1>  were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of  <e2> STADOL NS </e2>  was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.
false	In neither case were the pharmacokinetics of  <e1> sumatriptan </e1>  affected by coadministration with  <e2> STADOL NS </e2> .
false	The safety of using  <e1> STADOL NS </e1>  and IMITREX ( <e2> sumatriptan </e2> ) Nasal Spray during the same episode of migraine has not been established.
false	DOSTINEX should not be administered concurrently with D2-antagonists, such as  <e1> phenothiazines </e1> , butyrophenones, thioxanthines, or  <e2> metoclopramide </e2> .
false	DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines,  <e1> butyrophenones </e1> , thioxanthines, or  <e2> metoclopramide </e2> .
advise	 <e1> DOSTINEX </e1>  should not be administered concurrently with D2-antagonists, such as phenothiazines,  <e2> butyrophenones </e2> , thioxanthines, or metoclopramide.
false	Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and  <e1> ketoconazole </e1> ) and higher caffeine doses may be needed following coadministration of drugs that increase  <e2> caffeine </e2>  elimination (e.g., phenobarbital and phenytoin).
false	Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease  <e1> caffeine </e1>  elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g.,  <e2> phenobarbital </e2>  and phenytoin).
false	Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g.,  <e1> cimetidine </e1>  and  <e2> ketoconazole </e2> ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
false	Based on adult data, lower doses of  <e1> caffeine </e1>  may be needed following coadministration of drugs which are reported to decrease  <e2> caffeine </e2>  elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
false	Interconversion between  <e1> caffeine </e1>  and  <e2> theophylline </e2>  has been reported in preterm neonates.
advise	 <e1> DOSTINEX </e1>  should not be administered concurrently with D2-antagonists, such as phenothiazines,  <e2> butyrophenones </e2> , thioxanthines, or metoclopramide.
false	Since blood level of  <e1> calcitriol </e1> /ergocalcitriol will be reduced, higher doses of  <e2> Rocaltrol </e2>  may be necessary if these drugs are administered simultaneously.
false	 <e1> Vitamin D </e1> : The coadministration of any of the  <e2> vitamin D analogues </e2>  should be avoided as this could create possible additive effects and hypercalcemia.
false	Phenytoin/ <e1> Phenobarbital </e1> : The coadministration of  <e2> phenytoin </e2>  or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	Interactions for vitamin D analogues ( <e1> Vitamin D2 </e1> , Vitamin D3,  <e2> Calcitriol </e2> , and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3,  <e1> Calcitriol </e1> , and Calcidiol): Cholestyramine:  <e2> Cholestyramine </e2>  has been reported to reduce intestinal absorption of fat soluble vitamins;
mechanism	Phenytoin/Phenobarbital: The coadministration of phenytoin or  <e1> phenobarbital </e1>  will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of  <e2> calcitriol </e2> /ergocalcitriol by accelerating metabolism.
false	Phenytoin/Phenobarbital: The coadministration of  <e1> phenytoin </e1>  or phenobarbital will not affect plasma concentrations of  <e2> vitamin D </e2> , but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	Interactions for  <e1> vitamin D analogues </e1>  (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of  <e2> fat soluble vitamins </e2> ;
false	Interactions for  <e1> vitamin D analogues </e1>  ( <e2> Vitamin D2 </e2> , Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
advise	Digitalis:  <e1> Vitamin D </e1>  dosage must be determined with care in patients undergoing treatment with  <e2> digitalis </e2> , as hypercalcemia in such patients may precipitate cardiac arrhythmias.
false	Interactions for vitamin D analogues ( <e1> Vitamin D2 </e1> , Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of  <e2> fat soluble vitamins </e2> ;
false	 <e1> Ketoconazole </e1> :  <e2> Ketoconazole </e2>  may inhibit both synthetic and catabolic enzymes of vitamin D.
false	Interactions for  <e1> vitamin D analogues </e1>  (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol):  <e2> Cholestyramine </e2> : Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3,  <e1> Calcitriol </e1> , and Calcidiol):  <e2> Cholestyramine </e2> : Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	 <e1> Corticosteroids </e1> : A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and  <e2> corticosteroids </e2> , which inhibit calcium absorption.
mechanism	Phenytoin/Phenobarbital: The coadministration of phenytoin or  <e1> phenobarbital </e1>  will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of  <e2> calcitriol </e2> /ergocalcitriol by accelerating metabolism.
false	 <e1> Phenytoin </e1> /Phenobarbital: The coadministration of phenytoin or  <e2> phenobarbital </e2>  will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	Interactions for vitamin D analogues (Vitamin D2,  <e1> Vitamin D3 </e1> , Calcitriol, and Calcidiol): Cholestyramine:  <e2> Cholestyramine </e2>  has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Phenytoin/ <e1> Phenobarbital </e1> : The coadministration of  <e2> phenytoin </e2>  or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	Phenytoin/Phenobarbital: The coadministration of  <e1> phenytoin </e1>  or  <e2> phenobarbital </e2>  will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	 <e1> Thiazides </e1> :  <e2> Thiazides </e2>  are known to induce hypercalcemia by the reduction of calcium excretion in urine.
false	Phenytoin/ <e1> Phenobarbital </e1> : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of  <e2> vitamin D </e2> , but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
advise	Magnesium:  <e1> Magnesium </e1> -containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with  <e2> vitamin D </e2>  by patients on chronic renal dialysis.
false	Interactions for vitamin D analogues ( <e1> Vitamin D2 </e1> , Vitamin D3,  <e2> Calcitriol </e2> , and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and  <e1> Calcidiol </e1> ):  <e2> Cholestyramine </e2> : Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Interactions for  <e1> vitamin D analogues </e1>  (Vitamin D2,  <e2> Vitamin D3 </e2> , Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Since blood level of  <e1> calcitriol </e1> /ergocalcitriol will be reduced, higher doses of  <e2> Rocaltrol </e2>  may be necessary if these drugs are administered simultaneously.
false	 <e1> Magnesium </e1> :  <e2> Magnesium </e2> -containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
false	 <e1> Magnesium </e1> : Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with  <e2> vitamin D </e2>  by patients on chronic renal dialysis.
false	 <e1> Phenytoin </e1> /Phenobarbital: The coadministration of  <e2> phenytoin </e2>  or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	Since blood level of  <e1> calcitriol </e1> /ergocalcitriol will be reduced, higher doses of  <e2> Rocaltrol </e2>  may be necessary if these drugs are administered simultaneously.
false	 <e1> Phenytoin </e1> /Phenobarbital: The coadministration of phenytoin or  <e2> phenobarbital </e2>  will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	Using  <e1> calcium acetate </e1>  with digitalis glycosides (heart medicine) may cause hypercalcemia (too much  <e2> calcium </e2>  in the blood), which could increase the chance of developing an irregular heartbeat.
false	 <e1> Thiazides </e1> :  <e2> Thiazides </e2>  are known to induce hypercalcemia by the reduction of calcium excretion in urine.
false	May interact with cefamandole naftate, cephalothin sodium,  <e1> magnesium sulfate </e1> , prednisolone sodium succinate, and  <e2> prochlorperazine edisylate </e2> .
false	 <e1> Phenytoin </e1> /Phenobarbital: The coadministration of phenytoin or  <e2> phenobarbital </e2>  will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	May interact with cefamandole naftate,  <e1> cephalothin sodium </e1> , magnesium sulfate, prednisolone sodium succinate, and  <e2> prochlorperazine edisylate </e2> .
false	No significant drug interactions have been reported in studies of  <e1> candesartan cilexetil </e1>  given with other drugs such as glyburide, nifedipine,  <e2> digoxin </e2> , warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide,  <e1> nifedipine </e1> , digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with  <e2> enalapril </e2>  to patients with heart failure (NYHA class II and III).
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as  <e1> glyburide </e1> , nifedipine,  <e2> digoxin </e2> , warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
false	 <e1> Lithium </e1>  Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some  <e2> angiotensin II receptor antagonists </e2> .
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine,  <e1> digoxin </e1> , warfarin,  <e2> hydrochlorothiazide </e2> , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin,  <e1> hydrochlorothiazide </e1> , and oral  <e2> contraceptives </e2>  in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide,  <e1> nifedipine </e1> , digoxin, warfarin,  <e2> hydrochlorothiazide </e2> , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
false	An increase in serum  <e1> lithium </e1>  concentration has been reported during concomitant administration of  <e2> lithium </e2>  with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as  <e1> glyburide </e1> , nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with  <e2> enalapril </e2>  to patients with heart failure (NYHA class II and III).
false	 <e1> Antacid </e1> : The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid ( <e2> Maalox </e2> )* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as  <e1> glyburide </e1> , nifedipine,  <e2> digoxin </e2> , warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine,  <e1> digoxin </e1> , warfarin,  <e2> hydrochlorothiazide </e2> , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
false	Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing  <e1> antacid </e1>  (Maalox)* on the pharmacokinetics of  <e2> capecitabine </e2>  was investigated in 12 cancer patients.
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin,  <e1> hydrochlorothiazide </e1> , and oral  <e2> contraceptives </e2>  in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
false	 <e1> Antacid </e1> : The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of  <e2> capecitabine </e2>  was investigated in 12 cancer patients.
false	Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing  <e1> antacid </e1>  ( <e2> Maalox </e2> )* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.
effect	Agents Causing Renin Release  <e1> Captopril </e1> 's effect will be augmented by  <e2> antihypertensive agents </e2>  that cause renin release.
false	Potassium-sparing diuretics such as  <e1> spironolactone </e1> ,  <e2> triamterene </e2> , or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.
false	 <e1> Loop Diuretics </e1> : Furosemide administered concurrently with  <e2> captopril </e2>  does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.
false	 <e1> Lithium </e1> : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and  <e2> ACE inhibitor </e2>  therapy.
false	The possibility of hypotensive effects with captopril can be minimized by either discontinuing the  <e1> diuretic </e1>  or increasing the salt intake approximately one week prior to initiation of treatment with  <e2> captopril </e2>  (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).
false	Loop Diuretics:  <e1> Furosemide </e1>  administered concurrently with captopril does not alter the pharmacokinetics of  <e2> captopril </e2>  in renally impaired hypertensive patients.
false	Potassium-sparing diuretics such as spironolactone, triamterene, or  <e1> amiloride </e1> , or  <e2> potassium </e2>  supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.
false	 <e1> Potassium-sparing diuretics </e1>  such as spironolactone, triamterene, or  <e2> amiloride </e2> , or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.
advise	therefore,  <e1> nitroglycerin </e1>  or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting  <e2> captopril </e2> .
false	Potassium-sparing diuretics such as spironolactone,  <e1> triamterene </e1> , or amiloride, or  <e2> potassium </e2>  supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.
false	 <e1> Antacid </e1> : The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of  <e2> capecitabine </e2>  was investigated in 12 cancer patients.
false	Lithium: Increased serum  <e1> lithium </e1>  levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and  <e2> ACE inhibitor </e2>  therapy.
false	 <e1> Lithium </e1> : Increased serum lithium levels and symptoms of  <e2> lithium </e2>  toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
effect	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant  <e1> lithium </e1>  and  <e2> ACE inhibitor </e2>  therapy.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e2> lamotrigine </e2> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e1> ethosuximide </e1> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e1> methadone </e1> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin,  <e1> phenobarbital </e1> , Phenytoin(2),  <e2> primidone </e2> , methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e1> mirtazapine </e1> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel,  <e2> protease inhibitors </e2> , quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e1> topiramate </e1> , tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e1> Phenytoin </e1> (4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e2> diazepam </e2> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel,  <e2> protease inhibitors </e2> , quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e1> risperidone </e1> , theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e1> ethosuximide </e1> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion,  <e1> buspirone </e1> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e2> diazepam </e2> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine,  <e2> quinupristin </e2> , troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin,  <e2> troleandomycin </e2> , valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> , bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1),  <e1> dalfopristin </e1> , danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone,  <e2> niacinamide </e2> , nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e1> olanzapine </e1> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e2> itraconazole </e2> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin,  <e1> doxorubicin HCL </e1> , felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  <e2> EQUETROTM </e2>  may be necessary.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine,  <e1> fluvoxamine </e1> , grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide,  <e2> nicotinamide </e2> , protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e2> quetiapine </e2> , risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e1> praziquantel </e1> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e1> mirtazapine </e1> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e2> glucocorticoids </e2> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e1> felbamate </e1> , felodipine, glucocorticoids, haloperidol,  <e2> itraconazole </e2> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide,  <e2> nicotinamide </e2> , protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e1> quetiapine </e1> , risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e1> nefazodone </e1> , niacinamide, nicotinamide, protease inhibitors, propoxyphene,  <e2> quinine </e2> , quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following:  <e1> Acetazolamide </e1> , azole antifungals, cimetidine,  <e2> clarithromycin </e2> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin,  <e1> phenobarbital </e1> , Phenytoin(2), primidone,  <e2> methsuximide </e2> , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice,  <e1> isoniazid </e1> , itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e2> propoxyphene </e2> , quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital,  <e1> Phenytoin </e1> (2),  <e2> primidone </e2> , methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> , desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e2> diazepam </e2> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e1> tramadol </e1> , triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e1> nortriptyline </e1> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e2> quetiapine </e2> , risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice,  <e1> isoniazid </e1> , itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene,  <e2> quinine </e2> , quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol,  <e2> delavirdine </e2> , diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1),  <e1> fluoxetine </e1> , fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1),  <e2> verapamil </e2> , zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1),  <e1> fluoxetine </e1> , fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide,  <e2> protease inhibitors </e2> , propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> ,  <e2> alprazolam </e2> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital,  <e1> Phenytoin </e1> (2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  <e2> EQUETROTM </e2>  may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e1> mirtazapine </e1> , nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> , lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e2> felbamate </e2> , felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following:  <e1> Acetazolamide </e1> , azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
mechanism	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  <e1> EQUETROTM </e1>  are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and  <e2> theophylline </e2>  Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene,  <e2> quinine </e2> , quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e2> felbamate </e2> , felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> , methadone, midazolam, mirtazapine,  <e2> nortriptyline </e2> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e2> glucocorticoids </e2> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice,  <e1> isoniazid </e1> , itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine,  <e2> quinupristin </e2> , troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> ,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> , bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel,  <e2> protease inhibitors </e2> , quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone,  <e1> niacinamide </e1> , nicotinamide, protease inhibitors, propoxyphene, quinine,  <e2> quinupristin </e2> , troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e1> theophylline </e1> ,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e2> delavirdine </e2> , desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL,  <e1> felbamate </e1> , rifampin, phenobarbital,  <e2> Phenytoin </e2> (2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e1> methadone </e1> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice,  <e2> isoniazid </e2> , itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e2> nortriptyline </e2> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e2> clobazam </e2> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> , bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e1> tiagabine </e1> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin,  <e1> danazol </e1> , delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e1> theophylline </e1> , topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e1> ethosuximide </e1> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin,  <e2> troleandomycin </e2> , valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e1> ketoconazole </e1> , loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1),  <e2> verapamil </e2> , zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e1> midazolam </e1> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e2> lamotrigine </e2> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL,  <e1> felbamate </e1> , rifampin, phenobarbital, Phenytoin(2), primidone,  <e2> methsuximide </e2> , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate,  <e2> felodipine </e2> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e1> valproate </e1> , warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e2> ethosuximide </e2> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin,  <e2> delavirdine </e2> , desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e1> Phenytoin </e1> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e1> midazolam </e1> ,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents:  <e1> Clomipramine HCl </e1> ,  <e2> Phenytoin </e2> (6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e1> praziquantel </e1> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1),  <e1> dalfopristin </e1> , danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3),  <e2> oxcarbazepine </e2> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e2> diazepam </e2> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e2> haloperidol </e2> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e2> Phenytoin </e2> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e1> ketoconazole </e1> , loratadine, nefazodone,  <e2> niacinamide </e2> , nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1),  <e1> dalfopristin </e1> , danazol, delavirdine, diltiazem,  <e2> erythromycin </e2> (1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> , lorazepam, methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin,  <e1> danazol </e1> ,  <e2> delavirdine </e2> , diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e1> methadone </e1> , midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e1> quetiapine </e1> , risperidone, theophylline, topiramate, tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid,  <e2> itraconazole </e2> , ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol,  <e1> delavirdine </e1> , diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine,  <e2> quinupristin </e2> , troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e2> dicumarol </e2> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e1> cyclosporin </e1> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin,  <e2> danazol </e2> , delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine,  <e2> fluvoxamine </e2> , grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide,  <e1> nicotinamide </e1> , protease inhibitors, propoxyphene, quinine,  <e2> quinupristin </e2> , troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3),  <e1> oxcarbazepine </e1> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e1> cyclosporin </e1> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
effect	Additionally, anti-malarial drugs, such as  <e1> chloroquine </e1>  and mefloquine, may antagonize the activity of  <e2> carbamazepine </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> , desipramine, diazepam,  <e2> dicumarol </e2> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1),  <e2> verapamil </e2> , zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone,  <e2> citalopram </e2> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e1> mirtazapine </e1> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole,  <e1> loratadine </e1> , nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1),  <e2> verapamil </e2> , zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e1> cyclosporin </e1> , delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e2> ethosuximide </e2> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid,  <e1> itraconazole </e1> , ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene,  <e1> quinine </e1> ,  <e2> quinupristin </e2> , troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine,  <e2> diazepam </e2> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide,  <e2> protease inhibitors </e2> , propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid,  <e1> itraconazole </e1> , ketoconazole, loratadine, nefazodone,  <e2> niacinamide </e2> , nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e1> quetiapine </e1> , risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> , desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1),  <e1> fluoxetine </e1> , fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin,  <e2> valproate </e2> (1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e2> propoxyphene </e2> , quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e2> Phenytoin </e2> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine,  <e1> fluvoxamine </e1> , grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1),  <e2> verapamil </e2> , zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e2> clobazam </e2> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e1> contraceptives </e1> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2),  <e1> primidone </e1> ,  <e2> methsuximide </e2> , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e2> haloperidol </e2> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin,  <e1> doxorubicin HCL </e1> , felbamate, rifampin, phenobarbital, Phenytoin(2), primidone,  <e2> methsuximide </e2> , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e1> contraceptives </e1> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e2> nortriptyline </e2> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e1> nortriptyline </e1> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e2> desipramine </e2> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion,  <e2> buspirone </e2> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e1> felbamate </e1> ,  <e2> felodipine </e2> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1),  <e1> dalfopristin </e1> , danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide,  <e2> nicotinamide </e2> , protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e2> ketoconazole </e2> , loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1),  <e2> fluoxetine </e2> , fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3),  <e2> oxcarbazepine </e2> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e1> propoxyphene </e1> ,  <e2> quinine </e2> , quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine,  <e1> diltiazem </e1> , erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin,  <e2> valproate </e2> (1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram,  <e2> clobazam </e2> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole,  <e1> loratadine </e1> ,  <e2> nefazodone </e2> , niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Potassium-sparing diuretics such as  <e1> spironolactone </e1> ,  <e2> triamterene </e2> , or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e2> nefazodone </e2> , niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e1> ethosuximide </e1> , felbamate, felodipine, glucocorticoids,  <e2> haloperidol </e2> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol,  <e1> delavirdine </e1> ,  <e2> diltiazem </e2> , erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion,  <e1> buspirone </e1> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion,  <e1> buspirone </e1> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e1> methadone </e1> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion,  <e1> buspirone </e1> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e2> glucocorticoids </e2> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam,  <e2> clonazepam </e2> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide,  <e1> nicotinamide </e1> , protease inhibitors, propoxyphene, quinine, quinupristin,  <e2> troleandomycin </e2> , valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e1> tiagabine </e1> , tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e2> nefazodone </e2> , niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide,  <e1> protease inhibitors </e1> , propoxyphene, quinine, quinupristin, troleandomycin,  <e2> valproate </e2> (1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e1> cyclosporin </e1> , delavirdine, desipramine, diazepam, dicumarol,  <e2> doxycycline </e2> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e1> midazolam </e1> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e1> dicumarol </e1> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e1> tiagabine </e1> , tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e2> lamotrigine </e2> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e2> delavirdine </e2> , desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin,  <e1> doxorubicin HCL </e1> , felbamate, rifampin, phenobarbital,  <e2> Phenytoin </e2> (2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e1> midazolam </e1> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
mechanism	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  <e1> EQUETROTM </e1>  are the following:  <e2> Cisplatin </e2> , doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam,  <e2> clozapine </e2> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e2> propoxyphene </e2> , quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e1> praziquantel </e1> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> , bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e2> nortriptyline </e2> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide,  <e1> protease inhibitors </e1> ,  <e2> propoxyphene </e2> , quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone,  <e2> citalopram </e2> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e1> nefazodone </e1> , niacinamide, nicotinamide,  <e2> protease inhibitors </e2> , propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol,  <e2> doxycycline </e2> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e2> clonazepam </e2> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine,  <e1> fluvoxamine </e1> , grapefruit juice,  <e2> isoniazid </e2> , itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine,  <e1> diltiazem </e1> , erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide,  <e2> nicotinamide </e2> , protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> , bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e2> nefazodone </e2> , niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e1> dicumarol </e1> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e2> nortriptyline </e2> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine,  <e1> diltiazem </e1> , erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1),  <e2> verapamil </e2> , zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> , bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e2> cyclosporin </e2> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1),  <e2> verapamil </e2> , zileuton.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate,  <e1> rifampin </e1> ,  <e2> phenobarbital </e2> , Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e2> cyclosporin </e2> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate,  <e1> rifampin </e1> , phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  <e2> EQUETROTM </e2>  may be necessary.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e1> ketoconazole </e1> , loratadine, nefazodone, niacinamide, nicotinamide,  <e2> protease inhibitors </e2> , propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e1> dicumarol </e1> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e2> itraconazole </e2> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e1> mirtazapine </e1> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole,  <e1> loratadine </e1> , nefazodone,  <e2> niacinamide </e2> , nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> , desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e1> risperidone </e1> , theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e2> lamotrigine </e2> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e1> olanzapine </e1> , oral contraceptives(3),  <e2> oxcarbazepine </e2> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e2> lamotrigine </e2> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide,  <e1> protease inhibitors </e1> , propoxyphene, quinine, quinupristin,  <e2> troleandomycin </e2> , valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e1> ketoconazole </e1> , loratadine, nefazodone, niacinamide,  <e2> nicotinamide </e2> , protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine,  <e1> diltiazem </e1> , erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e2> nefazodone </e2> , niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion,  <e1> buspirone </e1> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e2> Phenytoin </e2> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine,  <e1> diltiazem </e1> , erythromycin(1), fluoxetine,  <e2> fluvoxamine </e2> , grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1),  <e2> fluoxetine </e2> , fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> , desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e2> felbamate </e2> , felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e1> midazolam </e1> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel,  <e2> protease inhibitors </e2> , quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e1> dicumarol </e1> , doxycycline, ethosuximide, felbamate,  <e2> felodipine </e2> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion,  <e1> buspirone </e1> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e2> haloperidol </e2> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin,  <e1> danazol </e1> , delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide,  <e2> protease inhibitors </e2> , propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin,  <e1> phenobarbital </e1> ,  <e2> Phenytoin </e2> (2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e1> quetiapine </e1> ,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3),  <e2> oxcarbazepine </e2> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine,  <e2> desipramine </e2> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e1> dicumarol </e1> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e2> haloperidol </e2> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> ,  <e2> bupropion </e2> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid,  <e2> itraconazole </e2> , ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e2> itraconazole </e2> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e2> itraconazole </e2> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine,  <e2> quinupristin </e2> , troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine,  <e2> quinupristin </e2> , troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3),  <e2> oxcarbazepine </e2> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel,  <e2> protease inhibitors </e2> , quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> , bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole,  <e1> loratadine </e1> , nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e2> propoxyphene </e2> , quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine,  <e1> diltiazem </e1> , erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e2> ketoconazole </e2> , loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion,  <e1> buspirone </e1> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e2> itraconazole </e2> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel,  <e1> protease inhibitors </e1> ,  <e2> quetiapine </e2> , risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL,  <e1> felbamate </e1> ,  <e2> rifampin </e2> , phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e1> cyclosporin </e1> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e1> midazolam </e1> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1),  <e2> verapamil </e2> , zileuton.
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol,  <e2> delavirdine </e2> , diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e2> clobazam </e2> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1),  <e2> fluoxetine </e2> , fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e1> nefazodone </e1> , niacinamide, nicotinamide,  <e2> protease inhibitors </e2> , propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e1> risperidone </e1> , theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Potassium-sparing diuretics such as  <e1> spironolactone </e1> ,  <e2> triamterene </e2> , or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion,  <e1> buspirone </e1> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole,  <e1> loratadine </e1> , nefazodone,  <e2> niacinamide </e2> , nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine,  <e1> diltiazem </e1> , erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin,  <e2> valproate </e2> (1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone,  <e2> citalopram </e2> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> , bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e2> propoxyphene </e2> , quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e2> ketoconazole </e2> , loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e1> ketoconazole </e1> , loratadine, nefazodone, niacinamide,  <e2> nicotinamide </e2> , protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate,  <e2> felodipine </e2> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e2> nefazodone </e2> , niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e1> ketoconazole </e1> , loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1),  <e2> verapamil </e2> , zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e1> quetiapine </e1> , risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> ,  <e2> bupropion </e2> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e2> nortriptyline </e2> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e2> clonazepam </e2> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate,  <e1> rifampin </e1> , phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  <e2> EQUETROTM </e2>  may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e1> ketoconazole </e1> , loratadine, nefazodone,  <e2> niacinamide </e2> , nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e2> diazepam </e2> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole,  <e1> loratadine </e1> , nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e2> propoxyphene </e2> , quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin,  <e1> phenobarbital </e1> , Phenytoin(2), primidone,  <e2> methsuximide </e2> , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e2> clobazam </e2> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e2> nefazodone </e2> , niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide,  <e1> protease inhibitors </e1> , propoxyphene, quinine, quinupristin, troleandomycin,  <e2> valproate </e2> (1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice,  <e1> isoniazid </e1> , itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e2> propoxyphene </e2> , quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following:  <e1> Acetazolamide </e1> , azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e1> midazolam </e1> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e1> mirtazapine </e1> , nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e2> itraconazole </e2> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e1> dicumarol </e1> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Patients taking these drugs with LODOSYN and levodopa or  <e1> carbidopa </e1> - <e2> levodopa </e2>  combination products should be carefully observed for loss of therapeutic response.
false	Caution should be exercised when the following drugs are administered concomitantly with  <e1> LODOSYN </e1>  (Carbidopa) given with levodopa or  <e2> carbidopa </e2> -levodopa combination products.
false	Patients taking these drugs with  <e1> LODOSYN </e1>  and levodopa or carbidopa- <e2> levodopa </e2>  combination products should be carefully observed for loss of therapeutic response.
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol,  <e2> delavirdine </e2> , diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e2> itraconazole </e2> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e2> propoxyphene </e2> , quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by  <e1> phenytoin </e1>  and  <e2> papaverine </e2> .
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e2> ketoconazole </e2> , loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	 <e1> Dopamine D2 receptor antagonists </e1>  (e.g., phenothiazines,  <e2> butyrophenones </e2> , risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
effect	Dopamine D2 receptor antagonists (e.g., phenothiazines,  <e1> butyrophenones </e1> , risperidone) and isoniazid may reduce the therapeutic effects of  <e2> levodopa </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e1> risperidone </e1> , theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Caution should be exercised when the following drugs are administered concomitantly with LODOSYN ( <e1> Carbidopa </e1> ) given with levodopa or  <e2> carbidopa </e2> -levodopa combination products.
effect	Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and  <e1> isoniazid </e1>  may reduce the therapeutic effects of  <e2> levodopa </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e1> ketoconazole </e1> , loratadine, nefazodone,  <e2> niacinamide </e2> , nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Patients taking these drugs with  <e1> LODOSYN </e1>  and levodopa or carbidopa- <e2> levodopa </e2>  combination products should be carefully observed for loss of therapeutic response.
false	In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by  <e1> phenytoin </e1>  and  <e2> papaverine </e2> .
false	Iodine or  <e1> iodine </e1>  excess may decrease the effect of Carbimazole, and an  <e2> iodine </e2>  deficiency can increase the effect of Carbimazole.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	 <e1> Iodine </e1>  or  <e2> iodine </e2>  excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
effect	Dopamine D2 receptor antagonists (e.g., phenothiazines,  <e1> butyrophenones </e1> , risperidone) and isoniazid may reduce the therapeutic effects of  <e2> levodopa </e2> .
false	Sympathomimetic amines may reduce the antihypertensive effects of reserpine,  <e1> veratrum alkaloids </e1> ,  <e2> methyldopa </e2>  and mecamylamine.
effect	 <e1> Antihistamines </e1>  may enhance the effects of tricyclic antidepressants,  <e2> barbiturates </e2> , alcohol, and other CNS depressants.
false	Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids,  <e1> methyldopa </e1>  and  <e2> mecamylamine </e2> .
effect	 <e1> Antihistamines </e1>  may enhance the effects of  <e2> tricyclic antidepressants </e2> , barbiturates, alcohol, and other CNS depressants.
effect	Effects of  <e1> sympathomimetics </e1>  are increased with MAO inhibitors and  <e2> beta adrenergic blockers </e2> .
false	Patients taking these drugs with  <e1> LODOSYN </e1>  and levodopa or carbidopa- <e2> levodopa </e2>  combination products should be carefully observed for loss of therapeutic response.
advise	 <e1> Ocupress </e1>  should be used with caution in patients who are receiving a  <e2> beta-adrenergic blocking agent </e2>  orally because of the potential for additive effects on systemic beta-blockade.
effect	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and  <e1> propafenone </e1> ) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of  <e2> carvedilol </e2>  .
false	As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the  <e1> verapamil </e1>  or  <e2> diltiazem </e2>  type, it is recommended that ECG and blood pressure be monitored.
false	As with other agents with b-blocking properties, if COREG is to be administered orally with  <e1> calcium channel blockers </e1>  of the  <e2> verapamil </e2>  or diltiazem type, it is recommended that ECG and blood pressure be monitored.
advise	Due to wide interindividual variability in the dose adjustment required, it is recommended that  <e1> cyclosporine </e1>  concentrations be monitored closely after initiation of  <e2> carvedilol </e2>  therapy and that the dose of cyclosporine be adjusted as appropriate.
false	Due to wide interindividual variability in the dose adjustment required, it is recommended that  <e1> cyclosporine </e1>  concentrations be monitored closely after initiation of carvedilol therapy and that the dose of  <e2> cyclosporine </e2>  be adjusted as appropriate.
false	Digoxin:  <e1> Digoxin </e1>  concentrations are increased by about 15% when digoxin and  <e2> carvedilol </e2>  are administered concomitantly.
false	Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g.,  <e1> reserpine </e1>  and  <e2> monoamine oxidase inhibitors </e2> ) should be observed closely for signs of hypotension and/or severe bradycardia.
advise	As with other agents with b-blocking properties, if  <e1> COREG </e1>  is to be administered orally with calcium channel blockers of the verapamil or  <e2> diltiazem </e2>  type, it is recommended that ECG and blood pressure be monitored.
effect	Insulin or Oral Hypoglycemics:  <e1> Agents with b-blocking properties </e1>  may enhance the blood-sugar-reducing effect of  <e2> insulin </e2>  and oral hypoglycemics.
false	Insulin or Oral  <e1> Hypoglycemics </e1> : Agents with b-blocking properties may enhance the blood-sugar-reducing effect of  <e2> insulin </e2>  and oral hypoglycemics.
false	poor metabolizers of  <e1> debrisoquin </e1> : Interactions of  <e2> carvedilol </e2>  with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
false	poor metabolizers of debrisoquin: Interactions of  <e1> carvedilol </e1>  with strong inhibitors of CYP2D6 (such as  <e2> quinidine </e2> , fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
false	 <e1> Cyclosporine </e1> : Modest increases in mean trough cyclosporine concentrations were observed following initiation of  <e2> carvedilol </e2>  treatment in 21 renal transplant patients suffering from chronic vascular rejection.
false	As with other  <e1> agents with b-blocking properties </e1> , if COREG is to be administered orally with  <e2> calcium channel blockers </e2>  of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
false	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with  <e1> CANCIDAS </e1>  may result in clinically meaningful reductions in  <e2> caspofungin </e2>  concentrations.
false	 <e1> CANCIDAS </e1>  reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of  <e2> CANCIDAS </e2>  70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
advise	When  <e1> CANCIDAS </e1>  is co-administered with inducers of drug clearance, such as efavirenz,  <e2> nevirapine </e2> , phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
false	CANCIDAS reduced the blood AUC0-12 of  <e1> tacrolimus </e1>  by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of  <e2> CANCIDAS </e2>  70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
false	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine,  <e1> phenytoin </e1> ,  <e2> dexamethasone </e2> , or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
false	 <e1> CANCIDAS </e1>  reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which  <e2> tacrolimus </e2>  was administered alone.
false	CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when  <e1> tacrolimus </e1>  (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of  <e2> CANCIDAS </e2>  70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
false	Insulin or Oral  <e1> Hypoglycemics </e1> : Agents with b-blocking properties may enhance the blood-sugar-reducing effect of  <e2> insulin </e2>  and oral hypoglycemics.
false	poor metabolizers of  <e1> debrisoquin </e1> : Interactions of  <e2> carvedilol </e2>  with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
mechanism	A drug-drug interaction study with  <e1> rifampin </e1>  in healthy volunteers has shown a 30% decrease in  <e2> caspofungin </e2>  trough concentrations.
false	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by  <e1> itraconazole </e1> , amphotericin B, mycophenolate,  <e2> nelfinavir </e2> , or tacrolimus.
false	When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz,  <e1> nevirapine </e1> ,  <e2> phenytoin </e2> , dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
false	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole,  <e1> amphotericin B </e1> , mycophenolate,  <e2> nelfinavir </e2> , or tacrolimus.
false	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B,  <e1> mycophenolate </e1> ,  <e2> nelfinavir </e2> , or tacrolimus.
false	Due to wide interindividual variability in the dose adjustment required, it is recommended that  <e1> cyclosporine </e1>  concentrations be monitored closely after initiation of carvedilol therapy and that the dose of  <e2> cyclosporine </e2>  be adjusted as appropriate.
false	When CANCIDAS is co-administered with inducers of drug clearance, such as  <e1> efavirenz </e1> , nevirapine, phenytoin,  <e2> dexamethasone </e2> , or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
false	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with  <e1> CANCIDAS </e1>  may result in clinically meaningful reductions in  <e2> caspofungin </e2>  concentrations.
false	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B,  <e1> mycophenolate </e1> ,  <e2> nelfinavir </e2> , or tacrolimus.
false	 <e1> CANCIDAS </e1>  reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of  <e2> CANCIDAS </e2>  70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
false	 <e1> Probenecid </e1>  may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged  <e2> cephalosporin </e2>  blood levels.
false	 <e1> Iron Supplements </e1>  and Foods Fortified With Iron Concomitant administration of  <e2> cefdinir </e2>  with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
false	If  <e1> antacids </e1>  are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the  <e2> antacid </e2> .
false	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic  <e1> iron supplement </e1>  containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental  <e2> iron </e2>  reduced extent of absorption by 80% and 31%, respectively.
false	Concomitantly administered  <e1> iron </e1> -fortified infant formula (2.2 mg elemental  <e2> iron </e2> /6 oz) has no significant effect on cefdinir pharmacokinetics.
false	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic  <e1> iron supplement </e1>  containing 60 mg of elemental iron (as FeSO4) or  <e2> vitamins </e2>  supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
false	 <e1> Antacids </e1>  (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL  <e2> Maalox TC </e2>  suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.
false	Probenecid: As with other b-lactam antibiotics,  <e1> probenecid </e1>  inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak  <e2> cefdinir </e2>  plasma levels, and a 50% prolongation in the apparent elimination half-life.
advise	If  <e1> iron supplements </e1>  are required during OMNICEF therapy,  <e2> OMNICEF </e2>  should be taken at least 2 hours before or after the supplement.
false	 <e1> Iron Supplements </e1>  and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or  <e2> vitamins </e2>  supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
mechanism	The reddish color is due to the formation of a nonabsorbable complex between  <e1> cefdinir </e1>  or its breakdown products and  <e2> iron </e2>  in the gastrointestinal tract.
false	If  <e1> iron supplements </e1>  are required during  <e2> OMNICEF </e2>  therapy, OMNICEF should be taken at least 2 hours before or after the supplement.
false	Iron Supplements and Foods Fortified With Iron Concomitant administration of  <e1> cefdinir </e1>  with a therapeutic  <e2> iron supplement </e2>  containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
false	Antacids (aluminum- or  <e1> magnesium </e1> -containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL  <e2> Maalox TC </e2>  suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.
false	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic  <e1> iron supplement </e1>  containing 60 mg of elemental iron (as FeSO4) or  <e2> vitamins </e2>  supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
advise	If  <e1> iron supplements </e1>  are required during OMNICEF therapy,  <e2> OMNICEF </e2>  should be taken at least 2 hours before or after the supplement.
false	Probenecid: As with other b-lactam antibiotics,  <e1> probenecid </e1>  inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak  <e2> cefdinir </e2>  plasma levels, and a 50% prolongation in the apparent elimination half-life.
mechanism	Probenecid: As with other  <e1> b-lactam antibiotics </e1> , co-administration of probenecid with  <e2> cefditoren pivoxil </e2>  resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
false	Oral  <e1> Contraceptives </e1>  Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of  <e2> ethinyl estradiol </e2> , the estrogenic component in most oral contraceptives.
false	Oral Contraceptives Multiple doses of  <e1> cefditoren pivoxil </e1>  had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral  <e2> contraceptives </e2> .
false	 <e1> H2-Receptor Antagonists </e1> : Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of  <e2> cefditoren pivoxil </e2>  administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.
advise	If  <e1> iron supplements </e1>  are required during OMNICEF therapy,  <e2> OMNICEF </e2>  should be taken at least 2 hours before or after the supplement.
effect	Nephrotoxicity has been reported following concomitant administration of other  <e1> cephalosporins </e1>  with potent  <e2> diuretics </e2>  such as furosemide.
false	Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with  <e1> MAXIPIME </e1>  because of the increased potential of nephrotoxicity and ototoxicity of  <e2> aminoglycoside antibiotics </e2> .
false	 <e1> Warfarin </e1>  and  <e2> Anticoagulants </e2> : Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.
false	Drug/Laboratory Test Interactions  <e1> Cephalosporins </e1> , including  <e2> cefotaxime sodium </e2> , are known to occasionally induce a positive direct Coombs test.
false	Drug/Laboratory Test Interactions  <e1> Cephalosporins </e1> , including  <e2> cefotaxime sodium </e2> , are known to occasionally induce a positive direct Coombs test.
false	Drug/Laboratory Test Interactions  <e1> Cephalosporins </e1> , including  <e2> cefotaxime sodium </e2> , are known to occasionally induce a positive direct Coombs test.
false	The bioavailability of the capsule formulation of  <e1> cefprozil </e1>  was not affected when administered 5 minutes following an  <e2> antacid </e2> .
false	Nephrotoxicity has been reported following concomitant administration of cephalosporins with  <e1> aminoglycoside antibiotics </e1>  or potent  <e2> diuretics </e2>  such as furosemide.
effect	 <e1> Chloramphenicol </e1>  has been shown to be antagonistic to  <e2> beta-lactam antibiotics </e2> , including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
mechanism	however, 150 mg of  <e1> ranitidine </e1>  q12h for 3 days increased the  <e2> ceftibuten </e2>  C max by 23% and ceftibuten AUC by 16%.
false	A single dose of liquid  <e1> antacid </e1>  did not affect the C max or AUC of  <e2> ceftibuten </e2> ;
false	The effect of  <e1> ceftibuten </e1>  on the pharmacokinetics of  <e2> theophylline </e2>  administered orally has not been investigated.
false	The effect of  <e1> ceftibuten </e1>  on the pharmacokinetics of  <e2> theophylline </e2>  administered orally has not been investigated.
false	Warfarin: The effect of celecoxib on the anti-coagulant effect of  <e1> warfarin </e1>  was studied in a group of healthy subjects receiving daily doses of 2-5 mg of  <e2> warfarin </e2> .
false	Experience with  <e1> nonsteroidal anti-inflammatory drugs </e1>  ( <e2> NSAIDs </e2> ) suggests the potential for interactions with furosemide and ACE inhibitors.
advise	This interaction should be given consideration in patients taking  <e1> CELEBREX </e1>  concomitantly with  <e2> ACE-inhibitors </e2> .
false	Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with  <e1> CELEBREX </e1>  200 mg BID as compared to subjects receiving  <e2> lithium </e2>  alone.
false	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole,  <e1> methotrexate </e1> ,  <e2> phenytoin </e2> , tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.
false	The effects  <e1> celecoxib </e1>  on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin,  <e2> tolbutamide </e2> , and warfarin have been studied in vivo and clinically important interactions have not been found.
false	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole,  <e1> methotrexate </e1> , phenytoin, tolbutamide, and  <e2> warfarin </e2>  have been studied in vivo and clinically important interactions have not been found.
false	 <e1> Methotrexate </e1> : In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of  <e2> methotrexate </e2> .
false	The effects  <e1> celecoxib </e1>  on the pharmacokinetics and/or pharmacodynamics of  <e2> glyburide </e2> , ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.
false	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of  <e1> glyburide </e1> , ketoconazole, methotrexate,  <e2> phenytoin </e2> , tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.
false	 <e1> Furosemide </e1> : Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of  <e2> furosemide </e2>  and thiazides in some patients.
int	Experience with  <e1> nonsteroidal anti-inflammatory drugs </e1>  (NSAIDs) suggests the potential for interactions with  <e2> furosemide </e2>  and ACE inhibitors.
effect	Furosemide: Clinical studies, as well as post marketing observations, have shown that  <e1> NSAIDs </e1>  can reduce the natriuretic effect of  <e2> furosemide </e2>  and thiazides in some patients.
false	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole,  <e1> methotrexate </e1> , phenytoin,  <e2> tolbutamide </e2> , and warfarin have been studied in vivo and clinically important interactions have not been found.
false	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide,  <e1> ketoconazole </e1> , methotrexate, phenytoin, tolbutamide, and  <e2> warfarin </e2>  have been studied in vivo and clinically important interactions have not been found.
false	Metformin: In healthy subjects given single 500 mg doses of  <e1> cephalexin </e1>  and metformin, plasma  <e2> metformin </e2>  mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.
false	Probenecid: As with other  <e1> b-lactams </e1> , the renal excretion of cephalexin is inhibited by  <e2> probenecid </e2> .
false	 <e1> Methotrexate </e1> : In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of  <e2> methotrexate </e2> .
false	Warfarin: The effect of celecoxib on the anti-coagulant effect of  <e1> warfarin </e1>  was studied in a group of healthy subjects receiving daily doses of 2-5 mg of  <e2> warfarin </e2> .
false	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole,  <e1> methotrexate </e1> , phenytoin, tolbutamide, and  <e2> warfarin </e2>  have been studied in vivo and clinically important interactions have not been found.
advise	Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking  <e1> cephalexin </e1>  and  <e2> metformin </e2> .
false	The effects  <e1> celecoxib </e1>  on the pharmacokinetics and/or pharmacodynamics of  <e2> glyburide </e2> , ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.
false	Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin ( <e1> Nicotinic Acid </e1> ,  <e2> Erythromycin </e2> , Azole Antifungals: Skeletal Muscle.
false	 <e1> CIMETlDINE </e1> :  <e2> Cerivastatin </e2>  plasma concentrations were not affected by co-administration of cimetidine.
false	 <e1> CHOLESTYRAMINE </e1> : The influence of the bile-acidsequestering agent  <e2> cholestyramine </e2>  on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies.
false	 <e1> Methotrexate </e1> : In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of  <e2> methotrexate </e2> .
false	 <e1> WARFARIN </e1> : Co- administration of warfarin and  <e2> cerivastatin </e2>  to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.
false	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers,  <e1> diuretics </e1> , and nonsteroidal anti-inflammatory drugs ( <e2> NSAIDs </e2> ) without evidence of clinically significant adverse interactions.
false	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with  <e1> angiotensin- converting enzyme (ACE) inhibitors </e1> , betablockers, calcium-channel blockers, diuretics, and  <e2> nonsteroidal anti-inflammatory drugs </e2>  (NSAIDs) without evidence of clinically significant adverse interactions.
false	 <e1> ERYTHROMYCIN </e1> : In hypercholesterolemic patients, steady-state  <e2> cerivastatin </e2>  AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.
false	 <e1> DIGOXIN </e1> : Plasma  <e2> digoxin </e2>  levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.
false	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole,  <e1> methotrexate </e1> , phenytoin, tolbutamide, and  <e2> warfarin </e2>  have been studied in vivo and clinically important interactions have not been found.
false	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies,  <e1> cerivastatin sodium </e1>  was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs ( <e2> NSAIDs </e2> ) without evidence of clinically significant adverse interactions.
false	ANTACID (Magnesium-Aluminum Hydroxide):  <e1> Cerivastatin </e1>  plasma concentrations were not affected by co-administration of  <e2> antacid </e2> .
false	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors,  <e1> betablockers </e1> , calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs ( <e2> NSAIDs </e2> ) without evidence of clinically significant adverse interactions.
false	 <e1> Cerivastatin </e1>  plasma concentrations were also not affected by co-administration of  <e2> digoxin </e2> .
false	WARFARIN: Co- administration of  <e1> warfarin </e1>  and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of  <e2> warfarin </e2>  and placebo.
false	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies,  <e1> cerivastatin sodium </e1>  was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers,  <e2> diuretics </e2> , and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.
false	Drug-Drug Interactions: No clinically significant drug interactions have been found with  <e1> theophylline </e1>  at a low dose, azithromycin,  <e2> pseudoephedrine </e2> , ketoconazole, or erythromycin.
false	 <e1> CHOLESTYRAMINE </e1> : The influence of the bile-acidsequestering agent  <e2> cholestyramine </e2>  on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies.
false	Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin ( <e1> Nicotinic Acid </e1> ,  <e2> Erythromycin </e2> , Azole Antifungals: Skeletal Muscle.
false	Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin,  <e1> pseudoephedrine </e1> , ketoconazole, or  <e2> erythromycin </e2> .
false	 <e1> CIMETlDINE </e1> :  <e2> Cerivastatin </e2>  plasma concentrations were not affected by co-administration of cimetidine.
mechanism	In a multiple dose study of  <e1> theophylline </e1>  (400 mg once daily for 3 days) and  <e2> cetirizine </e2>  (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.
false	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors,  <e1> betablockers </e1> , calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs ( <e2> NSAIDs </e2> ) without evidence of clinically significant adverse interactions.
false	 <e1> DIGOXIN </e1> : Plasma  <e2> digoxin </e2>  levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.
false	Pharmacokinetic interaction studies with cetirizine in adults were conducted with  <e1> pseudoephedrine </e1> , antipyrine, ketoconazole, erythromycin and  <e2> azithromycin </e2> .
false	Drug-Drug Interactions: No clinically significant drug interactions have been found with  <e1> theophylline </e1>  at a low dose,  <e2> azithromycin </e2> , pseudoephedrine, ketoconazole, or erythromycin.
false	Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin,  <e1> pseudoephedrine </e1> , ketoconazole, or  <e2> erythromycin </e2> .
false	Pharmacokinetic interaction studies with cetirizine in adults were conducted with  <e1> pseudoephedrine </e1> , antipyrine, ketoconazole, erythromycin and  <e2> azithromycin </e2> .
false	Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin,  <e1> pseudoephedrine </e1> , ketoconazole, or  <e2> erythromycin </e2> .
false	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or  <e2> norepinephrine </e2>  to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
false	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving  <e1> monoamine oxidase inhibitors </e1> ,  <e2> tricyclic antidepressants </e2>  or phenothiazines may produce severe, prolonged hypotension or hypertension.
effect	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or norepinephrine to patients receiving  <e2> monoamine oxidase inhibitors </e2> , tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
effect	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or norepinephrine to patients receiving monoamine oxidase inhibitors,  <e2> tricyclic antidepressants </e2>  or phenothiazines may produce severe, prolonged hypotension or hypertension.
false	 <e1> Antacids </e1>  and kaolin:  <e2> Antacids </e2>  and kaolin can reduce absorption of chloroquine;
false	 <e1> Antacids </e1>  and kaolin: Antacids and kaolin can reduce absorption of  <e2> chloroquine </e2> ;
mechanism	Antacids and kaolin: Antacids and  <e1> kaolin </e1>  can reduce absorption of  <e2> chloroquine </e2> ;
false	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or  <e2> norepinephrine </e2>  to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
false	 <e1> Antacids </e1>  and  <e2> kaolin </e2> : Antacids and kaolin can reduce absorption of chloroquine;
effect	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or norepinephrine to patients receiving monoamine oxidase inhibitors,  <e2> tricyclic antidepressants </e2>  or phenothiazines may produce severe, prolonged hypotension or hypertension.
false	- Cholestyramine and colestipol resins: Cholestytamine and colestipol  <e1> resins </e1>  have the potential of binding  <e2> thiazide diuretics </e2>  and reducing diuretic absorption from the gastrointestinal tract
false	- Skeletal muscle relaxants, nondepolarizing (e.g.,  <e1> tubocurarine </e1> ): Possible increased responsiveness to the  <e2> muscle relaxant </e2> 
false	- Cholestyramine and colestipol  <e1> resins </e1> :  <e2> Cholestytamine </e2>  and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
false	-  <e1> Cholestyramine </e1>  and  <e2> colestipol </e2>  resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
false	- Cholestyramine and colestipol resins: Cholestytamine and  <e1> colestipol </e1>   <e2> resins </e2>  have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
false	-  <e1> Skeletal muscle relaxants </e1> , nondepolarizing (e.g.,  <e2> tubocurarine </e2> ): Possible increased responsiveness to the muscle relaxant
false	Diuretic agents reduce the renal clearance of  <e1> lithium </e1>  and add a high risk of  <e2> lithium </e2>  toxicity.
false	- Cholestyramine and colestipol resins:  <e1> Cholestytamine </e1>  and colestipol resins have the potential of binding thiazide diuretics and reducing  <e2> diuretic </e2>  absorption from the gastrointestinal tract
effect	- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a  <e1> non-steroidal anti-inflammatory agent </e1>  can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and  <e2> thiazide diuretics </e2> .
mechanism	 <e1> Diuretic agents </e1>  reduce the renal clearance of lithium and add a high risk of  <e2> lithium </e2>  toxicity.
false	-  <e1> Cholestyramine </e1>  and colestipol resins:  <e2> Cholestytamine </e2>  and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
false	- Cholestyramine and colestipol resins: Cholestytamine and colestipol  <e1> resins </e1>  have the potential of binding thiazide diuretics and reducing  <e2> diuretic </e2>  absorption from the gastrointestinal tract
false	Chlorotrianisene may interact with antidepressants,  <e1> aspirin </e1> , barbiturates, bromocriptine, calcium supplements,  <e2> corticosteroids </e2> , corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants,  <e1> aspirin </e1> , barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene,  <e2> nicotine </e2> , somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with  <e1> antidepressants </e1> , aspirin, barbiturates, bromocriptine,  <e2> calcium </e2>  supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin,  <e1> barbiturates </e1> , bromocriptine, calcium supplements, corticosteroids,  <e2> corticotropin </e2> , cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates,  <e1> bromocriptine </e1> , calcium supplements,  <e2> corticosteroids </e2> , corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates,  <e1> bromocriptine </e1> , calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin,  <e2> tamoxifen </e2> , and warfarin.
false	Chlorotrianisene may interact with  <e1> antidepressants </e1> , aspirin, barbiturates, bromocriptine, calcium supplements,  <e2> corticosteroids </e2> , corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates,  <e1> bromocriptine </e1> , calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene,  <e2> nicotine </e2> , somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin,  <e1> barbiturates </e1> , bromocriptine,  <e2> calcium </e2>  supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine,  <e1> calcium </e1>  supplements,  <e2> corticosteroids </e2> , corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin,  <e1> barbiturates </e1> , bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine,  <e2> somatropin </e2> , tamoxifen, and warfarin.
false	-  <e1> Cholestyramine </e1>  and colestipol resins:  <e2> Cholestytamine </e2>  and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements,  <e1> corticosteroids </e1> , corticotropin, cyclosporine, dantrolene, nicotine, somatropin,  <e2> tamoxifen </e2> , and warfarin.
false	- Cholestyramine and colestipol  <e1> resins </e1> :  <e2> Cholestytamine </e2>  and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
int	 <e1> Chlorotrianisene </e1>  may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene,  <e2> nicotine </e2> , somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene,  <e1> nicotine </e1> , somatropin,  <e2> tamoxifen </e2> , and warfarin.
int	 <e1> Chlorotrianisene </e1>  may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin,  <e2> cyclosporine </e2> , dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine,  <e1> calcium </e1>  supplements, corticosteroids, corticotropin, cyclosporine, dantrolene,  <e2> nicotine </e2> , somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids,  <e1> corticotropin </e1> , cyclosporine, dantrolene, nicotine, somatropin,  <e2> tamoxifen </e2> , and warfarin.
false	Chlorotrianisene may interact with antidepressants,  <e1> aspirin </e1> , barbiturates, bromocriptine, calcium supplements,  <e2> corticosteroids </e2> , corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates,  <e1> bromocriptine </e1> , calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin,  <e2> tamoxifen </e2> , and warfarin.
false	- Cholestyramine and colestipol  <e1> resins </e1> :  <e2> Cholestytamine </e2>  and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
int	 <e1> Chlorotrianisene </e1>  may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene,  <e2> nicotine </e2> , somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine,  <e1> calcium </e1>  supplements, corticosteroids, corticotropin, cyclosporine, dantrolene,  <e2> nicotine </e2> , somatropin, tamoxifen, and warfarin.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin,  <e1> imatinib </e1> , isoniazid, nefazodone,  <e2> nicardipine </e2> , propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin,  <e1> clarithromycin </e1> , diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine,  <e2> propofol </e2> , protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine,  <e1> propofol </e1> , protease inhibitors,  <e2> quinidine </e2> , and verapamil.
false	Example inhibitors include  <e1> azole antifungals </e1> , ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib,  <e2> isoniazid </e2> , nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin,  <e1> imatinib </e1> , isoniazid,  <e2> nefazodone </e2> , nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac,  <e1> doxycycline </e1> , erythromycin,  <e2> imatinib </e2> , isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals,  <e1> ciprofloxacin </e1> ,  <e2> clarithromycin </e2> , diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin,  <e1> clarithromycin </e1> , diclofenac, doxycycline, erythromycin, imatinib,  <e2> isoniazid </e2> , nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid,  <e1> nefazodone </e1> , nicardipine, propofol,  <e2> protease inhibitors </e2> , quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin,  <e1> clarithromycin </e1> , diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone,  <e2> nicardipine </e2> , propofol, protease inhibitors, quinidine, and verapamil.
false	Increased toxicity (CNS depression): CNS depressants, MAO inhibitors,  <e1> tricyclic antidepressants </e1> ,  <e2> phenothiazines </e2> .
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin,  <e1> diclofenac </e1> , doxycycline, erythromycin, imatinib, isoniazid,  <e2> nefazodone </e2> , nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Increased toxicity (CNS depression): CNS depressants,  <e1> MAO inhibitors </e1> ,  <e2> tricyclic antidepressants </e2> , phenothiazines.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine,  <e1> propofol </e1> ,  <e2> protease inhibitors </e2> , quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid,  <e1> nefazodone </e1> ,  <e2> nicardipine </e2> , propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin,  <e1> imatinib </e1> ,  <e2> isoniazid </e2> , nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib,  <e1> isoniazid </e1> , nefazodone,  <e2> nicardipine </e2> , propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin,  <e1> clarithromycin </e1> ,  <e2> diclofenac </e2> , doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin,  <e1> clarithromycin </e1> , diclofenac,  <e2> doxycycline </e2> , erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib,  <e1> isoniazid </e1> , nefazodone, nicardipine,  <e2> propofol </e2> , protease inhibitors, quinidine, and verapamil.
false	Interactions may also occur with the following: anti-depressants/ <e1> anti-anxiety drugs </e1> , drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g.,  <e2> codeine </e2> ), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an  <e1> antipsychotic drug </e1>  (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a  <e2> tricyclic antidepressant </e2>  (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid,  <e1> beta-blockers </e1>  (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing  <e2> antihistamines </e2>  (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following:  <e1> anti-depressants </e1> /anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g.,  <e2> diphenhydramine </e2> ), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium,  <e1> narcotic </e1>  pain medication (e.g.,  <e2> codeine </e2> ), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel,  <e1> metrizamide </e1> , cabergoline, lithium,  <e2> narcotic </e2>  pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following:  <e1> anti-depressants </e1> /anti-anxiety drugs, drugs used to treat an overactive thyroid,  <e2> beta-blockers </e2>  (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g.,  <e1> propranolol </e1> ), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g.,  <e2> diphenhydramine </e2> ), any other drugs that may make you drowsy.
false	Increased toxicity (CNS depression): CNS depressants,  <e1> MAO inhibitors </e1> ,  <e2> tricyclic antidepressants </e2> , phenothiazines.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g.,  <e1> codeine </e1> ), drugs used to aid sleep, drowsiness-causing antihistamines (e.g.,  <e2> diphenhydramine </e2> ), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin,  <e1> grepafloxacin </e1> , guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g.,  <e2> codeine </e2> ), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Example inhibitors include azole antifungals, ciprofloxacin,  <e1> clarithromycin </e1> , diclofenac, doxycycline, erythromycin, imatinib,  <e2> isoniazid </e2> , nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin,  <e1> grepafloxacin </e1> , guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing  <e2> antihistamines </e2>  (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid,  <e1> beta-blockers </e1>  (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium,  <e2> narcotic </e2>  pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an  <e1> antiparkinsonian drug </e1>  (eg, trihexyphenidyl), and/or a  <e2> tricyclic antidepressant </e2>  (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid,  <e1> beta-blockers </e1>  (e.g., propranolol), sparfloxacin, grepafloxacin,  <e2> guanethidine </e2> , guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg,  <e1> chlorpromazine </e1> ), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg,  <e2> amitriptyline </e2> )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
false	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an  <e1> antiparkinsonian drug </e1>  (eg,  <e2> trihexyphenidyl </e2> ), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
false	Interactions may also occur with the following:  <e1> anti-depressants </e1> / <e2> anti-anxiety drugs </e2> , drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline,  <e1> lithium </e1> ,  <e2> narcotic </e2>  pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol),  <e1> sparfloxacin </e1> , grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium,  <e2> narcotic </e2>  pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following:  <e1> anti-depressants </e1> /anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide,  <e2> cabergoline </e2> , lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g.,  <e1> propranolol </e1> ), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing  <e2> antihistamines </e2>  (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g.,  <e1> propranolol </e1> ), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide,  <e2> cabergoline </e2> , lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol),  <e1> sparfloxacin </e1> , grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing  <e2> antihistamines </e2>  (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide,  <e1> cabergoline </e1> , lithium, narcotic pain medication (e.g.,  <e2> codeine </e2> ), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol),  <e1> sparfloxacin </e1> , grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline,  <e2> lithium </e2> , narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol),  <e1> sparfloxacin </e1> , grepafloxacin,  <e2> guanethidine </e2> , guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids,  <e2> phenothiazines </e2> , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines, thyroid products,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	Interactions may also occur with the following:  <e1> anti-depressants </e1> / <e2> anti-anxiety drugs </e2> , drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid,  <e2> sympathomimetics </e2> , calcium channel blocking drugs, and isoniazid.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an  <e1> antiparkinsonian drug </e1>  (eg, trihexyphenidyl), and/or a  <e2> tricyclic antidepressant </e2>  (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> ,  <e2> phenothiazines </e2> , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids,  <e1> phenothiazines </e1> , thyroid products,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin,  <e1> nicotinic acid </e1> , sympathomimetics,  <e2> calcium channel blocking drugs </e2> , and isoniazid.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and  <e2> beta adrenergic blocking agents </e2> .
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound,  <e1> salicylates </e1> , sulfonamides, chloramphenicol,  <e2> probenecid </e2> , coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol,  <e2> probenecid </e2> , coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid,  <e2> sympathomimetics </e2> , calcium channel blocking drugs, and isoniazid.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium,  <e1> narcotic </e1>  pain medication (e.g.,  <e2> codeine </e2> ), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel blocking drugs </e2> , and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin,  <e1> nicotinic acid </e1> ,  <e2> sympathomimetics </e2> , calcium channel blocking drugs, and isoniazid.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g.,  <e1> propranolol </e1> ), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g.,  <e2> diphenhydramine </e2> ), any other drugs that may make you drowsy.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives,  <e2> phenytoin </e2> , nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides,  <e1> chloramphenicol </e1> , probenecid, coumarins, monoamine oxidase inhibitors, and  <e2> beta adrenergic blocking agents </e2> .
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound, salicylates, sulfonamides,  <e2> chloramphenicol </e2> , probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	Interactions may also occur with the following: anti-depressants/ <e1> anti-anxiety drugs </e1> , drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g.,  <e2> codeine </e2> ), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol),  <e1> sparfloxacin </e1> , grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing  <e2> antihistamines </e2>  (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins,  <e2> monoamine oxidase inhibitors </e2> , and beta adrenergic blocking agents.
effect	The hypoglycemic action of  <e1> sulfonylurea </e1>  may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides,  <e2> chloramphenicol </e2> , probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin,  <e2> nicotinic acid </e2> , sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel blocking drugs </e2> , and isoniazid.
effect	If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because  <e1> chlorprothixene </e1>  amplifies the therapeutic actions and side-effects of  <e2> opioids </e2>  massively.
false	If chlorprothixene is given concomitantly with opioids, the  <e1> opioid </e1>  dose should be reduced (by approx. 50%), because  <e2> chlorprothixene </e2>  amplifies the therapeutic actions and side-effects of opioids massively.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives,  <e2> phenytoin </e2> , nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	Exert particular caution in combining chlorprothixene with other anticholinergic drugs ( <e1> tricyclic antidepressants </e1>  and  <e2> antiparkinsonian agents </e2> ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
advise	Exert particular caution in combining  <e1> chlorprothixene </e1>  with other  <e2> anticholinergic drugs </e2>  (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and  <e2> beta adrenergic blocking agents </e2> .
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol,  <e2> probenecid </e2> , coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	If chlorprothixene is given concomitantly with  <e1> opioids </e1> , the  <e2> opioid </e2>  dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol,  <e2> probenecid </e2> , coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
effect	 <e1> Chlorthalidone </e1>  and related drugs may decrease arterial responsiveness to  <e2> norepinephrine </e2> .
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives,  <e2> phenytoin </e2> , nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
effect	Magnesium:  <e1> Magnesium </e1> -containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with  <e2> vitamin D </e2>  by patients on chronic renal dialysis.
false	Interactions for vitamin D analogues ( <e1> Vitamin D2 </e1> , Vitamin D3,  <e2> Calcitriol </e2> , and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	 <e1> Thiazides </e1> :  <e2> Thiazides </e2>  are known to induce hypercalcemia by the reduction of calcium excretion in urine.
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and  <e1> Calcidiol </e1> ): Cholestyramine:  <e2> Cholestyramine </e2>  has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Interactions for vitamin D analogues (Vitamin D2,  <e1> Vitamin D3 </e1> , Calcitriol, and Calcidiol): Cholestyramine:  <e2> Cholestyramine </e2>  has been reported to reduce intestinal absorption of fat soluble vitamins;
false	 <e1> Phenytoin </e1> /Phenobarbital: The coadministration of phenytoin or  <e2> phenobarbital </e2>  will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
mechanism	Ketoconazole:  <e1> Ketoconazole </e1>  may inhibit both synthetic and catabolic enzymes of  <e2> vitamin D </e2> .
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and  <e1> Calcidiol </e1> ):  <e2> Cholestyramine </e2> : Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol):  <e1> Cholestyramine </e1> : Cholestyramine has been reported to reduce intestinal absorption of  <e2> fat soluble vitamins </e2> ;
false	Interactions for vitamin D analogues ( <e1> Vitamin D2 </e1> , Vitamin D3, Calcitriol, and Calcidiol):  <e2> Cholestyramine </e2> : Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Magnesium:  <e1> Magnesium </e1> -containing preparations (eg,  <e2> antacids </e2> ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3,  <e1> Calcitriol </e1> , and  <e2> Calcidiol </e2> ): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Phenytoin/ <e1> Phenobarbital </e1> : The coadministration of phenytoin or  <e2> phenobarbital </e2>  will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	Interactions for vitamin D analogues (Vitamin D2,  <e1> Vitamin D3 </e1> ,  <e2> Calcitriol </e2> , and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	SINCE CHOLESTYRAMINE  <e1> RESIN </e1>  MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER  <e2> CHOLESTYRAMINE </e2>  RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as  <e1> tetracycline </e1>  penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and  <e2> digitalis </e2> .
mechanism	 <e1> Cholestyramine </e1>  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone,  <e2> warfarin </e2> , thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Cholestyramine  <e1> resin </e1>  may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or  <e2> propranolol </e2>  (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Cholestyramine  <e1> resin </e1>  may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  <e2> resin </e2>  could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations,  <e1> estrogens </e1>  and progestins, and  <e2> digitalis </e2> .
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or  <e1> propranolol </e1>  (basic), as well as  <e2> tetracycline </e2>  penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or  <e1> propranolol </e1>  (basic), as well as tetracycline penicillin G,  <e2> phenobarbital </e2> , thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Cholestyramine  <e1> resin </e1>  may delay or reduce the absorption of concomitant oral medication such as  <e2> phenylbutazone </e2> , warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER  <e1> CHOLESTYRAMINE </e1>   <e2> RESIN </e2>  (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or  <e1> propranolol </e1>  (basic), as well as tetracycline  <e2> penicillin G </e2> , phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as  <e1> tetracycline </e1>  penicillin G, phenobarbital, thyroid and  <e2> thyroxine </e2>  preparations, estrogens and progestins, and digitalis.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline  <e1> penicillin G </e1> , phenobarbital, thyroid and  <e2> thyroxine </e2>  preparations, estrogens and progestins, and digitalis.
false	 <e1> Cholestyramine </e1>  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as  <e2> digitalis </e2>  has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
false	Cholestyramine  <e1> resin </e1>  may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of  <e2> cholestyramine </e2>  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as  <e1> phenylbutazone </e1> , warfarin, thiazide diuretics (acidic) or  <e2> propranolol </e2>  (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Phenytoin/ <e1> Phenobarbital </e1> : The coadministration of phenytoin or  <e2> phenobarbital </e2>  will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
mechanism	 <e1> Cholestyramine </e1>  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin,  <e2> thiazide diuretics </e2>  (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and  <e1> Calcidiol </e1> ):  <e2> Cholestyramine </e2> : Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as  <e1> tetracycline </e1>  penicillin G, phenobarbital, thyroid and thyroxine preparations,  <e2> estrogens </e2>  and progestins, and digitalis.
false	Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  <e1> resin </e1>  could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  <e2> resin </e2> .
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and  <e1> thyroxine </e1>  preparations, estrogens and progestins, and  <e2> digitalis </e2> .
false	Cholestyramine  <e1> resin </e1>  may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline  <e2> penicillin G </e2> , phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as  <e1> digitalis </e1>  has been filtrated to a maintenance level while the patient was taking  <e2> cholestyramine </e2>  resin.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline  <e1> penicillin G </e1> , phenobarbital, thyroid and thyroxine preparations,  <e2> estrogens </e2>  and progestins, and digitalis.
false	In vitro studies demonstrated that the plasma protein binding of  <e1> des-ciclesonide </e1>  was not affected by  <e2> warfarin </e2>  or salicylic acid, indicating no potential for protein binding-based drug interactions.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or  <e1> propranolol </e1>  (basic), as well as tetracycline  <e2> penicillin G </e2> , phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Phenytoin/ <e1> Phenobarbital </e1> : The coadministration of phenytoin or  <e2> phenobarbital </e2>  will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or  <e1> propranolol </e1>  (basic), as well as tetracycline penicillin G,  <e2> phenobarbital </e2> , thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	 <e1> Cholestyramine </e1>  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as  <e2> digitalis </e2>  has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
false	In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either  <e1> des-ciclesonide </e1>  or  <e2> erythromycin </e2> .
false	In another drug interaction study, co-administration of orally inhaled  <e1> ciclesonide </e1>  and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of  <e2> des-ciclesonide </e2>  by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as  <e1> phenylbutazone </e1> , warfarin, thiazide diuretics (acidic) or  <e2> propranolol </e2>  (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous  <e1> aminoglycosides </e1>  (e.g., tobramycin,  <e2> gentamicin </e2> , and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
false	 <e1> Probenecid </e1>  : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  <e2> acetaminophen </e2> , acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors,  <e1> aminosalicylic acid </e1> , barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate,  <e2> famotidine </e2> , furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g.,  <e1> tobramycin </e1> , gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine,  <e2> vancomycin </e2> , and non-steroidal anti-inflammatory agents] is contraindicated.
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g.,  <e1> tobramycin </e1> , gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and  <e2> non-steroidal anti-inflammatory agents </e2> ] is contraindicated.
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous  <e1> pentamidine </e1> , vancomycin, and  <e2> non-steroidal anti-inflammatory agents </e2> ] is contraindicated.
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir,  <e1> angiotensin-converting enzyme inhibitors </e1> , aminosalicylic acid, barbiturates, benzodiazepines, bumetanide,  <e2> clofibrate </e2> , methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	 <e1> Probenecid </e1>  : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors,  <e2> aminosalicylic acid </e2> , barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir,  <e1> angiotensin-converting enzyme inhibitors </e1> , aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide,  <e2> nonsteroidal anti-inflammatory </e2>  agents, theophylline, and zidovudine).
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin,  <e1> gentamicin </e1> , and amikacin), amphotericin B, foscarnet, intravenous pentamidine,  <e2> vancomycin </e2> , and non-steroidal anti-inflammatory agents] is contraindicated.
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B,  <e1> foscarnet </e1> , intravenous pentamidine, vancomycin, and  <e2> non-steroidal anti-inflammatory agents </e2> ] is contraindicated.
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate,  <e1> methotrexate </e1> , famotidine, furosemide,  <e2> nonsteroidal anti-inflammatory </e2>  agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors,  <e1> aminosalicylic acid </e1> , barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and  <e2> zidovudine </e2> ).
false	Phenytoin/ <e1> Phenobarbital </e1> : The coadministration of phenytoin or  <e2> phenobarbital </e2>  will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin),  <e1> amphotericin B </e1> , foscarnet, intravenous  <e2> pentamidine </e2> , vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide,  <e1> clofibrate </e1> ,  <e2> methotrexate </e2> , famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  <e1> acetaminophen </e1> , acyclovir,  <e2> angiotensin-converting enzyme inhibitors </e2> , aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
advise	Nephrotoxic agents : Concomitant administration of  <e1> VISTIDE </e1>  and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and  <e2> non-steroidal anti-inflammatory agents </e2> ] is contraindicated.
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid,  <e1> barbiturates </e1> , benzodiazepines, bumetanide, clofibrate, methotrexate,  <e2> famotidine </e2> , furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  <e1> acetaminophen </e1> , acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide,  <e2> clofibrate </e2> , methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  <e1> acetaminophen </e1> , acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates,  <e2> benzodiazepines </e2> , bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous  <e1> aminoglycosides </e1>  (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and  <e2> non-steroidal anti-inflammatory agents </e2> ] is contraindicated.
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors,  <e1> aminosalicylic acid </e1> , barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide,  <e2> nonsteroidal anti-inflammatory </e2>  agents, theophylline, and zidovudine).
mechanism	Probenecid :  <e1> Probenecid </e1>  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  <e2> acetaminophen </e2> , acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine,  <e1> furosemide </e1> , nonsteroidal anti-inflammatory agents, theophylline, and  <e2> zidovudine </e2> ).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide,  <e1> nonsteroidal anti-inflammatory </e1>  agents, theophylline, and  <e2> zidovudine </e2> ).
mechanism	Probenecid :  <e1> Probenecid </e1>  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid,  <e2> barbiturates </e2> , benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and  <e1> amikacin </e1> ),  <e2> amphotericin B </e2> , foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
advise	Nephrotoxic agents : Concomitant administration of  <e1> VISTIDE </e1>  and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B,  <e2> foscarnet </e2> , intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide,  <e1> nonsteroidal anti-inflammatory </e1>  agents,  <e2> theophylline </e2> , and zidovudine).
mechanism	Probenecid :  <e1> Probenecid </e1>  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide,  <e2> clofibrate </e2> , methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	 <e1> Probenecid </e1>  : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine,  <e2> furosemide </e2> , nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  <e1> acetaminophen </e1> , acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate,  <e2> famotidine </e2> , furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine,  <e1> furosemide </e1> ,  <e2> nonsteroidal anti-inflammatory </e2>  agents, theophylline, and zidovudine).
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g.,  <e1> tobramycin </e1> , gentamicin, and amikacin), amphotericin B, foscarnet, intravenous  <e2> pentamidine </e2> , vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine,  <e1> furosemide </e1> , nonsteroidal anti-inflammatory agents,  <e2> theophylline </e2> , and zidovudine).
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g.,  <e1> tobramycin </e1> , gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and  <e2> non-steroidal anti-inflammatory agents </e2> ] is contraindicated.
advise	Nephrotoxic agents : Concomitant administration of  <e1> VISTIDE </e1>  and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B,  <e2> foscarnet </e2> , intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors,  <e1> aminosalicylic acid </e1> , barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and  <e2> zidovudine </e2> ).
false	Since  <e1> PLETAL </e1>  is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as  <e2> omeprazole </e2> .
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B,  <e1> foscarnet </e1> , intravenous pentamidine, vancomycin, and  <e2> non-steroidal anti-inflammatory agents </e2> ] is contraindicated.
false	 <e1> Probenecid </e1>  : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors,  <e2> aminosalicylic acid </e2> , barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide,  <e1> clofibrate </e1> ,  <e2> methotrexate </e2> , famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid,  <e1> barbiturates </e1> , benzodiazepines, bumetanide, clofibrate, methotrexate,  <e2> famotidine </e2> , furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
mechanism	Probenecid :  <e1> Probenecid </e1>  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid,  <e2> barbiturates </e2> , benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir,  <e1> angiotensin-converting enzyme inhibitors </e1> , aminosalicylic acid, barbiturates, benzodiazepines, bumetanide,  <e2> clofibrate </e2> , methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants,  <e1> phenytoin </e1> , propranolol, nifedipine, chlordiazepoxide, diazepam, certain  <e2> tricyclic antidepressants </e2> , lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
advise	therefore, close monitoring of prothrombin time is recommended, and adjustment of the  <e1> anticoagulant </e1>  dose may be necessary when  <e2> Tagamet </e2>  is administered concomitantly.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine,  <e1> chlordiazepoxide </e1> , diazepam, certain tricyclic antidepressants, lidocaine,  <e2> theophylline </e2>  and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide,  <e1> diazepam </e1> , certain tricyclic antidepressants,  <e2> lidocaine </e2> , theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin,  <e1> propranolol </e1> , nifedipine, chlordiazepoxide,  <e2> diazepam </e2> , certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol,  <e1> nifedipine </e1> , chlordiazepoxide, diazepam, certain  <e2> tricyclic antidepressants </e2> , lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin,  <e1> propranolol </e1> , nifedipine,  <e2> chlordiazepoxide </e2> , diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of  <e1> warfarin-type anticoagulants </e1> , phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain  <e2> tricyclic antidepressants </e2> , lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B,  <e1> foscarnet </e1> , intravenous pentamidine, vancomycin, and  <e2> non-steroidal anti-inflammatory agents </e2> ] is contraindicated.
mechanism	 <e1> Tagamet </e1> , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine,  <e2> theophylline </e2>  and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine,  <e1> chlordiazepoxide </e1> ,  <e2> diazepam </e2> , certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants,  <e1> phenytoin </e1> ,  <e2> propranolol </e2> , nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of  <e1> theophylline </e1>  (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state  <e2> theophylline </e2>  peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain  <e1> tricyclic antidepressants </e1> , lidocaine, theophylline and  <e2> metronidazole </e2> , thereby delaying elimination and increasing blood levels of these drugs.
mechanism	 <e1> Tagamet </e1> , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants,  <e2> lidocaine </e2> , theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin,  <e1> propranolol </e1> , nifedipine,  <e2> chlordiazepoxide </e2> , diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
advise	Dose adjustment of  <e1> Sensipar </e1>  may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole,  <e2> erythromycin </e2> , itraconazole;
false	Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased  <e1> cinacalcet </e1>  exposure following a single 90 mg dose of  <e2> Sensipar </e2>  by 2.3 fold.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide,  <e1> diazepam </e1> , certain tricyclic antidepressants,  <e2> lidocaine </e2> , theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of  <e1> theophylline </e1>  (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state  <e2> theophylline </e2>  peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
mechanism	Amitriptyline: Concurrent administration of 25 mg or 100 mg  <e1> cinacalcet </e1>  with 50 mg  <e2> amitriptyline </e2>  increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
false	 <e1> Amitriptyline </e1> : Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg  <e2> amitriptyline </e2>  increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
false	Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg  <e1> amitriptyline </e1>  increased  <e2> amitriptyline </e2>  exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain  <e1> tricyclic antidepressants </e1> , lidocaine, theophylline and  <e2> metronidazole </e2> , thereby delaying elimination and increasing blood levels of these drugs.
mechanism	 <e1> Antacids </e1>  or sucralfate substantially interfere with the absorption of some  <e2> quinolones </e2> , resulting in low urine levels.
false	However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of  <e1> theophylline </e1>  (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state  <e2> theophylline </e2>  peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
false	Also, concomitant administration of quinolones with products containing  <e1> iron </e1> , multivitamins containing zinc, or Videx ( <e2> didanosine </e2> ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
false	Also, concomitant administration of quinolones with products containing  <e1> iron </e1> , multivitamins containing zinc, or  <e2> Videx </e2>  (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
effect	Quinolones, including  <e1> cinoxacin </e1> , may enhance the effects of oral anticoagulants, such as  <e2> warfarin </e2>  or its derivatives.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin,  <e1> propranolol </e1> , nifedipine,  <e2> chlordiazepoxide </e2> , diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
effect	Quinolones, including  <e1> cinoxacin </e1> , may enhance the effects of oral  <e2> anticoagulants </e2> , such as warfarin or its derivatives.
false	 <e1> Amitriptyline </e1> : Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg  <e2> amitriptyline </e2>  increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
mechanism	Also, concomitant administration of  <e1> quinolones </e1>  with products containing iron, multivitamins containing zinc, or  <e2> Videx </e2>  (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide,  <e1> diazepam </e1> , certain tricyclic antidepressants,  <e2> lidocaine </e2> , theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when  <e1> Proquin XR </e1>  was given alone or when  <e2> Proquin XR </e2>  was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
effect	Glyburide: The concomitant administration of  <e1> ciprofloxacin </e1>  with the  <e2> sulfonylurea </e2>  glyburide has, on rare occasions, resulted in severe hypoglycemia.
advise	Therefore, patients under  <e1> methotrexate </e1>  therapy should be carefully monitored when concomitant  <e2> ciprofloxacin </e2>  therapy is indicated.
false	 <e1> Omeprazole </e1> : The rate and extent of absorption of ciprofloxacin was bioequivalent when  <e2> Proquin XR </e2>  was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
false	Omeprazole: The rate and extent of absorption of  <e1> ciprofloxacin </e1>  was bioequivalent when  <e2> Proquin XR </e2>  was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
effect	Some quinolones, including  <e1> ciprofloxacin </e1> , have been associated with transient elevations in serum creatinine in patients receiving  <e2> cyclosporine </e2>  concomitantly.
false	 <e1> Glyburide </e1> : The concomitant administration of ciprofloxacin with the  <e2> sulfonylurea </e2>  glyburide has, on rare occasions, resulted in severe hypoglycemia.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate,  <e1> VIDEX </e1>  chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or  <e2> zinc </e2>  may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	 <e1> Warfarin </e1> : Quinolones have been reported to enhance the effects of the oral anticoagulant  <e2> warfarin </e2>  or its derivatives.
mechanism	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including  <e1> ciprofloxacin </e1> , with multivalent cation-containing products such as magnesium or aluminum  <e2> antacids </e2> , sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as  <e1> magnesium </e1>  or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or  <e2> zinc </e2>  may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing  <e1> calcium </e1> ,  <e2> iron </e2> , or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
mechanism	Phenytoin: Altered serum levels of  <e1> phenytoin </e1>  (increased and decreased) have been reported in patients receiving concomitant  <e2> ciprofloxacin </e2> .
mechanism	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including  <e1> ciprofloxacin </e1> , with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of  <e2> ciprofloxacin </e2> , resulting in serum and urine levels considerably lower than desired.
mechanism	Methotrexate Renal tubular transport of  <e1> methotrexate </e1>  may be inhibited by concomitant administration of  <e2> ciprofloxacin </e2> , potentially leading to increased plasma levels of methotrexate.
mechanism	Probenecid:  <e1> Probenecid </e1>  interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of  <e2> ciprofloxacin </e2>  in serum.
false	 <e1> Non-steroidal anti-inflammatory drugs </e1>  (but not aspirin): These drugs in combination with very high doses of  <e2> quinolones </e2>  have been shown to provoke convulsions in pre-clinical studies.
false	Omeprazole: The rate and extent of absorption of  <e1> ciprofloxacin </e1>  was bioequivalent when Proquin XR was given alone or when  <e2> Proquin XR </e2>  was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide,  <e1> diazepam </e1> , certain tricyclic antidepressants,  <e2> lidocaine </e2> , theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of  <e1> theophylline </e1>  (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state  <e2> theophylline </e2>  peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium,  <e1> iron </e1> , or  <e2> zinc </e2>  may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	 <e1> Amitriptyline </e1> : Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg  <e2> amitriptyline </e2>  increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or  <e1> aluminum </e1>  antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or  <e2> zinc </e2>  may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	 <e1> Omeprazole </e1> : The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after  <e2> omeprazole </e2>  at the dose that maximally suppresses gastric acid secretion.
mechanism	Multivalent Cation-Containing Products: Concurrent administration of a  <e1> quinolone </e1> , including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing  <e2> calcium </e2> , iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum  <e1> antacids </e1> , sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or  <e2> zinc </e2>  may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or  <e1> aluminum </e1>   <e2> antacids </e2> , sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	 <e1> Omeprazole </e1> : The rate and extent of absorption of ciprofloxacin was bioequivalent when  <e2> Proquin XR </e2>  was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
mechanism	Antibiotics: In vitro and/or in vivo data show that clarithromycin,  <e1> erythromycin </e1> , and troleandomycin markedly inhibit the metabolism of  <e2> cisapride </e2> , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
advise	It is advisable to check coagulation time within the first few days after the start and discontinuation of  <e1> cisapride </e1>  therapy, with an appropriate adjustment of the  <e2> anticoagulant </e2>  dose, if necessary.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum  <e1> antacids </e1> , sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or  <e2> zinc </e2>  may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
mechanism	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including  <e1> ciprofloxacin </e1> , with multivalent cation-containing products such as magnesium or aluminum  <e2> antacids </e2> , sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	 <e1> Anticoagulants </e1>  (Oral): In patients receiving oral  <e2> anticoagulants </e2> , the coagulation times were increased in some cases.
false	 <e1> tricyclic antidepressants </e1>  (such as  <e2> amitriptyline </e2> );
false	 <e1> Antibiotics </e1> : In vitro and/or in vivo data show that  <e2> clarithromycin </e2> , erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
effect	Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and  <e1> dicyclomine </e1> , would be expected to compromise the beneficial effects of  <e2> cisapride </e2> .
false	 <e1> Antibiotics </e1> : In vitro and/or in vivo data show that clarithromycin,  <e2> erythromycin </e2> , and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of  <e1> theophylline </e1>  (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state  <e2> theophylline </e2>  peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
false	 <e1> H2 Receptor Antagonists </e1> : Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on  <e2> cisapride </e2>  absorption when it is coadministered with ranitidine.
false	Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when  <e1> Proquin XR </e1>  was given alone or when  <e2> Proquin XR </e2>  was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
mechanism	H2 Receptor Antagonists:  <e1> Cimetidine </e1>  coadministration leads to an increased peak plasma concentration and AUC of  <e2> cisapride </e2> , there is no effect on cisapride absorption when it is coadministered with ranitidine.
mechanism	The gastrointestinal absorption of  <e1> cimetidine </e1>  and ranitidine is accelerated when they are coadministered with  <e2> cisapride </e2> .
false	 <e1> Anticholinergics </e1> : Concurrent administration of certain  <e2> anticholinergic compounds </e2> , such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
false	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain  <e1> antiarrhythmics </e1> , including those of Class IA (such as quinidine and  <e2> procainamide </e2> ) and Class III (such as sotalol);
false	Protease Inhibitors: In vitro data indicate that  <e1> indinavir </e1>  and  <e2> ritonavir </e2>  markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	Antibiotics: In vitro and/or in vivo data show that  <e1> clarithromycin </e1> , erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma  <e2> cisapride </e2>  levels and prolongation of the QT interval on the ECG.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or  <e1> aluminum </e1>   <e2> antacids </e2> , sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	 <e1> Antifungals </e1> : In vitro and/or in vivo data indicate that fluconazole,  <e2> itraconazole </e2> , and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	Antibiotics: In vitro and/or in vivo data show that  <e1> clarithromycin </e1> ,  <e2> erythromycin </e2> , and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of  <e1> cisapride </e1> , which can result in an increase in plasma  <e2> cisapride </e2>  levels and prolongation of the QT interval on the ECG.
false	certain  <e1> tetracyclic antidepressants </e1>  (such as  <e2> maprotiline </e2> );
false	H2 Receptor Antagonists:  <e1> Cimetidine </e1>  coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with  <e2> ranitidine </e2> .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> NIMBEX </e1>  include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts,  <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.
false	However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of  <e1> theophylline </e1>  (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state  <e2> theophylline </e2>  peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
effect	Infusion requirements of NIMBEX in patients administered  <e1> succinylcholine </e1>  prior to infusions of  <e2> NIMBEX </e2>  were comparable to or slightly greater than when succinylcholine was not administered.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin,  <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Isoflurane or enflurane administered with nitrous oxide/ <e1> oxygen </e1>  to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of  <e2> NIMBEX </e2> .
effect	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins,  <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	 <e1> Omeprazole </e1> : The rate and extent of absorption of ciprofloxacin was bioequivalent when  <e2> Proquin XR </e2>  was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
false	Although not studied systematically in clinical trials, no drug interactions were observed when  <e1> vecuronium </e1> , pancuronium, or  <e2> atracurium </e2>  were administered following varying degrees of recovery from single doses or infusions of NIMBEX.
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> NIMBEX </e1>  include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins,  <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin,  <e2> colistin </e2> , and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine.
false	 <e1> Antibiotics </e1> : In vitro and/or in vivo data show that clarithromycin,  <e2> erythromycin </e2> , and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	The use of  <e1> NIMBEX </e1>  before  <e2> succinylcholine </e2>  to attenuate some of the side effects of succinylcholine has not been studied.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics,  <e1> procainamide </e1> , and  <e2> quinidine </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines, bacitracin,  <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered  <e1> phenytoin </e1>  or  <e2> carbamazepine </e2> .
false	Prior administration of  <e1> succinylcholine </e1>  had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of  <e2> NIMBEX </e2> .
false	Fifteen to 30 minutes of exposure to 1.25 MAC  <e1> isoflurane </e1>  or  <e2> enflurane </e2>  had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.
effect	Isoflurane or enflurane administered with  <e1> nitrous oxide </e1> /oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of  <e2> NIMBEX </e2> .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> NIMBEX </e1>  include certain  <e2> antibiotics </e2>  (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine.
effect	Resistance to the neuromuscular blocking action of  <e1> nondepolarizing neuromuscular blocking agents </e1>  has been demonstrated in patients chronically administered phenytoin or  <e2> carbamazepine </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin,  <e2> colistin </e2> , and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides,  <e1> tetracyclines </e1> ,  <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
mechanism	Antibiotics: In vitro and/or in vivo data show that clarithromycin,  <e1> erythromycin </e1> , and troleandomycin markedly inhibit the metabolism of  <e2> cisapride </e2> , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium,  <e1> pancuronium </e1> , or atracurium were administered following varying degrees of recovery from single doses or infusions of  <e2> NIMBEX </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts,  <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin,  <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistemethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine.
false	 <e1> Anticholinergics </e1> : Concurrent administration of certain  <e2> anticholinergic compounds </e2> , such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local  <e1> anesthetics </e1> ,  <e2> procainamide </e2> , and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin,  <e2> colistin </e2> , and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e1> clindamycin </e1> , colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> .
false	The use of  <e1> NIMBEX </e1>  before succinylcholine to attenuate some of the side effects of  <e2> succinylcholine </e2>  has not been studied.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins,  <e1> lincomycin </e1> , clindamycin, colistin, and sodium colistemethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine.
effect	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin,  <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	 <e1> Antibiotics </e1> : In vitro and/or in vivo data show that  <e2> clarithromycin </e2> , erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e1> clindamycin </e1> , colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin,  <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistemethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine.
false	 <e1> Omeprazole </e1> : The rate and extent of absorption of ciprofloxacin was bioequivalent when  <e2> Proquin XR </e2>  was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
false	The use of  <e1> NIMBEX </e1>  before  <e2> succinylcholine </e2>  to attenuate some of the side effects of succinylcholine has not been studied.
effect	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins,  <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
mechanism	Antibiotics: In vitro and/or in vivo data show that clarithromycin,  <e1> erythromycin </e1> , and troleandomycin markedly inhibit the metabolism of  <e2> cisapride </e2> , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin,  <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Central nervous system depressant (CNS) drugs including alcohol,  <e1> antidepressants </e1> , antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and  <e2> tranquilizers </e2> 
false	 <e1> Central nervous system depressant </e1>  (CNS) drugs including alcohol,  <e2> antidepressants </e2> , antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants,  <e1> antihistamines </e1> ,  <e2> antipsychotics </e2> , blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including  <e1> alcohol </e1> , antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and  <e2> tranquilizers </e2> 
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa,  <e1> beta-blockers </e1> ), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and  <e2> tranquilizers </e2> 
false	Central nervous system depressant (CNS) drugs including  <e1> alcohol </e1> , antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications,  <e2> muscle relaxants </e2> , narcotics, sedatives, sleeping pills and tranquilizers
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin,  <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications ( <e1> reserpine </e1> , methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and  <e2> tranquilizers </e2> 
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines,  <e1> antipsychotics </e1> , blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics,  <e2> sedatives </e2> , sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa,  <e1> beta-blockers </e1> ), motion sickness medications, muscle relaxants, narcotics,  <e2> sedatives </e2> , sleeping pills and tranquilizers
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin,  <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistemethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine.
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications ( <e1> reserpine </e1> ,  <e2> methyldopa </e2> , beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications,  <e1> muscle relaxants </e1> , narcotics,  <e2> sedatives </e2> , sleeping pills and tranquilizers
false	 <e1> Central nervous system depressant </e1>  (CNS) drugs including  <e2> alcohol </e2> , antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e1> clindamycin </e1> , colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> .
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications ( <e1> reserpine </e1> ,  <e2> methyldopa </e2> , beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including  <e1> alcohol </e1> , antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications,  <e2> muscle relaxants </e2> , narcotics, sedatives, sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications,  <e1> muscle relaxants </e1> , narcotics,  <e2> sedatives </e2> , sleeping pills and tranquilizers
effect	It is not known whether this potentiation of  <e1> ampicillin </e1>  rashes is due to  <e2> allopurinol </e2>  or the hyperuricemia present in these patients.
false	In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant  <e1> allopurinol </e1>  and  <e2> AUGMENTIN XR </e2> .
false	In controlled clinical trials of  <e1> AUGMENTIN XR </e1> , 22 patients received concomitant allopurinol and  <e2> AUGMENTIN XR </e2> .
effect	Additive CNS depression may occur when  <e1> antihistamines </e1>  are administered concomitantly with other  <e2> CNS depressants </e2>  including barbiturates, tranquilizers, and alcohol.
false	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates,  <e1> tranquilizers </e1> , and  <e2> alcohol </e2> .
effect	 <e1> Amantadine </e1> , tricyclic antidepressants, and MAOIs may increase anticholinergic effect of  <e2> clidinium </e2> .
effect	Additive CNS depression may occur when  <e1> antihistamines </e1>  are administered concomitantly with other  <e2> CNS depressants </e2>  including barbiturates, tranquilizers, and alcohol.
false	Amantadine,  <e1> tricyclic antidepressants </e1> , and  <e2> MAOIs </e2>  may increase anticholinergic effect of clidinium.
false	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates,  <e1> tranquilizers </e1> , and  <e2> alcohol </e2> .
false	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates,  <e1> tranquilizers </e1> , and  <e2> alcohol </e2> .
effect	 <e1> Amantadine </e1> , tricyclic antidepressants, and MAOIs may increase anticholinergic effect of  <e2> clidinium </e2> .
false	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates,  <e1> tranquilizers </e1> , and  <e2> alcohol </e2> .
false	Atromid-S may displace acidic drugs such as  <e1> phenytoin </e1>  or  <e2> tolbutamide </e2>  from their binding sites.
mechanism	 <e1> Atromid-S </e1>  may displace acidic drugs such as  <e2> phenytoin </e2>  or tolbutamide from their binding sites.
advise	Caution should be exercised when  <e1> anticoagulants </e1>  are given in conjunction with  <e2> Atromid-S </e2> .
false	While it is not known whether this interaction occurs with fibrates other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of  <e1> fibrates </e1>  alone, including  <e2> clofibrate </e2> .
false	Atromid-S may displace acidic drugs such as  <e1> phenytoin </e1>  or  <e2> tolbutamide </e2>  from their binding sites.
false	While all the selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ), e.g., fluoxetine,  <e2> sertraline </e2> , paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
false	cimetidine) and many that are substrates for P450 2D6 (many other  <e1> antidepressants </e1> , phenothiazines, and the  <e2> Type 1C antiarrhythmics </e2>  propafenone and flecainide).
false	Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g.,  <e1> warfarin </e1> ,  <e2> digoxin </e2> ) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
false	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g.,  <e1> cimetidine </e1> ,  <e2> fluoxetine </e2> ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
false	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the  <e1> Type 1C antiarrhythmics </e1>   <e2> propafenone </e2>  and flecainide).
false	While all the selective serotonin reuptake inhibitors (SSRIs), e.g.,  <e1> fluoxetine </e1> , sertraline,  <e2> paroxetine </e2> , and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
false	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics  <e1> propafenone </e1>  and  <e2> flecainide </e2> ).
effect	Several  <e1> tricyclic antidepressants </e1>  have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with  <e2> CMI </e2>  because of its structural similarity to other tricyclic antidepressants.
false	Several tricyclic antidepressants have been reported to block the pharmacologic effects of  <e1> guanethidine </e1> , clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other  <e2> tricyclic antidepressants </e2> .
mechanism	plasma levels of several closely related  <e1> tricyclic antidepressants </e1>  have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g.,  <e2> cimetidine </e2> , fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
false	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine,  <e1> sertraline </e1> , paroxetine, and  <e2> fluvoxamine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
mechanism	Administration of  <e1> CMI </e1>  has been reported to increase the plasma levels of  <e2> phenobarbital </e2> , if given concomitantly.
false	While all the selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ), e.g., fluoxetine, sertraline, paroxetine, and  <e2> fluvoxamine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	While all the selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ), e.g.,  <e2> fluoxetine </e2> , sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
false	While all the  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and  <e2> fluvoxamine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
mechanism	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine,  <e1> fluoxetine </e1> ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with  <e2> CMI </e2>  as well.
advise	Of particular importance, sufficient time must elapse before initiating  <e1> TCA </e1> treatment in a patient being withdrawn from  <e2> fluoxetine </e2> , given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
false	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g.,  <e1> cimetidine </e1> , fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates,  <e2> phenytoin </e2> ), and such an effect may be anticipated with CMI as well.
effect	Pharmacodynamic Interactions: The CNS-depressant action of the  <e1> benzodiazepine class </e1>  of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents,  <e2> monoamine oxidase inhibitors </e2>  and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by  <e1> alcohol </e1> , narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other  <e2> anticonvulsant drugs </e2> .
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics,  <e1> antianxiety agents </e1> , the phenothiazines, thioxanthene and  <e2> butyrophenone classes of antipsychotic agents </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
effect	Pharmacodynamic Interactions: The CNS-depressant action of the  <e1> benzodiazepine class </e1>  of drugs may be potentiated by  <e2> alcohol </e2> , narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
mechanism	Cytochrome P-450 inducers, such as  <e1> phenytoin </e1> , carbamazepine and phenobarbital, induce  <e2> clonazepam </e2>  metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by  <e1> alcohol </e1> , narcotics,  <e2> barbiturates </e2> , nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
advise	Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral  <e1> antifungal agents </e1> , should be used cautiously in patients receiving  <e2> clonazepam </e2> .
false	Cytochrome P-450 inducers, such as phenytoin, carbamazepine and  <e1> phenobarbital </e1> , induce clonazepam metabolism, causing an approximately 30% decrease in plasma  <e2> clonazepam </e2>  levels.
false	Cytochrome P-450 inducers, such as phenytoin,  <e1> carbamazepine </e1>  and  <e2> phenobarbital </e2> , induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and  <e1> butyrophenone c <e2> lasses of antipsychotic agents </e1>  </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics,  <e1> barbiturates </e1> , nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone  <e2> classes of antipsychotic agents </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the  <e1> tricyclic antidepressants </e1> , and by other  <e2> anticonvulsant drugs </e2> .
false	In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without  <e1> propantheline </e1>  (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of  <e2> clonazepam </e2>  was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol,  <e1> narcotics </e1> , barbiturates,  <e2> nonbarbiturate hypnotics </e2> , antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Effect of  <e1> Clonazepam </e1>  on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin,  <e2> carbamazepine </e2> , or phenobarbital.
false	Effect of  <e1> Clonazepam </e1>  on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or  <e2> phenobarbital </e2> .
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol,  <e1> narcotics </e1> , barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and  <e2> butyrophenone classes of antipsychotic agents </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Cytochrome P-450 inducers, such as phenytoin,  <e1> carbamazepine </e1>  and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma  <e2> clonazepam </e2>  levels.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol,  <e1> narcotics </e1> , barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone  <e2> classes of antipsychotic agents </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics,  <e1> antianxiety agents </e1> , the phenothiazines, thioxanthene and butyrophenone  <e2> classes of antipsychotic agents </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and  <e1> butyrophenone c <e2> lasses of antipsychotic agents </e1>  </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of  <e1> phenytoin </e1> ,  <e2> carbamazepine </e2> , or phenobarbital.
false	In a study in which the 2 mg  <e1> clonazepam </e1>  orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of  <e2> clonazepam </e2>  was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
effect	Pharmacodynamic Interactions: The CNS-depressant action of the  <e1> benzodiazepine class </e1>  of drugs may be potentiated by alcohol, narcotics, barbiturates,  <e2> nonbarbiturate hypnotics </e2> , antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and  <e1> butyrophenone classes of antipsychotic agents </e1> ,  <e2> monoamine oxidase inhibitors </e2>  and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Effect of Clonazepam on the Pharmacokinetics of Other Drugs:  <e1> Clonazepam </e1>  does not appear to alter the pharmacokinetics of  <e2> phenytoin </e2> , carbamazepine, or phenobarbital.
effect	 <e1> Clonidine hydrochloride </e1>  may enhance the CNS-depressive effects of  <e2> alcohol </e2> , barbiturates or other sedatives.
false	In a study in which the 2 mg  <e1> clonazepam </e1>  orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of  <e2> clonazepam </e2>  was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol,  <e1> narcotics </e1> , barbiturates,  <e2> nonbarbiturate hypnotics </e2> , antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the  <e1> tricyclic antidepressants </e1> , and by other  <e2> anticonvulsant drugs </e2> .
false	Amitriptyline in combination with  <e1> clonidine </e1>  enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol,  <e2> barbiturates </e2>  or other sedating drugs.
false	Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of  <e1> alcohol </e1> , barbiturates or other  <e2> sedating drugs </e2> .
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics,  <e1> barbiturates </e1> , nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone  <e2> classes of antipsychotic agents </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
advise	Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral  <e1> antifungal agents </e1> , should be used cautiously in patients receiving  <e2> clonazepam </e2> .
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by  <e1> alcohol </e1> , narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other  <e2> anticonvulsant drugs </e2> .
false	Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g.,  <e1> digitalis </e1> ,  <e2> calcium channel blockers </e2> , and beta-blockers.)
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and  <e1> butyrophenone c <e2> lasses of antipsychotic agents </e1>  </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
effect	Tablet If a patient receiving  <e1> clonidine hydrochloride </e1>  is also taking  <e2> tricyclic antidepressants </e2> , the effect of clonidine may be reduced, thus necessitating an increase in dosage.
effect	 <e1> Clonidine hydrochloride </e1>  may enhance the CNS-depressive effects of alcohol, barbiturates or other  <e2> sedatives </e2> .
false	Aspirin,  <e1> warfarin </e1> ,  <e2> heparin </e2> , NSAIDs
false	 <e1> Aspirin </e1> , warfarin,  <e2> heparin </e2> , NSAIDs
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics,  <e1> barbiturates </e1> , nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone  <e2> classes of antipsychotic agents </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
effect	The actions of the  <e1> benzodiazepines </e1>  may be potentiated by  <e2> barbiturates </e2> , narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
false	The actions of the benzodiazepines may be potentiated by barbiturates,  <e1> narcotics </e1> ,  <e2> phenothiazines </e2> , monoamine oxidase inhibitors or other antidepressants.
false	Aspirin,  <e1> warfarin </e1> ,  <e2> heparin </e2> , NSAIDs
false	The actions of the benzodiazepines may be potentiated by  <e1> barbiturates </e1> ,  <e2> narcotics </e2> , phenothiazines, monoamine oxidase inhibitors or other antidepressants.
false	In bioavailability studies with normal subjects, the concurrent administration of  <e1> antacids </e1>  at therapeutic levels did not significantly influence the bioavailability of  <e2> TRANXENE </e2>  tablets.
false	Cimetidine,  <e1> caffeine </e1> , and  <e2> erythromycin </e2>  may increase plasma levels of Clozapine, potentially resulting in adverse effects.
false	Although it has not been established that there is an interaction between Clozapine and  <e1> benzodiazepines </e1>  or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other  <e2> psychotropic drug </e2> .
false	Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a  <e1> benzodiazepine </e1>  or any other  <e2> psychotropic drug </e2> .
mechanism	However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when  <e1> clozapine </e1>  was taken with paroxetine, fluoxetine, and  <e2> sertraline </e2> .
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including  <e1> antidepressants </e1> , phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g.,  <e2> quinidine </e2> ), should be approached with caution.
false	Although it has not been established that there is an interaction between  <e1> Clozapine </e1>  and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other  <e2> psychotropic drug </e2> .
false	Although it has not been established that there is an interaction between  <e1> Clozapine </e1>  and benzodiazepines or other  <e2> psychotropics </e2> , caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.
false	Such individuals are referred to as poor metabolizers of drugs such as  <e1> debrisoquin </e1> , dextromethorphan, the  <e2> tricyclic antidepressants </e2> , and clozapine.
effect	Given the primary CNS effects of  <e1> Clozapine </e1> , caution is advised in using it concomitantly with other CNS-active drugs or  <e2> alcohol </e2> .
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants,  <e1> phenothiazines </e1> ,  <e2> carbamazepine </e2> , and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	Although it has not been established that there is an interaction between Clozapine and  <e1> benzodiazepines </e1>  or other psychotropics, caution is advised when  <e2> clozapine </e2>  is initiated in patients taking a benzodiazepine or any other psychotropic drug.
false	In addition, certain drugs that are metabolized by this isozyme, including many  <e1> antidepressants </e1>  (clozapine,  <e2> selective serotonin reuptake inhibitors </e2> , and others), may inhibit the activity of this isozyme, and thus may make normal metabolizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interaction.
advise	Therefore, co-administration of  <e1> clozapine </e1>  with other drugs that are metabolized by this isozyme, including  <e2> antidepressants </e2> , phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	 <e1> Phenytoin </e1> ,  <e2> nicotine </e2> , and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
false	Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other  <e1> psychotropics </e1> , caution is advised when  <e2> clozapine </e2>  is initiated in patients taking a benzodiazepine or any other psychotropic drug.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including  <e1> antidepressants </e1> , phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and  <e2> encainide </e2> ), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	However, other published reports describe modest elevations (less than two-fold) of  <e1> clozapine </e1>  and metabolite concentrations when clozapine was taken with  <e2> paroxetine </e2> , fluoxetine, and sertraline.
mechanism	However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when  <e1> clozapine </e1>  was taken with  <e2> paroxetine </e2> , fluoxetine, and sertraline.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants,  <e1> phenothiazines </e1> , carbamazepine, and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	Although concomitant use of  <e1> Clozapine </e1>  and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in  <e2> Clozapine </e2>  plasma levels.
advise	Although concomitant use of  <e1> Clozapine </e1>  and  <e2> carbamazepine </e2>  is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.
false	Although concomitant use of  <e1> Clozapine </e1>  and carbamazepine is not recommended, it should be noted that discontinuation of concomitant  <e2> carbamazepine </e2>  administration may result in an increase in Clozapine plasma levels.
advise	Therefore, co-administration of  <e1> clozapine </e1>  with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including  <e1> antidepressants </e1> , phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and  <e2> encainide </e2> ), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	Although concomitant use of  <e1> Clozapine </e1>  and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in  <e2> Clozapine </e2>  plasma levels.
false	 <e1> Phenytoin </e1> ,  <e2> nicotine </e2> , and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
mechanism	However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when  <e1> clozapine </e1>  was taken with paroxetine, fluoxetine, and  <e2> sertraline </e2> .
false	Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e.,  <e1> tranexamic acid </e1> ,  <e2> aminocaproic acid </e2> ) and NovoSeven.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants,  <e1> phenothiazines </e1> ,  <e2> carbamazepine </e2> , and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	Codeine in combination with other narcotic analgesics, general anesthetics,  <e1> phenothiazines </e1> , tranquilizers, sedative-hypnotics, or other  <e2> CNS depressants </e2>  (including alcohol) has additive depressant effects.
false	Codeine in combination with other  <e1> narcotic analgesics </e1> , general anesthetics, phenothiazines,  <e2> tranquilizers </e2> , sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
false	Codeine in combination with other  <e1> narcotic analgesics </e1> , general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other  <e2> CNS depressants </e2>  (including alcohol) has additive depressant effects.
false	Codeine in combination with other  <e1> narcotic analgesics </e1> , general  <e2> anesthetics </e2> , phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
false	Codeine in combination with other  <e1> narcotic analgesics </e1> , general anesthetics,  <e2> phenothiazines </e2> , tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
effect	 <e1> Codeine </e1>  in combination with other narcotic analgesics, general anesthetics, phenothiazines,  <e2> tranquilizers </e2> , sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
effect	 <e1> Codeine </e1>  in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers,  <e2> sedative-hypnotics </e2> , or other CNS depressants (including alcohol) has additive depressant effects.
false	Codeine in combination with other  <e1> narcotic analgesics </e1> , general anesthetics, phenothiazines,  <e2> tranquilizers </e2> , sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
effect	Response to  <e1> sympathomimetic agents </e1>  may be enhanced by  <e2> colchicine </e2> .
mechanism	The action of  <e1> colchicine </e1>  is potentiated by  <e2> alkalinizing agents </e2> .
false	WelChol  was found to have no significant effect on the bioavailability of digoxin,  <e1> lovastatin </e1> ,  <e2> metoprolol </e2> , quinidine, valproic acid, and warfarin.
false	In clinical studies, coadministration of WelChol  with  <e1> atorvastatin </e1> ,  <e2> lovastatin </e2> , or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.
false	WelChol  was found to have no significant effect on the bioavailability of digoxin,  <e1> lovastatin </e1> , metoprolol, quinidine, valproic acid, and  <e2> warfarin </e2> .
false	 <e1> WelChol </e1>   was found to have no significant effect on the bioavailability of  <e2> digoxin </e2> , lovastatin, metoprolol, quinidine, valproic acid, and warfarin.
false	In clinical studies, coadministration of WelChol  with  <e1> atorvastatin </e1> , lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the  <e2> HMG-CoA reductase inhibitor </e2> .
false	 <e1> WelChol </e1>   was found to have no significant effect on the bioavailability of digoxin, lovastatin, metoprolol, quinidine, valproic acid, and  <e2> warfarin </e2> .
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin,  <e1> clofibrate </e1> , methyldopa, nicotinic acid (niacin),  <e2> tolbutamide </e2> , phenytoin or warfarin.
false	The absorption of  <e1> tetracycline </e1> ,  <e2> furosemide </e2> , penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
mechanism	Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of  <e1> colestipol hydrochloride </e1>  on the availability of  <e2> digoxin </e2>  and digitoxin.
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa,  <e1> nicotinic acid </e1>  (niacin),  <e2> tolbutamide </e2> , phenytoin or warfarin.
false	The absorption of  <e1> tetracycline </e1> , furosemide, penicillin G, hydrochlorothiazide, and  <e2> gemfibrozil </e2>  was significantly decreased when given simultaneously with colestipol hydrochloride;
mechanism	 <e1> Bile acid binding resins </e1>  may also interfere with the absorption of oral phosphate supplements and  <e2> hydrocortisone </e2> .
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin),  <e1> tolbutamide </e1> ,  <e2> phenytoin </e2>  or warfarin.
false	Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of  <e1> digoxin </e1>  and  <e2> digitoxin </e2> .
false	The absorption of tetracycline,  <e1> furosemide </e1> , penicillin G, hydrochlorothiazide, and  <e2> gemfibrozil </e2>  was significantly decreased when given simultaneously with colestipol hydrochloride;
false	No depressant effect on blood levels in humans was noted when  <e1> colestipol hydrochloride </e1>  was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or  <e2> warfarin </e2> .
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin,  <e1> clofibrate </e1> , methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or  <e2> warfarin </e2> .
false	The absorption of tetracycline,  <e1> furosemide </e1> , penicillin G,  <e2> hydrochlorothiazide </e2> , and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
false	Particular caution should be observed with  <e1> digitalis preparations </e1>  since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and  <e2> digitoxin </e2> .
false	No depressant effect on blood levels in humans was noted when  <e1> colestipol hydrochloride </e1>  was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide,  <e2> phenytoin </e2>  or warfarin.
false	 <e1> WelChol </e1>   was found to have no significant effect on the bioavailability of  <e2> digoxin </e2> , lovastatin, metoprolol, quinidine, valproic acid, and warfarin.
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin,  <e1> clindamycin </e1> , clofibrate, methyldopa, nicotinic acid ( <e2> niacin </e2> ), tolbutamide, phenytoin or warfarin.
false	Bile acid binding resins may also interfere with the absorption of oral  <e1> phosphate </e1>  supplements and  <e2> hydrocortisone </e2> .
mechanism	 <e1> Bile acid binding resins </e1>  may also interfere with the absorption of oral phosphate supplements and  <e2> hydrocortisone </e2> .
false	Certain other antibiotics ( <e1> aminoglycosides </e1>  and  <e2> polymyxin </e2> ) have also been reported to interfere with the nerve transmission at the neuromuscular junction.
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin),  <e1> tolbutamide </e1> ,  <e2> phenytoin </e2>  or warfarin.
false	The absorption of tetracycline,  <e1> furosemide </e1> , penicillin G,  <e2> hydrochlorothiazide </e2> , and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
false	Curariform muscle relaxants (eg,  <e1> tubocurarine </e1> ) and other drugs, including ether,  <e2> succinylcholine </e2> , gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
false	No depressant effect on blood levels in humans was noted when  <e1> colestipol hydrochloride </e1>  was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide,  <e2> phenytoin </e2>  or warfarin.
effect	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine,  <e1> decamethonium </e1>  and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with  <e2> Coly-Mycin M </e2>  Parenteral.
false	Bile acid binding resins may also interfere with the absorption of oral  <e1> phosphate </e1>  supplements and  <e2> hydrocortisone </e2> .
effect	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine,  <e1> gallamine </e1> , decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with  <e2> Coly-Mycin M </e2>  Parenteral.
false	 <e1> Digoxin </e1> : Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in  <e2> digoxin </e2>  Cmax and AUC values.
false	Bile acid binding resins may also interfere with the absorption of oral  <e1> phosphate </e1>  supplements and  <e2> hydrocortisone </e2> .
effect	Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine,  <e1> gallamine </e1> , decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with  <e2> Coly-Mycin M </e2>  Parenteral.
false	decreased levels of anti-factor Xa and  <e1> antithrombin III </e1> , decreased  <e2> antithrombin III </e2>  activity;
advise	 <e1> Aspirin </e1>  should be used cautiously in conjunction with  <e2> cortico-steroids </e2>  in patients suffering from hypopro-thrombinemia.
false	This could lead to decreased  <e1> salicylate </e1>  serum levels or increase the risk of salicylate toxicity when  <e2> corticosteroid </e2>  is withdrawn.
mechanism	Drugs that induce hepatic enzymes such as phenobarbital,  <e1> phenytoin </e1>  and rifampin may increase the clearance of  <e2> corticosteroids </e2>  and may require increases in corticosteroid dose to achieve the desired response.
effect	 <e1> Corticosteroids </e1>  may increase the clearance of chronic high dose  <e2> aspirin </e2> .
false	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of  <e1> corticosteroids </e1>  and may require increases in  <e2> corticosteroid </e2>  dose to achieve the desired response.
false	This could lead to decreased  <e1> salicylate </e1>  serum levels or increase the risk of salicylate toxicity when  <e2> corticosteroid </e2>  is withdrawn.
effect	 <e1> Corticotropin </e1>  may accentuate the electrolyte loss associated with  <e2> diuretic </e2>  therapy.
false	Drug Interaction During Pregnancy:  <e1> Cromolyn sodium </e1>  and  <e2> isoproterenol </e2>  were studied following subcutaneous injections in pregnant mice.
effect	 <e1> Corticotropin </e1>  may accentuate the electrolyte loss associated with  <e2> diuretic </e2>  therapy.
false	Colchicine  <e1> para-aminosalicylic acid </e1>  and heavy  <e2> alcohol </e2>  intake for longer than 2 weeks may produce malabsorption of vitamin B12.
false	Persons taking most  <e1> antibiotics </e1> , methotrexate and pyrimethamine invalidate  <e2> folic acid </e2>  and vitamin B12 diagnostic blood assays.
effect	 <e1> Tricyclic antidepressants </e1>  may block the antihypertensive action of  <e2> guanethidine </e2>  and similarly acting compounds.
false	Persons taking most  <e1> antibiotics </e1> , methotrexate and pyrimethamine invalidate  <e2> folic acid </e2>  and vitamin B12 diagnostic blood assays.
false	Cyclopentolate may interfere with the anti-glaucoma action of  <e1> carbachol </e1>  or  <e2> pilocarpine </e2> ;
false	Cyclopentolate may interfere with the anti-glaucoma action of  <e1> carbachol </e1>  or  <e2> pilocarpine </e2> ;
false	Cyclopentolate may interfere with the anti-glaucoma action of  <e1> carbachol </e1>  or  <e2> pilocarpine </e2> ;
effect	 <e1> Antihistamines </e1>  may have additive effects with  <e2> alcohol </e2>  and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
false	Antihistamines may have additive effects with  <e1> alcohol </e1>  and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers,  <e2> antianxiety agents </e2> .
false	Antihistamines may have additive effects with alcohol and other CNS depressants, e.g.,  <e1> hypnotics </e1> , sedatives, tranquilizers,  <e2> antianxiety agents </e2> .
false	Antihistamines may have additive effects with alcohol and other  <e1> CNS depressants </e1> , e.g., hypnotics,  <e2> sedatives </e2> , tranquilizers, antianxiety agents.
effect	 <e1> Antihistamines </e1>  may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives,  <e2> tranquilizers </e2> , antianxiety agents.
effect	 <e1> Antihistamines </e1>  may have additive effects with  <e2> alcohol </e2>  and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
false	The combination of therapeutic doses of intravenous  <e1> dantrolene sodium </e1>  and  <e2> verapamil </e2>  in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.
advise	It is recommended that the combination of intravenous  <e1> dantrolene sodium </e1>  and  <e2> calcium channel blockers </e2> , such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.
false	It is recommended that the combination of intravenous dantrolene sodium and  <e1> calcium channel blockers </e1> , such as  <e2> verapamil </e2> , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.
false	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg)  <e1> trimethoprim </e1> /sulfamethoxazole ( <e2> TMP </e2> /SMX).
effect	With oral  <e1> dapsone </e1>  treatment,  <e2> folic acid antagonists </e2>  such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
false	A drug-drug interaction study evaluated the effect of the use of  <e1> ACZONE </e1>  Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole ( <e2> TMP </e2> /SMX).
false	A drug-drug interaction study evaluated the effect of the use of  <e1> ACZONE </e1>  Gel, 5%, in combination with double strength (160 mg/800 mg)  <e2> trimethoprim </e2> /sulfamethoxazole (TMP/SMX).
false	Notably, systemic exposure (AUC0-12) of  <e1> dapsone hydroxylamine </e1>  (DHA) was more than doubled in the presence of TMP/ <e2> SMX </e2> .
false	A drug-drug interaction study evaluated the effect of the use of  <e1> ACZONE </e1>  Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole ( <e2> TMP </e2> /SMX).
false	There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which 10 healthy subjects on stable  <e1> simvastatin </e1>  therapy were treated concurrently with  <e2> daptomycin </e2>  (4 mg/kg once every 24 hours) for 14 days.
false	Warfarin: Concomitant administration of  <e1> daptomycin </e1>  (6 mg/kg once every 24 hours for 5 days) and  <e2> warfarin </e2>  (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.
false	The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  <e1> ketoconazole </e1> , itraconazole,  <e2> ritonavir </e2> , nelfinavir, clarithromycin and nefazadone) .
advise	The daily dose of  <e1> ENABLEX </e1>  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir,  <e2> clarithromycin </e2>  and nefazadone) .
false	Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide,  <e1> thioridazine </e1>  and  <e2> tricyclic antidepressants </e2>  (see CLINICAL PHARMACOLOGY).
false	The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g.,  <e1> ketoconazole </e1> , itraconazole,  <e2> ritonavir </e2> , nelfinavir, clarithromycin and nefazadone) .
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine,  <e1> cisapride </e1> ,  <e2> cyclosporine </e2> , fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
advise	The concomitant use of H2 blockers or  <e1> proton pump inhibitors </e1>  with  <e2> SPRYCEL </e2>  is not recommended.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as  <e1> alfentanil </e1> , astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide,  <e2> quinidine </e2> , sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine,  <e1> fentanyl </e1> ,  <e2> pimozide </e2> , quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine,  <e1> cisapride </e1> , cyclosporine, fentanyl, pimozide, quinidine,  <e2> sirolimus </e2> , tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil,  <e1> astemizole </e1> , terfenadine, cisapride, cyclosporine, fentanyl, pimozide,  <e2> quinidine </e2> , sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin,  <e1> ritonavir </e1> , atazanavir, indinavir,  <e2> nefazodone </e2> , nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
advise	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus,  <e1> tacrolimus </e1> , or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving  <e2> SPRYCEL </e2> .
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine,  <e1> cisapride </e1> , cyclosporine, fentanyl, pimozide,  <e2> quinidine </e2> , sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole,  <e1> itraconazole </e1> , erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir,  <e2> telithromycin </e2> ) may increase exposure to dasatinib and should be avoided.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin,  <e1> clarithromycin </e1> ,  <e2> ritonavir </e2> , atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
advise	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil,  <e1> astemizole </e1> , terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving  <e2> SPRYCEL </e2> .
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg,  <e1> ketoconazole </e1> , itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone,  <e2> nelfinavir </e2> , saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil,  <e1> astemizole </e1> , terfenadine,  <e2> cisapride </e2> , cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir,  <e1> telithromycin </e1> ) may increase exposure to  <e2> dasatinib </e2>  and should be avoided.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole,  <e1> terfenadine </e1> , cisapride, cyclosporine, fentanyl, pimozide, quinidine,  <e2> sirolimus </e2> , tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir,  <e1> indinavir </e1> , nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to  <e2> dasatinib </e2>  and should be avoided.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone,  <e1> nelfinavir </e1> ,  <e2> saquinavir </e2> , telithromycin) may increase exposure to dasatinib and should be avoided.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg,  <e1> ketoconazole </e1> , itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir,  <e2> nefazodone </e2> , nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole,  <e1> terfenadine </e1> , cisapride, cyclosporine, fentanyl, pimozide,  <e2> quinidine </e2> , sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg,  <e1> ketoconazole </e1> , itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir,  <e2> saquinavir </e2> , telithromycin) may increase exposure to dasatinib and should be avoided.
false	 <e1> Antacids </e1> : Nonclinical data demonstrate that the solubility of  <e2> dasatinib </e2>  is pH dependent.
false	In patients in whom CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine,  <e1> rifampicin </e1> ,  <e2> phenobarbital </e2> ) are indicated, alternative agents with less enzyme induction potential should be used.
false	 <e1> H2 Blockers </e1> / <e2> Proton Pump Inhibitors </e2> : Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole,  <e1> itraconazole </e1> , erythromycin,  <e2> clarithromycin </e2> , ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	The use of  <e1> antacids </e1>  should be considered in place of H2 blockers or  <e2> proton pump inhibitors </e2>  in patients receiving SPRYCEL therapy.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir,  <e1> atazanavir </e1> , indinavir, nefazodone,  <e2> nelfinavir </e2> , saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin,  <e1> clarithromycin </e1> , ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir,  <e2> telithromycin </e2> ) may increase exposure to dasatinib and should be avoided.
false	The concomitant use of  <e1> H2 blockers </e1>  or  <e2> proton pump inhibitors </e2>  with SPRYCEL is not recommended.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or  <e1> ergot alkaloids </e1>  (ergotamine,  <e2> dihydroergotamine </e2> ) should be administered with caution in patients receiving SPRYCEL.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin,  <e1> clarithromycin </e1> , ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to  <e2> dasatinib </e2>  and should be avoided.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine,  <e1> cisapride </e1> , cyclosporine, fentanyl, pimozide, quinidine, sirolimus,  <e2> tacrolimus </e2> , or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole,  <e1> terfenadine </e1> , cisapride, cyclosporine,  <e2> fentanyl </e2> , pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride,  <e1> cyclosporine </e1> ,  <e2> fentanyl </e2> , pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Concomitant use of  <e1> SPRYCEL </e1>  and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to  <e2> dasatinib </e2>  and should be avoided.
mechanism	Concomitant use of  <e1> SPRYCEL </e1>  and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir,  <e2> nefazodone </e2> , nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride,  <e1> cyclosporine </e1> , fentanyl, pimozide, quinidine, sirolimus,  <e2> tacrolimus </e2> , or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin,  <e1> ritonavir </e1> , atazanavir,  <e2> indinavir </e2> , nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
effect	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by  <e1> H2 blockers </e1>  or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce  <e2> dasatinib </e2>  exposure.
advise	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride,  <e1> cyclosporine </e1> , fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving  <e2> SPRYCEL </e2> .
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as  <e1> alfentanil </e1> , astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or  <e2> ergot alkaloids </e2>  (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
mechanism	Concomitant use of  <e1> SPRYCEL </e1>  and drugs that inhibit CYP3A4 (eg,  <e2> ketoconazole </e2> , itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	In patients in whom CYP3A4 inducers (eg,  <e1> dexamethasone </e1> , phenytoin,  <e2> carbamazepine </e2> , rifampicin, phenobarbital) are indicated, alternative agents with less enzyme induction potential should be used.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine,  <e1> cisapride </e1> , cyclosporine, fentanyl, pimozide, quinidine,  <e2> sirolimus </e2> , tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as  <e1> alfentanil </e1> , astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide,  <e2> quinidine </e2> , sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	 <e1> Cerubidine </e1>  should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or  <e2> Cerubidine </e2> .
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or  <e1> ergot alkaloids </e1>  (ergotamine,  <e2> dihydroergotamine </e2> ) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride,  <e1> cyclosporine </e1> , fentanyl, pimozide, quinidine, sirolimus,  <e2> tacrolimus </e2> , or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole,  <e1> terfenadine </e1> , cisapride, cyclosporine,  <e2> fentanyl </e2> , pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole,  <e1> terfenadine </e1> , cisapride, cyclosporine, fentanyl, pimozide,  <e2> quinidine </e2> , sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir,  <e1> atazanavir </e1> , indinavir, nefazodone,  <e2> nelfinavir </e2> , saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
advise	 <e1> Cerubidine </e1>  should not be used in patients who have previously received the recommended maximum cumulative doses of  <e2> doxorubicin </e2>  or Cerubidine.
mechanism	Concomitant use of  <e1> SPRYCEL </e1>  and drugs that inhibit CYP3A4 (eg,  <e2> ketoconazole </e2> , itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	In addition, neuromuscular blocking action is enhanced by general  <e1> anesthetics </e1> , local  <e2> anesthetics </e2>  like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.
false	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine,  <e1> beta-blockers </e1> , metaclopramide, lithium carbonate, and  <e2> terbutaline </e2> .
false	 <e1> Anticholinesterases </e1>  (neostgmine, physostigmine), lignocaine,  <e2> quinine </e2> , procainamide can enhance toxicity and cause cardio respiratory depression.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride,  <e1> cyclosporine </e1> , fentanyl, pimozide, quinidine, sirolimus,  <e2> tacrolimus </e2> , or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	 <e1> Anticholinesterases </e1>  (neostgmine, physostigmine),  <e2> lignocaine </e2> , quinine, procainamide can enhance toxicity and cause cardio respiratory depression.
false	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like  <e1> lidocaine </e1> , procaine, beta-blockers, metaclopramide,  <e2> lithium carbonate </e2> , and terbutaline.
false	Anticholinesterases (neostgmine,  <e1> physostigmine </e1> ), lignocaine, quinine,  <e2> procainamide </e2>  can enhance toxicity and cause cardio respiratory depression.
false	Anticholinesterases (neostgmine, physostigmine),  <e1> lignocaine </e1> ,  <e2> quinine </e2> , procainamide can enhance toxicity and cause cardio respiratory depression.
false	 <e1> Cerubidine </e1>  should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or  <e2> Cerubidine </e2> .
false	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like  <e1> lidocaine </e1> , procaine, beta-blockers, metaclopramide,  <e2> lithium carbonate </e2> , and terbutaline.
false	 <e1> Anticholinesterases </e1>  (neostgmine, physostigmine),  <e2> lignocaine </e2> , quinine, procainamide can enhance toxicity and cause cardio respiratory depression.
false	Although  <e1> deferasirox </e1>  has a lower affinity for  <e2> aluminum </e2>  than for iron, Exjade should not be taken with aluminum-containing antacid preparations.
false	Although  <e1> deferasirox </e1>  has a lower affinity for aluminum than for iron,  <e2> Exjade </e2>  should not be taken with aluminum-containing antacid preparations.
false	Although deferasirox has a lower affinity for aluminum than for  <e1> iron </e1> ,  <e2> Exjade </e2>  should not be taken with aluminum-containing antacid preparations.
false	No inhibition of  <e1> deferasirox </e1>  metabolism by  <e2> hydroxyurea </e2>  is expected based on the results of an in vitro study.
false	Although deferasirox has a lower affinity for aluminum than for  <e1> iron </e1> , Exjade should not be taken with aluminum-containing  <e2> antacid preparations </e2> .
false	Antiacid, clarithromycin,  <e1> Didanosine </e1> , Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin,  <e2> Rifampin </e2> , Ritanovir, Saquinavir.
false	Antiacid, clarithromycin,  <e1> Didanosine </e1> , Fluconazole, Fluoxetine, Indanavir,  <e2> Ketoconazole </e2> , Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
false	Antiacid, clarithromycin, Didanosine, Fluconazole,  <e1> Fluoxetine </e1> , Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin,  <e2> Rifampin </e2> , Ritanovir, Saquinavir.
false	Antiacid, clarithromycin,  <e1> Didanosine </e1> , Fluconazole,  <e2> Fluoxetine </e2> , Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
false	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole,  <e1> Phenytoin </e1> , Phenobarbitol, carbamazepine,  <e2> Rifabutin </e2> , Rifampin, Ritanovir, Saquinavir.
false	Antiacid,  <e1> clarithromycin </e1> , Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole,  <e2> Phenytoin </e2> , Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
false	Antiacid, clarithromycin, Didanosine, Fluconazole,  <e1> Fluoxetine </e1> , Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir,  <e2> Saquinavir </e2> .
false	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir,  <e1> Ketoconazole </e1> , Phenytoin, Phenobarbitol,  <e2> carbamazepine </e2> , Rifabutin, Rifampin, Ritanovir, Saquinavir.
false	Antiacid, clarithromycin, Didanosine,  <e1> Fluconazole </e1> ,  <e2> Fluoxetine </e2> , Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
false	Antiacid,  <e1> clarithromycin </e1> , Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol,  <e2> carbamazepine </e2> , Rifabutin, Rifampin, Ritanovir, Saquinavir.
false	Antiacid, clarithromycin,  <e1> Didanosine </e1> , Fluconazole, Fluoxetine, Indanavir,  <e2> Ketoconazole </e2> , Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
false	Antiacid, clarithromycin, Didanosine,  <e1> Fluconazole </e1> ,  <e2> Fluoxetine </e2> , Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
int	Possible drug interactions of  <e1> HUMORSOL </e1>  with succinylcholine or with other  <e2> anticholinesterase agents </e2> .
false	Antiacid, clarithromycin,  <e1> Didanosine </e1> , Fluconazole, Fluoxetine, Indanavir,  <e2> Ketoconazole </e2> , Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
effect	Since bacteriostatic drugs, such as the  <e1> tetracycline class </e1>  of antibiotics, may interfere with the bactericidal action of  <e2> penicillins </e2> , it is not advisable to administer these drugs concomitantly.
false	Like isoflurane,  <e1> desflurane </e1>  does not predispose to premature ventricular arrhythmias in the presence of exogenously infused  <e2> epinephrine </e2>  in swine.
false	While all the  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs), e.g., fluoxetine, seriraline, and  <e2> paroxetine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of  <e1> cimetidine </e1>  which may result in the loss of the therapeutic efficacy of the  <e2> tricyclic antidepressant </e2>  6.
false	The extent to which  <e1> SSRI </e1> -TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the  <e2> SSRI </e2>  involved.
false	If desipramine hydrochloride is to be combined with other  <e1> psychotropic agents </e1>  such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or  <e2> diazepam </e2> ) are additive.
false	If desipramine hydrochloride is to be combined with other  <e1> psychotropic agents </e1>  such as tranquilizers or sedative/ <e2> hypnotics </e2> , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
effect	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  <e1> desipramine </e1>  and  <e2> benzodiazepines </e2>  (e.g., chlordiazepoxide or diazepam) are additive.
false	While all the selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ), e.g., fluoxetine, seriraline, and  <e2> paroxetine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	While all the  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs), e.g.,  <e2> fluoxetine </e2> , seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
false	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or  <e1> sedative </e1> / <e2> hypnotics </e2> , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
false	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g.,  <e1> chlordiazepoxide </e1>  or  <e2> diazepam </e2> ) are additive.
false	cimetidine) and many that are substrates for P450 2D6 (many other  <e1> antidepressants </e1> , phenothiazines, and the Type 1C antiarrhythrnics propatenone and  <e2> flecainide </e2> ).
false	Concurrent administration of cimetidine and  <e1> tricyclic antidepressants </e1>  can produce clinically significant increases in the plasma levels of the  <e2> tricyclic antidepressants </e2> .
false	In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers,  <e1> desloratadine </e1>  7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or  <e2> ketoconazole </e2>  200 mg every 12 hours for 10 days.
false	In three separate controlled, parallel group clinical pharmacology studies,  <e1> desloratadine </e1>  at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with  <e2> cimetidine </e2>  600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.
false	Concurrent administration of cimetidine and  <e1> tricyclic antidepressants </e1>  can produce clinically significant increases in the plasma levels of the  <e2> tricyclic antidepressants </e2> .
false	In three separate controlled, parallel group clinical pharmacology studies,  <e1> desloratadine </e1>  at the clinical dose of 5 mg has been coadministered with  <e2> azithromycin </e2>  500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.
false	In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with  <e1> azithromycin </e1>  500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with  <e2> cimetidine </e2>  600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.
false	Although increased plasma concentrations (C max and AUC 0-24 hrs) of  <e1> desloratadine </e1>  and  <e2> 3-hydroxydesloratadine </e2>  were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.
false	Although the pressor activity of  <e1> Desmopressin </e1>  is very low compared to its antidiuretic activity, large doses of  <e2> Desmopressin </e2>  Tablets should be used with other pressor agents only with careful patient monitoring.
false	Although increased plasma concentrations (C max and AUC 0-24 hrs) of  <e1> desloratadine </e1>  and  <e2> 3-hydroxydesloratadine </e2>  were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.
false	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone,  <e1> phenytoin sodium </e1> , carbamazepine and possibly with griseofulvin,  <e2> ampicillin </e2> , and tetracyclines (72)
false	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium,  <e1> carbamazepine </e1>  and possibly with griseofulvin,  <e2> ampicillin </e2> , and tetracyclines (72)
false	A similar association, though less marked, has been suggested with  <e1> barbiturates </e1> , phenyl-butazone, phenytoin sodium,  <e2> carbamazepine </e2>  and possibly with griseofulvin, ampicillin, and tetracyclines (72)
false	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium,  <e1> carbamazepine </e1>  and possibly with  <e2> griseofulvin </e2> , ampicillin, and tetracyclines (72)
false	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium,  <e1> carbamazepine </e1>  and possibly with griseofulvin,  <e2> ampicillin </e2> , and tetracyclines (72)
effect	Vaccines: Patients on  <e1> corticosteroid </e1>  therapy may exhibit a diminished response to toxoids and live or  <e2> inactivated vaccines </e2>  due to inhibition of antibody response.
false	 <e1> Digitalis glycosides </e1> : Patients on  <e2> digitalis glycosides </e2>  may be at increased risk of arrhythmias due to hypokalemia.
advise	Routine administration of  <e1> vaccines </e1>  or toxoids should be deferred until  <e2> corticosteroid </e2>  therapy is discontinued if possible.
false	 <e1> Anticoagulants </e1> , oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to  <e2> warfarin </e2> , although there have been some conflicting reports.
false	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin,  <e1> carbamazepine </e1> , rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the  <e2> corticosteroid </e2>  be increased.
false	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium,  <e1> carbamazepine </e1>  and possibly with griseofulvin,  <e2> ampicillin </e2> , and tetracyclines (72)
mechanism	Ephedrine:  <e1> Ephedrine </e1>  may enhance the metabolic clearance of  <e2> corticosteroids </e2> , resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.
mechanism	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin,  <e1> carbamazepine </e1> , rifampin) may enhance the metabolism of  <e2> corticosteroids </e2>  and require that the dosage of the corticosteroid be increased.
false	Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain  <e1> corticosteroids </e1>  by up to 60%, leading to increased risk of  <e2> corticosteroid </e2>  side effects.
false	Ketoconazole:  <e1> Ketoconazole </e1>  has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of  <e2> corticosteroid </e2>  side effects.
false	 <e1> Ephedrine </e1> : Ephedrine may enhance the metabolic clearance of  <e2> corticosteroids </e2> , resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.
false	 <e1> Aminoglutethimide </e1> : Aminoglutethimide may diminish adrenal suppression by  <e2> corticosteroids </e2> .
effect	In addition, there have been cases reported in which concomitant use of  <e1> amphotericin B </e1>  and  <e2> hydrocortisone </e2>  was followed by cardiac enlargement and congestive heart failure.
false	 <e1> Antidiabetics </e1> : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of  <e2> antidiabetic agents </e2>  may be required.
false	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine,  <e1> rifampin </e1> ) may enhance the metabolism of corticosteroids and require that the dosage of the  <e2> corticosteroid </e2>  be increased.
effect	Vaccines: Patients on  <e1> corticosteroid </e1>  therapy may exhibit a diminished response to toxoids and live or inactivated  <e2> vaccines </e2>  due to inhibition of antibody response.
false	Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or  <e1> inactivated v <e2> accines </e1>  </e2>  due to inhibition of antibody response.
mechanism	The clearance of  <e1> salicylates </e1>  may be increased with concurrent use of  <e2> corticosteroids </e2> .
false	 <e1> Estrogens </e1> , including oral contraceptives:  <e2> Estrogens </e2>  may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.
false	 <e1> Vaccines </e1> : Patients on  <e2> corticosteroid </e2>  therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
false	 <e1> Aminoglutethimide </e1> : Aminoglutethimide may diminish adrenal suppression by  <e2> corticosteroids </e2> .
false	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium,  <e1> carbamazepine </e1>  and possibly with griseofulvin,  <e2> ampicillin </e2> , and tetracyclines (72)
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or  <e1> antihistamines </e1> ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e2> monoamine oxidase (MAO) inhibitors </e2>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	 <e1> Antidiabetics </e1> : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of  <e2> antidiabetic agents </e2>  may be required.
false	 <e1> Vaccines </e1> : Patients on  <e2> corticosteroid </e2>  therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
int	 <e1> Dexbrompheniramine </e1>  can interact with  <e2> alcohol </e2>  or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or  <e1> antihistamines </e1> ),  <e2> anticholinergics </e2>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	 <e1> Dexbrompheniramine </e1>  can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  <e2> antihistamines </e2> ), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other  <e1> CNS depressants </e1>  (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of  <e2> antihistamines </e2> ).
false	Dexbrompheniramine can interact with alcohol or other  <e1> CNS depressants </e1>  (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with  <e2> antihistamines </e2>  may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with  <e1> serotoninergic agents </e1>  (e.g., fluoxetine,  <e2> fluvoxamine </e2> , paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine oxidase inhibitors ( <e1> MAOIs </e1> ) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine,  <e2> fluvoxamine </e2> , paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
effect	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs) and agents for migraine therapy, such as Imitrex ( <e2> sumatriptan succinate </e2> ) and dihydroergotamine.
effect	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g.,  <e1> selegiline hydrochloride </e1> ) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline,  <e2> venlafaxine </e2> ), there have been reports of serious, sometimes fatal, reactions.
advise	At least 14 days should elapse between discontinuation of a  <e1> MAO inhibitor </e1>  and initiation of treatment with  <e2> dexfenfluramine </e2> .
false	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as  <e1> Imitrex </e1>  (sumatriptan succinate) and  <e2> dihydroergotamine </e2> .
false	Because  <e1> dexfenfluramine </e1>  is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a  <e2> MAO inhibitor </e2> .
false	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with  <e1> serotoninergic agents </e1>  (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline,  <e2> venlafaxine </e2> ), there have been reports of serious, sometimes fatal, reactions.
effect	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and  <e2> dihydroergotamine </e2> .
false	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  <e1> selective serotonin reuptake inhibitors </e1>  ( <e2> SSRIs </e2> ) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
false	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine,  <e1> fluvoxamine </e1> ,  <e2> paroxetine </e2> , sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine oxidase inhibitors ( <e1> MAOIs </e1> ) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine,  <e2> paroxetine </e2> , sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
false	Anesthetics/Sedatives/ <e1> Hypnotics </e1> /Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and  <e2> opioids </e2>  is likely to lead to an enhancement of effects.
false	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives,  <e1> hypnotics </e1> , and  <e2> opioids </e2>  is likely to lead to an enhancement of effects.
false	 <e1> Anesthetics </e1> /Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives,  <e2> hypnotics </e2> , and opioids is likely to lead to an enhancement of effects.
false	No pharmacokinetic interactions between dexmedetomidine and isoflurane,  <e1> propofol </e1> ,  <e2> alfentanil </e2> , and midazolam have been demonstrated.
false	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as  <e1> Imitrex </e1>  (sumatriptan succinate) and  <e2> dihydroergotamine </e2> .
false	However, due to possible pharmacodynamic interactions, when co-administered with  <e1> PRECEDEX </e1> , a reduction in dosage of PRECEDEX on the concomitant  <e2> anesthetic </e2> , sedative, hypnotic or opioid may be required.
false	However, due to possible pharmacodynamic interactions, when co-administered with  <e1> PRECEDEX </e1> , a reduction in dosage of PRECEDEX on the concomitant anesthetic,  <e2> sedative </e2> , hypnotic or opioid may be required.
false	 <e1> Anesthetics </e1> /Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics,  <e2> sedatives </e2> , hypnotics, and opioids is likely to lead to an enhancement of effects.
false	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics,  <e1> sedatives </e1> , hypnotics, and  <e2> opioids </e2>  is likely to lead to an enhancement of effects.
advise	At least 14 days should elapse between discontinuation of a  <e1> MAO inhibitor </e1>  and initiation of treatment with  <e2> dexfenfluramine </e2> .
false	Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol,  <e1> alfentanil </e1> , and  <e2> midazolam </e2> .
effect	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of  <e1> PRECEDEX </e1>  with  <e2> anesthetics </e2> , sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
false	 <e1> Anesthetics </e1> /Sedatives/ <e2> Hypnotics </e2> /Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
false	Specific studies have confirmed these effects with  <e1> sevoflurane </e1> ,  <e2> isoflurane </e2> , propofol, alfentanil, and midazolam.
false	Specific studies have confirmed these effects with sevoflurane,  <e1> isoflurane </e1> ,  <e2> propofol </e2> , alfentanil, and midazolam.
false	Specific studies have confirmed these effects with  <e1> sevoflurane </e1> , isoflurane,  <e2> propofol </e2> , alfentanil, and midazolam.
false	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative,  <e1> hypnotic </e1>  or  <e2> opioid </e2>  may be required.
effect	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and  <e2> dihydroergotamine </e2> .
false	However, due to possible pharmacodynamic interactions, when co-administered with  <e1> PRECEDEX </e1> , a reduction in dosage of PRECEDEX on the concomitant  <e2> anesthetic </e2> , sedative, hypnotic or opioid may be required.
false	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as  <e1> Imitrex </e1>  (sumatriptan succinate) and  <e2> dihydroergotamine </e2> .
effect	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and  <e2> dihydroergotamine </e2> .
false	Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol,  <e1> alfentanil </e1> , and  <e2> midazolam </e2> .
false	 <e1> Antidepressants </e1> , tricyclic: Amphetamines may enhance the activity of tricyclic or  <e2> sympathomimetic agents </e2> ;
mechanism	MAO inhibitors:  <e1> MAOI antidepressants </e1> , as well as a metabolite of furazolidone, slow  <e2> amphetamine </e2>  metabolism.
false	 <e1> Meperidine </e1> : Amphetamines potentiate the analgesic effect of  <e2> meperidine </e2> .
false	 <e1> Chlorpromazine </e1> : Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of  <e2> amphetamines </e2> , and can be used to treat amphetamine poisoning.
false	Acidifying agents: Gastrointestinal acidifying agents ( <e1> guanethidine </e1> , reserpine, glutamic acid HCl,  <e2> ascorbic acid </e2> , fruit juices, etc.) lower absorption of amphetamines.
mechanism	Urinary acidifying agents ( <e1> ammonium chloride </e1> , sodium acid phosphate, etc.) increase the concentration of the ionized species of the  <e2> amphetamine </e2>  molecule, thereby increasing urinary excretion.
false	 <e1> Acidifying agents </e1> : Gastrointestinal acidifying agents (guanethidine, reserpine,  <e2> glutamic acid HCl </e2> , ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
false	Urinary acidifying agents ( <e1> ammonium chloride </e1> ,  <e2> sodium acid phosphate </e2> , etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
effect	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and  <e2> dihydroergotamine </e2> .
false	d-amphetamine with desipramine or protriptyline and possibly other  <e1> tricyclics </e1>  cause striking and sustained increases in the concentration of  <e2> d-amphetamine </e2>  in the brain;
false	Acidifying agents: Gastrointestinal acidifying agents (guanethidine,  <e1> reserpine </e1> ,  <e2> glutamic acid HCl </e2> , ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
false	 <e1> Ethosuximide </e1> :  <e2> Amphetamines </e2>  may delay intestinal absorption of ethosuximide.
false	Antidepressants,  <e1> tricyclic </e1> : Amphetamines may enhance the activity of tricyclic or  <e2> sympathomimetic agents </e2> ;
false	 <e1> Phenytoin </e1> :  <e2> Amphetamines </e2>  may delay intestinal absorption of phenytoin;
false	 <e1> Phenobarbital </e1> : Amphetamines may delay intestinal absorption of  <e2> phenobarbital </e2> ;
false	Antidepressants, tricyclic: Amphetamines may enhance the activity of  <e1> tricyclic </e1>  or  <e2> sympathomimetic agents </e2> ;
false	Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol,  <e1> alfentanil </e1> , and  <e2> midazolam </e2> .
false	Urinary alkalinizing agents ( <e1> acetazolamide </e1> , some  <e2> thiazides </e2> ) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
effect	Haloperidol:  <e1> Haloperidol </e1>  blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of  <e2> amphetamines </e2> .
mechanism	 <e1> d-amphetamine </e1>  with  <e2> desipramine </e2>  or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
mechanism	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine,  <e1> glutamic acid HCl </e1> , ascorbic acid, fruit juices, etc.) lower absorption of  <e2> amphetamines </e2> .
false	 <e1> Phenytoin </e1> : Amphetamines may delay intestinal absorption of  <e2> phenytoin </e2> ;
mechanism	 <e1> d-amphetamine </e1>  with  <e2> desipramine </e2>  or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
false	 <e1> Phenytoin </e1> : Amphetamines may delay intestinal absorption of  <e2> phenytoin </e2> ;
false	Urinary acidifying agents ( <e1> ammonium chloride </e1> ,  <e2> sodium acid phosphate </e2> , etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
false	Additive depressant effect when used with general anesthetics, sedatives,  <e1> antianxiety drugs </e1> , hypnotics, alcohol, and other  <e2> opiate analgesics </e2> .
effect	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and  <e2> dihydroergotamine </e2> .
false	 <e1> Ethosuximide </e1> :  <e2> Amphetamines </e2>  may delay intestinal absorption of ethosuximide.
false	Urinary alkalinizing agents ( <e1> acetazolamide </e1> , some  <e2> thiazides </e2> ) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
false	Additive depressant effect when used with general anesthetics,  <e1> sedatives </e1> , antianxiety drugs, hypnotics,  <e2> alcohol </e2> , and other opiate analgesics.
false	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products,  <e1> antacids </e1> , H2-antagonists (e.g., famotidine, ranitidine), and  <e2> proton pump inhibitors </e2>  (e.g., lansoprazole, omeprazole).
false	 <e1> Ethosuximide </e1> :  <e2> Amphetamines </e2>  may delay intestinal absorption of ethosuximide.
false	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g.,  <e1> famotidine </e1> ,  <e2> ranitidine </e2> ), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
false	May interact with thyroid medication (e.g., levothyroxine),  <e1> iodine </e1> -containing products, antacids, H2-antagonists (e.g., famotidine,  <e2> ranitidine </e2> ), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
false	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products,  <e1> antacids </e1> , H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g.,  <e2> lansoprazole </e2> , omeprazole).
false	May interact with thyroid medication (e.g.,  <e1> levothyroxine </e1> ), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and  <e2> proton pump inhibitors </e2>  (e.g., lansoprazole, omeprazole).
false	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine,  <e1> ranitidine </e1> ), and proton pump inhibitors (e.g.,  <e2> lansoprazole </e2> , omeprazole).
false	May interact with thyroid medication (e.g., levothyroxine),  <e1> iodine </e1> -containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g.,  <e2> lansoprazole </e2> , omeprazole).
false	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products,  <e1> antacids </e1> ,  <e2> H2-antagonists </e2>  (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
false	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g.,  <e1> famotidine </e1> ,  <e2> ranitidine </e2> ), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
false	May interact with thyroid medication (e.g., levothyroxine),  <e1> iodine </e1> -containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g.,  <e2> lansoprazole </e2> , omeprazole).
false	 <e1> Diuretics </e1> : Diclofenac and other NSAIDs can inhibit the activity of  <e2> diuretics </e2> .
false	Aspirin: Concomitant administration of  <e1> diclofenac </e1>  and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of  <e2> aspirin </e2> , resulting in lower plasma concentrations, peak plasma levels, and AUC values.
advise	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including  <e1> diclofenac </e1> , and  <e2> warfarin </e2>  requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
false	Because prostaglandins play an important role in hemostasis, and  <e1> NSAIDs </e1>  affect platelet function as well, concurrent therapy with all  <e2> NSAIDs </e2> , including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
false	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline,  <e1> cephalothin </e1> , erythromycin, and  <e2> sulfamethoxazole </e2>  have no influence in vitro on the protein binding of diclofenac in human serum.
false	Benzylpenicillin, ampicillin, oxacillin,  <e1> chlortetracycline </e1> ,  <e2> doxycycline </e2> , cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
false	Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking  <e1> digoxin </e1> , methotrexate, or  <e2> cyclosporine </e2>  may develop toxicity characteristics for these drugs.
false	Benzylpenicillin, ampicillin,  <e1> oxacillin </e1> , chlortetracycline, doxycycline,  <e2> cephalothin </e2> , erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
false	Benzylpenicillin, ampicillin,  <e1> oxacillin </e1> ,  <e2> chlortetracycline </e2> , doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
mechanism	Protein Binding In vitro,  <e1> diclofenac </e1>  interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or  <e2> warfarin </e2> .
effect	Patients who begin taking  <e1> diclofenac </e1>  or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or  <e2> cyclosporine </e2>  may develop toxicity characteristics for these drugs.
false	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all  <e1> NSAIDs </e1> , including  <e2> diclofenac </e2> , and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
false	Because prostaglandins play an important role in hemostasis, and  <e1> NSAIDs </e1>  affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their  <e2> anticoagulant </e2>  dosage is required.
false	Patients who begin taking diclofenac or who increase their  <e1> diclofenac </e1>  dose or any other NSAID while taking digoxin, methotrexate, or  <e2> cyclosporine </e2>  may develop toxicity characteristics for these drugs.
false	 <e1> Anticoagulants </e1> : While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other  <e2> NSAIDs </e2> .
effect	Patients who begin taking diclofenac or who increase their diclofenac dose or any other  <e1> NSAID </e1>  while taking  <e2> digoxin </e2> , methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
false	Benzylpenicillin, ampicillin,  <e1> oxacillin </e1> , chlortetracycline, doxycycline, cephalothin,  <e2> erythromycin </e2> , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine,  <e1> gold </e1> , chloroquine,  <e2> D-penicillamine </e2> , prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  <e1> azathioprine </e1> , gold, chloroquine,  <e2> D-penicillamine </e2> , prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.
false	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and  <e1> sulfamethoxazole </e1>  have no influence in vitro on the protein binding of  <e2> diclofenac </e2>  in human serum.
false	 <e1> Benzylpenicillin </e1> , ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin,  <e2> erythromycin </e2> , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
false	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline,  <e1> doxycycline </e1> , cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of  <e2> diclofenac </e2>  in human serum.
false	 <e1> Diuretics </e1> : Diclofenac and other  <e2> NSAIDs </e2>  can inhibit the activity of diuretics.
false	 <e1> Digoxin </e1> , Methotrexate,  <e2> Cyclosporine </e2> : Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.
effect	Diuretics: Diclofenac and other  <e1> NSAIDs </e1>  can inhibit the activity of  <e2> diuretics </e2> .
mechanism	Protein Binding In vitro,  <e1> diclofenac </e1>  interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding),  <e2> tolbutamide </e2> , prednisolone (10% decrease in binding), or warfarin.
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or  <e1> digitoxin </e1>  did not significantly affect the peak levels and AUC values of  <e2> diclofenac </e2> .
false	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline,  <e1> doxycycline </e1> ,  <e2> cephalothin </e2> , erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  <e1> azathioprine </e1> , gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of  <e2> diclofenac </e2> .
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold,  <e1> chloroquine </e1> , D-penicillamine, prednisolone, doxycycline, or  <e2> digitoxin </e2>  did not significantly affect the peak levels and AUC values of diclofenac.
false	 <e1> Benzylpenicillin </e1> , ampicillin, oxacillin,  <e2> chlortetracycline </e2> , doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
false	Benzylpenicillin, ampicillin,  <e1> oxacillin </e1> , chlortetracycline, doxycycline, cephalothin, erythromycin, and  <e2> sulfamethoxazole </e2>  have no influence in vitro on the protein binding of diclofenac in human serum.
false	There are rare reports, however, from marketing experiences, of changes in effects of  <e1> insulin </e1>  or oral  <e2> hypoglycemic agents </e2>  in the presence of diclofenac that necessitated changes in the doses of such agents.
false	Benzylpenicillin, ampicillin, oxacillin,  <e1> chlortetracycline </e1> ,  <e2> doxycycline </e2> , cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
false	 <e1> Diuretics </e1> : Diclofenac and other  <e2> NSAIDs </e2>  can inhibit the activity of diuretics.
false	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline,  <e1> cephalothin </e1> , erythromycin, and  <e2> sulfamethoxazole </e2>  have no influence in vitro on the protein binding of diclofenac in human serum.
false	 <e1> Anticoagulants </e1> : While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other  <e2> NSAIDs </e2> .
false	Patients who begin taking diclofenac or who increase their  <e1> diclofenac </e1>  dose or any other NSAID while taking digoxin, methotrexate, or  <e2> cyclosporine </e2>  may develop toxicity characteristics for these drugs.
effect	Patients who begin taking diclofenac or who increase their diclofenac dose or any other  <e1> NSAID </e1>  while taking  <e2> digoxin </e2> , methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
mechanism	Protein Binding In vitro,  <e1> diclofenac </e1>  interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding),  <e2> tolbutamide </e2> , prednisolone (10% decrease in binding), or warfarin.
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or  <e1> digitoxin </e1>  did not significantly affect the peak levels and AUC values of  <e2> diclofenac </e2> .
false	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine  <e1> antiarrhythmic agents </e1>  of class (e.g. quinidine), antihistamines  <e2> antipsychotic agents </e2>  (e.g. phenothiazines), benzodiazepines.
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or  <e1> digitoxin </e1>  did not significantly affect the peak levels and AUC values of  <e2> diclofenac </e2> .
mechanism	Because  <e1> antacids </e1>  may interfere with the absorption of  <e2> anticholinergic agents </e2> , simultaneous use of these drugs should be avoided.
false	The following agents may increase certain actions or side effects of  <e1> anticholinergic drugs </e1> . amantadine antiarrhythmic agents of class (e.g.  <e2> quinidine </e2> ), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.
false	The following agents may increase certain actions or side effects of anticholinergic drugs.  <e1> amantadine </e1>   <e2> antiarrhythmic agents </e2>  of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.
false	MAO inhibitors, narcotic analgesics (e.g., meperidine),  <e1> nitrates </e1>  and  <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
false	The following agents may increase certain actions or side effects of  <e1> anticholinergic drugs </e1> . amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines  <e2> antipsychotic agents </e2>  (e.g. phenothiazines), benzodiazepines.
false	MAO inhibitors,  <e1> narcotic analgesics </e1>  (e.g., meperidine), nitrates and nitrites, sympathomimetic agents,  <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.
false	Benzylpenicillin, ampicillin, oxacillin,  <e1> chlortetracycline </e1> ,  <e2> doxycycline </e2> , cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
false	The following agents may increase certain actions or side effects of  <e1> anticholinergic drugs </e1> . amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g.  <e2> phenothiazines </e2> ), benzodiazepines.
false	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine  <e1> antiarrhythmic agents </e1>  of class (e.g.  <e2> quinidine </e2> ), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.
false	The following agents may increase certain actions or side effects of anticholinergic drugs.  <e1> amantadine </e1>  antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines),  <e2> benzodiazepines </e2> .
false	 <e1> Antacids </e1> : Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the  <e2> antacid </e2>  components.
false	The following agents may increase certain actions or side effects of  <e1> anticholinergic drugs </e1> . amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g.  <e2> phenothiazines </e2> ), benzodiazepines.
false	A 21 (17)% decrease in the steady-state AUC of  <e1> ganciclovir </e1>  was observed when  <e2> VIDEX </e2>  was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).
false	Antacids: Concomitant administration of antacids containing magnesium or aluminum with  <e1> VIDEX </e1>  Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the  <e2> antacid </e2>  components.
false	 <e1> Allopurinol </e1> : The AUC of didanosine was increased about 4-fold when  <e2> allopurinol </e2>  at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).
false	Quinolone Antibiotics:  <e1> VIDEX </e1>  should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with  <e2> antacids </e2>  containing magnesium, calcium, or aluminum.
false	A 21 (17)% decrease in the steady-state AUC of  <e1> ganciclovir </e1>  was observed when VIDEX was administered 2 hours prior to  <e2> ganciclovir </e2> , but not when the two drugs were administered simultaneously (n = 12).
false	Antacids: Concomitant administration of  <e1> antacids </e1>  containing magnesium or  <e2> aluminum </e2>  with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
advise	To avoid this interaction, delavirdine or  <e1> indinavir </e1>  should be given 1 hour prior to dosing with  <e2> VIDEX </e2> .
mechanism	Plasma concentrations of  <e1> quinolone antibiotics </e1>  are decreased when administered with antacids containing  <e2> magnesium </e2> , calcium, or aluminum.
false	The optimal dosing interval for coadministration with  <e1> VIDEX </e1>  should be determined by consulting the appropriate  <e2> quinolone </e2>  package insert.
false	In a single subject given one dose of  <e1> ciprofloxacin </e1>  2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of  <e2> ciprofloxacin </e2>  was observed.
false	The pharmacokinetics of  <e1> nelfinavir </e1>  are not altered to a clinically significant degree when it is administered with a light meal 1 hour after  <e2> VIDEX </e2> .
mechanism	Plasma concentrations of  <e1> quinolone antibiotics </e1>  are decreased when administered with antacids containing magnesium, calcium, or  <e2> aluminum </e2> .
false	 <e1> Quinolone Antibiotic </e1> s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or  <e2> aluminum </e2> .
mechanism	Because  <e1> antacids </e1>  may interfere with the absorption of  <e2> anticholinergic agents </e2> , simultaneous use of these drugs should be avoided.
false	Interactions with Other  <e1> Antiretroviral Drugs </e1> : Significant decreases in the AUC of  <e2> delavirdine </e2>  (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.
false	 <e1> Ganciclovir </e1> : Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of  <e2> didanosine </e2>  (n = 12).
false	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium,  <e1> calcium </e1> , or  <e2> aluminum </e2> .
false	MAO inhibitors,  <e1> narcotic analgesics </e1>  (e.g., meperidine), nitrates and nitrites, sympathomimetic agents,  <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.
false	 <e1> Quinolone Antibiotic </e1> s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium,  <e2> calcium </e2> , or aluminum.
false	Quinolone Antibiotics:  <e1> VIDEX </e1>  should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with  <e2> antacids </e2>  containing magnesium, calcium, or aluminum.
false	 <e1> Quinolone Antibiotic </e1> s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium,  <e2> calcium </e2> , or aluminum.
false	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium,  <e1> calcium </e1> , or  <e2> aluminum </e2> .
false	conversely, diethylpropion may interfere with  <e1> antihypertensive drugs </e1>  (i.e., guanethidine,  <e2> a-methyldopa </e2> ).
false	 <e1> Quinolone Antibiotic </e1> s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium,  <e2> calcium </e2> , or aluminum.
false	May interact  <e1> anticoagulants </e1>  (altered hypo-prothrombinemic effect),  <e2> barbiturates </e2> , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).
false	May interact anticoagulants (altered hypo-prothrombinemic effect),  <e1> barbiturates </e1> , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of  <e2> corticosteroids </e2> ).
false	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates,  <e1> rifampin </e1>  and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of  <e2> corticosteroids </e2> ).
false	May interact  <e1> anticoagulants </e1>  (altered hypo-prothrombinemic effect), barbiturates,  <e2> rifampin </e2>  and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).
false	May interact  <e1> anticoagulants </e1>  (altered hypo-prothrombinemic effect),  <e2> barbiturates </e2> , rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).
false	Tolbutamide: In diabetic patients receiving diflunisal and  <e1> tolbutamide </e1> , no significant effects were seen on  <e2> tolbutamide </e2>  plasma levels or fasting blood glucose.
false	Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and  <e1> warfarin </e1> , acenocoumarol, or  <e2> phenprocoumon </e2>  resulted in prolongation of prothrombin time.
advise	Therefore,  <e1> indomethacin </e1>  and  <e2> diflunisal </e2>  should not be used concomitantly.
false	 <e1> Cyclosporine </e1> : Administration of  <e2> nonsteroial anti-inflammatory drugs </e2>  concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
false	 <e1> Naproxen </e1> : The concomitant administration of diflunisal and  <e2> naproxen </e2>  in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
false	Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and  <e1> warfarin </e1> ,  <e2> acenocoumarol </e2> , or phenprocoumon resulted in prolongation of prothrombin time.
false	 <e1> Aspirin </e1> : In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of  <e2> diflunisal </e2>  and aspirin were administered concomitantly.
mechanism	Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of  <e1> diflunisal </e1>  and  <e2> aspirin </e2>  were administered concomitantly.
mechanism	Nonsteroidal Anti-Inflammatory Drugs: The administration of  <e1> diflunisal </e1>  to normal volunteers receiving  <e2> indomethacin </e2>  decreased the renal clearance and significantly increased the plasma levels of indomethacin.
false	Hydrochlorothiazide: In normal volunteers, concomitant administration of  <e1> diflunisal </e1>  and hydrochlorothiazide resulted in significantly increased plasma levels of  <e2> hydrochlorothiazide </e2> .
false	Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of  <e1> naproxen </e1> , but significantly decreased the urinary excretion of  <e2> naproxen </e2>  and its glucuronide metabolite.
false	 <e1> Nonsteroidal Anti-Inflammatory Drugs </e1> : The administration of diflunisal to normal volunteers receiving  <e2> indomethacin </e2>  decreased the renal clearance and significantly increased the plasma levels of indomethacin.
false	Naproxen: The concomitant administration of diflunisal and  <e1> naproxen </e1>  in normal volunteers had no effect on the plasma levels of  <e2> naproxen </e2> , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
false	Naproxen: The concomitant administration of diflunisal and  <e1> naproxen </e1>  in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of  <e2> naproxen </e2>  and its glucuronide metabolite.
effect	Oral Anticoagulants: In some normal volunteers, the concomitant administration of  <e1> diflunisal </e1>  and  <e2> warfarin </e2> , acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
false	Furosemide: In normal volunteers, the concomitant administration of diflunisal and  <e1> furosemide </e1>  had no effect on the diuretic activity of  <e2> furosemide </e2> .
false	 <e1> Acetaminophen </e1> : In normal volunteers, concomitant administration of  <e2> diflunisal </e2>  and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.
false	 <e1> Quinidine </e1> , verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  <e2> digitalis </e2>  intoxication may result.
false	 <e1> Naproxen </e1> : The concomitant administration of diflunisal and  <e2> naproxen </e2>  in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
false	Quinidine, verapamil, amiodarone, propafenone,  <e1> indomethacin </e1> , itraconazole, alprazolam, and  <e2> spironolactone </e2>  raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
false	 <e1> Erythromycin </e1>  and clarithromycin (and possibly other macrolide antibiotics) and  <e2> tetracycline </e2>  may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
false	 <e1> Quinidine </e1> , verapamil,  <e2> amiodarone </e2> , propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
false	Quinidine, verapamil, amiodarone, propafenone,  <e1> indomethacin </e1> ,  <e2> itraconazole </e2> , alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
false	Quinidine,  <e1> verapamil </e1> , amiodarone, propafenone,  <e2> indomethacin </e2> , itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
false	Antacids,  <e1> kaolin </e1> -pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and  <e2> metoclopramide </e2>  may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
false	Erythromycin and clarithromycin (and possibly other  <e1> macrolide antibiotics </e1> ) and tetracycline may increase digoxin absorption in patients who inactivate  <e2> digoxin </e2>  by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
false	 <e1> Rifampin </e1>  may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of  <e2> digoxin </e2> .
mechanism	Propantheline and  <e1> diphenoxylate </e1> , by decreasing gut motility, may increase  <e2> digoxin </e2>  absorption.
mechanism	Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and  <e1> metoclopramide </e1>  may interfere with intestinal  <e2> digoxin </e2>  absorption, resulting in unexpectedly low serum concentrations.
false	Erythromycin and  <e1> clarithromycin </e1>  (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that  <e2> digitalis </e2>  intoxication may result.
false	Antacids, kaolin-pectin, sulfasalazine,  <e1> neomycin </e1> ,  <e2> cholestyramine </e2> , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
advise	Therefore,  <e1> indomethacin </e1>  and  <e2> diflunisal </e2>  should not be used concomitantly.
effect	Concomitant use of  <e1> digoxin </e1>  and  <e2> sympathomimetics </e2>  increases the risk of cardiac arrhythmias.
mechanism	 <e1> Antacids </e1> , kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal  <e2> digoxin </e2>  absorption, resulting in unexpectedly low serum concentrations.
false	There have been inconsistent reports regarding the effects of other drugs (e.g., quinine,  <e1> penicillamine </e1> ) on serum  <e2> digoxin </e2>  concentration.
false	 <e1> Quinidine </e1> , verapamil, amiodarone, propafenone, indomethacin,  <e2> itraconazole </e2> , alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
false	 <e1> Erythromycin </e1>  and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that  <e2> digitalis </e2>  intoxication may result.
mechanism	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and  <e1> tetracycline </e1>  may increase  <e2> digoxin </e2>  absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
false	Erythromycin and clarithromycin (and possibly other  <e1> macrolide antibiotics </e1> ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that  <e2> digitalis </e2>  intoxication may result.
false	Antacids,  <e1> kaolin </e1> -pectin, sulfasalazine,  <e2> neomycin </e2> , cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
false	Quinidine,  <e1> verapamil </e1> , amiodarone,  <e2> propafenone </e2> , indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
false	 <e1> Macrolide Antibiotics </e1>  (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which  <e2> D.H.E. 45 </e2>   (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
false	Sumatriptan and  <e1> D.H.E. 45 </e1>   ( <e2> dihydroergotamine mesylate </e2> ) Injection, USP should not be taken within 24 hours of each other..
mechanism	Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which  <e1> D.H.E. 45 </e1>   (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the  <e2> macrolide class </e2> , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
false	Antacids,  <e1> kaolin </e1> -pectin, sulfasalazine,  <e2> neomycin </e2> , cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
false	Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which  <e1> D.H.E. 45 </e1>   ( <e2> dihydroergotamine mesylate </e2> ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
false	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of  <e1> D.H.E. 45 </e1>   (dihydroergotamine mesylate) Injection, USP to subjects already receiving  <e2> propranolol </e2> , there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
false	There have been no reported cases from spontaneous reports of drug interaction between SSRIs and  <e1> D.H.E. 45 </e1>   ( <e2> dihydroergotamine mesylate </e2> ) Injection, USP.
false	Macrolide Antibiotics (e. g.  <e1> erythromycin </e1>  and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with  <e2> antibiotics </e2>  of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
false	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving  <e1> propranolol </e1> , there have been reports that  <e2> propranolol </e2>  may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
false	 <e1> Rifampin </e1>  may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of  <e2> digoxin </e2> .
mechanism	 <e1> Antacids </e1> , kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal  <e2> digoxin </e2>  absorption, resulting in unexpectedly low serum concentrations.
false	Macrolide Antibiotics (e. g.  <e1> erythromycin </e1>  and  <e2> troleandomycin </e2> ): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
effect	SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when  <e1> 5-HT1 agonists </e1>  have been co-administered with  <e2> SSRIs </e2>  (e. g.
false	Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the  <e1> ergot alkaloid class </e1> , of which  <e2> D.H.E. 45 </e2>   (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
false	There have been no reported cases from spontaneous reports of drug interaction between  <e1> SSRIs </e1>  and D.H.E. 45  ( <e2> dihydroergotamine mesylate </e2> ) Injection, USP.
false	 <e1> SSRIs </e1> : Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with  <e2> SSRIs </e2>  (e. g.
false	Antacids, kaolin-pectin, sulfasalazine,  <e1> neomycin </e1> ,  <e2> cholestyramine </e2> , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
false	 <e1> Erythromycin </e1>  and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that  <e2> digitalis </e2>  intoxication may result.
false	Antacids,  <e1> kaolin </e1> -pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and  <e2> metoclopramide </e2>  may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
false	 <e1> fluoxetine </e1> , fluvoxamine, paroxetine,  <e2> sertraline </e2> ).
effect	Vasospastic reactions have been reported with therapeutic doses of  <e1> ergotamine </e1> -containing drugs when co-administered with these  <e2> antibiotics </e2> .
mechanism	 <e1> Antacids </e1> , kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal  <e2> digoxin </e2>  absorption, resulting in unexpectedly low serum concentrations.
false	Sumatriptan and  <e1> D.H.E. 45 </e1>   ( <e2> dihydroergotamine mesylate </e2> ) Injection, USP should not be taken within 24 hours of each other..
false	Macrolide Antibiotics (e. g.  <e1> erythromycin </e1>  and  <e2> troleandomycin </e2> ): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
false	Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which  <e1> D.H.E. 45 </e1>   ( <e2> dihydroergotamine mesylate </e2> ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
false	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving  <e1> propranolol </e1> , there have been reports that  <e2> propranolol </e2>  may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
mechanism	Studies showed that  <e1> diltiazem </e1>  increased the AUC of midazolam and  <e2> triazolam </e2>  by 3-4 fold and the Cmax by 2-fold, compared to placebo.
false	Administration of diltiazem hydrochloride with  <e1> digoxin </e1>  in 24 healthy male subjects increased plasma  <e2> digoxin </e2>  concentrations approximately 20%.
mechanism	Coadministration of  <e1> rifampin </e1>  with  <e2> diltiazem </e2>  lowered the diltiazem plasma concentrations to undetectable levels.
mechanism	 <e1> Antacids </e1> , kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal  <e2> digoxin </e2>  absorption, resulting in unexpectedly low serum concentrations.
false	Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased  <e1> propranolol </e1>  levels in all subjects and bioavailability of  <e2> propranolol </e2>  was increased approximately 50%.
false	In a ten-subject study, coadministration of  <e1> diltiazem </e1>  (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs.  <e2> lovastatin </e2>  alone;
false	Administration of  <e1> diltiazem hydrochloride </e1>  with digoxin in 24 healthy male subjects increased plasma  <e2> digoxin </e2>  concentrations approximately 20%.
effect	Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or  <e1> digitalis </e1>  concomitantly with  <e2> Tiazac </e2> .
false	In renal and cardiac transplant recipients, a reduction of  <e1> cyclosporine </e1>  dose ranging from 15% to 48% was necessary to maintain  <e2> cyclosporine </e2>  trough concentrations similar to those seen prior to the addition of diltiazem.
false	Administration of diltiazem hydrochloride concomitantly with  <e1> propranolol </e1>  in five normal volunteers resulted in increased  <e2> propranolol </e2>  levels in all subjects and bioavailability of propranolol was increased approximately 50%.
advise	Patients currently receiving  <e1> diltiazem </e1>  therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with  <e2> cimetidine </e2> .
false	Concomitant administration of  <e1> diltiazem </e1>  with carbamazepine has been reported to result in elevated serum levels of  <e2> carbamazepine </e2>  (40% to 72% increase), resulting in toxicity in some cases.
false	Concomitant administration of diltiazem with  <e1> carbamazepine </e1>  has been reported to result in elevated serum levels of  <e2> carbamazepine </e2>  (40% to 72% increase), resulting in toxicity in some cases.
false	Administration of diltiazem hydrochloride concomitantly with  <e1> propranolol </e1>  in five normal volunteers resulted in increased  <e2> propranolol </e2>  levels in all subjects and bioavailability of propranolol was increased approximately 50%.
effect	Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or  <e1> digitalis </e1>  concomitantly with  <e2> Tiazac </e2> .
false	Dimenhydrinate may decrease  <e1> emetic </e1>  response to  <e2> apomorphine </e2> .
false	Diphenhydramine hydrochloride has additive effects with alcohol and other  <e1> CNS depressants </e1>  (hypnotics,  <e2> sedatives </e2> , tranquilizers, etc).
false	Diphenhydramine hydrochloride has additive effects with alcohol and other  <e1> CNS depressants </e1>  (hypnotics, sedatives,  <e2> tranquilizers </e2> , etc).
effect	 <e1> Diphenhydramine hydrochloride </e1>  has additive effects with alcohol and other CNS depressants (hypnotics,  <e2> sedatives </e2> , tranquilizers, etc).
effect	 <e1> Diphenhydramine hydrochloride </e1>  has additive effects with alcohol and other CNS depressants (hypnotics,  <e2> sedatives </e2> , tranquilizers, etc).
false	 <e1> apomorphine </e1>  - prior ingestion of  <e2> diphenidol </e2>  may decrease the emetic response to apomorphine in the treatment of poisoning.
false	Known drug interactions include  <e1> barbiturates </e1> , tranquilizers, and  <e2> alcohol </e2> .
int	 <e1> Diphenoxylate HCl </e1>  and atropine sulfate may interact with  <e2> MAO inhibitors </e2>  In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e1> anticholinergics </e1>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with  <e2> antihistamines </e2>  may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or  <e1> antihistamines </e1> ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e2> monoamine oxidase (MAO) inhibitors </e2>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with  <e1> alcohol </e1>  or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of  <e2> antihistamines </e2> ).
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e1> monoamine oxidase (MAO) inhibitors </e1>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of  <e2> antihistamines </e2> ).
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e1> anticholinergics </e1>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  <e2> antihistamines </e2> ), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with  <e1> alcohol </e1>  or other  <e2> CNS depressants </e2>  (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	 <e1> Adenosine </e1> : Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of  <e2> adenosine </e2> .
false	No pharmacokinetic drug-drug interaction studies were conducted with  <e1> PERSANTINE </e1>   ( <e2> dipyridamole </e2>  USP) Tablets.
false	 <e1> Triazolam </e1> : Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of  <e2> triazolam </e2> .
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide,  <e1> phenytoin </e1> ,  <e2> bromocriptine </e2> , valproate, astemizole, and lovastatin.
false	 <e1> Triazolam </e1> : Erythromycin has been reported to decrease the clearance of  <e2> triazolam </e2>  and, thus, may increase the pharmacologic effect of triazolam.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil,  <e1> disopyramide </e1> , phenytoin,  <e2> bromocriptine </e2> , valproate, astemizole, and lovastatin.
false	The pharmacokinetics of terfenadine and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with  <e1> terfenadine </e1>  alone, and with terfenadine plus  <e2> dirithromycin </e2> .
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin,  <e1> bromocriptine </e1> ,  <e2> valproate </e2> , astemizole, and lovastatin.
false	Antacids or  <e1> H 2 receptor antagonists </e1> : When dirithromycin is administered immediately following antacids or  <e2> H 2 -receptor antagonists </e2> , the absorption of dirithromycin is slightly enhanced.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine,  <e1> alfentanil </e1> , disopyramide, phenytoin, bromocriptine, valproate, astemizole, and  <e2> lovastatin </e2> .
false	The pharmacokinetics of  <e1> terfenadine </e1>  and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with  <e2> terfenadine </e2>  alone, and with terfenadine plus dirithromycin.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine,  <e1> alfentanil </e1> , disopyramide, phenytoin, bromocriptine, valproate,  <e2> astemizole </e2> , and lovastatin.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide,  <e1> phenytoin </e1> , bromocriptine,  <e2> valproate </e2> , astemizole, and lovastatin.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine,  <e1> alfentanil </e1> , disopyramide, phenytoin, bromocriptine,  <e2> valproate </e2> , astemizole, and lovastatin.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide,  <e1> phenytoin </e1> , bromocriptine, valproate, astemizole, and  <e2> lovastatin </e2> .
int	Other drugs Drug interactions have been reported with concomitant administration of  <e1> erythromycin </e1>  and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and  <e2> lovastatin </e2> .
false	 <e1> Terfenadine </e1> : In a prospective study involving six-healthy-male volunteers, dirithromycin did not affect the metabolism of  <e2> terfenadine </e2> .
false	 <e1> Theophylline </e1> : Following co-administration of two 250-mg dirithromycin tablets administered once daily with 200-mg  <e2> theophylline </e2>  tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine,  <e1> hexobarbital </e1> , carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate,  <e2> astemizole </e2> , and lovastatin.
effect	Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving  <e1> terfenadine </e1>  concomitantly with other  <e2> macrolide antibiotics </e2> .
false	However,  <e1> theophylline </e1>  plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given  <e2> theophylline </e2>  plasma concentration for optimal pulmonary function or in patients with theophylline concentrations at the higher end of the therapeutic range.
false	 <e1> Ergotamine </e1> : Concurrent use of erythromycin and ergotamine or  <e2> dihydroergotamine </e2>  has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
false	No pharmacokinetic drug-drug interaction studies were conducted with  <e1> PERSANTINE </e1>   ( <e2> dipyridamole </e2>  USP) Tablets.
int	Other drugs Drug interactions have been reported with concomitant administration of  <e1> erythromycin </e1>  and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil,  <e2> disopyramide </e2> , phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
false	Theophylline: Following co-administration of two 250-mg  <e1> dirithromycin </e1>  tablets administered once daily with 200-mg  <e2> theophylline </e2>  tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.
false	In general, most patients treated with dirithromycin who are receiving concomitant  <e1> theophylline </e1>  therapy may not require empiric adjustment of  <e2> theophylline </e2>  dosage or monitoring of theophylline plasma concentrations.
false	Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or  <e1> H 2 -receptor antagonists </e1> , the absorption of  <e2> dirithromycin </e2>  is slightly enhanced.
mechanism	Triazolam:  <e1> Erythromycin </e1>  has been reported to decrease the clearance of  <e2> triazolam </e2>  and, thus, may increase the pharmacologic effect of triazolam.
false	 <e1> Ergotamine </e1> : Concurrent use of erythromycin and  <e2> ergotamine </e2>  or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin,  <e1> bromocriptine </e1> ,  <e2> valproate </e2> , astemizole, and lovastatin.
false	Other antiarrhythmic drugs (eg,  <e1> quinidine </e1> , procainamide,  <e2> lidocaine </e2> , propranolol) have occasionally been used concurrently with Norpace.
false	Concomitant administration of Norpace and quinidine resulted in slight increases in plasma  <e1> disopyramide </e1>  levels and slight decreases in plasma  <e2> quinidine </e2>  levels.
false	Other  <e1> antiarrhythmic drugs </e1>  (eg, quinidine,  <e2> procainamide </e2> , lidocaine, propranolol) have occasionally been used concurrently with Norpace.
false	Until data on possible interactions between  <e1> verapamil </e1>  and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after  <e2> verapamil </e2>  administration.
false	Concomitant administration of Norpace and  <e1> quinidine </e1>  resulted in slight increases in plasma disopyramide levels and slight decreases in plasma  <e2> quinidine </e2>  levels.
false	If  <e1> phenytoin </e1>  or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of  <e2> disopyramide </e2>  may occur.
int	Other drugs Drug interactions have been reported with concomitant administration of  <e1> erythromycin </e1>  and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and  <e2> lovastatin </e2> .
false	Concomitant administration of  <e1> Norpace </e1>  and quinidine resulted in slight increases in plasma  <e2> disopyramide </e2>  levels and slight decreases in plasma quinidine levels.
false	If phenytoin or other hepatic enzyme inducers are taken concurrently with  <e1> Norpace </e1>  or  <e2> Norpace CR </e2> , lower plasma levels of disopyramide may occur.
false	In healthy subjects, no significant drug-drug interaction was observed when  <e1> Norpace </e1>  was coadministered with either  <e2> propranolol </e2>  or diazepam.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine,  <e1> hexobarbital </e1> , carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate,  <e2> astemizole </e2> , and lovastatin.
mechanism	If  <e1> phenytoin </e1>  or other hepatic enzyme inducers are taken concurrently with  <e2> Norpace </e2>  or Norpace CR, lower plasma levels of disopyramide may occur.
false	It may be necessary to adjust the dosage of oral  <e1> anticoagulants </e1>  upon beginning or stopping disulfiram. since  <e2> disulfiram </e2>  may prolong prothrombin time.
false	In healthy subjects, no significant drug-drug interaction was observed when  <e1> Norpace </e1>  was coadministered with either  <e2> propranolol </e2>  or diazepam.
false	Concomitant administration of  <e1> Norpace </e1>  and quinidine resulted in slight increases in plasma  <e2> disopyramide </e2>  levels and slight decreases in plasma quinidine levels.
false	In rats, simultaneous ingestion of  <e1> disulfiram </e1>  and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with  <e2> nitrites </e2>  in the rat stomach to form a nitrosamine, which is tumorigenic.
false	If  <e1> phenytoin </e1>  or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of  <e2> disopyramide </e2>  may occur.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate,  <e1> isosorbide dinitrate </e1> , morphine, atropine, heparin, protamine, potassium chloride, folic acid, and  <e2> acetaminophen </e2> .
false	Concomitant administration of  <e1> Norpace </e1>  and quinidine resulted in slight increases in plasma  <e2> disopyramide </e2>  levels and slight decreases in plasma quinidine levels.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine,  <e1> heparin </e1> ,  <e2> protamine </e2> , potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine,  <e1> heparin </e1> , protamine, potassium chloride, folic acid, and  <e2> acetaminophen </e2> .
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride,  <e1> folic acid </e1> , and  <e2> acetaminophen </e2> .
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide,  <e1> spironolactone </e1> , lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and  <e2> acetaminophen </e2> .
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate,  <e1> isosorbide dinitrate </e1> , morphine, atropine, heparin,  <e2> protamine </e2> , potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate,  <e1> morphine </e1> ,  <e2> atropine </e2> , heparin, protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations,  <e1> furosemide </e1> , spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate,  <e2> morphine </e2> , atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
effect	Animal studies indicate that  <e1> dobutamine </e1>  may be ineffective if the patient has recently received a  <e2> b-blocking drug </e2> .
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine,  <e1> glyceryl trinitrate </e1> , isosorbide dinitrate, morphine,  <e2> atropine </e2> , heparin, protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone,  <e1> lidocaine </e1> , glyceryl trinitrate, isosorbide dinitrate, morphine, atropine,  <e2> heparin </e2> , protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine,  <e1> heparin </e1> , protamine, potassium chloride,  <e2> folic acid </e2> , and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate,  <e1> morphine </e1> , atropine, heparin,  <e2> protamine </e2> , potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate,  <e1> morphine </e1> , atropine, heparin, protamine, potassium chloride,  <e2> folic acid </e2> , and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin,  <e1> protamine </e1> , potassium chloride,  <e2> folic acid </e2> , and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which  <e1> dobutamine </e1>  was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine,  <e2> glyceryl trinitrate </e2> , isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations,  <e1> furosemide </e1> , spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and  <e2> acetaminophen </e2> .
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations,  <e1> furosemide </e1> , spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine,  <e2> atropine </e2> , heparin, protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine,  <e1> atropine </e1> , heparin, protamine, potassium chloride, folic acid, and  <e2> acetaminophen </e2> .
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations,  <e1> furosemide </e1> , spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine,  <e2> atropine </e2> , heparin, protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations,  <e1> furosemide </e1> , spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate,  <e2> morphine </e2> , atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
mechanism	In vitro studies have shown that the metabolism of  <e1> docetaxel </e1>  may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine,  <e2> ketoconazole </e2> , erythromycin, and troleandomycin.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine,  <e1> atropine </e1> , heparin, protamine, potassium chloride, folic acid, and  <e2> acetaminophen </e2> .
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate,  <e1> morphine </e1> , atropine, heparin,  <e2> protamine </e2> , potassium chloride, folic acid, and acetaminophen.
false	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as  <e1> cyclosporine </e1> , terfenadine, ketoconazole, erythromycin, and  <e2> troleandomycin </e2> .
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine,  <e1> heparin </e1> , protamine, potassium chloride, folic acid, and  <e2> acetaminophen </e2> .
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice,  <e1> nefazadone </e1> , norfloxacin, quinine,  <e2> zafirlukast </e2> ) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Inhibitors of this isoenzyme (e.g.,  <e1> macrolide antibiotics </e1> , azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors,  <e2> amiodarone </e2> , cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
advise	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors,  <e1> amiodarone </e1> , cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with  <e2> TIKOSYN </e2>  as they can potentially increase dofetilide levels.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors,  <e1> amiodarone </e1> , cannabinoids, diltiazem, grapefruit juice, nefazadone,  <e2> norfloxacin </e2> , quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Other Drug Interaction Information Digoxin: Studies in healthy volunteers have shown that  <e1> TIKOSYN </e1>  does not affect the pharmacokinetics of  <e2> digoxin </e2> .
false	In the DIAMOND trials, 1252 patients were treated with TIKOSYN and  <e1> diuretics </e1>  concomitantly of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and  <e2> diuretics </e2> .
false	Hydrochlorothiazide ( <e1> HCTZ </e1> ) Alone or in Combination with  <e2> Triamterene </e2> : Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors,  <e1> serotonin reuptake inhibitors </e1> , amiodarone,  <e2> cannabinoids </e2> , diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors,  <e1> amiodarone </e1> , cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine,  <e2> zafirlukast </e2> ) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations,  <e1> furosemide </e1> , spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine,  <e2> atropine </e2> , heparin, protamine, potassium chloride, folic acid, and acetaminophen.
false	If a patient requires TIKOSYN and  <e1> anti-ulcer </e1>  therapy, it is suggested that omeprazole, ranitidine, or  <e2> antacids </e2>  (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin,  <e1> glyburide </e1> , ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated  <e2> estrogens </e2>  and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and  <e1> theophylline </e1>  did not affect the pharmacokinetics of  <e2> TIKOSYN </e2> .
false	Cimetidine at 400 mg BID (the usual prescription dose) co-administered with  <e1> TIKOSYN </e1>  (500 mcg BID) for 7 days has been shown to increase  <e2> dofetilide </e2>  plasma levels by 58%.
mechanism	In patients receiving  <e1> HCTZ </e1>  alone,  <e2> dofetilide </e2>  AUC increased by 27% and Cmax by 21%.
false	Concomitant medications were grouped as ACE inhibitors, oral  <e1> anticoagulants </e1> , calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics,  <e2> thiazide diuretics </e2> , substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	 <e1> HCTZ </e1>  50 mg QD or  <e2> HCTZ </e2> /triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose).
false	Other Drug Interaction Information  <e1> Digoxin </e1> : Studies in healthy volunteers have shown that  <e2> TIKOSYN </e2>  does not affect the pharmacokinetics of digoxin.
false	 <e1> Hydrochlorothiazide </e1>  (HCTZ) Alone or in Combination with  <e2> Triamterene </e2> : Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.
advise	In addition, drugs that are actively secreted via this route (e.g., triamterene,  <e1> metformin </e1>  and amiloride) should be co-administered with care as they might increase  <e2> dofetilide </e2>  levels.
false	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas,  <e1> loop diuretics </e1> ,  <e2> potassium sparing diuretics </e2> , thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	Trimethoprim Alone or in Combination with  <e1> Sulfamethoxazole </e1> : Concomitant use of  <e2> trimethoprim </e2>  alone or in combination with sulfamethoxazole is contraindicated.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents,  <e1> protease inhibitors </e1> ,  <e2> serotonin reuptake inhibitors </e2> , amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin,  <e1> quinine </e1> ,  <e2> zafirlukast </e2> ) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Other Drugs: In healthy volunteers, amlodipine,  <e1> phenytoin </e1> , glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated  <e2> estrogens </e2>  and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or  <e1> antacids </e1>  (aluminum and  <e2> magnesium hydroxide </e2> s) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
false	Concomitant medications were grouped as  <e1> ACE inhibitors </e1> , oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein,  <e2> nitrates </e2> , sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids,  <e1> diltiazem </e1> , grapefruit juice, nefazadone, norfloxacin, quinine,  <e2> zafirlukast </e2> ) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	If a patient requires  <e1> TIKOSYN </e1>  and  <e2> anti-ulcer </e2>  therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
false	If a patient requires TIKOSYN and  <e1> anti-ulcer </e1>  therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of  <e2> TIKOSYN </e2> .
false	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants,  <e1> calcium channel blockers </e1> ,  <e2> beta blockers </e2> , cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of  <e1> warfarin </e1> , or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral  <e2> contraceptives </e2> .
false	Other Drugs: In healthy volunteers, amlodipine,  <e1> phenytoin </e1> , glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone),  <e2> antacid </e2>  (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole,  <e1> ranitidine </e1> , or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of  <e2> TIKOSYN </e2> .
false	In addition, studies in healthy volunteers have shown that  <e1> TIKOSYN </e1>  does not affect the pharmacokinetics or pharmacodynamics of  <e2> warfarin </e2> , or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.
false	 <e1> HCTZ </e1>  50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of  <e2> diuretic </e2>  use at half dose).
advise	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin,  <e1> quinine </e1> , zafirlukast) should be cautiously coadministered with  <e2> TIKOSYN </e2>  as they can potentially increase dofetilide levels.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and  <e1> medroxyprogesterone </e1> ),  <e2> antacid </e2>  (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	 <e1> Trimethoprim </e1>  Alone or in Combination with Sulfamethoxazole: Concomitant use of trimethoprim alone or in combination with  <e2> sulfamethoxazole </e2>  is contraindicated.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids,  <e1> diltiazem </e1> , grapefruit juice, nefazadone, norfloxacin,  <e2> quinine </e2> , zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide,  <e1> ranitidine </e1> ,  <e2> omeprazole </e2> , hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	 <e1> Trimethoprim </e1>  Alone or in Combination with Sulfamethoxazole: Concomitant use of  <e2> trimethoprim </e2>  alone or in combination with sulfamethoxazole is contraindicated.
mechanism	 <e1> Cimetidine </e1>  at doses of 100 mg BID (OTC dose) resulted in a 13% increase in  <e2> dofetilide </e2>  plasma levels (500 mcg single dose).
false	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas,  <e1> loop diuretics </e1> , potassium sparing diuretics,  <e2> thiazide diuretics </e2> , substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	If a patient requires  <e1> TIKOSYN </e1>  and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium  <e2> hydroxide </e2> s) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice,  <e1> nefazadone </e1> , norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase  <e2> dofetilide </e2>  levels.
false	Co-administration of  <e1> TIKOSYN </e1>  with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to  <e2> dofetilide </e2>  was not significantly increased.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone),  <e1> antacid </e1>  (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of  <e2> TIKOSYN </e2> .
false	Other Drugs: In healthy volunteers,  <e1> amlodipine </e1> , phenytoin, glyburide, ranitidine,  <e2> omeprazole </e2> , hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Concomitant medications were grouped as ACE inhibitors, oral  <e1> anticoagulants </e1> , calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates,  <e2> sulphonylureas </e2> , loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants,  <e1> calcium channel blockers </e1> , beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics,  <e2> potassium sparing diuretics </e2> , thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	Drug-Drug Interactions  <e1> Cimetidine </e1> : Concomitant use of  <e2> cimetidine </e2>  is contraindicated.
effect	In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of  <e1> verapamil </e1>  with  <e2> dofetilide </e2>  was associated with a higher occurrence of torsade de pointes.
false	Concomitant medications were grouped as  <e1> ACE inhibitors </e1> , oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics,  <e2> potassium sparing diuretics </e2> , thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents,  <e1> protease inhibitors </e1> , serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase  <e2> dofetilide </e2>  levels.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin,  <e1> glyburide </e1> , ranitidine,  <e2> omeprazole </e2> , hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium  <e1> hydroxide </e1> s) and  <e2> theophylline </e2>  did not affect the pharmacokinetics of TIKOSYN.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate,  <e1> morphine </e1> , atropine, heparin,  <e2> protamine </e2> , potassium chloride, folic acid, and acetaminophen.
false	Other Drugs: In healthy volunteers,  <e1> amlodipine </e1> , phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and  <e2> magnesium hydroxide </e2> s) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents,  <e1> protease inhibitors </e1> , serotonin reuptake inhibitors, amiodarone, cannabinoids,  <e2> diltiazem </e2> , grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	If a patient requires  <e1> TIKOSYN </e1>  and anti-ulcer therapy, it is suggested that  <e2> omeprazole </e2> , ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors,  <e1> serotonin reuptake inhibitors </e1> , amiodarone, cannabinoids, diltiazem, grapefruit juice,  <e2> nefazadone </e2> , norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin,  <e1> 5-fluorouracil </e1> ,  <e2> doxorubicin </e2> , cyclophosphamide) in four murine models.
false	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors,  <e1> verapamil </e1> , glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of  <e2> hydrodolasetron </e2> .
false	In patients taking  <e1> furosemide </e1> , nifedipine, diltiazem, ACE inhibitors,  <e2> verapamil </e2> , glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
false	In patients taking furosemide,  <e1> nifedipine </e1> , diltiazem, ACE inhibitors, verapamil,  <e2> glyburide </e2> , propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
false	In patients taking furosemide, nifedipine,  <e1> diltiazem </e1> , ACE inhibitors, verapamil,  <e2> glyburide </e2> , propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
false	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas,  <e1> loop diuretics </e1> ,  <e2> potassium sparing diuretics </e2> , thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	In patients taking furosemide,  <e1> nifedipine </e1> , diltiazem, ACE inhibitors, verapamil, glyburide,  <e2> propranolol </e2> , and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
false	In addition, studies in healthy volunteers have shown that  <e1> TIKOSYN </e1>  does not affect the pharmacokinetics or pharmacodynamics of  <e2> warfarin </e2> , or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.
false	Concomitant medications were grouped as  <e1> ACE inhibitors </e1> , oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein,  <e2> nitrates </e2> , sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas,  <e1> loop diuretics </e1> , potassium sparing diuretics,  <e2> thiazide diuretics </e2> , substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
mechanism	Blood levels of hydrodolasetron increased 24% when  <e1> dolasetron </e1>  was coadministered with  <e2> cimetidine </e2>  (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
false	The potential for clinically significant drug-drug interactions posed by  <e1> dolasetron </e1>  and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because  <e2> hydrodolasetron </e2>  is eliminated by multiple routes.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin,  <e1> glyburide </e1> , ranitidine,  <e2> omeprazole </e2> , hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	In patients taking furosemide, nifedipine,  <e1> diltiazem </e1> ,  <e2> ACE inhibitors </e2> , verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
false	Other Drugs: In healthy volunteers, amlodipine,  <e1> phenytoin </e1> , glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone),  <e2> antacid </e2>  (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin,  <e1> 5-fluorouracil </e1> , doxorubicin,  <e2> cyclophosphamide </e2> ) in four murine models.
false	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors,  <e1> verapamil </e1> ,  <e2> glyburide </e2> , propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
false	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil,  <e1> glyburide </e1> , propranolol, and various chemotherapy agents, no effect was shown on the clearance of  <e2> hydrodolasetron </e2> .
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids,  <e1> diltiazem </e1> , grapefruit juice, nefazadone, norfloxacin, quinine,  <e2> zafirlukast </e2> ) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide,  <e1> ranitidine </e1> ,  <e2> omeprazole </e2> , hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	The potential for clinically significant drug-drug interactions posed by  <e1> dolasetron </e1>  and  <e2> hydrodolasetron </e2>  appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.
false	Inhibitors of this isoenzyme (e.g.,  <e1> macrolide antibiotics </e1> , azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors,  <e2> amiodarone </e2> , cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Inhibitors of this isoenzyme (e.g.,  <e1> macrolide antibiotics </e1> , azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors,  <e2> amiodarone </e2> , cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	The potential for clinically significant drug-drug interactions posed by  <e1> dolasetron </e1>  and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because  <e2> hydrodolasetron </e2>  is eliminated by multiple routes.
false	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors,  <e1> verapamil </e1> , glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of  <e2> hydrodolasetron </e2> .
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin,  <e1> glyburide </e1> , ranitidine,  <e2> omeprazole </e2> , hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
effect	The concomitant use of  <e1> vasopressor </e1> s, vasoconstricting agents (such as ergonovine) and some  <e2> oxytocic drugs </e2>  may result in severe hypertension.
false	Cardiac effects of dopamine are antagonized by  <e1> beta-adrenergic blocking agents </e1> , such as  <e2> propranolol </e2>  and metoprolol.
false	Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of  <e1> dopamine HCl </e1>  should receive initial doses of  <e2> dopamine HCl </e2>  no greater than one-tenth (1/10) of the usual dose.
advise	Patients who have been treated with  <e1> MAO inhibitors </e1>  within two to three weeks prior to the administration of  <e2> dopamine HCl </e2>  should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.
false	Cardiac effects of dopamine are antagonized by  <e1> beta-adrenergic blocking agents </e1> , such as propranolol and  <e2> metoprolol </e2> .
false	Butyrophenones (such as  <e1> haloperidol </e1> ) and  <e2> phenothiazines </e2>  can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
effect	It has been reported that results of studies in animals indicate that  <e1> dopamine </e1> -induced ventricular arrhythmias during anesthesia can be reversed by  <e2> propranolol </e2> .
effect	Butyrophenones (such as  <e1> haloperidol </e1> ) and phenothiazines can suppress the  <e2> dopamine </e2> rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.
false	Dopamine-induced renal and mesenteric vasodilation is not antagonized by either alpha- or  <e1> beta-a <e2> drenergic blocking agents </e1>  </e2> .
false	Clinical trials have indicated that  <e1> Pulmozyme </e1>  can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral  <e2> antibiotics </e2> , bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.
false	Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled  <e1> corticosteroids </e1> , and  <e2> analgesics </e2> .
false	Clinical trials have indicated that  <e1> Pulmozyme </e1>  can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and  <e2> analgesics </e2> .
false	Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics,  <e1> bronchodilators </e1> , enzyme supplements, vitamins, oral or inhaled  <e2> corticosteroids </e2> , and analgesics.
false	Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral  <e1> carbonic anhydrase inhibitors </e1>  and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose  <e2> salicylate </e2>  therapy).
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> NUROMAX </e1>  include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics,  <e1> procainamide </e1> , and  <e2> quinidine </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides,  <e2> tetracyclines </e2> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts,  <e1> lithium </e1> , local anesthetics, procainamide, and  <e2> quinidine </e2> .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> NUROMAX </e1>  include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin,  <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins,  <e1> lincomycin </e1> , clindamycin,  <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin,  <e1> colistin </e1> , and sodium colistimethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e1> sodium colistimethate </e1> ), magnesium salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e1> clindamycin </e1> ,  <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin,  <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e1> clindamycin </e1> , colistin, and sodium colistimethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts,  <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate),  <e1> magnesium </e1>  salts,  <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins,  <e1> lincomycin </e1> , clindamycin, colistin, and  <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g.,  <e1> aminoglycosides </e1> ,  <e2> tetracyclines </e2> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral  <e1> carbonic anhydrase inhibitors </e1>  and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose  <e2> salicylate </e2>  therapy).
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e1> clindamycin </e1> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain  <e1> antibiotics </e1>  (e. g.,  <e2> aminoglycosides </e2> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g.,  <e1> aminoglycosides </e1> , tetracyclines,  <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines,  <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> NUROMAX </e1>  include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g.,  <e1> aminoglycosides </e1> ,  <e2> tetracyclines </e2> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
effect	Administration of  <e1> doxapram </e1>  to patients who are receiving  <e2> sympathomimetic </e2>  or monoamine oxidase inhibiting drugs may result in an additive pressor effect .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e1> sodium colistimethate </e1> ), magnesium salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain  <e1> antibiotics </e1>  (e. g.,  <e2> aminoglycosides </e2> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e1> clindamycin </e1> ,  <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines,  <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	 <e1> Analgesic </e1> /anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen,  <e2> indomethacin </e2> ).
false	 <e1> Analgesic </e1> / <e2> anti-inflammatory </e2>  (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin).
false	 <e1> Antibiotics </e1>  (e.g., erythromycin, trimethoprim and sulfamethoxazole,  <e2> amoxicillin </e2> ).
false	Cardiovascular agents (e.g.,  <e1> atenolol </e1> , hydrochlorothiazide,  <e2> propranolol </e2> ).
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e1> sodium colistimethate </e1> ), magnesium salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine.
false	Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving  <e1> thiazide diuretics </e1> , beta-blocking agents, and  <e2> nonsteroidal anti-inflammatory drugs </e2> .
false	 <e1> Antibiotics </e1>  (e.g., erythromycin,  <e2> trimethoprim </e2>  and sulfamethoxazole, amoxicillin).
false	Analgesic/ <e1> anti-inflammatory </e1>  (e.g., acetaminophen, aspirin, codeine and codeine combinations,  <e2> ibuprofen </e2> , indomethacin).
false	 <e1> Sedatives </e1>  and  <e2> tranquilizers </e2>  (e.g., diazepam).
false	Antibiotics (e.g., erythromycin,  <e1> trimethoprim </e1>  and  <e2> sulfamethoxazole </e2> , amoxicillin).
false	Cardiovascular agents (e.g.,  <e1> atenolol </e1> ,  <e2> hydrochlorothiazide </e2> , propranolol).
false	In vitro data in human plasma indicate that  <e1> doxazosin mesylate </e1>  has no effect on protein binding of digoxin,  <e2> warfarin </e2> , phenytoin or indomethacin.
false	In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin,  <e1> warfarin </e1> ,  <e2> phenytoin </e2>  or indomethacin.
false	 <e1> Sedatives </e1>  and tranquilizers (e.g.,  <e2> diazepam </e2> ).
false	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the  <e1> Type 1C antiarrhythmics </e1>  propafenone and  <e2> flecainide </e2> ).
false	 <e1> MAO Inhibitors </e1> : Serious side effects and even death have been reported following the concomitant use of certain drugs with  <e2> MAO inhibitors </e2> .
false	The extent to which  <e1> SSRI </e1> -TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the  <e2> SSRI </e2>  involved.
false	cimetidine) and many that are substrates for P450 2D6 (many other  <e1> antidepressants </e1> , phenothiazines, and the Type 1C antiarrhythmics  <e2> propafenone </e2>  and flecainide).
false	Cardiovascular agents (e.g.,  <e1> atenolol </e1> , hydrochlorothiazide,  <e2> propranolol </e2> ).
false	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram,  <e1> escitalopram </e1> , fluoxetine,  <e2> sertraline </e2> , and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
false	Antibiotics (e.g., erythromycin,  <e1> trimethoprim </e1>  and  <e2> sulfamethoxazole </e2> , amoxicillin).
false	Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving  <e1> thiazide diuretics </e1> , beta-blocking agents, and  <e2> nonsteroidal anti-inflammatory drugs </e2> .
effect	Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of  <e1> tricyclic antidepressant </e1>  when  <e2> cimetidine </e2>  therapy is initiated.
false	While all the selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ), e.g., citalopram, escitalopram, fluoxetine, sertraline, and  <e2> paroxetine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	 <e1> Sedatives </e1>  and  <e2> tranquilizers </e2>  (e.g., diazepam).
false	Concomitant use of  <e1> tricyclic antidepressants </e1>  with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the  <e2> tricyclic antidepressant </e2>  or the other drug.
false	While all the selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ), e.g., citalopram,  <e2> escitalopram </e2> , fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
mechanism	Inhibitors or substrates of CYP2D6 (i.e., quinidine,  <e1> selective serotonin reuptake inhibitors </e1>  [SSRIs]) may increase the plasma concentration of  <e2> doxepin </e2>  when administered concomitantly.
advise	Therefore,  <e1> MAO inhibitors </e1>  should be discontinued at least two weeks prior to the cautious initiation of therapy with  <e2> SINEQUAN </e2> .
false	In vitro data in human plasma indicate that  <e1> doxazosin mesylate </e1>  has no effect on protein binding of digoxin,  <e2> warfarin </e2> , phenytoin or indomethacin.
mechanism	Alcohol: It should be borne in mind that  <e1> alcohol </e1>  ingestion may increase the danger inherent in any intentional or unintentional  <e2> SINEQUAN </e2>  overdosage.
false	While all the selective serotonin reuptake inhibitors (SSRIs), e.g.,  <e1> citalopram </e1> ,  <e2> escitalopram </e2> , fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
false	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the  <e1> Type 1C antiarrhythmics </e1>  propafenone and  <e2> flecainide </e2> ).
false	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram,  <e1> escitalopram </e1> , fluoxetine,  <e2> sertraline </e2> , and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
false	 <e1> Sedatives </e1>  and  <e2> tranquilizers </e2>  (e.g., diazepam).
mechanism	Alcohol: It should be borne in mind that  <e1> alcohol </e1>  ingestion may increase the danger inherent in any intentional or unintentional  <e2> SINEQUAN </e2>  overdosage.
false	 <e1> Barbiturates </e1> , carbamazepine, and  <e2> phenytoin </e2>  decrease the half-life of doxycycline.
false	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram,  <e1> escitalopram </e1> , fluoxetine,  <e2> sertraline </e2> , and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
mechanism	Absorption of  <e1> tetracyclines </e1>  is impaired by antacids containing  <e2> aluminum </e2> , calcium, or magnesium, and iron-containing preparations.
mechanism	 <e1> Barbiturates </e1> , carbamazepine, and phenytoin decrease the half-life of  <e2> doxycycline </e2> .
advise	Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving  <e1> tetracyclines </e1>  in conjunction with  <e2> penicillin </e2> .
false	Absorption of tetracyclines is impaired by antacids containing  <e1> aluminum </e1> , calcium, or magnesium, and  <e2> iron </e2> -containing preparations.
false	Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on  <e1> anticoagulant </e1>  therapy may require downward adjustment of their  <e2> anticoagulant </e2>  dosage.
false	Because  <e1> tetracyclines </e1>  have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their  <e2> anticoagulant </e2>  dosage.
false	Antihistamines may partially counteract the anticoagulation effects of  <e1> heparin </e1>  or  <e2> warfarin </e2> .
mechanism	 <e1> Barbiturates </e1> , carbamazepine, and phenytoin decrease the half-life of  <e2> doxycycline </e2> .
effect	 <e1> Doxylamine </e1>  may enhance the effects of  <e2> epinephrine </e2> .
mechanism	Concurrent administration of  <e1> oxyphenbutazone </e1>  and  <e2> androgens </e2>  may result in elevated serum levels of oxyphenbutazone.
effect	 <e1> Doxylamine </e1>  may enhance the effects of  <e2> epinephrine </e2> .
false	Other CNS depressant drugs (e.g. barbiturates,  <e1> tranquilizers </e1> , opioids and general  <e2> anesthetics </e2> ) have additive or potentiating effects with INAPSINE.
false	Other CNS depressant drugs (e.g. barbiturates, tranquilizers,  <e1> opioids </e1>  and general  <e2> anesthetics </e2> ) have additive or potentiating effects with INAPSINE.
effect	 <e1> Doxylamine </e1>  may enhance the effects of  <e2> epinephrine </e2> .
false	Other CNS depressant drugs (e.g. barbiturates,  <e1> tranquilizers </e1> , opioids and general  <e2> anesthetics </e2> ) have additive or potentiating effects with INAPSINE.
false	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs:  <e1> Alcohol </e1> : When Duloxetine and  <e2> ethanol </e2>  were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.
advise	Therefore, co-administration of  <e1> Duloxetine </e1>  with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline,  <e1> amitriptyline </e1> , and  <e2> imipramine </e2> ), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [ <e1> TCAs </e1> ], such as nortriptyline, amitriptyline, and  <e2> imipramine </e2> ), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [ <e1> TCAs </e1> ], such as nortriptyline, amitriptyline, and imipramine),  <e2> phenothiazines </e2>  and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	However, co-administration of Duloxetine with  <e1> aluminum </e1> - and magnesium-containing antacids (51 mEq) or  <e2> Duloxetine </e2>  with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [ <e1> TCAs </e1> ], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone,  <e2> flecainide </e2> ), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as  <e1> nortriptyline </e1> , amitriptyline, and imipramine), phenothiazines and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide), should be approached with caution.
false	Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of  <e1> thioridazine </e1> ,  <e2> Duloxetine </e2>  and thioridazine should not be co-administered.
false	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and  <e1> ethanol </e1>  were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by  <e2> alcohol </e2> .
false	Plasma  <e1> TCA </e1>  concentrations may need to be monitored and the dose of the  <e2> TCA </e2>  may need to be reduced if a TCA is co-administered with Duloxetine.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and  <e1> imipramine </e1> ), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone,  <e2> flecainide </e2> ), should be approached with caution.
advise	Therefore, co-administration of  <e1> Duloxetine </e1>  with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain  <e2> antidepressants </e2>  (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and  <e1> imipramine </e1> ), phenothiazines and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine),  <e1> phenothiazines </e1>  and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide), should be approached with caution.
false	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When  <e1> Duloxetine </e1>  and ethanol were administered several hours apart so that peak concentrations of each would coincide,  <e2> Duloxetine </e2>  did not increase the impairment of mental and motor skills caused by alcohol.
advise	Therefore, co-administration of  <e1> Duloxetine </e1>  with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and  <e2> imipramine </e2> ), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	However, co-administration of Duloxetine with aluminum- and magnesium-containing  <e1> antacids </e1>  (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of  <e2> duloxetine </e2>  absorption after administration of a 40-mg oral dose.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as  <e1> nortriptyline </e1> ,  <e2> amitriptyline </e2> , and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants ( <e1> tricyclic antidepressants </e1>  [TCAs], such as nortriptyline, amitriptyline, and  <e2> imipramine </e2> ), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or  <e1> Duloxetine </e1>  with famotidine, had no significant effect on the rate or extent of  <e2> duloxetine </e2>  absorption after administration of a 40-mg oral dose.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants ( <e1> tricyclic antidepressants </e1>  [ <e2> TCAs </e2> ], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of  <e1> desipramine </e1> , a CYP2D6 substrate, the AUC of  <e2> desipramine </e2>  increased 3-fold.
false	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When  <e1> Duloxetine </e1>  and ethanol were administered several hours apart so that peak concentrations of each would coincide,  <e2> Duloxetine </e2>  did not increase the impairment of mental and motor skills caused by alcohol.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and  <e1> imipramine </e1> ), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone,  <e2> flecainide </e2> ), should be approached with caution.
false	Synergism between  <e1> xanthine bronchodilators </e1>  (e.g., theophylline),  <e2> ephedrine </e2> , and other sympathomimetic bronchodilators has been reported.
false	Synergism between  <e1> xanthine bronchodilators </e1>  (e.g.,  <e2> theophylline </e2> ), ephedrine, and other sympathomimetic bronchodilators has been reported.
false	However, co-administration of Duloxetine with aluminum- and magnesium-containing  <e1> antacids </e1>  (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of  <e2> duloxetine </e2>  absorption after administration of a 40-mg oral dose.
false	Phospholine Iodide potentiates other  <e1> cholinesterase inhibitors </e1>  such as succinylcholine or organophosphate and carbamate  <e2> insecticide </e2> s.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and  <e1> imipramine </e1> ), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone,  <e2> flecainide </e2> ), should be approached with caution.
effect	 <e1> Phospholine Iodide </e1>  potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate  <e2> insecticide </e2> s.
false	Phospholine Iodide potentiates other  <e1> cholinesterase inhibitors </e1>  such as succinylcholine or organophosphate and carbamate  <e2> insecticide </e2> s.
false	Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7  <e1> Edetate calcium disodium </e1>  interferes with the action of zinc insulin preparations by chelating the  <e2> zinc </e2> . 7
false	Steroids enhance the renal toxicity of  <e1> edetate calcium disodium </e1>  in animals. 7 Edetate calcium disodium interferes with the action of  <e2> zinc insulin </e2>  preparations by chelating the zinc. 7
false	Steroids enhance the renal toxicity of  <e1> edetate calcium disodium </e1>  in animals. 7 Edetate calcium disodium interferes with the action of  <e2> zinc insulin </e2>  preparations by chelating the zinc. 7
advise	Acellular, live and live-attenuated  <e1> vaccines </e1>  should not be administered during  <e2> RAPTIVA </e2>  treatment.
false	Acellular, live and live-attenuated  <e1> v <e2> accines </e1>  </e2>  should not be administered during RAPTIVA treatment.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin,  <e1> cetirizine </e1> , famotidine, fluconazole, lamivudine, lorazepam,  <e2> nelfinavir </e2> , paroxetine, and zidovudine.
false	 <e1> Anti-HIV protease inhibitors </e1> : Saquinavir/ <e2> ritonavir </e2>  combination
advise	A dose increase of lopinavir/ <e1> ritonavir </e1>  to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with  <e2> SUSTIVA </e2> .
false	Drug interaction studies with  <e1> SUSTIVA </e1>  and these imidazole and  <e2> triazole antifungals </e2>  have not been conducted.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  <e1> SUSTIVA </e1>  (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine,  <e2> fluconazole </e2> , lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
false	When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of  <e1> atazanavir </e1>  is 300 mg with  <e2> ritonavir </e2>  100 mg and SUSTIVA 600 mg (all once daily).
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  <e1> SUSTIVA </e1>  (efavirenz) is given with the following:  <e2> aluminum/magnesium hydroxide antacids </e2> , azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine,  <e1> lorazepam </e1> ,  <e2> nelfinavir </e2> , paroxetine, and zidovudine.
mechanism	Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased  <e1> indinavir </e1>  metabolism due to  <e2> SUSTIVA </e2> .
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following:  <e1> aluminum/magnesium hydroxide antacids </e1> , azithromycin, cetirizine, famotidine, fluconazole, lamivudine,  <e2> lorazepam </e2> , nelfinavir, paroxetine, and zidovudine.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  <e1> SUSTIVA </e1>  (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole,  <e2> lamivudine </e2> , lorazepam, nelfinavir, paroxetine, and zidovudine.
false	astemizole  <e1> midazolam </e1> ,  <e2> triazolam </e2>  cisapride ergot derivatives voriconazole
false	Drugs which induce CYP3A4 activity (eg, phenobarbital,  <e1> rifampin </e1> ,  <e2> rifabutin </e2> ) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
false	 <e1> Antifungals </e1> : Itraconazole  <e2> Ketoconazole </e2> 
false	Antihistamines:  <e1> Benzodiazepines </e1>  GI Motility Agents  <e2> Anti-Migraine </e2>  Antifungal
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids,  <e1> azithromycin </e1> , cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir,  <e2> paroxetine </e2> , and zidovudine.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA ( <e1> efavirenz </e1> ) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine,  <e2> famotidine </e2> , fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
false	Drugs which induce CYP3A4 activity (eg,  <e1> phenobarbital </e1> ,  <e2> rifampin </e2> , rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
false	When  <e1> indinavir </e1>  at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when  <e2> indinavir </e2>  (800 mg every 8 hours) was given alone.
false	No dose adjustment of  <e1> SUSTIVA </e1>  is recommended when given with  <e2> clarithromycin </e2> .
false	astemizole midazolam,  <e1> triazolam </e1>  cisapride ergot derivatives  <e2> voriconazole </e2> 
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole,  <e1> lamivudine </e1> ,  <e2> lorazepam </e2> , nelfinavir, paroxetine, and zidovudine.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole,  <e1> lamivudine </e1> , lorazepam, nelfinavir,  <e2> paroxetine </e2> , and zidovudine.
false	A dose increase of  <e1> lopinavir </e1> / <e2> ritonavir </e2>  to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.
false	astemizole  <e1> midazolam </e1> , triazolam cisapride ergot derivatives  <e2> voriconazole </e2> 
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  <e1> SUSTIVA </e1>  (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir,  <e2> paroxetine </e2> , and zidovudine.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine,  <e1> famotidine </e1> , fluconazole, lamivudine, lorazepam, nelfinavir,  <e2> paroxetine </e2> , and zidovudine.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine,  <e1> lorazepam </e1> , nelfinavir,  <e2> paroxetine </e2> , and zidovudine.
false	 <e1> Anticoagulants </e1> :  <e2> Warfarin </e2> 
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  <e1> SUSTIVA </e1>  (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine,  <e2> famotidine </e2> , fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
false	Drug interaction studies with  <e1> SUSTIVA </e1>  and these imidazole and  <e2> triazole antifungals </e2>  have not been conducted.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole,  <e1> lamivudine </e1> ,  <e2> lorazepam </e2> , nelfinavir, paroxetine, and zidovudine.
false	The potential for drug interactions with EMTRIVA has been studied in combination with indinavir,  <e1> stavudine </e1> , famciclovir, and  <e2> tenofovir disoproxil fumarate </e2> .
false	 <e1> Anti-HIV protease inhibitors </e1> : Saquinavir/ <e2> ritonavir </e2>  combination
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin,  <e1> cetirizine </e1> , famotidine, fluconazole, lamivudine, lorazepam,  <e2> nelfinavir </e2> , paroxetine, and zidovudine.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine,  <e1> lorazepam </e1> , nelfinavir,  <e2> paroxetine </e2> , and zidovudine.
false	astemizole  <e1> midazolam </e1> ,  <e2> triazolam </e2>  cisapride ergot derivatives voriconazole
false	 <e1> Potassium-sparing diuretics </e1>  (e.g.,  <e2> spironolactone </e2> , triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
false	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents,  <e1> methyldopa </e1> , nitrates, calcium-blocking agents,  <e2> hydralazine </e2> , prazosin and digoxin without evidence of clinically significant adverse interactions.
false	Other Cardiovascular Agents:  <e1> Enalapril </e1>  and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents,  <e2> hydralazine </e2> , prazosin and digoxin without evidence of clinically significant adverse interactions.
false	Potassium-sparing diuretics (e.g., spironolactone, triamterene, or  <e1> amiloride </e1> ),  <e2> potassium </e2>  supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
effect	Agents Causing Renin Release: The antihypertensive effect of enalapril and  <e1> enalapril </e1>  IV is augmented by  <e2> antihypertensive agents </e2>  that cause renin release (e.g., diuretics).
false	 <e1> Lithium </e1> : Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including  <e2> ACE inhibitors </e2> .
false	Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride),  <e1> potassium </e1>  supplements, or  <e2> potassium </e2> -containing salt substitutes may lead to significant increases in serum potassium.
false	The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with  <e1> enalapril </e1>  or  <e2> enalaprilat </e2> .
false	Other Cardiovascular Agents: Enalapril and  <e1> enalapril </e1>  IV have been used concomitantly with beta adrenergic-blocking agents,  <e2> methyldopa </e2> , nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
false	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa,  <e1> nitrates </e1> , calcium-blocking agents,  <e2> hydralazine </e2> , prazosin and digoxin without evidence of clinically significant adverse interactions.
advise	This interaction should be given consideration in patients taking  <e1> NSAIDs </e1>  concomitantly with  <e2> ACE inhibitors </e2> .
false	Other Cardiovascular Agents:  <e1> Enalapril </e1>  and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa,  <e2> nitrates </e2> , calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
false	The possibility of hypotensive effects with enalapril or  <e1> enalaprilat </e1>  can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with  <e2> enalapril </e2>  or enalaprilat.
false	 <e1> Potassium-sparing diuretics </e1>  (e.g., spironolactone, triamterene, or  <e2> amiloride </e2> ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
false	The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the  <e1> diuretic </e1>  or increasing the salt intake prior to initiation of treatment with  <e2> enalapril </e2>  or enalaprilat.
false	 <e1> Potassium-sparing diuretics </e1>  (e.g., spironolactone, triamterene, or amiloride),  <e2> potassium </e2>  supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
effect	Hypotension: Patients on Diuretic Therapy: Patients on  <e1> diuretics </e1>  and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with  <e2> enalapril </e2>  or enalaprilat.
false	Drug interaction studies with  <e1> SUSTIVA </e1>  and these imidazole and  <e2> triazole antifungals </e2>  have not been conducted.
false	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents,  <e1> methyldopa </e1> ,  <e2> nitrates </e2> , calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
false	If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when  <e1> halothane </e1>  or  <e2> nitrous oxide </e2>  with a balanced technique are used.
false	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents,  <e1> methyldopa </e1> , nitrates, calcium-blocking agents,  <e2> hydralazine </e2> , prazosin and digoxin without evidence of clinically significant adverse interactions.
effect	Hypotension: Patients on Diuretic Therapy: Patients on  <e1> diuretics </e1>  and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with  <e2> enalapril </e2>  or enalaprilat.
false	The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the  <e1> diuretic </e1>  or increasing the salt intake prior to initiation of treatment with  <e2> enalapril </e2>  or enalaprilat.
false	 <e1> Potassium-sparing diuretics </e1>  (e.g.,  <e2> spironolactone </e2> , triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
false	 <e1> Antiretroviral Agents </e1> : No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other  <e2> antiretroviral medication </e2> .
false	Antiretroviral Agents: No drug interactions with other  <e1> antiretroviral medications </e1>  have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other  <e2> antiretroviral medication </e2> .
false	 <e1> Non-steroidal anti-inflammatory agents </e1> : Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug  <e2> fenbufen </e2> .
mechanism	Warfarin: Quinolones, including  <e1> enoxacin </e1> , decrease the clearance of  <e2> R-warfarin </e2> , the less active isomer of racemic warfarin.
false	Sucralfate and  <e1> antacids </e1> :  <e2> Quinolones </e2>  form chelates with metal cations.
false	Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when  <e1> enoxacin </e1>  and  <e2> warfarin </e2>  were coadministered.
false	Therefore, administration of quinolones with  <e1> antacids </e1>  containing calcium,  <e2> magnesium </e2> , or aluminum;
advise	Thus, concomitant administration of  <e1> enoxacin </e1>  and  <e2> bismuth subsalicylate </e2>  should be avoided.
false	Therefore, administration of quinolones with antacids containing calcium,  <e1> magnesium </e1> , or  <e2> aluminum </e2> ;
effect	Caffeine-related adverse effects have occurred in patients consuming  <e1> caffeine </e1>  while on therapy with  <e2> enoxacin </e2> .
false	Warfarin:  <e1> Quinolones </e1> , including  <e2> enoxacin </e2> , decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
mechanism	In a multiple-dose study,  <e1> enoxacin </e1>  caused a dose-related increase in the mean elimination half-life of  <e2> caffeine </e2> , thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.
false	 <e1> Caffeine </e1> :  <e2> Enoxacin </e2>  is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
false	 <e1> Warfarin </e1> : Quinolones, including  <e2> enoxacin </e2> , decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
false	Antacids containing  <e1> aluminum hydroxide </e1>  and  <e2> magnesium hydroxide </e2>  reduce the oral absorption of enoxacin by 75%.
false	Cyclosporine: Elevated serum levels of  <e1> cyclosporine </e1>  have been reported with concomitant use of cyclosporine with other members of the  <e2> quinolone class </e2> .
false	If signs and symptoms suggestive of digoxin toxicity occur when  <e1> enoxacin </e1>  and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust  <e2> digoxin </e2>  doses appropriately.
false	If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and  <e1> digoxin </e1>  are given concomitantly, physicians are advised to obtain serum  <e2> digoxin </e2>  levels and adjust digoxin doses appropriately.
false	 <e1> Cyclosporine </e1> : Elevated serum levels of  <e2> cyclosporine </e2>  have been reported with concomitant use of cyclosporine with other members of the quinolone class.
false	 <e1> Bismuth </e1> : Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased  <e2> enoxacin </e2>  bioavailability by approximately 25%.
false	 <e1> Caffeine </e1> -related adverse effects have occurred in patients consuming  <e2> caffeine </e2>  while on therapy with enoxacin.
false	Therefore, administration of quinolones with  <e1> antacids </e1>  containing calcium, magnesium, or  <e2> aluminum </e2> ;
mechanism	Antacids containing  <e1> aluminum hydroxide </e1>  and magnesium hydroxide reduce the oral absorption of  <e2> enoxacin </e2>  by 75%.
false	These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates,  <e1> NSAIDs </e1>  (including ketorolac tromethamine),  <e2> dipyridamole </e2> , or sulfinpyrazone.
false	Therefore, administration of quinolones with antacids containing calcium,  <e1> magnesium </e1> , or  <e2> aluminum </e2> ;
false	These agents include medications such as:  <e1> anticoagulants </e1> , platelet inhibitors including  <e2> acetylsalicylic acid </e2> , sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.
false	These agents include medications such as:  <e1> anticoagulants </e1> , platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including  <e2> ketorolac tromethamine </e2> ), dipyridamole, or sulfinpyrazone.
false	 <e1> Bismuth </e1> : Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased  <e2> enoxacin </e2>  bioavailability by approximately 25%.
false	If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and  <e1> digoxin </e1>  are given concomitantly, physicians are advised to obtain serum  <e2> digoxin </e2>  levels and adjust digoxin doses appropriately.
false	These agents include medications such as: anticoagulants, platelet inhibitors including  <e1> acetylsalicylic acid </e1> , sali-cylates,  <e2> NSAIDs </e2>  (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.
false	These agents include medications such as: anticoagulants,  <e1> platelet inhibitors </e1>  including  <e2> acetylsalicylic acid </e2> , sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.
false	No interaction with the  <e1> tricyclic antidepressant </e1>  imipramine was shown in a single-dose study with  <e2> entacapone </e2>  without coadministered levodopa/dopa-decarboxylase inhibitor.
false	In vitro studies have shown no binding displacement between  <e1> entacapone </e1>  and other highly bound drugs, such as warfarin, salicylic acid,  <e2> phenylbutazone </e2> , and diazepam.
false	These include  <e1> probenecid </e1> , cholestyramine, and some antibiotics (e.g.  <e2> erythromycin </e2> , rifamipicin, ampicillin and chloramphenicol).
false	These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates,  <e1> NSAIDs </e1>  (including ketorolac tromethamine),  <e2> dipyridamole </e2> , or sulfinpyrazone.
false	These include probenecid,  <e1> cholestyramine </e1> , and some antibiotics (e.g. erythromycin, rifamipicin,  <e2> ampicillin </e2>  and chloramphenicol).
false	No interaction was noted with the MAO-B inhibitor  <e1> selegiline </e1>  in two multiple-dose interaction studies when entacapone was coadministered with a  <e2> levodopa </e2> /dopa decarboxylase inhibitor (n=29).
false	These include probenecid, cholestyramine, and some  <e1> antibiotics </e1>  (e.g. erythromycin, rifamipicin,  <e2> ampicillin </e2>  and chloramphenicol).
false	No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered  <e1> levodopa </e1> / <e2> dopa-decarboxylase inhibitor </e2> .
false	These include  <e1> probenecid </e1> ,  <e2> cholestyramine </e2> , and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).
false	Treatment with  <e1> entacapone </e1>  coadministered with  <e2> levodopa </e2> /dopa decarboxylase inhibitor does not change these effects.
false	No interaction was noted with the  <e1> MAO-B inhibitor </e1>  selegiline in two multiple-dose interaction studies when entacapone was coadministered with a  <e2> levodopa </e2> /dopa decarboxylase inhibitor (n=29).
false	No interaction was noted with the  <e1> MAO-B inhibitor </e1>  selegiline in two multiple-dose interaction studies when entacapone was coadministered with a levodopa/ <e2> dopa decarboxylase inhibitor </e2>  (n=29).
false	No interaction was noted with the  <e1> MAO-B inhibitor </e1>  selegiline in two multiple-dose interaction studies when entacapone was coadministered with a levodopa/ <e2> dopa decarboxylase inhibitor </e2>  (n=29).
false	No interaction was noted with the  <e1> MAO-B inhibitor </e1>  selegiline in two multiple-dose interaction studies when entacapone was coadministered with a  <e2> levodopa </e2> /dopa decarboxylase inhibitor (n=29).
false	These include probenecid,  <e1> cholestyramine </e1> , and some antibiotics (e.g. erythromycin, rifamipicin,  <e2> ampicillin </e2>  and chloramphenicol).
false	Coadministration of  <e1> entecavir </e1>  with  <e2> lamivudine </e2> , adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.
false	Coadministration of entecavir with lamivudine,  <e1> adefovir dipivoxil </e1> ,or  <e2> tenofovir disoproxil fumarate </e2>  did not result in significant drug interactions.
false	No interaction was noted with the  <e1> MAO-B inhibitor </e1>  selegiline in two multiple-dose interaction studies when entacapone was coadministered with a  <e2> levodopa </e2> /dopa decarboxylase inhibitor (n=29).
false	Administration of epinephrine to patients receiving  <e1> cyclopropane </e1>  or halogenated hydrocarbon general anesthetics such as  <e2> halothane </e2>  which sensitize the myocardium, may induce cardiac arrhythmia..
false	 <e1> Epinephrine </e1>  also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of  <e2> sympathomimetic drugs </e2> .
effect	Administration of  <e1> epinephrine </e1>  to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as  <e2> halothane </e2>  which sensitize the myocardium, may induce cardiac arrhythmia..
advise	 <e1> Epinephrine </e1>  also should be used cautiously with other drugs (e.g.,  <e2> digitalis </e2> , glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.
false	 <e1> Epinephrine </e1>  also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of  <e2> sympathomimetic drugs </e2> .
false	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received  <e1> ACE inhibitors </e1>  or  <e2> angiotensin II receptor antagonists </e2>  (ACEI/ARB).
false	Administration of eplerenone with other CYP3A4 inhibitors (e.g.,  <e1> erythromycin </e1>  500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID,  <e2> fluconazole </e2>  200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
false	ACE Inhibitors and  <e1> Angiotensin II Receptor Antagonists </e1>  (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ <e2> ARB </e2> ).
false	In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor  <e1> enalapril </e1>  10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on  <e2> enalapril </e2>  alone to 38%.
false	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or  <e1> angiotensin II receptor antagonists </e1>  ( <e2> ACEI </e2> /ARB).
false	 <e1> ACE Inhibitors </e1>  and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of  <e2> INSPRA </e2>  50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
false	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID,  <e1> fluconazole </e1>  200 mg QD) resulted in increases in Cmax of  <e2> eplerenone </e2>  ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
false	A pharmacokinetic study evaluating the administration of a single dose of  <e1> INSPRA </e1>  100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of  <e2> eplerenone </e2> .
mechanism	Administration of  <e1> eplerenone </e1>  with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD,  <e2> saquinavir </e2>  1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
effect	The administration of other  <e1> potassium-sparing antihypertensives </e1>  with  <e2> NSAIDs </e2>  has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.
advise	Serum lithium levels should be monitored frequently if  <e1> INSPRA </e1>  is administered concomitantly with  <e2> lithium </e2> .
false	Rates of patients with maximum potassium levels  5.5 mEq/L were similar regardless of the use of  <e1> ACEI </e1> / <e2> ARB </e2> .
false	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID,  <e1> verapamil </e1>  240 mg QD,  <e2> saquinavir </e2>  1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
false	ACE Inhibitors and  <e1> Angiotensin II Receptor Antagonists </e1>  (Hypertension)- In clinical studies of patients with hypertension, the addition of  <e2> INSPRA </e2>  50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
false	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving  <e1> INSPRA </e1>  25 to 50 mg also received ACE inhibitors or  <e2> angiotensin II receptor antagonists </e2>  (ACEI/ARB).
false	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID,  <e1> fluconazole </e1>  200 mg QD) resulted in increases in Cmax of  <e2> eplerenone </e2>  ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
false	Administration of eplerenone with other CYP3A4 inhibitors (e.g.,  <e1> erythromycin </e1>  500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID,  <e2> fluconazole </e2>  200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
false	ACE Inhibitors and  <e1> Angiotensin II Receptor Antagonists </e1>  (Hypertension)- In clinical studies of patients with hypertension, the addition of  <e2> INSPRA </e2>  50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
false	In clinical trials, FLOLAN was used with digoxin, diuretics,  <e1> anticoagulants </e1> , oral vasodilators, and supplemental  <e2> oxygen </e2> .In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	ACE Inhibitors and  <e1> Angiotensin II Receptor Antagonists </e1>  (Hypertension)- In clinical studies of patients with hypertension, the addition of  <e2> INSPRA </e2>  50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
false	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for  <e1> furosemide </e1>  (n = 23) and  <e2> digoxin </e2>  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with digoxin,  <e1> diuretics </e1> , anticoagulants, oral  <e2> vasodilators </e2> , and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental  <e1> oxygen </e1> .In a pharmacokinetic substudy in patients with congestive heart failure receiving  <e2> furosemide </e2>  or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	However, patients on digoxin may show elevations of  <e1> digoxin </e1>  concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to  <e2> digoxin </e2>  toxicity.
false	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral  <e1> vasodilators </e1> , and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and  <e2> digoxin </e2>  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with digoxin,  <e1> diuretics </e1> , anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for  <e2> furosemide </e2>  (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or  <e1> digoxin </e1>  in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and  <e2> digoxin </e2>  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with  <e1> digoxin </e1> , diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for  <e2> furosemide </e2>  (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with digoxin, diuretics,  <e1> anticoagulants </e1> , oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or  <e2> digoxin </e2>  in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials,  <e1> FLOLAN </e1>  was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and  <e2> digoxin </e2>  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials,  <e1> FLOLAN </e1>  was used with digoxin, diuretics, anticoagulants, oral  <e2> vasodilators </e2> , and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
effect	When other  <e1> antiplatelet agents </e1>  or anticoagulants are used concomitantly, there is the potential for  <e2> FLOLAN </e2>  to increase the risk of bleeding.
false	 <e1> Eprosartan </e1>  (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic ( <e2> hydrochlorothiazide </e2> ).
false	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental  <e1> oxygen </e1> .In a pharmacokinetic substudy in patients with congestive heart failure receiving  <e2> furosemide </e2>  or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with digoxin, diuretics,  <e1> anticoagulants </e1> , oral vasodilators, and supplemental  <e2> oxygen </e2> .In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	 <e1> Eprosartan </e1>  has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and  <e2> glyburide </e2> .
false	 <e1> Ranitidine </e1>  also has no effect on  <e2> eprosartan </e2>  pharmacokinetics.
false	Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and  <e1> ketoconazole </e1>  and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on  <e2> eprosartan </e2>  pharmacokinetics.
false	Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and  <e1> fluconazole </e1> , potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on  <e2> eprosartan </e2>  pharmacokinetics.
false	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental  <e1> oxygen </e1> .In a pharmacokinetic substudy in patients with congestive heart failure receiving  <e2> furosemide </e2>  or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental  <e1> oxygen </e1> .In a pharmacokinetic substudy in patients with congestive heart failure receiving  <e2> furosemide </e2>  or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
mechanism	 <e1> Mineral oil </e1>  interferes with the absorption of  <e2> fat-soluble vitamins </e2> , including vitamin D preparations.
mechanism	The effects of  <e1> ERGOMAR </e1>  may be potentiated by  <e2> triacetyloleandomycin </e2>  which inhibits the metabolism of ergotamine.
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir,  <e1> saquinavir </e1> ,  <e2> telithromycin </e2> , troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone,  <e1> nelfinavir </e1> ,  <e2> ritonavir </e2> , saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with  <e1> ketoconazole </e1>  and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin ( <e2> TAO </e2> ), and voriconazole .
false	Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine,  <e1> phenytoin </e1> , carbamazepine,  <e2> phenobarbital </e2>  and St. Johns Wort.
advise	Caution should be used when administering or taking  <e1> TARCEVA </e1>  with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone,  <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to,  <e1> atazanavir </e1> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and  <e2> voriconazole </e2>  .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir,  <e1> clarithromycin </e1> , indinavir,  <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir,  <e1> clarithromycin </e1> , indinavir, itraconazole,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with  <e1> ketoconazole </e1>  and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and  <e2> voriconazole </e2>  .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir,  <e1> clarithromycin </e1> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir,  <e2> saquinavir </e2> , telithromycin, troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to,  <e1> atazanavir </e1> , clarithromycin, indinavir, itraconazole, nefazodone,  <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone,  <e1> nelfinavir </e1> , ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and  <e2> voriconazole </e2>  .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir,  <e1> ritonavir </e1> ,  <e2> saquinavir </e2> , telithromycin, troleandomycin (TAO), and voriconazole .
advise	Caution should be used when administering or taking  <e1> TARCEVA </e1>  with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and  <e2> voriconazole </e2>  .
false	Other CYP3A4 inducers include, but are not limited to, rifabutin,  <e1> rifapentine </e1> ,  <e2> phenytoin </e2> , carbamazepine, phenobarbital and St. Johns Wort.
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir,  <e1> saquinavir </e1> , telithromycin,  <e2> troleandomycin </e2>  (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir,  <e1> saquinavir </e1> , telithromycin, troleandomycin ( <e2> TAO </e2> ), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir,  <e1> saquinavir </e1> , telithromycin, troleandomycin (TAO), and  <e2> voriconazole </e2>  .
advise	Caution should be used when administering or taking  <e1> TARCEVA </e1>  with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin,  <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to,  <e1> atazanavir </e1> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin,  <e2> troleandomycin </e2>  (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir,  <e1> clarithromycin </e1> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir,  <e2> telithromycin </e2> , troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir,  <e1> ritonavir </e1> ,  <e2> saquinavir </e2> , telithromycin, troleandomycin (TAO), and voriconazole .
false	Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine,  <e1> phenytoin </e1> , carbamazepine,  <e2> phenobarbital </e2>  and St. Johns Wort.
false	In vitro studies indicate that  <e1> ertapenem </e1>  does not inhibit P-glycoprotein-mediated transport of digoxin or  <e2> vinblastine </e2>  and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
mechanism	When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours),  <e1> probenecid </e1>  competes for active tubular secretion and reduces the renal clearance of  <e2> ertapenem </e2> .
false	In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of  <e1> digoxin </e1>  or vinblastine and that  <e2> ertapenem </e2>  is not a substrate for P-glycoprotein-mediated transport.
false	When ertapenem is co-administered with  <e1> probenecid </e1>  (500 mg p.o. every 6 hours),  <e2> probenecid </e2>  competes for active tubular secretion and reduces the renal clearance of ertapenem.
false	Caution should be used when administering or taking TARCEVA with  <e1> ketoconazole </e1>  and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin ( <e2> TAO </e2> ), and voriconazole .
advise	Caution should be used when administering or taking  <e1> TARCEVA </e1>  with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and  <e2> voriconazole </e2>  .
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride,  <e1> disopyramide </e1> , lovastatin, bromocriptine,  <e2> valproate </e2> , terfenadine, and astemizole.
false	Erythromycin has been reported to decrease the clearance of  <e1> triazolam </e1>  and  <e2> midazolam </e2>  and thus may increase the pharmacologic effect of these benzodiazepines.
effect	 <e1> Erythromycin </e1>  use in patients who are receiving high doses of  <e2> theophylline </e2>  may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
false	There have been reports of interactions of erythromycin with  <e1> carbamazepine </e1> , cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin,  <e2> bromocriptine </e2> , valproate, terfenadine, and astemizole.
false	Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine,  <e1> phenytoin </e1> , carbamazepine,  <e2> phenobarbital </e2>  and St. Johns Wort.
false	There have been reports of interactions of erythromycin with  <e1> carbamazepine </e1> , cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride,  <e2> disopyramide </e2> , lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus,  <e1> hexobarbital </e1> , phenytoin,  <e2> alfentanil </e2> , cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
mechanism	 <e1> Erythromycin </e1>  has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and  <e2> astemizole </e2>  when taken concomitantly.
int	There have been reports of interactions of  <e1> erythromycin </e1>  with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine,  <e2> valproate </e2> , terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine,  <e1> cyclosporine </e1> ,  <e2> tacrolimus </e2> , hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir,  <e1> ritonavir </e1> ,  <e2> saquinavir </e2> , telithromycin, troleandomycin (TAO), and voriconazole .
effect	There have been postmarketing reports of drug interactions when  <e1> erythromycin </e1>  is coadministered with  <e2> cisapride </e2> , resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine,  <e1> valproate </e1> , terfenadine, and  <e2> astemizole </e2> .
mechanism	 <e1> Erythromycin </e1>  has been reported to decrease the clearance of  <e2> triazolam </e2>  and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin,  <e1> bromocriptine </e1> , valproate, terfenadine, and  <e2> astemizole </e2> .
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine,  <e1> valproate </e1> ,  <e2> terfenadine </e2> , and astemizole.
int	There have been reports of interactions of  <e1> erythromycin </e1>  with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate,  <e2> terfenadine </e2> , and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine,  <e1> tacrolimus </e1> , hexobarbital, phenytoin, alfentanil,  <e2> cisapride </e2> , disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin,  <e1> alfentanil </e1> , cisapride,  <e2> disopyramide </e2> , lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital,  <e1> phenytoin </e1> ,  <e2> alfentanil </e2> , cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with  <e1> carbamazepine </e1> , cyclosporine, tacrolimus, hexobarbital, phenytoin,  <e2> alfentanil </e2> , cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine,  <e1> cyclosporine </e1> , tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride,  <e2> disopyramide </e2> , lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride,  <e1> disopyramide </e1> , lovastatin,  <e2> bromocriptine </e2> , valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine,  <e1> tacrolimus </e1> , hexobarbital, phenytoin,  <e2> alfentanil </e2> , cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital,  <e1> phenytoin </e1> , alfentanil, cisapride, disopyramide, lovastatin,  <e2> bromocriptine </e2> , valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine,  <e1> cyclosporine </e1> , tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate,  <e2> terfenadine </e2> , and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital,  <e1> phenytoin </e1> , alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and  <e2> astemizole </e2> .
false	 <e1> Metoprolol </e1>  - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker  <e2> metoprolol </e2>  (given in a single dose of 100 mg).
false	Ritonavir - Combined administration of a single dose of  <e1> ritonavir </e1>  (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either  <e2> ritonavir </e2>  or escitalopram.
false	 <e1> Triazolam </e1>  - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate  <e2> triazolam </e2>  (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.
false	Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine,  <e1> phenytoin </e1> , carbamazepine,  <e2> phenobarbital </e2>  and St. Johns Wort.
false	 <e1> Pimozide </e1>  and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to  <e2> pimozide </e2>  given alone.
false	 <e1> Ritonavir </e1>  - Combined administration of a single dose of  <e2> ritonavir </e2>  (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.
false	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine,  <e1> fluvoxamine </e1> , paroxetine,  <e2> sertraline </e2> , citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and  <e1> lithium </e1>  (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or  <e2> lithium </e2> .
false	In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of  <e1> citalopram </e1> , suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on  <e2> escitalopram </e2>  metabolism.
false	 <e1> Warfarin </e1>  - Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of  <e2> warfarin </e2> , a CYP3A4 substrate.
false	Triazolam - Combined administration of racemic  <e1> citalopram </e1>  (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either  <e2> citalopram </e2>  or triazolam.
false	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an  <e1> NSAID </e1>  or  <e2> aspirin </e2>  potentiated the risk of bleeding.
false	 <e1> Sumatriptan </e1>  - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor ( <e2> SSRI </e2> ) and sumatriptan.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin,  <e1> bromocriptine </e1> , valproate, terfenadine, and  <e2> astemizole </e2> .
false	 <e1> Pimozide </e1>  and  <e2> Celexa </e2>  - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.
false	Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of  <e1> citalopram </e1>  and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or  <e2> digoxin </e2> .
false	 <e1> Sumatriptan </e1>  - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a  <e2> selective serotonin reuptake inhibitor </e2>  (SSRI) and sumatriptan.
false	Lithium - Coadministration of racemic  <e1> citalopram </e1>  (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or  <e2> lithium </e2> .
mechanism	Cimetidine - In subjects who had received 21 days of 40 mg/day racemic  <e1> citalopram </e1> , combined administration of 400 mg/day  <e2> cimetidine </e2>  for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.
false	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine,  <e1> sertraline </e1> ,  <e2> citalopram </e2> , escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	Concomitant Administration with Racemic  <e1> Citalopram </e1>  Citalopram - Since escitalopram is the active isomer of racemic citalopram ( <e2> Celexa </e2> ), the two agents should not be coadministered.
false	Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and  <e1> digoxin </e1>  (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or  <e2> digoxin </e2> .
effect	 <e1> Erythromycin </e1>  use in patients who are receiving high doses of  <e2> theophylline </e2>  may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
false	Digoxin - In subjects who had received 21 days of 40 mg/day racemic  <e1> citalopram </e1> , combined administration of  <e2> citalopram </e2>  and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.
false	Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate  <e1> triazolam </e1>  (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or  <e2> triazolam </e2> .
false	Concomitant Administration with Racemic Citalopram  <e1> Citalopram </e1>  - Since  <e2> escitalopram </e2>  is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
advise	If concomitant treatment with  <e1> sumatriptan </e1>  and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline,  <e2> citalopram </e2> , escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and  <e1> digoxin </e1>  (single dose of 1 mg) did not significantly affect the pharmacokinetics of either  <e2> citalopram </e2>  or digoxin.
advise	Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when  <e1> LEXAPRO </e1>  and  <e2> lithium </e2>  are coadministered.
false	Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day  <e1> cimetidine </e1>  for 8 days resulted in an increase in  <e2> citalopram </e2>  AUC and Cmax of 43% and 39%, respectively.
false	If concomitant treatment with sumatriptan and an  <e1> SSRI </e1>  (e.g., fluoxetine, fluvoxamine, paroxetine,  <e2> sertraline </e2> , citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	 <e1> Alcohol </e1>  - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of  <e2> alcohol </e2>  by patients taking LEXAPRO is not recommended.
false	 <e1> Carbamazepine </e1>  - Combined administration of racemic citalopram (40 mg/day for 14 days) and  <e2> carbamazepine </e2>  (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.
int	There have been reports of interactions of  <e1> erythromycin </e1>  with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine,  <e2> valproate </e2> , terfenadine, and astemizole.
false	In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of  <e1> citalopram </e1> , suggesting that coadministration, with  <e2> escitalopram </e2> , of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.
false	 <e1> Carbamazepine </e1>  - Combined administration of racemic  <e2> citalopram </e2>  (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.
false	Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and  <e1> escitalopram </e1>  (20 mg) did not affect the pharmacokinetics of either  <e2> ritonavir </e2>  or escitalopram.
false	If concomitant treatment with sumatriptan and an  <e1> SSRI </e1>  (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram,  <e2> escitalopram </e2> ) is clinically warranted, appropriate observation of the patient is advised.
false	Racemic  <e1> citalopram </e1>  did not alter the mean AUC or Cmax of  <e2> pimozide </e2> .
false	There have been reports of interactions of erythromycin with carbamazepine,  <e1> cyclosporine </e1> , tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate,  <e2> terfenadine </e2> , and astemizole.
false	 <e1> Carbamazepine </e1>  - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of  <e2> carbamazepine </e2> , a CYP3A4 substrate.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine,  <e1> valproate </e1> ,  <e2> terfenadine </e2> , and astemizole.
advise	If concomitant treatment with  <e1> sumatriptan </e1>  and an SSRI (e.g., fluoxetine, fluvoxamine,  <e2> paroxetine </e2> , sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
mechanism	Ketoconazole - Combined administration of racemic  <e1> citalopram </e1>  (40 mg) and  <e2> ketoconazole </e2>  (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.
false	Although trough  <e1> citalopram </e1>  plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of  <e2> escitalopram </e2>  should be considered if the two drugs are coadministered.
false	 <e1> Theophylline </e1>  - Combined administration of racemic  <e2> citalopram </e2>  (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.
false	Concomitant Administration with Racemic  <e1> Citalopram </e1>  Citalopram - Since escitalopram is the active isomer of racemic citalopram ( <e2> Celexa </e2> ), the two agents should not be coadministered.
false	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an  <e1> NSAID </e1>  or  <e2> aspirin </e2>  potentiated the risk of bleeding.
false	Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and  <e1> lithium </e1>  (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or  <e2> lithium </e2> .
false	 <e1> Carbamazepine </e1>  - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of  <e2> carbamazepine </e2> , a CYP3A4 substrate.
advise	Although the interactions observed in these studies do not appear to be of major clinical importance,  <e1> BREVIBLOC </e1>  should be titrated with caution in patients being treated concurrently with digoxin, morphine,  <e2> succinylcholine </e2>  or warfarin.
false	When intravenous  <e1> morphine </e1>  and  <e2> BREVIBLOC </e2>  were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.
false	 <e1> Theophylline </e1>  - Combined administration of racemic  <e2> citalopram </e2>  (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.
false	 <e1> Ritonavir </e1>  - Combined administration of a single dose of  <e2> ritonavir </e2>  (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.
false	When intravenous morphine and  <e1> BREVIBLOC </e1>  were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of  <e2> morphine </e2> .
false	When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on  <e1> morphine </e1>  blood levels was seen, but  <e2> BREVIBLOC </e2>  steady-state blood levels were increased by 46% in the presence of morphine.
false	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine,  <e1> sertraline </e1> ,  <e2> citalopram </e2> , escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	When digoxin and  <e1> BREVIBLOC </e1>  were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in  <e2> digoxin </e2>  blood levels at some time points.
false	A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of  <e1> BREVIBLOC </e1>  and warfarin does not alter  <e2> warfarin </e2>  plasma levels.
mechanism	 <e1> BREVIBLOC </e1>  concentrations were equivocally higher when given with  <e2> warfarin </e2> , but this is not likely to be clinically important.
false	Concomitant Administration with Racemic Citalopram  <e1> Citalopram </e1>  - Since  <e2> escitalopram </e2>  is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
advise	Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when  <e1> LEXAPRO </e1>  and  <e2> lithium </e2>  are coadministered.
false	If concomitant treatment with sumatriptan and an  <e1> SSRI </e1>  (e.g., fluoxetine, fluvoxamine, paroxetine,  <e2> sertraline </e2> , citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	The effect of  <e1> BREVIBLOC </e1>  on the duration of  <e2> succinylcholine </e2> -induced neuromuscular blockade was studied in patients undergoing surgery.
false	When digoxin and  <e1> BREVIBLOC </e1>  were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in  <e2> digoxin </e2>  blood levels at some time points.
false	Coadministration of oral  <e1> contraceptives </e1> ,  <e2> diazepam </e2> , phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.
false	Drug interaction studies have shown that  <e1> esomeprazole </e1>  does not have any clinically significant interactions with phenytoin,  <e2> warfarin </e2> , quinidine, clarithromycin or amoxicillin.
false	When intravenous morphine and  <e1> BREVIBLOC </e1>  were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of  <e2> morphine </e2> .
false	Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant  <e1> warfarin </e1>  and  <e2> esomeprazole </e2>  therapy.
false	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin,  <e1> warfarin </e1> , quinidine, clarithromycin or  <e2> amoxicillin </e2> .
false	Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg,  <e1> ketoconazole </e1> ,  <e2> iron </e2>  salts and digoxin).
false	Drug interaction studies have shown that  <e1> esomeprazole </e1>  does not have any clinically significant interactions with phenytoin, warfarin,  <e2> quinidine </e2> , clarithromycin or amoxicillin.
false	 <e1> Theophylline </e1>  - Combined administration of racemic  <e2> citalopram </e2>  (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.
mechanism	Therefore,  <e1> esomeprazole </e1>  may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg,  <e2> ketoconazole </e2> , iron salts and digoxin).
false	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine,  <e1> clarithromycin </e1>  or  <e2> amoxicillin </e2> .
false	Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg,  <e1> ketoconazole </e1> ,  <e2> iron </e2>  salts and digoxin).
false	 <e1> Estazolam </e1> : Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite  <e2> 4-hydroxy-estazolam </e2>  and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.
false	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin,  <e1> warfarin </e1> , quinidine, clarithromycin or  <e2> amoxicillin </e2> .
false	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A:  <e1> nefazodone </e1> , fluvoxamine, cimetidine,  <e2> diltiazem </e2> , isoniazide, and some macrolide antibiotics.
false	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine,  <e1> cimetidine </e1> , diltiazem, isoniazide, and some  <e2> macrolide antibiotics </e2> .
false	The action of the benzodiazepines may be potentiated by anticonvulsants,  <e1> antihistamines </e1> , alcohol,  <e2> barbiturates </e2> , monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
false	The action of the benzodiazepines may be potentiated by  <e1> anticonvulsants </e1> , antihistamines, alcohol, barbiturates,  <e2> monoamine oxidase inhibitors </e2> , narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
mechanism	The following are examples of drugs known to inhibit the metabolism of other related  <e1> benzodiazepines </e1> , presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine,  <e2> diltiazem </e2> , isoniazide, and some macrolide antibiotics.
false	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine,  <e1> diltiazem </e1> ,  <e2> isoniazide </e2> , and some macrolide antibiotics.
advise	Consequently,  <e1> estazolam </e1>  should be avoided in patients receiving ketoconazole and  <e2> itraconazole </e2> , which are very potent inhibitors of CYP3A.
false	The action of the benzodiazepines may be potentiated by  <e1> anticonvulsants </e1> , antihistamines,  <e2> alcohol </e2> , barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
false	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines,  <e1> alcohol </e1> , barbiturates,  <e2> monoamine oxidase inhibitors </e2> , narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
false	While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine,  <e1> phenytoin </e1> , rifampin, and  <e2> barbiturates </e2> ) would be expected to decrease estazolam concentrations.
false	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol,  <e1> barbiturates </e1> , monoamine oxidase inhibitors,  <e2> narcotics </e2> , phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
false	When intravenous morphine and  <e1> BREVIBLOC </e1>  were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of  <e2> morphine </e2> .
mechanism	The following are examples of drugs known to inhibit the metabolism of other related  <e1> benzodiazepines </e1> , presumably through inhibition of CYP3A:  <e2> nefazodone </e2> , fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
false	Coadministration of oral  <e1> contraceptives </e1> ,  <e2> diazepam </e2> , phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.
effect	The action of the  <e1> benzodiazepines </e1>  may be potentiated by anticonvulsants,  <e2> antihistamines </e2> , alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
mechanism	The following are examples of drugs known to inhibit the metabolism of other related  <e1> benzodiazepines </e1> , presumably through inhibition of CYP3A: nefazodone, fluvoxamine,  <e2> cimetidine </e2> , diltiazem, isoniazide, and some macrolide antibiotics.
false	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine,  <e1> cimetidine </e1> ,  <e2> diltiazem </e2> , isoniazide, and some macrolide antibiotics.
false	The action of the benzodiazepines may be potentiated by  <e1> anticonvulsants </e1> , antihistamines, alcohol, barbiturates,  <e2> monoamine oxidase inhibitors </e2> , narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
false	Coadministration of oral  <e1> contraceptives </e1> ,  <e2> diazepam </e2> , phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.
false	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine,  <e1> cimetidine </e1> , diltiazem, isoniazide, and some  <e2> macrolide antibiotics </e2> .
effect	CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of  <e1> eszopiclone </e1>  and  <e2> ethanol </e2>  0.70 g/kg for up to 4 hours after ethanol administration.
false	Other strong inhibitors of CYP3A4 (e.g.,  <e1> itraconazole </e1> , clarithromycin, nefazodone,  <e2> troleandomycin </e2> , ritonavir, nelfinavir) would be expected to behave similarly.
false	Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin,  <e1> nefazodone </e1> ,  <e2> troleandomycin </e2> , ritonavir, nelfinavir) would be expected to behave similarly.
false	Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin,  <e1> nefazodone </e1> , troleandomycin, ritonavir,  <e2> nelfinavir </e2> ) would be expected to behave similarly.
false	Warfarin:  <e1> Eszopiclone </e1>  3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of  <e2> warfarin </e2> 
false	Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or  <e1> (S)-warfarin </e1> , nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of  <e2> warfarin </e2> 
false	 <e1> Paroxetine </e1> : Coadministration of single doses of  <e2> eszopiclone </e2>  3 mg and paroxetine 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.
false	Paroxetine: Coadministration of single doses of  <e1> eszopiclone </e1>  3 mg and  <e2> paroxetine </e2>  20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.
false	Drugs That Induce CYP3A4 ( <e1> Rifampicin </e1> ) Racemic  <e2> zopiclone </e2>  exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.
false	CNS-Active Drugs  <e1> Ethanol </e1>  An additive effect on psychomotor performance was seen with coadministration of eszopiclone and  <e2> ethanol </e2>  0.70 g/kg for up to 4 hours after ethanol administration.
mechanism	The AUC of  <e1> eszopiclone </e1>  was increased 2.2-fold by coadministration of  <e2> ketoconazole </e2> , a potent inhibitor of CYP3A4, 400 mg daily for 5 days.
effect	Two percent of patients treated concurrently with  <e1> ENBREL </e1>   and  <e2> anakinra </e2>  developed neutropenia (ANC   1 x 109/L).
false	Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or  <e1> (S)-warfarin </e1> , nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of  <e2> warfarin </e2> 
false	Patients in a clinical study who were on established therapy with  <e1> sulfasalazine </e1> , to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or  <e2> sulfasalazine </e2>  alone.
false	Paroxetine: Coadministration of single doses of  <e1> eszopiclone </e1>  3 mg and  <e2> paroxetine </e2>  20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.
false	Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either  <e1> ENBREL </e1>  CI or  <e2> sulfasalazine </e2>  alone.
effect	Therefore, when  <e1> EDECRIN </e1>  and  <e2> non- steroidal anti- inflammatory agents </e2>  are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
false	Therefore, when EDECRIN and  <e1> non- steroidal anti- inflammatory agents </e1>  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  <e2> diuretic </e2>  is obtained.
effect	Two percent of patients treated concurrently with  <e1> ENBREL </e1>   and  <e2> anakinra </e2>  developed neutropenia (ANC   1 x 109/L).
false	In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide  <e1> d <e2> iuretics </e1>  </e2> .
mechanism	 <e1> Lithium </e1>  generally should not be given with  <e2> diuretics </e2>  because they reduce its renal clearance and add a high risk of lithium toxicity.
false	In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and  <e1> thiazide d <e2> iuretics </e1>  </e2> .
effect	Therefore, when  <e1> EDECRIN </e1>  and  <e2> non- steroidal anti- inflammatory agents </e2>  are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
false	It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing  <e1> antacids </e1>  for at least 4 hours following  <e2> ethambutol </e2>  administration.
false	The results of a study of coadministration of ethambutol (50 mg/kg) with an  <e1> aluminum hydroxide </e1>  containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these  <e2> antacid products </e2> .
mechanism	 <e1> Lithium </e1>  generally should not be given with  <e2> diuretics </e2>  because they reduce its renal clearance and add a high risk of lithium toxicity.
false	It is recommended to avoid concurrent administration of  <e1> ethambutol </e1>  with aluminum hydroxide containing antacids for at least 4 hours following  <e2> ethambutol </e2>  administration.
false	The results of a study of coadministration of  <e1> ethambutol </e1>  (50 mg/kg) with an aluminum hydroxide containing  <e2> antacid </e2>  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.
false	The results of a study of coadministration of ethambutol (50 mg/kg) with an  <e1> aluminum hydroxide </e1>  containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  <e2> ethambutol </e2>  of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.
effect	Other depressasnts such as alcohol,  <e1> barbiturates </e1> , and MAOIs may enhance CNS depression when administered with  <e2> ethchlorvynol </e2> .
false	Other depressasnts such as alcohol,  <e1> barbiturates </e1> , and  <e2> MAOIs </e2>  may enhance CNS depression when administered with ethchlorvynol.
false	It is recommended to avoid concurrent administration of  <e1> ethambutol </e1>  with aluminum hydroxide containing antacids for at least 4 hours following  <e2> ethambutol </e2>  administration.
false	It is recommended to avoid concurrent administration of  <e1> ethambutol </e1>  with aluminum hydroxide containing antacids for at least 4 hours following  <e2> ethambutol </e2>  administration.
false	Certain endocrine and liver function tests may be affected by  <e1> estrogen </e1> -containing oral  <e2> contraceptives </e2> .
effect	In particular, convulsions have been reported when  <e1> ethionamide </e1>  is administered with  <e2> cycloserine </e2>  and special care should be taken when the treatment regimen includes both of these drugs.
false	It may also interact with  <e1> amantadine </e1>  or other  <e2> anticholinergic drugs </e2>  or MAOIs, which may intensify the anticholinergic action.
false	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate  <e1> phenytoin </e1>  serum levels and  <e2> valproic acid </e2>  has been reported to both increase and decrease ethosuximide levels).
mechanism	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and  <e1> valproic acid </e1>  has been reported to both increase and decrease  <e2> ethosuximide </e2>  levels).
int	Since  <e1> Zarontin </e1>  (ethosuximide) may interact with concurrently administered  <e2> antiepileptic drugs </e2> , periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
false	Since Zarontin ( <e1> ethosuximide </e1> ) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate  <e2> phenytoin </e2>  serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
false	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate  <e1> phenytoin </e1>  serum levels and valproic acid has been reported to both increase and decrease  <e2> ethosuximide </e2>  levels).
mechanism	Presumably,  <e1> phenytoin </e1>  acts as a stimulator of  <e2> coumarin </e2>  metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.
false	Considerable caution should be exercised if PEGANONE is administered concurrently with  <e1> Phenurone </e1>  ( <e2> phenacemide </e2> ) since paranoid symptoms have been reported during therapy with this combination.
false	Although there is no documentation of such, a similar interaction between  <e1> ethotoin </e1>  and the  <e2> coumarin anticoagulants </e2>  may occur.
effect	Coadministration of  <e1> ethoxzolamide </e1>  with other diuretics,  <e2> amphotericin B </e2> , and corticosteroids may cause hypokalemia.
false	Ethoxzolamide may increase the action of tricyclics,  <e1> amphetamines </e1> , procainamide, and  <e2> quinidine </e2> .
false	It may increase excretion of  <e1> barbiturates </e1> , lithium, and  <e2> ASA </e2>  and may also increase the toxicity of salicylates.
false	Ethoxzolamide may increase the action of tricyclics,  <e1> amphetamines </e1> ,  <e2> procainamide </e2> , and quinidine.
false	Ethoxzolamide may increase the action of  <e1> tricyclics </e1> , amphetamines,  <e2> procainamide </e2> , and quinidine.
effect	 <e1> Ethoxzolamide </e1>  may increase the action of tricyclics,  <e2> amphetamines </e2> , procainamide, and quinidine.
false	 <e1> Prednisolone </e1> :  <e2> Ethinyl estradiol </e2>  may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.
mechanism	 <e1> Indinavir </e1>  has been shown to increase plasma levels of  <e2> combination hormonal contraceptives </e2> .
false	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some  <e1> benzodiazepines </e1>  (alprazolam, chlordiazepoxide,  <e2> diazepam </e2> ) and increase the clearance of others (lorazepam, oxazepam, temazepam).
false	 <e1> Protease inhibitors </e1> : Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of  <e2> combination hormonal contraceptives </e2> ;
effect	 <e1> Ethoxzolamide </e1>  may increase the action of tricyclics,  <e2> amphetamines </e2> , procainamide, and quinidine.
false	 <e1> Anticonvulsants </e1>  ( <e2> carbamazepine </e2> , felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some  <e1> benzodiazepines </e1>  (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam,  <e2> temazepam </e2> ).
false	It may increase excretion of  <e1> barbiturates </e1> , lithium, and  <e2> ASA </e2>  and may also increase the toxicity of salicylates.
false	Example inducers include aminoglutethimide, carbamazepine, nafcillin,  <e1> nevirapine </e1> , phenobarbital,  <e2> phenytoin </e2> , and rifamycins.
mechanism	Tricyclic antidepressants (amitriptyline,  <e1> imipramine </e1> , nortriptyline): Metabolism may be inhibited by  <e2> combination hormonal contraceptives </e2> , increasing plasma levels of antidepressant;
false	 <e1> Tricyclic antidepressants </e1>  (amitriptyline,  <e2> imipramine </e2> , nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
false	 <e1> Theophylline </e1> : Ethinyl estradiol may inhibit the metabolism of  <e2> theophylline </e2> , leading to increased plasma concentrations.
false	Anticonvulsants (carbamazepine, felbamate,  <e1> phenobarbital </e1> ,  <e2> phenytoin </e2> , topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	Antibiotics (ampicillin,  <e1> tetracycline </e1> ): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of  <e2> synthetic steroids </e2> .
false	 <e1> Tricyclic antidepressants </e1>  ( <e2> amitriptyline </e2> , imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
mechanism	Anticonvulsants ( <e1> carbamazepine </e1> , felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of  <e2> ethinyl estradiol </e2>  and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	 <e1> Tricyclic antidepressants </e1>  (amitriptyline, imipramine,  <e2> nortriptyline </e2> ): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
false	Rifampin: Rifampin increases the metabolism of  <e1> ethinyl estradiol </e1>  and some  <e2> progestins </e2>  (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
mechanism	Griseofulvin:  <e1> Griseofulvin </e1>  may induce the metabolism of  <e2> combination hormonal contraceptives </e2>  causing menstrual changes;
false	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines ( <e1> alprazolam </e1> , chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam,  <e2> temazepam </e2> ).
mechanism	 <e1> Anticonvulsants </e1>  (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some  <e2> progestins </e2> , leading to possible decrease in contraceptive effectiveness.
false	Tricyclic antidepressants ( <e1> amitriptyline </e1> ,  <e2> imipramine </e2> , nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
false	Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some  <e1> progestins </e1>  ( <e2> norethindrone </e2> ) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
mechanism	Morphine: Combination  <e1> hormonal contraceptives </e1>  may increase the clearance of  <e2> morphine </e2> .
false	 <e1> Theophylline </e1> :  <e2> Ethinyl estradiol </e2>  may inhibit the metabolism of theophylline, leading to increased plasma concentrations.
false	 <e1> Tricyclic antidepressants </e1>  (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of  <e2> antidepressant </e2> ;
false	Example inducers include aminoglutethimide,  <e1> carbamazepine </e1> , nafcillin, nevirapine, phenobarbital, phenytoin, and  <e2> rifamycins </e2> .
mechanism	Protease inhibitors: Amprenavir, lopinavir,  <e1> nelfinavir </e1> , and ritonavir have been shown to decrease plasma levels of  <e2> combination hormonal contraceptives </e2> ;
mechanism	Benzodiazepines: Combination  <e1> hormonal contraceptives </e1>  may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam,  <e2> temazepam </e2> ).
false	Antibiotics (ampicillin,  <e1> tetracycline </e1> ): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these  <e2> antibiotics </e2>  on plasma concentrations of synthetic steroids.
mechanism	Combination  <e1> hormonal contraceptives </e1>  may also decrease the plasma concentration of  <e2> acetaminophen </e2> .
false	Anticonvulsants ( <e1> carbamazepine </e1> , felbamate, phenobarbital,  <e2> phenytoin </e2> , topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	 <e1> Benzodiazepines </e1> : Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam,  <e2> oxazepam </e2> , temazepam).
false	 <e1> Protease inhibitors </e1> : Amprenavir,  <e2> lopinavir </e2> , nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
false	Anticonvulsants ( <e1> carbamazepine </e1> ,  <e2> felbamate </e2> , phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	 <e1> Antibiotics </e1>  (ampicillin,  <e2> tetracycline </e2> ): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.
false	Example inducers include aminoglutethimide, carbamazepine, nafcillin,  <e1> nevirapine </e1> ,  <e2> phenobarbital </e2> , phenytoin, and rifamycins.
mechanism	Prednisolone:  <e1> Ethinyl estradiol </e1>  may inhibit the metabolism of  <e2> prednisolone </e2> , leading to increased plasma concentrations.
false	Example inducers include  <e1> aminoglutethimide </e1> , carbamazepine,  <e2> nafcillin </e2> , nevirapine, phenobarbital, phenytoin, and rifamycins.
false	Protease inhibitors:  <e1> Amprenavir </e1> , lopinavir,  <e2> nelfinavir </e2> , and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
false	 <e1> Antibiotics </e1>  (ampicillin,  <e2> tetracycline </e2> ): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.
mechanism	Benzodiazepines: Combination  <e1> hormonal contraceptives </e1>  may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam,  <e2> temazepam </e2> ).
false	Anticonvulsants ( <e1> carbamazepine </e1> , felbamate, phenobarbital,  <e2> phenytoin </e2> , topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	Antibiotics (ampicillin,  <e1> tetracycline </e1> ): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these  <e2> antibiotics </e2>  on plasma concentrations of synthetic steroids.
false	 <e1> Tricyclic antidepressants </e1>  (amitriptyline, imipramine,  <e2> nortriptyline </e2> ): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
false	Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some  <e1> progestins </e1>  ( <e2> norethindrone </e2> ) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
mechanism	 <e1> Anticonvulsants </e1>  (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some  <e2> progestins </e2> , leading to possible decrease in contraceptive effectiveness.
effect	There have been isolated reports of patients experiencing increases in their prothrombin times when  <e1> etidronate </e1>  was added to  <e2> warfarin </e2>  therapy.
false	Example inducers include aminoglutethimide, carbamazepine, nafcillin,  <e1> nevirapine </e1> ,  <e2> phenobarbital </e2> , phenytoin, and rifamycins.
effect	ACE-inhibitors Reports suggest that  <e1> NSAIDs </e1>  may diminish the antihypertensive effect of  <e2> ACE-inhibitors </e2> .
false	 <e1> Antibiotics </e1>  (ampicillin,  <e2> tetracycline </e2> ): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.
false	Anticonvulsants ( <e1> carbamazepine </e1> , felbamate, phenobarbital,  <e2> phenytoin </e2> , topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
mechanism	Cyclosporine, Digoxin, Methotrexate  <e1> Lodine </e1> , like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine,  <e2> digoxin </e2> , methotrexate, and increased toxicity.
false	Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine,  <e1> digoxin </e1> ,  <e2> methotrexate </e2> , and increased toxicity.
false	 <e1> Aspirin </e1> : When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free  <e2> etodolac </e2>  is not altered.
false	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and  <e1> Lodine </e1>   (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free  <e2> warfarin </e2> .
false	 <e1> Lithium </e1> : NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal  <e2> lithium </e2>  clearance.
false	Lithium: NSAIDs have produced an elevation of plasma  <e1> lithium </e1>  levels and a reduction in renal  <e2> lithium </e2>  clearance.
false	 <e1> Phenytoin </e1> : Etodolac has no apparent pharmacokinetic interaction when administered with  <e2> phenytoin </e2> .
effect	There have been isolated reports of patients experiencing increases in their prothrombin times when  <e1> etidronate </e1>  was added to  <e2> warfarin </e2>  therapy.
false	 <e1> Antacids </e1> : The concomitant administration of antacids has no apparent effect on the extent of absorption of  <e2> Lodine </e2> .
false	Short-term pharmacokinetic studies have demonstrated that concomitant administration of  <e1> warfarin </e1>  and Lodine  (etodolac capsules and tablets) results in reduced protein binding of  <e2> warfarin </e2> , but there was no change in the clearance of free warfarin.
mechanism	Phenylbutazone:  <e1> Phenylbutazone </e1>  causes increase (by about 80%) in the free fraction of  <e2> etodolac </e2> .
false	Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of  <e1> cyclosporine </e1> ,  <e2> digoxin </e2> , methotrexate, and increased toxicity.
false	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  ( <e1> etodolac </e1>  capsules and tablets) results in reduced protein binding of  <e2> warfarin </e2> , but there was no change in the clearance of free warfarin.
effect	ACE-inhibitors Reports suggest that  <e1> NSAIDs </e1>  may diminish the antihypertensive effect of  <e2> ACE-inhibitors </e2> .
false	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  ( <e1> etodolac </e1>  capsules and tablets) results in reduced protein binding of  <e2> warfarin </e2> , but there was no change in the clearance of free warfarin.
false	 <e1> Lithium </e1> : NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal  <e2> lithium </e2>  clearance.
false	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and  <e1> Lodine </e1>   (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free  <e2> warfarin </e2> .
mechanism	Phenylbutazone:  <e1> Phenylbutazone </e1>  causes increase (by about 80%) in the free fraction of  <e2> etodolac </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e2> Trileptal </e2> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin,  <e2> Phenobarbital </e2> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal,  <e2> Topamax </e2> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e1> clofibrate </e1>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e2> Fortovase </e2> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e1> Viracept </e1> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e2> Lipitor </e2> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e1> Sandimmune </e1> ), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e1> Kadian </e1> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e1> Sandimmune </e1> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e2> Nizoral </e2> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e1> Invirase </e1> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e2> Nizoral </e2> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e1> Nizoral </e1> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e2> Tegretol </e2> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> , Nizoral, Sporanox), atorvastatin (Lipitor),  <e2> clofibrate </e2>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e1> Nizoral </e1> , Sporanox), atorvastatin ( <e2> Lipitor </e2> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e2> Atromid-S </e2> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e1> Neoral </e1> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e2> Atromid-S </e2> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e2> Norvir </e2> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e1> Norvir </e1> , Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e1> Agenerase </e1> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e2> clofibrate </e2>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e2> Fortovase </e2> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e1> Invirase </e1> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral,  <e1> Sporanox </e1> ), atorvastatin (Lipitor),  <e2> clofibrate </e2>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e1> MS Contin </e1> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e1> Nizoral </e1> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> ,  <e2> Tegretol </e2> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline,  <e2> anticonvulsants </e2>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e2> Topamax </e2> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e1> Agenerase </e1> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e2> Dilantin </e2> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e2> Gris-PEG </e2> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	 <e1> Lithium </e1> : NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal  <e2> lithium </e2>  clearance.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e2> Lipitor </e2> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e2> Lipitor </e2> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen ( <e2> Tylenol </e2> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e1> Agenerase </e1> , Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e1> Agenerase </e1> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e2> Fortovase </e2> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e1> Nizoral </e1> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants ( <e2> Dilantin </e2> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> ,  <e2> Nizoral </e2> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e1> rifadin </e1>  (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e1> Neoral </e1> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e1> Invirase </e1> , Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor),  <e2> clofibrate </e2>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as  <e2> ampicillin </e2>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e1> Crixivan </e1> , Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol), antifungals ( <e2> Gris-PEG </e2> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e2> Topamax </e2> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> ,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e2> atorvastatin </e2>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e1> Sandimmune </e1> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e1> Invirase </e1> , Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral,  <e2> Sporanox </e2> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e1> Crixivan </e1> , Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e1> Lipitor </e1> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e1> Prelone </e1> ), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e2> Norvir </e2> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e2> Fortovase </e2> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  ( <e2> Gris-PEG </e2> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e2> Felbatol </e2> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e1> Neoral </e1> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e2> antifungals </e2>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e1> Lipitor </e1> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e2> Norvir </e2> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e2> Lipitor </e2> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e1> Nizoral </e1> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e1> morphine </e1>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e1> prednisolone </e1>  ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e2> clofibrate </e2>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral,  <e2> Sporanox </e2> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral,  <e2> Sporanox </e2> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e1> morphine </e1>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e2> atorvastatin </e2>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e2> Lipitor </e2> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e1> Kaletra </e1> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e1> Lipitor </e1> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e2> Crixivan </e2> , Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e2> Gris-PEG </e2> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral,  <e2> Sandimmune </e2> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e2> Atromid-S </e2> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e2> anticonvulsants </e2>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e1> Lipitor </e1> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral,  <e1> Sporanox </e1> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e2> Fortovase </e2> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e1> MS Contin </e1> ), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e1> Viracept </e1> ), morphine (Astramorph, Kadian, MS Contin),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e1> Nizoral </e1> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e2> Gris-PEG </e2> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e1> Invirase </e1> , Kaletra, Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol),  <e2> antifungals </e2>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e1> Kaletra </e1> , Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e1> Nizoral </e1> , Sporanox), atorvastatin (Lipitor), clofibrate ( <e2> Atromid-S </e2> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e1> Agenerase </e1> , Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e1> clofibrate </e1>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e2> Norvir </e2> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e1> Neoral </e1> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e2> Norvir </e2> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e1> Nizoral </e1> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e1> Agenerase </e1> ,  <e2> Crixivan </e2> , Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e2> Crixivan </e2> , Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral,  <e1> Sporanox </e1> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e2> Lipitor </e2> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e2> Tegretol </e2> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e1> phenylbutazone </e1> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra,  <e2> Norvir </e2> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e2> Sandimmune </e2> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e1> clofibrate </e1>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e2> Gris-PEG </e2> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e1> Crixivan </e1> , Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e1> Neoral </e1> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e1> clofibrate </e1>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e2> antifungals </e2>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor),  <e2> clofibrate </e2>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> , Nizoral, Sporanox), atorvastatin (Lipitor),  <e2> clofibrate </e2>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in  <e1> etoposide </e1>  exposure with a 38% decrease in total body clearance of etoposide compared to  <e2> etoposide </e2>  alone.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e1> Neoral </e1> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e2> Atromid-S </e2> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e1> Crixivan </e1> , Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in  <e1> etoposide </e1>  exposure with a 38% decrease in total body clearance of  <e2> etoposide </e2>  compared to etoposide alone.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e2> Topamax </e2> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e1> Lipitor </e1> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e1> morphine </e1>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral  <e1> etoposide </e1>  has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of  <e2> etoposide </e2>  compared to etoposide alone.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e1> MS Contin </e1> ), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as  <e2> ampicillin </e2>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in  <e1> etoposide </e1>  exposure with a 38% decrease in total body clearance of etoposide compared to  <e2> etoposide </e2>  alone.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e2> Atromid-S </e2> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e2> Topamax </e2> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral  <e1> etoposide </e1>  has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of  <e2> etoposide </e2>  compared to etoposide alone.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
mechanism	Co-medications that induce CYP 3A4 (e.g.,  <e1> rifampicin </e1> , phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to  <e2> exemestane </e2> .
false	Co-medications that induce CYP 3A4 (e.g.,  <e1> rifampicin </e1> , phenytoin, carbamazepine,  <e2> phenobarbital </e2> , or St. John s wort) may significantly decrease exposure to exemestane.
false	Co-medications that induce CYP 3A4 (e.g., rifampicin,  <e1> phenytoin </e1> , carbamazepine,  <e2> phenobarbital </e2> , or St. John s wort) may significantly decrease exposure to exemestane.
mechanism	Concurrent use with  <e1> probenecid </e1>  or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of  <e2> penciclovir </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e2> Atromid-S </e2> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Compounds tested in man include warfarin, theophylline, phenytoin, diazepam,  <e1> aminopyrine </e1>  and  <e2> antipyrine </e2> .
false	Compounds tested in man include warfarin, theophylline, phenytoin,  <e1> diazepam </e1> , aminopyrine and  <e2> antipyrine </e2> .
false	Compounds tested in man include warfarin,  <e1> theophylline </e1> , phenytoin, diazepam, aminopyrine and  <e2> antipyrine </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Compounds tested in man include warfarin,  <e1> theophylline </e1> , phenytoin, diazepam, aminopyrine and  <e2> antipyrine </e2> .
false	Effects of Other  <e1> Antiepileptic Drugs </e1>  on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of  <e2> phenytoin </e2>  causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
mechanism	Carbamazepine:  <e1> Carbamazepine </e1>  causes an approximate 50% increase in the clearance of  <e2> Felbatol </e2>   at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
false	Phenobarbital: Coadministration of felbamate with  <e1> phenobarbital </e1>  causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting  <e2> phenobarbital </e2> , the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
false	Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of  <e1> Felbatol </e1>   (felbamate) at steady state and, therefore, the addition of  <e2> phenytoin </e2>  causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
false	 <e1> Valproate </e1> : Available data suggest that there is no significant effect of  <e2> valproate </e2>  on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.
false	Valproate: Available data suggest that there is no significant effect of  <e1> valproate </e1>  on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  ( <e2> felbamate </e2> ) plasma concentrations.
false	Effects of Antacids on Felbatol  The rate and extent of absorption of a 2400 mg dose of  <e1> Felbatol </e1>   as monotherapy given as tablets was not affected when coadministered with  <e2> antacids </e2> .
false	Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of  <e1> Felbatol </e1>   at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of  <e2> Felbatol </e2>   as compared to the same dose of Felbatol  given as monotherapy.
false	In order to maintain  <e1> phenytoin </e1>  levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a  <e2> phenytoin </e2>  dose reduction of approximately 40% was necessary for eight of these 10 subjects.
false	The net effect of these interactions is summarized in the following table:  <e1> AED </e1>  AED  <e2> Felbatol </e2> 
false	Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in  <e1> phenobarbital </e1>  plasma concentrations, In 12 otherwise healthy male volunteers ingesting  <e2> phenobarbital </e2> , the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
false	Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of  <e1> Felbatol </e1>   as compared to the same dose of  <e2> Felbatol </e2>   given as monotherapy.
false	Effects of Felbatol  on Low-Dose  <e1> Combination Oral Contraceptives </e1>  A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of  <e2> felbamate </e2>  from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.
false	Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to  <e1> antiepileptic drugs </e1>  ( <e2> AEDs </e2> ) affects the steady-state plasma concentrations of AEDs.
false	Effects of  <e1> Erythromycin </e1>  on Felbatol  The coadministration of  <e2> erythromycin </e2>  (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.
false	Use in Conjunction with Other  <e1> Antiepileptic Drugs </e1> : The addition of  <e2> Felbatol </e2>   to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.
false	Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  ( <e1> felbamate </e1> ) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of  <e2> Felbatol </e2>   as compared to the same dose of Felbatol  given as monotherapy.
false	 <e1> Valproate </e1> : Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of  <e2> valproate </e2>  is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.
false	Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in  <e1> phenobarbital </e1>  plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin)  <e2> phenobarbital </e2>  concentration was 14.2 micrograms/mL.
false	Specific Effects of Felbatol  on Other  <e1> Antiepileptic Drugs </e1>   <e2> Phenytoin </e2> : Felbatol  causes an increase in steady-state phenytoin plasma concentrations.
false	 <e1> Phenobarbital </e1> : Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting  <e2> phenobarbital </e2> , the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
false	Effects of  <e1> Felbatol </e1>   on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg  <e2> ethinyl estradiol </e2>  and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.
false	Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral  <e1> contraceptive </e1>  regimen containing 30 mg ethinyl estradiol and 75 mg  <e2> gestodene </e2>  for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.
false	Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  ( <e1> felbamate </e1> ) at steady state and, therefore, the addition of  <e2> phenytoin </e2>  causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
false	Carbamazepine: Felbatol  causes a decrease in the steady-state  <e1> carbamazepine </e1>  plasma concentrations and an increase in the steady-state  <e2> carbamazepine epoxide </e2>  plasma concentration.
false	The net effect of these interactions is summarized in the following table: AED  <e1> AED </e1>   <e2> Felbatol </e2> 
false	Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs ( <e1> AEDs </e1> ) affects the steady-state plasma concentrations of  <e2> AEDs </e2> .
false	Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg  <e1> ethinyl estradiol </e1>  and 75 mg  <e2> gestodene </e2>  for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.
false	In four subjects with epilepsy ingesting  <e1> valproate </e1> , the steady-state trough (Cmin)  <e2> valproate </e2>  plasma concentration was 63 16 micrograms/mL.
false	The ratios of the AUCs of unbound valproate to the AUCs of the total  <e1> valproate </e1>  were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of  <e2> Felbatol </e2>  , respectively.
mechanism	Phenobarbital: It appears that  <e1> phenobarbital </e1>  may reduce plasma  <e2> felbamate </e2>  concentrations.
false	Specific Effects of  <e1> Felbatol </e1>   on Other Antiepileptic Drugs  <e2> Phenytoin </e2> : Felbatol  causes an increase in steady-state phenytoin plasma concentrations.
mechanism	Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin:  <e1> Phenytoin </e1>  causes an approximate doubling of the clearance of Felbatol  ( <e2> felbamate </e2> ) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
false	Effects of Other  <e1> Antiepileptic Drugs </e1>  on  <e2> Felbatol </e2>   Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
false	Effects of Felbatol  on Low-Dose  <e1> Combination Oral Contraceptives </e1>  A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral  <e2> contraceptive </e2>  cycles.
false	Digoxin  When given concomitantly with  <e1> PLENDIL </e1>  the pharmacokinetics of  <e2> digoxin </e2>  in patients with heart failure were not significantly altered.
mechanism	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of  <e1> felodipine </e1>  were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg,  <e2> phenytoin </e2> , carbamazepine, or phenobarbital) than in healthy volunteers.
false	In controlled clinical trials, however,  <e1> beta blockers </e1>  including  <e2> metoprolol </e2>  were concurrently administered with felodipine and were well tolerated.
false	Effects of  <e1> Erythromycin </e1>  on Felbatol  The coadministration of  <e2> erythromycin </e2>  (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.
false	 <e1> Anticonvulsants </e1> : In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or  <e2> phenobarbital </e2> ) than in healthy volunteers.
mechanism	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of  <e1> felodipine </e1>  were considerably lower in epileptic patients on long-term  <e2> anticonvulsant </e2>  therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
false	Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with  <e1> felodipine </e1>  may lead to several- fold increases in the plasma levels of  <e2> felodipine </e2> , either due to an increase in bioavailability or due to a decrease in metabolism.
false	Effects of Other  <e1> Antiepileptic Drugs </e1>  on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of  <e2> phenytoin </e2>  causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
false	Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when  <e1> felodipine </e1>  was given concomitantly with indomethacin or  <e2> spironolactone </e2> .
false	The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of felodipine with  <e1> itraconazole </e1>  resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of  <e2> felodipine </e2> .
false	Co-administration of CYP3A4 inhibitors (eg,  <e1> ketoconazole </e1> , itraconazole, erythromycin, grapefruit juice,  <e2> cimetidine </e2> ) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.
false	Compounds tested in man include warfarin,  <e1> theophylline </e1> , phenytoin, diazepam, aminopyrine and  <e2> antipyrine </e2> .
false	The net effect of these interactions is summarized in the following table:  <e1> AED </e1>  AED  <e2> Felbatol </e2> 
false	 <e1> Anticonvulsants </e1> : In a pharmacokinetic study, maximum plasma concentrations of  <e2> felodipine </e2>  were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
false	The ratios of the AUCs of unbound valproate to the AUCs of the total  <e1> valproate </e1>  were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of  <e2> Felbatol </e2>  , respectively.
false	Grapefruit juice Co-administration of  <e1> felodipine </e1>  with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of  <e2> felodipine </e2> .
false	Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to  <e1> antiepileptic drugs </e1>  ( <e2> AEDs </e2> ) affects the steady-state plasma concentrations of AEDs.
false	Co-administration of CYP3A4 inhibitors (eg, ketoconazole,  <e1> itraconazole </e1> , erythromycin, grapefruit juice, cimetidine) with  <e2> felodipine </e2>  may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.
false	 <e1> Anticonvulsants </e1> : In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin,  <e2> carbamazepine </e2> , or phenobarbital) than in healthy volunteers.
false	When given concomitantly with  <e1> felodipine </e1> , the  <e2> tacrolimus </e2>  blood concentration should be followed and the tacrolimus dose may need to be adjusted.
false	 <e1> Anticonvulsants </e1> : In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or  <e2> phenobarbital </e2> ) than in healthy volunteers.
mechanism	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of  <e1> felodipine </e1>  were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg,  <e2> phenytoin </e2> , carbamazepine, or phenobarbital) than in healthy volunteers.
false	Co-administration of CYP3A4 inhibitors (eg,  <e1> ketoconazole </e1> , itraconazole, erythromycin, grapefruit juice,  <e2> cimetidine </e2> ) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.
false	Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to  <e1> antiepileptic drugs </e1>  ( <e2> AEDs </e2> ) affects the steady-state plasma concentrations of AEDs.
false	Grapefruit juice Co-administration of  <e1> felodipine </e1>  with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of  <e2> felodipine </e2> .
false	Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when  <e1> felodipine </e1>  was given concomitantly with indomethacin or  <e2> spironolactone </e2> .
effect	 <e1> Fenfluramine </e1>  may increase slightly the effect of antihypertensive drugs, e.g., guanethidine,  <e2> methyldopa </e2> , reserpine.
false	 <e1> Resins </e1> : Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a  <e2> bile acid binding resin </e2>  to avoid impeding its absorption.
advise	Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN  <e1> COUMARIN ANTICOAGULANTS </e1>  ARE GIVEN IN CONJUNCTION WITH  <e2> TRICOR </e2> .
mechanism	Concomitant administration of fenofibrate (equivalent to 145 mg  <e1> TRICOR </e1> ) with  <e2> atorvastatin </e2>  (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.
false	Concomitant administration of  <e1> fenofibrate </e1>  (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for  <e2> pravastatin </e2>  by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.
false	Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with  <e1> pravastatin </e1>  (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for  <e2> pravastatin </e2>  by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.
false	 <e1> HMG-CoA reductase inhibitors </e1> : The combined use of  <e2> TRICOR </e2>  and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.
false	Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of  <e1> fibrate drugs </e1>  including  <e2> TRICOR </e2> , there is a risk that an interaction will lead to deterioration.
false	Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with  <e1> atorvastatin </e1>  (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in  <e2> atorvastatin </e2>  AUC values in 22 healthy males.
advise	Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN  <e1> COUMARIN ANTICOAGULANTS </e1>  ARE GIVEN IN CONJUNCTION WITH  <e2> TRICOR </e2> .
false	There is limited experience with concomitant  <e1> antihypertensive agents </e1>  such as alpha-blockers,  <e2> calcium channel-blockers </e2> , ACE inhibitors, and diuretics (both thiazide-like and loop).
false	There is limited experience with concomitant antihypertensive agents such as alpha-blockers, calcium channel-blockers,  <e1> ACE inhibitors </e1> , and  <e2> diuretics </e2>  (both thiazide-like and loop).
false	There is limited experience with concomitant antihypertensive agents such as  <e1> alpha-blockers </e1> ,  <e2> calcium channel-blockers </e2> , ACE inhibitors, and diuretics (both thiazide-like and loop).
false	There is limited experience with concomitant antihypertensive agents such as alpha-blockers, calcium channel-blockers, ACE inhibitors, and  <e1> diuretics </e1>  (both  <e2> thiazide </e2> -like and loop).
false	Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of  <e1> fibrate drugs </e1>  including  <e2> TRICOR </e2> , there is a risk that an interaction will lead to deterioration.
false	Because Nalfon has not been shown to produce any additional effect beyond that obtained with  <e1> aspirin </e1>  alone and because aspirin increases the rate of excretion of  <e2> Nalfon </e2> , the concomitant use of Nalfon and salicylates is not recommended.
effect	In patients receiving  <e1> coumarin-type anticoagulants </e1> , the addition of  <e2> Nalfon </e2>  to therapy could prolong the prothrombin time.
false	There is limited experience with concomitant  <e1> antihypertensive agents </e1>  such as alpha-blockers,  <e2> calcium channel-blockers </e2> , ACE inhibitors, and diuretics (both thiazide-like and loop).
false	In patients receiving  <e1> Nalfon </e1>  and a steroid concomitantly, any reduction in  <e2> steroid </e2>  dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.
false	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because  <e1> aspirin </e1>  increases the rate of excretion of Nalfon, the concomitant use of Nalfon and  <e2> salicylates </e2>  is not recommended.
advise	Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN  <e1> COUMARIN ANTICOAGULANTS </e1>  ARE GIVEN IN CONJUNCTION WITH  <e2> TRICOR </e2> .
false	Because  <e1> Nalfon </e1>  has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and  <e2> salicylates </e2>  is not recommended.
false	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because  <e1> aspirin </e1>  increases the rate of excretion of Nalfon, the concomitant use of  <e2> Nalfon </e2>  and salicylates is not recommended.
mechanism	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because  <e1> aspirin </e1>  increases the rate of excretion of  <e2> Nalfon </e2> , the concomitant use of Nalfon and salicylates is not recommended.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics,  <e1> tranquilizers </e1>  (e.g., benzodiazepines), general anesthetics,  <e2> phenothiazines </e2> , skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics,  <e1> phenothiazines </e1> , skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received  <e1> MAOI </e1>  within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with  <e2> opioid analgesics </e2> 
false	The concomitant use of transdermal fentanyl with  <e1> ritonavir </e1>  or other potent 3A4 inhibitors such as ketoconazole,  <e2> itraconazole </e2> , troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
effect	Central Nervous System Depressants: The concomitant use of DURAGESIC  ( <e1> fentanyl </e1>  transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general  <e2> anesthetics </e2> , phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	 <e1> Central Nervous System Depressants </e1> : The concomitant use of  <e2> DURAGESIC </e2>   (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	 <e1> Central Nervous System Depressants </e1> : The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	 <e1> Central Nervous System Depressants </e1> : The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other  <e2> opioids </e2> , sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as  <e1> ketoconazole </e1> , itraconazole,  <e2> troleandomycin </e2> , clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
effect	Central Nervous System Depressants: The concomitant use of DURAGESIC  ( <e1> fentanyl </e1>  transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	In patients receiving  <e1> coumarin-type anticoagulants </e1> , the addition of  <e2> Nalfon </e2>  to therapy could prolong the prothrombin time.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other  <e1> central nervous system depressants </e1> , including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central Nervous System Depressants: The concomitant use of DURAGESIC  ( <e1> fentanyl </e1>  transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines,  <e2> skeletal muscle relaxants </e2> , and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other  <e1> opioids </e1> , sedatives,  <e2> hypnotics </e2> , tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other  <e1> opioids </e1> , sedatives, hypnotics,  <e2> tranquilizers </e2>  (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	 <e1> MAO Inhibitors </e1> : DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with  <e2> opioid analgesics </e2> 
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other  <e1> opioids </e1> , sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics,  <e2> phenothiazines </e2> , skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	 <e1> Central Nervous System Depressants </e1> : The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general  <e2> anesthetics </e2> , phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	 <e1> Central Nervous System Depressants </e1> : The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics,  <e2> phenothiazines </e2> , skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin,  <e1> nelfinavir </e1> , and nefazadone may result in an increase in  <e2> fentanyl </e2>  plasma concentrations.
mechanism	The concomitant use of transdermal  <e1> fentanyl </e1>  with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole,  <e2> troleandomycin </e2> , clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other  <e1> central nervous system depressants </e1> , including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g.,  <e2> benzodiazepines </e2> ), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
mechanism	The concomitant use of transdermal  <e1> fentanyl </e1>  with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin,  <e2> clarithromycin </e2> , nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
false	Central Nervous System Depressants: The concomitant use of  <e1> DURAGESIC </e1>   ( <e2> fentanyl </e2>  transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g.,  <e1> benzodiazepines </e1> ), general anesthetics, phenothiazines, skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because  <e1> aspirin </e1>  increases the rate of excretion of Nalfon, the concomitant use of  <e2> Nalfon </e2>  and salicylates is not recommended.
false	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and  <e1> magnesium </e1>  containing antacid ( <e2> Maalox </e2>  ) decreased fexofenadine AUC by 41% and cmax by 43%.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics,  <e1> tranquilizers </e1>  (e.g., benzodiazepines), general anesthetics,  <e2> phenothiazines </e2> , skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
advise	 <e1> ALLEGRA </e1>  should not be taken closely in time with  <e2> aluminum </e2>  and magnesium containing antacids.
false	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an  <e1> aluminum </e1>  and magnesium containing antacid ( <e2> Maalox </e2>  ) decreased fexofenadine AUC by 41% and cmax by 43%.
false	ALLEGRA should not be taken closely in time with  <e1> aluminum </e1>  and  <e2> magnesium </e2>  containing antacids.
false	In 2 separate studies,  <e1> fexofenadine hydrochloride </e1>  120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or  <e2> ketoconazole </e2>  400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other  <e1> central nervous system depressants </e1> , including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g.,  <e2> benzodiazepines </e2> ), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received  <e1> MAOI </e1>  within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with  <e2> opioid analgesics </e2> 
effect	Central Nervous System Depressants: The concomitant use of DURAGESIC  ( <e1> fentanyl </e1>  transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption,  <e1> ketoconazole </e1>  decreases fexofenadine gastrointestinal secretion, while  <e2> erythromycin </e2>  may also decrease biliary excretion.
false	The concomitant use of transdermal fentanyl with  <e1> ritonavir </e1>  or other potent 3A4 inhibitors such as ketoconazole,  <e2> itraconazole </e2> , troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
mechanism	These studies indicate that  <e1> ketoconazole </e1>  or erythromycin co-administration enhances  <e2> fexofenadine </e2>  gastrointestinal absorption.
false	 <e1> Central Nervous System Depressants </e1> : The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Drug Interactions with  <e1> Antacids </e1>  Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing  <e2> antacid </e2>  (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
false	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid ( <e1> Maalox </e1>  ) decreased  <e2> fexofenadine </e2>  AUC by 41% and cmax by 43%.
false	Drug Interaction with Erythromycin and  <e1> Ketoconazole </e1>   <e2> Fexofenadine </e2>  has been shown to exhibit minimal (ca. 5%) metabolism.
mechanism	However, co  administration of  <e1> fexofenadine hydrochloride </e1>  with either  <e2> ketoconazole </e2>  or erythromycin led to increased plasma concentrations of fexofenadine.
mechanism	These studies indicate that  <e1> ketoconazole </e1>  or erythromycin co-administration enhances  <e2> fexofenadine </e2>  gastrointestinal absorption.
false	Drug Interaction with Erythromycin and  <e1> Ketoconazole </e1>   <e2> Fexofenadine </e2>  has been shown to exhibit minimal (ca. 5%) metabolism.
false	Drug Interactions with  <e1> Antacids </e1>  Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing  <e2> antacid </e2>  (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers,  <e1> calcium-channel blockers </e1> , cardiac nitrates,  <e2> diuretics </e2> , H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen,  <e1> acetylsalicylic acid </e1> , a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers,  <e2> calcium-channel blockers </e2> , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics,  <e1> angiotensin-converting enzyme (ACE) inhibitors </e1> , anticonvulsants, benzodiazepines, beta blockers,  <e2> calcium-channel blockers </e2> , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates,  <e1> diuretics </e1> , H2 antagonists, HMG-CoA reductase inhibitors,  <e2> prostaglandin synthetase inhibitors </e2>  (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed,  <e1> finasteride </e1>  doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists,  <e2> HMG-CoA reductase inhibitors </e2> , prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen,  <e1> acetylsalicylic acid </e1> , a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as  <e2> NSAIDs </e2> ), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	In clinical studies with  <e1> PROPECIA </e1>  ( <e2> finasteride </e2> , 1 mg) in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors,  <e1> anticonvulsants </e1> , benzodiazepines, beta blockers, calcium-channel blockers, cardiac  <e2> nitrates </e2> , diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors,  <e1> prostaglandin synthetase inhibitors </e1>  (also referred to as  <e2> NSAIDs </e2> ), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics,  <e1> H2 antagonists </e1> , HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as  <e2> NSAIDs </e2> ), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Compounds that have been tested in man include  <e1> antipyrine </e1> , digoxin, propranolol, theophylline, and  <e2> warfarin </e2>  and no clinically meaningful interactions were found.
false	Compounds that have been tested in man include antipyrine, digoxin,  <e1> propranolol </e1> ,  <e2> theophylline </e2> , and warfarin and no clinically meaningful interactions were found.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen,  <e1> acetylsalicylic acid </e1> , a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics,  <e2> H2 antagonists </e2> , HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Compounds that have been tested in man include antipyrine, digoxin,  <e1> propranolol </e1> , theophylline, and  <e2> warfarin </e2>  and no clinically meaningful interactions were found.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics,  <e1> angiotensin-converting enzyme (ACE) inhibitors </e1> , anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates,  <e2> diuretics </e2> , H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants,  <e1> benzodiazepines </e1> , beta blockers,  <e2> calcium-channel blockers </e2> , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics,  <e1> angiotensin-converting enzyme (ACE) inhibitors </e1> , anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as  <e2> NSAIDs </e2> ), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen,  <e1> acetylsalicylic acid </e1> , a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors,  <e2> prostaglandin synthetase inhibitors </e2>  (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines,  <e1> beta blockers </e1> , calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as  <e2> NSAIDs </e2> ), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers,  <e1> calcium-channel blockers </e1> , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors,  <e2> prostaglandin synthetase inhibitors </e2>  (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants,  <e1> benzodiazepines </e1> , beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists,  <e2> HMG-CoA reductase inhibitors </e2> , prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers,  <e1> analgesics </e1> , angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers,  <e2> calcium-channel blockers </e2> , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with  <e1> acetaminophen </e1> , acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants,  <e2> benzodiazepines </e2> , beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines,  <e1> beta blockers </e1> , calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors,  <e2> prostaglandin synthetase inhibitors </e2>  (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines,  <e1> beta blockers </e1> , calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists,  <e2> HMG-CoA reductase inhibitors </e2> , prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen,  <e1> acetylsalicylic acid </e1> , a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines,  <e2> beta blockers </e2> , calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac  <e1> nitrates </e1> , diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and  <e2> quinolone anti-infectives </e2>  without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors,  <e1> anticonvulsants </e1> , benzodiazepines, beta blockers, calcium-channel blockers, cardiac  <e2> nitrates </e2> , diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	When  <e1> amiodarone </e1>  is added to flecainide therapy, plasma  <e2> flecainide </e2>  levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.
false	There has been little experience with the coadministration of  <e1> TAMBOCOR </e1>  and either disopyramide or  <e2> verapamil </e2> .
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with  <e1> acetaminophen </e1> , acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants,  <e2> benzodiazepines </e2> , beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines,  <e1> beta blockers </e1> , calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as  <e2> NSAIDs </e2> ), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of  <e1> flecainide </e1>  in patients that are on chronic  <e2> flecainide </e2>  therapy;
false	Other concomitant therapy Although specific interaction studies were not performed,  <e1> finasteride </e1>  doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists,  <e2> HMG-CoA reductase inhibitors </e2> , prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
mechanism	During administration of multiple oral doses of  <e1> TAMBOCOR </e1>  to healthy subjects stabilized on a maintenance dose of  <e2> digoxin </e2> , a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.
false	 <e1> TAMBOCOR </e1>  has been administered to patients receiving digitalis preparations or  <e2> beta-adrenergic blocking agents </e2>  without adverse effects.
effect	The effects of concomitant administration of  <e1> TAMBOCOR </e1>  and  <e2> propranolol </e2>  on the PR interval were less than additive.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen,  <e1> acetylsalicylic acid </e1> , a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers,  <e2> calcium-channel blockers </e2> , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
advise	Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither  <e1> disopyramide </e1>  nor verapamil should be administered concurrently with  <e2> TAMBOCOR </e2>  unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants,  <e1> benzodiazepines </e1> , beta blockers,  <e2> calcium-channel blockers </e2> , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Because both of these drugs have negative inotropic properties and the effects of coadministration with  <e1> TAMBOCOR </e1>  are unknown, neither disopyramide nor verapamil should be administered concurrently with  <e2> TAMBOCOR </e2>  unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
false	During administration of multiple oral doses of  <e1> TAMBOCOR </e1>  to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma  <e2> digoxin </e2>  levels occurred at six hours postdose.
false	Because both of these drugs have negative inotropic properties and the effects of coadministration with  <e1> TAMBOCOR </e1>  are unknown, neither disopyramide nor verapamil should be administered concurrently with  <e2> TAMBOCOR </e2>  unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
false	 <e1> TAMBOCOR </e1>  has been administered to patients receiving digitalis preparations or  <e2> beta-adrenergic blocking agents </e2>  without adverse effects.
false	When  <e1> amiodarone </e1>  is added to flecainide therapy, plasma  <e2> flecainide </e2>  levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.
false	When  <e1> amiodarone </e1>  is added to flecainide therapy, plasma  <e2> flecainide </e2>  levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.
false	 <e1> Amphotericin B </e1>  or  <e2> potassium-depleting diuretics </e2>  (benzothiadiazines and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.
false	 <e1> Antidiabetic drugs </e1>  (oral agents and  <e2> insulin </e2> ) diminished antidiabetic effect.
false	Amphotericin B or  <e1> potassium-depleting diuretics </e1>  ( <e2> benzothiadiazines </e2>  and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.
false	Anabolic steroids (particularly C-17 alkylated  <e1> androgens </e1>  such as oxymetholone, methandrostenolone,  <e2> norethandrolone </e2> , and similar compounds) enhanced tendency toward edema.
false	Rarely  <e1> salicylate </e1>  toxicity may occur in patients who discontinue  <e2> steroids </e2>  after concurrent high-dose aspirin therapy.
false	 <e1> Anabolic steroids </e1>  (particularly C-17 alkylated  <e2> androgens </e2>  such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.
false	When estrogen therapy is initiated, a reduction in  <e1> corticosteroid </e1>  dosage may be required, and increased amounts may be required when  <e2> estrogen </e2>  is terminated.
false	Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially  <e1> cyclic antidepressants </e1> ) may emerge with the reversal of the  <e2> benzodiazepine </e2>  effect by flumazenil.
effect	Although  <e1> ROMAZICON </e1>  exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a  <e2> benzodiazepine </e2>  agonist can give rise to convulsions in epileptic patients.
false	Rarely  <e1> salicylate </e1>  toxicity may occur in patients who discontinue  <e2> steroids </e2>  after concurrent high-dose aspirin therapy.
false	Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about  <e1> benzodiazepine </e1> , alcohol and  <e2> sedative </e2>  use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
false	An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as  <e1> diazepam </e1> ) or large doses of  <e2> short-acting benzodiazepines </e2>  (such as  10 mg of midazolam) have been used.
false	however, no deleterious interactions were seen when ROMAZICON was administered after  <e1> narcotics </e1> , inhalational  <e2> anesthetics </e2> , muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.
false	 <e1> Anabolic steroids </e1>  (particularly C-17 alkylated  <e2> androgens </e2>  such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.
false	Anabolic steroids (particularly C-17 alkylated  <e1> androgens </e1>  such as oxymetholone, methandrostenolone,  <e2> norethandrolone </e2> , and similar compounds) enhanced tendency toward edema.
false	An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as  <e1> diazepam </e1> ) or large doses of  <e2> short-acting benzodiazepines </e2>  (such as  10 mg of midazolam) have been used.
false	Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about  <e1> benzodiazepine </e1> , alcohol and  <e2> sedative </e2>  use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol  <e1> antihistamines </e1>  carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox)  <e2> ketoconazole </e2>  (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole ( <e1> Sporanox </e1> )  <e2> ketoconazole </e2>  (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol  <e1> antihistamines </e1>  carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole ( <e2> Nizoral </e2> ) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other  <e1> antidepressants </e1>  metoprolol antihistamines carbamazepine ( <e2> Tegretol </e2> ) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine ( <e1> Tegretol </e1> ) cimetidine (Tagamet) estrogens  <e2> fluoxetine </e2>  (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants  <e1> metoprolol </e1>  antihistamines carbamazepine ( <e2> Tegretol </e2> ) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Caution should be exercised when taking this medicine certain  <e1> antibiotics </e1> , such as  <e2> erythromycin </e2> , clarithromycin, or azithromycin.
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole ( <e1> Sporanox </e1> ) ketoconazole (Nizoral) levodopa  <e2> lithium </e2>  muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs:  <e1> blood thinner </e1> s (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole ( <e2> Sporanox </e2> ) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines  <e1> carbamazepine </e1>  (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa  <e2> lithium </e2>  muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet)  <e1> estrogens </e1>  fluoxetine ( <e2> Prozac </e2> ) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants  <e1> metoprolol </e1>  antihistamines carbamazepine (Tegretol) cimetidine ( <e2> Tagamet </e2> ) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners ( <e1> Coumadin </e1> ) other antidepressants  <e2> metoprolol </e2>  antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine ( <e1> Tagamet </e1> ) estrogens fluoxetine (Prozac) intraconazole ( <e2> Sporanox </e2> ) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine ( <e1> Tagamet </e1> ) estrogens fluoxetine ( <e2> Prozac </e2> ) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet)  <e1> estrogens </e1>  fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral)  <e2> levodopa </e2>  lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants  <e1> metoprolol </e1>  antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole ( <e2> Sporanox </e2> ) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs:  <e1> blood thinner </e1> s (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox)  <e2> ketoconazole </e2>  (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Caution should be exercised when taking this medicine certain  <e1> antibiotics </e1> , such as erythromycin,  <e2> clarithromycin </e2> , or azithromycin.
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol  <e1> antihistamines </e1>  carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole ( <e2> Sporanox </e2> ) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs:  <e1> blood thinner </e1> s (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine ( <e2> Tagamet </e2> ) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other  <e1> antidepressants </e1>  metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral)  <e2> levodopa </e2>  lithium muscle relaxants birth control pills sleeping pills thyroid medications
advise	Wait 5 weeks after stopping  <e1> escitalopram </e1>  before starting a  <e2> non-selective MAO inhibitor </e2> .
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine ( <e1> Prozac </e1> ) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa  <e2> lithium </e2>  muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet)  <e1> estrogens </e1>  fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa  <e2> lithium </e2>  muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines  <e1> carbamazepine </e1>  (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium  <e2> muscle relaxants </e2>  birth control pills sleeping pills thyroid medications
false	Talk to your doctor if you are taking certain antibiotics such as  <e1> erythromycin </e1> , clarithromycin or  <e2> azithromycin </e2> .
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other  <e1> antidepressants </e1>  metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine ( <e2> Prozac </e2> ) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole ( <e1> Sporanox </e1> ) ketoconazole (Nizoral)  <e2> levodopa </e2>  lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about  <e1> benzodiazepine </e1> , alcohol and  <e2> sedative </e2>  use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine ( <e1> Prozac </e1> ) intraconazole (Sporanox) ketoconazole (Nizoral)  <e2> levodopa </e2>  lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other  <e1> antidepressants </e1>  metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole ( <e2> Nizoral </e2> ) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol  <e1> antihistamines </e1>  carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine ( <e2> Prozac </e2> ) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other  <e1> antidepressants </e1>  metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox)  <e2> ketoconazole </e2>  (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners ( <e1> Coumadin </e1> ) other antidepressants metoprolol  <e2> antihistamines </e2>  carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other  <e1> antidepressants </e1>  metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox)  <e2> ketoconazole </e2>  (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs:  <e1> blood thinner </e1> s (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox)  <e2> ketoconazole </e2>  (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about  <e1> benzodiazepine </e1> , alcohol and  <e2> sedative </e2>  use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
false	Caution should be exercised when taking this medicine certain  <e1> antibiotics </e1> , such as  <e2> erythromycin </e2> , clarithromycin, or azithromycin.
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet)  <e1> estrogens </e1>  fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa  <e2> lithium </e2>  muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine ( <e1> Prozac </e1> ) intraconazole (Sporanox) ketoconazole (Nizoral)  <e2> levodopa </e2>  lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol  <e1> antihistamines </e1>  carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole ( <e2> Sporanox </e2> ) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Drug Interactions:  <e1> Flupenthixol </e1>  may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine -  <e2> Ethanol </e2> : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression -  <e1> Tricyclic antidepressants </e1> : Flupenthixol increases the effect of  <e2> Tricyclic antidepressants </e2> 
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI):  <e1> MAOI </e1>  could theoretically affect flupenthixol pharmacodynamics -  <e2> Arecoline </e2>  - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect  <e1> flupenthixol </e1>  pharmacodynamics -  <e2> Arecoline </e2>  - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect  <e1> flupenthixol </e1>  pharmacodynamics - Arecoline - Eproxindine - Ethanol:  <e2> Flupenthixol </e2>  and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine -  <e1> Ethanol </e1> : Flupenthixol and Ethanol cause additive CNS depression -  <e2> Tricyclic antidepressants </e2> : Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions:  <e1> Flupenthixol </e1>  may interact with some drugs, like Monoamine oxidase inhibitors (MAOI):  <e2> MAOI </e2>  could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like  <e1> Monoamine oxidase inhibitors </e1>  (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression -  <e2> Tricyclic antidepressants </e2> : Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and  <e1> Ethanol </e1>  cause additive CNS depression -  <e2> Tricyclic antidepressants </e2> : Flupenthixol increases the effect of Tricyclic antidepressants
false	Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about  <e1> benzodiazepine </e1> , alcohol and  <e2> sedative </e2>  use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect  <e1> flupenthixol </e1>  pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression -  <e2> Tricyclic antidepressants </e2> : Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and  <e1> Ethanol </e1>  cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of  <e2> Tricyclic antidepressants </e2> 
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI):  <e1> MAOI </e1>  could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of  <e2> Tricyclic antidepressants </e2> 
int	Drug Interactions:  <e1> Flupenthixol </e1>  may interact with some drugs, like Monoamine oxidase inhibitors ( <e2> MAOI </e2> ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect  <e1> flupenthixol </e1>  pharmacodynamics - Arecoline - Eproxindine - Ethanol:  <e2> Flupenthixol </e2>  and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
false	Oral  <e1> Hypoglycemic Agents </e1> : In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with  <e2> phenformin </e2>  (n=6).
false	 <e1> Anticoagulants </e1> : Flurbiprofen like other  <e2> nonsteroidal anti-inflammatory drugs </e2> , has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.
false	Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to  <e1> propranolol </e1>  and  <e2> atenolol </e2>  was evaluated in men with mild uncomplicated hypertension (n = 10).
false	Patients receiving flurbiprofen and  <e1> furosemide </e1>  or other  <e2> diuretics </e2>  should be observed closely to determine if the desired effect is obtained.
false	 <e1> Antacids </e1> : Administration of flurbiprofen to volunteers under fasting conditions, or with  <e2> antacid </e2>  suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).
mechanism	Aspirin: Concurrent administration of  <e1> aspirin </e1>  and  <e2> flurbiprofen </e2>  resulted in 50% lower serum flurbiprofen concentrations.
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and  <e1> Ethanol </e1>  cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of  <e2> Tricyclic antidepressants </e2> 
false	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4),  <e1> metformin </e1>  (n=2) chlorpropamide with phenformin (n= 3) or  <e2> glyburide </e2>  with phenformin (n=6).
false	 <e1> Cimetidine </e1> ,  <e2> Ranitidine </e2> : In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.
effect	Anticoagulants:  <e1> Flurbiprofen </e1>  like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving  <e2> anti-coagulants </e2> , and serious clinical bleeding has been reported.
int	Drug Interactions:  <e1> Flupenthixol </e1>  may interact with some drugs, like Monoamine oxidase inhibitors ( <e2> MAOI </e2> ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI):  <e1> MAOI </e1>  could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of  <e2> Tricyclic antidepressants </e2> 
false	 <e1> Aspirin </e1> : Concurrent administration of aspirin and  <e2> flurbiprofen </e2>  resulted in 50% lower serum flurbiprofen concentrations.
false	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2)  <e1> chlorpropamide </e1>  with phenformin (n= 3) or  <e2> glyburide </e2>  with phenformin (n=6).
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression -  <e1> Tricyclic antidepressants </e1> : Flupenthixol increases the effect of  <e2> Tricyclic antidepressants </e2> 
false	Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with  <e1> thiazide diuretics </e1>  in some studies and with  <e2> potassium-sparing diuretics </e2> .
false	Aspirin: Concurrent administration of  <e1> aspirin </e1>  and flurbiprofen resulted in 50% lower serum  <e2> flurbiprofen </e2>  concentrations.
false	 <e1> Diuretics </e1> : Studies in normal volunteers have shown that flurbiprofen like other  <e2> nonsteroidal anti-inflammatory drugs </e2> , can interfere with the effects of furosemide.
false	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with  <e1> phenformin </e1>  (n= 3) or glyburide with  <e2> phenformin </e2>  (n=6).
false	Drug Interactions:  <e1> Flupenthixol </e1>  may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine -  <e2> Ethanol </e2> : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
false	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with  <e1> cimetidine </e1>  or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with  <e2> cimetidine </e2> .
advise	Concurrent use of  <e1> flurbiprofen </e1>  and  <e2> aspirin </e2>  is therefore not recommended.
false	Therefore, close monitoring of prothrombin time is recommended and adjustment of the  <e1> anticoagulant </e1>  dose may be necessary when  <e2> EULEXIN </e2>  Capsules are administered concomitantly with warfarin.
false	Aspirin: Concurrent administration of  <e1> aspirin </e1>  and flurbiprofen resulted in 50% lower serum  <e2> flurbiprofen </e2>  concentrations.
advise	Concurrent use of  <e1> flurbiprofen </e1>  and  <e2> aspirin </e2>  is therefore not recommended.
false	 <e1> Cimetidine </e1> ,  <e2> Ranitidine </e2> : In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.
effect	Increases in prothrombin time have been noted in patients receiving long- term  <e1> warfarin </e1>  therapy after  <e2> flutamide </e2>  was initiated.
false	 <e1> Antacids </e1> : Administration of flurbiprofen to volunteers under fasting conditions, or with  <e2> antacid </e2>  suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).
advise	Therefore, if  <e1> theophylline </e1>  is co-administered with  <e2> fluvoxamine maleate </e2> , its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.
mechanism	Because  <e1> fluvoxamine </e1>  reduces the clearance of both diazepam and its active metabolite,  <e2> N-desmethyldiazepam </e2> , there is a strong likelihood of substantial accumulation of both species during chronic co-administration.
false	Although it has not been definitively demonstrated that  <e1> fluvoxamine </e1>  is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with  <e2> alprazolam </e2> .
false	Other Potentially Important Drug Interactions: Benzodiazepines:  <e1> Benzodiazepines </e1>  metabolized by hepatic oxidation (e.g.,  <e2> alprazolam </e2> , midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
false	Other Potentially Important Drug Interactions:  <e1> Benzodiazepines </e1> : Benzodiazepines metabolized by hepatic oxidation (e.g.,  <e2> alprazolam </e2> , midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
false	Alprazolam: When  <e1> fluvoxamine maleate </e1>  (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of  <e2> alprazolam </e2>  were approximately twice those observed when alprazolam was administered alone;
false	 <e1> Alprazolam </e1> : When fluvoxamine maleate (100 mg qd) and  <e2> alprazolam </e2>  (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;
false	Consequently, it is recommended that fluvoxamine not be used in combination with either  <e1> terbinafine </e1> , astemizole, or  <e2> cisapride </e2> .
false	The clearance of benzodiazepines metabolized by glucuronidation (e. g., lorazepam, oxazepam,  <e1> temazepam </e1> ) is unlikely to be affected by  <e2> fluvoxamine </e2> .
false	Other Potentially Important Drug Interactions: Benzodiazepines:  <e1> Benzodiazepines </e1>  metabolized by hepatic oxidation (e.g., alprazolam, midazolam,  <e2> triazolam </e2>  elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
false	Other Potentially Important Drug Interactions: Benzodiazepines:  <e1> Benzodiazepines </e1>  metabolized by hepatic oxidation (e.g., alprazolam,  <e2> midazolam </e2> , triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
false	This interaction, which has not been investigated using higher doses of  <e1> fluvoxamine </e1> , may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If  <e2> alprazolam </e2>  is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.
false	The clearance of benzodiazepines metabolized by glucuronidation (e. g.,  <e1> lorazepam </e1> , oxazepam,  <e2> temazepam </e2> ) is unlikely to be affected by fluvoxamine.
false	Therefore, if  <e1> theophylline </e1>  is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of  <e2> theophylline </e2>  should to monitored.
false	Aspirin: Concurrent administration of  <e1> aspirin </e1>  and flurbiprofen resulted in 50% lower serum  <e2> flurbiprofen </e2>  concentrations.
false	 <e1> Warfarin </e1> : When fluvoxamine maleate (50 mg tid) was administered concomitantly with  <e2> warfarin </e2>  for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.
false	 <e1> Theophylline </e1> : The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg  <e2> aminophylline </e2>  was evaluated in 12 healthy non-smoking, male volunteers.
false	This interaction, which has not been investigated using higher doses of  <e1> fluvoxamine </e1> , may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with  <e2> Fluvoxamine </e2>  Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.
advise	Concurrent use of  <e1> flurbiprofen </e1>  and  <e2> aspirin </e2>  is therefore not recommended.
false	 <e1> Antacids </e1> : Administration of flurbiprofen to volunteers under fasting conditions, or with  <e2> antacid </e2>  suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).
effect	Increases in prothrombin time have been noted in patients receiving long- term  <e1> warfarin </e1>  therapy after  <e2> flutamide </e2>  was initiated.
mechanism	Terfenadine, astemizole and  <e1> cisapride </e1>  are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that  <e2> ketoconazole </e2> , a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
mechanism	Terfenadine, astemizole and  <e1> cisapride </e1>  are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that  <e2> ketoconazole </e2> , a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
advise	Therefore, if  <e1> theophylline </e1>  is co-administered with  <e2> fluvoxamine maleate </e2> , its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone)  <e1> metformin </e1>  (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and  <e2> folic acid </e2> .
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as  <e1> phenytoin </e1> , and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic)  <e2> Methotrexate </e2>  There has been concern about the interaction between vitamin B12 and folic acid.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and  <e1> primidone </e1> ) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and  <e2> folic acid </e2> .
false	Medications can interfere with folate utilization, including:  <e1> anticonvulsant medications </e1>  (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between  <e2> vitamin B12 </e2>  and folic acid.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a  <e1> diuretic </e1> ) Methotrexate There has been concern about the interaction between vitamin B12 and  <e2> folic acid </e2> .
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis)  <e1> triamterene </e1>  (a  <e2> diuretic </e2> ) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis)  <e1> triamterene </e1>  (a diuretic)  <e2> Methotrexate </e2>  There has been concern about the interaction between vitamin B12 and folic acid.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and  <e1> primidone </e1> ) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a  <e2> diuretic </e2> ) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
false	Consequently, it is recommended that fluvoxamine not be used in combination with either  <e1> terbinafine </e1> , astemizole, or  <e2> cisapride </e2> .
false	 <e1> Theophylline </e1> : The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg  <e2> aminophylline </e2>  was evaluated in 12 healthy non-smoking, male volunteers.
false	Medications can interfere with folate utilization, including:  <e1> anticonvulsant medications </e1>  (such as  <e2> phenytoin </e2> , and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes)  <e1> sulfasalazine </e1>  (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic)  <e2> Methotrexate </e2>  There has been concern about the interaction between vitamin B12 and folic acid.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as  <e1> phenytoin </e1> , and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic)  <e2> Methotrexate </e2>  There has been concern about the interaction between vitamin B12 and folic acid.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone)  <e1> metformin </e1>  (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and  <e2> folic acid </e2> .
false	Medications can interfere with folate utilization, including:  <e1> anticonvulsant medications </e1>  (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between  <e2> vitamin B12 </e2>  and folic acid.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as  <e1> phenytoin </e1> , and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic)  <e2> Methotrexate </e2>  There has been concern about the interaction between vitamin B12 and folic acid.
mechanism	Reciprocal interactions may occur with concomitant use of  <e1> Antizol </e1>  and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine,  <e2> ketoconazole </e2> ), though this has not been studied
false	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin,  <e1> carbamazepine </e1> , cimetidine,  <e2> ketoconazole </e2> ), though this has not been studied
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants ( <e1> warfarin </e1> ), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of  <e2> fondaparinux sodium </e2> .
false	In addition, Fondaparinux neither influenced the pharmacodynamics of  <e1> warfarin </e1> , acetylsalicylic acid,  <e2> piroxicam </e2> , and digoxin, nor the pharmacokinetics of digoxin at steady state.
false	In clinical studies performed with Fondaparinux, the concomitant use of oral  <e1> anticoagulants </e1>  ( <e2> warfarin </e2> ), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors ( <e1> acetylsalicylic acid </e1> ), NSAIDs ( <e2> piroxicam </e2> ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin),  <e1> platelet inhibitors </e1>  (acetylsalicylic acid), NSAIDs (piroxicam), and  <e2> digoxin </e2>  did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants ( <e1> warfarin </e1> ), platelet inhibitors ( <e2> acetylsalicylic acid </e2> ), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin,  <e1> acetylsalicylic acid </e1> , piroxicam, and digoxin, nor the pharmacokinetics of  <e2> digoxin </e2>  at steady state.
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin),  <e1> platelet inhibitors </e1>  (acetylsalicylic acid),  <e2> NSAIDs </e2>  (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
mechanism	Reciprocal interactions may occur with concomitant use of  <e1> Antizol </e1>  and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine,  <e2> ketoconazole </e2> ), though this has not been studied
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid),  <e1> NSAIDs </e1>  ( <e2> piroxicam </e2> ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid,  <e1> piroxicam </e1> , and digoxin, nor the pharmacokinetics of  <e2> digoxin </e2>  at steady state.
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid),  <e1> NSAIDs </e1>  (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of  <e2> fondaparinux sodium </e2> .
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid),  <e1> NSAIDs </e1>  (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of  <e2> fondaparinux sodium </e2> .
effect	Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with  <e1> xanthine derivatives </e1> , steroids, or diuretics may potentiate a possible hypokalemic effect of   <e2> beta2-agonists. </e2> 
false	Monoamine Oxidase Inhibitors and  <e1> Tricyclic Antidepressants </e1> : FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of  <e2> formoterol </e2>  on the cardiovascular system may be potentiated by these agents.
false	Other Drugs:Drugs such as  <e1> quinidine </e1> , disopyramide, procainamide, phenothiazines,  <e2> antihistamines </e2> , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.
false	It is important that patients understand how to use  <e1> FORADIL </e1>   ( <e2> formoterol fumarate </e2> ) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking.
false	Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives,  <e1> steroids </e1> , or  <e2> diuretics </e2>  may potentiate a possible hypokalemic effect of  beta2-agonists.
false	Other Drugs:Drugs such as quinidine, disopyramide,  <e1> procainamide </e1> ,  <e2> phenothiazines </e2> , antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.
false	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with  <e1> monoamine oxidase inhibitors </e1>  or tricyclic antidepressants because the action of  <e2> formoterol </e2>  on the cardiovascular system may be potentiated by these agents.
false	Other Drugs:Drugs such as quinidine,  <e1> disopyramide </e1> , procainamide, phenothiazines, antihistamines, and  <e2> tricyclic antidepressants </e2>  may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.
false	Corticosteroids,  <e1> Methylxanthines </e1>  and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or  <e2> diuretics </e2>  may potentiate a possible hypokalemic effect of  beta2-agonists.
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid),  <e1> NSAIDs </e1>  ( <e2> piroxicam </e2> ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	In clinical studies performed with Fondaparinux, the concomitant use of oral  <e1> anticoagulants </e1>  ( <e2> warfarin </e2> ), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	Other Drugs:Drugs such as  <e1> quinidine </e1> , disopyramide,  <e2> procainamide </e2> , phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.
false	 <e1> Corticosteroids </e1> ,  <e2> Methylxanthines </e2>  and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.
advise	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants:  <e1> FORADIL </e1>  should be administered with extreme caution in patients being treated with  <e2> monoamine oxidase inhibitors </e2>  or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.
advise	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants:  <e1> FORADIL </e1>  should be administered with extreme caution in patients being treated with  <e2> monoamine oxidase inhibitors </e2>  or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.
false	Because of  <e1> foscarnet </e1> s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous  <e2> pentamidine </e2>  unless the potential benefits outweigh the risks to the patient.
false	 <e1> Ganciclovir </e1> : The pharmacokinetics of foscarnet and  <e2> ganciclovir </e2>  were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.
effect	Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with  <e1> xanthine derivatives </e1> , steroids, or diuretics may potentiate a possible hypokalemic effect of   <e2> beta2-agonists. </e2> 
false	Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as  <e1> aminoglycosides </e1> , amphotericin B and intravenous  <e2> pentamidine </e2>  unless the potential benefits outweigh the risks to the patient.
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid),  <e1> NSAIDs </e1>  ( <e2> piroxicam </e2> ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	 <e1> Metoclopramide </e1> : When coadministered with  <e2> MONUROL </e2> , metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.
false	Cimetidine: Cimetidine does not affect the pharmacokinetics of  <e1> fosfomycin </e1>  when coadministered with  <e2> MONUROL </e2> .
false	Cimetidine:  <e1> Cimetidine </e1>  does not affect the pharmacokinetics of  <e2> fosfomycin </e2>  when coadministered with MONUROL.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline,  <e1> digoxin </e1> , and  <e2> warfarin </e2> , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	 <e1> Antacids </e1> : In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with  <e2> fosinopril </e2>  administered alone, suggesting that antacids may impair absorption of fosinopril.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and  <e1> warfarin </e1> , the bioavailability of fosinoprilat was not altered by coadministration of  <e2> fosinopril </e2>  with any one of these drugs.
false	 <e1> Potassium-sparing diuretics </e1>  (spironolactone, amiloride, <e2> triamterene </e2> , and others) or potassium supplements can increase the risk of hyperkalemia.
false	In separate single or multiple dose pharmacokinetic interaction studies with  <e1> chlorthalidone </e1> , nifedipine, propanolol, hydrochlorothiazide,  <e2> cimetidine </e2> , metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	Potassium-sparing diuretics (spironolactone,  <e1> amiloride </e1> ,triamterene, and others) or  <e2> potassium </e2>  supplements can increase the risk of hyperkalemia.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine,  <e1> metoclopramide </e1> , propantheline,  <e2> digoxin </e2> , and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	Potassium-sparing diuretics ( <e1> spironolactone </e1> , amiloride,triamterene, and others) or  <e2> potassium </e2>  supplements can increase the risk of hyperkalemia.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone,  <e1> nifedipine </e1> , propanolol, hydrochlorothiazide, cimetidine, metoclopramide,  <e2> propantheline </e2> , digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of  <e1> fosinoprilat </e1>  as compared with fosinopril administered alone, suggesting that  <e2> antacids </e2>  may impair absorption of fosinopril.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine,  <e1> propanolol </e1> , hydrochlorothiazide, cimetidine, metoclopramide,  <e2> propantheline </e2> , digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	Antacids: In a clinical pharmacology study, coadministration of an antacid ( <e1> aluminum hydroxide </e1> , magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of  <e2> fosinopril </e2> .
false	Antacids: In a clinical pharmacology study, coadministration of an antacid ( <e1> aluminum hydroxide </e1> , magnesium hydroxide, and  <e2> simethicone </e2> ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline,  <e1> digoxin </e1> , and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of  <e2> fosinopril </e2>  with any one of these drugs.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone,  <e1> nifedipine </e1> , propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of  <e2> fosinopril </e2>  with any one of these drugs.
mechanism	Antacids: In a clinical pharmacology study, coadministration of an antacid ( <e1> aluminum hydroxide </e1> , magnesium hydroxide, and simethicone) with  <e2> fosinopril </e2>  reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
false	Lithium: Increased serum  <e1> lithium </e1>  levels and symptoms of  <e2> lithium </e2>  toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone,  <e1> nifedipine </e1> , propanolol, hydrochlorothiazide,  <e2> cimetidine </e2> , metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of  <e1> fosinoprilat </e1>  as compared with  <e2> fosinopril </e2>  administered alone, suggesting that antacids may impair absorption of fosinopril.
false	In a pharmacokinetic interaction study with  <e1> warfarin </e1> , bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of  <e2> warfarin </e2>  were not significantly changed.
false	Drug/Laboratory Test Interaction  <e1> Fosinopril </e1>  may cause a false low measurement of serum  <e2> digoxin </e2>  levels with the Digi- Tab  RIA Kit for Digoxin.
false	In separate single or multiple dose pharmacokinetic interaction studies with  <e1> chlorthalidone </e1> , nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of  <e2> fosinoprilat </e2>  was not altered by coadministration of fosinopril with any one of these drugs.
false	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide,  <e1> magnesium hydroxide </e1> , and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of  <e2> fosinopril </e2> .
false	 <e1> Antacids </e1> : In a clinical pharmacology study, coadministration of an  <e2> antacid </e2>  (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
effect	The possibility of hypotensive effects can be minimized by either discontinuing the  <e1> diuretic </e1>  or increasing salt intake prior to initiation of treatment with  <e2> fosinopril sodium </e2> .
false	 <e1> Potassium </e1>  Supplements and  <e2> Potassium-Sparing Diuretics </e2> : Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine,  <e1> propanolol </e1> , hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and  <e2> warfarin </e2> , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide,  <e1> magnesium hydroxide </e1> , and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that  <e2> antacids </e2>  may impair absorption of fosinopril.
false	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide,  <e1> magnesium hydroxide </e1> , and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of  <e2> fosinopril </e2> .
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens,  <e2> ethosuximide </e2> , fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide,  <e1> cimetidine </e1> , diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane,  <e2> isoniazid </e2> , methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	 <e1> Antacids </e1> : In a clinical pharmacology study, coadministration of an  <e2> antacid </e2>  (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane,  <e2> isoniazid </e2> , methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most significant drug interactions following administration of  <e1> Cerebyx </e1>  are expected to occur with drugs that interact with  <e2> phenytoin </e2> .
false	The pharmacokinetics and protein binding of fosphenytoin,  <e1> phenytoin </e1> , and diazepam were not altered when diazepam and  <e2> Cerebyx </e2>  were concurrently administered in single submaximal doses.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol,  <e1> disulfiram </e1> , estrogens, ethosuximide, fluoxetine,  <e2> H2-antagonists </e2> , halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
effect	- Drugs whose efficacy is impaired by  <e1> phenytoin </e1>  include: anticoagulants, corticosteroids, coumarin, digitoxin,  <e2> doxycycline </e2> , estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin,  <e1> doxycycline </e1> , estrogens, furosemide, oral  <e2> contraceptives </e2> , rifampin, quinidine, theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake,  <e1> amiodarone </e1> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid,  <e2> methylphenidate </e2> , phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants,  <e1> corticosteroids </e1> ,  <e2> coumarin </e2> , digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral  <e1> contraceptives </e1> , rifampin,  <e2> quinidine </e2> , theophylline, vitamin D.
mechanism	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  <e1> phenytoin </e1>  concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine,  <e2> diazepam </e2> , dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral  <e1> contraceptives </e1> , rifampin, quinidine,  <e2> theophylline </e2> , vitamin D.
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline,  <e1> estrogens </e1> , furosemide, oral contraceptives, rifampin, quinidine,  <e2> theophylline </e2> , vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake,  <e1> amiodarone </e1> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate,  <e2> phenothiazines </e2> , phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate,  <e2> phenothiazines </e2> , phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake,  <e1> amiodarone </e1> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists,  <e2> halothane </e2> , isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates,  <e2> succinimides </e2> , sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram,  <e1> estrogens </e1> , ethosuximide,  <e2> fluoxetine </e2> , H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
mechanism	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  <e1> phenytoin </e1>  concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide,  <e2> trazodone </e2> 
false	The pharmacokinetics and protein binding of  <e1> fosphenytoin </e1> , phenytoin, and diazepam were not altered when diazepam and  <e2> Cerebyx </e2>  were concurrently administered in single submaximal doses.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides,  <e1> tolbutamide </e1> ,  <e2> trazodone </e2> 
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines,  <e1> phenylbutazone </e1> , salicylates, succinimides, sulfonamides, tolbutamide,  <e2> trazodone </e2> 
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine,  <e1> H2-antagonists </e1> , halothane,  <e2> isoniazid </e2> , methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid,  <e1> methylphenidate </e1> , phenothiazines,  <e2> phenylbutazone </e2> , salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol,  <e1> chlordiazepoxide </e1> , cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide,  <e2> trazodone </e2> 
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate,  <e1> phenothiazines </e1> , phenylbutazone,  <e2> salicylates </e2> , succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide,  <e1> cimetidine </e1> , diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid,  <e2> methylphenidate </e2> , phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists,  <e1> halothane </e1> , isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides,  <e2> sulfonamides </e2> , tolbutamide, trazodone
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine,  <e1> propanolol </e1> , hydrochlorothiazide, cimetidine, metoclopramide,  <e2> propantheline </e2> , digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine,  <e1> metoclopramide </e1> , propantheline,  <e2> digoxin </e2> , and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
mechanism	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  <e1> phenytoin </e1>  concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane,  <e2> isoniazid </e2> , methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram,  <e1> estrogens </e1> , ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates,  <e2> succinimides </e2> , sulfonamides, tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include:  <e1> anticoagulants </e1> , corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine,  <e2> theophylline </e2> , vitamin D.
mechanism	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  <e1> phenytoin </e1>  concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam,  <e2> dicumarol </e2> , disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
mechanism	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  <e1> phenytoin </e1>  concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides,  <e2> sulfonamides </e2> , tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral  <e1> contraceptives </e1> ,  <e2> rifampin </e2> , quinidine, theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol,  <e1> chlordiazepoxide </e1> , cimetidine, diazepam, dicumarol, disulfiram, estrogens,  <e2> ethosuximide </e2> , fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens,  <e1> ethosuximide </e1> , fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide,  <e2> trazodone </e2> 
effect	Similarly, the effects of  <e1> phenytoin </e1>  on  <e2> phenobarbital </e2> , valproic acid and sodium plasma valproate concentrations are unpredictable
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids,  <e1> coumarin </e1> , digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine,  <e2> theophylline </e2> , vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol,  <e1> chlordiazepoxide </e1> , cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid,  <e2> methylphenidate </e2> , phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram,  <e1> estrogens </e1> , ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides,  <e2> tolbutamide </e2> , trazodone
false	Potassium-sparing diuretics (spironolactone,  <e1> amiloride </e1> ,triamterene, and others) or  <e2> potassium </e2>  supplements can increase the risk of hyperkalemia.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine,  <e1> H2-antagonists </e1> , halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates,  <e2> succinimides </e2> , sulfonamides, tolbutamide, trazodone
false	Similarly, the effects of phenytoin on phenobarbital,  <e1> valproic acid </e1>  and sodium plasma  <e2> valproate </e2>  concentrations are unpredictable
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide,  <e1> cimetidine </e1> , diazepam,  <e2> dicumarol </e2> , disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
effect	- Drugs whose efficacy is impaired by  <e1> phenytoin </e1>  include: anticoagulants,  <e2> corticosteroids </e2> , coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens,  <e1> furosemide </e1> , oral contraceptives, rifampin,  <e2> quinidine </e2> , theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol,  <e1> disulfiram </e1> , estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide,  <e2> trazodone </e2> 
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides,  <e2> tolbutamide </e2> , trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake,  <e1> amiodarone </e1> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides,  <e2> tolbutamide </e2> , trazodone
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin,  <e1> digitoxin </e1> , doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine,  <e2> theophylline </e2> , vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid,  <e1> methylphenidate </e1> , phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide,  <e2> trazodone </e2> 
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline,  <e1> digoxin </e1> , and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of  <e2> fosinopril </e2>  with any one of these drugs.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake,  <e1> amiodarone </e1> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram,  <e2> estrogens </e2> , ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam,  <e1> dicumarol </e1> , disulfiram, estrogens, ethosuximide, fluoxetine,  <e2> H2-antagonists </e2> , halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid,  <e2> methylphenidate </e2> , phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide,  <e1> cimetidine </e1> , diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide,  <e2> trazodone </e2> 
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake,  <e1> amiodarone </e1> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane,  <e2> isoniazid </e2> , methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine,  <e1> diazepam </e1> , dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists,  <e2> halothane </e2> , isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine,  <e1> diazepam </e1> ,  <e2> dicumarol </e2> , disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
mechanism	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  <e1> phenytoin </e1>  concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone,  <e2> salicylates </e2> , succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane,  <e1> isoniazid </e1> , methylphenidate,  <e2> phenothiazines </e2> , phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin,  <e1> doxycycline </e1> , estrogens, furosemide, oral contraceptives, rifampin,  <e2> quinidine </e2> , theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens,  <e1> ethosuximide </e1> , fluoxetine,  <e2> H2-antagonists </e2> , halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
effect	- Drugs whose efficacy is impaired by  <e1> phenytoin </e1>  include: anticoagulants, corticosteroids,  <e2> coumarin </e2> , digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin,  <e1> doxycycline </e1> , estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline,  <e2> vitamin D </e2> .
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone,  <e1> nifedipine </e1> , propanolol, hydrochlorothiazide,  <e2> cimetidine </e2> , metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline,  <e1> estrogens </e1> , furosemide, oral contraceptives, rifampin,  <e2> quinidine </e2> , theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake,  <e2> amiodarone </e2> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include:  <e1> anticoagulants </e1> , corticosteroids, coumarin, digitoxin,  <e2> doxycycline </e2> , estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide,  <e1> cimetidine </e1> , diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid,  <e2> methylphenidate </e2> , phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	Selective serotonin reuptake inhibitors (SSRIs) (e.g.,  <e1> fluoxetine </e1> ,  <e2> fluvoxamine </e2> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants,  <e1> corticosteroids </e1> ,  <e2> coumarin </e2> , digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
false	Selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ) (e.g., fluoxetine, fluvoxamine,  <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
false	 <e1> Selective serotonin reuptake inhibitors </e1>  (SSRIs) (e.g., fluoxetine, fluvoxamine,  <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens,  <e1> ethosuximide </e1> , fluoxetine,  <e2> H2-antagonists </e2> , halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
advise	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or  <e1> ergot-type medications </e1>  (like dihydroergotamine or methysergide) and  <e2> FROVA </e2>  within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
effect	 <e1> Selective serotonin reuptake inhibitors </e1>  (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  <e2> 5-HT1 agonists </e2> .
effect	Selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  <e2> 5-HT1 agonists </e2> .
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram,  <e1> estrogens </e1> , ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates,  <e2> succinimides </e2> , sulfonamides, tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include:  <e1> anticoagulants </e1> , corticosteroids, coumarin, digitoxin,  <e2> doxycycline </e2> , estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine,  <e1> H2-antagonists </e1> , halothane,  <e2> isoniazid </e2> , methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	Selective serotonin reuptake inhibitors (SSRIs) (e.g.,  <e1> fluoxetine </e1> , fluvoxamine,  <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid,  <e1> methylphenidate </e1> , phenothiazines,  <e2> phenylbutazone </e2> , salicylates, succinimides, sulfonamides, tolbutamide, trazodone
mechanism	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  <e1> phenytoin </e1>  concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine,  <e2> diazepam </e2> , dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane,  <e2> isoniazid </e2> , methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake,  <e1> amiodarone </e1> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate,  <e2> phenothiazines </e2> , phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include:  <e1> anticoagulants </e1> , corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine,  <e2> theophylline </e2> , vitamin D.
false	 <e1> Selective serotonin reuptake inhibitors </e1>  (SSRIs) (e.g.,  <e2> fluoxetine </e2> , fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake,  <e1> amiodarone </e1> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides,  <e2> tolbutamide </e2> , trazodone
false	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide,  <e1> magnesium hydroxide </e1> , and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of  <e2> fosinopril </e2> .
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens,  <e1> ethosuximide </e1> , fluoxetine,  <e2> H2-antagonists </e2> , halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	Selective serotonin reuptake inhibitors (SSRIs) (e.g.,  <e1> fluoxetine </e1> ,  <e2> fluvoxamine </e2> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid,  <e1> methylphenidate </e1> , phenothiazines,  <e2> phenylbutazone </e2> , salicylates, succinimides, sulfonamides, tolbutamide, trazodone
effect	 <e1> Selective serotonin reuptake inhibitors </e1>  (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  <e2> 5-HT1 agonists </e2> .
false	Lithium generally should not be given with  <e1> diuretics </e1>  because they reduce lithiums renal clearance and add a high risk of  <e2> lithium </e2>  toxicity.
effect	There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when  <e1> furosemide </e1>  was used in conjunction with  <e2> NSAIDs </e2> .
false	Selective serotonin reuptake inhibitors (SSRIs) (e.g.,  <e1> fluoxetine </e1> ,  <e2> fluvoxamine </e2> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
advise	The intake of  <e1> furosemide </e1>  and  <e2> sucralfate </e2>  should be separated by at least two hours.
false	Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of  <e1> tubocurarine </e1>  and may potentiate the action of  <e2> succinylcholine </e2> .
effect	 <e1> Selective serotonin reuptake inhibitors </e1>  (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  <e2> 5-HT1 agonists </e2> .
effect	There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when  <e1> furosemide </e1>  was used in conjunction with  <e2> NSAIDs </e2> .
false	 <e1> Morphine </e1> : A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without  <e2> morphine </e2> .
false	 <e1> Phenobarbital </e1> : Estimates of steady-state pharmacokinetic parameters for phenobarbital or  <e2> gabapentin </e2>  (300 mg TID;
false	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of  <e1> phenytoin </e1>  and phenytoin had no effect on  <e2> gabapentin </e2>  pharmacokinetics.
false	 <e1> Phenobarbital </e1> : Estimates of steady-state pharmacokinetic parameters for  <e2> phenobarbital </e2>  or gabapentin (300 mg TID;
false	 <e1> Naproxen </e1> : Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of  <e2> gabapentin </e2>  absorbed by 12% to 15%.
false	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  <e1> norethindrone </e1>  and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of  <e2> ethinyl estradiol </e2>  were similar with and without coadministration of gabapentin (400 mg TID;
false	Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean  <e1> gabapentin </e1>  AUC increased by 44% compared to gabapentin administered without  <e2> morphine </e2> .
false	Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg  <e1> Neurontin </e1>   capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without  <e2> morphine </e2> .
false	Morphine: A literature article reported that when a 60-mg controlled-release  <e1> morphine </e1>  capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without  <e2> morphine </e2> .
false	Valproic Acid: The mean steady-state trough serum  <e1> valproic acid </e1>  concentrations prior to and during concomitant  <e2> gabapentin </e2>  administration (400 mg TID;
false	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of  <e1> ethinyl estradiol </e1>  were similar with and without coadministration of  <e2> gabapentin </e2>  (400 mg TID;
false	 <e1> Phenytoin </e1> : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on  <e2> gabapentin </e2>  pharmacokinetics.
mechanism	Morphine: A literature article reported that when a 60-mg controlled-release  <e1> morphine </e1>  capsule was administered 2 hours prior to a 600-mg  <e2> Neurontin </e2>   capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.
advise	It is recommended that  <e1> gabapentin </e1>  be taken at least 2 hours following  <e2> Maalox </e2>  administration.
false	 <e1> Cimetidine </e1> : In the presence of  <e2> cimetidine </e2>  at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.
mechanism	Antacid (Maalox ):  <e1> Maalox </e1>  reduced the bioavailability of  <e2> gabapentin </e2>  (N=16) by about 20%.
false	Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean  <e1> gabapentin </e1>  AUC increased by 44% compared to  <e2> gabapentin </e2>  administered without morphine.
false	 <e1> Antacid </e1>  (Maalox ): Maalox reduced the bioavailability of  <e2> gabapentin </e2>  (N=16) by about 20%.
false	Lithium generally should not be given with  <e1> diuretics </e1>  because they reduce lithiums renal clearance and add a high risk of  <e2> lithium </e2>  toxicity.
false	Antacid ( <e1> Maalox </e1>  ):  <e2> Maalox </e2>  reduced the bioavailability of gabapentin (N=16) by about 20%.
false	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of  <e1> Neurontin </e1>  in epileptic patients (N=8) maintained on  <e2> phenytoin </e2>  monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.
false	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of  <e1> phenytoin </e1>  and phenytoin had no effect on  <e2> gabapentin </e2>  pharmacokinetics.
false	 <e1> Cimetidine </e1> : In the presence of  <e2> cimetidine </e2>  at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.
mechanism	Morphine: A literature article reported that when a 60-mg controlled-release  <e1> morphine </e1>  capsule was administered 2 hours prior to a 600-mg  <e2> Neurontin </e2>   capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.
false	Valproic Acid: The mean steady-state trough serum  <e1> valproic acid </e1>  concentrations prior to and during concomitant  <e2> gabapentin </e2>  administration (400 mg TID;
mechanism	Substances that are potent inhibitors of CYP3A4 activity (eg,  <e1> ketoconazole </e1>  and itraconazole) decrease  <e2> gefitinib </e2>  metabolism and increase gefitinib plasma concentrations.
false	Substances that are potent inhibitors of CYP3A4 activity (eg,  <e1> ketoconazole </e1>  and  <e2> itraconazole </e2> ) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
mechanism	Substances that are potent inhibitors of CYP3A4 activity (eg,  <e1> ketoconazole </e1>  and itraconazole) decrease gefitinib metabolism and increase  <e2> gefitinib </e2>  plasma concentrations.
false	Phase II clinical trial data, where IRESSA and  <e1> vinorelbine </e1>  have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of  <e2> vinorelbine </e2> .
effect	International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking  <e1> warfarin </e1>  while on  <e2> IRESSA </e2>  therapy.
mechanism	Substances that are potent inhibitors of CYP3A4 activity (eg,  <e1> ketoconazole </e1>  and itraconazole) decrease  <e2> gefitinib </e2>  metabolism and increase gefitinib plasma concentrations.
false	Administration of repeat doses of  <e1> FACTIVE </e1>  had no effect on the repeat dose pharmacokinetics of  <e2> theophylline </e2> , digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.
false	Concomitant administration of FACTIVE and calcium carbonate, cimetidine,  <e1> omeprazole </e1> , or an  <e2> estrogen </e2> /progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
false	Concomitant administration of FACTIVE and calcium carbonate,  <e1> cimetidine </e1> ,  <e2> omeprazole </e2> , or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
false	Concomitant administration of  <e1> FACTIVE </e1>  and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of  <e2> gemifloxacin </e2> , which were considered to be without clinical significance.
false	Concomitant administration of FACTIVE and  <e1> calcium carbonate </e1> , cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of  <e2> gemifloxacin </e2> , which were considered to be without clinical significance.
advise	Magnesium- and/or aluminum-containing antacids, products containing  <e1> ferrous sulfate </e1>  (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after  <e2> FACTIVE </e2> .
false	Concomitant administration of  <e1> FACTIVE </e1>  with probenecid resulted in a 45% increase in systemic exposure to  <e2> gemifloxacin </e2> .
advise	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate ( <e1> iron </e1> ), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after  <e2> FACTIVE </e2> .
false	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate ( <e1> iron </e1> ), multivitamin preparations containing  <e2> zinc </e2>  or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	Concomitant administration of FACTIVE and  <e1> calcium carbonate </e1> ,  <e2> cimetidine </e2> , omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
false	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron),  <e1> multivitamin preparations </e1>  containing  <e2> zinc </e2>  or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	Concomitant administration of FACTIVE and  <e1> calcium carbonate </e1> , cimetidine,  <e2> omeprazole </e2> , or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
mechanism	The absorption of oral  <e1> gemifloxacin </e1>  is significantly reduced by the concomitant administration of an antacid containing aluminum and  <e2> magnesium </e2> .
false	Concomitant administration of FACTIVE and calcium carbonate, cimetidine,  <e1> omeprazole </e1> , or an estrogen/ <e2> progesterone </e2>  oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
false	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/ <e1> progesterone </e1>  oral  <e2> contraceptive </e2>  produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
false	Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline,  <e1> digoxin </e1>  or an  <e2> ethinylestradiol </e2> /levonorgestrol oral contraceptive product in healthy subjects.
false	The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an  <e1> antacid </e1>  containing  <e2> aluminum </e2>  and magnesium.
false	Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of  <e1> theophylline </e1> , digoxin or an ethinylestradiol/levonorgestrol oral  <e2> contraceptive product </e2>  in healthy subjects.
false	Concomitant administration of FACTIVE and calcium carbonate,  <e1> cimetidine </e1> , omeprazole, or an estrogen/ <e2> progesterone </e2>  oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
false	FACTIVE had no significant effect on the anticoagulant effect of  <e1> warfarin </e1>  in healthy subjects on stable  <e2> warfarin </e2>  therapy.
mechanism	Concomitant administration of  <e1> FACTIVE </e1>  and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral  <e2> contraceptive </e2>  produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
advise	Magnesium- and/or aluminum-containing antacids, products containing  <e1> ferrous sulfate </e1>  (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after  <e2> FACTIVE </e2> .
mechanism	The absorption of oral  <e1> gemifloxacin </e1>  is significantly reduced by the concomitant administration of an antacid containing aluminum and  <e2> magnesium </e2> .
false	Concomitant administration of FACTIVE and  <e1> calcium carbonate </e1> , cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of  <e2> gemifloxacin </e2> , which were considered to be without clinical significance.
false	Concomitant administration of FACTIVE and calcium carbonate, cimetidine,  <e1> omeprazole </e1> , or an  <e2> estrogen </e2> /progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
false	Concomitant administration of FACTIVE and  <e1> calcium carbonate </e1> , cimetidine,  <e2> omeprazole </e2> , or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
false	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate ( <e1> iron </e1> ), multivitamin preparations containing  <e2> zinc </e2>  or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate ( <e1> iron </e1> ), multivitamin preparations containing  <e2> zinc </e2>  or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	Concomitant administration of FACTIVE and calcium carbonate, cimetidine,  <e1> omeprazole </e1> , or an  <e2> estrogen </e2> /progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
false	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate ( <e1> iron </e1> ), multivitamin preparations containing  <e2> zinc </e2>  or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides,  <e1> chloramphenicol </e1> ,  <e2> probenecid </e2> , coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines,  <e1> thyroid products </e1> ,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phe-nothiazines, thyroid products,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
effect	The hypoglycemic action of  <e1> sulfonylureas </e1>  may be potentiated by certain drugs including  <e2> nonsteroidal anti-inflammatory agents </e2>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid,  <e1> coumarins </e1> ,  <e2> monoamine oxidase inhibitors </e2> , and beta adrenergic blocking agents.
false	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound,  <e1> salicylates </e1> ,  <e2> sulfonamides </e2> , chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products,  <e1> estrogens </e1> , oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics,  <e2> calcium channel blocking drugs </e2> , and isoniazid.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phe-nothiazines, thyroid products, estrogens, oral contraceptives,  <e2> phenytoin </e2> , nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates,  <e1> sulfonamides </e1> ,  <e2> chloramphenicol </e2> , probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and  <e2> isoniazid </e2> .
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and  <e2> isoniazid </e2> .
false	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound,  <e2> salicylates </e2> , sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral  <e1> contraceptives </e1> ,  <e2> phenytoin </e2> , nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	Coadministration of gly-buride and  <e1> metformin </e1>  did not result in any changes in either  <e2> metformin </e2>  pharmacokinetics or pharmaco-dynamics.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phe-nothiazines, thyroid products,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products,  <e1> estrogens </e1> , oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and  <e2> isoniazid </e2> .
effect	The hypoglycemic action of  <e1> sulfonylureas </e1>  may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid,  <e2> coumarins </e2> , monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phe-nothiazines, thyroid products,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin),  <e2> nabumetone </e2>  (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam),  <e2> etodolac </e2>  (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as  <e1> ibuprofen </e1>  (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin ( <e2> Indocin </e2> ), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin ( <e2> Indocin </e2> ), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug ( <e1> NSAID </e1> ) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone ( <e2> Relafen </e2> ), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a  <e1> monoamine oxidase inhibitor </e1>  (MAOI) such as isocarboxazid (Marplan), tranylcypromine ( <e2> Parnate </e2> ), or phenelzine (Nardil);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as  <e1> magnesium/choline salicylate </e1>  ( <e2> Trilisate </e2> ), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone ( <e2> Relafen </e2> ), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others), ketoprofen ( <e2> Orudis </e2> , Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone ( <e1> Medrol </e1> , others),  <e2> prednisolone </e2>  (Prelone, Pediapred, others), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac ( <e1> Voltaren </e1> , Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	- a  <e1> steroid medicine </e1>  such as  <e2> prednisone </e2>  (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phe-nothiazines, thyroid products,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole ( <e1> Gantrisin </e1> ), or  <e2> sulfasalazine </e2>  (Azulfidine);
false	- a monoamine oxidase inhibitor ( <e1> MAOI </e1> ) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine ( <e2> Nardil </e2> );
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren,  <e1> Cataflam </e1> ), etodolac (Lodine), indomethacin ( <e2> Indocin </e2> ), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail),  <e1> diclofenac </e1>  (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin),  <e2> nabumetone </e2>  (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin ( <e1> Daypro </e1> ), and naproxen ( <e2> Anaprox </e2> , Naprosyn, Aleve);
false	- a beta-blocker such as  <e1> propranolol </e1>  (Inderal), atenolol (Tenormin), acebutolol ( <e2> Sectral </e2> ), metoprolol (Lopressor), and others;
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate ( <e1> Disalcid </e1> , others), choline salicylate (Arthropan),  <e2> magnesium salicylate </e2>  (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	-  <e1> rifampin </e1>  ( <e2> Rifadin </e2> , Rifamate);
false	- a beta-blocker such as propranolol (Inderal), atenolol ( <e1> Tenormin </e1> ),  <e2> acebutolol </e2>  (Sectral), metoprolol (Lopressor), and others;
false	- a sulfa-based drug such as sulfamethoxazole-trimethoprim ( <e1> Bactrim </e1> , Septra), sulfisoxazole (Gantrisin), or  <e2> sulfasalazine </e2>  (Azulfidine);
false	- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine ( <e1> Compazine </e1> ),  <e2> promethazine </e2>  (Phenergan), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin ( <e1> Indocin </e1> ), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate),  <e1> salsalate </e1>  ( <e2> Disalcid </e2> , others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a diuretic (water pill) such as  <e1> hydrochlorothiazide </e1>  ( <e2> HCTZ </e2> , Hydrodiuril), chlorothiazide (Diuril), and others;
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate),  <e1> salsalate </e1>  (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or  <e2> bismuth subsalicylate </e2>  (Pepto-Bismol);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam),  <e1> etodolac </e1>  (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin ( <e2> Daypro </e2> ), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others),  <e1> ketoprofen </e1>  (Orudis,  <e2> Orudis KT </e2> , Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as  <e1> magnesium/choline salicylate </e1>  (Trilisate), salsalate ( <e2> Disalcid </e2> , others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate),  <e1> salsalate </e1>  (Disalcid, others), choline salicylate (Arthropan),  <e2> magnesium salicylate </e2>  (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine ( <e1> Prolixin </e1> ,  <e2> Permitil </e2> ), prochlorperazine (Compazine), promethazine (Phenergan), and others;
false	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines,  <e1> thyroid products </e1> ,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as  <e2> ibuprofen </e2>  (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others),  <e1> ketoprofen </e1>  (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone ( <e2> Relafen </e2> ), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and  <e2> naproxen </e2>  (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren,  <e1> Cataflam </e1> ), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn,  <e2> Aleve </e2> );
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam),  <e1> etodolac </e1>  (Lodine), indomethacin (Indocin),  <e2> nabumetone </e2>  (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT,  <e1> Oruvail </e1> ), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen ( <e2> Anaprox </e2> , Naprosyn, Aleve);
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phe-nothiazines, thyroid products, estrogens, oral contraceptives,  <e2> phenytoin </e2> , nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another  <e1> salicylate </e1>  such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan),  <e2> magnesium salicylate </e2>  (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin ( <e1> Indocin </e1> ), nabumetone (Relafen),  <e2> oxaprozin </e2>  (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a beta-blocker such as propranolol (Inderal), atenolol ( <e1> Tenormin </e1> ), acebutolol ( <e2> Sectral </e2> ), metoprolol (Lopressor), and others;
false	- a  <e1> beta-blocker </e1>  such as propranolol (Inderal),  <e2> atenolol </e2>  (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac ( <e2> Lodine </e2> ), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a  <e1> steroid medicine </e1>  such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone ( <e2> Prelone </e2> , Pediapred, others), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine),  <e1> indomethacin </e1>  (Indocin), nabumetone (Relafen),  <e2> oxaprozin </e2>  (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine),  <e1> promethazine </e1>  ( <e2> Phenergan </e2> ), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine),  <e2> indomethacin </e2>  (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a  <e1> monoamine oxidase inhibitor </e1>  ( <e2> MAOI </e2> ) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);
false	- a steroid medicine such as  <e1> prednisone </e1>  ( <e2> Deltasone </e2> , Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;
advise	Before taking  <e1> glimepiride </e1> , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as  <e2> magnesium/choline salicylate </e2>  (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a monoamine oxidase inhibitor (MAOI) such as  <e1> isocarboxazid </e1>  (Marplan), tranylcypromine (Parnate), or  <e2> phenelzine </e2>  (Nardil);
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin ( <e2> Daypro </e2> ), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others),  <e2> ketoprofen </e2>  (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug ( <e1> NSAID </e1> ) such as  <e2> ibuprofen </e2>  (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT,  <e1> Oruvail </e1> ), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone ( <e2> Relafen </e2> ), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a  <e1> steroid medicine </e1>  such as prednisone (Deltasone,  <e2> Orasone </e2> , others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT,  <e1> Oruvail </e1> ),  <e2> diclofenac </e2>  (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another  <e1> salicylate </e1>  such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate ( <e2> Magan </e2> ), or bismuth subsalicylate (Pepto-Bismol);
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and  <e2> isoniazid </e2> .
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen ( <e1> Anaprox </e1> ,  <e2> Naprosyn </e2> , Aleve);
false	- a  <e1> diuretic </e1>  (water pill) such as hydrochlorothiazide ( <e2> HCTZ </e2> , Hydrodiuril), chlorothiazide (Diuril), and others;
false	- a  <e1> beta-blocker </e1>  such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol ( <e2> Lopressor </e2> ), and others;
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others),  <e1> choline salicylate </e1>  ( <e2> Arthropan </e2> ), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen ( <e2> Orudis </e2> , Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine ( <e1> Compazine </e1> ), promethazine ( <e2> Phenergan </e2> ), and others;
false	- a steroid medicine such as prednisone (Deltasone,  <e1> Orasone </e1> , others), methylprednisolone (Medrol, others), prednisolone (Prelone,  <e2> Pediapred </e2> , others), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT,  <e1> Oruvail </e1> ), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin ( <e2> Indocin </e2> ), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a  <e1> phenothiazine </e1>  such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine ( <e2> Compazine </e2> ), promethazine (Phenergan), and others;
false	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral  <e1> contraceptives </e1> ,  <e2> phenytoin </e2> , nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail),  <e1> diclofenac </e1>  (Voltaren, Cataflam), etodolac ( <e2> Lodine </e2> ), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a steroid medicine such as prednisone (Deltasone, Orasone, others),  <e1> methylprednisolone </e1>  (Medrol, others),  <e2> prednisolone </e2>  (Prelone, Pediapred, others), and others;
false	- a steroid medicine such as prednisone (Deltasone,  <e1> Orasone </e1> , others),  <e2> methylprednisolone </e2>  (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as  <e1> ibuprofen </e1>  (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn,  <e2> Aleve </e2> );
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin,  <e1> Advil </e1> , Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac ( <e2> Voltaren </e2> , Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
advise	Before taking  <e1> glimepiride </e1> , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others),  <e2> choline salicylate </e2>  (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a sulfa-based drug such as sulfamethoxazole- <e1> trimethoprim </e1>  (Bactrim, Septra), sulfisoxazole ( <e2> Gantrisin </e2> ), or sulfasalazine (Azulfidine);
false	- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim,  <e1> Septra </e1> ), sulfisoxazole ( <e2> Gantrisin </e2> ), or sulfasalazine (Azulfidine);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others),  <e1> ketoprofen </e1>  (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac ( <e2> Lodine </e2> ), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a steroid medicine such as prednisone ( <e1> Deltasone </e1> , Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone,  <e2> Pediapred </e2> , others), and others;
false	- a diuretic (water pill) such as hydrochlorothiazide (HCTZ,  <e1> Hydrodiuril </e1> ), chlorothiazide ( <e2> Diuril </e2> ), and others;
false	- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone ( <e1> Medrol </e1> , others), prednisolone (Prelone,  <e2> Pediapred </e2> , others), and others;
false	- a sulfa-based drug such as sulfamethoxazole-trimethoprim ( <e1> Bactrim </e1> ,  <e2> Septra </e2> ), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);
false	- a phenothiazine such as  <e1> chlorpromazine </e1>  (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine),  <e2> promethazine </e2>  (Phenergan), and others;
false	- a sulfa-based drug such as sulfamethoxazole- <e1> trimethoprim </e1>  ( <e2> Bactrim </e2> , Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);
false	- a nonsteroidal anti-inflammatory drug ( <e1> NSAID </e1> ) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen),  <e2> oxaprozin </e2>  (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a phenothiazine such as chlorpromazine (Thorazine),  <e1> fluphenazine </e1>  (Prolixin, Permitil),  <e2> prochlorperazine </e2>  (Compazine), promethazine (Phenergan), and others;
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as  <e1> magnesium/choline salicylate </e1>  (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate ( <e2> Pepto-Bismol </e2> );
false	- a diuretic (water pill) such as hydrochlorothiazide ( <e1> HCTZ </e1> , Hydrodiuril), chlorothiazide ( <e2> Diuril </e2> ), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen),  <e1> oxaprozin </e1>  (Daypro), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	- a  <e1> diuretic </e1>  (water pill) such as  <e2> hydrochlorothiazide </e2>  (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac ( <e1> Voltaren </e1> , Cataflam),  <e2> etodolac </e2>  (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen (Orudis,  <e2> Orudis KT </e2> , Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis,  <e1> Orudis KT </e1> , Oruvail),  <e2> diclofenac </e2>  (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a sulfa-based drug such as  <e1> sulfamethoxazole </e1> -trimethoprim (Bactrim, Septra),  <e2> sulfisoxazole </e2>  (Gantrisin), or sulfasalazine (Azulfidine);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin,  <e1> Advil </e1> , Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen),  <e2> oxaprozin </e2>  (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a phenothiazine such as chlorpromazine ( <e1> Thorazine </e1> ), fluphenazine (Prolixin, Permitil),  <e2> prochlorperazine </e2>  (Compazine), promethazine (Phenergan), and others;
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: -  <e1> aspirin </e1>  or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate ( <e2> Disalcid </e2> , others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam),  <e1> etodolac </e1>  (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and  <e2> naproxen </e2>  (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen ( <e1> Orudis </e1> , Orudis KT, Oruvail),  <e2> diclofenac </e2>  (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine),  <e2> indomethacin </e2>  (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: -  <e1> aspirin </e1>  or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan),  <e2> magnesium salicylate </e2>  (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil,  <e2> Nuprin </e2> , others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral),  <e1> metoprolol </e1>  ( <e2> Lopressor </e2> ), and others;
false	- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim,  <e1> Septra </e1> ),  <e2> sulfisoxazole </e2>  (Gantrisin), or sulfasalazine (Azulfidine);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: -  <e1> aspirin </e1>  or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate ( <e2> Arthropan </e2> ), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
advise	Before taking  <e1> glimepiride </e1> , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate ( <e2> Disalcid </e2> , others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a sulfa-based drug such as sulfamethoxazole- <e1> trimethoprim </e1>  (Bactrim, Septra),  <e2> sulfisoxazole </e2>  (Gantrisin), or sulfasalazine (Azulfidine);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen ( <e2> Orudis </e2> , Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug ( <e1> NSAID </e1> ) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac ( <e2> Voltaren </e2> , Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn,  <e2> Aleve </e2> );
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin ( <e1> Indocin </e1> ), nabumetone (Relafen), oxaprozin (Daypro), and naproxen ( <e2> Anaprox </e2> , Naprosyn, Aleve);
effect	The hypoglycemic action of  <e1> sulfonylureas </e1>  may be potentiated by certain drugs including  <e2> nonsteroidal anti-inflammatory agents </e2>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam),  <e1> etodolac </e1>  (Lodine), indomethacin ( <e2> Indocin </e2> ), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: -  <e1> aspirin </e1>  or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate ( <e2> Pepto-Bismol </e2> );
false	- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin,  <e1> Permitil </e1> ), prochlorperazine (Compazine),  <e2> promethazine </e2>  (Phenergan), and others;
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives,  <e1> phenytoin </e1> ,  <e2> nicotinic acid </e2> , sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some  <e1> azoles </e1>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and  <e2> beta adrenergic blocking agents </e2> .
false	- a  <e1> diuretic </e1>  (water pill) such as  <e2> hydrochlorothiazide </e2>  (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products,  <e1> estrogens </e1> , oral  <e2> contraceptives </e2> , phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	- a sulfa-based drug such as  <e1> sulfamethoxazole </e1> -trimethoprim (Bactrim, Septra),  <e2> sulfisoxazole </e2>  (Gantrisin), or sulfasalazine (Azulfidine);
false	- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim,  <e1> Septra </e1> ),  <e2> sulfisoxazole </e2>  (Gantrisin), or sulfasalazine (Azulfidine);
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some  <e1> azoles </e1>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid,  <e2> coumarins </e2> , monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	- a diuretic (water pill) such as hydrochlorothiazide (HCTZ,  <e1> Hydrodiuril </e1> ), chlorothiazide ( <e2> Diuril </e2> ), and others;
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: -  <e1> aspirin </e1>  or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan),  <e2> magnesium salicylate </e2>  (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac ( <e1> Voltaren </e1> , Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	- a diuretic (water pill) such as  <e1> hydrochlorothiazide </e1>  ( <e2> HCTZ </e2> , Hydrodiuril), chlorothiazide (Diuril), and others;
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines, thyroid products,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	All subjects received  <e1> glipizide </e1>  alone and following treatment with 100 mg of  <e2> fluconazole </e2>  as a single daily oral dose for seven days.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products,  <e1> estrogens </e1> , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and  <e2> isoniazid </e2> .
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin),  <e2> nabumetone </e2>  (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some  <e1> azoles </e1>  and other drugs that are highly protein bound, salicylates,  <e2> sulfonamides </e2> , chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen),  <e1> oxaprozin </e1>  (Daypro), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren,  <e1> Cataflam </e1> ), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn,  <e2> Aleve </e2> );
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin ( <e2> Daypro </e2> ), and naproxen (Anaprox, Naprosyn, Aleve);
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel blocking drugs </e2> , and isoniazid.
false	- a monoamine oxidase inhibitor ( <e1> MAOI </e1> ) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine ( <e2> Nardil </e2> );
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol,  <e1> probenecid </e1> , coumarins,  <e2> monoamine oxidase inhibitors </e2> , and beta adrenergic blocking agents.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines,  <e1> thyroid products </e1> , estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and  <e2> isoniazid </e2> .
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin,  <e1> nicotinic acid </e1> , sympathomimetics, calcium channel blocking drugs, and  <e2> isoniazid </e2> .
int	The effect of concomitant administration of  <e1> fluconazole </e1>  and  <e2> glipizide </e2>  has been demonstrated in a placebo-controlled crossover study in normal volunteers.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> ,  <e2> phenothiazines </e2> , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
effect	The hypoglycemic action of  <e1> sulfonylureas </e1>  may be potentiated by certain drugs including  <e2> nonsteroidal anti-inflammatory agents </e2>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives,  <e2> phenytoin </e2> , nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	- a nonsteroidal anti-inflammatory drug ( <e1> NSAID </e1> ) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac ( <e2> Voltaren </e2> , Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1> , some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and  <e2> beta adrenergic blocking agents </e2> .
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam),  <e1> etodolac </e1>  (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and  <e2> naproxen </e2>  (Anaprox, Naprosyn, Aleve);
false	- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin,  <e1> Permitil </e1> ), prochlorperazine (Compazine),  <e2> promethazine </e2>  (Phenergan), and others;
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines, thyroid products, estrogens, oral  <e2> contraceptives </e2> , phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others), ketoprofen ( <e2> Orudis </e2> , Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
effect	Immediate and Extended Release Tablets The hypoglycemic action of  <e1> sulfonylureas </e1>  may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins,  <e2> monoamine oxidase inhibitors </e2> , and beta adrenergic blocking agents.
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound,  <e1> salicylates </e1> , sulfonamides,  <e2> chloramphenicol </e2> , probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	- a monoamine oxidase inhibitor (MAOI) such as  <e1> isocarboxazid </e1>  (Marplan), tranylcypromine (Parnate), or  <e2> phenelzine </e2>  (Nardil);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen ( <e1> Anaprox </e1> ,  <e2> Naprosyn </e2> , Aleve);
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some  <e1> azoles </e1>  and other drugs that are highly protein bound, salicylates, sulfonamides,  <e2> chloramphenicol </e2> , probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid,  <e2> sympathomimetics </e2> , calcium channel blocking drugs, and isoniazid.
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound,  <e1> salicylates </e1> , sulfonamides, chloramphenicol,  <e2> probenecid </e2> , coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	- a steroid medicine such as  <e1> prednisone </e1>  ( <e2> Deltasone </e2> , Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;
false	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines,  <e1> thyroid products </e1> ,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as  <e1> magnesium/choline salicylate </e1>  ( <e2> Trilisate </e2> ), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another  <e1> salicylate </e1>  such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan),  <e2> magnesium salicylate </e2>  (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid,  <e1> coumarins </e1> ,  <e2> monoamine oxidase inhibitors </e2> , and beta adrenergic blocking agents.
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives,  <e1> phenytoin </e1> , nicotinic acid,  <e2> sympathomimetics </e2> , calcium channel blocking drugs, and isoniazid.
false	- a sulfa-based drug such as  <e1> sulfamethoxazole </e1> -trimethoprim (Bactrim, Septra),  <e2> sulfisoxazole </e2>  (Gantrisin), or sulfasalazine (Azulfidine);
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some  <e1> azoles </e1>  and other drugs that are highly protein bound, salicylates,  <e2> sulfonamides </e2> , chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	- a monoamine oxidase inhibitor (MAOI) such as  <e1> isocarboxazid </e1>  (Marplan), tranylcypromine (Parnate), or  <e2> phenelzine </e2>  (Nardil);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others), ketoprofen ( <e2> Orudis </e2> , Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products,  <e1> estrogens </e1> , oral  <e2> contraceptives </e2> , phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin ( <e2> Daypro </e2> ), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac ( <e1> Voltaren </e1> , Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
effect	The concurrent use of  <e1> Robinul </e1>  Injection with other anticholinergics or medications with anticholinergic activity, such as  <e2> phenothiazines </e2> , antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
false	- a steroid medicine such as  <e1> prednisone </e1>  ( <e2> Deltasone </e2> , Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol,  <e1> probenecid </e1> , coumarins,  <e2> monoamine oxidase inhibitors </e2> , and beta adrenergic blocking agents.
false	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines,  <e1> thyroid products </e1> ,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin ( <e2> Daypro </e2> ), and naproxen (Anaprox, Naprosyn, Aleve);
false	The gonadotropin levels may be transiently elevated by  <e1> spironolactone </e1> , minimally elevated by levodopa, and suppressed by oral  <e2> contraceptives </e2>  and digoxin.
false	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines,  <e1> thyroid products </e1> ,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral  <e1> contraceptives </e1>  and  <e2> digoxin </e2> .
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin ( <e2> Daypro </e2> ), and naproxen (Anaprox, Naprosyn, Aleve);
false	Caffeine  <e1> Theobromine </e1>  Grepafloxacin, like other quinolones, may inhibit the metabolism of  <e2> caffeine </e2>  and theobromine.
false	Administration of quinolones with antacids containing  <e1> aluminum </e1> , magnesium, or  <e2> calcium </e2> , with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of  <e1> grepafloxacin </e1>  on theophylline indicates that  <e2> grepafloxacin </e2>  inhibits theophylline metabolism, which is mediated by CYP1A2.
advise	However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a  <e1> quinolone antimicrobial </e1>  is administered with  <e2> warfarin </e2>  or its derivatives.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as  <e1> VIDEX </e1>  ( <e2> didanosine </e2> ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
mechanism	Administration of  <e1> quinolones </e1>  with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing  <e2> iron </e2>  or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum,  <e1> magnesium </e1> , or calcium, with sucralfate, with metal cations such as  <e2> iron </e2> , or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum,  <e1> magnesium </e1> , or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as  <e2> VIDEX </e2>  (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
mechanism	Administration of  <e1> quinolones </e1>  with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as  <e2> VIDEX </e2>  (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as  <e1> iron </e1> , or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX ( <e2> didanosine </e2> ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	However, because some  <e1> quinolones </e1>  have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with  <e2> warfarin </e2>  or its derivatives.
false	include terfenadine,  <e1> astemizole </e1> , cisapride,  <e2> midazolam </e2> , and triazolam.
false	 <e1> Warfarin </e1> : In subjects receiving  <e2> warfarin </e2> , no significant change in clotting time was observed when grepafloxacin was coadministered.
false	Administration of quinolones with antacids containing  <e1> aluminum </e1> , magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as  <e2> VIDEX </e2>  (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	include  <e1> terfenadine </e1> , astemizole,  <e2> cisapride </e2> , midazolam, and triazolam.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as  <e1> iron </e1> , or with  <e2> multivitamins </e2>  containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with  <e1> multivitamins </e1>  containing  <e2> iron </e2>  or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum,  <e1> magnesium </e1> , or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX ( <e2> didanosine </e2> ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as  <e1> iron </e1> , or with multivitamins containing iron or  <e2> zinc </e2> , or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	include terfenadine, astemizole,  <e1> cisapride </e1> , midazolam, and  <e2> triazolam </e2> .
false	Administration of quinolones with antacids containing  <e1> aluminum </e1> , magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing  <e2> iron </e2>  or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	When initiating a multi-day course of  <e1> grepafloxacin </e1>  in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of  <e2> grepafloxacin </e2>  and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with  <e1> multivitamins </e1>  containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX ( <e2> didanosine </e2> ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with  <e1> antacids </e1>  containing aluminum, magnesium, or calcium, with  <e2> sucralfate </e2> , with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum,  <e1> magnesium </e1> , or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of  <e2> quinolones </e2> , resulting in systemic concentrations considerably lower than desired.
false	 <e1> Theophylline </e1> :  <e2> Grepafloxacin </e2>  is a competitive inhibitor of the metabolism of theophylline.
mechanism	Administration of  <e1> quinolones </e1>  with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX ( <e2> didanosine </e2> ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum, magnesium, or  <e1> calcium </e1> , with sucralfate, with metal cations such as iron, or with multivitamins containing  <e2> iron </e2>  or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with  <e1> sucralfate </e1> , with metal cations such as iron, or with multivitamins containing  <e2> iron </e2>  or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with  <e1> sucralfate </e1> , with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as  <e2> VIDEX </e2>  (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
effect	Concomitant use of  <e1> barbiturates </e1>  usually depresses  <e2> griseofulvin </e2>  activity and may necessitate raising the dosage.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as  <e1> iron </e1> , or with  <e2> multivitamins </e2>  containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	 <e1> Warfarin </e1> : In subjects receiving  <e2> warfarin </e2> , no significant change in clotting time was observed when grepafloxacin was coadministered.
false	Administration of quinolones with antacids containing aluminum,  <e1> magnesium </e1> , or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as  <e2> VIDEX </e2>  (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	When initiating a multi-day course of  <e1> grepafloxacin </e1>  in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of  <e2> grepafloxacin </e2>  and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.
advise	However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a  <e1> quinolone antimicrobial </e1>  is administered with  <e2> warfarin </e2>  or its derivatives.
false	 <e1> Theophylline </e1> :  <e2> Grepafloxacin </e2>  is a competitive inhibitor of the metabolism of theophylline.
effect	The use of  <e1> codeine </e1>  may result in additive CNS depressant effects when coadministered with alcohol,  <e2> antihistamines </e2> , psychotropics or other drugs that produce CNS depression.
effect	Serious toxicity may result if  <e1> dextromethorphan </e1>  is coadministered with monoamine oxidase inhibitors ( <e2> MAOIs </e2> ).
false	When initiating a multi-day course of  <e1> grepafloxacin </e1>  in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of  <e2> grepafloxacin </e2>  and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.
false	The use of codeine may result in additive CNS depressant effects when coadministered with  <e1> alcohol </e1> , antihistamines,  <e2> psychotropics </e2>  or other drugs that produce CNS depression.
false	Serious toxicity may result if dextromethorphan is coadministered with  <e1> monoamine oxidase inhibitors </e1>  ( <e2> MAOIs </e2> ).
effect	Serious toxicity may result if  <e1> dextromethorphan </e1>  is coadministered with monoamine oxidase inhibitors ( <e2> MAOIs </e2> ).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38),  <e1> antihyperlipidemics </e1>  (29), antigout drugs (24), oral contraceptives (18),  <e2> bronchodilators </e2>  (13), insulin (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and  <e1> hypnotics </e1>  (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral  <e2> contraceptives </e2>  (18), bronchodilators (13), insulin (10), and beta blockers (10).
mechanism	The administration of  <e1> guanfacine </e1>  concomitantly with known microsomal enzyme inducer (phenobarbital or  <e2> phenytoin </e2> ) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13),  <e1> insulin </e1>  (10), and  <e2> beta blockers </e2>  (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45),  <e1> NSAIDs </e1>  (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18),  <e2> bronchodilators </e2>  (13), insulin (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38),  <e1> antihyperlipidemics </e1>  (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13),  <e2> insulin </e2>  (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103),  <e1> coronary vasodilators </e1>  (52), oral hypoglycemics (45), cough and cold preparations (45),  <e2> NSAIDs </e2>  (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and  <e1> hypnotics </e1>  (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38),  <e2> antihyperlipidemics </e2>  (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were:  <e1> cardiac glycosides </e1>  (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45),  <e2> NSAIDs </e2>  (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38),  <e1> antihyperlipidemics </e1>  (29), antigout drugs (24), oral  <e2> contraceptives </e2>  (18), bronchodilators (13), insulin (10), and beta blockers (10).
false	 <e1> Anticoagulants </e1> : Ten patients who were stabilized on oral anticoagulants were given  <e2> guanfacine </e2> , 1-2 mg/day, for 4 weeks.
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and  <e1> hypnotics </e1>  (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29),  <e2> antigout drugs </e2>  (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45),  <e1> NSAIDs </e1>  (38), antihyperlipidemics (29),  <e2> antigout drugs </e2>  (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
effect	 <e1> Noncardioselective beta-blockers </e1>  (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when  <e2> guanfacine </e2>  is withdrawn.
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral  <e1> hypoglycemics </e1>  (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral  <e2> contraceptives </e2>  (18), bronchodilators (13), insulin (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral  <e1> hypoglycemics </e1>  (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13),  <e2> insulin </e2>  (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115),  <e1> sedatives </e1>  and hypnotics (103),  <e2> coronary vasodilators </e2>  (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
false	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics,  <e1> opiates </e1> , and  <e2> alcohol </e2> .
false	In a study of 12 schizophrenic patients coadministered oral haloperidol and  <e1> rifampin </e1> , plasma  <e2> haloperidol </e2>  levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.
false	In 5 other schizophrenic patients treated with oral  <e1> haloperidol </e1>  and  <e2> rifampin </e2> , discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38),  <e1> antihyperlipidemics </e1>  (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13),  <e2> insulin </e2>  (10), and beta blockers (10).
effect	As with other antipsychotic agents, it should be noted that  <e1> HALDOL </e1>  may be capable of potentiating  <e2> CNS depressants </e2>  such as anesthetics, opiates, and alcohol.
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45),  <e1> NSAIDs </e1>  (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18),  <e2> bronchodilators </e2>  (13), insulin (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38),  <e1> antihyperlipidemics </e1>  (29), antigout drugs (24), oral  <e2> contraceptives </e2>  (18), bronchodilators (13), insulin (10), and beta blockers (10).
effect	As with other  <e1> antipsychotic agents </e1> , it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and  <e2> alcohol </e2> .
false	FLUOTHANE augments the action of  <e1> non-depolarising muscle relaxant </e1> s and the muscle relaxant effects of  <e2> aminoglycosides </e2> .
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38),  <e1> antihyperlipidemics </e1>  (29), antigout drugs (24), oral  <e2> contraceptives </e2>  (18), bronchodilators (13), insulin (10), and beta blockers (10).
effect	 <e1> FLUOTHANE </e1>  augments the action of  <e2> non-depolarising muscle relaxant </e2> s and the muscle relaxant effects of aminoglycosides.
false	Caution should also be applied for other  <e1> sympathomimetics </e1> , and for aminophylline and theophylline and  <e2> tricyclic antidepressants </e2> , which may also precipitate arrhythmias.
false	Heparin Sodium Injection should not be mixed with doxorubicin, droperidol,  <e1> ciprofloxacin </e1> , or mitoxantrone, since it has been reported that these drugs are incompatible with  <e2> heparin </e2>  and a precipitate may form.
effect	The anticoagulant effect of  <e1> heparin </e1>  is enhanced by concurrent treatment with  <e2> antithrombin III </e2>  (human) in patients with hereditary antithrombin III deficiency.
false	Heparin Sodium Injection should not be mixed with  <e1> doxorubicin </e1> , droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with  <e2> heparin </e2>  and a precipitate may form.
false	Drugs Decreasing  <e1> Heparin </e1>  Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of  <e2> heparin sodium </e2> .
false	Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran,  <e1> phenylbutazone </e1> , ibuprofen,  <e2> indomethacin </e2> , dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
false	Platelet inhibitors: Drugs such as  <e1> acetylsalicylic acid </e1> , dextran, phenylbutazone, ibuprofen, indomethacin,  <e2> dipyridamole </e2> , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
false	Drugs Decreasing Heparin Effect:  <e1> Digitalis </e1> ,  <e2> tetracyclines </e2> , nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
false	Drugs Decreasing Heparin Effect: Digitalis,  <e1> tetracyclines </e1> ,  <e2> nicotine </e2> , or antihistamines may partially counteract the anticoagulant action of heparin sodium.
false	Heparin Sodium Injection should not be mixed with doxorubicin,  <e1> droperidol </e1> , ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with  <e2> heparin </e2>  and a precipitate may form.
false	 <e1> Platelet inhibitors </e1> : Drugs such as  <e2> acetylsalicylic acid </e2> , dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
false	Drug Interactions: a. Drugs Enhancing Heparin Effect: Oral  <e1> anticoagulants </e1> :  <e2> Heparin sodium </e2>  may prolong the one-stage prothrombin time.
false	 <e1> Platelet inhibitors </e1> : Drugs such as acetylsalicylic acid,  <e2> dextran </e2> , phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
effect	Drugs Decreasing Heparin Effect: Digitalis,  <e1> tetracyclines </e1> , nicotine, or antihistamines may partially counteract the anticoagulant action of  <e2> heparin sodium </e2> .
false	Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin,  <e1> dipyridamole </e1> ,  <e2> hydroxychloroquine </e2>  and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
false	Drugs Decreasing Heparin Effect: Digitalis, tetracyclines,  <e1> nicotine </e1> , or  <e2> antihistamines </e2>  may partially counteract the anticoagulant action of heparin sodium.
effect	Toxicology studies of  <e1> heroin </e1> -related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as  <e2> diazepam </e2>  (Valium), and, to a rising degree, methadone.
false	Platelet inhibitors: Drugs such as  <e1> acetylsalicylic acid </e1> , dextran, phenylbutazone, ibuprofen, indomethacin,  <e2> dipyridamole </e2> , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
false	 <e1> Opioids </e1>  are strong  <e2> central nervous system depressants </e2> , but regular users develop physiological tolerance allowing gradually increased dosages.
false	Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as  <e1> diazepam </e1>  ( <e2> Valium </e2> ), and, to a rising degree, methadone.
false	Drugs Decreasing  <e1> Heparin </e1>  Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of  <e2> heparin sodium </e2> .
false	Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including  <e1> alcohol </e1> ,  <e2> benzodiazepines </e2>  such as diazepam (Valium), and, to a rising degree, methadone.
effect	Toxicology studies of  <e1> heroin </e1> -related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree,  <e2> methadone </e2> .
false	 <e1> Platelet inhibitors </e1> : Drugs such as acetylsalicylic acid,  <e2> dextran </e2> , phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
effect	Toxicology studies of  <e1> heroin </e1> -related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as  <e2> diazepam </e2>  (Valium), and, to a rising degree, methadone.
false	Drugs Decreasing  <e1> Heparin </e1>  Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of  <e2> heparin sodium </e2> .
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain  <e1> antibiotics </e1> , quinidine, theophylline,  <e2> corticosteroids </e2> , anticoagulants, and beta blockers.
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids,  <e1> anticoagulants </e1> , and  <e2> beta blockers </e2> .
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain  <e1> antibiotics </e1> , quinidine, theophylline, corticosteroids, anticoagulants, and  <e2> beta blockers </e2> .
effect	 <e1> Barbiturates </e1>  may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine,  <e2> theophylline </e2> , corticosteroids, anticoagulants, and beta blockers.
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain  <e1> antibiotics </e1> , quinidine,  <e2> theophylline </e2> , corticosteroids, anticoagulants, and beta blockers.
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline,  <e1> corticosteroids </e1> ,  <e2> anticoagulants </e2> , and beta blockers.
false	 <e1> Acebutolol </e1> ,  <e2> atenolol </e2> , and nadolol (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.
false	When other potent parental antihypertensive drugs, such as  <e1> diazoxide </e1> , are used in combination with  <e2> hydralazine </e2> , patients should be continuously observed for several hours for any excessive fall in blood pressure.
effect	 <e1> Barbiturates </e1>  may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine,  <e2> theophylline </e2> , corticosteroids, anticoagulants, and beta blockers.
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain  <e1> antibiotics </e1> , quinidine, theophylline, corticosteroids, anticoagulants, and  <e2> beta blockers </e2> .
false	 <e1> Non-steroidal Anti-inflammatory Drugs </e1> : In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide  <e2> diuretics </e2> .
mechanism	Single doses of either cholestyramine or  <e1> colestipol </e1>  resins bind the  <e2> hydrochlorothiazide </e2>  and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
false	 <e1> Corticosteroids </e1> ,  <e2> ACTH </e2> : intensified electrolyte depletion, particularly hypokalemia.
false	Cholestyramine and colestipol  <e1> resins </e1> : Absorption of hydrochlorothiazide is impaired in the presence of  <e2> anionic exchange resins </e2> .
false	 <e1> Antidiabetic drugs </e1> : (oral agents and insulin) - dosage adjustment of the  <e2> antidiabetic drug </e2>  may be required.
false	Therefore, when Hydrochlorothiazide and  <e1> non-steroidal anti-inflammatory agents </e1>  are used concomitantly, the patient should be observed closely to determine if the desired effect of the  <e2> diuretic </e2>  is obtained.
effect	Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a  <e1> non-steroidal anti-inflammatory agent </e1>  can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide  <e2> diuretics </e2> .
false	Diuretic agents reduce the renal clearance of  <e1> lithium </e1>  and add a high risk of  <e2> lithium </e2>  toxicity.
false	Cholestyramine and  <e1> colestipol </e1>  resins: Absorption of hydrochlorothiazide is impaired in the presence of  <e2> anionic exchange resins </e2> .
false	Patients receiving other  <e1> narcotic analgesics </e1> ,  <e2> antipsychotics </e2> , antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
false	Patients receiving other  <e1> narcotic analgesics </e1> , antipsychotics,  <e2> antianxiety agents </e2> , or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics, antipsychotics,  <e1> antianxiety agents </e1> , or other CNS depressants (including alcohol) concomitantly with hydrocodone and  <e2> acetaminophen </e2>  tablets may exhibit an additive CNS depression.
effect	Patients receiving other narcotic analgesics,  <e1> antipsychotics </e1> , antianxiety agents, or other CNS depressants (including alcohol) concomitantly with  <e2> hydrocodone </e2>  and acetaminophen tablets may exhibit an additive CNS depression.
false	Patients receiving other  <e1> narcotic analgesics </e1> , antipsychotics, antianxiety agents, or other  <e2> CNS depressants </e2>  (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
false	Patients receiving other  <e1> narcotic analgesics </e1> , antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and  <e2> acetaminophen </e2>  tablets may exhibit an additive CNS depression.
effect	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including  <e1> alcohol </e1> ) concomitantly with  <e2> hydrocodone </e2>  and acetaminophen tablets may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics, antipsychotics,  <e1> antianxiety agents </e1> , or other  <e2> CNS depressants </e2>  (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
false	Patients receiving other  <e1> narcotic analgesics </e1> , antipsychotics,  <e2> antianxiety agents </e2> , or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
effect	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including  <e1> alcohol </e1> ) concomitantly with  <e2> hydrocodone </e2>  and acetaminophen tablets may exhibit an additive CNS depression.
false	 <e1> Amphotericin B </e1>  or Corticosteroids or Corticotropin ( <e2> ACTH </e2> )
advise	for adult-onset diabetics, dosage adjustment of  <e1> hypoglycemic medications </e1>  may be necessary during and after  <e2> thiazide diuretic </e2>  therapy;
false	Antihypertensive medications, other, especially  <e1> diazoxide </e1> , or pre <e2> anesthetic </e2>  and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery
false	 <e1> Amphotericin B </e1>  or  <e2> Corticosteroids </e2>  or Corticotropin (ACTH)
effect	(In some patients, the  <e1> steroidal anti-inflammatory agent </e1>  can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and  <e2> thiazide diuretics </e2> .
effect	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including  <e1> alcohol </e1> ) concomitantly with  <e2> hydrocodone </e2>  and acetaminophen tablets may exhibit an additive CNS depression.
false	Amphotericin B or  <e1> Corticosteroids </e1>  or  <e2> Corticotropin </e2>  (ACTH)
effect	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics,  <e1> tricyclic antidepressants </e1>  or other CNS depressants (including alcohol) concomitantly with  <e2> DILAUDID </e2>  may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics, general  <e1> anesthetics </e1> , phenothiazines, tranquilizers, sedative-hypnotics,  <e2> tricyclic antidepressants </e2>  or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
effect	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including  <e1> alcohol </e1> ) concomitantly with  <e2> hydrocodone </e2>  and acetaminophen tablets may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics, general  <e1> anesthetics </e1> , phenothiazines, tranquilizers,  <e2> sedative-hypnotics </e2> , tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	Patients receiving other  <e1> narcotic analgesic </e1> s, general anesthetics,  <e2> phenothiazines </e2> , tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	Patients receiving other  <e1> narcotic analgesic </e1> s, general anesthetics, phenothiazines, tranquilizers,  <e2> sedative-hypnotics </e2> , tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers,  <e1> sedative-hypnotics </e1> , tricyclic antidepressants or other  <e2> CNS depressants </e2>  (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics, general  <e1> anesthetics </e1> ,  <e2> phenothiazines </e2> , tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics, general  <e1> anesthetics </e1> , phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other  <e2> CNS depressants </e2>  (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers,  <e1> sedative-hypnotics </e1> , tricyclic antidepressants or other  <e2> CNS depressants </e2>  (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	Patients receiving other  <e1> narcotic analgesic </e1> s, general anesthetics,  <e2> phenothiazines </e2> , tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
effect	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics,  <e1> tricyclic antidepressants </e1>  or other CNS depressants (including alcohol) concomitantly with  <e2> DILAUDID </e2>  may exhibit an additive CNS depression.
false	Patients receiving other  <e1> narcotic analgesic </e1> s, general anesthetics,  <e2> phenothiazines </e2> , tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
effect	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics,  <e1> tricyclic antidepressants </e1>  or other CNS depressants (including alcohol) concomitantly with  <e2> DILAUDID </e2>  may exhibit an additive CNS depression.
effect	THE POTENTIATING ACTION OF  <e1> HYDROXYZINE </e1>  MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS  <e2> NARCOTICS </e2> , NON-NARCOTIC ANALGESICS AND BARBITURATES.
false	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH  <e1> CENTRAL NERVOUS SYSTEM DEPRESSANTS </e1>  SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND  <e2> BARBITURATES </e2> .
false	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other  <e1> antimuscarinics </e1> , amantadine,  <e2> haloperidol </e2> , phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
false	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics,  <e1> amantadine </e1> , haloperidol,  <e2> phenothiazines </e2> , monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
effect	Additive adverse effects resulting from cholinergic blockade may occur when  <e1> LEVSIN </e1>  is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines,  <e2> monoamine oxidase (MAO) inhibitors </e2> , tricyclic antidepressants or some antihistamines.
false	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines,  <e1> monoamine oxidase (MAO) inhibitors </e1> , tricyclic antidepressants or some  <e2> antihistamines </e2> .
false	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other  <e1> antimuscarinics </e1> , amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some  <e2> antihistamines </e2> .
false	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines,  <e1> monoamine oxidase (MAO) inhibitors </e1> ,  <e2> tricyclic antidepressants </e2>  or some antihistamines.
false	However, since  <e1> aspirin </e1> ,  <e2> NSAIDs </e2> , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
false	Among  <e1> aspirin </e1>  or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with  <e2> ibandronate </e2>  2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).
false	Among aspirin or  <e1> NSAID </e1>  users, the incidence of upper gastrointestinal adverse events in patients treated with  <e2> ibandronate </e2>  2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).
false	Products containing  <e1> calcium </e1>  and other multivalent cations (such as aluminum,  <e2> magnesium </e2> , iron) are likely to interfere with absorption of Ibandronate.
false	Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily  <e1> H2 blockers </e1>  and  <e2> PPIs </e2> ).
false	However, since aspirin,  <e1> NSAIDs </e1> , and  <e2> bisphosphonates </e2>  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
false	However, since  <e1> aspirin </e1> , NSAIDs, and  <e2> bisphosphonates </e2>  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
false	However, since aspirin, NSAIDs, and  <e1> bisphosphonates </e1>  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with  <e2> Ibandronate </e2> .
advise	 <e1> Ibandronate </e1>  should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or  <e2> vitamins </e2> ).
mechanism	Products containing calcium and other multivalent cations (such as aluminum, magnesium,  <e1> iron </e1> ) are likely to interfere with absorption of  <e2> Ibandronate </e2> .
false	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other  <e1> antimuscarinics </e1> , amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some  <e2> antihistamines </e2> .
false	Products containing  <e1> calcium </e1>  and other multivalent cations (such as aluminum,  <e2> magnesium </e2> , iron) are likely to interfere with absorption of Ibandronate.
false	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other  <e1> antimuscarinics </e1> , amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some  <e2> antihistamines </e2> .
effect	This may indicate that  <e1> ibuprofen </e1>  could enhance the toxicity of  <e2> methotrexate </e2> .
false	However, because bleeding has been reported when ibuprofen and other  <e1> nonsteroidal anti-inflammatory agents </e1>  have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering  <e2> ibuprofen </e2>  to patients on anticoagulants.
false	Methotrexate:  <e1> Ibuprofen </e1> , as well as other  <e2> nonsteroidal anti-inflammatory drugs </e2> , probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
false	 <e1> Aspirin </e1> : Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including  <e2> ibuprofen </e2> , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
effect	However, because bleeding has been reported when ibuprofen and other  <e1> nonsteroidal anti-inflammatory agents </e1>  have been administered to patients on  <e2> coumarin-type anticoagulants </e2> , the physician should be cautious when administering ibuprofen to patients on anticoagulants.
false	During concomitant therapy with  <e1> ibuprofen </e1> , the patient should be observed closely for signs of renal failure, as well as to assure  <e2> diuretic </e2>  efficacy.
false	Single dose bioavailability studies in normal volunteers have failed to wshow an effect of  <e1> aspirin </e1>  on  <e2> ibuprofen </e2>  blood levels.
false	H-2 Antagonists: In studies with human volunteers, co-administration of  <e1> cimetidine </e1>  or ranitidine with ibuprofen had no substantive effect on  <e2> ibuprofen </e2>  serum concentrations.
false	Aspirin: Animal studies wshow that aspirin given with  <e1> nonsteroidal anti-inflammatory agents </e1> , including  <e2> ibuprofen </e2> , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
false	Coumarin-Type Anticoagulants: Several short-term controlled studies failed to wshow that  <e1> ibuprofen </e1>  significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on  <e2> coumarin-type anticoagulants </e2> .
false	During concomitant therapy with  <e1> ibuprofen </e1> , the patient should be observed closely for signs of renal failure, as well as to assure  <e2> diuretic </e2>  efficacy.
false	Methotrexate:  <e1> Ibuprofen </e1> , as well as other  <e2> nonsteroidal anti-inflammatory drugs </e2> , probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
effect	However, because bleeding has been reported when ibuprofen and other  <e1> nonsteroidal anti-inflammatory agents </e1>  have been administered to patients on  <e2> coumarin-type anticoagulants </e2> , the physician should be cautious when administering ibuprofen to patients on anticoagulants.
false	 <e1> Beta-adrenergic blocking agents </e1> : Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of  <e2> ibutilide </e2>  in the clinical trials.
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of  <e1> vancomycin </e1> , cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with  <e2> EXTRANEAL </e2> .
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin,  <e1> ampicillin </e1> , ampicillin/flucoxacillin, ceftazidime, gentamicin, and  <e2> amphotericin </e2>  demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
false	Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on  <e1> insulin </e1> s ability to control blood glucose when insulin was administered intraperitoneally with  <e2> EXTRANEAL </e2> .
false	Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on  <e1> insulin </e1>  absorption from the peritoneal cavity or on  <e2> insulin </e2> s ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL.
false	Methotrexate:  <e1> Ibuprofen </e1> , as well as other  <e2> nonsteroidal anti-inflammatory drugs </e2> , probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
false	 <e1> Insulin </e1> : A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulins ability to control blood glucose when insulin was administered intraperitoneally with  <e2> EXTRANEAL </e2> .
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and  <e1> amphotericin </e1>  demonstrated no evidence of incompatibility of these antibiotics with  <e2> EXTRANEAL </e2> .
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and  <e1> amphotericin </e1>  demonstrated no evidence of incompatibility of these  <e2> antibiotics </e2>  with EXTRANEAL.
false	Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on  <e1> insulin </e1> s ability to control blood glucose when  <e2> insulin </e2>  was administered intraperitoneally with EXTRANEAL.
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin,  <e1> ampicillin </e1> /flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these  <e2> antibiotics </e2>  with EXTRANEAL.
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin,  <e1> ampicillin </e1> ,  <e2> ampicillin </e2> /flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
false	Methotrexate:  <e1> Ibuprofen </e1> , as well as other  <e2> nonsteroidal anti-inflammatory drugs </e2> , probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin,  <e1> ampicillin </e1> /flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these  <e2> antibiotics </e2>  with EXTRANEAL.
int	Interactions may occur between  <e1> EPA </e1>  supplements and aspirin and other  <e2> non-steroidal anti-inflammatory drugs </e2>  and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
false	Interactions may occur between EPA supplements and aspirin and other  <e1> non-steroidal anti-inflammatory drugs </e1>  and herbs such as garlic (Allium sativum) and ginkgo ( <e2> Ginkgo biloba </e2> ).
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and  <e1> amphotericin </e1>  demonstrated no evidence of incompatibility of these  <e2> antibiotics </e2>  with EXTRANEAL.
false	Boric acid may interact with the  <e1> idoxuridine </e1>  preparation causing a gritty substance to form or may interact with the preservative in the  <e2> idoxuridine </e2>  preparation causing a toxic effect in the eye.
false	Boric acid may interact with the  <e1> idoxuridine </e1>  preparation causing a gritty substance to form or may interact with the preservative in the  <e2> idoxuridine </e2>  preparation causing a toxic effect in the eye.
false	During clinical trials,  <e1> iloprost </e1>  was used concurrently with anticoagulants, diuretics, cardiac glycosides,  <e2> calcium channel blockers </e2> , analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
false	In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous  <e1> iloprost </e1>  and either nifedipine, diltiazem, or  <e2> captopril </e2> .
false	During clinical trials, iloprost was used concurrently with  <e1> anticoagulants </e1> , diuretics, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories,  <e2> corticosteroids </e2> , and other medications.
false	In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous  <e1> iloprost </e1>  and either  <e2> nifedipine </e2> , diltiazem, or captopril.
false	During clinical trials,  <e1> iloprost </e1>  was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics,  <e2> antipyretics </e2> , nonsteroidal antiinflammatories, corticosteroids, and other medications.
false	During clinical trials, iloprost was used concurrently with  <e1> anticoagulants </e1> , diuretics, cardiac glycosides, calcium channel blockers,  <e2> analgesics </e2> , antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
false	During clinical trials, iloprost was used concurrently with anticoagulants, diuretics,  <e1> cardiac glycosides </e1> , calcium channel blockers, analgesics, antipyretics,  <e2> nonsteroidal antiinflammatories </e2> , corticosteroids, and other medications.
false	During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides,  <e1> calcium channel blockers </e1> , analgesics, antipyretics, nonsteroidal antiinflammatories,  <e2> corticosteroids </e2> , and other medications.
false	During clinical trials, iloprost was used concurrently with anticoagulants,  <e1> diuretics </e1> ,  <e2> cardiac glycosides </e2> , calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
false	Drugs that may alter imatinib plasma concentrations Drugs that may increase  <e1> imatinib </e1>  plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin,  <e2> clarithromycin </e2> ).
false	Because  <e1> warfarin </e1>  is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard  <e2> heparin </e2> .
false	Pretreatment of healthy volunteers with multiple doses of  <e1> rifampin </e1>  followed by a single dose of Gleevec, increased  <e2> Gleevec </e2>  oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).
false	During clinical trials, iloprost was used concurrently with anticoagulants,  <e1> diuretics </e1> ,  <e2> cardiac glycosides </e2> , calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
false	In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous  <e1> iloprost </e1>  and either  <e2> nifedipine </e2> , diltiazem, or captopril.
false	Co-medications that induce CYP3A4 (e.g.,  <e1> dexamethasone </e1> ,  <e2> phenytoin </e2> , carbamazepine, rifampin, phenobarbital or St.
false	Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of  <e1> simvastatin </e1>  (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by  <e2> Gleevec </e2> .
false	Drugs that may have their plasma concentration altered by  <e1> Gleevec </e1>  Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by  <e2> Gleevec </e2> .
advise	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering  <e1> Gleevec </e1>  with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole,  <e2> erythromycin </e2> , clarithromycin).
false	During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides,  <e1> calcium channel blockers </e1> , analgesics, antipyretics, nonsteroidal antiinflammatories,  <e2> corticosteroids </e2> , and other medications.
false	Co-medications that induce CYP3A4 (e.g.,  <e1> dexamethasone </e1> , phenytoin, carbamazepine,  <e2> rifampin </e2> , phenobarbital or St.
mechanism	Pretreatment of healthy volunteers with multiple doses of  <e1> rifampin </e1>  followed by a single dose of  <e2> Gleevec </e2> , increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).
mechanism	 <e1> Gleevec </e1>  will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo- <e2> benzodiazepines </e2> , dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).
false	Co-medications that induce CYP3A4 (e.g.,  <e1> dexamethasone </e1> , phenytoin, carbamazepine,  <e2> rifampin </e2> , phenobarbital or St.
false	Avoid the use of preparations such as decongestants and local  <e1> anesthetics </e1>  which contain any sympathomimetic amine (e.g.,  <e2> epinephrine </e2> , norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
false	While all the selective serotonin reuptake inhibitors (SSRIs), e. g.,  <e1> fluoxetine </e1> , sertraline, and  <e2> paroxetine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g.,  <e1> cimetidine </e1> , fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g.,  <e2> barbiturates </e2> , phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
false	The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g.,  <e1> barbiturates </e1> , phenytoin), and adjustment of the dosage of  <e2> imipramine </e2>  may therefore be necessary.
false	While all the  <e1> selective serotonin reuptake inhibitors </e1>  ( <e2> SSRIs </e2> ), e. g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
false	Avoid the use of preparations such as  <e1> decongestants </e1>  and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine,  <e2> norepinephrine </e2> ), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
false	While all the selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ), e. g., fluoxetine, sertraline, and  <e2> paroxetine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	Avoid the use of preparations such as  <e1> decongestants </e1>  and local anesthetics which contain any  <e2> sympathomimetic amine </e2>  (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
false	Avoid the use of preparations such as  <e1> decongestants </e1>  and local  <e2> anesthetics </e2>  which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
false	Drugs that may have their plasma concentration altered by  <e1> Gleevec </e1>  Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by  <e2> Gleevec </e2> .
advise	Avoid the use of preparations such as decongestants and local  <e1> anesthetics </e1>  which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that  <e2> tricyclic antidepressants </e2>  can potentiate the effects of catecholamines.
mechanism	Pretreatment of healthy volunteers with multiple doses of  <e1> rifampin </e1>  followed by a single dose of  <e2> Gleevec </e2> , increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).
false	Avoid the use of preparations such as decongestants and local anesthetics which contain any  <e1> sympathomimetic amine </e1>  (e.g.,  <e2> epinephrine </e2> , norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
false	Avoid the use of preparations such as decongestants and local  <e1> anesthetics </e1>  which contain any sympathomimetic amine (e.g.,  <e2> epinephrine </e2> , norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
false	While all the selective serotonin reuptake inhibitors (SSRIs), e. g.,  <e1> fluoxetine </e1> , sertraline, and  <e2> paroxetine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	Avoid the use of preparations such as  <e1> decongestants </e1>  and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine,  <e2> norepinephrine </e2> ), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
false	 <e1> Antiarrhythmics </e1> :  <e2> bepridil </e2> , lidocaine (systemic) and quinidine
false	Calcium Channel Blockers, Dihydropyridine: e.g., felodipine,  <e1> nifedipine </e1> ,  <e2> nicardipine </e2> 
false	Use lowest possible dose of atorvastatin with careful monitoring, or consider  <e1> HMG-CoA reductase inhibitors </e1>  that are not primarily metabolized by CYP3A4, such as  <e2> pravastatin </e2> , fluvastatin, or rosuvastatin in combination with CRIXIVAN.
false	Both  <e1> CRIXIVAN </e1>  and  <e2> atazanavir </e2>  are associated with indirect (unconjugated) hyperbilirubinemia.
false	Use lowest possible dose of  <e1> atorvastatin </e1>  with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or  <e2> rosuvastatin </e2>  in combination with CRIXIVAN.
false	Immunosuppressants: cyclosporine,  <e1> tacrolimus </e1> ,  <e2> sirolimus </e2> 
false	 <e1> Calcium Channel Blockers </e1> , Dihydropyridine: e.g., felodipine, nifedipine,  <e2> nicardipine </e2> 
advise	Combinations of these drugs have not been studied and coadministration of  <e1> CRIXIVAN </e1>  and  <e2> atazanavir </e2>  is not recommended.
false	 <e1> Antiarrhythmics </e1> : bepridil,  <e2> lidocaine </e2>  (systemic) and quinidine
false	Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of  <e1> indinavir </e1>  and may result in increased plasma concentrations of  <e2> indinavir </e2> .
advise	Use lowest possible dose of  <e1> atorvastatin </e1>  with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with  <e2> CRIXIVAN </e2> .
false	Ergot derivatives:  <e1> dihydroergotamine </e1> , ergonovine,  <e2> ergotamine </e2> , methylergonovine
false	Immunosuppressants:  <e1> cyclosporine </e1> , tacrolimus,  <e2> sirolimus </e2> 
false	 <e1> Sedative </e1> /hypnotics: midazolam,  <e2> triazolam </e2> 
false	Calcium Channel Blockers, Dihydropyridine: e.g.,  <e1> felodipine </e1> ,  <e2> nifedipine </e2> , nicardipine
mechanism	 <e1> Indinavir </e1>  concentrations may be decreased in the presence of  <e2> nevirapine </e2> .
effect	 <e1> CRIXIVAN </e1>  may not be effective due to decreased  <e2> indinavir </e2>  concentrations in patients taking these agents concomitantly.
false	 <e1> Sedative </e1> /hypnotics:  <e2> midazolam </e2> , triazolam
false	Dose reduction of  <e1> rifabutin </e1>  to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and  <e2> CRIXIVAN </e2>  are coadministered.
false	Avoid the use of preparations such as  <e1> decongestants </e1>  and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine,  <e2> norepinephrine </e2> ), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
false	Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or  <e1> rosuvastatin </e1>  in combination with  <e2> CRIXIVAN </e2> .
advise	Therefore,  <e1> diflunisal </e1>  and  <e2> INDOCIN </e2>  should not be used concomitantly.
advise	Combinations of these drugs have not been studied and coadministration of  <e1> CRIXIVAN </e1>  and  <e2> atazanavir </e2>  is not recommended.
false	Immunosuppressants: cyclosporine,  <e1> tacrolimus </e1> ,  <e2> sirolimus </e2> 
false	Calcium Channel Blockers, Dihydropyridine: e.g., felodipine,  <e1> nifedipine </e1> ,  <e2> nicardipine </e2> 
false	 <e1> Sedative </e1> /hypnotics:  <e2> midazolam </e2> , triazolam
false	Immunosuppressants:  <e1> cyclosporine </e1> , tacrolimus,  <e2> sirolimus </e2> 
effect	The potential effects of  <e1> INDOCIN </e1>  and  <e2> potassium-sparing diuretics </e2>  on potassium kinetics and renal function should be considered when these agents are administered concurrently.
false	In normal volunteers receiving  <e1> indomethacin </e1> , the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of  <e2> indomethacin </e2> .
effect	 <e1> CRIXIVAN </e1>  may not be effective due to decreased  <e2> indinavir </e2>  concentrations in patients taking these agents concomitantly.
mechanism	Capsules  <e1> INDOCIN </e1>  50 mg t.i.d. produced a clinically relevant elevation of plasma  <e2> lithium </e2>  and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.
false	Therefore, when  <e1> INDOCIN </e1>  and digoxin are used concomitantly, serum  <e2> digoxin </e2>  levels should be closely monitored.
false	Therefore, when  <e1> INDOCIN </e1>  and  <e2> INDOCIN </e2> .
effect	It has been reported that the addition of  <e1> triamterene </e1>  to a maintenance schedule of  <e2> INDOCIN </e2>  resulted in reversible acute renal failure in two of four healthy volunteers.
mechanism	 <e1> INDOCIN </e1>  given concomitantly with  <e2> digoxin </e2>  has been reported to increase the serum concentration and prolong the half-life of digoxin.
false	 <e1> INDOCIN </e1>  given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of  <e2> digoxin </e2> .
false	As a consequence, when INDOCIN and  <e1> lithium </e1>  are given concomitantly, the patient should be carefully observed for signs of  <e2> lithium </e2>  toxicity.
false	In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as  <e1> nonsteroidal anti-inflammatory agents </e1> ,  <e2> folic acid </e2>  and corticosteroids.
false	Concomitant Crohn s disease medications were antibiotics, antivirals,  <e1> corticosteroids </e1> ,  <e2> 6-MP </e2> /AZA and aminosalicylates.
false	Concomitant Crohn s disease medications were antibiotics, antivirals, corticosteroids,  <e1> 6-MP </e1> / <e2> AZA </e2>  and aminosalicylates.
false	In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents,  <e1> folic acid </e1> , corticosteroids and/or  <e2> narcotics </e2> .
advise	Therefore,  <e1> diflunisal </e1>  and  <e2> INDOCIN </e2>  should not be used concomitantly.
effect	Other  <e1> TNFa-blocking agents </e1>  (including REMICADE) used in combination with  <e2> anakinra </e2>  may also result in similar toxicities.
false	Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including  <e1> corticosteroids </e1> , antibiotics ( <e2> metronidazole </e2>  or ciprofloxacin) and aminosalicylates.
false	In rheumatoid arthritis, concomitant medications besides MTX were  <e1> nonsteroidal anti-inflammatory agents </e1> , folic acid, corticosteroids and/or  <e2> narcotics </e2> .
false	Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics ( <e1> metronidazole </e1>  or  <e2> ciprofloxacin </e2> ) and aminosalicylates.
mechanism	Capsules  <e1> INDOCIN </e1>  50 mg t.i.d. produced a clinically relevant elevation of plasma  <e2> lithium </e2>  and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.
false	Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including  <e1> corticosteroids </e1> , antibiotics (metronidazole or  <e2> ciprofloxacin </e2> ) and aminosalicylates.
false	In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal anti-inflammatory agents,  <e1> folic acid </e1>  and  <e2> corticosteroids </e2> .
false	Therefore, when  <e1> INDOCIN </e1>  and  <e2> INDOCIN </e2> .
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine,  <e1> albuterol </e1> ,  <e2> terbutaline </e2> ), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin,  <e1> thyroid hormones </e1> ,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics,  <e1> sympathomimetic agents </e1>  (e.g., epinephrine, albuterol, terbutaline),  <e2> isoniazid </e2> , phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin:  <e1> corticosteroids </e1> , danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol,  <e2> terbutaline </e2> ), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide,  <e1> fibrates </e1> , fluoxetine, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide),  <e2> sulfonamide antibiotics </e2> .
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of  <e1> insulin </e1> : corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral  <e2> contraceptives </e2> ).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol,  <e1> diuretics </e1> , sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives,  <e2> somatropin </e2> , thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids,  <e1> danazol </e1> , diuretics,  <e2> sympathomimetic agents </e2>  (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin:  <e1> corticosteroids </e1> , danazol, diuretics,  <e2> sympathomimetic agents </e2>  (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol,  <e1> diuretics </e1> , sympathomimetic agents (e.g., epinephrine,  <e2> albuterol </e2> , terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal anti-inflammatory agents,  <e1> folic acid </e1>  and  <e2> corticosteroids </e2> .
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid,  <e1> phenothiazine derivatives </e1> , somatropin,  <e2> thyroid hormones </e2> , estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products,  <e1> ACE inhibitors </e1> , disopyramide, fibrates,  <e2> fluoxetine </e2> , MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors,  <e1> disopyramide </e1> , fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide),  <e2> sulfonamide antibiotics </e2> .
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of  <e1> insulin </e1> : corticosteroids, danazol, diuretics,  <e2> sympathomimetic agents </e2>  (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of  <e1> insulin </e1> : corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin:  <e1> corticosteroids </e1> , danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin,  <e1> thyroid hormones </e1> , estrogens, progestogens (e.g., in oral  <e2> contraceptives </e2> ).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products,  <e1> ACE inhibitors </e1> , disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide),  <e2> sulfonamide antibiotics </e2> .
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol,  <e1> terbutaline </e1> ),  <e2> isoniazid </e2> , phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol,  <e1> diuretics </e1> , sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide,  <e1> fibrates </e1> , fluoxetine,  <e2> MAO inhibitors </e2> , propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin:  <e1> corticosteroids </e1> , danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline),  <e2> isoniazid </e2> , phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin:  <e1> corticosteroids </e1> , danazol, diuretics, sympathomimetic agents (e.g.,  <e2> epinephrine </e2> , albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents,  <e1> folic acid </e1> , corticosteroids and/or  <e2> narcotics </e2> .
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g.,  <e1> epinephrine </e1> , albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin:  <e1> corticosteroids </e1> ,  <e2> danazol </e2> , diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid,  <e1> phenothiazine derivatives </e1> , somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g.,  <e1> octreotide </e1> ),  <e2> sulfonamide antibiotics </e2> .
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids,  <e1> danazol </e1> , diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral  <e2> contraceptives </e2> ).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene,  <e1> salicylates </e1> ,  <e2> somatostatin analog </e2>  (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids,  <e1> danazol </e1> , diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline),  <e2> isoniazid </e2> , phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products,  <e1> ACE inhibitors </e1> , disopyramide, fibrates, fluoxetine, MAO inhibitors,  <e2> propoxyphene </e2> , salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
effect	Beta-blockers,  <e1> clonidine </e1> , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of  <e2> insulin </e2> .
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates,  <e1> fluoxetine </e1> , MAO inhibitors,  <e2> propoxyphene </e2> , salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of  <e1> insulin </e1> : corticosteroids, danazol,  <e2> diuretics </e2> , sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol,  <e1> diuretics </e1> , sympathomimetic agents (e.g., epinephrine,  <e2> salbutamol </e2> , terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol,  <e1> terbutaline </e1> ), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral  <e2> contraceptives </e2> ).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine,  <e1> albuterol </e1> ,  <e2> terbutaline </e2> ), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives,  <e1> somatropin </e1> , thyroid hormones, estrogens,  <e2> progestogens </e2>  (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products,  <e1> ACE inhibitors </e1> , disopyramide, fibrates, fluoxetine, MAO inhibitors,  <e2> propoxyphene </e2> , salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine,  <e1> monoamine oxidase (MAO) inhibitors </e1> , propoxyphene,  <e2> salicylates </e2> , somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors,  <e1> disopyramide </e1> , fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,  <e2> propoxyphene </e2> , salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids,  <e1> danazol </e1> , diuretics,  <e2> sympathomimetic agents </e2>  (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids,  <e1> niacin </e1> , danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid,  <e1> phenothiazine derivatives </e1> , somatropin,  <e2> thyroid hormones </e2> , estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics,  <e1> sympathomimetic agents </e1>  (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of  <e1> insulin </e1> : corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol,  <e1> diuretics </e1> , sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral  <e1> antidiabetic products </e1> , ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide),  <e2> sulfonamide antibiotics </e2> .
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral  <e1> antidiabetic products </e1> , ACE inhibitors, disopyramide,  <e2> fibrates </e2> , fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The effects of mixing  <e1> NovoLog </e1>  with insulins of animal source or  <e2> insulin </e2>  preparations produced by other manufacturers have not been studied .
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol,  <e1> diuretics </e1> , sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives,  <e2> somatropin </e2> , thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	Because there are no data on the compatibility of  <e1> NovoLog </e1>  and crystalline  <e2> zinc insulin </e2>  preparations, NovoLog should not be mixed with these preparations.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene,  <e1> salicylates </e1> , somatostatin analog (e.g., octreotide),  <e2> sulfonamide antibiotics </e2> .
false	The following are examples of substances that may reduce the blood-glucose-lowering effect:  <e1> corticosteroids </e1> , niacin,  <e2> danazol </e2> , diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene,  <e1> salicylates </e1> , somatostatin analog (e.g.,  <e2> octreotide </e2> ), sulfonamide antibiotics.
false	In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine,  <e1> guanethidine </e1> , and  <e2> reserpine </e2> , the signs of hypoglycemia may be reduced or absent.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral  <e1> antidiabetic products </e1> , ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,  <e2> propoxyphene </e2> , salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics,  <e1> sympathomimetic agents </e1>  (e.g., epinephrine,  <e2> salbutamol </e2> , terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH human insulin immediately before injection produced some attenuation in the peak concentration of  <e1> NovoLog </e1> , but that the time to peak and the total bioavailability of  <e2> NovoLog </e2>  were not significantly affected.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide,  <e1> fibrates </e1> , fluoxetine,  <e2> MAO inhibitors </e2> , propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors,  <e1> disopyramide </e1> , fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene,  <e2> salicylates </e2> , somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect:  <e1> corticosteroids </e1> , niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens,  <e2> progestogens </e2>  (e.g., in oral contraceptives).
false	In addition, under the influence of sympatholytic medicinal products such as  <e1> beta-blockers </e1> , clonidine,  <e2> guanethidine </e2> , and reserpine, the signs of hypoglycemia may be reduced or absent.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect:  <e1> corticosteroids </e1> , niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine,  <e2> salbutamol </e2> , terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide,  <e1> fibrates </e1> , fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene,  <e2> salicylates </e2> , somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol,  <e1> diuretics </e1> , sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin,  <e2> thyroid hormones </e2> , estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g.,  <e1> epinephrine </e1> , salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect:  <e1> corticosteroids </e1> , niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin,  <e1> danazol </e1> , diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids,  <e1> niacin </e1> , danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens,  <e2> progestogens </e2>  (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,  <e1> propoxyphene </e1> ,  <e2> salicylates </e2> , somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates,  <e1> somatostatin analog </e1>  (e.g.,  <e2> octreotide </e2> ), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin,  <e1> danazol </e1> , diuretics, sympathomimetic agents (e.g.,  <e2> epinephrine </e2> , salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of  <e1> insulin </e1> : corticosteroids, danazol, diuretics,  <e2> sympathomimetic agents </e2>  (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
effect	Beta-blockers,  <e1> clonidine </e1> , lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of  <e2> insulin </e2> .
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,  <e1> propoxyphene </e1> , salicylates, somatostatin analog (e.g.,  <e2> octreotide </e2> ), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin,  <e1> thyroid hormones </e1> ,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	In addition, under the influence of sympatholytic medicinal products such as beta-blockers,  <e1> clonidine </e1> , guanethidine, and  <e2> reserpine </e2> , the signs of hypoglycemia may be reduced or absent.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products,  <e1> ACE inhibitors </e1> , disopyramide, fibrates, fluoxetine,  <e2> monoamine oxidase (MAO) inhibitors </e2> , propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	Beta-blockers, clonidine,  <e1> lithium </e1>  salts, and  <e2> alcohol </e2>  may either potentiate or weaken the blood-glucose-lowering effect of insulin.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g.,  <e1> epinephrine </e1> , salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect:  <e1> corticosteroids </e1> , niacin,  <e2> danazol </e2> , diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect:  <e1> corticosteroids </e1> , niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol,  <e1> diuretics </e1> , sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin,  <e2> thyroid hormones </e2> , estrogens, progestogens (e.g., in oral contraceptives).
false	In addition, under the influence of sympatholytic medicinal products such as beta-blockers,  <e1> clonidine </e1> , guanethidine, and  <e2> reserpine </e2> , the signs of hypoglycemia may be reduced or absent.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors,  <e1> disopyramide </e1> , fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene,  <e2> salicylates </e2> , somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene,  <e1> salicylates </e1> , somatostatin analog (e.g., octreotide),  <e2> sulfonamide antibiotics </e2> .
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine,  <e1> albuterol </e1> ,  <e2> terbutaline </e2> ), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	Also, the potential for hepatic injury should be considered when  <e1> Rebif </e1>   is used in combination with other products associated with hepatic injury, or when new agents are added to the regimen of patients already on  <e2> Rebif </e2>  .
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors,  <e1> disopyramide </e1> , fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene,  <e2> salicylates </e2> , somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	 <e1> Betaseron </e1>  administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of  <e2> Betaseron </e2>  on drug metabolism in MS patients is unknown.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect:  <e1> corticosteroids </e1> , niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	 <e1> Anticholinergic agents </e1> : Although  <e2> ipratropium bromide </e2>  is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.
false	ATROVENT Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic bronchodilators,  <e1> methylxanthines </e1> , and  <e2> steroids </e2> , commonly used in the treatment of chronic obstructive pulmonary disease.
false	 <e1> ATROVENT </e1>  Inhalation Aerosol has been used concomitantly with other drugs, including  <e2> sympathomimetic bronchodilators </e2> , methylxanthines, and steroids, commonly used in the treatment of chronic obstructive pulmonary disease.
false	ATROVENT Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic bronchodilators,  <e1> methylxanthines </e1> , and  <e2> steroids </e2> , commonly used in the treatment of chronic obstructive pulmonary disease.
false	In separate studies of patients receiving maintenance doses of  <e1> warfarin </e1> ,  <e2> hydrochlorothiazide </e2> , or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.
false	In separate studies of patients receiving maintenance doses of warfarin,  <e1> hydrochlorothiazide </e1> , or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of  <e2> digoxin </e2> .
false	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or  <e1> digoxin </e1> , irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of  <e2> digoxin </e2> .
false	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole,  <e1> tolbutamide </e1>  and  <e2> nifedipine </e2> .
false	No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with  <e1> hydrochlorothiazide </e1> , digoxin, warfarin, and  <e2> nifedipine </e2> .
effect	In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold  <e1> diuretics </e1>  during dosing with  <e2> CAMPTOSAR </e2>  and, certainly, during periods of active vomiting or diarrhea.
false	In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by  <e1> CAMPTOSAR </e1> , the physician may wish to withhold  <e2> diuretics </e2>  during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.
effect	In a single study, rats given high intraperitoneal doses of an  <e1> MAO inhibitor </e1>  plus  <e2> disulfiram </e2>  experienced severe toxicity, including convulsions and death.
false	May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and  <e1> disopyramide </e1> , quinidine,  <e2> phenothiazines </e2> , and procainamide (these medicines may increase the risk of heart problems).
false	May interact with the following:  <e1> beta-adrenergic blocking agents </e1>  (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide, quinidine,  <e2> phenothiazines </e2> , and procainamide (these medicines may increase the risk of heart problems).
false	May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the  <e1> adrenergic bronchodilators </e1>  from working properly) and disopyramide, quinidine,  <e2> phenothiazines </e2> , and procainamide (these medicines may increase the risk of heart problems).
effect	 <e1> Isoflurane </e1>  potentiates the muscle relaxant effect of all muscle relaxants, most notably  <e2> nondepolarizing muscle relaxants </e2> , and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
false	Isoflurane potentiates the muscle relaxant effect of all  <e1> muscle relaxants </e1> , most notably  <e2> nondepolarizing muscle relaxants </e2> , and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
false	Carbamazepine:  <e1> Isoniazid </e1>  is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of  <e2> carbamazepine </e2>  toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
false	 <e1> Acetaminophen </e1> : A report of severe  <e2> acetaminophen </e2>  toxicity was reported in a patient receiving Isoniazid.
false	Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of  <e1> theophylline </e1> , and in some instances a slight decrease in the elimination of  <e2> isoniazid </e2> .
false	 <e1> Carbamazepine </e1> : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with  <e2> isoniazid </e2> , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
false	 <e1> Ketoconazole </e1> : Potential interaction of Ketoconazole and  <e2> Isoniazid </e2>  may exist.
mechanism	Valproate: A recent case study has shown a possible increase in the plasma level of  <e1> valproate </e1>  when co administered with  <e2> isoniazid </e2> .
false	 <e1> Valproate </e1> : A recent case study has shown a possible increase in the plasma level of  <e2> valproate </e2>  when co administered with isoniazid.
false	Therophylline: A recent study has shown that concomitan administration of  <e1> isoniazid </e1>  and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of  <e2> isoniazid </e2> .
false	Carbamazepine: Isoniazid is known to slow the metabolism of  <e1> carbamazepine </e1>  and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with  <e2> isoniazid </e2> , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
false	 <e1> Phenytoin </e1> : Isoniazid may increase serum levels of  <e2> phenytoin </e2> .
advise	Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels  <e1> Carbamazepine </e1>  levels should be determined prior to concurrent administration with  <e2> isoniazid </e2> , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
false	 <e1> Acetaminophen </e1> : A report of severe  <e2> acetaminophen </e2>  toxicity was reported in a patient receiving Isoniazid.
advise	 <e1> ISUPREL </e1>  should be used with caution, if at all, when potent inhalational  <e2> anesthetics </e2>  such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.
false	 <e1> Phenytoin </e1> : Isoniazid may increase serum levels of  <e2> phenytoin </e2> .
false	 <e1> Phenytoin </e1> : Isoniazid may increase serum levels of  <e2> phenytoin </e2> .
effect	Marked symptomatic orthostatic hypotension has been reported when  <e1> calcium channel blockers </e1>  and  <e2> organic nitrates </e2>  were used in combination.
false	Tetracyclines: Concomitant treatment with  <e1> Accutane </e1>  and tetracyclines should be avoided because  <e2> Accutane </e2>  use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
effect	Marked symptomatic orthostatic hypotension has been reported when  <e1> calcium channel blockers </e1>  and  <e2> organic nitrates </e2>  were used in combination.
false	 <e1> Tetracyclines </e1> : Concomitant treatment with Accutane and  <e2> tetracyclines </e2>  should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
false	Vitamin A: Because of the relationship of  <e1> Accutane </e1>  to vitamin A, patients should be advised against taking vitamin supplements containing  <e2> vitamin A </e2>  to avoid additive toxic effects
false	 <e1> Tetracyclines </e1> : Concomitant treatment with  <e2> Accutane </e2>  and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
false	Tetracyclines: Concomitant treatment with Accutane and  <e1> tetracyclines </e1>  should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of  <e2> tetracyclines </e2> 
false	Micro-dosed  <e1> Progesterone </e1>  Preparations: Micro-dosed progesterone preparations (minipills that do not contain an  <e2> estrogen </e2> ) may be an inadequate method of contraception during Accutane therapy.
false	 <e1> Cimetidine </e1> : In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in  <e2> isradipine </e2>  mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).
false	Rifampicin: In a study in healthy volunteers, a six-day course of  <e1> rifampicin </e1>  at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in  <e2> isradipine </e2>  levels to below detectable limits.
false	 <e1> Fentanyl </e1>  Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a  <e2> beta blocker </e2>  and a calcium channel blocker.
false	Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of  <e1> DynaCirc </e1>   (isradipine) and  <e2> hydrochlorothiazide </e2>  does not result in altered pharmacoktnetics of either drug.
false	 <e1> Cimetidine </e1> : In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of  <e2> isradipine </e2>  on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).
false	 <e1> Nitroglycerin </e1> :  <e2> DynaCirc </e2>   (isradipine) has been safely coadministered with nitroglycerin.
false	 <e1> propranolol </e1>  to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between  <e2> propranolol </e2>  given singly and in combination with isradipine.
false	Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of  <e1> DynaCirc </e1>   ( <e2> isradipine </e2> ) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.
false	 <e1> Fentanyl </e1>  Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a  <e2> calcium channel blocker </e2> .
false	 <e1> Hydrochlorothiazide </e1> : A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  ( <e2> isradipine </e2> ) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.
false	Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  ( <e1> isradipine </e1> ) and  <e2> hydrochlorothiazide </e2>  does not result in altered pharmacoktnetics of either drug.
false	Digoxin: The concomitant administration of DynaCirc  ( <e1> isradipine </e1> ) and  <e2> digoxin </e2>  in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin.
false	In a study in hypertensive patients, addition of  <e1> isradipine </e1>  to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and  <e2> isradipine </e2>  had an additional antihypertensive effect.
false	 <e1> Hydrochlorothiazide </e1> : A study in normal healthy volunteers has shown that concomitant administration of  <e2> DynaCirc </e2>   (isradipine) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.
false	 <e1> Rifampicin </e1> : In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of  <e2> isradipine </e2>  resulted in a reduction in isradipine levels to below detectable limits.
advise	Blood glucose concentrations should be carefully monitored when  <e1> Itraconazole </e1>  and oral  <e2> hypoglycemic agents </e2>  are coadministered.
false	The results from a study in which eight HIV-infected individuals were treated with  <e1> zidovudine </e1> , 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of zidovudine were not affected during concomitant administration of  <e2> Itraconazole </e2> , 100 mg b.i.d.
advise	 <e1> Cyclosporine </e1> , tacrolimus and digoxin concentrations should be monitored at the initiation of  <e2> Itraconazole </e2>  therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
false	Coadministration of terfenadine with  <e1> Itraconazole </e1>  has led to elevated plasma concentrations of  <e2> terfenadine </e2> , resulting in rare instances of life- threatening cardiac dysrhythmias and one death.
mechanism	Coadministration of  <e1> terfenadine </e1>  with  <e2> Itraconazole </e2>  has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.
mechanism	When  <e1> Itraconazole </e1>  was coadministered with phenytoin,  <e2> rifampin </e2> , or H2antagonists, reduced plasma concentrations of itraconazole were reported.
effect	Severe hypoglycemia has been reported in patients concomitantly receiving  <e1> azole antifungal agents </e1>  and oral  <e2> hypoglycemic agents </e2> .
false	When Itraconazole was coadministered with  <e1> phenytoin </e1> ,  <e2> rifampin </e2> , or H2antagonists, reduced plasma concentrations of itraconazole were reported.
false	When Itraconazole was coadministered with phenytoin,  <e1> rifampin </e1> , or H2antagonists, reduced plasma concentrations of  <e2> itraconazole </e2>  were reported.
false	When Itraconazole was coadministered with  <e1> phenytoin </e1> , rifampin, or H2antagonists, reduced plasma concentrations of  <e2> itraconazole </e2>  were reported.
false	Coadministration of Itraconazole and  <e1> cyclosporine </e1> , tacrolimus or  <e2> digoxin </e2>  has led to increased plasma concentrations of the latter three drugs.
effect	Edema has been reported in patients concomitantly receiving  <e1> Itraconazole </e1>  and  <e2> dihydropyridine calcium channel blockers </e2> .
false	 <e1> Itraconazole </e1>  plasma concentrations should be monitored when  <e2> Itraconazole </e2>  and isoniazid are coadministered.
false	Another oral azole antifungal, ketoconazole, inhibits the metabolism of  <e1> astemizole </e1> , resulting in elevated plasma concentrations of astemizole and its active metabolite  <e2> desmethylastermizole </e2>  which may prolong QT intervals.
false	 <e1> Rifampicin </e1> : In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of  <e2> isradipine </e2>  resulted in a reduction in isradipine levels to below detectable limits.
false	Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with  <e1> immunosuppressive drugs </e1>  including  <e2> cyclosporine </e2> .
mechanism	Another oral azole antifungal,  <e1> ketoconazole </e1> , inhibits the metabolism of  <e2> astemizole </e2> , resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.
false	Coadministration of Itraconazole and cyclosporine,  <e1> tacrolimus </e1>  or  <e2> digoxin </e2>  has led to increased plasma concentrations of the latter three drugs.
advise	 <e1> Cyclosporine </e1> , tacrolimus and digoxin concentrations should be monitored at the initiation of  <e2> Itraconazole </e2>  therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
mechanism	When  <e1> Itraconazole </e1>  was coadministered with phenytoin,  <e2> rifampin </e2> , or H2antagonists, reduced plasma concentrations of itraconazole were reported.
false	Coadministration of Itraconazole and cyclosporine,  <e1> tacrolimus </e1>  or  <e2> digoxin </e2>  has led to increased plasma concentrations of the latter three drugs.
effect	In vitro mixing of an  <e1> aminoglycoside </e1>  with beta-lactamtype antibiotics (penicillins or  <e2> cephalosporins </e2> ) may result in a significant mutual inactivation.
false	Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with  <e1> immunosuppressive drugs </e1>  including  <e2> cyclosporine </e2> .
false	When Itraconazole was coadministered with  <e1> phenytoin </e1> ,  <e2> rifampin </e2> , or H2antagonists, reduced plasma concentrations of itraconazole were reported.
false	Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with  <e1> immunosuppressive drugs </e1>  including  <e2> cyclosporine </e2> .
false	Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of  <e1> astemizole </e1> , resulting in elevated plasma levels of astemizole and its active metabolite  <e2> desmethylastemizole </e2>  which may prolong QT intervals.
false	The following drug interactions have been identified involving  <e1> NIZORAL </e1>  Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of  <e2> terfenadine </e2> , resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.
false	After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of  <e1> loratadine </e1>  to 11 subjects, the AUC and Cmax of  <e2> loratadine </e2>  averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.
effect	When taken orally , imidazole compounds like  <e1> ketoconazole </e1>  may enhance the anticoagulant effect of  <e2> coumarin </e2> -like drugs.
false	Dosage adjustment may be required if  <e1> cyclosporine </e1> , tacrolimus, or methylprednisolone are given concomitantly with  <e2> NIZORAL </e2>   Tablets.
mechanism	 <e1> Ketoconazole </e1>  tablets may alter the metabolism of cyclosporine,  <e2> tacrolimus </e2> , and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
false	Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with  <e1> immunosuppressive drugs </e1>  including  <e2> cyclosporine </e2> .
false	Coadministration of NIZORAL  Tablets with  <e1> midazolam </e1>  or  <e2> triazolam </e2>  has resulted in elevated plasma concentrations of the latter two drugs.
advise	Coadministration of  <e1> astemizole </e1>  with  <e2> ketoconazole </e2>  tablets is therefore contraindicated.
false	Dosage adjustment may be required if cyclosporine,  <e1> tacrolimus </e1> , or methylprednisolone are given concomitantly with  <e2> NIZORAL </e2>   Tablets.
mechanism	Coadministration of  <e1> NIZORAL </e1>   Tablets with  <e2> midazolam </e2>  or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
mechanism	Coadministration of  <e1> NIZORAL </e1>   Tablets with midazolam or  <e2> triazolam </e2>  has resulted in elevated plasma concentrations of the latter two drugs.
false	The following drug interactions have been identified involving  <e1> NIZORAL </e1>  Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of  <e2> terfenadine </e2>  and a delay in the elimination of its acid metabolite.
false	 <e1> Probenecid </e1> : Probenecid increases both free and bound  <e2> ketoprofen </e2>  by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.
false	Antacids: Concomitant administration of magnesium hydroxide and  <e1> aluminum hydroxide </e1>  does not interfere with the rate or extent of the absorption of ketoprofen administered as  <e2> Orudis </e2> .
false	Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of  <e1> ketoprofen </e1>  administered as  <e2> Orudis </e2> .
false	Methotrexate:  <e1> Ketoprofen </e1> , like other  <e2> NSAIDs </e2> , may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.
effect	Diuretic:  <e1> Hydrochlorothiazide </e1> , given concomitantly with  <e2> ketoprofen </e2> , produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.
mechanism	Coadministration of  <e1> NIZORAL </e1>   Tablets with  <e2> midazolam </e2>  or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
false	Diuretic:  <e1> Hydrochlorothiazide </e1> , given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to  <e2> hydrochlorothiazide </e2>  alone.
false	Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and  <e1> digoxin </e1>  were concomitantly administered,  <e2> ketoprofen </e2>  did not alter the serum levels of digoxin.
false	The following drug interactions have been identified involving  <e1> NIZORAL </e1>  Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of  <e2> terfenadine </e2>  and a delay in the elimination of its acid metabolite.
false	 <e1> Antacids </e1> : Concomitant administration of  <e2> magnesium hydroxide </e2>  and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.
advise	Coadministration of  <e1> astemizole </e1>  with  <e2> ketoconazole </e2>  tablets is therefore contraindicated.
false	The following drug interactions have been identified involving  <e1> NIZORAL </e1>  Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of  <e2> terfenadine </e2> , resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.
false	 <e1> Warfarin </e1> : In a short-term controlled study in 14 normal volunteers, ketoprofen did not significantly interfere with the effect of  <e2> warfarin </e2>  on prothrombin time.
false	Because prostaglandina play an important role in hemostasis and  <e1> ketoprofen </e1>  has an effect on platelet function as well, concurent therapy with ketoprofen and  <e2> warfarin </e2>  requires close monitoring of patients on both drugs.
false	Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered,  <e1> ketoprofen </e1>  did not alter the serum levels of  <e2> digoxin </e2> .
mechanism	Coadministration of  <e1> NIZORAL </e1>   Tablets with midazolam or  <e2> triazolam </e2>  has resulted in elevated plasma concentrations of the latter two drugs.
false	 <e1> Probenecid </e1> :  <e2> Probenecid </e2>  increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.
false	Warfarin,  <e1> Digoxin </e1> , Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by  <e2> ketorolac tromethamine </e2>  (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
effect	Psychoactive Drugs: Hallucinations have been reported when  <e1> TORADOL </e1>  was used in patients taking psychoactive drugs ( <e2> fluoxetine </e2> , thiothixene, alprazolam).
false	Therapeutic concentrations of digoxin, warfarin, ibuprofen,  <e1> naproxen </e1> , piroxicam, acetaminophen,  <e2> phenytoin </e2>  andtolbutamide did not alter ketorolac tromethamine protein binding.
false	Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of  <e1> ketoprofen </e1>  administered as  <e2> Orudis </e2> .
false	Methotrexate: Concomitant administration of  <e1> methotrexate </e1>  and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of  <e2> methotrexate </e2> .
effect	Psychoactive Drugs: Hallucinations have been reported when  <e1> TORADOL </e1>  was used in patients taking psychoactive drugs (fluoxetine,  <e2> thiothixene </e2> , alprazolam).
false	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking  <e1> psychoactive drugs </e1>  (fluoxetine, thiothixene,  <e2> alprazolam </e2> ).
false	Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of  <e1> methotrexate </e1> , enhancing the toxicity of  <e2> methotrexate </e2> .
false	Although these results do not indicate a significant interaction between  <e1> TORADOL </e1>  and  <e2> warfarin </e2>  or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.
false	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine,  <e1> thiothixene </e1> ,  <e2> alprazolam </e2> ).
false	Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen,  <e1> piroxicam </e1> , acetaminophen,  <e2> phenytoin </e2>  andtolbutamide did not alter ketorolac tromethamine protein binding.
false	 <e1> Methotrexate </e1> : Concomitant administration of methotrexate and some  <e2> NSAIDs </e2>  has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.
false	Therapeutic concentrations of digoxin,  <e1> warfarin </e1> ,  <e2> ibuprofen </e2> , naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.
false	Methotrexate: Concomitant administration of methotrexate and some  <e1> NSAIDs </e1>  has been reported to reduce the clearance of  <e2> methotrexate </e2> , enhancing the toxicity of methotrexate.
false	Warfarin, Digoxin,  <e1> Salicylate </e1> , and  <e2> Heparin </e2>  The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
false	Furosemide: TORADOL IV/IM reduced the  <e1> diuretic </e1>  response to  <e2> furosemide </e2>  in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
false	 <e1> Warfarin </e1> , Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by  <e2> ketorolac tromethamine </e2>  (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
false	 <e1> Probenecid </e1> :  <e2> Probenecid </e2>  increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.
false	 <e1> ACE Inhibitors </e1> : Concomitant use of  <e2> ACE inhibitors </e2>  may increase the risk of renal impairment, particularly in volume-depleted patients.
false	The effect of  <e1> TORADOL </e1>  on plasma lithium has not been studied, but cases of increased lithium plasma levels during  <e2> TORADOL </e2>  therapy have been reported.
false	 <e1> Furosemide </e1> : TORADOL IV/IM reduced the diuretic response to  <e2> furosemide </e2>  in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
mechanism	Coadministration of  <e1> NIZORAL </e1>   Tablets with midazolam or  <e2> triazolam </e2>  has resulted in elevated plasma concentrations of the latter two drugs.
false	Do not mix  <e1> TORADOL </e1>  and  <e2> morphine </e2>  in the same syringe.
false	 <e1> Furosemide </e1> : TORADOL IV/IM reduced the  <e2> diuretic </e2>  response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
false	Methotrexate:  <e1> Ketoprofen </e1> , like other  <e2> NSAIDs </e2> , may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.
false	Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam,  <e1> acetaminophen </e1> ,  <e2> phenytoin </e2>  andtolbutamide did not alter ketorolac tromethamine protein binding.
false	Therapeutic concentrations of digoxin,  <e1> warfarin </e1> , ibuprofen, naproxen,  <e2> piroxicam </e2> , acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.
mechanism	Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of  <e1> warfarin </e1>  to plasma proteins is only slightly reduced by  <e2> ketorolac tromethamine </e2>  (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
false	Although these results do not indicate a significant interaction between TORADOL and  <e1> warfarin </e1>  or heparin, the administration of  <e2> TORADOL </e2>  to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.
false	Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by  <e1> ketorolac tromethamine </e1>  (99.5% control vs 99.3%) when  <e2> ketorolac </e2>  plasma concentrations reach 5 to10 m g/mL.
effect	Cyclosporine -  <e1> L-arginine </e1>  may counteract the antinaturetic effect of  <e2> cyclosporin </e2> .
false	Organic  <e1> nitrates </e1>  - L-arginine supplements theoretically may potentiate the effects of organic  <e2> nitrates </e2>  if taken concomitantly.
false	 <e1> Furosemide </e1> : TORADOL IV/IM reduced the diuretic response to  <e2> furosemide </e2>  in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
false	Although these results do not indicate a significant interaction between TORADOL and  <e1> warfarin </e1>  or heparin, the administration of  <e2> TORADOL </e2>  to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.
false	 <e1> Cyclosporine </e1>  -  <e2> L-arginine </e2>  may counteract the antinaturetic effect of cyclosporin.
false	Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by  <e1> ketorolac tromethamine </e1>  (99.5% control vs 99.3%) when  <e2> ketorolac </e2>  plasma concentrations reach 5 to10 m g/mL.
false	Do not mix  <e1> TORADOL </e1>  and  <e2> morphine </e2>  in the same syringe.
false	Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of  <e1> methotrexate </e1> , enhancing the toxicity of  <e2> methotrexate </e2> .
false	 <e1> Cyclosporine </e1>  -  <e2> L-arginine </e2>  may counteract the antinaturetic effect of cyclosporin.
false	Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of  <e1> methotrexate </e1> , enhancing the toxicity of  <e2> methotrexate </e2> .
false	Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of  <e1> methotrexate </e1> , enhancing the toxicity of  <e2> methotrexate </e2> .
false	 <e1> Human growth hormone </e1>  - Concomitant use of  <e2> L-glutamine </e2>  and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.
false	 <e1> Paclitaxel </e1>  - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving  <e2> paclitaxel </e2> , appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.
false	 <e1> Indomethacin </e1>  - Concomitant use of  <e2> L-glutamine </e2>  and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.
effect	Methotrexate - There is one report that  <e1> methotrexate </e1>  may decrease the possible effectiveness of supplemental  <e2> L-glutamine </e2>  for chemotherapy-induced mucositis.
effect	Methotrexate - There is one report that  <e1> methotrexate </e1>  may decrease the possible effectiveness of supplemental  <e2> L-glutamine </e2>  for chemotherapy-induced mucositis.
false	H1 and H2  <e1> Blockers </e1>  - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2  <e2> blockers </e2> .
false	H1 and  <e1> H2 Blockers </e1>  - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2  <e2> blockers </e2> .
false	H1 and  <e1> H2 Blockers </e1>  - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2  <e2> blockers </e2> .
false	Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with  <e1> acetaminophen </e1>  overdosage or in those taking  <e2> methotrexate </e2> .
false	 <e1> Acetaminophen </e1>  and methotrexate -  <e2> L-methionine </e2>  may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.
false	Selegiline -  <e1> L-phenylalanine </e1>  and the  <e2> selective MAO inhibitor </e2>  selegiline may have synergistic antidepressant activity if used concomitantly.
false	 <e1> Selegiline </e1>  -  <e2> L-phenylalanine </e2>  and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.
false	Non-selective monoamine oxidase (MAO) inhibitors - including  <e1> phenelzine sulfate </e1> ,  <e2> tranylcypromine sulfate </e2>  and pargyline HC1.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g.,  <e1> Marplan </e1> ), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane),  <e2> selegiline </e2>  (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	 <e1> Monoamine oxidase (MAO) inhibitors </e1>  such as isocarboxazid (e.g., Marplan), phenelzine (e.g.,  <e2> Nardil </e2> ), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as  <e1> isocarboxazid </e1>  (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and  <e2> tranylcypromine </e2>  (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan),  <e1> phenelzine </e1>  (e.g., Nardil), procarbazine (e.g., Matulane),  <e2> selegiline </e2>  (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	 <e1> Monoamine oxidase (MAO) inhibitors </e1>  such as isocarboxazid (e.g.,  <e2> Marplan </e2> ), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g.,  <e1> Eldepryl </e1> ), and tranylcypromine (e.g.,  <e2> Parnate </e2> ): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane),  <e1> selegiline </e1>  (e.g., Eldepryl), and tranylcypromine (e.g.,  <e2> Parnate </e2> ): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g.,  <e1> Matulane </e1> ), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with  <e2> L-tryptophan </e2>  may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil),  <e1> procarbazine </e1>  (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g.,  <e2> Parnate </e2> ): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as  <e1> isocarboxazid </e1>  (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane),  <e2> selegiline </e2>  (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g.,  <e1> Matulane </e1> ),  <e2> selegiline </e2>  (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g.,  <e1> Matulane </e1> ), selegiline (e.g., Eldepryl), and tranylcypromine (e.g.,  <e2> Parnate </e2> ): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g.,  <e1> Marplan </e1> ), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and  <e2> tranylcypromine </e2>  (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane),  <e1> selegiline </e1>  (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with  <e2> L-tryptophan </e2>  may increase the chance of side effects.
false	 <e1> Monoamine oxidase (MAO) inhibitors </e1>  such as isocarboxazid (e.g., Marplan), phenelzine (e.g.,  <e2> Nardil </e2> ), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g.,  <e1> Marplan </e1> ), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane),  <e2> selegiline </e2>  (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g.,  <e1> Matulane </e1> ), selegiline (e.g., Eldepryl), and tranylcypromine (e.g.,  <e2> Parnate </e2> ): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Non-selective MAO inhibitors including tranylcypromine sulfate,  <e1> phenelzine sulfate </e1> , and pargyline HC1: Concomitant use of  <e2> L-tyrosine </e2>  and non-selective MAO inhibitors may cause hypertension.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g.,  <e1> Matulane </e1> ), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with  <e2> L-tryptophan </e2>  may increase the chance of side effects.
effect	If  <e1> labetalol HCl </e1>  is used with  <e2> nitroglycerin </e2>  in patients with angina pectoris, additional antihypertensive effects may occur.
false	During controlled hypotensive anesthesia using labetalol HCl in association with  <e1> halothane </e1> , high concentrations (3% or above) of  <e2> halothane </e2>  should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.
false	 <e1> Monoamine oxidase (MAO) inhibitors </e1>  such as isocarboxazid (e.g., Marplan), phenelzine (e.g.,  <e2> Nardil </e2> ), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	 <e1> Monoamine oxidase (MAO) inhibitors </e1>  such as isocarboxazid (e.g., Marplan), phenelzine (e.g.,  <e2> Nardil </e2> ), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	There is no information regarding the effect on  <e1> lamivudine </e1>  pharmacokinetics of higher doses of  <e2> TMP </e2> /SMX such as those used to treat Pneumocystis carinii pneumonia.
false	Studies have shown that  <e1> lansoprazole </e1>  does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin,  <e2> antipyrine </e2> , indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol,  <e1> prednisone </e1> , diazepam,  <e2> clarithromycin </e2> , or terfenadine in healthy subjects.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin,  <e1> antipyrine </e1> , indomethacin, ibuprofen, phenytoin, propranolol,  <e2> prednisone </e2> , diazepam, clarithromycin, or terfenadine in healthy subjects.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as  <e1> warfarin </e1> ,  <e2> antipyrine </e2> , indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
false	Studies have shown that  <e1> lansoprazole </e1>  does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine,  <e2> indomethacin </e2> , ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as  <e1> warfarin </e1> , antipyrine, indomethacin,  <e2> ibuprofen </e2> , phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine,  <e1> indomethacin </e1> ,  <e2> ibuprofen </e2> , phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine,  <e1> indomethacin </e1> , ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or  <e2> terfenadine </e2>  in healthy subjects.
false	In a single-dose crossover study examining lansoprazole 30 mg and  <e1> omeprazole </e1>  20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with  <e2> sucralfate </e2> .
false	therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g.  <e1> ketoconazole </e1> , ampicillin esters, iron salts,  <e2> digoxin </e2> ).
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin,  <e1> propranolol </e1> , prednisone,  <e2> diazepam </e2> , clarithromycin, or terfenadine in healthy subjects.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as  <e1> warfarin </e1> , antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam,  <e2> clarithromycin </e2> , or terfenadine in healthy subjects.
false	therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters,  <e1> iron </e1>  salts,  <e2> digoxin </e2> ).
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin,  <e1> ibuprofen </e1> , phenytoin, propranolol, prednisone, diazepam,  <e2> clarithromycin </e2> , or terfenadine in healthy subjects.
mechanism	therefore, it is theoretically possible that  <e1> lansoprazole </e1>  may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g.  <e2> ketoconazole </e2> , ampicillin esters, iron salts, digoxin).
advise	Therefore,  <e1> proton pump inhibitors </e1>  should be taken at least 30 minutes prior to  <e2> sucralfate </e2> .
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam,  <e1> clarithromycin </e1> , or  <e2> terfenadine </e2>  in healthy subjects.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol,  <e1> prednisone </e1> , diazepam,  <e2> clarithromycin </e2> , or terfenadine in healthy subjects.
false	 <e1> Ketoconazole </e1> : In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to  <e2> lapatinib </e2>  was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.
false	Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with  <e1> capecitabine </e1>  did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of  <e2> capecitabine </e2> ).
false	Effects of  <e1> Lapatinib </e1>  on Drug Metabolizing Enzymes and Drug Transport Systems  <e2> Lapatinib </e2>  inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as  <e1> warfarin </e1> , antipyrine, indomethacin,  <e2> ibuprofen </e2> , phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol,  <e1> prednisone </e1> , diazepam,  <e2> clarithromycin </e2> , or terfenadine in healthy subjects.
false	In vitro studies have shown that precipitation occurs when eye drops containing  <e1> thimerosal </e1>  are mixed with  <e2> latanoprost </e2> .
false	 <e1> Tolbutamide </e1> : In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of  <e2> tolbutamide </e2>  at concentrations in the clinical range.
effect	In a small (n=30) combination study of  <e1> ARAVA </e1>  with  <e2> methotrexate </e2> , a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.
false	Rifampin: Following concomitant administration of a single dose of  <e1> ARAVA </e1>  to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when  <e2> ARAVA </e2>  was given alone.
false	NSAIDs: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of  <e1> diclofenac </e1>  and  <e2> ibuprofen </e2>  at concentrations in the clinical range.
false	 <e1> Cholestyramine </e1>  and Charcoal Administration of  <e2> cholestyramine </e2>  or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .
false	 <e1> Rifampin </e1> : Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when  <e2> ARAVA </e2>  was given alone.
false	NSAIDs: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of  <e1> diclofenac </e1>  and  <e2> ibuprofen </e2>  at concentrations in the clinical range.
false	 <e1> Tolbutamide </e1> : In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of  <e2> tolbutamide </e2>  at concentrations in the clinical range.
false	Concomitant treatment with  <e1> thrombolytics </e1>  (eg, rt-PA or  <e2> streptokinase </e2> ) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation
false	Concomitant treatment with  <e1> thrombolytics </e1>  (eg, rt-PA or  <e2> streptokinase </e2> ) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation
false	Folic acid in large amounts may counteract the antiepileptic effect of  <e1> phenobarbital </e1> , phenytoin and  <e2> primidone </e2> , and increase the frequency of seizures in susceptible pediatric patients.
effect	 <e1> Leucovorin </e1>  may enhance the toxicity of  <e2> 5-fluorouracil </e2> .
false	Folic acid in large amounts may counteract the antiepileptic effect of  <e1> phenobarbital </e1> , phenytoin and  <e2> primidone </e2> , and increase the frequency of seizures in susceptible pediatric patients.
false	Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent  <e1> levamisole </e1>  and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of  <e2> warfarin sodium </e2>  or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.
false	Drug-Drug Interactions Between Keppra  And Other  <e1> Antiepileptic Drugs </e1>  (AEDs)  <e2> Phenytoin </e2>  Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.
false	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin,  <e1> valproate </e1> , oral contraceptive, digoxin, warfarin,  <e2> probenecid </e2> ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
false	Other Drug Interactions Oral Contraceptives  <e1> Keppra </e1>   (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg  <e2> ethinyl estradiol </e2>  and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital,  <e1> phenytoin </e1> ,  <e2> primidone </e2>  and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive,  <e1> digoxin </e1> ,  <e2> warfarin </e2> , probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
false	Valproate  <e1> Keppra </e1>   (1500 mg twice daily) did not alter the pharmacokinetics of  <e2> valproate </e2>  in healthy volunteers.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin,  <e1> primidone </e1>  and  <e2> valproate </e2> ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	Potential drug interactions between Keppra  and other AEDs ( <e1> carbamazepine </e1> ,  <e2> gabapentin </e2> , lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	Drug-Drug Interactions Between  <e1> Keppra </e1>   And Other  <e2> Antiepileptic Drugs </e2>  (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.
false	Pharmacokinetics of  <e1> levetiracetam </e1>  were also not affected by  <e2> phenytoin </e2> .
false	Potential drug interactions between Keppra  and other  <e1> AEDs </e1>  (carbamazepine, gabapentin, lamotrigine, phenobarbital,  <e2> phenytoin </e2> , primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine,  <e1> gabapentin </e1> , lamotrigine, phenobarbital, phenytoin,  <e2> primidone </e2>  and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	Potential drug interactions between Keppra  and other AEDs ( <e1> carbamazepine </e1> , gabapentin, lamotrigine,  <e2> phenobarbital </e2> , phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	Potential drug interactions between  <e1> Keppra </e1>   and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin,  <e2> primidone </e2>  and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	Other Drug Interactions Oral  <e1> Contraceptives </e1>  Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg  <e2> ethinyl estradiol </e2>  and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.
false	Drug-Drug Interactions Between Keppra  And Other  <e1> Antiepileptic Drugs </e1>  ( <e2> AEDs </e2> ) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin,  <e1> lamotrigine </e1> ,  <e2> phenobarbital </e2> , phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies ( <e1> phenytoin </e1> , valproate, oral contraceptive,  <e2> digoxin </e2> , warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine,  <e1> gabapentin </e1> , lamotrigine,  <e2> phenobarbital </e2> , phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	 <e1> Probenecid </e1> : Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of  <e2> levetiracetam </e2>  1000 mg twice daily.
false	Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate,  <e1> topiramate </e1> , or  <e2> lamotrigine </e2> .
false	Potential drug interactions between  <e1> Keppra </e1>   and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and  <e2> valproate </e2> ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine,  <e1> gabapentin </e1> , lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these  <e2> AEDs </e2>  during placebo-controlled clinical studies.
false	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies ( <e1> phenytoin </e1> , valproate, oral  <e2> contraceptive </e2> , digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
false	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive,  <e1> digoxin </e1> , warfarin,  <e2> probenecid </e2> ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
false	Potential drug interactions between Keppra  and other AEDs ( <e1> carbamazepine </e1> , gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of  <e2> levetiracetam </e2>  and these AEDs during placebo-controlled clinical studies.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine,  <e1> gabapentin </e1> , lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of  <e2> levetiracetam </e2>  and these AEDs during placebo-controlled clinical studies.
false	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral  <e1> contraceptive </e1> , digoxin, warfarin,  <e2> probenecid </e2> ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin,  <e1> lamotrigine </e1> ,  <e2> phenobarbital </e2> , phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate,  <e1> topiramate </e1> , or  <e2> lamotrigine </e2> .
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine,  <e1> gabapentin </e1> , lamotrigine,  <e2> phenobarbital </e2> , phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
advise	Patients receiving  <e1> beta-adrenergic blocking agents </e1>  along with either oral or intravenous  <e2> calcium antagonists </e2>  should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.
false	Potential drug interactions between  <e1> Keppra </e1>   and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin,  <e2> primidone </e2>  and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	Other Drug Interactions Oral  <e1> Contraceptives </e1>  Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg  <e2> ethinyl estradiol </e2>  and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine,  <e1> gabapentin </e1> , lamotrigine, phenobarbital, phenytoin,  <e2> primidone </e2>  and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	and  <e1> calcium channel antagonists </e1>  e.g., verapamil), CYP1A2 inducers ( <e2> omeprazole </e2> ) and CYP1A2 inhibitors (furafylline and clarithromycin).
false	Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as  <e1> phenytoin </e1> , phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g.,  <e2> ketoconazole </e2> ;
mechanism	Although no clinical studies have been conducted, it is likely that the metabolism of  <e1> levobupivacaine </e1>  may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital,  <e2> rifampin </e2> ), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
false	and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors ( <e1> furafylline </e1>  and  <e2> clarithromycin </e2> ).
false	Dosage adjustment may be warranted when  <e1> levobupivacaine </e1>  is concurrently administered with CYP3A4 inhibitors and CYP1A2 inhibitors as systemic  <e2> levobupivacaine </e2>  levels may rise resulting in toxicity.
advise	Patients receiving  <e1> beta-adrenergic blocking agents </e1>  along with either oral or intravenous  <e2> calcium antagonists </e2>  should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.
false	Other Drug Interactions Oral  <e1> Contraceptives </e1>  Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg  <e2> ethinyl estradiol </e2>  and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.
false	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of  <e1> theophylline </e1> , interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic  <e2> cyclosporine </e2>  concomitantly.
false	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of  <e1> caffeine </e1> , and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic  <e2> cyclosporine </e2>  concomitantly.
false	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of  <e1> theophylline </e1> , interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant  <e2> warfarin </e2>  and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
effect	However, the systemic administration of some  <e1> quinolones </e1>  has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic  <e2> cyclosporine </e2>  concomitantly.
false	Interactions with  <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> : Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as  <e2> Levo-Dromoran </e2> .
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines,  <e1> tranquilizers </e1> ,  <e2> skeletal muscle relaxants </e2>  and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants,  <e1> phenothiazines </e1> ,  <e2> tranquilizers </e2> , skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg,  <e1> pentazocine </e1> ,  <e2> nalbuphine </e2> , butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	Interactions with  <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> : Agonist/antagonist analgesics (eg, pentazocine, nalbuphine,  <e2> butorphanol </e2> , dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives,  <e1> hypnotics </e1> , other opioids, general anesthetics, barbiturates,  <e2> tricyclic antidepressants </e2> , phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Most cases of serious or fatal adverse events involving  <e1> Levo-Dromoran </e1>  reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of  <e2> levorphanol </e2>  with other drugs affecting respiration.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general  <e1> anesthetics </e1> ,  <e2> barbiturates </e2> , tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine,  <e1> nalbuphine </e1> , butorphanol,  <e2> dezocine </e2>  and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg,  <e1> pentazocine </e1> , nalbuphine,  <e2> butorphanol </e2> , dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol,  <e1> sedatives </e1> , hypnotics, other opioids, general anesthetics, barbiturates,  <e2> tricyclic antidepressants </e2> , phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general  <e1> anesthetics </e1> , barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers,  <e2> skeletal muscle relaxants </e2>  and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol,  <e1> sedatives </e1> , hypnotics, other opioids, general anesthetics,  <e2> barbiturates </e2> , tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Although no interaction between  <e1> MAO inhibitors </e1>  and  <e2> Levo-Dromoran </e2>  has been observed, it is not recommended for use with MAO inhibitors.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics,  <e1> barbiturates </e1> ,  <e2> tricyclic antidepressants </e2> , phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of  <e1> Levo-Dromoran </e1>  with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines,  <e2> tranquilizers </e2> , skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of  <e1> Levo-Dromoran </e1>  with all  <e2> central nervous system depressants </e2>  (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with  <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> : Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and  <e2> buprenorphine </e2> ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other  <e1> opioids </e1> , general anesthetics, barbiturates,  <e2> tricyclic antidepressants </e2> , phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol,  <e1> dezocine </e1>  and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a  <e2> pure agonist opioid analgesic </e2>  such as Levo-Dromoran.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol,  <e1> sedatives </e1> , hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers,  <e2> skeletal muscle relaxants </e2>  and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Mixed Agonist/Antagonist Opioid Analgesics:  <e1> Agonist/antagonist analgesics </e1>  (eg, pentazocine, nalbuphine,  <e2> butorphanol </e2> , dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine,  <e1> butorphanol </e1> ,  <e2> dezocine </e2>  and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
advise	Although no interaction between MAO inhibitors and  <e1> Levo-Dromoran </e1>  has been observed, it is not recommended for use with  <e2> MAO inhibitors </e2> .
false	Interactions with  <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> : Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and  <e2> buprenorphine </e2> ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin,  <e1> warfarin </e1> ,  <e2> isosorbide mononitrate </e2> , carvedilol, ethanol or itraconazole.
false	No Important Interactions To Date  <e1> Levosimendan </e1>  does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or  <e2> itraconazole </e2> .
false	No Important Interactions To Date  <e1> Levosimendan </e1>  does not have clinically important pharmacokinetic interactions with captopril, beta-blockers,  <e2> felodipine </e2> , digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine,  <e1> digoxin </e1> ,  <e2> warfarin </e2> , isosorbide mononitrate, carvedilol, ethanol or itraconazole.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine,  <e1> digoxin </e1> , warfarin, isosorbide mononitrate, carvedilol,  <e2> ethanol </e2>  or itraconazole.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers,  <e1> felodipine </e1> , digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or  <e2> itraconazole </e2> .
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril,  <e1> beta-blockers </e1> , felodipine, digoxin, warfarin,  <e2> isosorbide mononitrate </e2> , carvedilol, ethanol or itraconazole.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin,  <e1> warfarin </e1> , isosorbide mononitrate, carvedilol, ethanol or  <e2> itraconazole </e2> .
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers,  <e1> felodipine </e1> , digoxin,  <e2> warfarin </e2> , isosorbide mononitrate, carvedilol, ethanol or itraconazole.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril,  <e1> beta-blockers </e1> , felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol,  <e2> ethanol </e2>  or itraconazole.
false	Although no interaction between  <e1> MAO inhibitors </e1>  and  <e2> Levo-Dromoran </e2>  has been observed, it is not recommended for use with MAO inhibitors.
effect	Interactions with Other CNS Agents: Concurrent use of  <e1> Levo-Dromoran </e1>  with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines,  <e2> tranquilizers </e2> , skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol,  <e1> sedatives </e1> , hypnotics, other opioids, general anesthetics, barbiturates,  <e2> tricyclic antidepressants </e2> , phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e1> somatostatin analogs </e1> ,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e1> dopamine agonists </e1> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e2> iodine-containing compounds </e2> , levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e1> lovastatin </e1> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital,  <e2> phenytoin </e2> , resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related  <e1> anabolic hormones </e1> , asparaginase,  <e2> clofibrate </e2> , estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Antidiabetic Agents ( <e1> Insulin </e1> , Sulfonylureas): Requirements for  <e2> insulin </e2>  or oral antidiabetic agents may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate,  <e1> diazepam </e1> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide,  <e2> mitotane </e2> , nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e1> b-adrenergic blocking agents </e1> , carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e2> iodine-containing compounds </e2> , levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine,  <e1> chloral hydrate </e1> , diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid,  <e1> mefenamic acid </e1> , methadone,  <e2> perphenazine </e2> , phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Antidiabetic Agents (Insulin, Sulfonylureas): Requirements for  <e1> insulin </e1>  or oral  <e2> antidiabetic agents </e2>  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e1> ethionamide </e1> , glucocorticoids, heparin, hepatic enzyme inducers,  <e2> insulin </e2> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil,  <e1> furosemide </e1> , glucocorticoids,  <e2> meclofenamic acid </e2> , mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide,  <e1> glucocorticoids </e1> , heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e2> metoclopramide </e2> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e1> perchlorate </e1> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e2> metoclopramide </e2> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine,  <e2> chloral hydrate </e2> , diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid,  <e1> methadone </e1> , perphenazine, phenylbutazone, phenytoin, salicylates,  <e2> tamoxifen </e2> .
mechanism	Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of  <e1> levothyroxine sodium </e1>  from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride,  <e2> ferrous sulfate </e2> , sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e1> 6-mercaptopurine </e1> , metoclopramide, mitotane,  <e2> nitroprusside </e2> , phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone,  <e1> perphenazine </e1> , phenylbutazone, phenytoin,  <e2> salicylates </e2> , tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e2> heparin </e2> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e1> b-adrenergic blocking agents </e1> , carbamazepine, chloral hydrate, diazepam, dopamine and  <e2> dopamine agonists </e2> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Antidiabetic Agents ( <e1> Insulin </e1> , Sulfonylureas): Requirements for insulin or oral  <e2> antidiabetic agents </e2>  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide,  <e1> p-aminosalicylic acid </e1> , amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e2> perchlorate </e2> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e1> dopamine agonists </e1> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase,  <e1> clofibrate </e1> , estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin,  <e2> salicylates </e2> , tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds,  <e1> 5-fluorouracil </e1> , furosemide, glucocorticoids, meclofenamic acid,  <e2> mefenamic acid </e2> , methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid,  <e1> methadone </e1> , perphenazine,  <e2> phenylbutazone </e2> , phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e1> ethionamide </e1> , glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins:  <e1> androgens </e1>  and related anabolic hormones, asparaginase, clofibrate, estrogens and  <e2> estrogen-containing compounds </e2> , 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide,  <e1> p-aminosalicylic acid </e1> , amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e2> lithium </e2> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents,  <e1> carbamazepine </e1> , chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate,  <e2> perchlorate </e2> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	 <e1> Antidiabetic Agents </e1>  (Insulin, Sulfonylureas): Requirements for insulin or oral  <e2> antidiabetic agents </e2>  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e1> insulin </e1> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas,  <e2> thiazide diuretics </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide,  <e1> glucocorticoids </e1> , heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas,  <e2> thiazide diuretics </e2> .
mechanism	Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of  <e1> levothyroxine sodium </e1>  from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate,  <e2> sodium polystyrene sulfonate </e2> , soybean flour (e.g., infant formula), sucralfate.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents,  <e1> carbamazepine </e1> , chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e2> levodopa </e2> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	 <e1> Anticoagulants </e1>  (Oral): The hypoprothrombinemic effect of  <e2> anticoagulants </e2>  may be potentiated, apparently by increased catabloism of vitamin K-dependent clotting factors.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid,  <e1> methadone </e1> , perphenazine, phenylbutazone,  <e2> phenytoin </e2> , salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e2> iodine-containing compounds </e2> , levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine,  <e1> chloral hydrate </e1> , diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e2> lithium </e2> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents,  <e2> carbamazepine </e2> , chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid,  <e1> mefenamic acid </e1> , methadone, perphenazine, phenylbutazone, phenytoin,  <e2> salicylates </e2> , tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones,  <e1> asparaginase </e1> ,  <e2> clofibrate </e2> , estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine,  <e1> chloral hydrate </e1> , diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital,  <e2> phenytoin </e2> , resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol,  <e1> rifampin </e1> , somatostatin analogs, sulfonamides, sulfonylureas,  <e2> thiazide diuretics </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide,  <e1> p-aminosalicylic acid </e1> , amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide,  <e2> mitotane </e2> , nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e1> dopamine agonists </e1> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol,  <e2> rifampin </e2> , somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e1> b-adrenergic blocking agents </e1> , carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate,  <e2> diazepam </e2> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones,  <e1> asparaginase </e1> , clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide,  <e2> glucocorticoids </e2> , meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide,  <e2> glucocorticoids </e2> , heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e1> insulin </e1> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins:  <e1> androgens </e1>  and related anabolic hormones, asparaginase,  <e2> clofibrate </e2> , estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins:  <e1> androgens </e1>  and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates,  <e2> tamoxifen </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents,  <e2> carbamazepine </e2> , chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e1> insulin </e1> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide,  <e2> mitotane </e2> , nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine,  <e1> chloral hydrate </e1> , diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e2> levodopa </e2> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e2> somatostatin analogs </e2> , sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e1> perchlorate </e1> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e1> levodopa </e1> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> ,  <e2> perchlorate </e2> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e1> metoclopramide </e1> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide,  <e1> glucocorticoids </e1> , heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e2> 6-mercaptopurine </e2> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e1> b-adrenergic blocking agents </e1> , carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e2> 6-mercaptopurine </e2> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e2> iodine-containing compounds </e2> , levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
mechanism	Binding to Serum Proteins: The following agents may either inhibit  <e1> levothyroxine sodium </e1>  binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone,  <e2> perphenazine </e2> , phenylbutazone, phenytoin, salicylates, tamoxifen.
mechanism	Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of  <e1> levothyroxine sodium </e1>  from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin,  <e2> colestipol hydrochloride </e2> , ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents,  <e1> carbamazepine </e1> , chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e2> heparin </e2> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e2> lithium </e2> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract:  <e1> aluminum hydoxide </e1> ,  <e2> cholestyramine </e2>  resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e2> 6-mercaptopurine </e2> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin,  <e2> resorcinol </e2> , rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e2> antithyroid drugs </e2> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e1> b-adrenergic blocking agents </e1> , carbamazepine, chloral hydrate,  <e2> diazepam </e2> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e2> insulin </e2> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds,  <e1> 5-fluorouracil </e1> , furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates,  <e2> tamoxifen </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate,  <e1> diazepam </e1> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e2> b-adrenergic blocking agents </e2> , carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	 <e1> Levothyroxine Sodium </e1>  Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide,  <e2> cholestyramine </e2>  resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine,  <e1> phenylbutazone </e1> , phenytoin, salicylates,  <e2> tamoxifen </e2> .
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones,  <e1> asparaginase </e1> , clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone,  <e2> perphenazine </e2> , phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e1> iodine-containing compounds </e1> , levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e1> dopamine agonists </e1> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e2> insulin </e2> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related  <e1> anabolic hormones </e1> , asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids,  <e2> meclofenamic acid </e2> , mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e1> iodine-containing compounds </e1> , levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin,  <e2> resorcinol </e2> , rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e1> metoclopramide </e1> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e2> pertechnetate </e2> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents,  <e1> carbamazepine </e1> , chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e1> iodine-containing compounds </e1> , levodopa, lovastatin, lithium, 6-mercaptopurine,  <e2> metoclopramide </e2> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e2> ethionamide </e2> , glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide,  <e2> mitotane </e2> , nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin,  <e2> resorcinol </e2> , rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane,  <e1> nitroprusside </e1> , phenobarbital, phenytoin,  <e2> resorcinol </e2> , rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e1> dopamine agonists </e1> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e2> metoclopramide </e2> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e2> lithium </e2> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e1> lovastatin </e1> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate,  <e1> diazepam </e1> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e2> metoclopramide </e2> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins:  <e1> androgens </e1>  and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin,  <e2> salicylates </e2> , tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam,  <e1> dopamine </e1>  and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e1> perchlorate </e1> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e2> somatostatin analogs </e2> , sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins:  <e1> androgens </e1>  and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids,  <e2> meclofenamic acid </e2> , mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine,  <e1> chloral hydrate </e1> , diazepam, dopamine and  <e2> dopamine agonists </e2> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas,  <e2> thiazide diuretics </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e2> ethionamide </e2> , glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e1> insulin </e1> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e2> somatostatin analogs </e2> , sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e1> ethionamide </e1> , glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e2> iodine-containing compounds </e2> , levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e1> insulin </e1> , iodinated cholestographic agents, iodine-containing compounds,  <e2> levodopa </e2> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
effect	Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of  <e1> levothyroxine sodium </e1>  and  <e2> ketamine </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e1> lithium </e1> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital,  <e2> phenytoin </e2> , resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide,  <e1> glucocorticoids </e1> , meclofenamic acid,  <e2> mefenamic acid </e2> , methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e1> ethionamide </e1> , glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin,  <e1> resorcinol </e1> , rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital,  <e2> phenytoin </e2> , resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital,  <e2> phenytoin </e2> , resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e2> antithyroid drugs </e2> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide,  <e1> p-aminosalicylic acid </e1> , amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e2> levodopa </e2> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone,  <e1> phenytoin </e1> , salicylates,  <e2> tamoxifen </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e2> ethionamide </e2> , glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e2> levodopa </e2> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e2> levodopa </e2> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers,  <e2> insulin </e2> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin,  <e2> resorcinol </e2> , rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents,  <e1> carbamazepine </e1> , chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e2> 6-mercaptopurine </e2> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e2> iodine-containing compounds </e2> , levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids,  <e1> meclofenamic acid </e1> , mefenamic acid,  <e2> methadone </e2> , perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e1> b-adrenergic blocking agents </e1> , carbamazepine,  <e2> chloral hydrate </e2> , diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e1> lithium </e1> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin,  <e2> resorcinol </e2> , rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e1> levodopa </e1> , lovastatin, lithium,  <e2> 6-mercaptopurine </e2> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin,  <e1> resorcinol </e1> ,  <e2> rifampin </e2> , somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane,  <e1> nitroprusside </e1> , phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas,  <e2> thiazide diuretics </e2> .
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins:  <e1> androgens </e1>  and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone,  <e2> phenytoin </e2> , salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e1> levodopa </e1> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs,  <e2> b-adrenergic blocking agents </e2> , carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine,  <e1> chloral hydrate </e1> ,  <e2> diazepam </e2> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid,  <e1> mefenamic acid </e1> , methadone, perphenazine, phenylbutazone,  <e2> phenytoin </e2> , salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e2> levodopa </e2> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e2> dopamine agonists </e2> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e1> insulin </e1> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide,  <e1> glucocorticoids </e1> , heparin, hepatic enzyme inducers,  <e2> insulin </e2> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e2> pertechnetate </e2> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e2> insulin </e2> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate,  <e1> diazepam </e1> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e2> somatostatin analogs </e2> , sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e1> iodine-containing compounds </e1> ,  <e2> levodopa </e2> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital,  <e2> phenytoin </e2> , resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e2> lithium </e2> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e1> insulin </e1> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e2> somatostatin analogs </e2> , sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid,  <e1> methadone </e1> , perphenazine, phenylbutazone,  <e2> phenytoin </e2> , salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e1> insulin </e1> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide,  <e1> glucocorticoids </e1> , heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e1> somatostatin analogs </e1> ,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e2> dopamine agonists </e2> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related  <e1> anabolic hormones </e1> , asparaginase,  <e2> clofibrate </e2> , estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents,  <e1> carbamazepine </e1> , chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e2> ethionamide </e2> , glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
effect	Phenothiazines and  <e1> butyrophenones </e1>  may reduce or reverse the pressor effect of  <e2> epinephrine </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins:  <e1> androgens </e1>  and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates,  <e2> tamoxifen </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate,  <e2> diazepam </e2> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine,  <e1> chloral hydrate </e1> ,  <e2> diazepam </e2> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins:  <e1> androgens </e1>  and related anabolic hormones, asparaginase, clofibrate, estrogens and  <e2> estrogen-containing compounds </e2> , 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e1> insulin </e1> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide,  <e2> mitotane </e2> , nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e2> ethionamide </e2> , glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones,  <e1> asparaginase </e1> ,  <e2> clofibrate </e2> , estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones,  <e1> asparaginase </e1> , clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone,  <e2> perphenazine </e2> , phenylbutazone, phenytoin, salicylates, tamoxifen.
mechanism	Binding to Serum Proteins: The following agents may either inhibit  <e1> levothyroxine sodium </e1>  binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone,  <e2> perphenazine </e2> , phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate,  <e2> perchlorate </e2> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or  <e2> norepinephrine </e2>  to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
effect	The administration of local anesthetic solutions containing epinephrine or  <e1> norepinephrine </e1>  to patients receiving  <e2> monoamine oxidase inhibitors </e2>  or tricyclic antidepressants may produce severe, prolonged hypertension.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid,  <e1> methadone </e1> , perphenazine,  <e2> phenylbutazone </e2> , phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e2> 6-mercaptopurine </e2> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e1> dopamine agonists </e1> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e2> insulin </e2> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e1> metoclopramide </e1> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	The administration of local  <e1> anesthetic solutions </e1>  containing  <e2> epinephrine </e2>  or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas,  <e2> thiazide diuretics </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital,  <e2> phenytoin </e2> , resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e1> lovastatin </e1> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e1> insulin </e1> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide,  <e2> mitotane </e2> , nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
effect	The administration of local anesthetic solutions containing epinephrine or  <e1> norepinephrine </e1>  to patients receiving  <e2> monoamine oxidase inhibitors </e2>  or tricyclic antidepressants may produce severe, prolonged hypertension.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e1> insulin </e1> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e1> somatostatin analogs </e1> ,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e2> dopamine agonists </e2> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid,  <e1> methadone </e1> , perphenazine,  <e2> phenylbutazone </e2> , phenytoin, salicylates, tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid,  <e1> methadone </e1> , perphenazine, phenylbutazone,  <e2> phenytoin </e2> , salicylates, tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid,  <e1> methadone </e1> , perphenazine, phenylbutazone,  <e2> phenytoin </e2> , salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e1> somatostatin analogs </e1> ,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and  <e1> serotonergic agents </e1> , including antidepressants such as  <e2> selective serotonin reuptake inhibitors </e2>  (SSRIs), have been reported.
false	 <e1> Adrenergic Agents </e1> :Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents,  <e2> vasopressor </e2>  or dopaminergic agents.
int	Therefore,  <e1> linezolid </e1>  has the potential for interaction with  <e2> adrenergic </e2>  and serotonergic agents.
false	Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting  <e1> sympathomimetic agents </e1> ,  <e2> vasopressor </e2>  or dopaminergic agents.
false	Initial doses of adrenergic agents, such as  <e1> dopamine </e1>  or  <e2> epinephrine </e2> , should be reduced and titrated to achieve the desired response.
effect	Spontaneous reports of serotonin syndrome associated with co-administration of  <e1> ZYVOX </e1>  and  <e2> serotonergic agents </e2> , including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
false	 <e1> Estrogen </e1> , Oral  <e2> Contraceptives </e2> : Estrogens tend to increase serum thyroxine-binding globulin (TBg).
false	Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or  <e1> estrogen </e1> -containing oral  <e2> contraceptives </e2>  are given.
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens,  <e1> corticosteroids </e1> , estrogens, oral  <e2> contraceptives </e2>  containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens,  <e1> corticosteroids </e1> , estrogens, oral contraceptives containing estrogens,  <e2> iodine </e2> -containing preparations and the numerous preparations containing salicylates.
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens,  <e1> corticosteroids </e1> , estrogens, oral contraceptives containing  <e2> estrogens </e2> , iodine-containing preparations and the numerous preparations containing salicylates.
false	 <e1> Cholestyramine </e1> :  <e2> Cholestyramine </e2>  binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids,  <e1> estrogens </e1> , oral  <e2> contraceptives </e2>  containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.
false	 <e1> Digitalis </e1> : Thyroid preparations may potentiate the toxic effects of  <e2> digitalis </e2> .
false	 <e1> Insulin </e1>  or Oral  <e2> Hypoglycemics </e2> : Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements.
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids,  <e1> estrogens </e1> , oral contraceptives containing  <e2> estrogens </e2> , iodine-containing preparations and the numerous preparations containing salicylates.
effect	Tricyclic Antidepressants: Use of  <e1> thyroid products </e1>  with imipramine and other  <e2> tricyclic antidepressants </e2>  may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
false	Insulin or Oral  <e1> Hypoglycemics </e1> : Initiating thyroid replacement therapy may cause increases in  <e2> insulin </e2>  or oral hypoglycemic requirements.
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens,  <e1> iodine </e1> -containing preparations and the numerous preparations containing  <e2> salicylates </e2> .
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens,  <e1> corticosteroids </e1> ,  <e2> estrogens </e2> , oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on  <e1> thyroid hormone </e1>  therapy: androgens, corticosteroids,  <e2> estrogens </e2> , oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.
effect	Vasopressors:  <e1> Thyroxine </e1>  increases the adrenergic effect of catecholamines such as  <e2> epinephrine </e2>  and norepinephrine.
advise	Therefore, patients without a functioning  <e1> thyroid </e1>  gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral  <e2> contraceptives </e2>  are given.
false	 <e1> Antihypertensives </e1> :  <e2> Amphetamines </e2>  may antagonize the hypotensive effects of antihypertensives.
effect	Haloperidol:  <e1> Haloperidol </e1>  blocks dopamine receptors, thus inhibiting the central stimulant effects of  <e2> amphetamines </e2> .
mechanism	Methenamine therapy Urinary excretion of  <e1> amphetamines </e1>  is increased, and efficacy is reduced by acidifying agents used in  <e2> methenamine </e2>  therapy.
mechanism	MAO inhibitors MAOI antidepressants, as well as a metabolite of  <e1> furazolidone </e1> , slow  <e2> amphetamine </e2>  metabolism.
false	d-amphetamine with  <e1> desipramine </e1>  or protriptyline and possibly other  <e2> tricyclics </e2>  cause striking and sustained increases in the concentration of d-amphetamine in the brain;
false	 <e1> Ethosuximide </e1> : Amphetamines may delay intestinal absorption of  <e2> ethosuximide </e2> .
false	 <e1> Antidepressants </e1> , tricyclic Amphetamines may enhance the activity of  <e2> tricyclic antidepressants </e2>  or sympathomimetic agents;
false	Insulin or Oral  <e1> Hypoglycemics </e1> : Initiating thyroid replacement therapy may cause increases in  <e2> insulin </e2>  or oral hypoglycemic requirements.
false	Antidepressants,  <e1> tricyclic </e1>  Amphetamines may enhance the activity of tricyclic antidepressants or  <e2> sympathomimetic agents </e2> ;
false	Antidepressants, tricyclic Amphetamines may enhance the activity of  <e1> tricyclic antidepressants </e1>  or  <e2> sympathomimetic agents </e2> ;
effect	Vasopressors:  <e1> Thyroxine </e1>  increases the adrenergic effect of catecholamines such as  <e2> epinephrine </e2>  and norepinephrine.
false	MAO inhibitors  <e1> MAOI antidepressants </e1> , as well as a metabolite of  <e2> furazolidone </e2> , slow amphetamine metabolism.
false	 <e1> Adrenergic blockers </e1>   <e2> Adrenergic blockers </e2>  are inhibited by amphetamines.
false	 <e1> Antidepressants </e1> ,  <e2> tricyclic </e2>  Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;
false	 <e1> Phenobarbital </e1> :  <e2> Amphetamines </e2>  may delay intestinal absorption of phenobarbital;
false	 <e1> Lithium carbonate </e1> : The anorectic and stimulatory effects of  <e2> amphetamines </e2>  may be inhibited by lithium carbonate.
false	 <e1> Antidepressants </e1> , tricyclic  <e2> Amphetamines </e2>  may enhance the activity of tricyclic antidepressants or sympathomimetic agents;
effect	Antidepressants, tricyclic  <e1> Amphetamines </e1>  may enhance the activity of  <e2> tricyclic antidepressants </e2>  or sympathomimetic agents;
false	 <e1> Lithium </e1> : Lithium toxicity has been reported in patients receiving  <e2> lithium </e2>  concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
effect	Use of  <e1> PRINIVIL </e1>  with potassium-sparing diuretics (e.g.,  <e2> spironolactone </e2> , triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
mechanism	MAO inhibitors MAOI antidepressants, as well as a metabolite of  <e1> furazolidone </e1> , slow  <e2> amphetamine </e2>  metabolism.
false	In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of  <e1> PRINIVIL </e1>  alone were compared to PRINIVIL given concomitantly with indomethacin, the use of  <e2> indomethacin </e2>  was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.
false	In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to  <e1> PRINIVIL </e1>  given concomitantly with indomethacin, the use of  <e2> indomethacin </e2>  was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.
effect	Hypotension - Patients on Diuretic Therapy: Patients on  <e1> diuretics </e1> , and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with  <e2> PRINIVIL </e2> .
effect	Antidepressants, tricyclic  <e1> Amphetamines </e1>  may enhance the activity of  <e2> tricyclic antidepressants </e2>  or sympathomimetic agents;
false	It is recommended that serum  <e1> lithium </e1>  levels be monitored frequently if  <e2> PRINIVIL </e2>  is administered concomitantly with lithium.
false	In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of  <e1> PRINIVIL </e1>  alone were compared to  <e2> PRINIVIL </e2>  given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.
advise	If it is necessary to continue the  <e1> diuretic </e1> , initiate therapy with  <e2> PRINIVIL </e2>  at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.
false	Use of PRINIVIL with potassium-sparing diuretics (e.g.,  <e1> spironolactone </e1> ,  <e2> triamterene </e2> , or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
false	The possibility of hypotensive effects with  <e1> PRINIVIL </e1>  can be minimized by either discontinuing the  <e2> diuretic </e2>  or increasing the salt intake prior to initiation of treatment with PRINIVIL.
false	Reports suggest that NSAIDs may diminish the antihypertensive effect of  <e1> ACE inhibitors </e1> , including  <e2> lisinopril </e2> .
effect	Use of  <e1> PRINIVIL </e1>  with potassium-sparing diuretics (e.g., spironolactone, triamterene, or  <e2> amiloride </e2> ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
false	Use of PRINIVIL with potassium-sparing diuretics (e.g.,  <e1> spironolactone </e1> , triamterene, or amiloride),  <e2> potassium </e2>  supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
false	Lithium:  <e1> Lithium </e1>  toxicity has been reported in patients receiving  <e2> lithium </e2>  concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
false	Studies with  <e1> ACE inhibitors </e1>  in combination with  <e2> diuretics </e2>  indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.
false	- Lofexidine may enhance the CNS depressive effects of  <e1> alcohol </e1> , barbiturates and other  <e2> sedatives </e2> 
false	Reports suggest that NSAIDs may diminish the antihypertensive effect of  <e1> ACE inhibitors </e1> , including  <e2> lisinopril </e2> .
effect	Hypotension - Patients on Diuretic Therapy: Patients on  <e1> diuretics </e1> , and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with  <e2> PRINIVIL </e2> .
false	- Lofexidine may enhance the CNS depressive effects of  <e1> alcohol </e1> ,  <e2> barbiturates </e2>  and other sedatives
effect	- Concomitant use of  <e1> tricyclic antidepressants </e1>  may reduce the efficacy of  <e2> lofexidine </e2> .
false	Magnesium- and  <e1> aluminum </e1> -containing  <e2> antacids </e2> , administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
mechanism	Magnesium- and aluminum-containing  <e1> antacids </e1> , administered concomitantly with  <e2> lomefloxacin </e2> , significantly decreased the bioavailability (48%) of lomefloxacin.
false	 <e1> Magnesium </e1> - and  <e2> aluminum </e2> -containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
mechanism	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  ( <e1> didanosine </e1> ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with  <e2> lomefloxacin </e2>  and interfere with its bioavailability.
false	Antacids and sucralfate: Sucralfate and antacids containing  <e1> magnesium </e1>  or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  ( <e2> didanosine </e2> ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
false	Antacids and sucralfate: Sucralfate and  <e1> antacids </e1>  containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with  <e2> lomefloxacin </e2>  and interfere with its bioavailability.
false	 <e1> Magnesium </e1> - and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of  <e2> lomefloxacin </e2> .
false	 <e1> Omeprazole </e1> : No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of  <e2> lomefloxacin </e2>  400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.
false	Antacids and sucralfate: Sucralfate and  <e1> antacids </e1>  containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  ( <e2> didanosine </e2> ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
false	Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of  <e1> lomefloxacin </e1>  and  <e2> terfenadine </e2>  at steady-state in 28 healthy males.
false	 <e1> Caffeine </e1> : Two hundred mg of caffeine (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of  <e2> lomefloxacin </e2>  after being dosed at 400 mg qd.
false	 <e1> Antacids </e1>  and sucralfate: Sucralfate and  <e2> antacids </e2>  containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
false	In clinical studies where patients were on chronic theophylline therapy,  <e1> lomefloxacin </e1>  had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of  <e2> theophylline </e2>  clearance.
false	Cyclosporine: Elevated serum levels of  <e1> cyclosporine </e1>  have been reported with concomitant use of  <e2> cyclosporine </e2>  with other members of the quinolone class.
false	Other  <e1> quinolones </e1>  have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of  <e2> caffeine </e2> .
false	Magnesium- and aluminum-containing  <e1> antacids </e1> , administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of  <e2> lomefloxacin </e2> .
false	Antacids and  <e1> sucralfate </e1> :  <e2> Sucralfate </e2>  and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
false	Other quinolones have demonstrated moderate to marked interference with the metabolism of  <e1> caffeine </e1> , resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of  <e2> caffeine </e2> .
effect	- Concomitant use of  <e1> tricyclic antidepressants </e1>  may reduce the efficacy of  <e2> lofexidine </e2> .
false	Cyclosporine: Elevated serum levels of  <e1> cyclosporine </e1>  have been reported with concomitant use of cyclosporine with other members of the  <e2> quinolone class </e2> .
false	Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or  <e1> lomefloxacin </e1>  pharmacokinetics, during concurrent administration of  <e2> lomefloxacin </e2>  and terfenadine at steady-state in 28 healthy males.
false	Magnesium- and aluminum-containing antacids, administered concomitantly with  <e1> lomefloxacin </e1> , significantly decreased the bioavailability (48%) of  <e2> lomefloxacin </e2> .
false	 <e1> Warfarin </e1> :  <e2> Quinolones </e2>  may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.
mechanism	Magnesium- and aluminum-containing  <e1> antacids </e1> , administered concomitantly with  <e2> lomefloxacin </e2> , significantly decreased the bioavailability (48%) of lomefloxacin.
false	Other quinolones have demonstrated moderate to marked interference with the metabolism of  <e1> caffeine </e1> , resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of  <e2> caffeine </e2> .
false	Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of  <e1> lomefloxacin </e1>  and  <e2> terfenadine </e2>  at steady-state in 28 healthy males.
false	Magnesium- and  <e1> aluminum </e1> -containing  <e2> antacids </e2> , administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
false	Other  <e1> quinolones </e1>  have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of  <e2> caffeine </e2> .
false	 <e1> Probenecid </e1> : As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by  <e2> probenecid </e2>  and resulted in an approximate 80% increase in the AUC for loracarbef.
false	Other  <e1> quinolones </e1>  have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of  <e2> caffeine </e2> .
false	Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of  <e1> lomefloxacin </e1>  and  <e2> terfenadine </e2>  at steady-state in 28 healthy males.
false	Although increased plasma concentrations (AUC 0-24 hrs) of  <e1> loratadine </e1>  and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of  <e2> loratadine </e2> , as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.
false	 <e1> Loratadine </e1>   <e2> Descarboethoxyloratadine </e2> 
false	TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of  <e1> Loratadine </e1>  and Descarboethoxyloratadine After 10 Days of Coadministration ( <e2> Loratadine </e2>  10 mg) in Normal Volunteers
false	 <e1> Loratadine </e1>  (10 mg once daily) has been coadministered with therapeutic doses of  <e2> erythromycin </e2> , cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.
effect	Injection: Lorazepam injection, like other injectable  <e1> benzodiazepines </e1> , produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other  <e2> antidepressants </e2> .When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol,  <e1> phenothiazines </e1> , barbiturates,  <e2> MAO inhibitors </e2> , and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol,  <e1> phenothiazines </e1> , barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable  <e2> lorazepam </e2> , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	 <e1> Loratadine </e1>  (10 mg once daily) has been coadministered with therapeutic doses of  <e2> erythromycin </e2> , cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.
false	Injection:  <e1> Lorazepam </e1>  injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When  <e2> scopolamine </e2>  is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	Injection:  <e1> Lorazepam </e1>  injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol,  <e2> phenothiazines </e2> , barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	Injection:  <e1> Lorazepam </e1>  injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other  <e2> antidepressants </e2> .When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines,  <e1> barbiturates </e1> , MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable  <e2> lorazepam </e2> , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines,  <e1> barbiturates </e1> , MAO inhibitors, and other  <e2> antidepressants </e2> .When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	Ketoconazole did not affect the conversion of  <e1> losartan </e1>  to the active metabolite after intravenous administration of losartan, and  <e2> erythromycin </e2>  had no clinically significant effect after oral administration.
mechanism	 <e1> Rifampin </e1> , an inducer of drug metabolism, decreased the concentrations of  <e2> losartan </e2>  and its active metabolite.
false	As with other  <e1> antihypertensive agents </e1> , the antihypertensive effect of  <e2> losartan </e2>  may be blunted by the non-steroidal anti-inflammatory drug indomethacin
false	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin,  <e1> warfarin </e1> ,  <e2> cimetidine </e2>  and phenobarbital.
false	As with other drugs that block angiotensin II or its effects, concomitant use of  <e1> potassium-sparing diuretics </e1>  (e.g.,  <e2> spironolactone </e2> , triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
false	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with  <e1> hydrochlorothiazide </e1> , digoxin,  <e2> warfarin </e2> , cimetidine and phenobarbital.
false	No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin,  <e1> warfarin </e1> , cimetidine and  <e2> phenobarbital </e2> .
false	 <e1> Ketoconazole </e1>  did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and  <e2> erythromycin </e2>  had no clinically significant effect after oral administration.
effect	As with other antihypertensive agents, the antihypertensive effect of  <e1> losartan </e1>  may be blunted by the non-steroidal anti-inflammatory drug  <e2> indomethacin </e2> 
false	As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene,  <e1> amiloride </e1> ),  <e2> potassium </e2>  supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
false	Oral Hypoglycemic Agents: In pharmacokinetic studies of  <e1> MEVACOR </e1>  in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with  <e2> chlorpropamide </e2> 
false	 <e1> Gemfibrozil </e1>  Other fibrates  <e2> Niacin </e2>  (nicotinic acid) (=1 g/day)
false	Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either  <e1> amiodarone </e1>  or  <e2> verapamil </e2>  is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).
false	 <e1> Propranolol </e1> : In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and  <e2> propranolol </e2> .
false	 <e1> Itraconazole </e1>  Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone  <e2> Cyclosporine </e2>  Large quantities of grapefruit juice ( 1 quart daily)
false	Itraconazole Ketoconazole Erythromycin  <e1> Clarithromycin </e1>  Telithromycin HIV protease inhibitors Nefazodone  <e2> Cyclosporine </e2>  Large quantities of grapefruit juice ( 1 quart daily)
false	Itraconazole Ketoconazole Erythromycin  <e1> Clarithromycin </e1>  Telithromycin HIV protease inhibitors  <e2> Nefazodone </e2>  Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
false	 <e1> Propranolol </e1> : In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of  <e2> lovastatin </e2>  and propranolol.
false	Itraconazole  <e1> Ketoconazole </e1>  Erythromycin Clarithromycin Telithromycin HIV protease inhibitors  <e2> Nefazodone </e2>  Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
false	 <e1> Gemfibrozil </e1>  Other fibrates Niacin ( <e2> nicotinic acid </e2> ) (=1 g/day)
false	Itraconazole Ketoconazole Erythromycin  <e1> Clarithromycin </e1>   <e2> Telithromycin </e2>  HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
false	Itraconazole Ketoconazole Erythromycin  <e1> Clarithromycin </e1>  Telithromycin  <e2> HIV protease inhibitors </e2>  Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
false	 <e1> Gemfibrozil </e1>  Other  <e2> fibrates </e2>  Niacin (nicotinic acid) (=1 g/day)
false	 <e1> Danazol </e1> : The risk of myopathy/rhabdomyolysis is increased by concomitant administration of  <e2> danazol </e2>  particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).
effect	Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either  <e1> amiodarone </e1>  or verapamil is used concomitantly with a closely related member of the  <e2> HMG-CoA reductase inhibitor class </e2>  (see WARNINGS, Myopathy/Rhabdomyolysis).
false	 <e1> Propranolol </e1> : In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and  <e2> propranolol </e2> .
false	Itraconazole Ketoconazole Erythromycin  <e1> Clarithromycin </e1>  Telithromycin HIV protease inhibitors  <e2> Nefazodone </e2>  Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
false	 <e1> Gemfibrozil </e1>  Other fibrates Niacin ( <e2> nicotinic acid </e2> ) (=1 g/day)
effect	There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of  <e1> loxapine </e1>  and  <e2> lorazepam </e2> .
false	 <e1> Propranolol </e1> : In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and  <e2> propranolol </e2> .
mechanism	The absorption of  <e1> lymecycline </e1>  may be affected by the simultaneous administration of indigestion remedies,  <e2> iron </e2>  or zinc supplements.
effect	Oral  <e1> contraceptives </e1>  may be less effective while you are taking  <e2> lymecycline </e2> .
false	The urinary excretion of  <e1> meclofenamate sodium </e1>  is unaffected by aspirin, indicating no change in  <e2> meclofenamate sodium </e2>  absorption.
effect	 <e1> Warfarin </e1> :  <e2> Meclofenamate sodium </e2>  enhances the effect of warfarin.
false	Warfarin:  <e1> Meclofenamate sodium </e1>  enhances the effect of  <e2> warfarin </e2> .
mechanism	The absorption of  <e1> lymecycline </e1>  may be affected by the simultaneous administration of indigestion remedies,  <e2> iron </e2>  or zinc supplements.
false	 <e1> Antacids </e1> : Concomitant administration of aluminum and magnesium hydroxides does not interfere with absorption of  <e2> meclofenamate sodium </e2> .
false	Therefore, when  <e1> meclofenamate sodium </e1>  is given to a patient receiving warfarin, the dosage of  <e2> warfarin </e2>  should be reduced to prevent excessive prolongation of the prothrombin time.
false	 <e1> Warfarin </e1> : The effects of  <e2> warfarin </e2>  and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.
false	Warfarin:  <e1> Meclofenamate sodium </e1>  enhances the effect of  <e2> warfarin </e2> .
advise	Caution should be used when  <e1> NSAIDs </e1>  are administered concomitantly with  <e2> methotrexate </e2> .
false	 <e1> ACE inhibitors </e1> : Reports suggest that  <e2> NSAIDs </e2>  may diminish the antihypertensive effect of ACE inhibitors.
false	 <e1> Antacids </e1> : Concomitant administration of aluminum and magnesium hydroxides does not interfere with absorption of  <e2> meclofenamate sodium </e2> .
false	Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole,  <e1> lovastatin </e1>  and  <e2> trimethoprim </e2> .
mechanism	Lithium:  <e1> NSAIDs </e1>  have produced an elevation of plasma lithium levels and a reduction in renal  <e2> lithium </e2>  clearance.
false	Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of  <e1> mefenamic acid </e1>  increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and  <e2> trimethoprim </e2> .
false	Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including  <e1> fluconazole </e1> ,  <e2> lovastatin </e2>  and trimethoprim.
false	 <e1> Methotrexate </e1> :  <e2> NSAIDs </e2>  have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.
false	 <e1> Antacids </e1> : In a single dose study (n=6), ingestion of an  <e2> antacid </e2>  containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.
false	Antacids: In a single dose study (n=6), ingestion of an  <e1> antacid </e1>  containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of  <e2> mefenamic acid </e2>  by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.
effect	Furosemide: Clinical studies, as well as post-marketing observations, have shown that  <e1> NSAIDs </e1>  can reduce the natriuretic effect of furosemide and  <e2> thiazides </e2>  in some patients.
false	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or  <e1> beta-adrenergic blocking agents </e1> , calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and  <e2> phenothiazines </e2> ) might also contribute to a prolongation of the QTc interval.
false	Concomitant administration of Mefloquine and other related compounds (eg, quinine,  <e1> quinidine </e1>  and  <e2> chloroquine </e2> ) may produce electrocardiographic abnormalities and increase the risk of convulsions.
effect	This appears to be the only clinically relevant interaction of this kind with  <e1> Mefloquine </e1> , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and  <e2> phenothiazines </e2> ) might also contribute to a prolongation of the QTc interval.
false	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or  <e1> beta-adrenergic blocking agents </e1> , calcium channel blockers, antihistamines or  <e2> H1-blocking agents </e2> , tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
false	In patients taking an  <e1> anticonvulsant </e1>  (eg, valproic acid,  <e2> carbamazepine </e2> , phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
false	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg,  <e1> anti-arrhythmic </e1>  or beta-adrenergic blocking agents, calcium channel blockers,  <e2> antihistamines </e2>  or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
effect	Furosemide: Clinical studies, as well as post-marketing observations, have shown that  <e1> NSAIDs </e1>  can reduce the natriuretic effect of furosemide and  <e2> thiazides </e2>  in some patients.
false	 <e1> Antacids </e1> : In a single dose study (n=6), ingestion of an  <e2> antacid </e2>  containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.
false	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg,  <e1> anti-arrhythmic </e1>  or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents,  <e2> tricyclic antidepressants </e2>  and phenothiazines) might also contribute to a prolongation of the QTc interval.
false	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg,  <e1> anti-arrhythmic </e1>  or  <e2> beta-adrenergic blocking agents </e2> , calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
false	Antacids: In a single dose study (n=6), ingestion of an  <e1> antacid </e1>  containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of  <e2> mefenamic acid </e2>  by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.
false	There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a  <e1> beta blocker </e1>  ( <e2> propranolol </e2> ).
false	In patients taking an  <e1> anticonvulsant </e1>  (eg, valproic acid, carbamazepine,  <e2> phenobarbital </e2>  or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
effect	This appears to be the only clinically relevant interaction of this kind with  <e1> Mefloquine </e1> , although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or  <e2> beta-adrenergic blocking agents </e2> , calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
effect	When  <e1> Mefloquine </e1>  is taken concurrently with oral  <e2> live typhoid vaccines </e2> , attenuation of immunization cannot be excluded.
false	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole,  <e1> latamoxef </e1> ) or methylthiadiazole ( <e2> cefazolin </e2> ) can cause vitamin K deficiency and hypoprothrombinemia.
false	There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a  <e1> beta blocker </e1>  ( <e2> propranolol </e2> ).
false	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan,  <e1> cefamandole </e1> ,  <e2> latamoxef </e2> ) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.
false	Cephalosporins- <e1> Cephalosporins </e1>  containing side chains of N-methylthiotetrazole ( <e2> cefmenoxime </e2> , cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.
mechanism	Orlistat- <e1> Orlistat </e1>  may decrease the absorption of  <e2> vitamin K </e2> .
false	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg,  <e1> anti-arrhythmic </e1>  or  <e2> beta-adrenergic blocking agents </e2> , calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
false	 <e1> Orlistat </e1> -Orlistat may decrease the absorption of  <e2> vitamin K </e2> .
false	 <e1> Broad-Spectrum Antibiotics </e1> -Broad-spectrum antibiotics may sterilize the bowel and decrease the  <e2> vitamin K </e2>  contribution to the body by the intestinal microflora.
false	Colestipol-Concomitant intake of  <e1> colestipol </e1>  and vitamin K may reduce the absorption of  <e2> vitamin K </e2> .
false	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg,  <e1> anti-arrhythmic </e1>  or beta-adrenergic blocking agents, calcium channel blockers,  <e2> antihistamines </e2>  or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
false	 <e1> Cephalosporins </e1> -Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan,  <e2> cefamandole </e2> , latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.
false	 <e1> Broad-Spectrum Antibiotics </e1> - <e2> Broad-spectrum antibiotics </e2>  may sterilize the bowel and decrease the vitamin K contribution to the body by the intestinal microflora.
effect	Furosemide: Clinical studies, as well as post-marketing observations, have shown that  <e1> NSAIDs </e1>  can reduce the natriuretic effect of furosemide and  <e2> thiazides </e2>  in some patients.
false	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( <e1> cefmenoxime </e1> , cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole ( <e2> cefazolin </e2> ) can cause vitamin K deficiency and hypoprothrombinemia.
false	In patients taking an  <e1> anticonvulsant </e1>  (eg, valproic acid, carbamazepine,  <e2> phenobarbital </e2>  or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
advise	 <e1> Nabilone </e1>  should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including  <e2> alcohol </e2> , barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
effect	Furosemide: Clinical studies, as well as post-marketing observations, have shown that  <e1> NSAIDs </e1>  can reduce the natriuretic effect of furosemide and  <e2> thiazides </e2>  in some patients.
false	Nabilone should be administered with caution to patients who are taking other  <e1> psychoactive drugs </e1>  or CNS depressants, including alcohol,  <e2> barbiturates </e2>  and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
false	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or  <e1> CNS depressants </e1> , including alcohol,  <e2> barbiturates </e2>  and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
false	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan,  <e1> cefamandole </e1> ,  <e2> latamoxef </e2> ) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.
false	Nabilone should be administered with caution to patients who are taking other  <e1> psychoactive drugs </e1>  or  <e2> CNS depressants </e2> , including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
false	 <e1> Broad-Spectrum Antibiotics </e1> - <e2> Broad-spectrum antibiotics </e2>  may sterilize the bowel and decrease the vitamin K contribution to the body by the intestinal microflora.
false	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg,  <e1> anti-arrhythmic </e1>  or beta-adrenergic blocking agents, calcium channel blockers,  <e2> antihistamines </e2>  or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
advise	 <e1> Nabilone </e1>  should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including  <e2> alcohol </e2> , barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
false	Nabilone should be administered with caution to patients who are taking other  <e1> psychoactive drugs </e1>  or  <e2> CNS depressants </e2> , including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
false	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or  <e1> CNS depressants </e1> , including alcohol,  <e2> barbiturates </e2>  and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
false	 <e1> Antidiabetic drugs </e1>  (oral agents and  <e2> insulin </e2> ): hypoglycemia or hyperglycemia;
false	 <e1> Tetracycline </e1> , a  <e2> bacteriostatic antibiotic </e2> , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
false	 <e1> Antacids </e1>  containing magnesium,  <e2> aluminum </e2> , or calcium;
effect	 <e1> Quinolones </e1> , including nalidixic acid, may enhance the effects of the oral anticoagulant  <e2> warfarin </e2>  or its derivatives.
mechanism	Elevated plasma levels of  <e1> theophylline </e1>  have been reported with concomitant  <e2> quinolone </e2>  use.
false	 <e1> Antacids </e1>  containing magnesium, aluminum, or  <e2> calcium </e2> ;
false	Quinolones, including nalidixic acid, may enhance the effects of the oral  <e1> anticoagulant </e1>   <e2> warfarin </e2>  or its derivatives.
false	Quinolones, including  <e1> nalidixic acid </e1> , may enhance the effects of the oral  <e2> anticoagulant </e2>  warfarin or its derivatives.
effect	Patients taking  <e1> REVIA </e1>  may not benefit from  <e2> opioid </e2>  containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.
false	 <e1> Antacids </e1>  containing magnesium, aluminum, or  <e2> calcium </e2> ;
false	Concomitant administration of  <e1> naproxen </e1>  and aspirin is not recommended because  <e2> naproxen </e2>  is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
effect	Patients taking  <e1> REVIA </e1>  may not benefit from  <e2> opioid </e2>  containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.
false	Naproxen,  <e1> naproxen sodium </e1>  and other  <e2> NSAIDs </e2>  have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
false	Concomitant administration of  <e1> naproxen </e1>  and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of  <e2> aspirin </e2> , resulting in lower plasma concentrations and peak plasma levels.
mechanism	Naproxen, naproxen sodium and other  <e1> NSAIDs </e1>  have been reported to reduce the tubular secretion of  <e2> methotrexate </e2>  in an animal model, possibly increasing the toxicity of methotrexate.
false	Concomitant administration of  <e1> naproxen </e1>  and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of  <e2> aspirin </e2> , resulting in lower plasma concentrations and peak plasma levels.
false	Selective serotonin reuptake inhibitors (SSRIs) (e.g.,  <e1> fluoxetine </e1> , fluvoxamine,  <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.
advise	If concomitant treatment with  <e1> naratriptan </e1>  and an  <e2> SSRI </e2>  is clinically warranted, appropriate observation of the patient is advised.
false	Selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ) (e.g., fluoxetine, fluvoxamine,  <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.
false	 <e1> Selective serotonin reuptake inhibitors </e1>  (SSRIs) (e.g., fluoxetine,  <e2> fluvoxamine </e2> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.
false	Concomitant administration of  <e1> naproxen </e1>  and aspirin is not recommended because  <e2> naproxen </e2>  is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
mechanism	After multiple dosing, interferon beta-1a ( <e1> AVONEX </e1>   30 mcg IM once weekly) reduced  <e2> TYSABRI </e2>   clearance by approximately 30%.
false	Results of studies in multiple sclerosis patients taking  <e1> TYSABRI </e1>   and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or  <e2> glatiramer acetate </e2>  were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.
false	The similarity of the  <e1> TYSABRI </e1>  -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the  <e2> TYSABRI </e2>   dose to maintain safety, General).
false	Selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ) (e.g., fluoxetine, fluvoxamine,  <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.
false	Concomitant administration of  <e1> naproxen </e1>  and aspirin is not recommended because  <e2> naproxen </e2>  is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
false	The similarity of the  <e1> TYSABRI </e1>  -associated adverse event profile between Study 1 (without co-administered  <e2> AVONEX </e2>  ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).
false	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant  <e1> interferon beta-1a </e1>  (AVONEX  30 mcg IM once weekly) or  <e2> glatiramer acetate </e2>  were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.
false	Similarly,  <e1> nateglinide </e1>  had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin,  <e2> acetylsalicylic acid </e2> , and tolbutamide in vitro .
false	 <e1> Diclofenac </e1> : Administration of morning and lunch doses of  <e2> Starlix </e2>  120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.
false	Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine,  <e1> warfarin </e1> ,  <e2> phenytoin </e2> , acetylsalicylic acid, and tolbutamide in vitro .
false	Certain drugs including thiazides, corticosteroids,  <e1> thyroid products </e1> , and  <e2> sympathomimetics </e2>  may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
false	Certain drugs, including nonsteroidal anti-inflammatory agents ( <e1> NSAIDs </e1> ), salicylates, monoamine oxidase inhibitors, and  <e2> non-selective beta-adrenergic-blocking agents </e2>  may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
false	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of  <e1> Starlix </e1>  and other oral  <e2> antidiabetic drugs </e2> .
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol,  <e1> captopril </e1> , nicardipine, pravastatin,  <e2> glyburide </e2> , warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	Similarly, nateglinide had no influence on the serum protein binding of  <e1> propranolol </e1> ,  <e2> glyburide </e2> , nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin,  <e1> acetylsalicylic acid </e1> ,  <e2> tolbutamide </e2> , and metformin showed no influence on the extent of nateglinide protein binding.
false	Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide,  <e1> nicardipine </e1> , warfarin, phenytoin,  <e2> acetylsalicylic acid </e2> , and tolbutamide in vitro .
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril,  <e1> nicardipine </e1> , pravastatin,  <e2> glyburide </e2> , warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide,  <e1> propranolol </e1> , captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin,  <e2> acetylsalicylic acid </e2> , tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	Diclofenac: Administration of morning and lunch doses of  <e1> Starlix </e1>  120 mg in combination with a single 75-mg dose of  <e2> diclofenac </e2>  in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril,  <e1> nicardipine </e1> , pravastatin, glyburide, warfarin,  <e2> phenytoin </e2> , acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	Similarly, nateglinide had no influence on the serum protein binding of  <e1> propranolol </e1> , glyburide,  <e2> nicardipine </e2> , warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .
false	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs),  <e1> salicylates </e1> , monoamine oxidase inhibitors, and  <e2> non-selective beta-adrenergic-blocking agents </e2>  may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
mechanism	 <e1> Starlix </e1>  is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of  <e2> tolbutamide </e2> .
false	In vitro displacement studies with highly protein-bound drugs such as furosemide,  <e1> propranolol </e1> , captopril, nicardipine, pravastatin, glyburide, warfarin,  <e2> phenytoin </e2> , acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as  <e1> furosemide </e1> ,  <e2> propranolol </e2> , captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	Glyburide: In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg  <e1> Starlix </e1>  three times a day before meals for 1 day in combination with  <e2> glyburide </e2>  10 mg daily.
false	Certain drugs including thiazides,  <e1> corticosteroids </e1> ,  <e2> thyroid products </e2> , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide,  <e1> warfarin </e1> , phenytoin, acetylsalicylic acid,  <e2> tolbutamide </e2> , and metformin showed no influence on the extent of nateglinide protein binding.
effect	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates,  <e1> monoamine oxidase inhibitors </e1> , and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of  <e2> Starlix </e2>  and other oral antidiabetic drugs.
false	Certain drugs, including  <e1> nonsteroidal anti-inflammatory agents </e1>  (NSAIDs), salicylates,  <e2> monoamine oxidase inhibitors </e2> , and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril,  <e1> nicardipine </e1> , pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of  <e2> nateglinide </e2>  protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine,  <e1> pravastatin </e1> , glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and  <e2> metformin </e2>  showed no influence on the extent of nateglinide protein binding.
effect	Certain drugs including thiazides, corticosteroids,  <e1> thyroid products </e1> , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral  <e2> antidiabetic drugs </e2> .
effect	Certain drugs including  <e1> thiazides </e1> , corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral  <e2> antidiabetic drugs </e2> .
false	In vitro displacement studies with highly protein-bound drugs such as furosemide,  <e1> propranolol </e1> , captopril, nicardipine, pravastatin,  <e2> glyburide </e2> , warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide,  <e1> propranolol </e1> ,  <e2> captopril </e2> , nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	Glyburide: In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg  <e1> Starlix </e1>  three times a day before meals for 1 day in combination with  <e2> glyburide </e2>  10 mg daily.
false	Certain drugs including thiazides,  <e1> corticosteroids </e1> ,  <e2> thyroid products </e2> , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide,  <e1> warfarin </e1> , phenytoin, acetylsalicylic acid,  <e2> tolbutamide </e2> , and metformin showed no influence on the extent of nateglinide protein binding.
false	Similarly, nateglinide had no influence on the serum protein binding of  <e1> propranolol </e1> , glyburide,  <e2> nicardipine </e2> , warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .
false	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs),  <e1> salicylates </e1> , monoamine oxidase inhibitors, and  <e2> non-selective beta-adrenergic-blocking agents </e2>  may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
false	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of  <e1> Starlix </e1>  and other oral  <e2> antidiabetic drugs </e2> .
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines  <e1> midazolam </e1> , triazolam GI motility agents:  <e2> cisapride </e2> 
false	 <e1> Ritonavir </e1> : Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in  <e2> nelfinavir </e2>  plasma AUC and very little change in ritonavir plasma A.C.
false	Drugs That Should Not Be Coadministered With VIRACEPT  <e1> Antiarrhythmics </e1> : amiodarone, quinidine Antihistamines: astemizole,  <e2> terfenadine </e2>  Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of  <e1> saquinavir </e1>  1200mg) with VIRACEPT resulted in an 18% increase in  <e2> nelfinavir </e2>  plasma AUC and a 4-fold increase in saquinavir plasma A.C.
false	 <e1> Saquinavir </e1> : Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in  <e2> nelfinavir </e2>  plasma AUC and a 4-fold increase in saquinavir plasma A.C.
false	Rifabutin: Coadministration of rifabutin and  <e1> VIRACEPT </e1>  resulted in a 32% decrease in  <e2> nelfinavir </e2>  plasma AUC and a 207% increase in rifabutin plasma A.C.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics:  <e1> amiodarone </e1> , quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines  <e2> midazolam </e2> , triazolam GI motility agents: cisapride
false	Indinavir: Coadministration of  <e1> indinavir </e1>  with VIRACEPT resulted in an 83% increase in  <e2> nelfinavir </e2>  plasma AUC and a 51% increase in indinavir plasma A.C.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone,  <e1> quinidine </e1>  Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents:  <e2> rifampin </e2>  Benzodiazepines midazolam, triazolam GI motility agents: cisapride
advise	A dose adjustment is not needed when  <e1> zidovudine </e1>  is administered with  <e2> VIRACEPT </e2> .
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines:  <e1> astemizole </e1> ,  <e2> terfenadine </e2>  Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics:  <e1> amiodarone </e1> , quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam,  <e2> triazolam </e2>  GI motility agents: cisapride
false	 <e1> Indinavir </e1> : Coadministration of  <e2> indinavir </e2>  with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.
false	 <e1> Terfenadine </e1> : Administration of  <e2> terfenadine </e2>  with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents:  <e1> rifampin </e1>  Benzodiazepines midazolam,  <e2> triazolam </e2>  GI motility agents: cisapride
false	Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in  <e1> nelfinavir </e1>  plasma AUC and a 207% increase in  <e2> rifabutin </e2>  plasma A.C.
false	 <e1> Rifabutin </e1> : Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in  <e2> rifabutin </e2>  plasma A.C.
false	 <e1> Ethinyl Estradiol </e1>  and  <e2> Norethindrone </e2> : Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.
false	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/ <e1> sulfamethoxazole </e1> , clarithromycin, erythromycin,  <e2> itraconazole </e2>  or fluconazole.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics:  <e1> amiodarone </e1> , quinidine  <e2> Antihistamines </e2> : astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
advise	Because a similar interaction is likely,  <e1> VIRACEPT </e1>  should also not be administered concurrently with  <e2> astemizole </e2> .
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole,  <e1> terfenadine </e1>  Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam,  <e2> triazolam </e2>  GI motility agents: cisapride
false	Terfenadine: Administration of  <e1> terfenadine </e1>  with VIRACEPT resulted in the appearance of unchanged  <e2> terfenadine </e2>  in plasma;
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines:  <e1> astemizole </e1> , terfenadine Antimigraine:  <e2> ergot derivatives </e2>  Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
mechanism	Indinavir: Coadministration of  <e1> indinavir </e1>  with  <e2> VIRACEPT </e2>  resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.
false	 <e1> Rifabutin </e1> : Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in  <e2> nelfinavir </e2>  plasma AUC and a 207% increase in rifabutin plasma A.C.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine:  <e1> ergot derivatives </e1>   <e2> Antimycobacterial agents </e2> : rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	Little or no change in the pharmacokinetics of either drug was observed when  <e1> VIRACEPT </e1>  was coadministered with  <e2> lamivudine </e2>  or stavudine.
false	Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with  <e1> OVCON-35 </e1>  resulted in a 47% decrease in  <e2> ethinyl estradiol </e2>  and an 18% decrease in norethindrone plasma concentrations.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone,  <e1> quinidine </e1>  Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives  <e2> Antimycobacterial agents </e2> : rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
mechanism	Saquinavir: Coadministration of  <e1> saquinavir </e1>  (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with  <e2> VIRACEPT </e2>  resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.
false	Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with  <e1> lamivudine </e1>  or  <e2> stavudine </e2> .
false	Indinavir: Coadministration of indinavir with  <e1> VIRACEPT </e1>  resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in  <e2> indinavir </e2>  plasma A.C.
false	Ritonavir: Coadministration of ritonavir with  <e1> VIRACEPT </e1>  resulted in a 152% increase in  <e2> nelfinavir </e2>  plasma AUC and very little change in ritonavir plasma A.C.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics:  <e1> amiodarone </e1> , quinidine Antihistamines: astemizole,  <e2> terfenadine </e2>  Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs),  <e1> salicylates </e1> , monoamine oxidase inhibitors, and  <e2> non-selective beta-adrenergic-blocking agents </e2>  may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
false	Ethinyl Estradiol and Norethindrone: Coadministration of  <e1> VIRACEPT </e1>  with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in  <e2> norethindrone </e2>  plasma concentrations.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine  <e1> Antihistamines </e1> : astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents:  <e2> cisapride </e2> 
false	This change was not considered clinically significant and no dose adjustment is needed when  <e1> ketoconazole </e1>  and  <e2> VIRACEPT </e2>  are coadministered.
false	 <e1> Rifabutin </e1> : Coadministration of  <e2> rifabutin </e2>  and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.
advise	 <e1> VIRACEPT </e1>  and  <e2> rifampin </e2>  should not be coadministered.
false	Based on known metabolic profiles, clinically significant drug interactions are not expected between  <e1> VIRACEPT </e1>  and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or  <e2> fluconazole </e2> .
advise	Drugs That Should Not Be Coadministered With  <e1> VIRACEPT </e1>  Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole,  <e2> terfenadine </e2>  Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	Ritonavir: Coadministration of  <e1> ritonavir </e1>  with VIRACEPT resulted in a 152% increase in  <e2> nelfinavir </e2>  plasma AUC and very little change in ritonavir plasma A.C.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines  <e1> midazolam </e1> , triazolam GI motility agents:  <e2> cisapride </e2> 
false	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs),  <e1> salicylates </e1> , monoamine oxidase inhibitors, and  <e2> non-selective beta-adrenergic-blocking agents </e2>  may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
false	Indinavir: Coadministration of indinavir with  <e1> VIRACEPT </e1>  resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in  <e2> indinavir </e2>  plasma A.C.
false	 <e1> Rifabutin </e1> : Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in  <e2> rifabutin </e2>  plasma A.C.
mechanism	Oral  <e1> neomycin </e1>  inhibits the gastrointestinal absorption of penicillin V, oral  <e2> vitamin B-12 </e2> , methotrexate and 5-fluorouracil.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics:  <e1> amiodarone </e1> , quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam,  <e2> triazolam </e2>  GI motility agents: cisapride
advise	 <e1> VIRACEPT </e1>  and  <e2> rifampin </e2>  should not be coadministered.
effect	Oral  <e1> neomycin sulfate </e1>  may enhance the effect of coumarin in  <e2> anticoagulants </e2>  by decreasing vitamin K availability.
false	Caution should also be taken in concurrent or serial use of other  <e1> aminoglycosides </e1>  and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate  <e2> neomycin sulfate </e2>  neuromuscular blocking effects.
false	 <e1> Saquinavir </e1> : Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in  <e2> nelfinavir </e2>  plasma AUC and a 4-fold increase in saquinavir plasma A.C.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics:  <e1> amiodarone </e1> , quinidine  <e2> Antihistamines </e2> : astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	 <e1> Terfenadine </e1> : Administration of  <e2> terfenadine </e2>  with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;
false	Certain  <e1> antibiotics </e1> , especially  <e2> neomycin </e2> , streptomycin and kanamycin, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines  <e1> midazolam </e1> , triazolam GI motility agents:  <e2> cisapride </e2> 
advise	 <e1> VIRACEPT </e1>  and  <e2> rifampin </e2>  should not be coadministered.
false	 <e1> Terfenadine </e1> : Administration of  <e2> terfenadine </e2>  with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;
false	The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside,  <e1> milrinone </e1> , or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with  <e2> Natrecor </e2>  in clinical trials).
false	The co-administration of  <e1> Natrecor </e1>  with IV vasodilators such as nitroglycerin,  <e2> nitroprusside </e2> , milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines  <e1> midazolam </e1> , triazolam GI motility agents:  <e2> cisapride </e2> 
false	The co-administration of Natrecor with IV vasodilators such as nitroglycerin,  <e1> nitroprusside </e1> ,  <e2> milrinone </e2> , or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).
false	The co-administration of  <e1> Natrecor </e1>  with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with  <e2> Natrecor </e2>  in clinical trials).
false	Netilmicin should not be administered concomitantly with potent  <e1> loop diuretics </e1>  such as furosemide and  <e2> ethacrynic acid </e2>  as the potential for ototoxicity is enhanced by the combination.
false	The in vitro interaction between  <e1> nevirapine </e1>  and the  <e2> antithrombotic agent </e2>  warfarin is complex.
false	Amiodarone,  <e1> disopyramide </e1> ,  <e2> lidocaine </e2> 
advise	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal.  <e1> Methadone </e1>  maintained patients beginning  <e2> nevirapine </e2>  therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.
false	Netilmicin should not be administered concomitantly with potent  <e1> loop diuretics </e1>  such as furosemide and  <e2> ethacrynic acid </e2>  as the potential for ototoxicity is enhanced by the combination.
false	Nevirapine and  <e1> rifampin </e1>  should not beadministered concomitantly becausedecreases in  <e2> nevirapine </e2>  plasmaconcentrations may reduce the efficacy ofthe drug.
false	Nevirapine and  <e1> ketoconazole </e1>  should not beadministered concomitantly becausedecreases in  <e2> ketoconazole </e2>  plasmaconcentrations may reduce the efficacy of the drug.
false	 <e1> Amiodarone </e1> , disopyramide,  <e2> lidocaine </e2> 
false	 <e1> Nevirapine </e1>  and rifampin should not beadministered concomitantly becausedecreases in  <e2> nevirapine </e2>  plasmaconcentrations may reduce the efficacy ofthe drug.
advise	When  <e1> warfarin </e1>  is co-administered with  <e2> nevirapine </e2> , anticoagulation levels should be monitored frequently.
false	Diltiazem,  <e1> nifedipine </e1> ,  <e2> verapamil </e2> 
false	 <e1> Aspirin </e1> : Concomitant aspirin may decrease the metabolic clearance of  <e2> nicotinic acid </e2> .
advise	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal.  <e1> Methadone </e1>  maintained patients beginning  <e2> nevirapine </e2>  therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.
false	 <e1> Aspirin </e1> : Concomitant  <e2> aspirin </e2>  may decrease the metabolic clearance of nicotinic acid.
false	Interactions for  <e1> Vitamin B3 </e1>  (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of  <e2> ganglionic blocking agents </e2>  and vasoactive drugs resulting in postural hypotension.
false	Netilmicin should not be administered concomitantly with potent  <e1> loop diuretics </e1>  such as furosemide and  <e2> ethacrynic acid </e2>  as the potential for ototoxicity is enhanced by the combination.
false	 <e1> Cyclosporine </e1> : Concomitant administration of  <e2> nicardipine </e2>  and cyclosporine levels.
false	When therapeutic concentrations of furosemide, propranolol,  <e1> dipyridamole </e1> , warfarin,  <e2> quinidine </e2> , or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
false	When therapeutic concentrations of furosemide, propranolol,  <e1> dipyridamole </e1> ,  <e2> warfarin </e2> , quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
false	 <e1> Aspirin </e1> : Concomitant  <e2> aspirin </e2>  may decrease the metabolic clearance of nicotinic acid.
false	When therapeutic concentrations of furosemide, propranolol, dipyridamole,  <e1> warfarin </e1> ,  <e2> quinidine </e2> , or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
false	 <e1> Cyclosporine </e1> : Concomitant administration of nicardipine and  <e2> cyclosporine </e2>  levels.
false	 <e1> Digoxin </e1> : Some calcium blockers may increase the concentration of  <e2> digitalis preparations </e2>  in the blood.
false	When therapeutic concentrations of furosemide,  <e1> propranolol </e1> , dipyridamole, warfarin, quinidine, or  <e2> naproxen </e2>  were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
mechanism	Cimetidine:  <e1> Cimetidine </e1>  increases  <e2> nicardipine HCl </e2>  plasma levels.
false	 <e1> Aspirin </e1> : Concomitant  <e2> aspirin </e2>  may decrease the metabolic clearance of nicotinic acid.
false	 <e1> Cyclosporine </e1> : Concomitant administration of nicardipine and  <e2> cyclosporine </e2>  levels.
false	Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated  <e1> digoxin </e1>  levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that  <e2> digoxin </e2>  levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
false	 <e1> Coumarin Anticoagulants </e1> : There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom  <e2> nifedipine </e2>  was administered.
false	 <e1> Cyclosporine </e1> : Concomitant administration of nicardipine and  <e2> cyclosporine </e2>  levels.
false	Long Acting Nitrates:  <e1> Nifedipine </e1>  may be safely co-administered with  <e2> nitrates </e2> , but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.
false	 <e1> Digitalis </e1> : Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and  <e2> nifedipine </e2> , it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
false	 <e1> Aspirin </e1> : Concomitant  <e2> aspirin </e2>  may decrease the metabolic clearance of nicotinic acid.
false	 <e1> Quinidine </e1> : Immediate Release Capsules: There have been rare reports of an interaction between quinidine and  <e2> nifedipine </e2>  (with a decreased plasma level of quinidine).
false	 <e1> Coumarin Anticoagulants </e1> : There have been rare reports of increased prothrombin time in patients taking  <e2> coumarin anticoagulants </e2>  to whom nifedipine was administered.
effect	Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of  <e1> nifedipine </e1>  and  <e2> beta-blocking agents </e2>  is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.
false	Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists,  <e1> phenytoin </e1> , and  <e2> theophylline </e2> , could have a delayed elimination and increases in their serum half-life leading to a toxic level.
false	 <e1> Quinidine </e1> : Immediate Release Capsules: There have been rare reports of an interaction between quinidine and  <e2> nifedipine </e2>  (with a decreased plasma level of quinidine).
effect	It is possible that the cardiovascular action of other  <e1> calcium channel blockers </e1>  could be enhanced by the addition of  <e2> Nimotop </e2>  .
false	 <e1> Quinidine </e1> : Immediate Release Capsules: There have been rare reports of an interaction between quinidine and  <e2> nifedipine </e2>  (with a decreased plasma level of quinidine).
false	Pharmacokinetic interactions between  <e1> nisoldipine </e1>  and beta-blockers (atenolol,  <e2> propranolol </e2> ) were variable and not significant.
false	Pharmacokinetic interactions between nisoldipine and  <e1> beta-blockers </e1>  (atenolol,  <e2> propranolol </e2> ) were variable and not significant.
false	The blood pressure effect of  <e1> SULAR </e1>  tended to be greater in patients on atenolol than in patients on no other  <e2> antihypertensive </e2>  therapy.
mechanism	The immediate release, but not the coat-core formulation of  <e1> nisoldipine </e1>  increased plasma  <e2> quinidine </e2>  concentrations by about 20%.
false	Pharmacokinetic interactions between  <e1> nisoldipine </e1>  and beta-blockers ( <e2> atenolol </e2> , propranolol) were variable and not significant.
false	The blood pressure effect of  <e1> SULAR </e1>  tended to be greater in patients on atenolol than in patients on no other  <e2> antihypertensive </e2>  therapy.
mechanism	The immediate release, but not the coat-core formulation of  <e1> nisoldipine </e1>  increased plasma  <e2> quinidine </e2>  concentrations by about 20%.
false	INOmax has been administered with  <e1> tolazoline </e1> ,  <e2> dopamine </e2> , dobutamine, steroids, surfactant, and high-frequency ventilation.
false	INOmax has been administered with  <e1> tolazoline </e1> , dopamine, dobutamine, steroids,  <e2> surfactant </e2> , and high-frequency ventilation.
false	INOmax has been administered with tolazoline, dopamine,  <e1> dobutamine </e1> ,  <e2> steroids </e2> , surfactant, and high-frequency ventilation.
false	INOmax has been administered with tolazoline,  <e1> dopamine </e1> , dobutamine, steroids,  <e2> surfactant </e2> , and high-frequency ventilation.
mechanism	 <e1> Uricosuric drugs </e1> , such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of  <e2> nitrofurantoin </e2> .
false	Uricosuric drugs, such as  <e1> probenecid </e1>  and  <e2> sulfinpyrazone </e2> , can inhibit renal tubular secretion of nitrofurantoin.
false	 <e1> Antacids </e1>  containing  <e2> magnesium trisilicate </e2> , when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.
effect	Marked symptomatic orthostatic hypotension has been reported when  <e1> calcium channel blockers </e1>  and organic  <e2> nitrates </e2>  were used in combination.
false	 <e1> Antacids </e1>  containing  <e2> magnesium trisilicate </e2> , when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.
effect	The hypotensive effect of  <e1> sodium nitroprusside </e1>  is augmented by that of most other  <e2> hypotensive drugs </e2> , including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.
false	The hypotensive effect of sodium nitroprusside is augmented by that of most other  <e1> hypotensive drugs </e1> , including  <e2> ganglionic blocking agents </e2> , negative inotropic agents, and inhaled anesthetics.
false	No interactions have been observed between  <e1> nizatidine </e1>  and  <e2> theophylline </e2> , chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin.
false	No interactions have been observed between nizatidine and  <e1> theophylline </e1> , chlordiazepoxide, lorazepam,  <e2> lidocaine </e2> , phenytoin, and warfarin.
false	No interactions have been observed between nizatidine and theophylline, chlordiazepoxide,  <e1> lorazepam </e1> , lidocaine, phenytoin, and  <e2> warfarin </e2> .
false	No interactions have been observed between nizatidine and theophylline,  <e1> chlordiazepoxide </e1> , lorazepam, lidocaine,  <e2> phenytoin </e2> , and warfarin.
false	No interactions have been observed between  <e1> nizatidine </e1>  and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and  <e2> warfarin </e2> .
false	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  <e1> phenytoin </e1> ,  <e2> carbamazepine </e2> , and barbiturates, and the antituberculosis drug rifampin.
false	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  <e1> phenytoin </e1> , carbamazepine, and barbiturates, and the  <e2> antituberculosis drug </e2>  rifampin.
false	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the  <e1> anticonvulsants </e1>   <e2> phenytoin </e2> , carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
effect	The effectiveness of  <e1> progestin </e1> -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug  <e2> rifampin </e2> .
false	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the  <e1> anticonvulsants </e1>  phenytoin, carbamazepine, and barbiturates, and the  <e2> antituberculosis drug </e2>  rifampin.
false	No interactions have been observed between nizatidine and theophylline,  <e1> chlordiazepoxide </e1> , lorazepam, lidocaine,  <e2> phenytoin </e2> , and warfarin.
effect	The concomitant administration of quinolones including  <e1> norfloxacin </e1>  with  <e2> glyburide </e2>  (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.
false	Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of  <e1> norfloxacin </e1> , because these products may interfere with absorption resulting in lower serum and urine levels of  <e2> norfloxacin </e2> .
effect	The concomitant use of nitrofurantoin is not recommended since  <e1> nitrofurantoin </e1>  may antagonize the antibacterial effect of  <e2> Norfloxacin </e2>  in the urinary tract.
false	Multivitamins, or other products containing iron or  <e1> zinc </e1> , antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of  <e2> norfloxacin </e2> .
false	Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of  <e1> norfloxacin </e1> , because they may interfere with absorption resulting in lower serum and urine levels of  <e2> norfloxacin </e2> .
false	Multivitamins, or other products containing  <e1> iron </e1>  or zinc, antacids or  <e2> sucralfate </e2>  should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
mechanism	Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of  <e1> probenecid </e1>  and  <e2> norfloxacin </e2> .
false	The concomitant administration of quinolones including  <e1> norfloxacin </e1>  with glyburide (a  <e2> sulfonylurea agent </e2> ) has, on rare occasions, resulted in severe hypoglycemia.
advise	Multivitamins, or other products containing iron or  <e1> zinc </e1> , antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of  <e2> norfloxacin </e2> , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
false	Diminished urinary excretion of  <e1> norfloxacin </e1>  has been reported during the concomitant administration of probenecid and  <e2> norfloxacin </e2> .
false	There have been reports of  <e1> theophylline </e1> -related side effects in patients on concomitant therapy with  <e2> norfloxacin </e2>  and theophylline.
advise	 <e1> Multivitamins </e1> , or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of  <e2> norfloxacin </e2> , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
false	Multivitamins, or other products containing  <e1> iron </e1>  or zinc,  <e2> antacids </e2>  or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
advise	 <e1> Multivitamins </e1> , or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of  <e2> norfloxacin </e2> , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
false	A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium,  <e1> carbamazepine </e1> , griseofulvin,  <e2> topiramate </e2> , and possibly with ampicillin and tetracyclines 72.
false	A similar association, though less marked, has been suggested with barbiturates,  <e1> phenylbutazone </e1> , phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and  <e2> tetracyclines </e2>  72.
effect	The concomitant use of nitrofurantoin is not recommended since  <e1> nitrofurantoin </e1>  may antagonize the antibacterial effect of  <e2> Norfloxacin </e2>  in the urinary tract.
false	A similar association, though less marked, has been suggested with barbiturates, phenylbutazone,  <e1> phenytoin sodium </e1> , carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and  <e2> tetracyclines </e2>  72.
false	A similar association, though less marked, has been suggested with barbiturates, phenylbutazone,  <e1> phenytoin sodium </e1> , carbamazepine, griseofulvin,  <e2> topiramate </e2> , and possibly with ampicillin and tetracyclines 72.
false	A similar association, though less marked, has been suggested with barbiturates,  <e1> phenylbutazone </e1> , phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with  <e2> ampicillin </e2>  and tetracyclines 72.
false	A similar association, though less marked, has been suggested with barbiturates, phenylbutazone,  <e1> phenytoin sodium </e1> , carbamazepine,  <e2> griseofulvin </e2> , topiramate, and possibly with ampicillin and tetracyclines 72.
false	Multivitamins, or other products containing  <e1> iron </e1>  or zinc,  <e2> antacids </e2>  or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
false	A similar association, though less marked, has been suggested with  <e1> barbiturates </e1> , phenylbutazone, phenytoin sodium,  <e2> carbamazepine </e2> , griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other  <e1> antidepressants </e1> , phenothiazines,  <e2> carbamazepine </e2> , and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone,  <e1> flecainide </e1> , and  <e2> encainide </e2> ), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
mechanism	There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including  <e1> nortriptyline </e1> , when  <e2> fluoxetine hydrochloride </e2>  has been administered in combination with these agents.
false	A similar association, though less marked, has been suggested with barbiturates, phenylbutazone,  <e1> phenytoin sodium </e1> , carbamazepine, griseofulvin,  <e2> topiramate </e2> , and possibly with ampicillin and tetracyclines 72.
false	In addition, certain drugs that are metabolized by this isoenzyme, including many  <e1> antidepressants </e1>  ( <e2> tricyclic antidepressants </e2> , selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.
advise	Close supervision and careful adjustment of the dosage are required when  <e1> nortriptyline hydrochloride </e1>  is used with other  <e2> anticholinergic drugs </e2>  or sympathomimetic drugs.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and  <e1> Type 1C antiarrhythmics </e1>  (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg,  <e2> quinidine </e2> ), should be approached with caution.
advise	Therefore, co-administration of  <e1> tricyclic antidepressants </e1>  with other drugs that are metabolized by this isoenzyme, including other antidepressants,  <e2> phenothiazines </e2> , carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
effect	Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of  <e1> tricyclic antidepressants </e1>  when  <e2> cimetidine </e2>  is added to the drug regimen.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other  <e1> antidepressants </e1> , phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and  <e2> encainide </e2> ), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone,  <e1> flecainide </e1> , and encainide), or that inhibit this enzyme (eg,  <e2> quinidine </e2> ), should be approached with caution.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other  <e1> antidepressants </e1> , phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone,  <e2> flecainide </e2> , and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines,  <e1> carbamazepine </e1> , and Type 1C antiarrhythmics (eg, propafenone, flecainide, and  <e2> encainide </e2> ), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
false	As  <e1> MHD </e1> , the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g.,  <e2> valproic acid </e2> , lamotrigine).
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines,  <e1> carbamazepine </e1> , and Type 1C antiarrhythmics (eg, propafenone, flecainide, and  <e2> encainide </e2> ), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
false	In addition, certain drugs that are metabolized by this isoenzyme, including many  <e1> antidepressants </e1>  ( <e2> tricyclic antidepressants </e2> , selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other  <e1> antidepressants </e1> , phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone,  <e2> flecainide </e2> , and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
false	In addition,  <e1> oxcarbazepine </e1>  and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral  <e2> contraceptives </e2> , resulting in a lower plasma concentration of these drugs.
false	Hormonal contraceptives Co-administration of Trileptal with an oral  <e1> contraceptive </e1>  has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and  <e2> levonorgestrel </e2>  (LNG).
false	Other drug interactions  <e1> Cimetidine </e1> , erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of  <e2> MHD </e2> .
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other  <e1> antidepressants </e1> , phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and  <e2> encainide </e2> ), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
false	In addition,  <e1> oxcarbazepine </e1>  and  <e2> MHD </e2>  induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.
mechanism	The increase of  <e1> phenobarbital </e1>  level, however, is small (15%) when given with  <e2> Trileptal </e2> .
effect	Therefore, concurrent use of  <e1> Trileptal </e1>  with  <e2> hormonal contraceptives </e2>  may render these contraceptives less effective.
false	Hormonal contraceptives Co-administration of  <e1> Trileptal </e1>  with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components,  <e2> ethinylestradiol </e2>  (EE) and levonorgestrel (LNG).
false	Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, phenytoin and  <e1> phenobarbital </e1> ) have been shown to decrease the plasma levels of  <e2> MHD </e2>  (29-40%).
false	As  <e1> MHD </e1> , the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g.,  <e2> valproic acid </e2> , lamotrigine).
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other  <e1> antidepressants </e1> , phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and  <e2> encainide </e2> ), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
false	Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite  <e1> doxorubicinol </e1> ) may be increased when paclitaxel and  <e2> doxorubicin </e2>  are used in combination.
false	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as  <e1> dexamethasone </e1> ), diphen-hydramine and H2 antagonists (such as cimetidine or  <e2> ranitidine </e2> ).
false	In addition, certain drugs that are metabolized by this isoenzyme, including many  <e1> antidepressants </e1>  ( <e2> tricyclic antidepressants </e2> , selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.
advise	Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and  <e1> teniposide </e1>  for injection concentrate) should not be treated with  <e2> TAXOL </e2> .
false	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after  <e1> cisplatin </e1>  than with the alternate sequence (ie, TAXOL before  <e2> cisplatin </e2> ).
false	Hormonal contraceptives Co-administration of  <e1> Trileptal </e1>  with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components,  <e2> ethinylestradiol </e2>  (EE) and levonorgestrel (LNG).
false	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and  <e1> H2 antagonists </e1>  (such as cimetidine or  <e2> ranitidine </e2> ).
false	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as  <e1> dexamethasone </e1> ), diphen-hydramine and  <e2> H2 antagonists </e2>  (such as cimetidine or ranitidine).
false	Potential interactions between  <e1> TAXOL </e1> , a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and  <e2> nelfinavir </e2> ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.
false	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and  <e1> H2 antagonists </e1>  (such as  <e2> cimetidine </e2>  or ranitidine).
false	Reports in the literature suggest that plasma levels of  <e1> doxorubicin </e1>  (and its active metabolite  <e2> doxorubicinol </e2> ) may be increased when paclitaxel and doxorubicin are used in combination.
false	In addition,  <e1> oxcarbazepine </e1>  and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral  <e2> contraceptives </e2> , resulting in a lower plasma concentration of these drugs.
effect	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  <e1> TAXOL </e1>  was given after  <e2> cisplatin </e2>  than with the alternate sequence (ie, TAXOL before cisplatin).
false	Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue  <e1> PEGASYS </e1>  and  <e2> COPEGUS </e2>  treatment.
false	Potential interactions between  <e1> TAXOL </e1> , a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and  <e2> nelfinavir </e2> ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.
false	 <e1> Stavudine </e1>  and Zidovudine  <e2> Ribavirin </e2>  can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
false	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after  <e1> cisplatin </e1>  than with the alternate sequence (ie, TAXOL before  <e2> cisplatin </e2> ).
false	Nursing Mothers It is not known whether  <e1> peginterferon </e1>  or  <e2> ribavirin </e2>  or its components are excreted in human milk.
false	In patients with chronic hepatitis C treated with PEGASYS in combination with  <e1> COPEGUS </e1> , PEGASYS treatment did not affect  <e2> ribavirin </e2>  distribution or clearance.
false	 <e1> Stavudine </e1>  and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of  <e2> stavudine </e2>  and zidovudine against HIV.
false	In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS,  <e1> PEGASYS </e1>  treatment did not affect  <e2> ribavirin </e2>  distribution or clearance.
false	Stavudine and  <e1> Zidovudine </e1>  Ribavirin can antagonize the in vitro antiviral activity of stavudine and  <e2> zidovudine </e2>  against HIV.
mechanism	Probenecid: The oral combination of  <e1> probenecid </e1>  before intramuscular injection of  <e2> PIPRACIL </e2>  produces an increase in piperacillin peak serum level of about 30%.
false	 <e1> Probenecid </e1> : The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in  <e2> piperacillin </e2>  peak serum level of about 30%.
effect	In one controlled clinical study, the ureidopenicillins, including  <e1> piperacillin </e1> , were reported to prolong the action of  <e2> vecuronium </e2> .
false	Aminoglycosides: The mixing of piperacillin with an  <e1> aminoglycoside </e1>  in vitro can result in substantial inactivation of the  <e2> aminoglycoside </e2> .
false	Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue  <e1> PEGASYS </e1>  and  <e2> COPEGUS </e2>  treatment.
false	 <e1> Methotrexate </e1> :  <e2> Piperacillin sodium </e2>  may reduce the excretion of methotrexate.
false	Nursing Mothers It is not known whether  <e1> peginterferon </e1>  or  <e2> ribavirin </e2>  or its components are excreted in human milk.
false	 <e1> Phenothiazines </e1>  - Taking piperazine and a  <e2> phenothiazine </e2>  together may increase the risk of convulsions (seizures).
false	 <e1> Pyrantel </e1>  (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of  <e2> piperazine </e2> .
false	Pyrantel (e.g.,  <e1> Antiminth </e1> ) - Taking piperazine and  <e2> pyrantel </e2>  together may decrease the effects of piperazine.
false	 <e1> Rifampin </e1> : Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in  <e2> rofecoxib </e2>  plasma concentrations.
false	 <e1> Aspirin </e1> : Concomitant administration of low-dose  <e2> aspirin </e2>  with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.
effect	Aspirin: Concomitant administration of low-dose  <e1> aspirin </e1>  with  <e2> VIOXX </e2>  may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.
false	In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated  <e1> aspirin </e1>  plus VIOXX 25 mg daily, as compared to those taking  <e2> ibuprofen </e2>  2400 mg daily alone.
false	Rifampin: Co-administration of VIOXX with  <e1> rifampin </e1>  600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in  <e2> rofecoxib </e2>  plasma concentrations.
false	 <e1> Lithium </e1> : NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal  <e2> lithium </e2>  clearance.
false	Digoxin:  <e1> Rofecoxib </e1>  75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of  <e2> digoxin </e2>  after a single 0.5 mg oral dose.
false	Prospective, long-term studies on concomitant administration of  <e1> VIOXX </e1>  and  <e2> aspirin </e2>  have not been conducted.
false	Oral  <e1> Contraceptives </e1>   <e2> Rofecoxib </e2>  did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone.
false	In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor  <e1> benazepril </e1> , 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to  <e2> ACE inhibitor </e2>  alone.
false	Standard monitoring of  <e1> methotrexate </e1> -related toxicity should be continued if VIOXX and  <e2> methotrexate </e2>  are administered concomitantly.
advise	Standard monitoring of methotrexate-related toxicity should be continued if  <e1> VIOXX </e1>  and  <e2> methotrexate </e2>  are administered concomitantly.
effect	In patients with mild to moderate hypertension, administration of 25 mg daily of  <e1> VIOXX </e1>  with the ACE inhibitor  <e2> benazepril </e2> , 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.
false	 <e1> Ketoconazole </e1> :  <e2> Ketoconazole </e2>  400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib.
false	 <e1> Methotrexate </e1>  VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly  <e2> methotrexate </e2>  doses of 7.5 to 20 mg for rheumatoid arthritis.
false	Ketoconazole:  <e1> Ketoconazole </e1>  400 mg daily did not have any clinically important effect on the pharmacokinetics of  <e2> rofecoxib </e2> .
mechanism	Rifampin: Co-administration of  <e1> VIOXX </e1>  with  <e2> rifampin </e2>  600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.
false	 <e1> Cimetidine </e1> : Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of  <e2> rofecoxib </e2>  by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.
false	Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of  <e1> methotrexate </e1>  as measured by AUC0-24hr in patients receiving single weekly  <e2> methotrexate </e2>  doses of 7.5 to 20 mg for rheumatoid arthritis.
false	 <e1> Phenothiazines </e1>  - Taking piperazine and a  <e2> phenothiazine </e2>  together may increase the risk of convulsions (seizures).
false	Oral  <e1> Contraceptives </e1>  Rofecoxib did not have any clinically important effect on the pharmacokinetics of  <e2> ethinyl estradiol </e2>  and norethindrone.
false	Antiarrhythmics:  <e1> Amiodarone </e1> , bepridil, flecainide, propafenone,  <e2> quinidine </e2>  CONTRAINDICATED due to potential for serious and/or life-threatening reactions.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers,  <e1> dapsone </e1> , disopyramide, quinine, amiodarone, quinidine, warfarin,  <e2> tacrolimus </e2> , cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Additional drugs that are not recommended for coadministration with  <e1> INVIRASE </e1>  and  <e2> ritonavir </e2>  are included below.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin,  <e1> tacrolimus </e1> , cyclosporine, ergot derivatives, pimozide,  <e2> carbamazepine </e2> , fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine,  <e1> amiodarone </e1> , quinidine,  <e2> warfarin </e2> , tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
mechanism	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone,  <e1> disopyramide </e1> , quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with  <e2> saquinavir </e2> ;
false	Antiarrhythmics: Amiodarone,  <e1> bepridil </e1> ,  <e2> flecainide </e2> , propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone,  <e1> quinidine </e1> ,  <e2> warfarin </e2> , tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Ergot Derivatives:  <e1> Dihydroergotamine </e1> , ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  <e2> ergot </e2>  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine,  <e1> amiodarone </e1> , quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and  <e2> triazolam </e2> ) may have elevated plasma concentrations when coadministered with saquinavir;
mechanism	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone,  <e1> carbamazepine </e1> ) may result in decreased plasma levels of  <e2> saquinavir </e2> .
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone,  <e1> disopyramide </e1> , quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and  <e2> triazolam </e2> ) may have elevated plasma concentrations when coadministered with saquinavir;
false	Garlic Capsules Garlic capsules should not be used while taking saquinavir ( <e1> FORTOVASE </e1> ) as the sole protease inhibitor due to the risk of decreased  <e2> saquinavir </e2>  plasma concentrations.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers,  <e1> dapsone </e1> , disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide,  <e2> carbamazepine </e2> , fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine,  <e1> ergot derivatives </e1> , pimozide, carbamazepine,  <e2> fentanyl </e2> , alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Garlic Capsules Garlic capsules should not be used while taking  <e1> saquinavir </e1>  ( <e2> FORTOVASE </e2> ) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide,  <e1> quinine </e1> , amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl,  <e2> alprazolam </e2> , and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide,  <e1> carbamazepine </e1> , fentanyl,  <e2> alfentanyl </e2> , alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  <e1> calcium channel blockers </e1> , dapsone, disopyramide, quinine, amiodarone, quinidine,  <e2> warfarin </e2> , tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	 <e1> Sedatives </e1> /Hypnotics:  <e2> triazolam </e2> , midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone,  <e1> quinidine </e1> , warfarin, tacrolimus,  <e2> cyclosporine </e2> , ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
mechanism	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine,  <e1> warfarin </e1> , tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with  <e2> saquinavir </e2> ;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine,  <e1> fentanyl </e1> , alfentanyl,  <e2> alprazolam </e2> , and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	 <e1> Aspirin </e1> : Concomitant administration of low-dose  <e2> aspirin </e2>  with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.
false	No data are available for the coadministration of INVIRASE/ <e1> ritonavir </e1>  or  <e2> FORTOVASE </e2> /ritonavir and garlic capsules.
false	Antiarrhythmics:  <e1> Amiodarone </e1> , bepridil, flecainide,  <e2> propafenone </e2> , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  <e1> calcium channel blockers </e1> , dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine,  <e2> fentanyl </e2> , alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	 <e1> Sedatives </e1> / <e2> Hypnotics </e2> : triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.
false	Antiarrhythmics: Amiodarone,  <e1> bepridil </e1> , flecainide,  <e2> propafenone </e2> , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.
effect	In patients with mild to moderate hypertension, administration of 25 mg daily of  <e1> VIOXX </e1>  with the ACE inhibitor  <e2> benazepril </e2> , 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.
false	Antiarrhythmics:  <e1> Amiodarone </e1> , bepridil,  <e2> flecainide </e2> , propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.
false	Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of  <e1> methotrexate </e1>  as measured by AUC0-24hr in patients receiving single weekly  <e2> methotrexate </e2>  doses of 7.5 to 20 mg for rheumatoid arthritis.
false	Garlic Capsules Garlic capsules should not be used while taking saquinavir ( <e1> FORTOVASE </e1> ) as the sole  <e2> protease inhibitor </e2>  due to the risk of decreased saquinavir plasma concentrations.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone,  <e1> quinidine </e1> , warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl,  <e2> alprazolam </e2> , and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
mechanism	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl,  <e1> alfentanyl </e1> , alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with  <e2> saquinavir </e2> ;
false	HMG-CoA Reductase Inhibitors:  <e1> lovastatin </e1> ,  <e2> simvastatin </e2>  WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine,  <e1> amiodarone </e1> , quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide,  <e2> carbamazepine </e2> , fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	 <e1> Ergot Derivatives </e1> : Dihydroergotamine, ergonovine, ergotamine,  <e2> methylergonovine </e2>  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  <e1> calcium channel blockers </e1> , dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine,  <e2> ergot derivatives </e2> , pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	 <e1> Phenothiazines </e1>  - Taking piperazine and a  <e2> phenothiazine </e2>  together may increase the risk of convulsions (seizures).
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl,  <e1> alfentanyl </e1> , alprazolam, and  <e2> triazolam </e2> ) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  <e1> calcium channel blockers </e1> , dapsone, disopyramide, quinine, amiodarone,  <e2> quinidine </e2> , warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	 <e1> Lithium </e1> : NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal  <e2> lithium </e2>  clearance.
advise	Since  <e1> INVIRASE </e1>  is coadministered with  <e2> ritonavir </e2> , the ritonavir label should be reviewed for additional drugs that should not be coadministered.
false	Digoxin:  <e1> Rofecoxib </e1>  75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of  <e2> digoxin </e2>  after a single 0.5 mg oral dose.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone,  <e1> disopyramide </e1> ,  <e2> quinine </e2> , amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine,  <e1> warfarin </e1> , tacrolimus, cyclosporine, ergot derivatives,  <e2> pimozide </e2> , carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	 <e1> Antimycobacterial Agents </e1> : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of  <e2> saquinavir </e2> .
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide,  <e1> quinine </e1> , amiodarone, quinidine, warfarin, tacrolimus, cyclosporine,  <e2> ergot derivatives </e2> , pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine,  <e1> warfarin </e1> , tacrolimus, cyclosporine, ergot derivatives,  <e2> pimozide </e2> , carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers,  <e1> dapsone </e1> , disopyramide, quinine, amiodarone, quinidine, warfarin,  <e2> tacrolimus </e2> , cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
mechanism	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone,  <e1> disopyramide </e1> , quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with  <e2> saquinavir </e2> ;
false	Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of  <e1> methotrexate </e1>  as measured by AUC0-24hr in patients receiving single weekly  <e2> methotrexate </e2>  doses of 7.5 to 20 mg for rheumatoid arthritis.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone,  <e1> disopyramide </e1> ,  <e2> quinine </e2> , amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide,  <e1> quinine </e1> , amiodarone, quinidine, warfarin, tacrolimus, cyclosporine,  <e2> ergot derivatives </e2> , pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  <e1> calcium channel blockers </e1> , dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine,  <e2> fentanyl </e2> , alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  <e1> calcium channel blockers </e1> , dapsone, disopyramide, quinine, amiodarone,  <e2> quinidine </e2> , warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Ergot Derivatives:  <e1> Dihydroergotamine </e1> , ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  <e2> ergot </e2>  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin],  <e1> mesoridazine </e1>  [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine],  <e2> triflupromazine </e2>  [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal],  <e1> chlorpromazine </e1>  [e.g.,  <e2> Thorazine </e2> ], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine],  <e1> promazine </e1>  [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin],  <e2> trimeprazine </e2>  [e.g., Temaril]) or
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril],  <e2> trifluoperazine </e2>  [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar],  <e1> oxymetholone </e1>  [e.g., Anadrol],  <e2> stanozolol </e2>  [e.g., Winstrol]) or
false	-  <e1> Nitrofurantoin </e1>  (e.g.,  <e2> Furadantin </e2> ) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil],  <e1> perphenazine </e1>  [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Anabolic steroids ( <e1> nandrolone </e1>  [e.g.,  <e2> Anabolin </e2> ], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e2> prochlorperazine </e2>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g.,  <e1> Prolixin </e1> ], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g.,  <e2> Sparine </e2> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g.,  <e1> Thorazine </e1> ], fluphenazine [e.g., Prolixin],  <e2> mesoridazine </e2>  [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g.,  <e1> Mellaril </e1> ], trifluoperazine [e.g., Stelazine],  <e2> triflupromazine </e2>  [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide,  <e1> quinine </e1> , amiodarone, quinidine, warfarin, tacrolimus, cyclosporine,  <e2> ergot derivatives </e2> , pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine],  <e2> triflupromazine </e2>  [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine],  <e1> fluphenazine </e1>  [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g.,  <e2> Trilafon </e2> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g., Sparine],  <e2> promethazine </e2>  [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Phenothiazines </e1>  ( <e2> acetophenazine </e2>  [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines ( <e1> acetophenazine </e1>  [e.g.,  <e2> Tindal </e2> ], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g.,  <e1> Phenergan </e1> ], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine],  <e1> promazine </e1>  [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g.,  <e2> Vesprin </e2> ], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g.,  <e1> Thorazine </e1> ], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin],  <e2> trimeprazine </e2>  [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g.,  <e2> Sparine </e2> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Carmustine </e1>  (e.g.,  <e2> BiCNU </e2> ) or
false	- Phenothiazines (acetophenazine [e.g.,  <e1> Tindal </e1> ], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil],  <e2> perphenazine </e2>  [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g., Tindal],  <e2> chlorpromazine </e2>  [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g.,  <e1> Mellaril </e1> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin],  <e2> trimeprazine </e2>  [e.g., Temaril]) or
effect	- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral  <e1> antidiabetics </e1>  with  <e2> sulfapyridine </e2>  may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g.,  <e1> Trilafon </e1> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan],  <e2> thioridazine </e2>  [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone,  <e1> disopyramide </e1> ,  <e2> quinine </e2> , amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	-  <e1> Anabolic steroids </e1>  (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g.,  <e2> Winstrol </e2> ]) or
false	- Anabolic steroids (nandrolone [e.g.,  <e1> Anabolin </e1> ], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g.,  <e2> Winstrol </e2> ]) or
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g.,  <e2> Sparine </e2> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g.,  <e1> Prolixin </e1> ], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine],  <e2> promethazine </e2>  [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin],  <e1> mesoridazine </e1>  [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan],  <e2> thioridazine </e2>  [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines ( <e1> acetophenazine </e1>  [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g.,  <e2> Compazine </e2> ], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines ( <e1> acetophenazine </e1>  [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g.,  <e2> Sparine </e2> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g.,  <e1> Thorazine </e1> ], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g.,  <e2> Phenergan </e2> ], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan],  <e1> thioridazine </e1>  [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g.,  <e2> Vesprin </e2> ], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g.,  <e1> Prolixin </e1> ], mesoridazine [e.g., Serentil], perphenazine [e.g.,  <e2> Trilafon </e2> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Methotrexate </e1>  (e.g., Mexate) Use of methotrexate with  <e2> sulfapyridine </e2>  may increase the chance of side effects affecting the liver and/or the side effects of methotrexate
false	- Anabolic steroids ( <e1> nandrolone </e1>  [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol],  <e2> stanozolol </e2>  [e.g., Winstrol]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g.,  <e1> Phenergan </e1> ], thioridazine [e.g.,  <e2> Mellaril </e2> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g.,  <e1> Serentil </e1> ], perphenazine [e.g., Trilafon], prochlorperazine [e.g.,  <e2> Compazine </e2> ], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenytoin (e.g., Dilantin) Use of phenytoin with  <e1> sulfapyridine </e1>  may increase the chance of side effects affecting the liver and/or the side effects of  <e2> phenytoin </e2> 
false	- Phenothiazines (acetophenazine [e.g.,  <e1> Tindal </e1> ], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin],  <e2> mesoridazine </e2>  [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
int	 <e1> Sulfapyridine </e1>  may interact with any of the following: - Acetaminophen (e.g.,  <e2> Tylenol </e2> ) (with long-term, high-dose use) or
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g.,  <e2> Serentil </e2> ], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Quinine </e1>  (e.g.,  <e2> Quinamm </e2> ) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine],  <e1> promazine </e1>  [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g.,  <e2> Mellaril </e2> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g.,  <e1> Trilafon </e1> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine],  <e1> fluphenazine </e1>  [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril],  <e2> trifluoperazine </e2>  [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin],  <e1> mesoridazine </e1>  [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine],  <e2> promethazine </e2>  [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Methyldopa (e.g.,  <e1> Aldomet </e1> ) Use of methyldopa with  <e2> sulfapyridine </e2>  may increase the chance of side effects affecting the liver and/or the blood
false	- Phenothiazines ( <e1> acetophenazine </e1>  [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil],  <e2> perphenazine </e2>  [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g.,  <e2> Mellaril </e2> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g.,  <e2> Vesprin </e2> ], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g.,  <e1> Prolixin </e1> ], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g.,  <e2> Temaril </e2> ]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g.,  <e1> Phenergan </e1> ], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g.,  <e2> Vesprin </e2> ], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril],  <e2> trifluoperazine </e2>  [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g.,  <e1> Thorazine </e1> ],  <e2> fluphenazine </e2>  [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g.,  <e1> Thorazine </e1> ], fluphenazine [e.g.,  <e2> Prolixin </e2> ], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin],  <e1> mesoridazine </e1>  [e.g., Serentil], perphenazine [e.g.,  <e2> Trilafon </e2> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Vitamin K (e.g.,  <e1> AquaMEPHYTON </e1> , Synkayvite) Use of  <e2> sulfapyridine </e2>  with these medicines may increase the chance of side effects affecting the blood
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g.,  <e1> Trilafon </e1> ], prochlorperazine [e.g., Compazine],  <e2> promazine </e2>  [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g.,  <e2> Trilafon </e2> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g.,  <e1> Mellaril </e1> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g.,  <e2> Vesprin </e2> ], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g.,  <e1> Tindal </e1> ], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine],  <e2> promethazine </e2>  [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Anabolic steroids (nandrolone [e.g.,  <e1> Anabolin </e1> ], oxandrolone [e.g., Anavar], oxymetholone [e.g.,  <e2> Anadrol </e2> ], stanozolol [e.g., Winstrol]) or
false	-  <e1> Vitamin K </e1>  (e.g., AquaMEPHYTON, Synkayvite) Use of  <e2> sulfapyridine </e2>  with these medicines may increase the chance of side effects affecting the blood
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g.,  <e1> Compazine </e1> ], promazine [e.g.,  <e2> Sparine </e2> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines ( <e1> acetophenazine </e1>  [e.g., Tindal],  <e2> chlorpromazine </e2>  [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan],  <e2> thioridazine </e2>  [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin],  <e1> mesoridazine </e1>  [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g.,  <e2> Compazine </e2> ], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Methotrexate (e.g., Mexate) Use of  <e1> methotrexate </e1>  with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of  <e2> methotrexate </e2> 
false	-  <e1> Antidiabetics </e1> , oral (diabetes medicine you take by mouth) Use of oral antidiabetics with  <e2> sulfapyridine </e2>  may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g.,  <e2> Vesprin </e2> ], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin],  <e2> trimeprazine </e2>  [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g.,  <e1> Tindal </e1> ], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril],  <e2> trifluoperazine </e2>  [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g.,  <e1> Tindal </e1> ], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine],  <e2> promazine </e2>  [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g.,  <e1> Serentil </e1> ], perphenazine [e.g.,  <e2> Trilafon </e2> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g.,  <e1> Sparine </e1> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin],  <e2> trimeprazine </e2>  [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g.,  <e1> Phenergan </e1> ], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine],  <e2> triflupromazine </e2>  [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e1> Stelazine </e1> ], triflupromazine [e.g., Vesprin],  <e2> trimeprazine </e2>  [e.g., Temaril]) or
false	This indicates that  <e1> tiagabine </e1>  does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of  <e2> antipyrine </e2> .
false	 <e1> Carbamazepine </e1> :  <e2> Tiagabine </e2>  had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy.
false	Interaction of  <e1> GABITRIL </e1>  with Highly Protein Bound Drugs: In vitro data showed that  <e2> tiagabine </e2>  is 96% bound to human plasma protein and therefore has the potential to interact with other highly protein bound compounds.
false	 <e1> Phenobarbital </e1>  (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing  <e2> AEDs </e2> .
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g.,  <e2> Sparine </e2> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone,  <e1> disopyramide </e1> ,  <e2> quinine </e2> , amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide,  <e1> quinine </e1> , amiodarone, quinidine, warfarin, tacrolimus, cyclosporine,  <e2> ergot derivatives </e2> , pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	-  <e1> Vitamin K </e1>  (e.g., AquaMEPHYTON, Synkayvite) Use of  <e2> sulfapyridine </e2>  with these medicines may increase the chance of side effects affecting the blood
false	 <e1> Warfarin </e1> : No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or  <e2> S-warfarin </e2>  with the addition of tiagabine given as a single dose.
false	The addition of  <e1> tiagabine </e1>  in a limited number of patients in three well-controlled studies caused no systematic changes in  <e2> phenobarbital </e2>  or primidone concentrations when compared to placebo.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g.,  <e1> Prolixin </e1> ], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g.,  <e2> Sparine </e2> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	 <e1> Digoxin </e1> : Concomitant administration of  <e2> tiagabine </e2>  did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g.,  <e1> Thorazine </e1> ],  <e2> fluphenazine </e2>  [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin],  <e1> mesoridazine </e1>  [e.g., Serentil], perphenazine [e.g.,  <e2> Trilafon </e2> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
advise	Because of the possible additive effects of drugs that may depress the nervous system, ethanol or  <e1> triazolam </e1>  should be used cautiously in combination with  <e2> tiagabine </e2> .
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g.,  <e1> Mellaril </e1> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g.,  <e2> Vesprin </e2> ], trimeprazine [e.g., Temaril]) or
false	Phenytoin: Population pharmacokinetic analyses indicate that  <e1> tiagabine </e1>  clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing  <e2> AEDs </e2> .
mechanism	Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that  <e1> tiagabine </e1>  clearance is 60% greater in patients taking  <e2> phenobarbital </e2>  (primidone) with or without other enzyme-inducing AEDs.
false	Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin:  <e1> Tiagabine </e1>  had no effect on the steady-state plasma concentrations of  <e2> phenytoin </e2>  in patients with epilepsy.
false	- Methyldopa (e.g.,  <e1> Aldomet </e1> ) Use of methyldopa with  <e2> sulfapyridine </e2>  may increase the chance of side effects affecting the liver and/or the blood
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g.,  <e1> Phenergan </e1> ], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g.,  <e1> Tindal </e1> ], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine],  <e2> promazine </e2>  [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL :  <e1> Carbamazepine </e1> : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing  <e2> AEDs </e2> .
false	 <e1> Phenobarbital </e1>  (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital ( <e2> primidone </e2> ) with or without other enzyme-inducing AEDs.
false	The addition of  <e1> tiagabine </e1>  in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or  <e2> primidone </e2>  concentrations when compared to placebo.
false	- Anabolic steroids (nandrolone [e.g.,  <e1> Anabolin </e1> ], oxandrolone [e.g., Anavar], oxymetholone [e.g.,  <e2> Anadrol </e2> ], stanozolol [e.g., Winstrol]) or
false	Valproate: The addition of tiagabine to patients taking  <e1> valproate </e1>  chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased  <e2> tiagabine </e2>  binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.
false	 <e1> Phenobarbital </e1>  or Primidone : No formal pharmacokinetic studies have been performed examining the addition of  <e2> tiagabine </e2>  to regimens containing phenobarbital or primidone.
false	- Phenothiazines ( <e1> acetophenazine </e1>  [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil],  <e2> perphenazine </e2>  [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Phenobarbital ( <e1> Primidone </e1> ): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing  <e2> AEDs </e2> .
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil],  <e1> perphenazine </e1>  [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL :  <e1> Carbamazepine </e1> : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking  <e2> carbamazepine </e2>  with or without other enzyme- inducing AEDs.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g.,  <e1> Trilafon </e1> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	 <e1> Tiagabine </e1>  has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or  <e2> alcohol </e2> .
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine],  <e1> fluphenazine </e1>  [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g.,  <e2> Trilafon </e2> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g.,  <e1> Mellaril </e1> ], trifluoperazine [e.g., Stelazine],  <e2> triflupromazine </e2>  [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Effects of  <e1> GABITRIL </e1>  on other Antiepilepsy Drugs (AEDs) :  <e2> Phenytoin </e2> : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g.,  <e2> Mellaril </e2> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Carmustine </e1>  (e.g.,  <e2> BiCNU </e2> ) or
false	Interaction of GABITRIL with Other Drugs :  <e1> Cimetidine </e1>  : Co-administration of cimetidine (800 mg/day) to patients taking  <e2> tiagabine </e2>  chronically had no effect on tiagabine pharmacokinetics.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan],  <e2> thioridazine </e2>  [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on  <e1> tiagabine </e1>  pharmacokinetics, but  <e2> valproate </e2>  significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.
false	Coadministration of  <e1> valdecoxib </e1>  (10 mg BID for 7 days) with  <e2> glyburide </e2>  (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of glyburide.
false	In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9),  <e1> valdecoxib </e1>  had no effect on in vitro  <e2> aspirin </e2> -mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.
false	-  <e1> Carmustine </e1>  (e.g.,  <e2> BiCNU </e2> ) or
false	Effects of  <e1> GABITRIL </e1>  on other Antiepilepsy Drugs (AEDs) :  <e2> Phenytoin </e2> : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil],  <e1> perphenazine </e1>  [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Anticonvulsants ( <e1> Phenytoin </e1> ): Steady state plasma exposure (AUC) of  <e2> valdecoxib </e2>  (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).
false	These increased exposures of norethindrone and  <e1> ethinyl estradiol </e1>  should be taken into consideration when selecting an oral  <e2> contraceptive </e2>  for women taking valdecoxib.
advise	Lithium serum concentrations should be monitored closely when initiating or changing therapy with  <e1> BEXTRA </e1>  in patients receiving  <e2> lithium </e2> .
false	Oral Contraceptives:  <e1> Valdecoxib </e1>  (40 mg BID) did not induce the metabolism of the combination oral  <e2> contraceptive </e2>  norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).
false	Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with  <e1> glyburide </e1>  (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of  <e2> glyburide </e2> .
false	Plasma exposure of  <e1> diazepam </e1>  (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of  <e2> diazepam </e2>  (10 mg BID) for 12 days.
false	 <e1> Aspirin </e1> : Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to  <e2> valdecoxib </e2>  alone.
false	Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and  <e1> S-warfarin </e1>  (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of  <e2> warfarin </e2> .
false	 <e1> Aspirin </e1> : Concomitant administration of  <e2> aspirin </e2>  with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.
false	Diazepam:  <e1> Diazepam </e1>  ( <e2> Valium </e2> ) is a CYP 3A4 and CYP 2C19 substrate.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g.,  <e1> Phenergan </e1> ], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Coadministration of  <e1> valdecoxib </e1>  (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in  <e2> glyburide </e2>  AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.
false	- Anabolic steroids (nandrolone [e.g.,  <e1> Anabolin </e1> ], oxandrolone [e.g., Anavar], oxymetholone [e.g.,  <e2> Anadrol </e2> ], stanozolol [e.g., Winstrol]) or
false	 <e1> Fluconazole </e1>  and  <e2> Ketoconazole </e2> : Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.
false	 <e1> Aspirin </e1> : Concomitant administration of aspirin with  <e2> valdecoxib </e2>  may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g.,  <e1> Mellaril </e1> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g.,  <e2> Vesprin </e2> ], trimeprazine [e.g., Temaril]) or
false	Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin:  <e1> Tiagabine </e1>  had no effect on the steady-state plasma concentrations of  <e2> phenytoin </e2>  in patients with epilepsy.
false	Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in  <e1> lithium </e1>  serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to  <e2> lithium </e2>  alone.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin],  <e1> mesoridazine </e1>  [e.g., Serentil], perphenazine [e.g.,  <e2> Trilafon </e2> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	 <e1> Phenobarbital </e1>  (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing  <e2> AEDs </e2> .
advise	Because of the possible additive effects of drugs that may depress the nervous system, ethanol or  <e1> triazolam </e1>  should be used cautiously in combination with  <e2> tiagabine </e2> .
mechanism	Even so  <e1> dextromethorphan </e1>  plasma concentrations in the presence of high doses of  <e2> valdecoxib </e2>  were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.
false	Aspirin: Concomitant administration of  <e1> aspirin </e1>  with valdecoxib may result in an increased risk of GI ulceration and complications compared to  <e2> valdecoxib </e2>  alone.
false	Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ <e1> ethinyl estradiol </e1>  (1 mg /35 mcg combination,  <e2> Ortho-Novum </e2>  1/35 ).
effect	Furosemide: Clinical studies, as well as post-marketing observations, have shown that  <e1> NSAIDs </e1>  can reduce the natriuretic effect of  <e2> furosemide </e2>  and thiazides in some patients.
false	Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  <e1> norethindrone </e1> /ethinyl estradiol (1 mg /35 mcg combination,  <e2> Ortho-Novum </e2>  1/35 ).
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone,  <e1> disopyramide </e1> ,  <e2> quinine </e2> , amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine],  <e1> fluphenazine </e1>  [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g.,  <e2> Trilafon </e2> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Although the magnitude of changes in  <e1> diazepam </e1>  plasma exposure when coadministered with  <e2> valdecoxib </e2>  were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.
mechanism	 <e1> Valdecoxib </e1>  caused a statistically significant increase in plasma exposures of  <e2> R-warfarin </e2>  and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
false	These increased exposures of norethindrone and  <e1> ethinyl estradiol </e1>  should be taken into consideration when selecting an oral contraceptive for women taking  <e2> valdecoxib </e2> .
mechanism	Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that  <e1> tiagabine </e1>  clearance is 60% greater in patients taking  <e2> phenobarbital </e2>  (primidone) with or without other enzyme-inducing AEDs.
false	 <e1> Furosemide </e1> : Clinical studies, as well as post-marketing observations, have shown that  <e2> NSAIDs </e2>  can reduce the natriuretic effect of furosemide and thiazides in some patients.
false	Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  <e1> norethindrone </e1> /ethinyl estradiol (1 mg /35 mcg combination,  <e2> Ortho-Novum </e2>  1/35 ).
false	 <e1> Aspirin </e1> : Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to  <e2> valdecoxib </e2>  alone.
false	HIV Protease Inhibitors:  <e1> Indinavir </e1>  (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in  <e2> vardenafil </e2>  AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
false	 <e1> Cimetidine </e1>  (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg  <e2> Vardenafil </e2>  in healthy volunteers.
false	Plasma exposure of  <e1> diazepam </e1>  (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of  <e2> diazepam </e2>  (10 mg BID) for 12 days.
advise	It is recommended not to exceed a single 5 mg dose of  <e1> Vardenafil </e1>  in a 24-hour period when used in combination with  <e2> erythromycin </e2> .
mechanism	HIV Protease Inhibitors:  <e1> Indinavir </e1>  (800 mg t.i.d.) co-administered with  <e2> Vardenafil </e2>  10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g.,  <e1> Mellaril </e1> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g.,  <e2> Vesprin </e2> ], trimeprazine [e.g., Temaril]) or
false	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs:  <e1> glyburide </e1> ,  <e2> warfarin </e2> , digoxin, Maalox, and ranitidine.
effect	With simultaneous dosing of  <e1> Vardenafil </e1>  10 mg and  <e2> terazosin </e2>  10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
false	 <e1> HIV Protease Inhibitors </e1> : Indinavir (800 mg t.i.d.) co-administered with  <e2> Vardenafil </e2>  10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
false	In a similar study with  <e1> tamsulosin </e1>  in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and  <e2> tamsulosin </e2>  0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.
mechanism	Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that  <e1> tiagabine </e1>  clearance is 60% greater in patients taking  <e2> phenobarbital </e2>  (primidone) with or without other enzyme-inducing AEDs.
mechanism	In vivo studies: Nitrates: The blood pressure lowering effects of sublingual  <e1> nitrates </e1>  (0.4 mg) taken 1 and 4 hours after  <e2> vardenafil </e2>  and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.
false	Alcohol:  <e1> Alcohol </e1>  (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and  <e2> vardenafil </e2>  plasma levels were not altered when dosed simultaneously.
false	Other Drug Interactions: No pharmacokinetic interactions were observed between  <e1> vardenafil </e1>  and the following drugs: glyburide,  <e2> warfarin </e2> , digoxin, Maalox, and ranitidine.
false	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs:  <e1> glyburide </e1> , warfarin, digoxin, Maalox, and  <e2> ranitidine </e2> .
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g.,  <e1> Phenergan </e1> ], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Ritonavir and  <e1> indinavir </e1> : Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of  <e2> ritonavir </e2>  were reduced by approximately 20%.
false	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs:  <e1> glyburide </e1> , warfarin,  <e2> digoxin </e2> , Maalox, and ranitidine.
false	Other interactions: Vardenafil had no effect on the pharmacodynamics of  <e1> glyburide </e1>  (glucose and insulin concentrations) and  <e2> warfarin </e2>  (prothrombin time or other pharmacodynamic parameters).
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil],  <e1> perphenazine </e1>  [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Effects of  <e1> GABITRIL </e1>  on other Antiepilepsy Drugs (AEDs) :  <e2> Phenytoin </e2> : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.
false	Ketoconazole (200 mg once daily) produced a 10-fold increase in  <e1> vardenafil </e1>  AUC and a 4-fold increase in Cmax when co-administered with  <e2> Vardenafil </e2>  (5 mg) in healthy volunteers.
false	Anticonvulsants ( <e1> Phenytoin </e1> ): Steady state plasma exposure (AUC) of  <e2> valdecoxib </e2>  (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).
false	Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in  <e1> lithium </e1>  serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to  <e2> lithium </e2>  alone.
false	Nifedipine:  <e1> Vardenafil </e1>  20 mg, when co-administered with slow-release  <e2> nifedipine </e2>  30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.
false	Coadministration of  <e1> valdecoxib </e1>  (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in  <e2> glyburide </e2>  AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.
advise	Based on these data,  <e1> Vardenafil </e1>  should not be used in patients on  <e2> alpha-blocker </e2>  therapy.
false	In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9),  <e1> valdecoxib </e1>  had no effect on in vitro  <e2> aspirin </e2> -mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.
false	In the  <e1> warfarin </e1>  study,  <e2> vardenafil </e2>  had no effect on the prothrombin time or other pharmacodynamic parameters.
false	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs:  <e1> glyburide </e1> , warfarin,  <e2> digoxin </e2> , Maalox, and ranitidine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone,  <e1> disulfiram </e1> , ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and  <e2> vincristine </e2> .
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine,  <e1> iodoquinol </e1> , isoniazid, metronidazole, nitrofurantoin, phenytoin,  <e2> ribavirin </e2> , and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole,  <e1> nitrofurantoin </e1> , phenytoin,  <e2> ribavirin </e2> , and vincristine.
false	 <e1> HIV Protease Inhibitors </e1> : Indinavir (800 mg t.i.d.) co-administered with  <e2> Vardenafil </e2>  10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid,  <e1> metronidazole </e1> , nitrofurantoin, phenytoin, ribavirin, and  <e2> vincristine </e2> .
false	In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9),  <e1> valdecoxib </e1>  had no effect on in vitro  <e2> aspirin </e2> -mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.
false	Amphotericin,  <e1> Foscarnet </e1> , and Aminoglycosides: Drugs such as  <e2> amphotericin </e2> , foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
false	Probenecid or  <e1> Cimetidine </e1> : Concomitant administration of probenecid or cimetidine decreases the elimination of  <e2> zalcitabine </e2> , most likely by inhibition of renal tubular secretion of zalcitabine.
false	 <e1> Lamivudine </e1> : In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited  <e2> zalcitabine </e2>  phosphorylation in a dose dependent manner.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold,  <e1> hydralazine </e1> , iodoquinol, isoniazid, metronidazole,  <e2> nitrofurantoin </e2> , phenytoin, ribavirin, and vincristine.
false	Probenecid or  <e1> Cimetidine </e1> : Concomitant administration of probenecid or  <e2> cimetidine </e2>  decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
false	Amphotericin, Foscarnet, and  <e1> Aminoglycosides </e1> : Drugs such as  <e2> amphotericin </e2> , foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
false	Alcohol:  <e1> Alcohol </e1>  (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and  <e2> vardenafil </e2>  plasma levels were not altered when dosed simultaneously.
false	These in vitro studies suggest that concomitant administration of  <e1> zalcitabine </e1>  and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased  <e2> antiretroviral </e2>  effect of zalcitabine.
false	Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with  <e1> magnesium </e1> / <e2> aluminum </e2> -containing antacid products.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid,  <e1> metronidazole </e1> , nitrofurantoin, phenytoin,  <e2> ribavirin </e2> , and vincristine.
false	 <e1> Probenecid </e1>  or Cimetidine: Concomitant administration of probenecid or  <e2> cimetidine </e2>  decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
false	Magnesium/ <e1> Aluminum </e1> -containing  <e2> Antacid Products </e2> : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.
false	 <e1> Magnesium </e1> /Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with  <e2> magnesium </e2> /aluminum-containing antacid products.
false	Zidovudine: There is no significant pharmacokinetic interaction between  <e1> ZDV </e1>  and  <e2> zalcitabine </e2>  which has been confirmed clinically.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide,  <e1> glutethimide </e1> , gold, hydralazine, iodoquinol,  <e2> isoniazid </e2> , metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide,  <e1> gold </e1> , hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and  <e2> vincristine </e2> .
false	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs:  <e1> glyburide </e1> ,  <e2> warfarin </e2> , digoxin, Maalox, and ranitidine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram,  <e1> ethionamide </e1> ,  <e2> glutethimide </e2> , gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
mechanism	Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when  <e1> zalcitabine </e1>  and  <e2> metoclopramide </e2>  are coadministered.
false	Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  <e1> norethindrone </e1> /ethinyl estradiol (1 mg /35 mcg combination,  <e2> Ortho-Novum </e2>  1/35 ).
false	 <e1> Zidovudine </e1> : There is no significant pharmacokinetic interaction between ZDV and  <e2> zalcitabine </e2>  which has been confirmed clinically.
false	HIV Protease Inhibitors:  <e1> Indinavir </e1>  (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in  <e2> vardenafil </e2>  AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
false	Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in  <e1> lithium </e1>  serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to  <e2> lithium </e2>  alone.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram,  <e1> ethionamide </e1> , glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin,  <e2> ribavirin </e2> , and vincristine.
false	 <e1> Lamivudine </e1> : In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that  <e2> lamivudine </e2>  significantly inhibited zalcitabine phosphorylation in a dose dependent manner.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol,  <e1> cisplatin </e1> , dapsone,  <e2> disulfiram </e2> , ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Saquinavir: The combination of HIVID,  <e1> saquinavir </e1> , and  <e2> ZDV </e2>  has been studied (as triple combination) in adults.
advise	The clinical significance of this reduction is not known, hence  <e1> zalcitabine </e1>  is not recommended to be ingested simultaneously with magnesium/aluminum-containing  <e2> antacids </e2> .
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone,  <e1> disulfiram </e1> ,  <e2> ethionamide </e2> , glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Magnesium/Aluminum-containing  <e1> Antacid Products </e1> : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with  <e2> magnesium </e2> /aluminum-containing antacid products.
effect	With simultaneous dosing of  <e1> Vardenafil </e1>  10 mg and  <e2> terazosin </e2>  10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
false	In the  <e1> warfarin </e1>  study,  <e2> vardenafil </e2>  had no effect on the prothrombin time or other pharmacodynamic parameters.
false	These in vitro studies suggest that concomitant administration of zalcitabine and  <e1> lamivudine </e1>  in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of  <e2> zalcitabine </e2> .
false	Effects of  <e1> GABITRIL </e1>  on other Antiepilepsy Drugs (AEDs) :  <e2> Phenytoin </e2> : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.
effect	 <e1> Zalcitabine </e1>  also has no significant effect on the intracellular phosphorylation of  <e2> ZDV </e2> , as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).
mechanism	Probenecid or Cimetidine: Concomitant administration of probenecid or  <e1> cimetidine </e1>  decreases the elimination of  <e2> zalcitabine </e2> , most likely by inhibition of renal tubular secretion of zalcitabine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues,  <e1> chloramphenicol </e1> , cisplatin, dapsone, disulfiram, ethionamide,  <e2> glutethimide </e2> , gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram,  <e1> ethionamide </e1> , glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin,  <e2> phenytoin </e2> , ribavirin, and vincristine.
false	The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with  <e1> magnesium </e1> / <e2> aluminum </e2> -containing antacids.
false	 <e1> Amphotericin </e1> , Foscarnet, and Aminoglycosides: Drugs such as amphotericin,  <e2> foscarnet </e2> , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
false	 <e1> Probenecid </e1>  or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of  <e2> zalcitabine </e2> , most likely by inhibition of renal tubular secretion of zalcitabine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone,  <e1> disulfiram </e1> , ethionamide, glutethimide, gold, hydralazine,  <e2> iodoquinol </e2> , isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Magnesium/Aluminum-containing Antacid Products: Absorption of  <e1> zalcitabine </e1>  is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing  <e2> antacid products </e2> .
false	 <e1> Probenecid </e1>  or Cimetidine: Concomitant administration of  <e2> probenecid </e2>  or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide,  <e1> glutethimide </e1> , gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and  <e2> vincristine </e2> .
false	CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of  <e1> ethanol </e1>  0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after  <e2> ethanol </e2>  administration.
false	An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as  <e1> rifampin </e1> , phenytoin,  <e2> carbamazepine </e2> , and phenobarbital.
effect	 <e1> Zalcitabine </e1>  also has no significant effect on the intracellular phosphorylation of  <e2> ZDV </e2> , as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).
false	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs:  <e1> glyburide </e1> , warfarin,  <e2> digoxin </e2> , Maalox, and ranitidine.
false	Drugs with a Narrow Therapeutic Index Digoxin:  <e1> Sonata </e1>  (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of  <e2> digoxin </e2>  (0.375 mg q24h for 8 days).
false	Coadministration of single, oral doses of zaleplon with  <e1> erythromycin </e1>  (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in  <e2> zaleplon </e2> s maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.
false	CNS-Active Drugs Ethanol:  <e1> Sonata </e1>  10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after  <e2> ethanol </e2>  administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.
mechanism	Other strong selective CYP3A4 inhibitors such as  <e1> ketoconazole </e1>  can also be expected to increase the exposure of  <e2> zaleplon </e2> .
false	Effects of  <e1> GABITRIL </e1>  on other Antiepilepsy Drugs (AEDs) :  <e2> Phenytoin </e2> : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid,  <e1> metronidazole </e1> , nitrofurantoin, phenytoin,  <e2> ribavirin </e2> , and vincristine.
false	Additionally,  <e1> paroxetine </e1>  did not alter the pharmacokinetics of Sonata, reflecting the absence of a role of CYP2D6 in  <e2> zaleplon </e2>  s metabolism.
false	Promethazine: Coadministration of a single dose of zaleplon and  <e1> promethazine </e1>  (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of  <e2> zaleplon </e2> , but no change in the area under the plasma concentration-time curve.
false	CNS-Active Drugs  <e1> Ethanol </e1> : Sonata 10 mg potentiated the CNS-impairing effects of  <e2> ethanol </e2>  0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.
false	 <e1> Magnesium </e1> /Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with  <e2> magnesium </e2> /aluminum-containing antacid products.
false	Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites,  <e1> 5-oxo-desethylzaleplon </e1>  and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a  <e2> zaleplon </e2>  dose.
false	Zidovudine: There is no significant pharmacokinetic interaction between  <e1> ZDV </e1>  and  <e2> zalcitabine </e2>  which has been confirmed clinically.
false	These in vitro studies suggest that concomitant administration of  <e1> zalcitabine </e1>  and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased  <e2> antiretroviral </e2>  effect of zalcitabine.
false	Venlafaxine: Coadministration of a single dose of  <e1> zaleplon </e1>  10 mg and multiple doses of  <e2> venlafaxine </e2>  ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.
false	Probenecid or  <e1> Cimetidine </e1> : Concomitant administration of probenecid or  <e2> cimetidine </e2>  decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
false	Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites,  <e1> 5-oxo-desethylzaleplon </e1>  and  <e2> 5-oxo-desethylzaleplon glucuronide </e2> , account for only 9% of the urinary recovery of a zaleplon dose.
false	 <e1> Probenecid </e1>  or Cimetidine: Concomitant administration of  <e2> probenecid </e2>  or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
false	In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9),  <e1> valdecoxib </e1>  had no effect on in vitro  <e2> aspirin </e2> -mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.
false	Drugs That Induce CYP3A4  <e1> Rifampin </e1> : CYP3A4 is ordinarily a minor metabolizing enzyme of  <e2> zaleplon </e2> .
false	Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of  <e1> warfarin </e1>  (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of  <e2> warfarin </e2> .
false	 <e1> Diphenhydramine </e1> :  <e2> Diphenhydramine </e2>  is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known.
false	These in vitro studies suggest that concomitant administration of zalcitabine and  <e1> lamivudine </e1>  in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of  <e2> zalcitabine </e2> .
false	Ethanol decreases the elimination of  <e1> abacavir </e1>  causing an increase in overall exposure . The addition of  <e2> methadone </e2>  has no clinically significant effect on the pharmacokinetic properties of abacavir. 
false	No clinically significant changes to  <e1> lamivudine </e1>  or  <e2> zidovudine </e2>  pharmacokinetics were observed following concomitant administration of abacavir. 
false	 <e1> Abacavir </e1>  has no effect on the pharmacokinetic properties of  <e2> ethanol </e2> . 
false	Pharmacokinetic properties of abacavir were not altered by the addition of either  <e1> lamivudine </e1>  or zidovudine or the combination of lamivudine and  <e2> zidovudine </e2> . 
false	Pharmacokinetic properties of  <e1> abacavir </e1>  were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and  <e2> zidovudine </e2> . 
false	An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as  <e1> rifampin </e1> , phenytoin,  <e2> carbamazepine </e2> , and phenobarbital.
false	Pharmacokinetic properties of  <e1> abacavir </e1>  were not altered by the addition of either lamivudine or  <e2> zidovudine </e2>  or the combination of lamivudine and zidovudine. 
false	 <e1> Diphenhydramine </e1> :  <e2> Diphenhydramine </e2>  is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known.
false	Ethanol decreases the elimination of  <e1> abacavir </e1>  causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of  <e2> abacavir </e2> . 
false	Multiple dose studies of ezetimibe given in combination with  <e1> HMG-CoA reductase inhibitors </e1>  ( <e2> statins </e2> ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. 
false	Multiple dose studies of  <e1> ezetimibe </e1>  given in combination with  <e2> HMG-CoA reductase inhibitors </e2>  (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. 
false	Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors ( <e1> statins </e1> ) in rats and rabbits during organogenesis result in higher  <e2> ezetimibe </e2>  and statin exposures. 
false	No clinically significant changes to  <e1> lamivudine </e1>  or  <e2> zidovudine </e2>  pharmacokinetics were observed following concomitant administration of abacavir. 
advise	Co-administration of  <e1> ZETIA </e1>  with  <e2> fibrates </e2>  is not recommended until use in patients is studied. 
false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when  <e1> ezetimibe </e1>  was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or  <e2> fluvastatin </e2> . 
false	Multiple dose studies of  <e1> ezetimibe </e1>  given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher  <e2> ezetimibe </e2>  and statin exposures. 
false	 <e1> Fibrates </e1> : The safety and effectiveness of  <e2> ezetimibe </e2>  administered with fibrates have not been established. 
false	A 104-week dietary carcinogenicity study with  <e1> ezetimibe </e1>  was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total  <e2> ezetimibe </e2> ). 
false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when  <e1> ezetimibe </e1>  was co-administered with  <e2> atorvastatin </e2> , simvastatin, pravastatin, lovastatin, or fluvastatin. 
false	 <e1> Cholestyramine </e1> : Concomitant  <e2> cholestyramine </e2>  administration decreased the mean AUC of total ezetimibe approximately 55%. 
false	 <e1> Cyclosporine </e1> : The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including  <e2> cyclosporine </e2> . 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole,  <e1> Rifabutin </e1> , Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral  <e2> hypoglycemic agents </e2> ; 
false	Another study at a 400-mg and 800-mg daily dose of  <e1> fluconazole </e1>  demonstrated that  <e2> DIFLUCAN </e2>  taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine,  <e1> Rifampin </e1> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of  <e2> DIFLUCAN </e2>  with oral hypoglycemic agents; 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride,  <e1> Astemizole </e1> , Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral  <e2> hypoglycemic agents </e2> ; 
false	 <e1> Coumarin-type anticoagulants </e1> : Prothrombin time may be increased in patients receiving concomitant  <e2> DIFLUCAN </e2>  and coumarin-type anticoagulants. 
false	While there is evidence that  <e1> fluconazole </e1>  can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of  <e2> ethinyl estradiol </e2>  or levonorgestrel metabolism. 
false	 <e1> Fluconazole </e1>  tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in  <e2> ethinyl estradiol </e2>  and levonorgestrel levels; 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin,  <e1> Tacrolimus </e1> , Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral  <e2> hypoglycemic agents </e2> ; 
mechanism	Theophylline:  <e1> DIFLUCAN </e1>  increases the serum concentrations of  <e2> theophylline </e2> . 
advise	Patients receiving  <e1> tacrolimus </e1>  and  <e2> fluconazole </e2>  concomitantly should be carefully monitored. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin,  <e1> Theophylline </e1> , Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral  <e2> hypoglycemic agents </e2> ; 
mechanism	Cyclosporine:  <e1> DIFLUCAN </e1>  may significantly increase  <e2> cyclosporine </e2>  levels in renal transplant patients with or without renal impairment. 
false	While there is evidence that fluconazole can inhibit the metabolism of  <e1> ethinyl estradiol </e1>  and levonorgestrel, there is no evidence that fluconazole is a net inducer of  <e2> ethinyl estradiol </e2>  or levonorgestrel metabolism. 
false	Careful monitoring of serum  <e1> theophylline </e1>  concentrations in patients receiving DIFLUCAN and  <e2> theophylline </e2>  is recommended. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin,  <e1> Cyclosporine </e1> ,  <e2> Rifampin </e2> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	These are described in greater detail below:  Oral  <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of  <e2> DIFLUCAN </e2>  with oral hypoglycemic agents; 
effect	In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving  <e1> fluconazole </e1>  concurrently with  <e2> warfarin </e2> . 
false	While there is evidence that  <e1> fluconazole </e1>  can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that  <e2> fluconazole </e2>  is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 
false	These are described in greater detail below:  Oral  <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus,  <e2> Short-acting benzodiazepines </e2> ,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	DIFLUCAN reduces the metabolism of  <e1> tolbutamide </e1> ,  <e2> glyburide </e2> , and glipizide and increases the plasma concentration of these agents. 
false	The data presently available indicate that the decreases in some individual ethinyl estradiol and  <e1> levonorgestrel </e1>  AUC values with  <e2> fluconazole </e2>  treatment are likely the result of random variation. 
false	 <e1> Short-acting Benzodiazepines </e1> : Following oral administration of midazolam, fluconazole resulted in substantial increases in  <e2> midazolam </e2>  concentrations and psychomotor effects. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline,  <e1> Terfenadine </e1> , Cisapride, Astemizole, Rifabutin, Tacrolimus,  <e2> Short-acting benzodiazepines </e2> ,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
mechanism	Rifampin:  <e1> Rifampin </e1>  enhances the metabolism of concurrently administered  <e2> DIFLUCAN </e2> . 
false	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and  <e1> levonorgestrel </e1> , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or  <e2> levonorgestrel </e2>  metabolism. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine,  <e1> Cisapride </e1> ,  <e2> Astemizole </e2> , Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	These are described in greater detail below:  Oral  <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline,  <e2> Terfenadine </e2> , Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	These are described in greater detail below:  Oral hypoglycemics,  <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine,  <e2> Rifampin </e2> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	 <e1> Terfenadine </e1> : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with  <e2> terfenadine </e2> , interaction studies have been performed. 
advise	Depending on clinical circumstances, consideration should be given to increasing the dose of  <e1> DIFLUCAN </e1>  when it is administered with  <e2> rifampin </e2> . 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants,  <e1> Phenytoin </e1> , Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole,  <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	Careful monitoring of  <e1> phenytoin </e1>  concentrations in patients receiving DIFLUCAN and  <e2> phenytoin </e2>  is recommended. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin,  <e1> Cyclosporine </e1> , Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral  <e2> hypoglycemic agents </e2> ; 
false	These are described in greater detail below:  Oral hypoglycemics,  <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of  <e2> DIFLUCAN </e2>  with oral hypoglycemic agents; 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus,  <e1> Short-acting benzodiazepines </e1> ,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of  <e2> DIFLUCAN </e2>  with oral hypoglycemic agents; 
false	Multiple dose studies of ezetimibe given in combination with  <e1> HMG-CoA reductase inhibitors </e1>  ( <e2> statins </e2> ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. 
false	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that  <e1> fluconazole </e1>  is a net inducer of  <e2> ethinyl estradiol </e2>  or levonorgestrel metabolism. 
false	 <e1> Terfenadine </e1> : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving  <e2> azole antifungals </e2>  in conjunction with terfenadine, interaction studies have been performed. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin,  <e1> Cyclosporine </e1> , Rifampin, Theophylline, Terfenadine,  <e2> Cisapride </e2> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
effect	Rifabutin: There have been reports of uveitis in patients to whom  <e1> fluconazole </e1>  and  <e2> rifabutin </e2>  were coadministered. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine,  <e1> Rifampin </e1> , Theophylline, Terfenadine, Cisapride,  <e2> Astemizole </e2> , Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	 <e1> Rifampin </e1> :  <e2> Rifampin </e2>  enhances the metabolism of concurrently administered DIFLUCAN. 
false	 <e1> Rifabutin </e1> : There have been reports of uveitis in patients to whom fluconazole and  <e2> rifabutin </e2>  were coadministered. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine,  <e1> Cisapride </e1> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral  <e2> hypoglycemic agents </e2> ; 
false	Fluconazole tablets coadministered with  <e1> ethinyl estradiol </e1> - and  <e2> levonorgestrel </e2> -containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil),  <e1> clomipramine </e1>  (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a  <e1> tricyclic antidepressant </e1>  such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin). 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> MAOI </e1> ) such as isocarboxazid (Marplan),  <e2> tranylcypromine </e2>  (Parnate), or phenelzine (Nardil) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil),  <e1> amoxapine </e1>  (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil),  <e2> protriptyline </e2>  (Vivactil), or desipramine (Norpramin). 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid ( <e1> Marplan </e1> ), tranylcypromine ( <e2> Parnate </e2> ), or phenelzine (Nardil) in the last 14 days. 
false	The data presently available indicate that the decreases in some individual ethinyl estradiol and  <e1> levonorgestrel </e1>  AUC values with  <e2> fluconazole </e2>  treatment are likely the result of random variation. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor),  <e2> imipramine </e2>  (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as  <e1> isocarboxazid </e1>  (Marplan),  <e2> tranylcypromine </e2>  (Parnate), or phenelzine (Nardil) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or  <e2> desipramine </e2>  (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil),  <e1> amoxapine </e1>  (Asendin), doxepin (Sinequan),  <e2> nortriptyline </e2>  (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil),  <e1> protriptyline </e1>  (Vivactil), or desipramine ( <e2> Norpramin </e2> ). 
false	Before taking this medication, tell your doctor if you are taking a  <e1> tricyclic antidepressant </e1>  such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil),  <e2> protriptyline </e2>  (Vivactil), or desipramine (Norpramin). 
advise	You cannot take  <e1> mazindol </e1>  if you have taken a monoamine oxidase inhibitor ( <e2> MAOI </e2> ) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e1> Tofranil </e1> ), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin). 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> MAOI </e1> ) such as  <e2> isocarboxazid </e2>  (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor),  <e1> imipramine </e1>  (Tofranil),  <e2> clomipramine </e2>  (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor),  <e2> imipramine </e2>  (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil),  <e1> clomipramine </e1>  (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin). 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as  <e1> isocarboxazid </e1>  (Marplan), tranylcypromine (Parnate), or phenelzine ( <e2> Nardil </e2> ) in the last 14 days. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride,  <e1> Astemizole </e1> , Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral  <e2> hypoglycemic agents </e2> ; 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as  <e1> amitriptyline </e1>  (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor),  <e2> imipramine </e2>  (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	 <e1> Terfenadine </e1> : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with  <e2> terfenadine </e2> , interaction studies have been performed. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil),  <e1> amoxapine </e1>  (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil),  <e2> clomipramine </e2>  (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
effect	In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving  <e1> fluconazole </e1>  concurrently with  <e2> warfarin </e2> . 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants,  <e1> Phenytoin </e1> , Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole,  <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	Before taking this medication, tell your doctor if you are taking a  <e1> tricyclic antidepressant </e1>  such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e2> Pamelor </e2> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as  <e1> isocarboxazid </e1>  (Marplan), tranylcypromine (Parnate), or  <e2> phenelzine </e2>  (Nardil) in the last 14 days. 
false	You cannot take mazindol if you have taken a  <e1> monoamine oxidase inhibitor </e1>  (MAOI) such as  <e2> isocarboxazid </e2>  (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), imipramine (Tofranil), clomipramine (Anafranil),  <e2> protriptyline </e2>  (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan),  <e1> nortriptyline </e1>  ( <e2> Pamelor </e2> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
advise	You cannot take  <e1> mazindol </e1>  if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid ( <e2> Marplan </e2> ), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ),  <e2> doxepin </e2>  (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ). 
false	These are described in greater detail below:  Oral hypoglycemics,  <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of  <e2> DIFLUCAN </e2>  with oral hypoglycemic agents; 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as  <e1> isocarboxazid </e1>  ( <e2> Marplan </e2> ), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil),  <e1> amoxapine </e1>  (Asendin), doxepin (Sinequan), nortriptyline (Pamelor),  <e2> imipramine </e2>  (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a  <e1> tricyclic antidepressant </e1>  such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a  <e1> tricyclic antidepressant </e1>  such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil),  <e2> clomipramine </e2>  (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor),  <e1> imipramine </e1>  (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or  <e2> desipramine </e2>  (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil),  <e1> amoxapine </e1>  (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor),  <e2> imipramine </e2>  (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants,  <e1> Phenytoin </e1> , Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole,  <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid ( <e1> Marplan </e1> ), tranylcypromine ( <e2> Parnate </e2> ), or phenelzine (Nardil) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e1> Tofranil </e1> ), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil),  <e1> amoxapine </e1>  (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), imipramine (Tofranil), clomipramine (Anafranil),  <e2> protriptyline </e2>  (Vivactil), or desipramine (Norpramin). 
false	Preliminary evidence suggests that  <e1> cimetidine </e1>  inhibits mebendazole metabolism and may result in an increase in plasma concentrations of  <e2> mebendazole </e2> .
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil),  <e1> protriptyline </e1>  (Vivactil), or desipramine ( <e2> Norpramin </e2> ). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan),  <e1> nortriptyline </e1>  ( <e2> Pamelor </e2> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
advise	You cannot take  <e1> mazindol </e1>  if you have taken a monoamine oxidase inhibitor ( <e2> MAOI </e2> ) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 
effect	The action of  <e1> Mecamylamine </e1>  may be potentiated by anesthesia, other  <e2> antihypertensive drugs </e2>  and alcohol.
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor),  <e2> imipramine </e2>  (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), imipramine (Tofranil), clomipramine (Anafranil),  <e2> protriptyline </e2>  (Vivactil), or desipramine (Norpramin). 
false	 <e1> Aminoglutethimide </e1>  administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of  <e2> MPA </e2> . 
false	The effects of  <e1> indinavir </e1> , zidovudine or  <e2> rifabutin </e2>  on the pharmacokinetics of megestrol acetate were not studied.
false	The effects of indinavir,  <e1> zidovudine </e1>  or rifabutin on the pharmacokinetics of  <e2> megestrol acetate </e2>  were not studied.
false	The effects of  <e1> indinavir </e1> , zidovudine or rifabutin on the pharmacokinetics of  <e2> megestrol acetate </e2>  were not studied.
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels),  <e1> fluoxetine </e1>  (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  <e2> corticosteroids </e2>  (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of  <e1> melatonin </e1>  with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and  <e2> corticosteroids </e2>  may interfere with the efficacy of the corticosteroids).
false	 <e1> Melatonin </e1>  may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with  <e2> progestin </e2>  can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs:  <e1> aspirin </e1>  and other  <e2> NSAIDs </e2>  (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered),  <e1> progestin </e1>  (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of  <e2> melatonin </e2>  and corticosteroids may interfere with the efficacy of the corticosteroids).
int	 <e1> Melatonin </e1>  may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women),  <e2> benzodiazepenes </e2>  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with  <e1> progestin </e1>  can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and  <e2> corticosteroids </e2>  may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels),  <e1> fluoxetine </e1>  (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the  <e2> corticosteroids </e2> ).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration),  <e1> beta blockers </e1>  (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  <e2> corticosteroids </e2>  (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  <e1> corticosteroids </e1>  (coadministration of melatonin and corticosteroids may interfere with the efficacy of the  <e2> corticosteroids </e2> ).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower  <e1> melatonin </e1>  levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the  <e2> corticosteroids </e2> ).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease  <e1> melatonin </e1>  levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of  <e2> melatonin </e2>  and corticosteroids may interfere with the efficacy of the corticosteroids).
effect	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of  <e1> melatonin </e1>  with  <e2> progestin </e2>  can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral  <e1> melatonin </e1>  is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of  <e2> melatonin </e2>  and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered),  <e1> progestin </e1>  (coadministration of melatonin with  <e2> progestin </e2>  can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease  <e2> melatonin </e2>  levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs:  <e1> aspirin </e1>  and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered),  <e2> progestin </e2>  (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels),  <e1> fluoxetine </e1>  (reports of psychotic episodes when coadministered), progestin (coadministration of  <e2> melatonin </e2>  with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower  <e2> melatonin </e2>  levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	 <e1> Melatonin </e1>  may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease  <e2> melatonin </e2>  levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of  <e2> melatonin </e2>  with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral  <e1> melatonin </e1>  is increased with coadministration), beta blockers (may decrease  <e2> melatonin </e2>  levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower  <e1> melatonin </e1>  levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women),  <e2> benzodiazepenes </e2>  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower melatonin levels),  <e2> fluvoxamine </e2>  (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women),  <e1> benzodiazepenes </e1>  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the  <e2> corticosteroids </e2> ).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels),  <e1> fluvoxamine </e1>  (bioavailability of oral melatonin is increased with coadministration),  <e2> beta blockers </e2>  (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels),  <e1> fluvoxamine </e1>  (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the  <e2> corticosteroids </e2> ).
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower melatonin levels), fluvoxamine (bioavailability of oral  <e2> melatonin </e2>  is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Concomitant administration of low-dose aspirin with  <e1> MOBIC </e1>  may result in an increased rate of GI ulceration or other complications, compared to use of  <e2> MOBIC </e2>  alone. 
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered),  <e1> progestin </e1>  (coadministration of melatonin with  <e2> progestin </e2>  can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	In these subjects,  <e1> meloxicam </e1>  did not alter  <e2> warfarin </e2>  pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. 
false	In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving  <e1> lithium </e1>  doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving  <e2> lithium </e2>  alone. 
advise	however, as with other NSAIDs, concomitant administration of  <e1> meloxicam </e1>  and  <e2> aspirin </e2>  is not generally recommended because of the potential for increased adverse effects. 
advise	however, as with other  <e1> NSAIDs </e1> , concomitant administration of meloxicam and  <e2> aspirin </e2>  is not generally recommended because of the potential for increased adverse effects. 
false	In these subjects,  <e1> meloxicam </e1>  did not alter warfarin pharmacokinetics and the average anticoagulant effect of  <e2> warfarin </e2>  as determined by prothrombin time. 
false	The effect of meloxicam on the anticoagulant effect of  <e1> warfarin </e1>  was studied in a group of healthy subjects receiving daily doses of  <e2> warfarin </e2>  that produced an INR (International Normalized Ratio) between 1.2 and 1.8. 
effect	Furosemide: Clinical studies, as well as post-marketing observations, have shown that  <e1> NSAIDs </e1>  can reduce the natriuretic effect of furosemide and  <e2> thiazide diuretics </e2>  in some patients. 
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower  <e2> melatonin </e2>  levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Caution should be used when administering  <e1> MOBIC </e1>  with warfarin since patients on  <e2> warfarin </e2>  may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.
false	 <e1> Digoxin </e1> : Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of  <e2> digoxin </e2>  after b-acetyldigoxin administration for 7 days at clinical doses. 
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral  <e1> melatonin </e1>  is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of  <e2> melatonin </e2>  and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of  <e2> melatonin </e2>  with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower melatonin levels),  <e2> fluvoxamine </e2>  (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease  <e2> melatonin </e2>  levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease  <e1> melatonin </e1>  levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of  <e2> melatonin </e2>  and corticosteroids may interfere with the efficacy of the corticosteroids).
mechanism	Cholestyramine: Pretreatment for four days with  <e1> cholestyramine </e1>  significantly increased the clearance of  <e2> meloxicam </e2>  by 50%. 
false	 <e1> Methotrexate </e1> : A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of  <e2> methotrexate </e2>  taken once weekly. 
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered),  <e1> progestin </e1>  (coadministration of melatonin with  <e2> progestin </e2>  can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral  <e1> melatonin </e1>  is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of  <e2> melatonin </e2>  and corticosteroids may interfere with the efficacy of the corticosteroids).
advise	however, as with other  <e1> NSAIDs </e1> , concomitant administration of meloxicam and  <e2> aspirin </e2>  is not generally recommended because of the potential for increased adverse effects. 
false	DRUG INTERACTIONS  There are no known drug/drug interactions with oral  <e1> ALKERAN </e1>   Vaccinations with live organism vaccines are not recommended in immunocompromised individuals   <e2> Nalidixic acid </e2>  together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of  <e2> melatonin </e2>  with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine),  <e1> antihistamines </e1> ,  <e2> antipsychotic agents </e2>  (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and  <e1> nitrites </e1> ,  <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of  <e2> melatonin </e2>  with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines),  <e1> benzodiazepines </e1> , MAO inhibitors, narcotic analgesics (e.g.,  <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine,  <e1> antiarrhythmic agents of class I </e1>  (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and  <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
mechanism	Because  <e1> antacids </e1>  may interfere with the absorption of  <e2> anticholinergic agents </e2> , simultaneous use of these drugs should be avoided. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine,  <e1> antiarrhythmic agents of class I </e1>  (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines,  <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites,  <e1> sympathomimetic agents </e1> ,  <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines,  <e1> MAO inhibitors </e1> ,  <e2> narcotic analgesics </e2>  (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines,  <e1> antipsychotic agents </e1>  (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites,  <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines),  <e1> benzodiazepines </e1> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites,  <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine),  <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents,  <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs:  <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g.,  <e2> quinidine </e2> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g.,  <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g.,  <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine,  <e1> antiarrhythmic agents of class I </e1>  (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine),  <e2> nitrates </e2>  and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g.,  <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines),  <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs:  <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g.,  <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
effect	The following agents may increase certain actions or side effects of  <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g.,  <e2> quinidine </e2> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
effect	The following agents may increase certain actions or side effects of  <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines),  <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors,  <e1> narcotic analgesics </e1>  (e.g., meperidine), nitrates and  <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine),  <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors,  <e2> narcotic analgesics </e2>  (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
effect	The following agents may increase certain actions or side effects of  <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors,  <e2> narcotic analgesics </e2>  (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
effect	The following agents may increase certain actions or side effects of  <e1> anticholinergic drugs </e1> : amantadine,  <e2> antiarrhythmic agents of class I </e2>  (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g.,  <e1> meperidine </e1> ), nitrates and nitrites, sympathomimetic agents,  <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine,  <e1> antiarrhythmic agents of class I </e1>  (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines,  <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS,  <e1> PHENOTHIAZINES </e1> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING  <e2> ALCOHOL </e2> ). 
false	The following agents may increase certain actions or side effects of anticholinergic drugs:  <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g.,  <e2> quinidine </e2> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
advise	Interaction with Other Central Nervous System Depressants:  <e1> MEPERIDINE </e1>  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS,  <e2> SEDATIVE-HYPNOTICS </e2>  (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Interaction with Other  <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS,  <e2> SEDATIVE-HYPNOTICS </e2>  (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
advise	Interaction with Other Central Nervous System Depressants:  <e1> MEPERIDINE </e1>  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  <e2> NARCOTIC ANALGESICS </e2> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Interaction with Other  <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL  <e2> ANESTHETICS </e2> , PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES),  <e1> TRICYCLIC ANTIDEPRESSANTS </e1>  AND OTHER CNS DEPRESSANTS (INCLUDING  <e2> ALCOHOL </e2> ). 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  <e1> NARCOTIC ANALGESICS </e1> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING  <e2> BARBITURATES </e2> ), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS,  <e1> PHENOTHIAZINES </e1> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES),  <e2> TRICYCLIC ANTIDEPRESSANTS </e2>  AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Interaction with Other  <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  <e2> NARCOTIC ANALGESICS </e2> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine,  <e1> antiarrhythmic agents of class I </e1>  (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine),  <e2> nitrates </e2>  and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	Interaction with Other  <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING  <e2> BARBITURATES </e2> ), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  <e1> NARCOTIC ANALGESICS </e1> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER  <e2> TRANQUILIZERS </e2> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
effect	The following agents may increase certain actions or side effects of  <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines),  <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL  <e1> ANESTHETICS </e1> , PHENOTHIAZINES, OTHER TRANQUILIZERS,  <e2> SEDATIVE-HYPNOTICS </e2>  (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
effect	 <e1> Mephenytoin </e1>  may also affect the effects of other drugs, which include some  <e2> steroid medications </e2> , warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
false	Mephenytoin may also affect the effects of other drugs, which include some  <e1> steroid medications </e1> ,  <e2> warfarin </e2> , certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
advise	Interaction with Other Central Nervous System Depressants:  <e1> MEPERIDINE </e1>  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  <e2> NARCOTIC ANALGESICS </e2> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS,  <e1> PHENOTHIAZINES </e1> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES),  <e2> TRICYCLIC ANTIDEPRESSANTS </e2>  AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills,  <e1> anti-infective medicines </e1> ,  <e2> furosemide </e2>  and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications,  <e1> warfarin </e1> , certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that  <e2> Mephenytoin </e2>  may interact with other drugs that are not listed here.
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES),  <e1> TRICYCLIC ANTIDEPRESSANTS </e1>  AND OTHER CNS DEPRESSANTS (INCLUDING  <e2> ALCOHOL </e2> ). 
false	Interaction with Other  <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL  <e2> ANESTHETICS </e2> , PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and  <e1> theophylline </e1>  Please note that  <e2> Mephenytoin </e2>  may interact with other drugs that are not listed here.
false	Mequitazine can interact with CNS depressant,  <e1> antichlolinergic </e1> ,  <e2> TCA </e2> , MAOIs, and alcohol.
false	Mephenytoin may also affect the effects of other drugs, which include some  <e1> steroid medications </e1> ,  <e2> warfarin </e2> , certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
false	Mequitazine can interact with  <e1> CNS depressant </e1> ,  <e2> antichlolinergic </e2> , TCA, MAOIs, and alcohol.
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES),  <e1> TRICYCLIC ANTIDEPRESSANTS </e1>  AND OTHER CNS DEPRESSANTS (INCLUDING  <e2> ALCOHOL </e2> ). 
int	 <e1> Mequitazine </e1>  can interact with CNS depressant, antichlolinergic,  <e2> TCA </e2> , MAOIs, and alcohol.
false	Mequitazine can interact with CNS depressant,  <e1> antichlolinergic </e1> ,  <e2> TCA </e2> , MAOIs, and alcohol.
mechanism	There is evidence that  <e1> meropenem </e1>  may reduce serum levels of  <e2> valproic acid </e2>  to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).
false	 <e1> Monoamine oxidase inhibitors </e1>  or  <e2> tricyclic antidepressants </e2>  may potentiate the action of sympathomimetic amines. 
false	SKELAXIN may enhance the effects of  <e1> alcohol </e1> ,  <e2> barbiturates </e2>  and other CNS depressants.
false	Caution is advised for patients receiving high-dose  <e1> aspirin </e1>  and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and  <e2> carbonic anhydrase inhibitors </e2> .
false	 <e1> Anticoagulants </e1>  (oral): The activity of oral  <e2> anticoagulants </e2>  may be potentiated by anti-vitamin-K activity attributed to methimazole.    
false	 <e1> Theophylline </e1> :  <e2> Theophylline </e2>  clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; 
false	Additive sedative effects and confusional states may emerge if levomepromazine is given with  <e1> benzodiazepines </e1>  or  <e2> barbiturates </e2> . 
false	Combination with  <e1> tramadol </e1>  ( <e2> Ultram </e2> ) is associated with increased risk of seizures. 
effect	Dosages of concomitantly administered opioids should be reduced by approximately half, because  <e1> levomepromazine </e1>  amplifies the therapeutic actions and side-effects of  <e2> opioids </e2> . 
effect	Additive sedative effects and confusional states may emerge if  <e1> levomepromazine </e1>  is given with benzodiazepines or  <e2> barbiturates </e2> . 
advise	Since  <e1> Celontin </e1>  (methsuximide) may interact with concurrently administered  <e2> antiepileptic drugs </e2> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
mechanism	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg  <e1> methsuximide </e1>  may increase the plasma concentrations of  <e2> phenytoin </e2>  and phenobarbital).
effect	Dosages of concomitantly administered opioids should be reduced by approximately half, because  <e1> levomepromazine </e1>  amplifies the therapeutic actions and side-effects of  <e2> opioids </e2> . 
false	Since Celontin ( <e1> methsuximide </e1> ) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg  <e2> methsuximide </e2>  may increase the plasma concentrations of phenytoin and phenobarbital).
false	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of  <e1> phenytoin </e1>  and  <e2> phenobarbital </e2> ).
false	Hypokalemia may develop during concomitant use of  <e1> steroids </e1>  or  <e2> ACTH </e2> . 
mechanism	 <e1> Lithium </e1>  renal clearance is reduced by  <e2> thiazides </e2> , increasing the risk of lithium toxicity. 
effect	 <e1> Thiazide drugs </e1>  may increase the responsiveness of  <e2> tubocurarine </e2> . 
false	Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with  <e1> ferrous sulfate </e1>  or  <e2> ferrous gluconate </e2> . 
false	Coadministration of methyldopa with  <e1> ferrous sulfate </e1>  or  <e2> ferrous gluconate </e2>  is not recommended. 
advise	Coadministration of  <e1> methyldopa </e1>  with ferrous sulfate or  <e2> ferrous gluconate </e2>  is not recommended. 
false	Methyldopa does not interfere with measurement of VMA ( <e1> vanillylmandelic acid </e1> ), a test for pheochromocytoma, by those methods which convert  <e2> VMA </e2>  to vanillin. 
effect	 <e1> Thiazide drugs </e1>  may increase the responsiveness of  <e2> tubocurarine </e2> . 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin,  <e1> clarithromycin </e1> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir,  <e2> nelfinavir </e2> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase  <e1> inhibitors </e1>  (e.g., ritonavir, indinavir,  <e2> nelfinavir </e2> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g.,  <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or  <e2> azole antifungals </e2>  (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin,  <e1> clarithromycin </e1> ), HIV protease or reverse transcriptase  <e2> inhibitors </e2>  (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin,  <e1> troleandomycin </e1> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g.,  <e2> ketoconazole </e2> , itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir,  <e1> nelfinavir </e1> , delavirdine) or  <e2> azole antifungals </e2>  (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin,  <e1> troleandomycin </e1> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir,  <e2> nelfinavir </e2> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g.,  <e1> ritonavir </e1> , indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole,  <e2> voriconazole </e2> ). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or  <e1> azole antifungals </e1>  (e.g., ketoconazole,  <e2> itraconazole </e2> , voriconazole). 
false	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice,  <e1> fluoxetine </e1> ,  <e2> fluvoxamine </e2> , zileuton, and clotrimazole. 
false	CYP 3A4 Inhibitors (e.g.  <e1> Macrolide Antibiotics </e1>  and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and  <e2> ergotamine </e2> ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin,  <e1> clarithromycin </e1> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir,  <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or  <e1> reverse transcriptase inhibitors </e1>  (e.g., ritonavir,  <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase  <e1> inhibitors </e1>  (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole,  <e2> voriconazole </e2> ). 
false	Less potent inhibitors include saquinavir, nefazodone,  <e1> fluconazole </e1> , grapefruit juice, fluoxetine, fluvoxamine,  <e2> zileuton </e2> , and clotrimazole. 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g.,  <e1> ritonavir </e1> ,  <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Caution should be exercised when Methergine    ( <e1> methylergonovine maleate </e1> ) is used concurrently with other vasoconstrictors or  <e2> ergot alkaloids </e2> .
false	Methyldopa does not interfere with measurement of VMA ( <e1> vanillylmandelic acid </e1> ), a test for pheochromocytoma, by those methods which convert  <e2> VMA </e2>  to vanillin. 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir,  <e1> nelfinavir </e1> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole,  <e2> voriconazole </e2> ). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g.,  <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole,  <e2> voriconazole </e2> ). 
false	Examples of some of the more potent CYP 3A4 inhibitors include  <e1> macrolide antibiotics </e1>  (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir,  <e2> delavirdine </e2> ) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
advise	Caution should be exercised when  <e1> Methergine </e1>     (methylergonovine maleate) is used concurrently with other vasoconstrictors or  <e2> ergot alkaloids </e2> .
false	Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with  <e1> ferrous sulfate </e1>  or  <e2> ferrous gluconate </e2> . 
false	Less potent inhibitors include  <e1> saquinavir </e1> , nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and  <e2> clotrimazole </e2> . 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir,  <e1> indinavir </e1> , nelfinavir, delavirdine) or  <e2> azole antifungals </e2>  (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include  <e1> macrolide antibiotics </e1>  (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g.,  <e2> ritonavir </e2> , indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants,  <e1> anticonvulsants </e1>  ( <e2> phenobarbital </e2> , diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or  <e1> reverse transcriptase inhibitors </e1>  (e.g., ritonavir,  <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include  <e1> macrolide antibiotics </e1>  (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir,  <e2> delavirdine </e2> ) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of  <e1> coumarin anticoagulants </e1> , anticonvulsants (phenobarbital, diphenylhydantoin,  <e2> primidone </e2> ), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 
mechanism	Human pharmacologic studies have shown that  <e1> Ritalin </e1>  may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and  <e2> tricyclic drugs </e2>  (imipramine, clomipramine, desipramine). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir,  <e1> nelfinavir </e1> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole,  <e2> voriconazole </e2> ). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital,  <e1> diphenylhydantoin </e1> , primidone),  <e2> phenylbutazone </e2> , and tricyclic drugs (imipramine, clomipramine, desipramine). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants ( <e1> phenobarbital </e1> , diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine,  <e2> clomipramine </e2> , desipramine). 
false	The safety of using  <e1> methylphenidate </e1>  in combination with  <e2> clonidine </e2>  or other centrally acting alpha-2 agonists has not been systemically evaluated.    
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital,  <e1> diphenylhydantoin </e1> ,  <e2> primidone </e2> ), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin,  <e1> primidone </e1> ), phenylbutazone, and tricyclic drugs (imipramine,  <e2> clomipramine </e2> , desipramine). 
mechanism	Human pharmacologic studies have shown that  <e1> Ritalin </e1>  may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin,  <e2> primidone </e2> ), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g.,  <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole,  <e2> voriconazole </e2> ). 
false	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice,  <e1> fluoxetine </e1> ,  <e2> fluvoxamine </e2> , zileuton, and clotrimazole. 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants,  <e1> anticonvulsants </e1>  (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and  <e2> tricyclic drugs </e2>  (imipramine, clomipramine, desipramine). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone),  <e1> phenylbutazone </e1> , and tricyclic drugs (imipramine, clomipramine,  <e2> desipramine </e2> ). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants ( <e1> phenobarbital </e1> , diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine,  <e2> clomipramine </e2> , desipramine). 
false	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of  <e1> methylprednisolone </e1>  and may require increased in  <e2> methylprednisolone </e2>  dose to achieve the desired response. 
mechanism	Human pharmacologic studies have shown that  <e1> Ritalin </e1>  may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and  <e2> tricyclic drugs </e2>  (imipramine, clomipramine, desipramine). 
false	Examples of some of the more potent CYP 3A4 inhibitors include  <e1> macrolide antibiotics </e1>  (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir,  <e2> delavirdine </e2> ) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
mechanism	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and  <e1> rifampin </e1>  may increase the clearance of  <e2> methylprednisolone </e2>  and may require increased in methylprednisolone dose to achieve the desired response. 
false	This could lead to decreased  <e1> salicylate </e1>  serum levels or increase the risk of  <e2> salicylate </e2>  toxicity when methylprednisolone is withdrawn. 
advise	 <e1> Aspirin </e1>  should be used cautiously in conjunction with  <e2> corticosteroids </e2>  in patients suffering from hypoprothrombinemia. 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or  <e1> reverse transcriptase inhibitors </e1>  (e.g., ritonavir,  <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Methscopolamine may interact with  <e1> antidepressants </e1>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine,  <e2> isocarboxazid </e2> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g.,  <e1> phenelzine </e1> ,  <e2> linezolid </e2> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine,  <e1> antihistamines </e1>  (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g.,  <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine,  <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline,  <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other  <e1> anticholinergics </e1> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin),  <e2> phenothiazines </e2>  (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type),  <e1> MAO inhibitors </e1>  (e.g., phenelzine,  <e2> linezolid </e2> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1>  type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone),  <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type),  <e1> MAO inhibitors </e1>  (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics,  <e2> potassium chloride </e2>  supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
mechanism	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and  <e1> rifampin </e1>  may increase the clearance of  <e2> methylprednisolone </e2>  and may require increased in methylprednisolone dose to achieve the desired response. 
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g.,  <e1> diphenhydramine </e1> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type),  <e1> MAO inhibitors </e1>  (e.g., phenelzine, linezolid, tranylcypromine,  <e2> isocarboxazid </e2> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with  <e1> antidepressants </e1>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine,  <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone),  <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics,  <e2> potassium chloride </e2>  supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type),  <e1> MAO inhibitors </e1>  (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin),  <e2> phenothiazines </e2>  (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine,  <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1>  type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements,  <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with  <e1> antidepressants </e1>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline,  <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone),  <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin),  <e2> phenothiazines </e2>  (e.g., chlorpromazine, promethazine).
false	 <e1> Methscopolamine </e1>  may interact with  <e2> antidepressants </e2>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g.,  <e1> kaolin </e1> - <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1>  type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine,  <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
int	 <e1> Methscopolamine </e1>  may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other  <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline,  <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids,  <e2> absorbent-type anti-diarrhea medicines </e2>  (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine,  <e1> linezolid </e1> , tranylcypromine, isocarboxazid,  <e2> selegiline </e2> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g.,  <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline,  <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid,  <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g.,  <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g.,  <e1> phenelzine </e1> , linezolid, tranylcypromine,  <e2> isocarboxazid </e2> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type),  <e1> MAO inhibitors </e1>  (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids,  <e2> absorbent-type anti-diarrhea medicines </e2>  (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid,  <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other  <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
int	 <e1> Methscopolamine </e1>  may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine,  <e2> promethazine </e2> ).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g.,  <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin),  <e2> phenothiazines </e2>  (e.g., chlorpromazine, promethazine).
int	 <e1> Methscopolamine </e1>  may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin),  <e2> phenothiazines </e2>  (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g.,  <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g.,  <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin),  <e1> phenothiazines </e1>  (e.g., chlorpromazine,  <e2> promethazine </e2> ).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid,  <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g.,  <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with  <e1> antidepressants </e1>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin),  <e2> phenothiazines </e2>  (e.g., chlorpromazine, promethazine).
int	 <e1> Methscopolamine </e1>  may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements,  <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine,  <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g.,  <e2> chlorpromazine </e2> , promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine,  <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements,  <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1>  type), MAO inhibitors (e.g.,  <e2> phenelzine </e2> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with  <e1> antidepressants </e1>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine,  <e2> promethazine </e2> ).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine,  <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine,  <e2> promethazine </e2> ).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone),  <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other  <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine,  <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid,  <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids,  <e2> absorbent-type anti-diarrhea medicines </e2>  (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine,  <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics,  <e2> potassium chloride </e2>  supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine,  <e1> isocarboxazid </e1> , selegiline, furazolidone),  <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	This could lead to decreased  <e1> salicylate </e1>  serum levels or increase the risk of  <e2> salicylate </e2>  toxicity when methylprednisolone is withdrawn. 
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid,  <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid,  <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine,  <e2> antihistamines </e2>  (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g.,  <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine,  <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin),  <e2> phenothiazines </e2>  (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g.,  <e1> diphenhydramine </e1> ), other anticholinergics,  <e2> potassium chloride </e2>  supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine,  <e1> antihistamines </e1>  (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g.,  <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g.,  <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin),  <e2> phenothiazines </e2>  (e.g., chlorpromazine, promethazine).
false	 <e1> Methscopolamine </e1>  may interact with  <e2> antidepressants </e2>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g.,  <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline,  <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type),  <e1> MAO inhibitors </e1>  (e.g., phenelzine,  <e2> linezolid </e2> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine,  <e1> linezolid </e1> , tranylcypromine, isocarboxazid,  <e2> selegiline </e2> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine,  <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone),  <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics,  <e2> potassium chloride </e2>  supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1>  type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone),  <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
int	 <e1> Methscopolamine </e1>  may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements,  <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
effect	Concurrent use of  <e1> alcohol </e1>  and other CNS depression-producing drugs may increase the CNS depressant effects of  <e2> methyprylon </e2>  or these other medications.
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid,  <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other  <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
effect	 <e1> Methysergide </e1>  may reverse the analgesic activity of  <e2> narcotic analgesics </e2> . 
false	Concurrent use with vasoconstrictor agents including  <e1> ergot alkaloids </e1> ,  <e2> sumatriptan </e2> , and nicotine (e.g. smoking) may result in enhanced vasoconstriction.
false	Concurrent use with  <e1> vasoconstrictor agents </e1>  including ergot alkaloids,  <e2> sumatriptan </e2> , and nicotine (e.g. smoking) may result in enhanced vasoconstriction.
false	 <e1> Methscopolamine </e1>  may interact with  <e2> antidepressants </e2>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Additive sedative effects can occur when metoclopramide is given with alcohol,  <e1> sedatives </e1> ,  <e2> hypnotics </e2> , narcotics, or tranquilizers. 
false	Absorption of drugs from the stomach may be diminished (e.g.,  <e1> digoxin </e1> ) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa,  <e2> ethanol </e2> , cyclosporine). 
false	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives,  <e1> hypnotics </e1> ,  <e2> narcotics </e2> , or tranquilizers. 
false	Concurrent use with  <e1> vasoconstrictor agents </e1>  including ergot alkaloids,  <e2> sumatriptan </e2> , and nicotine (e.g. smoking) may result in enhanced vasoconstriction.
advise	Because the action of  <e1> metoclopramide </e1>  will influence the delivery of food to the intestines and thus the rate of absorption,  <e2> insulin </e2>  dosage or timing of dosage may require adjustment.
false	 <e1> Methscopolamine </e1>  may interact with  <e2> antidepressants </e2>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by  <e1> metoclopramide </e1> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa,  <e2> ethanol </e2> , cyclosporine). 
effect	The effects of  <e1> metoclopramide </e1>  on gastrointestinal motility are antagonized by anticholinergic drugs and  <e2> narcotic analgesics </e2> . 
mechanism	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by  <e1> metoclopramide </e1> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  <e2> acetaminophen </e2> , tetracycline, levodopa, ethanol, cyclosporine). 
false	 <e1> Alcohol </e1> , Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with  <e2> metolazone </e2>  therapy. 
false	Anticoagulants: Metolazone, as well as other  <e1> thiazide-like diuretics </e1> , may affect the hypoprothrombinemic response to  <e2> anticoagulants </e2> ; 
false	 <e1> Curariform Drugs </e1> : Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of  <e2> curariform drugs </e2>  (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. 
false	 <e1> Diuretics </e1> : Furosemide and probably other  <e2> loop diuretics </e2>  given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. 
advise	Because the action of  <e1> metoclopramide </e1>  will influence the delivery of food to the intestines and thus the rate of absorption,  <e2> insulin </e2>  dosage or timing of dosage may require adjustment.
false	 <e1> Anticoagulants </e1> : Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to  <e2> anticoagulants </e2> ; 
effect	Diuretics: Furosemide and probably other  <e1> loop diuretics </e1>  given concomitantly with  <e2> metolazone </e2>  can cause unusually large or prolonged losses of fluid and electrolytes. 
false	 <e1> Alcohol </e1> , Barbiturates, and  <e2> Narcotics </e2> : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. 
effect	Digitalis Glycosides:  <e1> Diuretic </e1> -induced hypokalemia can increase the sensitivity of the myocardium to  <e2> digitalis </e2> . 
false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by  <e1> metoclopramide </e1> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa,  <e2> ethanol </e2> , cyclosporine). 
false	Anticoagulants: Metolazone, as well as other  <e1> thiazide-like diuretics </e1> , may affect the hypoprothrombinemic response to  <e2> anticoagulants </e2> ; 
false	 <e1> Diuretics </e1> : Furosemide and probably other  <e2> loop diuretics </e2>  given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. 
effect	Oral  <e1> metronidazole </e1>  has been reported to potentiate the anticoagulant effect of coumarin and  <e2> warfarin </e2> , resulting in a prolongation of prothrombin time. 
false	Drug interactions should be kept in mind when METROGEL ( <e1> metronidazole </e1>  gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical  <e2> metronidazole </e2>  administration because of low absorption.    
false	Drug interactions should be kept in mind when METROGEL ( <e1> metronidazole </e1>  gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical  <e2> metronidazole </e2>  administration because of low absorption.    
effect	Oral  <e1> metronidazole </e1>  has been reported to potentiate the anticoagulant effect of coumarin and  <e2> warfarin </e2> , resulting in a prolongation of prothrombin time. 
mechanism	 <e1> Metopirone </e1>  inhibits the glucuronidation of  <e2> acetaminophen </e2>  and could possibly potentiate acetaminophen toxicity.
advise	Caution should be observed in administering  <e1> DEMSER </e1>  to patients receiving  <e2> phenothiazines </e2>  or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. 
false	Since  <e1> MEXITIL </e1>  is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter  <e2> mexiletine </e2>  plasma concentrations. 
false	ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin,  <e1> diuretics </e1> , or  <e2> propranolol </e2> . 
false	When phenytoin or other hepatic enzyme inducers such as  <e1> rifampin </e1>  and phenobarbital have been taken concurrently with Mexitil   , lowered  <e2> Mexitil </e2>     plasma levels have been reported. 
false	A variety of  <e1> antiarrhythmics </e1>  such as quinidine or  <e2> propranolol </e2>  were also added, sometimes with improved control of ventricular ectopy. 
advise	Caution should be observed in administering  <e1> DEMSER </e1>  to patients receiving  <e2> phenothiazines </e2>  or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. 
mechanism	Mexitil    does not alter serum digoxin levels but  <e1> magnesium-aluminum hydroxide </e1> , when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum  <e2> digoxin </e2>  levels. 
false	This increase was observed at the first test point which was the second day after starting Mexitil   .  <e1> Theophylline </e1>  plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If  <e2> Mexitil </e2>  and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 
false	ECG intervals (PR, QRS, and QT) were not affected by concurrent  <e1> Mexitil </e1>     and digoxin, diuretics, or  <e2> propranolol </e2> . 
false	This increase was observed at the first test point which was the second day after starting  <e1> Mexitil </e1>    .  <e2> Theophylline </e2>  plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 
false	When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with  <e1> Mexitil </e1>    , lowered  <e2> Mexitil </e2>     plasma levels have been reported. 
false	Mexitil    does not alter serum  <e1> digoxin </e1>  levels but  <e2> magnesium-aluminum hydroxide </e2> , when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. 
false	ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and  <e1> digoxin </e1> , diuretics, or  <e2> propranolol </e2> . 
false	This increase was observed at the first test point which was the second day after starting  <e1> Mexitil </e1>    . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the  <e2> Mexitil </e2>     dose is changed. 
false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre- <e1> Mexitil </e1>     values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the  <e2> Mexitil </e2>     dose is changed. 
mechanism	When phenytoin or other hepatic enzyme inducers such as  <e1> rifampin </e1>  and phenobarbital have been taken concurrently with  <e2> Mexitil </e2>    , lowered Mexitil    plasma levels have been reported. 
false	In this crossover steady state study, the pharmacokinetics of  <e1> propafenone </e1>  were unaffected in either phenotype by the coadministration of  <e2> mexiletine </e2> . 
false	A variety of  <e1> antiarrhythmics </e1>  such as quinidine or  <e2> propranolol </e2>  were also added, sometimes with improved control of ventricular ectopy. 
mechanism	 <e1> Posicor </e1>  inhibits some of the liver's ability to metabolize some other drugs -  <e2> terfenadine </e2> , astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 
false	When phenytoin or other hepatic enzyme inducers such as  <e1> rifampin </e1>  and phenobarbital have been taken concurrently with Mexitil   , lowered  <e2> Mexitil </e2>     plasma levels have been reported. 
mechanism	 <e1> Posicor </e1>  inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and  <e2> tricyclic antidepressants </e2> . 
false	Posicor inhibits some of the liver's ability to metabolize some other drugs -  <e1> terfenadine </e1> ,  <e2> astemizole </e2> , cisapride, cyclosporine, and tricyclic antidepressants. 
false	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride,  <e1> cyclosporine </e1> , and  <e2> tricyclic antidepressants </e2> . 
false	There was no effect of a single dose or multiple doses of  <e1> MYCAMINE </e1>  on mycophenolate mofetil, cyclosporine,  <e2> tacrolimus </e2> , prednisolone, and fluconazole pharmacokinetics. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus,  <e1> prednisolone </e1> , sirolimus, nifedipine,  <e2> fluconazole </e2> , ritonavir, and rifampin. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  <e1> MYCAMINE </e1>  and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus,  <e2> nifedipine </e2> , fluconazole, ritonavir, and rifampin. 
false	Patients receiving  <e1> sirolimus </e1>  or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and  <e2> sirolimus </e2>  or nifedipine dosage should be reduced if necessary. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine,  <e1> fluconazole </e1> , ritonavir, and  <e2> rifampin </e2> . 
advise	Patients receiving sirolimus or  <e1> nifedipine </e1>  in combination with  <e2> MYCAMINE </e2>  should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 
mechanism	 <e1> Posicor </e1>  inhibits some of the liver's ability to metabolize some other drugs -  <e2> terfenadine </e2> , astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 
false	A variety of  <e1> antiarrhythmics </e1>  such as quinidine or  <e2> propranolol </e2>  were also added, sometimes with improved control of ventricular ectopy. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone,  <e1> sirolimus </e1> , nifedipine, fluconazole, ritonavir, and  <e2> rifampin </e2> . 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and  <e1> mycophenolate mofetil </e1> , cyclosporine, tacrolimus, prednisolone, sirolimus,  <e2> nifedipine </e2> , fluconazole, ritonavir, and rifampin. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine,  <e1> tacrolimus </e1> , prednisolone, sirolimus, nifedipine,  <e2> fluconazole </e2> , ritonavir, and rifampin. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  <e1> MYCAMINE </e1>  and  <e2> mycophenolate mofetil </e2> , cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone,  <e1> sirolimus </e1> ,  <e2> nifedipine </e2> , fluconazole, ritonavir, and rifampin. 
false	Patients receiving sirolimus or nifedipine in combination with  <e1> MYCAMINE </e1>  should be monitored for sirolimus or nifedipine toxicity and  <e2> sirolimus </e2>  or nifedipine dosage should be reduced if necessary. 
false	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or  <e1> nifedipine </e1>  toxicity and  <e2> sirolimus </e2>  or nifedipine dosage should be reduced if necessary. 
false	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and  <e1> sirolimus </e1>  or  <e2> nifedipine </e2>  dosage should be reduced if necessary. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and  <e1> mycophenolate mofetil </e1> , cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and  <e2> rifampin </e2> . 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine,  <e1> tacrolimus </e1> ,  <e2> prednisolone </e2> , sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus,  <e1> nifedipine </e1> ,  <e2> fluconazole </e2> , ritonavir, and rifampin. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and  <e1> mycophenolate mofetil </e1> , cyclosporine,  <e2> tacrolimus </e2> , prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide,  <e1> secobarbital </e1>  and  <e2> droperidol </e2> . 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine,  <e1> nitrous oxide </e1> , secobarbital and  <e2> droperidol </e2> . 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg,  <e1> morphine </e1> , meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and  <e2> droperidol </e2> . 
false	No significant adverse interactions with common premedications (such as atropine,  <e1> scopolamine </e1> , glycopyrrolate, diazepam, hydroxyzine, and other  <e2> muscle relaxants </e2> ) or local anesthetics have been observed.
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol,  <e1> ketamine </e1> ,  <e2> nitrous oxide </e2> , secobarbital and droperidol. 
false	No significant adverse interactions with common premedications (such as  <e1> atropine </e1> , scopolamine, glycopyrrolate,  <e2> diazepam </e2> , hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  <e1> narcotics </e1>  (eg, morphine,  <e2> meperidine </e2>  and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 
effect	The sedative effect of  <e1> VERSED Syrup </e1>  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine,  <e2> nitrous oxide </e2> , secobarbital and droperidol. 
false	Drugs such as erythromycin,  <e1> diltiazem </e1> , verapamil, ketoconazole, fluconazole and  <e2> itraconazole </e2>  were shown to significantly increase the C max and AUC of orally administered midazolam. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine,  <e1> meperidine </e1>  and fentanyl),  <e2> propofol </e2> , ketamine, nitrous oxide, secobarbital and droperidol. 
mechanism	Drugs such as erythromycin, diltiazem,  <e1> verapamil </e1> , ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered  <e2> midazolam </e2> . 
advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when  <e1> midazolam </e1>  is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and  <e2> macrolide antibiotics </e2> ). 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and  <e1> mycophenolate mofetil </e1> , cyclosporine, tacrolimus, prednisolone, sirolimus,  <e2> nifedipine </e2> , fluconazole, ritonavir, and rifampin. 
effect	The sedative effect of  <e1> VERSED Syrup </e1>  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and  <e2> droperidol </e2> . 
mechanism	Although not studied, the potent cytochrome P450 3A4 inhibitors  <e1> ritonavir </e1>  and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of  <e2> midazolam </e2> . 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl),  <e1> propofol </e1> , ketamine, nitrous oxide,  <e2> secobarbital </e2>  and droperidol. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine,  <e1> nitrous oxide </e1> ,  <e2> secobarbital </e2>  and droperidol. 
mechanism	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and  <e1> phenytoin </e1> , induce metabolism and caused a markedly decreased C max and AUC of oral  <e2> midazolam </e2>  in adult studies. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg,  <e1> morphine </e1> , meperidine and  <e2> fentanyl </e2> ), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine,  <e1> tacrolimus </e1> ,  <e2> prednisolone </e2> , sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine,  <e1> meperidine </e1>  and fentanyl), propofol, ketamine, nitrous oxide,  <e2> secobarbital </e2>  and droperidol. 
false	Drugs such as  <e1> erythromycin </e1> , diltiazem, verapamil, ketoconazole, fluconazole and  <e2> itraconazole </e2>  were shown to significantly increase the C max and AUC of orally administered midazolam. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg,  <e1> morphine </e1> , meperidine and fentanyl), propofol,  <e2> ketamine </e2> , nitrous oxide, secobarbital and droperidol. 
false	Drugs such as erythromycin, diltiazem,  <e1> verapamil </e1> ,  <e2> ketoconazole </e2> , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine,  <e1> meperidine </e1>  and fentanyl), propofol, ketamine,  <e2> nitrous oxide </e2> , secobarbital and droperidol. 
false	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and  <e1> sirolimus </e1>  or  <e2> nifedipine </e2>  dosage should be reduced if necessary. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  <e1> metformin </e1> , cimetidine, ranitidine, procainamide,  <e2> triamterene </e2> , flecainide, and quinidine. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin,  <e1> terazosin </e1> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide,  <e2> triamterene </e2> , flecainide, and quinidine. 
false	ProAmatine.  <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine,  <e2> procainamide </e2> , triamterene, flecainide, and quinidine. 
false	 <e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  <e2> desglymidodrine </e2>  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
effect	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine,  <e1> phenylpropanolamine </e1>  or dihydroergotamine) may enhance or potentiate the pressor effects of  <e2> ProAmatine </e2>    . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin,  <e1> terazosin </e1> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine,  <e2> procainamide </e2> , triamterene, flecainide, and quinidine. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine,  <e1> ranitidine </e1> ,  <e2> procainamide </e2> , triamterene, flecainide, and quinidine. 
effect	When administered concomitantly with  <e1> ProAmatine </e1>    ,  <e2> cardiac glycosides </e2>  may enhance or precipitate bradycardia, A.V. 
false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine,  <e1> pseudoephedrine </e1> , ephedrine,  <e2> phenylpropanolamine </e2>  or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 
false	 <e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of  <e2> ProAmatine </e2> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl),  <e1> propofol </e1> , ketamine, nitrous oxide,  <e2> secobarbital </e2>  and droperidol. 
false	 <e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide,  <e2> triamterene </e2> , flecainide, and quinidine. 
mechanism	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  <e1> desglymidodrine </e1>  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine,  <e2> ranitidine </e2> , procainamide, triamterene, flecainide, and quinidine. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin,  <e1> terazosin </e1> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene,  <e2> flecainide </e2> , and quinidine. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of  <e1> ProAmatine </e1> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin,  <e2> cimetidine </e2> , ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine,  <e1> pseudoephedrine </e1> , ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when  <e2> ProAmatine </e2>     is administered concomitantly with agents that cause vasoconstriction. 
false	ProAmatine.  <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  <e2> metformin </e2> , cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and  <e1> doxazosin </e1> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and  <e2> quinidine </e2> . 
effect	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and  <e1> doxazosin </e1> , can antagonize the effects of  <e2> ProAmatine </e2> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine,  <e1> ranitidine </e1> , procainamide,  <e2> triamterene </e2> , flecainide, and quinidine. 
false	 <e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  <e2> metformin </e2> , cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine,  <e1> nitrous oxide </e1> , secobarbital and  <e2> droperidol </e2> . 
false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine,  <e1> phenylpropanolamine </e1>  or  <e2> dihydroergotamine </e2> ) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 
false	 <e1> ProAmatine </e1>     has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e.,  <e2> fludrocortisone acetate </e2> ), with or without salt supplementation. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as  <e1> prazosin </e1> , terazosin, and  <e2> doxazosin </e2> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	ProAmatine.  <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  <e2> desglymidodrine </e2>  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine,  <e1> tacrolimus </e1> ,  <e2> prednisolone </e2> , sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 
mechanism	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  <e1> desglymidodrine </e1>  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine,  <e2> procainamide </e2> , triamterene, flecainide, and quinidine. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin,  <e1> cimetidine </e1> , ranitidine, procainamide, triamterene,  <e2> flecainide </e2> , and quinidine. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine,  <e1> tacrolimus </e1> ,  <e2> prednisolone </e2> , sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 
false	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole,  <e1> itraconazole </e1> ,  <e2> erythromycin </e2> , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 
false	John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce  <e1> mifepristone </e1>  metabolism (lowering serum levels of  <e2> mifepristone </e2> ). 
mechanism	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that  <e1> ketoconazole </e1> , itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of  <e2> mifepristone </e2> ). 
mechanism	John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital,  <e1> carbamazepine </e1> ) may induce  <e2> mifepristone </e2>  metabolism (lowering serum levels of mifepristone). 
false	John   s Wort, and certain  <e1> anticonvulsants </e1>  ( <e2> phenytoin </e2> , phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 
false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine,  <e1> pseudoephedrine </e1> , ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when  <e2> ProAmatine </e2>     is administered concomitantly with agents that cause vasoconstriction. 
false	John   s Wort, and certain anticonvulsants (phenytoin,  <e1> phenobarbital </e1> , carbamazepine) may induce mifepristone metabolism (lowering serum levels of  <e2> mifepristone </e2> ). 
false	John   s Wort, and certain  <e1> anticonvulsants </e1>  (phenytoin,  <e2> phenobarbital </e2> , carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 
false	Although specific drug or food interactions with  <e1> mifepristone </e1>  have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of  <e2> mifepristone </e2> ). 
false	Although specific drug or food interactions with  <e1> mifepristone </e1>  have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of  <e2> mifepristone </e2> ). 
advise	Combination therapy with Cerezyme    ( <e1> imiglucerase </e1> ) and  <e2> ZAVESCA </e2>     is not indicated.
false	While co-administration of ZAVESCA    appeared to increase the clearance of  <e1> Cerezyme </e1>  by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of  <e2> Cerezyme </e2> . 
mechanism	Absorption of  <e1> tetracyclines </e1>  is impaired by antacids containing  <e2> aluminum </e2> , calcium or magnesium, and iron-containing preparations. 
false	While co-administration of ZAVESCA    appeared to increase the clearance of  <e1> Cerezyme </e1>  by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of  <e2> Cerezyme </e2> . 
false	Absorption of tetracyclines is impaired by  <e1> antacids </e1>  containing  <e2> aluminum </e2> , calcium or magnesium, and iron-containing preparations. 
false	Absorption of tetracyclines is impaired by  <e1> antacids </e1>  containing aluminum, calcium or magnesium, and  <e2> iron </e2> -containing preparations. 
effect	The concurrent use of  <e1> tetracycline </e1>  and  <e2> methoxyflurane </e2>  has been reported to result in fatal renal toxicity. 
false	Absorption of tetracyclines is impaired by antacids containing  <e1> aluminum </e1> , calcium or  <e2> magnesium </e2> , and iron-containing preparations. 
effect	The concurrent use of  <e1> tetracycline </e1>  and  <e2> methoxyflurane </e2>  has been reported to result in fatal renal toxicity. 
false	Interaction with  <e1> Guanethidine </e1> : Although  <e2> minoxidil </e2>  does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. 
mechanism	Alcohol: Concomitant administration of  <e1> alcohol </e1>  (equivalent to 60 g) had a minimal effect on plasma levels of  <e2> mirtazapine </e2>  (15 mg) in 6 healthy male subjects. 
false	Accordingly, patients should be advised to avoid  <e1> alcohol </e1>  while taking REMERON SolTab.  <e2> Diazepam </e2> : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 
advise	Accordingly, patients should be advised to avoid  <e1> alcohol </e1>  while taking  <e2> REMERON SolTab </e2> . Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 
false	Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab.  <e1> Diazepam </e1> : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of  <e2> mirtazapine </e2>  (15 mg) in 12 healthy subjects. 
false	Accordingly, patients should be advised to avoid  <e1> alcohol </e1>  while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of  <e2> mirtazapine </e2>  (15 mg) in 12 healthy subjects. 
false	Mitotane has been reported to accelerate the metabolism of  <e1> warfarin </e1>  by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for  <e2> warfarin </e2> . 
false	Accordingly, patients should be advised to avoid  <e1> alcohol </e1>  while taking REMERON SolTab.  <e2> Diazepam </e2> : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 
advise	Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering  <e1> Mitotane </e1>  to patients on  <e2> coumarin-type anticoagulants </e2> . 
mechanism	 <e1> Mitotane </e1>  has been reported to accelerate the metabolism of  <e2> warfarin </e2>  by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain  <e1> antibiotics </e1>  (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e1> clindamycin </e1> , colistin, and sodium colistimethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium -  <e1> neostigmine </e1>  - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics -  <e2> succinylcholine </e2>  or other muscle relaxants
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts,  <e2> lithium </e2> , local anesthetics, procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine -  <e1> polymyxin B </e1>  or bacitracin - local  <e2> anesthetics </e2>  such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or  <e1> carbamazepine </e1>  - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other  <e2> muscle relaxants </e2> 
int	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines,  <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	The use of  <e1> MIVACRON </e1>  before succinylcholine to attenuate some of the side effects of  <e2> succinylcholine </e2>  has not been studied. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts,  <e2> lithium </e2> , local anesthetics, procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain  <e1> antibiotics </e1>  given by injection - cisplatin - edrophonium -  <e2> neostigmine </e2>  - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
int	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection -  <e1> cisplatin </e1>  -  <e2> edrophonium </e2>  - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	A greater potentiation of the neuromuscular blocking effects of  <e1> MIVACRON </e1>  may be expected with higher concentrations of enflurane or  <e2> isoflurane </e2> . 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate),  <e1> magnesium </e1>  salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine. 
false	The neuromuscular blocking effect of  <e1> MIVACRON </e1>  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered  <e2> phenytoin </e2>  or carbamazepine. 
false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  <e1> contraceptives </e1> , glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or  <e2> carbamazepine </e2> . 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin,  <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts,  <e2> lithium </e2> , local anesthetics, procainamide, and quinidine. 
effect	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  <e1> neuromuscular blocking agents </e1>  has been demonstrated in patients chronically administered  <e2> phenytoin </e2>  or carbamazepine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain  <e1> antibiotics </e1>  (e.g., aminoglycosides, tetracyclines,  <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin,  <e1> colistin </e1> , and sodium colistimethate), magnesium salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills -  <e1> corticosteroids </e1>  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other  <e2> muscle relaxants </e2> 
false	The neuromuscular blocking effect of  <e1> MIVACRON </e1>  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  <e2> neuromuscular blocking agents </e2>  has been demonstrated in patients chronically administered phenytoin or carbamazepine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> . 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g.,  <e1> aminoglycosides </e1> , tetracyclines,  <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Isoflurane and  <e1> enflurane </e1>  (administered with nitrous oxide/ <e2> oxygen </e2>  to achieve 1.25 M.C. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as  <e1> procaine </e1>  - general anesthetics -  <e2> succinylcholine </e2>  or other muscle relaxants
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium -  <e1> neostigmine </e1>  - polymyxin B or  <e2> bacitracin </e2>  - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
advise	Evidence of spontaneous recovery from  <e1> succinylcholine </e1>  should be observed before the administration of  <e2> MIVACRON </e2> . 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin -  <e1> edrophonium </e1>  - neostigmine -  <e2> polymyxin B </e2>  or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin,  <e1> colistin </e1> , and sodium colistimethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine. 
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> MIVACRON </e1>  include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin -  <e1> edrophonium </e1>  - neostigmine - polymyxin B or bacitracin - local  <e2> anesthetics </e2>  such as procaine - general anesthetics - succinylcholine or other muscle relaxants
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> MIVACRON </e1>  include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins,  <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
int	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as MIVACRON include certain antibiotics (e.g.,  <e2> aminoglycosides </e2> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin,  <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection -  <e1> cisplatin </e1>  - edrophonium - neostigmine - polymyxin B or  <e2> bacitracin </e2>  - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as  <e1> procaine </e1>  - general anesthetics - succinylcholine or other  <e2> muscle relaxants </e2> 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  <e1> phenytoin </e1>  or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general  <e2> anesthetics </e2>  - succinylcholine or other muscle relaxants
false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives,  <e1> glucocorticoids </e1> , or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered  <e2> phenytoin </e2>  or carbamazepine. 
false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  <e1> contraceptives </e1> ,  <e2> glucocorticoids </e2> , or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 
false	Accordingly, patients should be advised to avoid  <e1> alcohol </e1>  while taking REMERON SolTab.  <e2> Diazepam </e2> : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain  <e1> antibiotics </e1>  (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin,  <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between  <e1> MIVACRON </e1>  and  <e2> succinylcholine </e2>  has not been systematically studied. 
false	Some drug interactions are:  - birth control pills -  <e1> corticosteroids </e1>  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin -  <e2> edrophonium </e2>  - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin -  <e1> edrophonium </e1>  - neostigmine - polymyxin B or  <e2> bacitracin </e2>  - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts,  <e1> lithium </e1> , local anesthetics,  <e2> procainamide </e2> , and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides,  <e1> tetracyclines </e1> ,  <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Use of potassium-sparing diuretics (spironolactone,  <e1> triamterene </e1> ,  <e2> amiloride </e2> ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 
false	Potassium Supplements and  <e1> Potassium-Sparing Diuretics </e1> :  <e2> UNIVASC </e2>     can increase serum potassium because it decreases aldosterone secretion. 
false	Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with  <e1> hydrochlorothiazide </e1> , digoxin, or  <e2> cimetidine </e2> . 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium -  <e1> neostigmine </e1>  - polymyxin B or  <e2> bacitracin </e2>  - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
int	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as MIVACRON include certain antibiotics (e.g.,  <e2> aminoglycosides </e2> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	 <e1> UNIVASC </e1>     has been used in clinical trials concomitantly with calcium-channel-blocking agents,  <e2> diuretics </e2> , H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 
false	Accordingly, patients should be advised to avoid  <e1> alcohol </e1>  while taking REMERON SolTab.  <e2> Diazepam </e2> : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin,  <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	 <e1> Lithium </e1> : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving  <e2> ACE inhibitors </e2>  during therapy with lithium. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	 <e1> UNIVASC </e1>     has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers,  <e2> digoxin </e2> , oral hypoglycemic agents, and cholesterol-lowering agents. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or  <e1> carbamazepine </e1>  - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other  <e2> muscle relaxants </e2> 
false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives,  <e1> glucocorticoids </e1> , or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered  <e2> phenytoin </e2>  or carbamazepine. 
false	Use of potassium-sparing diuretics (spironolactone, triamterene,  <e1> amiloride </e1> ) or  <e2> potassium </e2>  supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 
effect	Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or  <e1> potassium </e1>  supplements concomitantly with  <e2> ACE inhibitors </e2>  can increase the risk of hyperkalemia. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts,  <e1> lithium </e1> , local anesthetics,  <e2> procainamide </e2> , and quinidine. 
false	 <e1> Lithium </e1> : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with  <e2> lithium </e2> . 
false	Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between  <e1> MIVACRON </e1>  and  <e2> succinylcholine </e2>  has not been systematically studied. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin -  <e1> edrophonium </e1>  - neostigmine - polymyxin B or  <e2> bacitracin </e2>  - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Some drug interactions are:  - birth control pills -  <e1> corticosteroids </e1>  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other  <e2> muscle relaxants </e2> 
false	 <e1> UNIVASC </e1>     has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers,  <e2> digoxin </e2> , oral hypoglycemic agents, and cholesterol-lowering agents. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin -  <e1> edrophonium </e1>  - neostigmine - polymyxin B or  <e2> bacitracin </e2>  - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as  <e1> phenobarbital </e1>  or  <e2> rifampin </e2> , are co-administered with montelukast. 
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as  <e1> phenobarbital </e1>  or rifampin, are co-administered with  <e2> montelukast </e2> . 
false	Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral  <e1> contraceptive </e1>  containing norethindrone 1 mg/ethinyl  <e2> estradiol </e2>  35 mcg. 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives ( <e1> norethindrone </e1>  1 mg/ethinyl estradiol 35 mcg),  <e2> terfenadine </e2> , digoxin, and warfarin. 
false	In drug-interaction studies, the recommended clinical dose of  <e1> montelukast </e1>  did not have clinically important effects on the pharmacokinetics of the following drugs:  <e2> theophylline </e2> , prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline,  <e1> prednisone </e1> , prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine,  <e2> digoxin </e2> , and warfarin. 
false	These medications included thyroid hormones, sedative hypnotics,  <e1> non-steroidal anti-inflammatory agents </e1> , benzodiazepines, and  <e2> decongestants </e2> . 
false	- did not change the pharmacokinetic profile of  <e1> warfarin </e1>  (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of  <e2> warfarin </e2>  on prothrombin time or the INR (International Normalized Ratio). 
false	In drug-interaction studies, the recommended clinical dose of  <e1> montelukast </e1>  did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone,  <e2> prednisolone </e2> , oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 
false	 <e1> Phenobarbital </e1> , which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of  <e2> montelukast </e2> . 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone,  <e1> prednisolone </e1> , oral contraceptives (norethindrone 1 mg/ <e2> ethinyl estradiol </e2>  35 mcg), terfenadine, digoxin, and warfarin. 
false	 <e1> Montelukast </e1>  at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl  <e2> estradiol </e2>  35 mcg. 
false	 <e1> Phenobarbital </e1> , which induces hepatic metabolism, decreased the AUC of  <e2> montelukast </e2>  approximately 40% following a single 10-mg dose of montelukast. 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral  <e1> contraceptives </e1>  (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and  <e2> warfarin </e2> . 
false	- did not change the plasma concentration profile of  <e1> terfenadine </e1>  (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with  <e2> terfenadine </e2>  60 mg twice daily. 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs:  <e1> theophylline </e1> , prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg),  <e2> terfenadine </e2> , digoxin, and warfarin. 
false	- did not cause any clinically significant change in plasma profiles of  <e1> prednisone </e1>  or  <e2> prednisolone </e2>  following administration of either oral prednisone or intravenous prednisolone.  
false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine,  <e1> nalbuphine </e1> , butorphanol, or  <e2> buprenorphine </e2> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 
false	- did not cause any clinically significant change in plasma profiles of  <e1> prednisone </e1>  or  <e2> prednisolone </e2>  following administration of either oral prednisone or intravenous prednisolone.  
effect	Use with Other Central Nervous System Depressants: The depressant effects of  <e1> morphine </e1>  are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or  <e2> psychotropic drugs </e2> . 
false	Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral  <e1> contraceptive </e1>  containing norethindrone 1 mg/ethinyl  <e2> estradiol </e2>  35 mcg. 
false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other  <e1> CNS depressants </e1>  such as alcohol, sedatives,  <e2> antihistaminics </e2> , or psychotropic drugs. 
false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e.,  <e1> pentazocine </e1> ,  <e2> nalbuphine </e2> , butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 
false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e.,  <e1> pentazocine </e1> , nalbuphine,  <e2> butorphanol </e2> , or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline,  <e1> prednisone </e1> , prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine,  <e2> digoxin </e2> , and warfarin. 
false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other  <e1> CNS depressants </e1>  such as alcohol, sedatives, antihistaminics, or  <e2> psychotropic drugs </e2> . 
advise	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e.,  <e1> pentazocine </e1> , nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  <e2> opioid agonist analgesic </e2> . 
false	In drug-interaction studies, the recommended clinical dose of  <e1> montelukast </e1>  did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone,  <e2> prednisolone </e2> , oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 
false	 <e1> Azathioprine </e1> /Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with  <e2> azathioprine </e2>  or mycophenolate mofetil. 
false	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and  <e1> mycophenolate mofetil </e1>  inhibit purine metabolism, it is recommended that  <e2> Myfortic </e2>  not be administered concomitantly with azathioprine or mycophenolate mofetil. 
false	 <e1> Cholestyramine </e1>  and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with  <e2> mycophenolate mofetil </e2> . 
false	Azathioprine/ <e1> Mycophenolate Mofetil </e1> : Given that azathioprine and  <e2> mycophenolate mofetil </e2>  inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 
false	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and  <e1> mycophenolate mofetil </e1>  inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with  <e2> azathioprine </e2>  or mycophenolate mofetil. 
false	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with  <e1> azathioprine </e1>  or  <e2> mycophenolate mofetil </e2> . 
false	Azathioprine/ <e1> Mycophenolate Mofetil </e1> : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with  <e2> azathioprine </e2>  or mycophenolate mofetil. 
false	 <e1> Antacids </e1> : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium- <e2> aluminum </e2>  containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 
false	 <e1> Antacids </e1> : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  <e2> Myfortic </e2>  was administered alone under fasting conditions. 
false	 <e1> Cholestyramine </e1>  and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce  <e2> MPA </e2>  exposure when coadministered with mycophenolate mofetil. 
false	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium- <e1> aluminum </e1>  containing  <e2> antacids </e2>  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 
false	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and  <e1> mycophenolate mofetil </e1>  inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or  <e2> mycophenolate mofetil </e2> . 
advise	Therefore, do not administer  <e1> Myfortic </e1>  with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral  <e2> activated charcoal </e2> , because of the potential to reduce the efficacy of Myfortic. 
false	Phenytoin,  <e1> Carbamazepine </e1> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of  <e2> ondansetron </e2>  was significantly increased and ondansetron blood concentrations were decreased. 
false	Phenytoin,  <e1> Carbamazepine </e1> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and  <e2> ondansetron </e2>  blood concentrations were decreased. 
false	Phenytoin,  <e1> Carbamazepine </e1> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and  <e2> rifampicin </e2> ), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 
false	However, on the basis of available data, no dosage adjustment for  <e1> ondansetron </e1>  is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and  <e2> tramadol </e2>  has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 
false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that  <e1> ondansetron </e1>  may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  <e2> ondansetron </e2> . 
false	In humans,  <e1> carmustine </e1> , etoposide, and cisplatin do not affect the pharmacokinetics of  <e2> ondansetron </e2> .  
false	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e.,  <e1> phenytoin </e1> , carbamazepine, and  <e2> rifampicin </e2> ), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 
false	 <e1> Antacids </e1> : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium- <e2> aluminum </e2>  containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 
false	 <e1> Azathioprine </e1> /Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with  <e2> azathioprine </e2>  or mycophenolate mofetil. 
false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of  <e1> tramadol </e1> .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  <e2> ondansetron </e2> . 
mechanism	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin,  <e1> carbamazepine </e1> , and rifampicin), the clearance of ondansetron was significantly increased and  <e2> ondansetron </e2>  blood concentrations were decreased. 
false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between  <e1> ondansetron </e1>  and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  <e2> ondansetron </e2> . 
false	Phenytoin,  <e1> Carbamazepine </e1> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin,  <e2> carbamazepine </e2> , and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 
false	 <e1> ondansetron </e1>  did not increase blood levels of high-dose  <e2> methotrexate </e2> .
false	Beta adrenergic agonists should be administered with caution to patients being treated with  <e1> monoamine oxidase inhibitors </e1>  or tricyclic antidepressants, since the action of  <e2> beta adrenergic agonists </e2>  on the vascular system may be potentiated.
false	Phenytoin,  <e1> Carbamazepine </e1> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and  <e2> rifampicin </e2> ), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 
false	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e.,  <e1> phenytoin </e1> , carbamazepine, and  <e2> rifampicin </e2> ), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 
advise	Other  <e1> beta adrenergic aerosol bronchodilators </e1>  should not be used concomitantly with Alupent    ( <e2> metaproterenol sulfate </e2>  USP) because they may have additive effects. 
false	 <e1> Warfarin </e1> : In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either  <e2> warfarin </e2>  pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). 
false	 <e1> Cyclosporine </e1> : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in  <e2> cyclosporine </e2>  plasma levels when XENICAL was coadministered with cyclosporine. 
false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics,  <e1> orlistat </e1>  pharmacodynamics (fecal fat excretion), or systemic exposure to  <e2> orlistat </e2> . 
false	Oral Contraceptives: In 20 normal-weight female subjects, the treatment of  <e1> XENICAL </e1>  120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral  <e2> contraceptives </e2> . 
false	Phenytoin,  <e1> Carbamazepine </e1> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and  <e2> rifampicin </e2> ), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 
false	Cyclosporine: Preliminary data from a XENICAL and  <e1> cyclosporine </e1>  drug interaction study indicate a reduction in cyclosporine plasma levels when  <e2> XENICAL </e2>  was coadministered with cyclosporine. 
false	The effect of orlistat on the absorption of supplemental  <e1> vitamin D </e1> , vitamin A, and nutritionally-derived  <e2> vitamin K </e2>  is not known at this time. 
false	 <e1> Phenytoin </e1> : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days,  <e2> XENICAL </e2>  did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. 
false	 <e1> Glyburide </e1> : In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days,  <e2> orlistat </e2>  did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. 
false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of  <e1> alcohol </e1>  (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to  <e2> orlistat </e2> . 
false	 <e1> Phenytoin </e1> : In 12 normal-weight subjects receiving  <e2> XENICAL </e2>  120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. 
false	Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days,  <e1> XENICAL </e1>  did not alter the pharmacokinetics of a single dose of  <e2> digoxin </e2> . 
false	 <e1> Pravastatin </e1> : In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of  <e2> pravastatin </e2> . 
false	Cyclosporine: Preliminary data from a  <e1> XENICAL </e1>  and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when  <e2> XENICAL </e2>  was coadministered with cyclosporine. 
advise	Other  <e1> beta adrenergic aerosol bronchodilators </e1>  should not be used concomitantly with Alupent    ( <e2> metaproterenol sulfate </e2>  USP) because they may have additive effects. 
mechanism	Therefore, as  <e1> vitamin K </e1>  absorption may be decreased with  <e2> XENICAL </e2> , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
false	 <e1> Glyburide </e1> : In 12 normal-weight subjects receiving  <e2> orlistat </e2>  80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. 
false	 <e1> Cyclosporine </e1> : Preliminary data from a  <e2> XENICAL </e2>  and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 
false	 <e1> Phenytoin </e1> : In 12 normal-weight subjects receiving  <e2> XENICAL </e2>  120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. 
false	 <e1> Warfarin </e1> : In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either  <e2> warfarin </e2>  pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). 
false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of  <e1> alcohol </e1>  (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to  <e2> orlistat </e2> . 
false	No pharmacokinetic interaction between 85 mg/m2  <e1> ELOXATIN </e1>  and infusional  <e2> 5-FU </e2>  has been observed in patients treated every 2 weeks. 
false	Warfarin: A multidose study of  <e1> oxandrolone </e1> , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in  <e2> S-warfarin </e2>  half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 
false	 <e1> Warfarin </e1> : A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  <e2> warfarin </e2> , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 
false	Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  <e1> warfarin </e1> , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in  <e2> R-warfarin </e2>  half-life and AUC were also detected. 
advise	Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the  <e1> warfarin </e1>  dosage if indicated are recommended when the  <e2> oxandrolone </e2>  dose is changed or discontinued. 
mechanism	Oral hypoglycemic agents  <e1> Oxandrolone </e1>  may inhibit the metabolism of oral  <e2> hypoglycemic agents </e2> . 
false	 <e1> Anticoagulants </e1>   <e2> Anabolic steroids </e2>  may increase sensitivity to oral anticoagulants. 
false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g.,  <e1> itraconazole </e1>  and miconazole) or macrolide antibiotics (e.g.,  <e2> erythromycin </e2>  and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 
false	Concurrent ingestion of antacid (20 mL of  <e1> antacid </e1>  containing aluminum hydroxide,  <e2> magnesium hydroxide </e2> , and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    
false	Mean  <e1> oxybutynin chloride </e1>  plasma concentrations were approximately 2 fold higher when  <e2> DITROPAN XL </e2>  was administered with ketoconazole, a potent CYP3A4 inhibitor. 
false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g.,  <e1> itraconazole </e1>  and miconazole) or  <e2> macrolide antibiotics </e2>  (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 
false	Concurrent ingestion of  <e1> antacid </e1>  (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or  <e2> desethyloxybutynin </e2> .    
false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or  <e1> macrolide antibiotics </e1>  (e.g.,  <e2> erythromycin </e2>  and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 
mechanism	Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when  <e1> DITROPAN XL </e1>  was administered with  <e2> ketoconazole </e2> , a potent CYP3A4 inhibitor. 
false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g.,  <e1> itraconazole </e1>  and miconazole) or macrolide antibiotics (e.g., erythromycin and  <e2> clarithromycin </e2> ), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 
false	Concurrent ingestion of antacid (20 mL of  <e1> antacid </e1>  containing aluminum hydroxide, magnesium hydroxide, and  <e2> simethicone </e2> ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    
false	 <e1> Warfarin </e1> : A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  <e2> warfarin </e2> , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 
false	Concurrent ingestion of antacid (20 mL of  <e1> antacid </e1>  containing aluminum hydroxide,  <e2> magnesium hydroxide </e2> , and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    
false	Concurrent ingestion of  <e1> antacid </e1>  (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or  <e2> desethyloxybutynin </e2> .    
false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids,  <e1> tricyclic antidepressants </e1> , monoamine oxidase (MAO) inhibitors, and  <e2> alcohol </e2>  may produce additive CNS depressant effects. 
false	The concomitant use of other CNS depressants including sedatives, hypnotics,  <e1> tranquilizers </e1> , general anesthetics, phenothiazines, other  <e2> opioids </e2> , tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 
false	The concomitant use of other  <e1> CNS depressants </e1>  including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other  <e2> opioids </e2> , tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 
false	The concomitant use of other  <e1> CNS depressants </e1>  including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and  <e2> alcohol </e2>  may produce additive CNS depressant effects. 
false	The concomitant use of other CNS depressants including  <e1> sedatives </e1> ,  <e2> hypnotics </e2> , tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 
false	The concomitant use of other  <e1> CNS depressants </e1>  including sedatives, hypnotics,  <e2> tranquilizers </e2> , general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 
false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids,  <e1> tricyclic antidepressants </e1> ,  <e2> monoamine oxidase (MAO) inhibitors </e2> , and alcohol may produce additive CNS depressant effects. 
false	The concomitant use of other CNS depressants including  <e1> sedatives </e1> , hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants,  <e2> monoamine oxidase (MAO) inhibitors </e2> , and alcohol may produce additive CNS depressant effects. 
false	The concomitant use of other CNS depressants including sedatives,  <e1> hypnotics </e1> , tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and  <e2> alcohol </e2>  may produce additive CNS depressant effects. 
false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general  <e1> anesthetics </e1> , phenothiazines, other opioids,  <e2> tricyclic antidepressants </e2> , monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 
false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids,  <e1> tricyclic antidepressants </e1> ,  <e2> monoamine oxidase (MAO) inhibitors </e2> , and alcohol may produce additive CNS depressant effects. 
false	Potential for  <e1> INVEGA </e1>     to Affect Other Drugs  <e2> Paliperidone </e2>  is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. 
effect	 <e1> Paliperidone </e1>  may antagonize the effect of  <e2> levodopa </e2>  and other dopamine agonists. 
advise	Given the primary CNS effects of  <e1> paliperidone </e1> , INVEGA    should be used with caution in combination with other  <e2> centrally acting drugs </e2>  and alcohol. 
false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids,  <e1> tricyclic antidepressants </e1> , monoamine oxidase (MAO) inhibitors, and  <e2> alcohol </e2>  may produce additive CNS depressant effects. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen,  <e1> piroxicam </e1> ,  <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam,  <e1> clarithromycin </e1> , metronidazole, or  <e2> amoxicillin </e2> . 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam,  <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine,  <e1> diazepam </e1>  (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin,  <e2> metronidazole </e2> , or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite,  <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine,  <e1> phenytoin </e1> , warfarin, midazolam, clarithromycin, metronidazole, or  <e2> amoxicillin </e2> . 
false	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most  <e1> proton pump inhibitors </e1> , including  <e2> pantoprazole </e2> . 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride,  <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e2> contraceptive </e2>  (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite,  <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine,  <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam),  <e1> diclofenac </e1> , naproxen, piroxicam, digoxin,  <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following:  <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine,  <e2> diazepam </e2>  (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine,  <e1> phenytoin </e1> , warfarin, midazolam,  <e2> clarithromycin </e2> , metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following:  <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam),  <e2> diclofenac </e2> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline,  <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e2> contraceptive </e2>  (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e1> naproxen </e1> , piroxicam, digoxin, ethanol,  <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam,  <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam,  <e2> clarithromycin </e2> , metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam),  <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam,  <e2> clarithromycin </e2> , metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline,  <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam),  <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine,  <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine,  <e1> diazepam </e1>  (and its active metabolite, desmethyldiazepam), diclofenac,  <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine,  <e1> diazepam </e1>  (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam,  <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of  <e1> pantoprazole </e1>  with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine,  <e2> diazepam </e2>  (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e1> contraceptive </e1>  (levonorgestrel/ethinyl estradiol), metoprolol,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline,  <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or  <e2> amoxicillin </e2> . 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite,  <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e2> contraceptive </e2>  (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen,  <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol,  <e1> glyburide </e1> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam,  <e2> clarithromycin </e2> , metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline,  <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin,  <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Therefore, when coadministered with  <e1> pantoprazole </e1> , adjustment of the dosage of  <e2> pantoprazole </e2>  or of such drugs may not be necessary. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine,  <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen,  <e2> piroxicam </e2> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e1> ethinyl estradiol </e1> ), metoprolol, nifedipine,  <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e1> midazolam </e1> , clarithromycin, metronidazole, or  <e2> amoxicillin </e2> . 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e1> warfarin </e1> , midazolam, clarithromycin, metronidazole, or  <e2> amoxicillin </e2> . 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine,  <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam,  <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine,  <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine,  <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol,  <e1> glyburide </e1> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e1> contraceptive </e1>  (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine,  <e1> diazepam </e1>  (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride,  <e1> antipyrine </e1> ,  <e2> caffeine </e2> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e1> ethinyl estradiol </e1> ), metoprolol, nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine,  <e1> diazepam </e1>  (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol,  <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
advise	Given the primary CNS effects of  <e1> paliperidone </e1> , INVEGA    should be used with caution in combination with other  <e2> centrally acting drugs </e2>  and alcohol. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine,  <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite,  <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam),  <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of  <e1> pantoprazole </e1>  with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine,  <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite,  <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin,  <e1> ethanol </e1> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or  <e2> amoxicillin </e2> . 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine,  <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin,  <e2> metronidazole </e2> , or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite,  <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin,  <e2> metronidazole </e2> , or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam,  <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam,  <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin,  <e2> metronidazole </e2> , or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e1> contraceptive </e1>  (levonorgestrel/ethinyl estradiol),  <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of  <e1> pantoprazole </e1>  with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol,  <e1> glyburide </e1> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin,  <e1> ethanol </e1> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following:  <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam),  <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite,  <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline,  <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline,  <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or  <e2> amoxicillin </e2> . 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled  <e1> paricalcitol </e1>  AUC0-   . Since paricalcitol is partially metabolized by CYP3A and  <e2> ketoconazole </e2>  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that  <e1> ketoconazole </e1>  approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir,  <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole. 
advise	Dose adjustment of  <e1> Zemplar </e1>  Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as  <e2> ketoconazole </e2> . 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since  <e1> paricalcitol </e1>  is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin,  <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite,  <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that  <e1> ketoconazole </e1>  approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  <e2> paricalcitol </e2>  with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam,  <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including  <e1> atazanavir </e1> ,  <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite,  <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e2> contraceptive </e2>  (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled  <e1> paricalcitol </e1>  AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir,  <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and  <e1> ketoconazole </e1>  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with  <e2> ketoconazole </e2>  and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that  <e1> ketoconazole </e1>  approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir,  <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that  <e1> ketoconazole </e1>  approximately doubled paricalcitol AUC0-   . Since  <e2> paricalcitol </e2>  is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled  <e1> paricalcitol </e1>  AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or  <e2> voriconazole </e2> . 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and  <e1> ketoconazole </e1>  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone,  <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since  <e1> paricalcitol </e1>  is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with  <e1> ketoconazole </e1>  and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin,  <e1> indinavir </e1> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or  <e2> voriconazole </e2> . 
false	A multiple dose drug-drug interaction study demonstrated that  <e1> ketoconazole </e1>  approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including  <e2> atazanavir </e2> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline,  <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol,  <e1> glyburide </e1> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam,  <e2> clarithromycin </e2> , metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone,  <e1> nelfinavir </e1> , ritonavir, saquinavir,  <e2> telithromycin </e2>  or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including  <e1> atazanavir </e1> , clarithromycin,  <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin,  <e1> indinavir </e1> , itraconazole,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and  <e1> ketoconazole </e1>  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir,  <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir,  <e1> clarithromycin </e1> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or  <e2> voriconazole </e2> . 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since  <e1> paricalcitol </e1>  is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir,  <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin,  <e1> indinavir </e1> , itraconazole, nefazodone, nelfinavir, ritonavir,  <e2> saquinavir </e2> , telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled  <e1> paricalcitol </e1>  AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir,  <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine,  <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen,  <e2> piroxicam </e2> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of  <e1> pantoprazole </e1>  with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that  <e1> ketoconazole </e1>  approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone,  <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and  <e1> ketoconazole </e1>  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir,  <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e1> contraceptive </e1>  (levonorgestrel/ethinyl estradiol), metoprolol,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  <e1> paricalcitol </e1>  with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir,  <e2> telithromycin </e2>  or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and  <e1> ketoconazole </e1>  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir,  <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since  <e1> paricalcitol </e1>  is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir,  <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and  <e1> ketoconazole </e1>  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with  <e2> ketoconazole </e2>  and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	Based on studies evaluating possible interactions of  <e1> pantoprazole </e1>  with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since  <e1> paricalcitol </e1>  is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that  <e1> ketoconazole </e1>  approximately doubled paricalcitol AUC0-   . Since  <e2> paricalcitol </e2>  is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and  <e1> ketoconazole </e1>  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with  <e2> ketoconazole </e2>  and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving  <e1> methadone </e1> , treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in  <e2> methadone </e2>  AUC; 
false	In clinical studies, patients on opioids often needed higher serum  <e1> pegvisomant </e1>  concentrations to achieve appropriate IGF-I suppression compared with patients not receiving  <e2> opioids </e2> . 
advise	Acromegalic patients with diabetes mellitus being treated with  <e1> insulin </e1>  and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with  <e2> SOMAVERT </e2> . 
false	In the absence of data regarding potential interaction between ALIMTA and  <e1> NSAIDs </e1>  with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following  <e2> ALIMTA </e2>  administration. 
advise	Patients with mild to moderate renal insufficiency should avoid taking  <e1> NSAIDs </e1>  with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of  <e2> ALIMTA </e2> . 
false	In the absence of data regarding potential interaction between  <e1> ALIMTA </e1>  and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following  <e2> ALIMTA </e2>  administration. 
false	 <e1> Penicillin </e1>  blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of  <e2> penicillins </e2> . 
false	TRENTAL has been used concurrently with antihypertensive drugs,  <e1> beta blockers </e1> ,  <e2> digitalis </e2> , diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 
false	 <e1> TRENTAL </e1>  has been used concurrently with antihypertensive drugs, beta blockers,  <e2> digitalis </e2> , diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 
false	Concomitant administration of TRENTAL and  <e1> theophylline </e1> -containing drugs leads to increased theophylline levels and  <e2> theophylline </e2>  toxicity in some individuals. 
false	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers,  <e1> digitalis </e1> , diuretics,  <e2> antidiabetic agents </e2> , and antiarrhythmics, without observed problems. 
effect	Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with  <e1> TRENTAL </e1>  with and without  <e2> anticoagulants </e2>  or platelet aggregation inhibitors. 
false	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers,  <e1> digitalis </e1> , diuretics, antidiabetic agents, and  <e2> antiarrhythmics </e2> , without observed problems. 
false	TRENTAL has been used concurrently with antihypertensive drugs,  <e1> beta blockers </e1> , digitalis, diuretics, antidiabetic agents, and  <e2> antiarrhythmics </e2> , without observed problems. 
false	 <e1> Dopamine antagonists </e1> , such as the  <e2> neuroleptics </e2>  (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 
false	Dopamine antagonists, such as the  <e1> neuroleptics </e1>  (phenothiazines, butyrophenones,  <e2> thioxanthines </e2>  ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 
false	Dopamine antagonists, such as the  <e1> neuroleptics </e1>  (phenothiazines,  <e2> butyrophenones </e2> , thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 
false	 <e1> Dopamine antagonists </e1> , such as the neuroleptics ( <e2> phenothiazines </e2> , butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 
advise	Dopamine antagonists, such as the neuroleptics (phenothiazines,  <e1> butyrophenones </e1> , thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with  <e2> Permax </e2>  (a dopamine agonist); 
false	Concomitant administration of TRENTAL and  <e1> theophylline </e1> -containing drugs leads to increased theophylline levels and  <e2> theophylline </e2>  toxicity in some individuals. 
false	TRENTAL has been used concurrently with antihypertensive drugs,  <e1> beta blockers </e1> ,  <e2> digitalis </e2> , diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 
false	 <e1> Lithium </e1> : Increased serum  <e2> lithium </e2>  and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. 
false	 <e1> Digoxin </e1> : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of  <e2> perindopril </e2> /perindoprilat has not been excluded. 
false	Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , amiloride,  <e2> triamterene </e2>  and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 
false	Use of potassium-sparing diuretics (spironolactone,  <e1> amiloride </e1> , triamterene and others),  <e2> potassium </e2>  supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 
false	Use of  <e1> potassium-sparing diuretics </e1>  (spironolactone, amiloride, triamterene and others),  <e2> potassium </e2>  supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 
effect	Diuretics: Patients on  <e1> diuretics </e1> , and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of  <e2> ACEON </e2>     Tablets therapy. 
mechanism	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of  <e1> digoxin </e1>  on the plasma concentration of perindopril/ <e2> perindoprilat </e2>  has not been excluded. 
false	Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( <e2> indomethacin </e2> , heparin, cyclosporine and others) can increase the risk of hyperkalemia. 
false	Food Interaction: Oral administration of  <e1> ACEON </e1>     Tablets with food does not significantly lower the rate or extent of  <e2> perindopril </e2>  absorption relative to the fasted state. 
false	 <e1> Dopamine antagonists </e1> , such as the  <e2> neuroleptics </e2>  (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 
false	 <e1> Potassium </e1>  Supplements and  <e2> Potassium-Sparing Diuretics </e2> : ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production. 
false	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( <e1> indomethacin </e1> , heparin,  <e2> cyclosporine </e2>  and others) can increase the risk of hyperkalemia. 
false	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with  <e1> ACEON </e1>     Tablets, but an effect of digoxin on the plasma concentration of perindopril/ <e2> perindoprilat </e2>  has not been excluded. 
advise	Dopamine antagonists, such as the neuroleptics (phenothiazines,  <e1> butyrophenones </e1> , thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with  <e2> Permax </e2>  (a dopamine agonist); 
false	The bioavailability of  <e1> perindoprilat </e1>  was reduced by  <e2> diuretics </e2> , however, and this was associated with a decrease in plasma ACE inhibition. 
false	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of  <e1> perindopril </e1> / <e2> perindoprilat </e2>  has not been excluded. 
false	 <e1> Dopamine antagonists </e1> , such as the  <e2> neuroleptics </e2>  (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 
false	 <e1> Lithium </e1> : Increased serum  <e2> lithium </e2>  and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. 
false	 <e1> Dopamine antagonists </e1> , such as the  <e2> neuroleptics </e2>  (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 
effect	The pressor response of  <e1> adrenergic agents </e1>  may also be potentiated by  <e2> tricyclic antidepressants </e2> .
false	 <e1> MAO Inhibitors </e1> : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving  <e2> monoamine oxidase inhibitors </e2>  (MAOI). 
false	 <e1> Vasopressors </e1> , particularly  <e2> metaraminol </e2> , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. 
false	 <e1> Dopamine antagonists </e1> , such as the  <e2> neuroleptics </e2>  (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 
effect	MAO Inhibitors - The pressor effect of  <e1> sympathomimetic pressor amines </e1>  is markedly potentiated in patients receiving  <e2> monoamine oxidase inhibitors </e2>  (MAOI). 
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins,  <e1> naproxen </e1> , omeprazole,  <e2> paracetamol </e2> , and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium,  <e1> conjugated estrogens </e1> , hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium,  <e2> medroxyprogesterone acetate </e2> , methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate,  <e1> ibuprofen </e1> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins,  <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium,  <e1> medroxyprogesterone acetate </e1> , methotrexate, multivitamins,  <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins,  <e1> naproxen </e1> ,  <e2> omeprazole </e2> , paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins,  <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate,  <e1> methotrexate </e1> ,  <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate,  <e1> ibuprofen </e1> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and  <e2> prednisone </e2> .
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens,  <e1> hydroxychloroquine sulfate </e1> , ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate,  <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens,  <e1> hydroxychloroquine sulfate </e1> , ibuprofen, levothyroxine sodium, medroxyprogesterone acetate,  <e2> methotrexate </e2> , multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
false	 <e1> Vasopressors </e1> , particularly  <e2> metaraminol </e2> , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. 
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium,  <e1> medroxyprogesterone acetate </e1> , methotrexate,  <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and  <e2> prednisone </e2> .
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate,  <e1> multivitamins </e1> , naproxen, omeprazole,  <e2> paracetamol </e2> , and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen,  <e1> omeprazole </e1> , paracetamol, and  <e2> prednisone </e2> .
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens,  <e1> hydroxychloroquine sulfate </e1> , ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen,  <e2> omeprazole </e2> , paracetamol, and prednisone.
false	Pindolol has been used with a variety of  <e1> antihypertensive agents </e1> , including hydrochlorothiazide, hydralazine, and  <e2> guanethidine </e2>  without unexpected adverse interactions. 
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium,  <e1> medroxyprogesterone acetate </e1> , methotrexate,  <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins,  <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.
false	 <e1> Pindolol </e1>  has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and  <e2> guanethidine </e2>  without unexpected adverse interactions. 
false	Pindolol has been used with a variety of  <e1> antihypertensive agents </e1> , including  <e2> hydrochlorothiazide </e2> , hydralazine, and guanethidine without unexpected adverse interactions. 
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium,  <e1> medroxyprogesterone acetate </e1> , methotrexate,  <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.
advise	It is recommended that plasma  <e1> lithium </e1>  levels be monitored when initiating, adjusting and discontinuing  <e2> FELDENE </e2> .
false	Plasma levels of  <e1> piroxicam </e1>  are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels .  <e2> Nonsteroidal anti-inflammatory agents </e2> , including FELDENE, have been reported to increase steady state plasma lithium levels. 
false	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with  <e1> FELDENE </e1>  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering  <e2> FELDENE </e2>  to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 
false	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with  <e1> FELDENE </e1>  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on  <e2> coumarin-type anticoagulants </e2>  and other highly protein-bound drugs. 
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium,  <e1> medroxyprogesterone acetate </e1> , methotrexate,  <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.
false	Plasma levels of  <e1> piroxicam </e1>  are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on  <e2> piroxicam </e2>  plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 
false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when  <e1> FELDENE </e1>  is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of  <e2> antacids </e2>  has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 
false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on  <e1> piroxicam </e1>  plasma levels . Nonsteroidal anti-inflammatory agents, including  <e2> FELDENE </e2> , have been reported to increase steady state plasma lithium levels. 
false	morphine, theophylline,  <e1> aminophylline </e1> , succinylcholine,  <e2> reserpine </e2> , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
false	 <e1> morphine </e1> , theophylline, aminophylline,  <e2> succinylcholine </e2> , reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
false	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of  <e1> pralidoxime </e1> : since barbiturates are potentiated by the  <e2> anticholinesterases </e2> , they should be used cautiously in the treatment of convulsions; 
false	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with  <e1> FELDENE </e1>  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on  <e2> coumarin-type anticoagulants </e2>  and other highly protein-bound drugs. 
effect	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since  <e1> barbiturates </e1>  are potentiated by the  <e2> anticholinesterases </e2> , they should be used cautiously in the treatment of convulsions; 
false	 <e1> morphine </e1> , theophylline, aminophylline, succinylcholine,  <e2> reserpine </e2> , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
false	Plasma levels of  <e1> piroxicam </e1>  are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels .  <e2> Nonsteroidal anti-inflammatory agents </e2> , including FELDENE, have been reported to increase steady state plasma lithium levels. 
false	 <e1> Dopamine antagonists </e1> : Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines,  <e2> butyrophenones </e2> , thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine,  <e1> diltiazem </e1> , triamterene, verapamil, quinidine, and  <e2> quinine </e2> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g.,  <e1> cephalosporins </e1> , penicillins, indomethacin,  <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene,  <e1> verapamil </e1> ,  <e2> quinidine </e2> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Dopamine antagonists: Since pramipexole is a  <e1> dopamine agonist </e1> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or  <e2> metoclopramide </e2> , may diminish the effectiveness of MIRAPEX. 
false	 <e1> Dopamine antagonists </e1> : Since pramipexole is a  <e2> dopamine agonist </e2> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  <e1> cimetidine </e1> ,  <e2> ranitidine </e2> , diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	 <e1> morphine </e1> , theophylline, aminophylline,  <e2> succinylcholine </e2> , reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
false	 <e1> Dopamine antagonists </e1> : Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones,  <e2> thioxanthenes </e2> ) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil,  <e1> quinidine </e1> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g.,  <e2> cephalosporins </e2> , penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of  <e1> pralidoxime </e1> : since barbiturates are potentiated by the  <e2> anticholinesterases </e2> , they should be used cautiously in the treatment of convulsions; 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene,  <e1> verapamil </e1> , quinidine, and  <e2> quinine </e2> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	 <e1> Carbidopa </e1> /Levodopa: Carbidopa/ <e2> Levodopa </e2>  does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 
false	Dopamine antagonists: Since pramipexole is a  <e1> dopamine agonist </e1> , it is possible that dopamine antagonists, such as the neuroleptics ( <e2> phenothiazines </e2> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem,  <e1> triamterene </e1> , verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins,  <e2> penicillins </e2> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that  <e1> dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, butyrophenones,  <e2> thioxanthenes </e2> ) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene,  <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of  <e2> pramipexole </e2> . 
false	Dopamine antagonists: Since  <e1> pramipexole </e1>  is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e2> phenothiazines </e2> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	 <e1> Dopamine antagonists </e1> : Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e2> phenothiazines </e2> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	Selegiline: In healthy volunteers (N= 11),  <e1> selegiline </e1>  did not influence the pharmacokinetics of  <e2> pramipexole </e2> . 
mechanism	Cimetidine:  <e1> Cimetidine </e1> , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in  <e2> pramipexole </e2>  AUC and a 40% increase in half-life (N= 12). 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene,  <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins,  <e2> penicillins </e2> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine,  <e1> diltiazem </e1> , triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin,  <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene,  <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of  <e2> pramipexole </e2>  by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil,  <e1> quinidine </e1> , and  <e2> quinine </e2> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  <e1> cimetidine </e1> , ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and  <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole. 
effect	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that  <e1> dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of  <e2> MIRAPEX </e2> . 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem,  <e1> triamterene </e1> , verapamil, quinidine, and  <e2> quinine </e2> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Dopamine antagonists: Since  <e1> pramipexole </e1>  is a dopamine agonist, it is possible that dopamine antagonists, such as the  <e2> neuroleptics </e2>  (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	Carbidopa/ <e1> Levodopa </e1> :  <e2> Carbidopa </e2> /Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene,  <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and  <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole. 
effect	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since  <e1> barbiturates </e1>  are potentiated by the  <e2> anticholinesterases </e2> , they should be used cautiously in the treatment of convulsions; 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine,  <e1> diltiazem </e1> , triamterene,  <e2> verapamil </e2> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Mixing  <e1> SYMLIN </e1>  and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant  <e2> human insulin </e2>  immediately prior to injection. 
false	Dopamine antagonists: Since  <e1> pramipexole </e1>  is a dopamine agonist, it is possible that dopamine antagonists, such as the  <e2> neuroleptics </e2>  (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	 <e1> Dopamine antagonists </e1> : Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines,  <e2> butyrophenones </e2> , thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
effect	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that  <e1> dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of  <e2> MIRAPEX </e2> . 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene,  <e1> verapamil </e1> ,  <e2> quinidine </e2> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene,  <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of  <e2> pramipexole </e2> . 
false	Dopamine antagonists: Since  <e1> pramipexole </e1>  is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e2> phenothiazines </e2> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene,  <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins,  <e2> penicillins </e2> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Mixing  <e1> SYMLIN </e1>  and  <e2> Insulin </e2>  The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. 
advise	Due to its effects on gastric emptying,  <e1> SYMLIN </e1>  therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as  <e2> atropine </e2> ) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). 
false	Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g.,  <e1> anticholinergic agents </e1>  such as atropine) and agents that slow the intestinal absorption of nutrients (e.g.,  <e2> alpha glucosidase inhibitors </e2> ). 
advise	Due to its effects on gastric emptying,  <e1> SYMLIN </e1>  therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as  <e2> atropine </e2> ) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene,  <e1> verapamil </e1> ,  <e2> quinidine </e2> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	This could lead to decreased  <e1> salicylate </e1>  serum levels or increase the risk of  <e2> salicylate </e2>  toxicity when corticosteroid is withdrawn. 
mechanism	Drugs such as troleandomycin and  <e1> ketoconazole </e1>  may inhibit the metabolism of  <e2> corticosteroids </e2>  and thus decrease their clearance. 
effect	The effect of  <e1> corticosteroids </e1>  on oral  <e2> anticoagulants </e2>  is variable. 
mechanism	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and  <e1> rifampin </e1>  may increase the clearance of corticosteroids and may require increases in  <e2> corticosteroid </e2>  dose to achieve the desired response. 
false	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of  <e1> corticosteroids </e1>  and may require increases in  <e2> corticosteroid </e2>  dose to achieve the desired response. 
false	 <e1> Sulfonamides </e1> : Concurrent use of procaine hydrochloride and  <e2> sulfonamides </e2>  may result in a reduction of the antibacterial action of the sulfonamide. 
false	Sulfonamides: Concurrent use of  <e1> procaine hydrochloride </e1>  and sulfonamides may result in a reduction of the antibacterial action of the  <e2> sulfonamide </e2> . 
false	Anticholinesterases: Concurrent use of procaine hydrochloride and  <e1> anticholinesterase agents </e1>  may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of  <e2> procaine hydrochloride </e2> . 
false	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of  <e1> corticosteroids </e1>  and may require increases in  <e2> corticosteroid </e2>  dose to achieve the desired response. 
mechanism	Hyaluronidase:  <e1> Hyaluronidase </e1>  may increase the diffusion rate of  <e2> procaine hydrochloride </e2> , resulting in a decreased time of onset, but an increase in systemic toxicity. 
false	Anticholinesterases: Concurrent use of  <e1> procaine hydrochloride </e1>  and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of  <e2> procaine hydrochloride </e2> . 
effect	CNS depressant medications: Concurrent use of  <e1> procaine hydrochloride </e1>  and  <e2> CNS depressant medications </e2>  may result in additive depressant effects. 
false	 <e1> Sulfonamides </e1> : Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the  <e2> sulfonamide </e2> . 
false	To minimize CNS depression and possible potentiation, barbiturates,  <e1> antihistamines </e1> ,  <e2> narcotics </e2> , hypotensive agents or phenothiazines should be used with caution. 
false	 <e1> Sulfonamides </e1> : Concurrent use of procaine hydrochloride and  <e2> sulfonamides </e2>  may result in a reduction of the antibacterial action of the sulfonamide. 
false	Because Matulane exhibits some monoamine oxidase inhibitory activity,  <e1> sympathomimetic drugs </e1> ,  <e2> tricyclic antidepressant </e2>  drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 
false	To minimize CNS depression and possible potentiation, barbiturates, antihistamines,  <e1> narcotics </e1> ,  <e2> hypotensive agents </e2>  or phenothiazines should be used with caution. 
false	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs,  <e1> tricyclic antidepressant </e1>  drugs (e.g.,  <e2> amitriptyline HCl </e2> , imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 
false	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g.,  <e1> amitriptyline HCl </e1> , imipramine HCl) and other drugs and foods with known high  <e2> tyramine </e2>  content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 
advise	Because  <e1> Matulane </e1>  exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high  <e2> tyramine </e2>  content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 
false	To minimize CNS depression and possible potentiation, barbiturates,  <e1> antihistamines </e1> ,  <e2> narcotics </e2> , hypotensive agents or phenothiazines should be used with caution. 
effect	 <e1> Thiazide diuretics </e1>  may accentuate the orthostatic hypotension that may occur with  <e2> phenothiazines </e2> . 
false	and combinations of  <e1> opioids </e1>  and  <e2> sedatives </e2>  (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 
false	and combinations of opioids and sedatives (eg,  <e1> benzodiazepines </e1> ,  <e2> barbiturates </e2> , chloral hydrate, droperidol, etc.). 
false	and combinations of opioids and  <e1> sedatives </e1>  (eg, benzodiazepines, barbiturates, chloral hydrate,  <e2> droperidol </e2> , etc.). 
false	The concurrent administration of potent inhalational agents (eg,  <e1> isoflurane </e1> ,  <e2> enflurane </e2> , and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. 
false	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg,  <e1> succinylcholine </e1>  and  <e2> nondepolarizing muscle relaxants </e2> ). 
false	The concurrent administration of potent inhalational agents (eg,  <e1> isoflurane </e1> , enflurane, and halothane) during maintenance with  <e2> DIPRIVAN </e2>  Injectable Emulsion has not been extensively evaluated. 
effect	 <e1> Thiazide diuretics </e1>  may accentuate the orthostatic hypotension that may occur with  <e2> phenothiazines </e2> . 
false	and combinations of opioids and  <e1> sedatives </e1>  (eg, benzodiazepines, barbiturates,  <e2> chloral hydrate </e2> , droperidol, etc.). 
false	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used  <e1> neuromuscular blocking agents </e1>  (eg, succinylcholine and  <e2> nondepolarizing muscle relaxants </e2> ). 
false	and combinations of opioids and  <e1> sedatives </e1>  (eg, benzodiazepines, barbiturates,  <e2> chloral hydrate </e2> , droperidol, etc.). 
false	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used  <e1> neuromuscular blocking agents </e1>  (eg, succinylcholine and  <e2> nondepolarizing muscle relaxants </e2> ). 
false	Such occurrences have been reported when propoxyphene was administered to patients on antidepressants,  <e1> anticonvulsants </e1> , or  <e2> warfarin </e2> -like drugs. 
effect	 <e1> Sympathomimetics </e1>  may reduce the antihypertensive effects of methyldopa,  <e2> mecamylamine </e2> , reserpine and veratrum alkaloids.
false	Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine,  <e1> reserpine </e1>  and  <e2> veratrum alkaloids </e2> .
false	Sympathomimetics may reduce the antihypertensive effects of  <e1> methyldopa </e1> , mecamylamine, reserpine and  <e2> veratrum alkaloids </e2> .
false	Pyrimethamine may be used with  <e1> sulfonamides </e1> , quinine and other antimalarials, and with other  <e2> antibiotics </e2> . 
effect	 <e1> Sympathomimetics </e1>  may reduce the antihypertensive effects of methyldopa,  <e2> mecamylamine </e2> , reserpine and veratrum alkaloids.
false	Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine,  <e1> reserpine </e1>  and  <e2> veratrum alkaloids </e2> .
false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate,  <e1> indomethacin </e1> , naproxen, ibuprofen,  <e2> diazepam </e2> , and diazoxide. 
false	In vitro, raloxifene did not affect the binding of warfarin,  <e1> phenytoin </e1> , or  <e2> tamoxifen </e2> . 
false	In vitro,  <e1> raloxifene </e1>  did not affect the binding of warfarin,  <e2> phenytoin </e2> , or tamoxifen. 
false	 <e1> Cholestyramine </e1> :  <e2> Cholestyramine </e2>  causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. 
advise	Caution should be used when  <e1> EVISTA </e1>  is coadministered with other highly protein-bound drugs, such as clofibrate,  <e2> indomethacin </e2> , naproxen, ibuprofen, diazepam, and diazoxide. 
false	In vitro,  <e1> raloxifene </e1>  did not affect the binding of  <e2> warfarin </e2> , phenytoin, or tamoxifen. 
false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen,  <e1> ibuprofen </e1> ,  <e2> diazepam </e2> , and diazoxide. 
false	In vitro, raloxifene did not affect the binding of warfarin,  <e1> phenytoin </e1> , or  <e2> tamoxifen </e2> . 
false	 <e1> Cholestyramine </e1> :  <e2> Cholestyramine </e2>  causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. 
false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate,  <e1> indomethacin </e1> , naproxen, ibuprofen,  <e2> diazepam </e2> , and diazoxide. 
false	Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of  <e1> ALTABAX </e1> ,  <e2> retapamulin </e2>  is unlikely to affect the metabolism of other P450 substrates. 
false	 <e1> Cholestyramine </e1> :  <e2> Cholestyramine </e2>  causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. 
effect	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as  <e1> aspirin </e1> , dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after  <e2> Retavase </e2>     therapy.
false	In addition to bleeding associated with  <e1> heparin </e1>  and vitamin K antagonists, drugs that alter platelet function (such as  <e2> aspirin </e2> , dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
false	 <e1> Cholestyramine </e1> :  <e2> Cholestyramine </e2>  causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. 
false	Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of  <e1> ALTABAX </e1> ,  <e2> retapamulin </e2>  is unlikely to affect the metabolism of other P450 substrates. 
effect	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as  <e1> aspirin </e1> , dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after  <e2> Retavase </e2>     therapy.
mechanism	Interactions for Vitamin B2 (Riboflavin):   <e1> Alcohol </e1>  - impairs the intestinal absorption of  <e2> riboflavin </e2> 
false	Interactions for  <e1> Vitamin B2 </e1>  (Riboflavin):  Alcohol - impairs the intestinal absorption of  <e2> riboflavin </e2> 
false	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total  <e1> rimantadine </e1>  clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total  <e2> rimantadine </e2>  clearance in the same subjects in the absence of cimetidine). 
false	Cimetidine: The effects of chronic  <e1> cimetidine </e1>  use on the metabolism of  <e2> rimantadine </e2>  are not known. 
false	 <e1> Acetaminophen </e1> :  <e2> Rimantadine HCl </e2> , 100 mg, was given twice daily for 13 days to 12 healthy volunteers. 
mechanism	Peak plasma concentrations and AUC of  <e1> rimantadine </e1>  were reduced approximately 10% in the presence of  <e2> aspirin </e2> .
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21),  <e1> nonsteroidal anti-inflammatory drugs </e1>  (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and  <e2> antihistamines </e2>  (n=15). 
false	No pharmacokinetic interaction was observed between rivastigmine and digoxin,  <e1> warfarin </e1> , diazepam, or  <e2> fluoxetine </e2>  in studies in healthy volunteers. 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as  <e1> antacids </e1>  (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70),  <e2> salicylate analgesics </e2>  (n=177), antianginals (n=35), and antihistamines (n=15). 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  <e1> rivastigmine </e1>  were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72),  <e2> calcium channel blockers </e2>  (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72),  <e1> calcium channel blockers </e1>  (n=75), antidiabetics (n=21),  <e2> nonsteroidal anti-inflammatory drugs </e2>  (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
effect	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when  <e1> cholinesterase inhibitors </e1>  are given concurrently with  <e2> succinylcholine </e2> , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
false	No pharmacokinetic interaction was observed between rivastigmine and  <e1> digoxin </e1> , warfarin,  <e2> diazepam </e2> , or fluoxetine in studies in healthy volunteers. 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72),  <e1> calcium channel blockers </e1>  (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177),  <e2> antianginals </e2>  (n=35), and antihistamines (n=15). 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72),  <e1> calcium channel blockers </e1>  (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70),  <e2> salicylate analgesics </e2>  (n=177), antianginals (n=35), and antihistamines (n=15). 
false	The elevation of prothrombin time induced by  <e1> warfarin </e1>  is not affected by administration of  <e2> Exelon </e2> . 
false	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total  <e1> rimantadine </e1>  clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total  <e2> rimantadine </e2>  clearance in the same subjects in the absence of cimetidine). 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75),  <e1> antidiabetics </e1>  (n=21),  <e2> nonsteroidal anti-inflammatory drugs </e2>  (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	No pharmacokinetic interaction was observed between rivastigmine and  <e1> digoxin </e1> , warfarin, diazepam, or  <e2> fluoxetine </e2>  in studies in healthy volunteers. 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  <e1> rivastigmine </e1>  were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177),  <e2> antianginals </e2>  (n=35), and antihistamines (n=15). 
false	Use with  <e1> Cholinomimetics </e1>  and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with  <e2> succinylcholine </e2> , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as  <e1> antacids </e1>  (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79),  <e2> estrogens </e2>  (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77),  <e1> antihypertensives </e1>  (n=72), calcium channel blockers (n=75),  <e2> antidiabetics </e2>  (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	Single dose pharmacokinetic studies demonstrated that the metabolism of  <e1> rivastigmine </e1>  is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or  <e2> fluoxetine </e2> . 
false	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with  <e1> succinylcholine </e1> , similar  <e2> neuromuscular blocking agents </e2>  or cholinergic agonists such as bethanechol.
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  <e1> rivastigmine </e1>  were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79),  <e2> estrogens </e2>  (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	Drug Interactions: The use of  <e1> ZEMURON </e1>     (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of  <e2> succinylcholine </e2> , has not been studied. 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as  <e1> antacids </e1>  (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70),  <e2> salicylate analgesics </e2>  (n=177), antianginals (n=35), and antihistamines (n=15). 
false	Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before  <e1> succinylcholine </e1> , for the purpose of attenuating some of the side effects of  <e2> succinylcholine </e2> , has not been studied. 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77),  <e1> antihypertensives </e1>  (n=72), calcium channel blockers (n=75),  <e2> antidiabetics </e2>  (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	Drug Interactions: The use of  <e1> ZEMURON </e1>     (rocuronium bromide) Injection before  <e2> succinylcholine </e2> , for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. 
false	Single dose pharmacokinetic studies demonstrated that the metabolism of  <e1> rivastigmine </e1>  is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or  <e2> fluoxetine </e2> . 
mechanism	In vivo, the plasma clearance of  <e1> ropivacaine </e1>  was reduced by 70% during coadministration of  <e2> fluvoxamine </e2>  (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. 
false	Drug Interactions: The use of  <e1> ZEMURON </e1>     (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of  <e2> succinylcholine </e2> , has not been studied. 
false	Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with  <e1> Ropivacaine </e1>  leading to increased  <e2> ropivacaine </e2>  plasma levels. 
false	Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with  <e1> ropivacaine </e1>  infusion administered 1 hour after  <e2> ketoconazole </e2> ) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.
false	Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as  <e1> theophylline </e1>  and  <e2> imipramine </e2>  may also occur. 
false	Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with  <e1> Ropivacaine </e1>  leading to increased  <e2> ropivacaine </e2>  plasma levels. 
false	- Cisapride, pimozide: Other drugs such as  <e1> cisapride </e1>  or  <e2> pimozide </e2> , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. 
false	Although such a reaction has not been demonstrated with  <e1> roxithromycin </e1> , concomitant administration of roxithromycin with terfenadine or  <e2> astemizole </e2>  is not recommended. 
false	Although such a reaction has not been demonstrated with  <e1> roxithromycin </e1> , concomitant administration of  <e2> roxithromycin </e2>  with terfenadine or astemizole is not recommended. 
false	Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with  <e1> Ropivacaine </e1>  leading to increased  <e2> ropivacaine </e2>  plasma levels. 
int	Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain  <e1> macrolides </e1>  interact with  <e2> terfenadine </e2>  and astemizole leading to increased serum concentrations of the latter. 
advise	Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of  <e1> roxithromycin </e1>  with  <e2> terfenadine </e2>  or astemizole is not recommended. 
false	Concomitant administrations not recommended:  -  <e1> Terfenadine </e1>  and astemizole: Certain macrolides interact with terfenadine and  <e2> astemizole </e2>  leading to increased serum concentrations of the latter. 
mechanism	- Cisapride, pimozide: Other drugs such as  <e1> cisapride </e1>  or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some  <e2> macrolide antibacterials </e2> . 
false	Although such a reaction has not been demonstrated with  <e1> roxithromycin </e1> , concomitant administration of  <e2> roxithromycin </e2>  with terfenadine or astemizole is not recommended. 
false	Salicylate competes with a number of drugs for protein binding sites, notably  <e1> penicillin </e1> , thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin,  <e2> methotrexate </e2> , and possibly corticosteroids. 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin,  <e1> thiopental </e1> , thyroxine,  <e2> triiodothyronine </e2> , phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine,  <e1> phenytoin </e1> , sulfinpyrazone,  <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids. 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental,  <e1> thyroxine </e1> , triiodothyronine, phenytoin,  <e2> sulfinpyrazone </e2> , naproxen, warfarin, methotrexate, and possibly corticosteroids. 
effect	 <e1> ASPIRIN </e1>  AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO  <e2> DISALCID </e2>  AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. 
mechanism	 <e1> Salicylate </e1>  competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly  <e2> corticosteroids </e2> . 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin,  <e1> sulfinpyrazone </e1> , naproxen, warfarin, methotrexate, and possibly  <e2> corticosteroids </e2> . 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental,  <e1> thyroxine </e1> , triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly  <e2> corticosteroids </e2> . 
mechanism	 <e1> Salicylate </e1>  competes with a number of drugs for protein binding sites, notably  <e2> penicillin </e2> , thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine,  <e1> triiodothyronine </e1> , phenytoin, sulfinpyrazone, naproxen, warfarin,  <e2> methotrexate </e2> , and possibly corticosteroids. 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine,  <e1> triiodothyronine </e1> , phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly  <e2> corticosteroids </e2> . 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental,  <e1> thyroxine </e1> ,  <e2> triiodothyronine </e2> , phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen,  <e1> warfarin </e1> , methotrexate, and possibly  <e2> corticosteroids </e2> . 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin,  <e1> thiopental </e1> , thyroxine,  <e2> triiodothyronine </e2> , phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin,  <e1> sulfinpyrazone </e1> , naproxen, warfarin, methotrexate, and possibly  <e2> corticosteroids </e2> . 
mechanism	 <e1> Salicylate </e1>  competes with a number of drugs for protein binding sites, notably  <e2> penicillin </e2> , thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 
false	e.g., other  <e1> belladonna alkaloids </e1> , antihistamines (including meclizine), tricyclic antidepressants, and  <e2> muscle relaxants </e2> . 
false	e.g., other  <e1> belladonna alkaloids </e1> , antihistamines (including  <e2> meclizine </e2> ), tricyclic antidepressants, and muscle relaxants. 
false	e.g., other belladonna alkaloids, antihistamines (including  <e1> meclizine </e1> ),  <e2> tricyclic antidepressants </e2> , and muscle relaxants. 
int	 <e1> Barbiturates </e1>  may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids,  <e2> anticoagulants </e2> , and beta blockers.
false	Barbiturates may decrease the effectiveness of oral  <e1> contraceptives </e1> , certain antibiotics, quinidine,  <e2> theophylline </e2> , corticosteroids, anticoagulants, and beta blockers.
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics,  <e1> quinidine </e1> , theophylline,  <e2> corticosteroids </e2> , anticoagulants, and beta blockers.
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine,  <e1> theophylline </e1> ,  <e2> corticosteroids </e2> , anticoagulants, and beta blockers.
int	 <e1> Barbiturates </e1>  may decrease the effectiveness of oral contraceptives, certain antibiotics,  <e2> quinidine </e2> , theophylline, corticosteroids, anticoagulants, and beta blockers.
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine,  <e1> theophylline </e1> , corticosteroids,  <e2> anticoagulants </e2> , and beta blockers.
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain  <e1> antibiotics </e1> ,  <e2> quinidine </e2> , theophylline, corticosteroids, anticoagulants, and beta blockers.
effect	Severe toxicity has also been reported in patients receiving the combination of  <e1> tricyclic antidepressants </e1>  and  <e2> ELDEPRYL </e2>  and selective serotonin reuptake inhibitors and ELDEPRYL. 
false	Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and  <e1> ELDEPRYL </e1>  and  <e2> selective serotonin reuptake inhibitors </e2>  and ELDEPRYL. 
false	Barbiturates may decrease the effectiveness of oral  <e1> contraceptives </e1> , certain antibiotics, quinidine,  <e2> theophylline </e2> , corticosteroids, anticoagulants, and beta blockers.
false	 <e1> Digoxin </e1> : There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg  <e2> sitagliptin </e2>  for 10 days. 
int	norepinephrine and  <e1> dobutamine </e1>  are incompatible with  <e2> sodium bicarbonate </e2>  solution. 
false	Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with  <e1> solifenacin </e1>  10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control  <e2> moxifloxacin </e2>  at its therapeutic dose. 
mechanism	These data suggest that  <e1> GH </e1>  administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants,  <e2> cyclosporin </e2> ). 
false	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g.,  <e1> corticosteroids </e1> , sex steroids, anticonvulsants,  <e2> cyclosporin </e2> ). 
mechanism	These data suggest that  <e1> GH </e1>  administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants,  <e2> cyclosporin </e2> ). 
advise	Caution is recommended when administering  <e1> NEXAVAR </e1>  with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g.  <e2> irinotecan </e2> ). 
advise	Therefore, use of  <e1> zidovudine </e1>  in combination with  <e2> ZERIT </e2>  should be avoided. 
false	Use of Anticoagulants and  <e1> Antiplatelet Agents </e1>  -- Streptase, Streptokinase, alone or in combination with  <e2> antiplatelet agents </e2>  and anticoagulants, may cause bleeding complications. 
effect	The addition of  <e1> aspirin </e1>  to  <e2> Streptokinase </e2>  causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see
false	Use of  <e1> Anticoagulants </e1>  and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and  <e2> anticoagulants </e2> , may cause bleeding complications. 
false	Anticoagulation and  <e1> Antiplatelets </e1>  After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of  <e2> aspirin </e2>  has been shown to reduce the incidence of reinfarction and stroke. 
effect	The addition of  <e1> aspirin </e1>  to  <e2> Streptokinase </e2>  causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see
false	Anticoagulation and  <e1> Antiplatelets </e1>  After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of  <e2> aspirin </e2>  has been shown to reduce the incidence of reinfarction and stroke. 
false	Anticoagulation and  <e1> Antiplatelets </e1>  After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of  <e2> aspirin </e2>  has been shown to reduce the incidence of reinfarction and stroke. 
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response),  <e1> warfarin </e1>  (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate),  <e2> phenytoin </e2>  (decreased hepatic clearance of phenytoin).
false	Anticoagulation and  <e1> Antiplatelets </e1>  After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of  <e2> aspirin </e2>  has been shown to reduce the incidence of reinfarction and stroke. 
false	Sulfamethizole may increase the effects of  <e1> barbiturates </e1> ,  <e2> tolbutamide </e2> , and uricosurics. 
false	It may also interact with  <e1> thiazides </e1>  (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of  <e2> methotrexate </e2> ), phenytoin (decreased hepatic clearance of phenytoin).
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect),  <e1> methotrexate </e1>  (decreased renal excretion of  <e2> methotrexate </e2> ), phenytoin (decreased hepatic clearance of phenytoin).
false	Sulfamethizole may increase the effects of  <e1> barbiturates </e1> , tolbutamide, and  <e2> uricosurics </e2> . 
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity),  <e1> sulfonylurea agents </e1>  (increased hypoglycemic response),  <e2> warfarin </e2>  (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity),  <e1> sulfonylurea agents </e1>  (increased hypoglycemic response),  <e2> warfarin </e2>  (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
false	 <e1> Sulfonamides </e1>  can also displace methotrexate from plasma protein-binding sites, thus increasing free  <e2> methotrexate </e2>  concentrations. 
false	Sulfamethizole may increase the effects of  <e1> barbiturates </e1> , tolbutamide, and  <e2> uricosurics </e2> . 
false	Reduced absorption of  <e1> folic acid </e1>  and  <e2> digoxin </e2>  have been reported when those agents were administered concomitantly with sulfasalazine. 
mechanism	Reduced absorption of folic acid and  <e1> digoxin </e1>  have been reported when those agents were administered concomitantly with  <e2> sulfasalazine </e2> . 
false	Sulfoxone may increase the effects of  <e1> barbiturates </e1> ,  <e2> tolbutamide </e2> , and uricosurics. 
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate),  <e1> phenytoin </e1>  (decreased hepatic clearance of  <e2> phenytoin </e2> ).
false	It may also interact with  <e1> thiazides </e1>  (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of  <e2> methotrexate </e2> ), phenytoin (decreased hepatic clearance of phenytoin).
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity),  <e1> sulfonylurea agents </e1>  (increased hypoglycemic response), warfarin (increased anticoagulant effect),  <e2> methotrexate </e2>  (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect),  <e1> methotrexate </e1>  (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of  <e2> phenytoin </e2> ).
false	It may also interact with thiazides (increased thrombocytopenia),  <e1> cyclosporine </e1>  (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response),  <e2> warfarin </e2>  (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
false	It may also interact with  <e1> thiazides </e1>  (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect),  <e2> methotrexate </e2>  (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
false	Therefore, the use of  <e1> sumatriptan succinate </e1>  tablets in patients receiving MAO-A inhibitors is contraindicated .  <e2> Selective serotonin reuptake inhibitors </e2>  (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
false	Therefore, the use of  <e1> sumatriptan succinate </e1>  tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine,  <e2> fluvoxamine </e2> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
effect	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine,  <e1> paroxetine </e1> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  <e2> sumatriptan </e2> . 
false	Therefore, the use of  <e1> sumatriptan succinate </e1>  tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  <e2> sumatriptan </e2> . 
false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine,  <e1> paroxetine </e1> ,  <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
advise	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or  <e1> ergot-type medications </e1>  (like dihydroergotamine or methysergide) and  <e2> sumatriptan </e2>  within 24 hours of each other should be avoided. 
false	Therefore, the use of sumatriptan succinate tablets in patients receiving  <e1> MAO-A inhibitors </e1>  is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine,  <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
false	Because there is a theoretical basis that these effects may be additive, use of  <e1> ergotamine </e1> -containing or ergot-type medications (like  <e2> dihydroergotamine </e2>  or methysergide) and sumatriptan within 24 hours of each other should be avoided. 
false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine,  <e1> fluvoxamine </e1> , paroxetine,  <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
false	Therefore, the use of sumatriptan succinate tablets in patients receiving  <e1> MAO-A inhibitors </e1>  is contraindicated .  <e2> Selective serotonin reuptake inhibitors </e2>  (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
false	Therefore, the use of  <e1> sumatriptan succinate </e1>  tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g.,  <e2> fluoxetine </e2> , fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole,  <e1> itraconazole </e1> , clarithromycin, atazanavir, indinavir, nefazodone,  <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
mechanism	Co-administration of  <e1> SUTENT </e1>  with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir,  <e2> indinavir </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g.,  <e1> ketoconazole </e1> , itraconazole,  <e2> clarithromycin </e2> , atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Because there is a theoretical basis that these effects may be additive, use of  <e1> ergotamine </e1> -containing or ergot-type medications (like  <e2> dihydroergotamine </e2>  or methysergide) and sumatriptan within 24 hours of each other should be avoided. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir,  <e1> nefazodone </e1> , nelfinavir, ritonavir, saquinavir,  <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone,  <e1> phenytoin </e1> , carbamazepine, rifampin, rifabutin, rifapentin,  <e2> phenobarbital </e2> , St. Johns Wort) may decrease sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone,  <e1> nelfinavir </e1> ,  <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole,  <e1> itraconazole </e1> ,  <e2> clarithromycin </e2> , atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
mechanism	Co-administration of  <e1> SUTENT </e1>  with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin,  <e2> atazanavir </e2> , indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin,  <e1> atazanavir </e1> , indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases  <e2> sunitinib </e2>  concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir,  <e1> saquinavir </e1> , telithromycin, voriconizole) may increases  <e2> sunitinib </e2>  concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole,  <e1> itraconazole </e1> , clarithromycin, atazanavir,  <e2> indinavir </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of  <e1> SUTENT </e1>  with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases  <e2> sunitinib </e2>  concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir,  <e1> indinavir </e1> , nefazodone, nelfinavir,  <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
mechanism	Co-administration of  <e1> SUTENT </e1>  with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir,  <e1> nefazodone </e1> , nelfinavir, ritonavir,  <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g.,  <e1> ketoconazole </e1> , itraconazole, clarithromycin, atazanavir, indinavir,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g.,  <e1> dexamethasone </e1> , phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease  <e2> sunitinib </e2>  concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone,  <e1> nelfinavir </e1> , ritonavir, saquinavir,  <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations. 
false	Therefore, the use of  <e1> sumatriptan succinate </e1>  tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g.,  <e2> fluoxetine </e2> , fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir,  <e1> indinavir </e1> ,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g.,  <e1> ketoconazole </e1> , itraconazole, clarithromycin,  <e2> atazanavir </e2> , indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone,  <e1> phenytoin </e1> ,  <e2> carbamazepine </e2> , rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir,  <e1> nefazodone </e1> , nelfinavir, ritonavir, saquinavir, telithromycin,  <e2> voriconizole </e2> ) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone,  <e1> nelfinavir </e1> , ritonavir, saquinavir,  <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations. 
false	Other eye drops or medications such as acetylcholine chloride ( <e1> Miochol </e1> ) and carbachol (Carboptic,  <e2> Isopto Carbachol </e2> ) may decrease the effects of suprofen ophthalmic.
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g.,  <e1> ketoconazole </e1> , itraconazole, clarithromycin,  <e2> atazanavir </e2> , indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Other eye drops or medications such as acetylcholine chloride (Miochol) and  <e1> carbachol </e1>  ( <e2> Carboptic </e2> , Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
effect	Other eye drops or medications such as  <e1> acetylcholine chloride </e1>  (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of  <e2> suprofen </e2>  ophthalmic.
false	Other eye drops or medications such as  <e1> acetylcholine chloride </e1>  (Miochol) and carbachol ( <e2> Carboptic </e2> , Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
false	Co-administration of  <e1> SUTENT </e1>  with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases  <e2> sunitinib </e2>  concentrations. 
false	Results from limited in vitro and in vivo drug-drug interaction studies between  <e1> tamsulosin HCI </e1>  and  <e2> warfarin </e2>  are inconclusive. 
false	The pharmacokinetic interaction between  <e1> cimetidine </e1>  and  <e2> FLOMAX </e2>  capsules was investigated. 
false	The pharmacokinetic interaction between  <e1> cimetidine </e1>  and  <e2> FLOMAX </e2>  capsules was investigated. 
effect	Anticoagulants (such as  <e1> heparin </e1>  and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  <e2> TNKase </e2>  therapy. 
false	Anticoagulants (such as heparin and  <e1> vitamin K antagonists </e1> ) and drugs that alter platelet function (such as acetylsalicylic acid,  <e2> dipyridamole </e2> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 
false	 <e1> Anticoagulants </e1>  (such as  <e2> heparin </e2>  and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 
false	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as  <e1> acetylsalicylic acid </e1> ,  <e2> dipyridamole </e2> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 
mechanism	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and  <e1> sulfamethizole </e1>  displaced protein-bound  <e2> teniposide </e2>  in fresh human serum to a small but significant extent. 
false	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide,  <e1> sodium salicylate </e1>  and  <e2> sulfamethizole </e2>  displaced protein-bound teniposide in fresh human serum to a small but significant extent. 
false	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers,  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs), and  <e2> monoamine oxidase inhibitors (MAO-Is) Type B </e2> , if they have a narrow therapeutic window. 
false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  <e1> contraceptives </e1> , hormone replacement therapies, hypoglycemics, theophyllines,  <e2> phenytoins </e2> , thiazide diuretics, beta blockers, and calcium channel blockers.
false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  <e1> contraceptives </e1> , hormone replacement therapies, hypoglycemics, theophyllines, phenytoins,  <e2> thiazide diuretics </e2> , beta blockers, and calcium channel blockers.
false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins,  <e1> thiazide diuretics </e1> ,  <e2> beta blockers </e2> , and calcium channel blockers.
false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines,  <e1> phenytoins </e1> , thiazide diuretics,  <e2> beta blockers </e2> , and calcium channel blockers.
false	In vitro studies with human liver microsomes showed that  <e1> terbinafine </e1>  does not inhibit the metabolism of  <e2> tolbutamide </e2> , ethinylestradiol, ethoxycoumarin, and cyclosporine. 
false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics,  <e1> theophyllines </e1> , phenytoins, thiazide diuretics,  <e2> beta blockers </e2> , and calcium channel blockers.
false	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of  <e1> tolbutamide </e1> ,  <e2> ethinylestradiol </e2> , ethoxycoumarin, and cyclosporine. 
false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  <e1> contraceptives </e1> , hormone replacement therapies,  <e2> hypoglycemics </e2> , theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.
mechanism	 <e1> Terbinafine </e1>  clearance is increased 100% by  <e2> rifampin </e2> , a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. 
false	Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and  <e1> itraconazole </e1>  in clinical trials of  <e2> itraconazole </e2>  and from foreign post-marketing sources. 
advise	Concomitant administration of  <e1> terfenadine </e1>  with clarithromycin, erythromycin, or  <e2> troleandomycin </e2>  is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 
false	 <e1> Macrolides </e1> : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of  <e2> ketoconazole </e2> , but to a lesser extent. 
false	Concomitant administration of terfenadine with  <e1> clarithromycin </e1> , erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including  <e2> azithromycin </e2> , is not recommended. 
false	Concomitant administration of terfenadine with  <e1> clarithromycin </e1> , erythromycin, or  <e2> troleandomycin </e2>  is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 
false	Due to the chemical similarity of other azole-type antifungal agents (including  <e1> fluconazole </e1> , metronidazole, and miconazole) to  <e2> ketoconazole </e2> , and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 
false	Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of  <e1> terfenadine </e1> , resulting in elevated plasma  <e2> terfenadine </e2>  levels. 
false	 <e1> Ketoconazole </e1> : Spontaneous adverse reaction reports of patients taking concomitant  <e2> ketoconazole </e2>  with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. 
false	Concomitant administration of  <e1> terfenadine </e1>  with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of  <e2> terfenadine </e2>  with other macrolide antibiotics, including azithromycin, is not recommended. 
false	Concomitant administration of terfenadine with  <e1> clarithromycin </e1> , erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of  <e2> terfenadine </e2>  with other macrolide antibiotics, including azithromycin, is not recommended. 
advise	Due to the chemical similarity of other azole-type antifungal agents (including  <e1> fluconazole </e1> , metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with  <e2> terfenadine </e2>  is not recommended pending full examination of potential interactions. 
false	Pharmacokinetic data indicate that  <e1> ketoconazole </e1>  markedly inhibits the metabolism of terfenadine, resulting in elevated plasma  <e2> terfenadine </e2>  levels. 
false	Itraconazole: Torsades de pointes and elevated parent  <e1> terfenadine </e1>  levels have been reported during concomitant use of  <e2> terfenadine </e2>  and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. 
false	Due to the chemical similarity of other azole-type antifungal agents (including  <e1> fluconazole </e1> , metronidazole, and  <e2> miconazole </e2> ) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 
false	Due to the chemical similarity of other  <e1> azole-type antifungal agents </e1>  (including fluconazole,  <e2> metronidazole </e2> , and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 
mechanism	Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of  <e1> terfenadine </e1>  and  <e2> itraconazole </e2>  in clinical trials of itraconazole and from foreign post-marketing sources. 
false	Due to the chemical similarity of other azole-type antifungal agents (including  <e1> fluconazole </e1> , metronidazole, and  <e2> miconazole </e2> ) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 
false	Pharmacokinetic data indicate that  <e1> ketoconazole </e1>  markedly inhibits the metabolism of terfenadine, resulting in elevated plasma  <e2> terfenadine </e2>  levels. 
advise	Due to the chemical similarity of other azole-type antifungal agents (including  <e1> fluconazole </e1> , metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with  <e2> terfenadine </e2>  is not recommended pending full examination of potential interactions. 
false	Due to the chemical similarity of other azole-type antifungal agents (including  <e1> fluconazole </e1> , metronidazole, and  <e2> miconazole </e2> ) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of  <e1> HIV-protease inhibitors </e1> , griseofulvin, modafinil, penicillins, rifampin, rifabutin,  <e2> phenytoin </e2> , carbamazepine, or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil,  <e1> penicillins </e1> ,  <e2> rifampin </e2> , rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil,  <e1> penicillins </e1> , rifampin,  <e2> rifabutin </e2> , phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with  <e1> Hormonal Contraceptives </e1> : Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin,  <e2> phenytoin </e2> , carbamazepine, or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors,  <e1> griseofulvin </e1> , modafinil,  <e2> penicillins </e2> , rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin,  <e1> modafinil </e1> , penicillins,  <e2> rifampin </e2> , rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin,  <e1> rifabutin </e1> , phenytoin,  <e2> carbamazepine </e2> , or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of  <e1> HIV-protease inhibitors </e1> , griseofulvin, modafinil,  <e2> penicillins </e2> , rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
effect	 <e1> John's Wort </e1>  with  <e2> hormonal contraceptive agents </e2>  may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies. 
false	 <e1> Thalidomide </e1>  has been reported to enhance the sedative activity of barbiturates,  <e2> alcohol </e2> , chlorpromazine, and reserpine. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin,  <e1> phenytoin </e1> ,  <e2> carbamazepine </e2> , or certain herbal supplements such as St. 
false	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and  <e1> ethinyl estradiol </e1>  following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of  <e2> ethinyl estradiol </e2>  were studied. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of  <e1> HIV-protease inhibitors </e1> ,  <e2> griseofulvin </e2> , modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin,  <e1> modafinil </e1> , penicillins,  <e2> rifampin </e2> , rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of  <e1> HIV-protease inhibitors </e1> ,  <e2> griseofulvin </e2> , modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral  <e1> Contraceptives </e1> , Stavudine,  <e2> Tricyclic Antidepressants </e2> 
int	Interactions for Vitamin B1 ( <e1> Thiamine </e1> ):  Loop Diuretics, Oral  <e2> Contraceptives </e2> , Stavudine, Tricyclic Antidepressants
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin,  <e1> modafinil </e1> , penicillins,  <e2> rifampin </e2> , rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
effect	 <e1> Phenothiazines </e1>  are capable of potentiating  <e2> CNS depressants </e2>  (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 
false	Phenothiazines are capable of potentiating CNS depressants (e.g.,  <e1> barbiturates </e1> , anesthetics, opiates,  <e2> alcohol </e2> , etc.) 
false	as well as  <e1> atropine </e1>  and  <e2> phosphorous insecticides </e2> .
mechanism	As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine,  <e1> mesalazine </e1> , or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent  <e2> thioguanine </e2>  therapy.    
false	As there is in vitro evidence that  <e1> aminosalicylate derivatives </e1>  (e.g., olsalazine,  <e2> mesalazine </e2> , or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    
effect	There is usually complete cross-resistance between  <e1> PURINETHOL </e1>  (mercaptopurine) and TABLOID brand  <e2> Thioguanine </e2> . 
false	As there is in vitro evidence that aminosalicylate derivatives (e.g.,  <e1> olsalazine </e1> ,  <e2> mesalazine </e2> , or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    
false	As there is in vitro evidence that aminosalicylate derivatives (e.g.,  <e1> olsalazine </e1> ,  <e2> mesalazine </e2> , or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    
false	The bioavailability of SKELID is decreased 80% by  <e1> calcium </e1> , when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing  <e2> antacids </e2> , when administered 1 hour before SKELID. 
false	The bioavailability of SKELID is decreased 80% by  <e1> calcium </e1> , when calcium and SKELID are administered at the same time, and 60% by some  <e2> aluminum </e2> - or magnesium-containing antacids, when administered 1 hour before SKELID. 
false	The bioavailability of SKELID is decreased 80% by  <e1> calcium </e1> , when calcium and SKELID are administered at the same time, and 60% by some aluminum- or  <e2> magnesium </e2> -containing antacids, when administered 1 hour before SKELID. 
false	The bioavailability of  <e1> SKELID </e1>  is decreased 80% by calcium, when calcium and  <e2> SKELID </e2>  are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 
false	The bioavailability of SKELID is decreased 80% by calcium, when calcium and  <e1> SKELID </e1>  are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before  <e2> SKELID </e2> . 
mechanism	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some  <e1> aluminum </e1> - or magnesium-containing antacids, when administered 1 hour before  <e2> SKELID </e2> . 
false	The bioavailability of SKELID is increased 2-4 fold by  <e1> indomethacin </e1>  but is not significantly altered by coadministration of  <e2> diclofenac </e2> . 
false	However, the co   administration of SPIRIVA with other  <e1> anticholinergic </e1>    containing drugs (e.g.,  <e2> ipratropium </e2> ) has not been studied and is therefore not recommended.
false	The bioavailability of SKELID is decreased 80% by  <e1> calcium </e1> , when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing  <e2> antacids </e2> , when administered 1 hour before SKELID. 
advise	However, the co   administration of  <e1> SPIRIVA </e1>  with other anticholinergic   containing drugs (e.g.,  <e2> ipratropium </e2> ) has not been studied and is therefore not recommended.
false	The use of AGGRASTAT, in combination with  <e1> heparin </e1>  and  <e2> aspirin </e2> , has been associated with an increase in bleeding compared to heparin and aspirin alone (see
effect	The use of  <e1> AGGRASTAT </e1> , in combination with heparin and  <e2> aspirin </e2> , has been associated with an increase in bleeding compared to heparin and aspirin alone (see
false	However, the co   administration of SPIRIVA with other  <e1> anticholinergic </e1>    containing drugs (e.g.,  <e2> ipratropium </e2> ) has not been studied and is therefore not recommended.
false	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled  <e1> corticosteroids </e1> , other anti-pseudomonal antibiotics, or parenteral  <e2> aminoglycosides </e2>  demonstrated adverse experience profiles similar to the study population as a whole. 
false	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech),  <e1> (beta)-agonists </e1> , inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral  <e2> aminoglycosides </e2>  demonstrated adverse experience profiles similar to the study population as a whole. 
false	In clinical studies of  <e1> TOBI </e1> , patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral  <e2> aminoglycosides </e2>  demonstrated adverse experience profiles similar to the study population as a whole. 
advise	 <e1> TOBI </e1>  should not be administered concomitantly with  <e2> ethacrynic acid </e2> , furosemide, urea, or mannitol.
false	In clinical studies of TOBI, patients taking TOBI concomitantly with  <e1> dornase alfa </e1>  (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other  <e2> anti-pseudomonal antibiotics </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 
effect	In clinical studies of TOBI, patients taking  <e1> TOBI </e1>  concomitantly with  <e2> dornase alfa </e2>  (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 
false	TOBI should not be administered concomitantly with  <e1> ethacrynic acid </e1> , furosemide, urea, or  <e2> mannitol </e2> .
false	TOBI should not be administered concomitantly with ethacrynic acid,  <e1> furosemide </e1> ,  <e2> urea </e2> , or mannitol.
false	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech),  <e1> (beta)-agonists </e1> , inhaled  <e2> corticosteroids </e2> , other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 
false	TOLECTIN and other  <e1> nonsteroidal anti-inflammatory drugs </e1>  have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of  <e2> methotrexate </e2> . 
mechanism	TOLECTIN and other  <e1> nonsteroidal anti-inflammatory drugs </e1>  have been reported to reduce the tubular secretion of  <e2> methotrexate </e2>  in an animal model, possibly enhancing the toxicity of methotrexate. 
false	In adult diabetic patients under treatment with either  <e1> sulfonylureas </e1>  or  <e2> insulin </e2>  there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. 
effect	In clinical studies of TOBI, patients taking  <e1> TOBI </e1>  concomitantly with  <e2> dornase alfa </e2>  (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 
false	 <e1> TOLECTIN </e1>  and other  <e2> nonsteroidal anti-inflammatory drugs </e2>  have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. 
false	In clinical studies of  <e1> TOBI </e1> , patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral  <e2> aminoglycosides </e2>  demonstrated adverse experience profiles similar to the study population as a whole. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg,  <e1> itraconazole </e1> , miconazole) or  <e2> macrolide antibiotics </e2>  (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or  <e1> macrolide antibiotics </e1>  (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of  <e2> DETROL LA </e2>  is 2 mg daily. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole,  <e1> miconazole </e1> ) or macrolide antibiotics (eg, erythromycin, clarithromycin) or  <e2> cyclosporine </e2>  or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg,  <e1> itraconazole </e1> , miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of  <e2> DETROL LA </e2>  is 2 mg daily. 
false	For patients receiving  <e1> ketoconazole </e1>  or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole,  <e2> miconazole </e2> ) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg,  <e1> erythromycin </e1> ,  <e2> clarithromycin </e2> ) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg,  <e1> itraconazole </e1> , miconazole) or macrolide antibiotics (eg, erythromycin,  <e2> clarithromycin </e2> ) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or  <e1> cyclosporine </e1>  or  <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily. 
mechanism	TOLECTIN and other  <e1> nonsteroidal anti-inflammatory drugs </e1>  have been reported to reduce the tubular secretion of  <e2> methotrexate </e2>  in an animal model, possibly enhancing the toxicity of methotrexate. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or  <e1> macrolide antibiotics </e1>  (eg, erythromycin,  <e2> clarithromycin </e2> ) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole,  <e1> miconazole </e1> ) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or  <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily. 
mechanism	TOLECTIN and other  <e1> nonsteroidal anti-inflammatory drugs </e1>  have been reported to reduce the tubular secretion of  <e2> methotrexate </e2>  in an animal model, possibly enhancing the toxicity of methotrexate. 
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg,  <e1> itraconazole </e1> , miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of  <e2> DETROL LA </e2>  is 2 mg daily. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or  <e1> cyclosporine </e1>  or  <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or  <e1> macrolide antibiotics </e1>  (eg, erythromycin,  <e2> clarithromycin </e2> ) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
int	 <e1> Trilostane </e1>  may interact with  <e2> aminoglutethimide </e2>  or mitotane (causing too great a decrease in adrenal function).
false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin,  <e1> rifampin </e1> ,  <e2> rifabutin </e2> , ketoconazole, and fluconazole. 
false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin,  <e1> rifabutin </e1> , ketoconazole, and  <e2> fluconazole </e2> . 
effect	Agents that might be coadministered with  <e1> trimetrexate </e1>  in AIDS patients for other indications that could elicit this activity include erythromycin,  <e2> rifampin </e2> , rifabutin, ketoconazole, and fluconazole. 
false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include  <e1> erythromycin </e1> , rifampin, rifabutin, ketoconazole, and  <e2> fluconazole </e2> . 
false	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs ( <e1> clotrimazole </e1> ,  <e2> ketoconazole </e2> , miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. 
mechanism	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole,  <e1> ketoconazole </e1> , miconazole) were potent, non-competitive inhibitors of  <e2> trimetrexate </e2>  metabolism. 
false	Triprolidine may enhance the sedative effects of central nervous system depressants including  <e1> alcohol </e1> , barbiturates, hypnotics,  <e2> narcotic analgesics </e2> , sedatives, and tranquillisers. 
effect	 <e1> Triprolidine </e1>  may enhance the sedative effects of central nervous system depressants including alcohol,  <e2> barbiturates </e2> , hypnotics, narcotic analgesics, sedatives, and tranquillisers. 
false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates,  <e1> hypnotics </e1> , narcotic analgesics,  <e2> sedatives </e2> , and tranquillisers. 
false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol,  <e1> barbiturates </e1> , hypnotics, narcotic analgesics, sedatives, and  <e2> tranquillisers </e2> . 
false	Triprolidine may enhance the sedative effects of central nervous system depressants including  <e1> alcohol </e1> , barbiturates, hypnotics, narcotic analgesics,  <e2> sedatives </e2> , and tranquillisers. 
false	Triprolidine may enhance the sedative effects of central nervous system depressants including  <e1> alcohol </e1> , barbiturates,  <e2> hypnotics </e2> , narcotic analgesics, sedatives, and tranquillisers. 
effect	 <e1> Triprolidine </e1>  may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics,  <e2> sedatives </e2> , and tranquillisers. 
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted,  <e1> Sanctura </e1>  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin,  <e2> procainamide </e2> , pancuronium, morphine, vancomycin, metformin and tenofovir). 
false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium,  <e1> morphine </e1> ,  <e2> vancomycin </e2> , metformin and tenofovir). 
false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  <e1> Sanctura </e1>  have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide,  <e2> pancuronium </e2> , morphine, vancomycin, metformin and tenofovir). 
false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin,  <e1> procainamide </e1> ,  <e2> pancuronium </e2> , morphine, vancomycin, metformin and tenofovir). 
false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  <e1> Sanctura </e1>  have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine,  <e2> vancomycin </e2> , metformin and tenofovir). 
false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide,  <e1> pancuronium </e1> ,  <e2> morphine </e2> , vancomycin, metformin and tenofovir). 
false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  <e1> Sanctura </e1>  have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and  <e2> tenofovir </e2> ). 
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted,  <e1> Sanctura </e1>  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  <e2> digoxin </e2> , procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 
false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol,  <e1> barbiturates </e1> , hypnotics, narcotic analgesics, sedatives, and  <e2> tranquillisers </e2> . 
false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin,  <e1> polymyxin B </e1> , colistin, viomycin, or  <e2> cisplatin </e2> , when indicated, requires careful monitoring.
false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin,  <e1> polymyxin B </e1> ,  <e2> colistin </e2> , viomycin, or cisplatin, when indicated, requires careful monitoring.
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted,  <e1> Sanctura </e1>  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  <e2> digoxin </e2> , procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 
false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin,  <e1> viomycin </e1> , or  <e2> cisplatin </e2> , when indicated, requires careful monitoring.
false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  <e1> amphotericin B </e1> , aminoglycosides, bacitracin, polymyxin B, colistin,  <e2> viomycin </e2> , or cisplatin, when indicated, requires careful monitoring.
false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  <e1> amphotericin B </e1> ,  <e2> aminoglycosides </e2> , bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.
false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin,  <e1> polymyxin B </e1> , colistin, viomycin, or  <e2> cisplatin </e2> , when indicated, requires careful monitoring.
false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  <e1> amphotericin B </e1> , aminoglycosides, bacitracin, polymyxin B, colistin,  <e2> viomycin </e2> , or cisplatin, when indicated, requires careful monitoring.
false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity -  <e1> Live virus vaccines </e1> : may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm -  <e2> Killed virus vaccines </e2> : may decrease patient's response to the vaccine
false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin,  <e1> polymyxin B </e1> , colistin, viomycin, or  <e2> cisplatin </e2> , when indicated, requires careful monitoring.
false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm -  <e1> Killed virus vaccines </e1> : may decrease patient's response to the  <e2> vaccine </e2> 
int	 <e1> Vindesine </e1>  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm -  <e2> Killed virus vaccines </e2> : may decrease patient's response to the vaccine
false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  <e1> Phenytoin </e1> : can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  <e2> Mitomycin-C </e2> : may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity -  <e1> Live virus vaccines </e1> : may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm -  <e2> Killed virus vaccines </e2> : may decrease patient's response to the vaccine
false	 <e1> Coumarin-Derivative Anticoagulants </e1> : Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving  <e2> ZOLINZA </e2>  concomitantly with coumarin-derivative anticoagulants. 
